<SEC-DOCUMENT>0001437749-18-006069.txt : 20180402
<SEC-HEADER>0001437749-18-006069.hdr.sgml : 20180402
<ACCEPTANCE-DATETIME>20180402171202
ACCESSION NUMBER:		0001437749-18-006069
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180402
DATE AS OF CHANGE:		20180402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MILESTONE SCIENTIFIC INC.
		CENTRAL INDEX KEY:			0000855683
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				133545623
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14053
		FILM NUMBER:		18730061

	BUSINESS ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039
		BUSINESS PHONE:		(973) 535-2717

	MAIL ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MILESTONE SCIENTIFIC INC/NJ
		DATE OF NAME CHANGE:	19970409

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	U S OPPORTUNITY SEARCH INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mlss20171231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<html>
<head>
	<title>mlss20171231_10k.htm</title>
	<!-- Created by RDG Portal --><meta charset="" utf-8""="" /><meta name="format-detection" content="telephone=no" />
</head>
<body autocomplete="off" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px; cursor: auto;">
<div contenteditable="false" docsect="2" id="13195" sectdesc="Cover Page">&nbsp;</div>

<div data-td-statement-type="cover" data-td-v2v-id="1522337830446">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>UNITED STATES</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>Washington, D.C. 20549 </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 8.25pt;text-align:center;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 8.25pt;text-align:center;"><b>FORM 10-K </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 8.25pt;text-align:center;"><b>(Mark One) </b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:5.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#9746;</b></p>
			</td>
			<td style="vertical-align:top;width:94.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:32.25pt;margin-right:7.5pt;margin-top:0pt;text-align:center;text-indent:-24.5pt;"><b>For the fiscal year ended December 31, 2017</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:32.25pt;margin-right:7.5pt;margin-top:0pt;text-align:center;text-indent:-24.5pt;">Or</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:5.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#9744;</b></p>
			</td>
			<td style="vertical-align:top;width:94.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>TRANSITION <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </font></b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">For the transition period from <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> to </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">Commission file number 001-14053</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<hr align="center" style="width: 25%;height: 2.25px;color: #000000;background-color: #000000;border: none;">
<p>&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt 7.5pt;text-align:center;"><b>Mile<font style="font-family:'Times New Roman', Times, serif;font-size:18pt;">stone Scientific Inc.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>(Exact name of registrant as specified in its charter) </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<hr align="center" style="width: 25%;height: 2.25px;color: #000000;background-color: #000000;border: none;">
<p>&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align:bottom;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>13-3545623</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>State or other jurisdiction of Incorporation or organization</b></p>
			</td>
			<td style="vertical-align:bottom;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(I.R.S. Employer Identification No.)</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>220 South Orange Avenue, Livingston, NJ 07039 </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>(Address of principal executive offices) </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>Registrant<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s telephone number, including area code: 973-535-2717</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>Securities registered pursuant to Section<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;12(b) of the Act: </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><u>Title of each class</u></p>
			</td>
			<td style="vertical-align:bottom;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><u>Name of each exchange on which registered</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Common Stock, par value $.001 per share</p>
			</td>
			<td style="vertical-align:bottom;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">NYSE American</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>Securities registered pursuant to section 12(g) of the Act: <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NONE</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<hr align="center" style="width: 25%;height: 2.25px;color: #000000;background-color: #000000;border: none;">
<p style="text-indent: 45pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9744;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9745;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;No </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 36pt;">Indicate by <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9744;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9745;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;No </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:36pt;">Indicate by check mark whether the registrant (1)<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9745;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9744;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;No </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:36pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9745;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9744;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;No </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:36pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;405 of Regulation S-K (&sect; 229.405 of this chapter) is not contained herein and will not be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment of this Form 10-K.&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9745;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:36pt;">Indicate by ch<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">eck mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act.</font></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:21.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Large<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;accelerated&nbsp;filer</font></p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:47.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744;</p>
			</td>
			<td style="vertical-align:bottom;width:1.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>
			</td>
			<td style="vertical-align:bottom;width:26.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accelerated<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;filer</font></p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:2.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:21.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;width:48.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;width:27.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;width:2.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:21.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Non-accelerated filer</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:47.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;(Do not check if a smaller reporting company)</font></p>
			</td>
			<td style="vertical-align:bottom;width:1.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>
			</td>
			<td style="vertical-align:bottom;width:26.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Smaller<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;reporting&nbsp;company</font></p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:2.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9745;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:36pt;">Indicate by check mark whether the registrant is a <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">shell company (as defined in Rule 12b-2 of the Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9744;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;No&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9745;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 36pt;">As of June<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;30, 2017, the last business day of the registrants&nbsp;most recently completed second fiscal quarter, the aggregate market value of the common stock held by non- affiliates of the issuer was&nbsp;$27,488,612. This amount is based on the closing price of $1.50&nbsp;per share of the registrant&#39;s common stock as of such date, as reported on the NYSE American.</font></p>

<p style="text-indent: 36pt;">As of <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">April 2, 2018, the registrant has a total of 33,183,238&nbsp;shares of Common Stock, $0.001 par value outstanding.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 15pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="margin: 0pt 7.5pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><b>DOCUMENTS INCORPORATED BY REFERENCE </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">None</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>
</div>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="3" id="13196" sectdesc="Table of Contents">&nbsp;</div>

<div data-td-statement-type="toc" data-td-v2v-id="1522337842135">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>MILESTONE SCIENTIFIC INC.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>Form 10-K Annual Report </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>TABLE OF CONTENTS </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">PART I</p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;1.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Business</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">4</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;1A.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Risk Factors</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">14</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;1B.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Unresolved Staff Comments</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">22</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;2.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Description of Property</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">22</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;3.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Legal Proceedings</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">23</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;4.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Mine Safety Disclosure</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">23</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">PART<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;II</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;5.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Market for Common Equity, Related Stockholder Matters and Small Business Issuer Purchases of Equity Securities</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">23</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;6.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Selected Financial Data</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">24</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;7.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Management&#39;s Discussion and Analysis or Plan of Operations</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">24</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;7A.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Quantitative and Qualitative Disclosure about Market Risk</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">31</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;8.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial Statements</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">31</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;9.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">31</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;9A.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Controls and Procedures</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">31</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;9B.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Other Information</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">32</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">PART<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;III</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;10.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Directors, Executive Officers, Promoters and Control Persons and<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Corporate Governance; Compliance with Section&nbsp;16&nbsp;(a) of the Exchange Act</font></p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">32</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;11.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Executive Compensation</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">35</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;12.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">40</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;13.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Certain Relationships and Related Transactions, and Director Independence<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">42</font></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;14.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Principal Accounting Fees and Services</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">42</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">PART<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;IV</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Item&nbsp;15.</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibits and Financial Statement Schedules</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">43</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:16.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">SIGNATURES</font></p>
			</td>
			<td style="vertical-align:middle;width:75.7%;">&nbsp;</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">44</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:92.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">EXHIBITS</p>
			</td>
			<td style="vertical-align:middle;width:7.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>
</div>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="12" id="13197" sectdesc="Other">&nbsp;</div>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b>FORWARD-LOOKING STATEMENTS</b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:24.5pt;"><i>Certain statements made in this Annual Report on Form 10-K are &ldquo;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">forward-looking statements&rdquo; (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Milestone Scientific Inc. (&ldquo;Milestone Scientific&rdquo;) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Milestone Scientific&rsquo;s plans and objectives are based, in part, on assumptions involving the continued expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Milestone Scientific. Although Milestone Scientific believes that its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate. Considering the significant uncertainties inherent in the forward-looking statements included herein, particularly in view of Milestone Scientific&rsquo;s early stage operations, the inclusion of such information should not be regarded as a representation by Milestone Scientific or any other person that the objectives and plans of Milestone Scientific will be achieved. Milestone Scientific undertakes no obligation to revise or update publicly any forward-looking statements for any reason. </font></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 15pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific is the owner of the following registered U.S. trademarks: <i>CompuDent&reg;; CompuMed&reg;; CompuFlo&reg;; DPS Dynamic Pressure Sensing Technology&reg;; Milestone Scientific &reg;;&nbsp;the Milestone logo &reg;; Safety Wand&reg;; STA Single Tooth Anesthesia System&reg;; and The Wand &reg;.</i></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>PART I </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">All references in this report to &ldquo;Milestone Scientific, Inc.,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;we,&rdquo; the &ldquo;Company &ldquo;or &ldquo;Milestone&rdquo; refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Advanced Cosmetic Inc. and Milestone Medical Inc. and affiliate, Milestone Education LLC, unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuDent</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">; <i>CompuMed</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">; <i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">; <i>DPS Dynamic Pressure Sensing technology</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">; <i>Milestone Scientific</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">; <i>the Milestone logo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">; <i>Safety Wand</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">; <i>STA Single Tooth Anesthesia System</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">; and <i>The Wand</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b style="font-size: 10pt;">Item<font style="font-size: 10pt;">&nbsp;1. Business</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Overview</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Milestone <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Scientific is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and devices for medical, dental, cosmetic and veterinary applications. We have focused our resources on redefining the worldwide standard of care for injection techniques by making the experience more comfortable for the patient by reducing the anxiety and stress of receiving injections from the healthcare provider. Our computer-controlled injection systems make injections precise, efficient and virtually painless. Milestone&rsquo;s proprietary <i>DPS</i> Dynamic Pressure Sensing technology</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i>&reg;</i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Since our inception, we have engaged in pioneering proprietary, innovative, computer-controlled injection technologies and solutions for the medical and dental markets. We believe our technologies are p<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">roven and well established. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In 1997, Milestone Scientific released its first commercial product, the first computer-controlled local anesthesia delivery (C-CLAD) system, into the North American marketplace. This product was our proprietary, computer-con<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">trolled anesthetic delivery device, initially marketed as <i>The Wand</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">, a computer-controlled local anesthesia delivery (C-CLAD) device with a single-use disposable handpiece for the dental market, regulating and controlling the flow rate of anesthetics.&nbsp; This device was later rebranded commercially as the <i>CompuDent</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> System with the addition of several new features.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In 2001, Milestone Scientific was issued the initial United States Patent for <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> technology, entitled &ldquo;Pressure/Force Computer Controlled Drug Delivery Instrument with Exit Pressure,&rdquo; allowing the device to continuously monitor and control the exit pressure of medication and/or fluid during an injection. We call this innovation <i>DPS</i> Dynamic Pressure Sensing technology. This same technology also enables doctors to accurately identify different tissue types based on detecting exit pressure during an injection. Later in 2004, the United States Patent Office issued a &ldquo;Notice of Allowance&rdquo; for patent protection on two additional critical elements of our <i>CompuFlo</i> technology: &ldquo;Drug Delivery Instrument with Profiles&rdquo; and &ldquo;Pressure/Force Computer Controlled Drug Delivery with Automated Charging&rdquo;.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Given our experience and established brand awareness within the dental industry, we elected to focus <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">our initial product development efforts on the integration of <i>CompuFlo&rsquo;s DPS</i> Dynamic Pressure Sensing technology into our legacy dental injection system.&nbsp; In 2006, the FDA cleared the first system utilizing <i>CompuFlo&#39;s</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&nbsp;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">DPS Dynamic Pressure Sensing technology&mdash; the STA (Single Tooth Anesthesia) System and handpiece for use in the dental market, providing continuous real-time visual and audible pressure feedback from the tip of the needle while also precisely regulating the flow rate.&nbsp; Because of combining the ability to regulate the flow rate and monitor pressure at the tip of the needle, Milestone Scientific developed the industry&rsquo;s first solution for painlessly administering an intra-ligamnetary injection, i.e., &ldquo;<i>single-tooth anesthesia</i>&rdquo; which could be used as the only injection necessary for achieving dental anesthesia, foregoing the need to administer traditional injections such as a nerve branch block.&nbsp; In addition to <i>single-tooth anesthesia </i>the STA System can effectively perform all the traditional injections that dentist&rsquo;s routine gives but can provide them virtually pain free and with a numerous clinical advantage.&nbsp; This device, which also utilizes a disposable handpiece, is currently marketed by Milestone Scientific as the <i>Wand&nbsp;STA</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> System.&nbsp; </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Miles<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">tone Scientific believes our dental devices have set a new standard of care for dental injections. Our dental devices have been used to administer tens of millions of injections worldwide. Each of our devices has a related single use disposable handpiece, leading to a continuing revenue stream following sale of the device. At present, we sell disposable handpieces unique to our legacy product (the <i>Wand</i> and <i>CompuDent</i>) to users who have not upgraded to our current dental product, the <i>Wand&nbsp;STA </i>System. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Build<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ing on the success of our proprietary, core technology platform for dental injections, and desiring to pursue other growth opportunities, we have recently begun to expand the uses and applications of our proprietary, patented technologies to achieve greater operational efficiencies, enhanced patient safety and therapeutic adherence, patient satisfaction, and improved quality of care across a broad range of medical specialties. In June 2017, we received FDA regulatory clearance to sell the <i>CompuFlo</i> Epidural Computer Controlled Anesthesia System in the United States for certain medical applications. We intend to continue to expand the uses and applications of our <i>DPS</i> Dynamic Pressure Sensing technology.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">We believe that we and our technology solutions are wid<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ely recognized by key opinion leaders (i.e., academics, anesthesiologists and practicing dentists whose opinions are widely respected), industry experts and medical and dental practitioners as a leader in the emerging, computer-controlled injection industry. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Milestone Scientific remains focused on advancing efforts to achieve the following five primary objectives:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Establishing Milestone&rsquo;s <i>DPS</i> Dynamic Pressure Sensing technology platform as the standard-of-care in painless and precise drug delivery, providing for the first time objective visual and audible in-tissue pressure feedback, and continuing to expand platform applications;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Following obtaining successful FDA clearance of our first medical device in June 2017, Milestone Scientific is transitioning from a research and development organization to a commercially focused medical device company;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Commercializing our <i>CompuFlo</i> Epidural System, a transformative device for epidural anesthesia procedures; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Expanding the global footprint of our <i>CompuFlo</i> Epidural System by partnering with distribution companies worldwide; and</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Continuing the commercial launch of our proprietary cosmetic injection device for delivery of botulinum toxin (such as <i>Botox</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> and <i>Dysport</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">).</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Our dental devices are sold in the United States, Canada and in 53<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;other countries with FDA, CE and other clearances Since receiving FDA clearance in 2017 our epidural devices have had minimal sales in the United States and Europe.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><i><b>DPS</b></i><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b> Dynamic Pressure Sensing Technology</b></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><b>&reg;</b></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b>; Our Proprietary Core Technology Platform</b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Our first commercial product, our proprietary, computer-controlled anesthetic delivery device, initially marketed as <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>The Wand</i> later rebranded commercially as the <i>CompuDent</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> System, for the dental market, uses patented technology, including a single-use disposable handpiece, to control the flow rate of the anesthesia during the injection, allowing virtually painless injections for all dental procedures with optimal effectiveness. Over the years, the <i>CompuDent</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup> </sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">System has been widely heralded as a revolutionary device, considered one of the major advances in dentistry in the 20th Century, and has been favorably evaluated in more than 50 peers reviewed or independent clinical research reports.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Our next significant intellectual property advancement was a quantum improvement over our <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuDent</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i>&reg;</i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> System &ndash; the development of our proprietary <i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i>&reg;</i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Computer-Controlled Drug Delivery System with <i>DPS</i> Dynamic Pressure Sensing technology, an advanced and FDA-approved technology for the painless and accurate delivery of drugs, anesthetics and other medicaments into all tissue types, as well as for the aspiration of bodily fluids or previously injected substances. Its regulation and control of the flow rate continues to provide painless delivery benefits, while its innovative dynamic pressure sensing capability provides visual and audible in-tissue pressure feedback, identifying tissue types to the healthcare provider. This pressure feedback extends the benefit of painlessness from anesthetics with known viscosities to a wide range of liquid drugs and other medicaments with varying viscosities and flow rates. Such pressure feedback, part of our <i>DPS</i> Dynamic Pressure Sensing technology, also allows the healthcare provider to know when certain types of tissues have been penetrated and permits the healthcare provider to inject medicaments precisely at the desired location. Thus, real-time continuous pressure feedback can prevent the injection to tissue outside the intended target area, an important characteristic in the injection of chemotherapeutics and other toxic substances. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In addition to the ability to determine exit pressure In-Situ (in the injecti<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">on site tissue) at the tip of the needle, minimizing tissue damage (and eliminating the pain of the injection) because the flow rate and pressure of the injection are precisely controlled, <i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i>&reg;</i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> computer-controlled Drug Delivery Systems features a proprietary algorithm, which allow for the measurement of the exit pressure. These algorithms contain the critical components of specific drugs, parameters of needles, tubing and syringes and all other pertinent components for the safe and efficacious delivery of medications for all procedures. <i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i>&reg; </i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">technology also enables devices to provide a digital record of the time and volume of anesthetic or medicament injected.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Each CompuFlo<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i>&reg;</i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> System also includes a disposable injection handpiece that is extremely comfortable, light and easy to use, providing for precise tactile control during the injection, an electromechanical (computer-controlled) fluid delivery instrument and the ability to record data from the injection event. The pencil grip used with the handpieces provides the practitioner with enhanced tactile sense and accurate control and allows bi-directional rotation, eliminating needle deflection, resulting in a greater accuracy and success. The handpiece is vibration-free because it does not have a motor or electrical component in it and, since the handpiece does not look like a typical syringe, we believe it also reduces patient anxiety and offers the possibility of curing dental phobia of which an estimated 40&nbsp;million Americans suffer.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">As confirmed <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">by numerous noted medical and dental experts within academia and the clinical practice arenas, <i>CompuFlo </i>Systems using <i>DPS</i> Dynamic Pressure Sensing technology have the potential to greatly increase the safety and efficacy of many drug delivery procedures that currently rely upon the over 150-year-old hypodermic syringe technology and the tactile senses and delivery expertise of the administrator.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Devices using <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>DPS</i> Dynamic Pressure Sensing technology such as the <i>CompuFlo</i> System can be used to inject a wide variety of liquid medicaments as well as anesthetics. We believe our <i>CompuFlo</i> System avoids the negative side effects from the use of traditional hypodermic drug delivery injection devices, which are well documented in dental and medical literature and include risk of death, transient or permanent paralysis, pain, tissue damage and post-operative complications. Pain and tissue damage often result from uncontrolled flow rates and pressure created during the administration of drug solutions into human tissue. While several technologies have can control the flow rate, we believe our patented <i>DPS</i> Dynamic Pressure Sensing technology and <i>CompuFlo</i> Systems provide the ability to accurately and precisely control the pressure of the injection as well.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">We <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">believe our DPS Dynamic Pressure Sensing technology and <i>CompuFlo</i> Systems provides the following benefits:</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">minimizes the pain associated with injections, resulting in a more comfortable injection experience for the patient;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">provides visual and audible in-tissue pressure feedback, identifying the desired target location&nbsp;to the healthcare provider, extending the benefit of painlessness from anesthetics with known viscosities to a wide range of liquid drugs and other medicaments with varying viscosities and flow rates;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">allows the healthcare provider to know when the target location is present&nbsp;and permits the healthcare provider to inject medicaments precisely at the desired location; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">provides a digital record of the time and volume of anesthetic or medicament injected; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">minimizes tissue damage because the flow rate and pressure of the injection are controlled; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">provides an integrated injection database of algorithms that have been defined which allow for the measurement of the exit pressure, containing the critical components of specific drugs, parameters of needles, tubing and syringes and all other pertinent components for the safe and efficacious delivery of medications;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">the pencil grip used with the handpieces allows significant tactile sense and accurate control;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">new injections made possible with the technology eliminate collateral numbness;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">bi-directional rotation of the handpieces eliminates needle deflection resulting in greater success and more rapid onset of anesthesia in injections;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>the use of a single patient use, disposable handpieces minimize the risk of cross contamination; and</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 81pt; text-align: left; text-indent: -27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:3pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:22.5pt;">Our first system utilizing a DPS Dynamic Pressure Sensing technology platform was our S<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">TA System and related handpiece for the dental market, currently marketed as the <i>Wand&nbsp;STA System</i>. Another platform extension of our DPS Dynamic Pressure Sensing technology</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> platform is the <i>CompuFlo</i> Epidural System. In addition, we have developed platform extensions of our DPS Dynamic Pressure Sensing technology platform for intra-articular (for administering corticosteroids, hyaluronic acid and other medicaments into both major and minor joints for the alleviation of pain associated with arthritis and other deleterious joint conditions), cosmetic and veterinary applications. We intend to continue to develop and commercialize new applications of our DPS Dynamic Pressure Sensing Technology Platform as commercial line extensions. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:3pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:22.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><u><i><b>CompuFlo </b></i></u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u><b>Epidural Computer Controlled Anesthesia System</b></u></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:3pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:22.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In June 2017, we received FDA regulatory clearance to sell the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo</i> Epidural Computer Controlled Anesthesia System in the United States for certain medical applications. The <i>CompuFlo</i> Epidural Computer Controlled Anesthesia System obtained CE mark approval in September 2014, allowing it to be marketed and sold in most European countries and many other countries accepting CE approved devices. Because of receiving such FDA clearance, we are transitioning from a research and development organization to a commercially focused medical device company and beginning to commercialize our DPS Dynamic Pressure Sensing technology platform and related devices for medical applications.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:3pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:22.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i> CompuFlo</i> Epidural Computer Controlled Anesthesia System is one such platform extension of our DPS Dynamic Pressure Sensing technology platform, providing anesthesiologists and other healthcare providers the ability, for the first time, to quantitatively determine and document the pressure at the needle tip in real-time for proper needle placement in epidural procedures used for labor/delivery and back pain management. Our proprietary DPS Dynamic Pressure Sensing technology allows the <i>CompuFlo</i> Epidural Computer Controlled Anesthesia System to provide objective visual and audible in-tissue pressure feedback that allows anesthesiologists to identify and confirm placement in the epidural space. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:3pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:22.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Our <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i> </i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>Epidural</i> Computer Controlled Anesthesia System provides an objective tool that we believe consistently and accurately identifies the epidural space by detecting the difference in pressure between the ligamentum flavum and the intrafilamentary tissue. In studies, the <i>CompuFlo </i>Epidural System<i> </i>with <i>DPS</i> Dynamic Pressure Sensing technology has been shown to be effective in correctly identifying the epidural space. Knowing the precise location of a needle tip during an epidural injection procedure provides a measure of safety not presently available to doctors using conventional syringes. In the absence of fluoroscopy, identifying the epidural space by relying on the subjective perception of loss of resistance to saline requires a very long education period and learning curve and could result in morbidity and lack of efficacy. During back pain management epidural procedures, where fluoroscopy is commonly used, the <i>CompuFlo</i> Epidural Computer Controlled Anesthesia System allows the clinician to locate the epidural space, without using fluoroscopy, thereby protecting the patient and clinician from unnecessary exposure to radiation along with significantly reducing capital and operating costs. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:3pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:22.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">An abstract presente<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">d at the 45th Chilean Congress of Anesthesiology on November 11, 2017, entitled: Utilization of Dynamic Pressure Sensing&trade; in Epidural Procedures for Child Birth and representing the first formal presentation of our <i>CompuFlo</i> Epidural Computer Controlled Anesthesia System device in South America, summarized the results of a recent independent, investigator-led clinical study evaluating the use of Milestone&rsquo;s <i>CompuFlo</i> Epidural device in 50 labor and delivery patients, concluding that the epidural space was correctly identified in 100% of the patients. In addition, the epidural space was located&nbsp;on the first attempt with all the patients. There were no cases of accidental puncture of the dura, a common risk factor for traditional epidural procedures using the loss of resistance technique. We believe that this represents a significant benefit for the payors, physicians, and most importantly, the patients.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In July 2017, Milestone Scie<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ntific acquired certain patent rights and other intellectual property rights related to the computer-controlled injection device of APAD Octrooi B.V. and APAD B.V. This patent portfolio solidifies our patent rights for computer-controlled local anesthetic delivery (C-CLAD) technology and expands our proprietary rights and provides low cost and simple instrument&nbsp;to deliver epidural injections.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:3pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:-3pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:3pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:-3pt;"><u><i><b>CompuFlo </b></i></u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u><b>Intra-Articular Computer Controlled Injection System</b></u></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Another platform extension utilizing our <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">DPS Dynamic Pressure Sensing technology platform and <i>CompuFlo</i> System are our devices for administering corticosteroids and other medicaments into both major and minor joints for the alleviation of pain associated with arthritis and other deleterious joint conditions. As features of our DPS Dynamic Pressure Sensing technology, this device also precisely controls in-tissue pressure, increasing patient safety by reducing the risk of tissue damage and post-treatment pain related to excessive pressure that may occur during certain injections. Identification of the tissue, in which the needle tip is imbedded, is believed to be highly important in intra-articular injections and numerous organ, subcutaneous and intramuscular injections. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">We believe our intra-artic<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ular injection device is particularly efficacious for arthritis patients who are obliged to endure multiple painful injections annually for a lifetime. Often these injections are not efficacious because the doctor using a syringe fails to locate the intra-articular space or does not inject the appropriate volume of corticosteroids or other medicament into that space. Our <i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup> System</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> has been shown successful in an independent animal study in administering medicaments into a certain intra-articular space using its computer-controlled pressure sensing capabilities. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The intra-articular device has obtained CE mark clearance and may be marketed and sold in most European countries and many other countries accepting CE approved devices. In December 2016, we <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">received notification from the FDA that our 510(k) applications for marketing approval of the intra-articular device did not demonstrate that the device was as safe and effective as legally marketed devices. We intend to submit a new 510(k) application that we believe will demonstrate substantial equivalency; however, we can provide no assurances of when, if ever, we will receive FDA clearance for our intra-articular device.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><u><b>Cosmetic Botulinum Injection Device</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">The American Society of Plastic Surgeons (ASPS) reported that among the 14.2 million cosmetic minimally-invasive procedures performed in 2015, the top performed procedure, at 6.7 million procedures, was <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Botulinum Toxin Type A (commonly known as Botox) injection. Leveraging our experience in minimizing the pain of dental anesthetic injections, we established a joint venture in 2014 to develop and commercialize a device for the pain free injection of botulinum toxin. The joint venture entity, Milestone Advanced Cosmetic Systems, Inc., is owned 50% by us and 50% by Milestone China&nbsp;Company Limited (&ldquo;Milestone China&rdquo;), a company organized under the laws of Hong Kong and then owned 40% by Milestone Scientific, but as to which Milestone Scientific now only has an option to purchase up to 40% of Milestone China (as more particularly described below under Distribution and Marketing Arrangements). Milestone China contributed $900,000 of cash to the joint venture and we have provided a royalty-free license to utilize our technology to the joint venture to develop a botulinum toxin injection device.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In November 2017, we announced plans for the commercial launch of our proprietary cosmetic injection device using our DPS Dynamic Pressure Sensing technology platform and our <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo </i>Cosmetic System for delivery of botulinum toxin. Our proprietary cosmetic injection device features improved needle placement with a comfortable stylus grip, precise dosing, the same technology platform that has made dental and epidural injections painless, and an intuitive touch-screen interface. Based on the positive outcomes of a series of multi-state human factor studies with targeted customers, we are moving&nbsp;towards the commercial launch of our cosmetic device and applying for marketing clearance&nbsp;in Europe (CE clearance), and United States (FDA clearance). Although the Company&rsquo;s instrument has&nbsp;progressed beyond the development stage, additional equity financing is necessary to fund the commercialization of the instrument. To this end, the Company is currently in the process of pursuing additional financing. However, the Company and Milestone China&nbsp;can provide no assurance that additional financing will be consummated on acceptable terms, or at all</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">We believe that the touch screen and other platform improvements embodied by our cosmetic device will form the basis for our ne<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">xt generation of devices.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 7.5pt;"><b>&nbsp;</b><u><b>Veterinary Nerve Block Anesthesia Device</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The effectiveness of our veterinary nerve block anesthesia device<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;(existing medical device)&nbsp;for such use was confirmed by a pilot study and final report completed by Cornell University, College of Veterinary Medicine. Additional studies with other universities are in process with respect to horses and small animals. We are exploring commercialization opportunities.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:15pt;margin-top:0pt;text-align:left;"><u><b>The Wand</b></u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u><i><b> </b></i></u><u><b>STA System</b></u></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.2pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">In 2006, we received FDA clearance for our <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>Wand&nbsp;STA </i>System and disposable handpiece, the first system utilizing <i>CompuFlo</i>&rsquo;s <i>DPS</i> Dynamic Pressure Sensing technology, for use in the dental market. The <i>Wand&nbsp;STA </i>System and handpiece continue to provide all of the benefits of the <i>CompuDent</i> System, allowing dentists to provide virtually painless injections for all dental procedures, including routine fillings, as well as more sophisticated implants, root canals and crowns, while better facilitating single tooth anesthesia (now generally performed with a high pressure spring loaded gun-like device), but also incorporates the &quot;pressure feedback&quot; elements of Milestone Scientific&#39;s patented <i>CompuFlo</i> System, thereby allowing dentists to administer injections accurately and painlessly into the periodontal ligament space, effectively anesthetizing a single tooth. Injections made by the <i>Wand&nbsp;STA </i>System eliminate collateral numbness of the tongue, lips and facial muscles and often hasten the onset of anesthesia by eliminating the need for&nbsp;mandibular blocks. The <i>Wand&nbsp;STA</i> also identifies intrafilamentary tissue, so dentists can find the precise location for <i>single tooth anesthesia</i>. This injection is of significant value in that it allows the dentist to profoundly anesthetize the tooth within one minute per root, versus up to 15-18 minutes for a block injection to take effect. The <i>Wand&nbsp;STA </i>System can perform all the injections that can be done with a conventional dental syringe, and in addition, we provide the ability to perform the following: the palatal-anterior superior alveolar, anterior middle superior alveolar and inferior alveolar nerve block. The <i>Wand&nbsp;STA </i>System achieves these injections predictably and reliably. To date, substantially all our revenue has been generated by the <i>Wand&nbsp;STA </i>System for dental applications. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Since its market i<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ntroduction in the spring of 2007, the <i>Wand&nbsp;STA </i>System has received favorable reviews and awards from the dental industry. In July 2007, noted industry publication Dentistry Today featured the <i>Wand&nbsp;STA </i>System as one of the &ldquo;Top 100 Products in 2007,&rdquo; helping to promote much broader recognition of the instrument and validating the <i>Wand&nbsp;STA </i>System&rsquo;s value proposition for dentists and patients, alike. In early 2008, Medical Device &amp; Diagnostic Industry magazine distinguished the <i>Wand&nbsp;STA </i>System as a 2008 Medical Design Excellence Award winner in the &ldquo;Dental Instruments, Equipment and Supplies&rdquo; product category. Of the 33 products to receive this coveted award, the <i>Wand&nbsp;STA </i>System was one of only two winning products that serve dental practitioners. In December 2008, Milestone Scientific continued to win broad acclaim for the <i>Wand&nbsp;STA </i>System by winning a &ldquo;Townie Choice Award&rdquo;. The &ldquo;Townie Choice&rdquo; awards were originally started by Dr. Howard Darran and Farran Media, publisher of Dentaltown Magazine, to assist dentists in making product purchasing decisions, and are considered the &ldquo;people&rsquo;s choice&rdquo; of the products and services available to the dental industry today. That same month, the <i>Wand&nbsp;STA </i>System was also named as a Dental Products Report &ldquo;Top 100 2008 Product of Distinction.&rdquo; Additionally, the <i>Wand&nbsp;STA </i>System was named one of Dentistry Today&rsquo;s &ldquo;Top 100 Products&rdquo; for the third consecutive year in 2010. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><u><b>Other Devices</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">At earlier stages of development are our products using <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo</i>&rsquo;s <i>DPS</i> Dynamic Pressure Sensing technology for less painful injections for use in rhinoplasty, colorectal surgery, podiatry and other disciplines. In the self-injectable market, there are many injectable drugs routinely self-administered in a home or office setting using spring loaded automatic injection devices by people who suffer from long term chronic conditions such as multiple sclerosis, rheumatoid arthritis, and other diseases of the auto immune system. We believe <i>CompuFlo</i>&rsquo;s <i>DPS</i> Dynamic Pressure Sensing technology, using pressure sensing capabilities, can serve as a painless subcutaneous injection method for these self-administered drugs. However, there can be no assurance that we will be able to successfully develop any such products, or that if developed, that we will be able to obtain FDA approval to market any such products, or even if we do obtain such FDA approval, that any such products will generate any revenue for us or be a commercial success.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10.5pt;margin-right:15pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10.5pt;margin-right:15pt;margin-top:0pt;text-align:left;"><b>Distribution and Marketing Arrangements</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">Our dental devices are sold in the United States, Canada, and in over 53<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;countries abroad. In June 2017, we received FDA regulatory clearance to sell our first medical device, the <i>CompuFlo</i> Epidural Computer Controlled Anesthesia System in the United States.&nbsp;</font>Since receiving FDA clearance in 2017 our epidural devices have had minimal sales in the United States and Europe.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><u><b>Dental Market </b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In the spring of 2009, Milestone Scientific signed a distribu<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">tion and marketing agreement with China National Medicines Corporation, dba Sinopharm. In early October 2012, the State Food and Drug Administration (&ldquo;CFDA&rdquo;) of the People&rsquo;s Republic of China approved the <i>Wand&nbsp;STA</i> System. However, the CFDA&rsquo;s approval of the <i>Wand&nbsp;STA</i> handpieces was not received until May 2014 and the distribution of these handpieces in China began in the fourth quarter of 2014. The distribution and marketing agreement with Sinopharm was terminated in September 2014. Proximate to that time, we entered into a new agreement with Milestone China to be our distributor for the <i>Wand&nbsp;STA</i> System and handpieces in China. Milestone Scientific then owned, but now has an option to purchase, forty (40%) percent of Milestone China (the &ldquo;Milestone China Shares&rdquo;). In June 2017, Milestone Scientific sold its Milestone China Shares to an unaffiliated United States domiciled purchaser for a promissory note secured by a pledge of the Milestone China Shares, and received a 10-year option to repurchase the Milestone China Shares at the same price as the purchase price paid for the Milestone China Shares within the first two years and at fair market value (as defined in such agreement) for the remainder of the 10-year term. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">As of March 2, 2018, the promissory note was in default. If Milestone Scientific exercises its rights as a secured party it may be obligated to return to the purchaser up to the $250,000 received for the Milestone China Shares as surplus. At this time Milestone Scientific has not received a response from the purchaser of the Milestone China Shares, Milestone Scientific has not recorded any financial benefit from the sale of Milestone China Shares to date.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In November 2012, Milestone Scientific si<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">gned an exclusive distributor and marketing agreement with a well-known U.S. domestic manufacturer and distributor, for the sale and distribution of the <i>Wand&nbsp;STA</i> System and handpieces in the United States and Canada. The marketing initiative included participation in United States and Canadian dental shows, as well as pediatric dental shows; an active advertising initiative targeting major dental publications; and direct mailing campaigns to over 150,000 dentists across the United States and Canada. This exclusive distributor and marketing agreement was converted to a non-exclusive agreement as of December 31, 2016.&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Beginning January 1, 2016, Milestone Scientific entered into a non-exclusive distribution agreement with<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Henry Schein. In June 2016, that agreement was replaced by a new agreement with Henry Schein providing for an exclusive distribution arrangement for our dental products in the United States and Canada by a newly formed marketing and sales group at Henry Schein. Under this arrangement, we have a semi-dedicated independent sales force visiting dentists. Henry Schein&rsquo;s exclusive products sales specialist team, which is comprised of 25 sales representatives and supported by over 1,000 field service representatives, will exclusively market and distribute the <i>Wand&nbsp;STA</i> System and handpieces, together with a select group of other devices in the United States and Canada. Our agreement with Henry Schein has minimum purchase orders to maintain exclusivity in the third through tenth years. We believe that this exclusive arrangement will be more effective than previous arrangements relying on Wand Dental&#39;s appearances at dental shows and catalog sales. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:3pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"><u><b>Medical Market </b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Having received FDA clearance to sell the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo </i>Epidural Computer Controlled Anesthesia System in June 2017, we are in discussions with a small number of regional and national distributors. Our immediate focus is on marketing our epidural device throughout Europe.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In February and March 2018 Milestone Scientific hired an Executive VP of Global Sales and Marketing and a Vice President of US Sales to fill a significant gap in our commercialization efforts of the CompuFlo Epidural System.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">We have entered into a limited number of distributor arrangements in Europe and the Middle East for our <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo </i>Epidural Computer Controlled Anesthesia System. Our distribution strategy is initially aimed at having KOLs use and accept the device and initiate their own studies.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: -9pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><u><b>Veterinary Market</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">We are exploring various commercialization opportunities.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>Patents and Intellectual Property</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific and its subsidiaries currently hold approximately 214 U.S. and foreign patents, and many patent applications. The Company<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s patents and patent applications relate to drug delivery methodologies, drug flow rate measurement, pressure/force computer-controlled drug delivery with exit pressure, dynamic pressure sensing, automated rate control, automated charging, drug profiles, audible and visual pressure/force feedback, tissue identification, drug delivery injection unit, drug drive unit for anesthetic, handpiece and injection device. Milestone Scientific and its subsidiaries also currently hold approximately 29 registered U.S. and foreign trademarks, including <i>CompuDent</i><sup>&reg;</sup><i>, CompuFlo</i><sup>&reg;</sup><i>, DPS Dynamic Pressure Sensing technology</i><sup>&reg;</sup><i>, Safety Wand</i><sup>&reg;</sup><i>, STA Single Tooth Anesthesia System</i><sup>&reg;</sup><i>, </i>and<i> The Wand</i><sup>&reg;</sup></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><i>&nbsp;</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific relies on a combination of patent, copyright, trade secret, and trademark laws and employee and third party non-disclosure agreements to protect its intellectual property rights. Despite the precautions taken by Milestone S<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">cientific to protect products, unauthorized parties may attempt to reverse engineer, copy, or obtain and use products and information that Milestone Scientific regards as proprietary, or may design products serving similar purposes that do not infringe on Milestone Scientific&rsquo;s patents. Milestone Scientific&rsquo;s failure to protect its proprietary information and the expenses of doing so could have a material adverse effect on our business, financial condition and results of operations.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">If Milestone Scientifi<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">c&rsquo;s products infringe upon patent or proprietary rights of others, we may be required to modify processes or to obtain licenses. There can be no assurance that Milestone Scientific would be able to do so in a timely manner, upon acceptable terms and conditions, or at all. The failure to do so could have a material adverse effect on our business, financial condition and results of operations.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Manufacturing</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">Milestone Scientific has informal arrangements with the manufacturer of the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>Wand&nbsp;STA</i> System, epidural and intra-articular devices and with one of the principal manufacturers of the handpieces for those items, respectively. Pursuant to these informal arrangements, our third-party manufacturers manufacture the <i>Wand&nbsp;STA</i> System under specific purchase orders without minimum purchase commitments, and at prices to be agreed upon in each such purchase order.</font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%; margin: 0pt; text-indent: 27pt;">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Our agreement with the principal manufacturer of handpieces includes pricing terms. Milestone Scientific has been supplied by the manufacturer of the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>Wand&nbsp;STA</i> System and its predecessor, the <i>CompuDent </i>System<i>,</i> since the commencement of production in 1998, and by the manufacturer of its handpieces since 2003. The manufacturer of our handpieces is in the People&rsquo;s Republic of China and the manufacturer of the device is in the United States. Changes to pricing of the <i>Wand&nbsp;STA</i> System by the manufacturer could have a material adverse effect on our financial condition, business and results of operations. Termination of the manufacturing relationship with any of these third-party manufacturers could significantly and adversely affect our ability to produce and sell the products. Though other alternate sources of supply for handpieces exist, Milestone Scientific would need to recover its existing tools or have new tools produced to establish relationships with new suppliers. Establishing new manufacturing relationships could involve significant expense and delay. Any curtailment or interruptions of the supply, whether as a result or termination of the relationship, would have a material adverse effect on our financial condition, business and results of operations.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Competition</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">Now, there is no subcutaneous drug delivery platform or device on the market regulating the flow rate <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>and </i>pressure of an injection capable of delivering a painless injection at the desired location like Milestone Scientific&rsquo;s proprietary, patented devices having our <i>DPS</i> Dynamic Pressure Sensing technology. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s devices compete based on their performance characteristics and the benefits provided to the practitioner, patient and the business operations. Clinical studies have shown that our devices reduce fear, pain and anxiety for many patients, and Milestone Scientific believes that they can reduce practitioner stress levels, as well. Other computer-controlled local anesthesia delivery (C-CLAD) options are the Quicksleeper and SleeperOne, from Dental Hi Tec, and the Comfort Control Syringe by Dentsply. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">The Quicksleeper was invented in France by Dr. Alain Villette in 1991. It i<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">s marketed as the only local anesthetic delivery device in France that allows the ability to perform all intraoral local anesthetic injection techniques, including osteocentral anesthesia, quickly and without failure. The extra feature that gives the Quicksleeper this ability is a built-in motor in the syringe/handpiece that renders the syringe both an injector and a perforator of bone. That is, the handpiece of the Quicksleeper can perform an intraosseous injection via a motor driven perforation of the cortical plate of bone. A standard dental needle that attaches to the syringe spins as the motor rotates the handpiece thus acting as a perforator. However, the handpiece is relatively heavy, weighing 240 g. as compared to a standard syringe that weighs 80 g. Injection speed increases during the injection, but the operator cannot control when the injection speed increases.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">Another computer-controlled injection instrument is called the Comfort Control Syringe or CCS. In the early 1990s, Dr. Mark Smith, a dentist from Ontario, Canada, invented a device that he incorporated into his <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">practice as the local anesthetic delivery method. After perfecting the system, he released the rights of this device to Dentsply. In this system, many of the functions of the computer can be controlled directly from the syringe during the injection process. The base unit allows the dentist to program one of five different injections by pressing a single button. The five buttons marked on the base unit are block, infiltration, PDL, intraosseous and palatal. Each of these injections has a specific corresponding rate of local anesthetic delivery associated with it. The CCS enables a wide range of injection speeds controlled by the operator and the ability to control the computer directly from the syringe, but, since the CCS computer can be controlled by hand, the syringe must contain a certain amount of electronic equipment and this adds bulk to its circumference. The circumference of the CCS syringe is 112mm compared to 36mm for a traditional syringe, and 17mm for the <i>Wand&nbsp;STA</i> System. In addition, because of the electronics in the syringe, the operator will feel a slight amount of vibration in the syringe while the injection occurs. This will not affect the anesthesia, but it certainly is a feeling that is different from the traditional syringe or the <i>Wand&nbsp;STA</i> System, which both have no such vibration. The vibration in the Quicksleeper is minimal. This instrument is no longer being marketed.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The newest competition is the Calajet instrument. This instrument is&nbsp;manufactured in Europe and has been very slow to grow market acceptances. It recently began marketing in the USA with similar result. The instrument is a higher price than the Wand STA and does not provide the DPS software. Although a competitor, without a substantial distribution network&nbsp;this instrument will have a difficult time to be successful in the USA.</p>

<p style="margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s proprietary, patented devices with its <i>DPS</i> Dynamic Pressure Sensing technology platform also compete with disposable and reusable syringes that generally sell at lower prices and that use established and well-understood methodologies in both the dental and medical marketplaces. </font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">Rapid technological change and research may affect our products. Current or new competitors could, at any time, intr<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">oduce new or enhanced products with features that render our products less marketable or even obsolete. Therefore, Milestone Scientific must devote substantial efforts and financial resources to improve existing products, bring products to market quickly, and develop new products for related markets. In addition, the ability to compete successfully requires that Milestone Scientific establish an effective distribution network with a strong marketing plan. Any new products must be first approved by applicable regulatory authorities before they may be marketed. Milestone Scientific cannot assure that it can compete successfully, that competitors will not develop technologies or products that render our products less marketable or obsolete, or, that Milestone Scientific will succeed in improving its existing products, effectively develop new products, or obtain required regulatory approval for those products. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>Government Regulation</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">The manufacture and sale of medical devices and other medical products are su<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">bject to extensive regulation by the FDA pursuant to the U.S. Food, Drug and Cosmetic Act (&ldquo;FDC Act&rdquo;), and by other federal, state and foreign authorities. Under the FDC Act, medical devices must receive FDA clearance before they can be marketed commercially in the United States. Some medical products must undergo rigorous pre-clinical and clinical testing and an extensive FDA approval process before they can be marketed. These processes can take many years and require the expenditure of substantial resources. The time required for completing such testing and obtaining such approvals is uncertain, and FDA clearance may never be obtained. Delays or rejections may be encountered based upon changes in FDA policy during the period of product development and FDA regulatory review of each product submitted. Similar delays also may be encountered in other countries. Following the enactment of the Medical Device Amendments to the U.S. Food, Drug and Cosmetic Act in May 1976, the FDA classified medical devices in commercial distribution into one of three classes. This classification is based on the controls necessary to&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">reasonably ensure the safety and effectiveness of the medical devices. Class I devices are those devices whose safety and effectiveness can reasonably be ensured through general controls, such as adequate labeling, pre-market notification, and adherence to the FDA<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Quality Instrument Regulation (&ldquo;QSR&rdquo;), also referred to as &ldquo;Good Manufacturing Practices&rdquo; (&ldquo;GMP&rdquo;) regulations. Some Class I devices are further exempted from some of the general controls. Class II devices are those devices whose safety and effectiveness reasonably can be ensured using special controls, such as performance standards, post-market surveillance, patient registries, and FDA guidelines. Class III devices are those which must receive pre-market approval by the FDA to ensure their safety and effectiveness. Generally, Class III devices are limited to life-sustaining, life-supporting or implantable devices.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Pre-market Notification, the manufacturer or distributor may not place the device into commercial distribution until an order is issued by the FDA. By regulation, the FDA has no specific time limit <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">by which it must respond to a 510(k) Pre-market Notification. Currently, the FDA typically responds to the submission of a 510(k) Pre-market Notification within 180 days. The FDA response may declare that the device is substantially equivalent to another legally marketed device and allow the proposed device to be marketed in the United States.&nbsp;</font>However, the FDA may determine that the proposed device is not substantially equivalent or may require further information, such as additional test data, before the<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> FDA is able to decide regarding substantial equivalence. Such determination or request for additional information could delay market introduction of products. If a device that has obtained 510(k) Pre-market Notification clearance is changed or modified in design, components, method of manufacture, or intended use, such that the safety or effectiveness of the device could be significantly affected, separate 510(k) Pre-market Notification clearance must be obtained before the modified device can be marketed in the United States. If a manufacturer or distributor cannot establish that a proposed device is substantially equivalent to a legally marketed device, the manufacturer or distributor will have to seek pre-market approval of the proposed device, a more difficult procedure requiring extensive data, including pre-clinical and human clinical trial data, as well as extensive literature to prove the safety and efficacy of the device.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">The FDA cleared the Wand, our <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuDent </i>System and its disposable handpieces, for marketing in the United States for dental applications in July 1996; the <i>CompuMed</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i><sup>&reg;</sup></i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> System for marketing in the United States for medical applications in May 2001; the <i>Safety Wand</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i><sup>&reg;</sup></i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> for marketing in the United States for dental applications in September 2003; the <i>Wand&nbsp;STA</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i><sup> </sup></i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">System for dental applications in August 2006; and our <i>CompuFlo </i>Epidural Computer Controlled Anesthesia System in June 2017. For us to commercialize other products in United States, Milestone Scientific would have to submit additional 510(k) applications to the FDA. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-indent: 27pt;">In 2017, the FDA reduced barrier to marketing clearance for certain dental devices. As<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;such the entry into the dental market for other manufactures of injection devices may increase. However, any new device will be very limited in sales volume without a significant distributor in the dental market.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">Though certain dental devices have received FDA marketing clearance, there can be no assurance that any of the other medical devices&nbsp;under development will obtain the required regulatory clearance in a timely manner, or at all. If regula<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">tory clearance of a product is granted, such clearance may entail limitations on the indicated uses for which the product may be marketed. In addition, modifications may be made to the products to incorporate and enhance their functionality and performance based upon new data and design review. There can be no assurance that the FDA will not request additional information relating to product improvements; that any such improvements would not require further regulatory review, thereby delaying the testing, approval and commercialization of product improvements; or, that ultimately any such improvements will receive FDA clearance.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">Compliance with applicable regulatory requirements is subject to continual review and will be monitored through periodic inspecti<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ons by the FDA. Later discovery of previously unknown problems with a product, manufacturer, or facility may result in restrictions on such product or manufacturer, including fines, delays or suspensions of regulatory clearances, seizures or recalls of products, operating restrictions and criminal prosecution.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">Milestone Scientific is subject to pervasive and continuing regulation by the FDA, whose regulations require manufacturers of medical devices to adhere to certain QSR requirements as defined by the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">FDC Act. QSR compliance requires testing, quality control and documentation procedures. Failure to comply with QSR requirements can result in the suspension or termination of production, product recall or fines and penalties. Products also must be manufactured in registered establishments. In addition, labeling and promotional activities are subject to scrutiny by the FDA and, in certain circumstances, by the Federal Trade Commission. The export of devices is also subject to regulation in certain instances.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">The Medical Device Reporting (&ldquo;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">MDR&rdquo;) regulation obligates us to provide information to the FDA on product malfunctions or injuries alleged to have been associated with the use of the product or in connection with certain product failures that could cause serious injury. If, because of FDA inspections, MDR reports or other information, the FDA believes that Milestone Scientific is not in compliance with the law, the FDA can institute proceedings to detain or seize products, enjoin future violations, or assess civil and/or criminal penalties against us, our officers or employees. Any action by the FDA could result in disruption of operations for an undetermined amount of time.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In September 2014 we received CE mark approval for the marketing of the <i>CompuFlo</i> Epidural Computer Controlled Anesthesia System, in each case allowing such product to be marketed in most European countries and many other countries accepting CE approved devices. In July 2003, Milestone Scientific obtained regulatory approval to sell the <i>CompuDent </i>System and its handpieces in Australia and New Zealand. As of May 2014, the <i>Wand&nbsp;STA </i>System was approved for sale in China.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:25.5pt;"><b>&nbsp;&nbsp;</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Employees</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">As of December 31, 2017, the Company had a total 14 full-time employees<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;consisting of two executive officers of Milestone Scientific. Milestone Scientific also has a consultant who serves as a Director of Clinical Affairs and a business development consultant. </font></p>

<p style="text-indent: 27pt;">None of our employees are subject to a collective bargaining agreement and we believe our employee relations are good.</p>

<p><b>Corporate Information</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">We were <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">organized in August 1989 under the laws of the State of Delaware. Our principal executive office is located at 220 South Orange Avenue, Livingston, New Jersey 07039 and our telephone number is (973) 535-2717. Our web address is www.milestonescientific.com. Information contained on or accessed through our website is not part of this prospectus supplement. Our common stock is listed on the NYSE American&nbsp;under the ticker symbol &ldquo;MLSS&rdquo;.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 15pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Item 1A. Risk Factors</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;font-variant:small-caps;margin:0pt 15pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The foll<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">owing factors may affect the growth and profitability of Milestone Scientific and should be considered by any prospective purchaser or current holder of our securities.&nbsp; Our business, financial condition, results of operations and stock price could be materially adversely affected by any of these risks.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>We have a history of operating losses that are expected to continue, and we are unable to predict the extent of future losses, whether we will generate significant revenues or whether we will achieve or sust<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ain profitability.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">We are a small, medical device company with a history of limited revenue and significant operating losses and our prospects must be considered considering the uncertainties, risks, expenses and difficulties frequently encountered by similarly situated companies.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; With only one exception (<i>i.e.,</i> 2013), we have generated net losses in all periods since the commencement of our operations, including operating losses of approximately $5.2&nbsp;million and $6.5 million for the years ended December 31, 2017 and 2016, respectively. Overall, at December 31, 2017, we had an accumulated deficit of approximately $78.6 million. We expect to make substantial expenditures and incur increasing operating costs in the future and our accumulated deficit will increase significantly as we undertake to commercialize our <i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><i><sup>&reg;</sup></i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Epidural Computer Controlled Anesthesia System.&nbsp; Our losses have had, and are expected to continue to have, an adverse impact on our working capital, total assets and stockholders&#39; equity.&nbsp; Because of the risks and uncertainties associated with product development, we are unable to predict the extent of any future losses, whether we will ever generate significant revenues or if we will ever achieve or sustain profitability</font></p>

<p style="margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>We require additional funding and may be unable to raise capital when needed, which may force us to <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">delay, curtail or eliminate commercialization efforts of our </font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i><b>CompuFlo</b></i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i><b>&reg;</b></i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b> Epidural Computer Controlled Anesthesia System</b></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i><b>.</b></i></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Our operations have consumed substantial amounts of cash since inception.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; During the years ended December 31, 2017 and 2016, net cash flow used in operations was approximately $ 1.2 million and approximately $5.4 million, respectively.&nbsp; We expect to continue to spend substantial amounts on product development and commercialization activities, including the commercialization of our recently FDA-approved <i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Epidural Computer Controlled Anesthesia System.&nbsp; Until such time, if ever, as we can generate a sufficient amount of product revenue and achieve profitability, we expect to seek to finance future cash needs through equity or debt financings or corporate collaboration and licensing arrangements.&nbsp; In addition, we may seek other alternatives to maximize the value of our intellectual property for dental applications, to focus more on, and finance, our medical applications.&nbsp; If we are unable to raise additional capital, we will have to delay, curtail or eliminate the commercialization of our <i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Epidural Computer Controlled Anesthesia System, our efforts to obtain FDA approval of our intra-articular device and/or our product development and other commercialization efforts.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Any future debt financing may involve covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, redeem our stock, make certain investments and engage in certain merger, consolidation or asset sale transactions, among other restrictions.&nbsp; In addition, if we raise additional funds through licensing arrangements or the disposition of any of our assets, it may be necessary to relinquish potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Relying <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">exclusively on third parties to manufacture our products, changes in our informal manufacturing arrangements made by the manufacturer of our devices and disruptions at the manufacturing facility of our manufacturer exposes us to risks that may harm our business.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">We have limited internal experience in manufacturing operations and have not historically established our own manufacturing facilities.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; We currently lack the internal resources to manufacture any of our products, including our <i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i>&reg;</i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Epidural Computer Controlled Anesthesia System.&nbsp; At present, we have an informal arrangement with the manufacturer of our products.&nbsp; While we have more than one manufacturer of the hand pieces for our devices, we only have a single manufacturer manufacturing our devices.&nbsp; Our current arrangement with such sole source of supply is on a purchase order by purchase order basis.&nbsp; As a result, we do not have price protection or a supply commitment for our devices.&nbsp; If the manufacturer insists on a material change in terms or determines to discontinue manufacture of our devices, it could have an adverse effect on our financial condition and results of operation.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">14</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">An operational disruption in the facility of the manufacturer of our devices could negatively impact production<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> and our financial results.&nbsp; The occurrence of a natural disaster, such as a hurricane, tropical storm, earthquake, tornado, severe weather, flood, fire or other unanticipated problems such as labor difficulties, equipment failure or unscheduled maintenance could cause operational disruptions of varied duration.&nbsp; These types of disruptions could materially adversely affect our financial condition and results of operations to varying degrees dependent upon the facility, the duration of the disruption, our ability to shift business to another facility or find alternative sources of supply.&nbsp; Any losses due to these events may not be covered by our existing insurance policies or may be subject to certain deductibles.&nbsp; Given our current manufacturing relationships, it is possible that our manufacturing requirements may exceed the available supply allotments under our existing agreements.&nbsp; Our anticipated future reliance on third-party manufacturers exposes us to the following additional risks:</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited, and the FDA must approve any replacement contractor.&nbsp; This approval would require new testing and compliance inspections. &nbsp;In addition, a new manufacturer would have to develop substantially equivalent processes for production of our products.</font></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 81pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify; text-indent: -18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9679;&nbsp; &nbsp;Contract manufacturers might be unable to manufacture our products in the volume and of the quality required to meet our clinical and commercial needs.</font></p>

<p style="margin: 0pt 0pt 0pt 81pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 81pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify; text-indent: -18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9679;&nbsp; &nbsp;Contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute our products.</font></p>

<p style="margin: 0pt 0pt 0pt 81pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 81pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify; text-indent: -18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9679;&nbsp; &nbsp;Contract manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state agencies to ensure strict compliance with current good manufacturing practice and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#39; compliance with these regulations and standards and our manufacturers may be found to be in noncompliance with certain regulations, which may impact their ability to manufacture our product.</font></p>

<p style="margin: 0pt 0pt 0pt 81pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 81pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify; text-indent: -18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9679;&nbsp; &nbsp;If any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the intellectual property rights to the innovation.&nbsp; We may be required to pay fees or other costs for access to such improvements</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:4.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Each</font> of these risks could delay the commercialization of our <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i>&reg;</i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Epidural Computer Controlled Anesthesia System, limit our available supply of The Wand</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;STA for dental applications, cause damage to our reputation, result in higher costs and/or deprive us of potential product revenues.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>We depend on two principal manufacturers. If we cannot maintain our existing relationships or develop new ones, we may have to cease operations.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">Milestone Scientific and its subsidiary has informal arrangements with the manufacturer of the Wand STA Instrument, CompuDent<font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">,&nbsp;CompuMed</font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;CompuFlo Epidural, and CompuFlo Intra-Articular and with one of the principal manufacturers of the handpieces, for those items, respectively. Pursuant to the informal arrangements, they manufacture these devices and handpieces under specific purchase orders without minimum purchase commitments. Milestone Scientific has a manufacturing agreement with one of the principal manufacturers, which is a related party, of its handpieces pursuant to which they manufacture products under specific purchase orders but without minimum purchase commitments. Milestone Scientific has been supplied by the manufacturer of the Wand STA Instrument, CompuDent</font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">,&nbsp;CompuMed</font><font style="font-family:'Times New Roman', Times, serif;font-size:12pt;"><sup>&reg;</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;CompuFlo Epidural and CompuFlo Intra-Articular devices since the commencement of production in 1998, and the manufacturer of its handpieces since 2003.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">However, termination of the manufacturing relationship with any of these manufacturers could significantly and adversely affect our ability to produce and sell these products. Though other alternate sources of supply for handpieces exist, Milestone Scientific would need to recover its existing tools or have new tools produced to establish relationships with new suppliers. Establishing new manufacturing relationships could involve significant expense and delay. Any curtailment or interruptions of the supply, whether as a result or termination of the relationship, would have a material adverse effect on our financial condition, business and results of operations.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Issues with product quality c<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ould have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">In general, our success depends upon the quality of our products.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Quality management plays an essential role in meeting customer requirements, preventing defects, improving our products and services and assuring the safety and efficacy of our products.&nbsp; Our future success depends on our ability to maintain and continuously improve our quality management program.&nbsp; A quality or safety issue may result in adverse inspection reports, warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses.&nbsp; An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully launching new products.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>We may be subject to product liability claims that are not f<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ully covered by insurance and that could put Milestone Scientific under financial strain.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Milestone Scientific could be subject to claims for personal injury from the alleged malfunction or misuse of the dental and medical products. While Milestone Scien<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">tific carries liability insurance that is believed to be adequate, there is no assurance that the insurance coverage will be sufficient to pay such claims should they be successful. A partially or completely uninsured claim, if successful and of significant magnitude, could have a material adverse effect on our business, financial condition and results of operations.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>If physicians do not accept nor use our </b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i><b>CompuFlo</b></i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i><b>&reg;</b></i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b> Epidural Computer Controlled Anesthesia System, our ability to generate revenue from sales will be materially impaired.</b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Although the FDA has cleared our application to begin marketing the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i>&reg;</i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Epidural Computer Controlled Anesthesia System, this is no assurance that physicians, hospitals, clinics and other health care providers will accept and use it.&nbsp; Acceptance and use of the <i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i>&reg;</i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Epidural Computer Controlled Anesthesia System will depend on many factors including:</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; perceptions by members of the health care community, including physicians, about the safety and effectiveness of our product;</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cost-effectiveness of our product relative to competing products and systems;</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convenience, ease of use and reliability of our product relative to competing products and systems;</font>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patient satisfaction;</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; product availability as well as, manufacturer warranty, maintenance, and customer and technical support;</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; availability of reimbursement for our product from government or other healthcare payers; and</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Because we expect sales of the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo</i></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup><i>&reg;</i></sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Epidural Computer Controlled Anesthesia System to generate substantially all our medical product revenues in the near-term, the failure of this product to find market acceptance would harm our business and could require us to seek additional financing or make such financing difficult to obtain on favorable terms, if at all.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Developments by competitors may render our products or technologies obsolete or <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">non-competitive.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The medical device industry is intensely competitive and subject to rapid and significant technological change.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; We expect that other companies (or individuals), whether located in the United States or abroad, will pursue the development of alternative injection-based or imaging-based systems that will compete with our products.&nbsp; Many of these potential competitors have substantially greater capital resources, larger research and development staffs and facilities, longer product development history in obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do.&nbsp; These companies also compete with us to attract qualified personnel and parties for acquisitions, joint ventures or other collaborations.&nbsp; As a result, we may not be able to compete effectively against these companies or their products.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">16</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>If we are unable to adequately protect our patents, trade secrets and other proprietary rights, if our patents are challenged or if our provisional patent applica<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">tions do not get approved, our competitiveness and business prospects may be materially damaged.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Intellectual property rights, including patents, trade secrets, confidential information, trademarks, trade names and trade dress, are important to our busin<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ess.&nbsp; We will endeavor to protect our intellectual property rights in key jurisdictions in which our products are produced or used and in jurisdictions into which our products are imported.&nbsp; Our success will depend to a significant degree upon our ability to protect and preserve our intellectual property rights.&nbsp; However, we may be unable to obtain or maintain protection for our intellectual property in key jurisdictions.&nbsp; Although we own and have applied for patents and trademarks throughout the world, we may have to rely on judicial enforcement of our patents and other proprietary rights.&nbsp; Our patents and other intellectual property rights may be challenged, invalidated, circumvented and rendered unenforceable or otherwise compromised.&nbsp; A failure to protect, defend or enforce our intellectual property could have an adverse effect on our financial condition and results of operations.&nbsp; Similarly, third parties may assert claims against us and our customers and distributors alleging our products infringe upon third party intellectual property rights.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">We believe that the intellectual property underlying our products is a competitive advantage.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; We rely on a combination of patent rights, trade secrets and nondisclosure and non-competition agreements to protect our proprietary intellectual property, and we will continue to do so.&nbsp; There can be no assurance that our patents, trade secret policies and practices or other agreements will adequately protect our intellectual property.&nbsp; Our issued patents may be challenged, found to be over-broad or otherwise invalidated in subsequent proceedings before courts or the U.S. Patent and Trademark Office.&nbsp; Even if enforceable, we cannot provide any assurances that they will provide significant protection from competition.&nbsp; The processes, systems, and/or security measures we use to preserve the integrity and confidentiality of our data and trade secrets may be breached, and we may not have adequate remedies resulting from such breaches.&nbsp; In addition, our trade secrets may otherwise become known or be independently discovered by competitors.&nbsp; There can be no assurance that the confidentiality, nondisclosure and non-competition agreements with employees, consultants and other parties with access to our proprietary information to protect our trade secrets, proprietary technology, processes and other proprietary rights, or any other security measures relating to such trade secrets, proprietary technology, processes and proprietary rights, will be adequate, will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge.&nbsp; To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">If we must take legal action to protect, defend or enfor<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ce our intellectual property rights, any suits or proceedings could result in significant costs and diversion of our resources and our management&rsquo;s attention, and we may not prevail in any such suits or proceedings.&nbsp; A failure to protect, defend or enforce our intellectual property rights could have an adverse effect on our results of operations.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>We could lose our market advantage earlier than expected.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">We believe that our products represent a significant improvement over any existing drug delivery injection system in use today.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; However, this competitive advantage can evaporate quickly if we are not able to commercialize our products quickly.&nbsp; In the medical device industry, the majority of an innovative product&rsquo;s commercial value is realized during the early stages of commercialization, before competing products are developed.&nbsp; Our market advantage is based, in part, on patent rights and the need for new competing products and systems to obtain regulatory approval before they can be commercialized.&nbsp; The scope of our patent rights may be limited and may also depend on the availability of meaningful legal remedies.&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Our failure to adequately protect our intellectual property rights, through patents or otherwise, or limitations on the use or loss of such rights, could have a material adverse effect on our ability to prevent the commercialization of <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">competing anesthetic delivery systems.&nbsp; In some countries, basic patent protections for our products may not exist because certain countries did not historically offer the right to obtain specific types of patents and/or we (or our licensors) did not file in those markets.&nbsp; In addition, the patent environment can be unpredictable, and the validity and enforceability of patents cannot be predicted with certainty.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>Third parties could obtain patents that may require us to negotiate licenses to commercialize our technologies, and we cannot assure you that the required licenses would be available on reasonable terms or at all.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">Third parties may claim that one or more aspects of our technologies or products may infringe on their intellectual property rights.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; </font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">17</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Our computer-controlled anesthesia systems are complex systems and numerous U.S. and foreign patents and pending patent applications owned by third parties exist in fields that relate to the development and commercialization of drug delivery systems.&nbsp; In addition, many companies have employed intellectual property litigation as a strategy to gain a competitive advantage.&nbsp; It is possible that infringement claims may occur as the number of products and competitors in our market increases.&nbsp; In addition, to the extent that we gain greater visibility and market exposure as a public company, we face a greater risk of being the subject of intellectual property infringement claims.&nbsp; We cannot be certain that the conduct of our business does not and will not infringe intellectual property or other proprietary rights of others in the U.S. and in foreign jurisdictions.&nbsp; If any of our computer-controlled anesthesia systems are found to infringe third party patent rights, we could be prohibited from manufacturing and commercializing the infringing technology unless we obtain a license under the applicable third-party patent and pay royalties or are able to design around such patent.&nbsp; We may be unable to obtain a license on terms acceptable to us, or at all, and we may not be able to redesign the system to avoid infringement.&nbsp; Even if we can redesign our products or processes to avoid an infringement claim, our efforts to design around the patent could require significant time, effort and expense and ultimately may lead to an inferior or costlier product.&nbsp; Any claim of infringement by a third party, even those without merit, could cause us to incur substantial costs defending against the claim and could distract our management from our business.&nbsp; Furthermore, if any such claim is successful, a court could order us to pay substantial damages, including compensatory damages for any infringement, plus prejudgment interest and could, in certain circumstances, treble the compensatory damages and award attorney fees.&nbsp; These damages could be substantial and could harm our reputation, business, financial condition and operating results.&nbsp; A court also could enter orders that temporarily, preliminarily or permanently prohibit us, our licensees, if any, and our customers from making, using, selling, offering to sell or importing one or more of our products or using our proprietary technologies or processes, or could enter an order mandating that we undertake certain remedial activities.&nbsp; Any of these events could seriously harm our business, operating results and financial condition.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>We are exposed to the risks inherent in international sales and operations.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:18pt;">In 2017, export sales outside of the United States made up approximately 57% of our total sales, and we sell our products to cust<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">omers in approximately 53&nbsp;countries.&nbsp; We have exposure to risks of operating in many foreign countries, including:</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:18pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:70.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluctuations in foreign currency exchange rates, could increase the end user cost for instruments;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:70.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; restrictions on, or difficulties and costs associated with, the currency exchange from foreign&nbsp;countries to obtain US dollars;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:70.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulties and costs associated with complying with a wide variety of complex laws, treaties and regulations;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:70.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexpected changes in political or regulatory environments;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:70.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; political and economic instability;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:70.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; import and export restrictions and other trade barriers;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:70.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulties in obtaining approval for significant transactions;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:70.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: -27pt;"><b>Continued <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">instability in the credit and financial markets may negatively impact our ability to commercialize our products</font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i><b>.</b></i></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;">Financial markets in the United States, Canada, Europe and Asia continue to experience disruption, including, among other things, significant<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> volatility in security prices, declining valuations of certain investments, as well as severely diminished liquidity and credit availability.&nbsp; Business activity across a wide range of industries and regions continues to be reduced.&nbsp; As a small medical device company, we rely on third parties for several important aspects of our business, including contract manufacturing of products, distribution of our products and sales and marketing.&nbsp; These third parties may be unable to satisfy their commitments to us due to tightening of global credit from time to time, which would adversely affect our business.&nbsp; The continued volatility&nbsp;in the credit and financial market conditions may also negatively impact our ability to access capital and credit markets and our ability to manage our cash balance.&nbsp; While we are unable to predict the continued duration and severity of any adverse conditions in the United States and other countries, any of the circumstances mentioned above could adversely affect our business, financial condition, operating results and cash flow or cash position.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><i><b>&nbsp;</b></i></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">18</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Our ability to commercialize our produc<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ts will depend in part on the extent to which reimbursement will be available from governmental agencies, health administration authorities, private health maintenance organizations and health insurers and other healthcare payers.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;">Our ability to generate<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> revenues from our products will be diminished if the products sell for inadequate prices or hospitals or physicians are unable to obtain adequate levels of reimbursement for the cost they incur in connection with the use of the product.&nbsp; Significant uncertainty exists as to the reimbursement status of newly approved healthcare products.&nbsp; Healthcare payers, including Medicare, are challenging the prices charged for medical products and services.&nbsp; Government and other healthcare payers increasingly attempt to contain healthcare costs by limiting both coverage and the level of reimbursement for products.&nbsp; Insurance coverage may not be available, or reimbursement levels may be inadequate, to cover the charges for the use of such product.&nbsp; If government and other healthcare payers do not provide adequate coverage and reimbursement for any of our products, market acceptance of such product could be reduced.&nbsp; Prices in many countries, including many in Europe, are subject to local regulation and price controls.&nbsp; In the United States, where pricing levels for medical products, procedures and services are substantially established by third-party payors, including Medicare, if payors reduce the amount of reimbursement for a product, it may cause groups or individuals dispensing the product to discontinue use of the product, to substitute lower cost products even if the alternatives are less effective or to seek additional price-related concessions.&nbsp; These actions could have a negative effect on our financial results.&nbsp; The existence of direct and indirect price controls and pressures on our products could materially adversely affect our financial prospects and performance.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>We are subject to substantial domestic and international government regulation, including regulato<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ry quality standards applicable to our manufacturing and quality processes. Failure by us to comply with these standards could have an adverse effect on our business, financial condition or results of operations.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;">The FDA regulates the approval, manufactu<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ring and sales and marketing of many of our products in the United States. Significant government regulation also exists in other countries in which we conduct business. As a device manufacturer, we are required to register with the FDA and are subject to periodic inspection by the FDA for compliance with the FDA&rsquo;s Quality System Regulation requirements, which require manufacturers of medical devices to adhere to certain regulations, including testing, quality control and documentation procedures. In addition, the federal Medical Device Reporting regulations require us to provide information to the FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or, if a malfunction were to occur, could cause or contribute to a death or serious injury. Compliance with applicable regulatory requirements is subject to continual review and is rigorously monitored through periodic inspections by the FDA. In the European community, we are required to maintain certain ISO certifications to sell our products and must undergo periodic inspections by notified bodies to obtain and maintain these certifications. Failure to comply with current governmental regulations and quality assurance guidelines could lead to temporary manufacturing shutdowns, product recalls or related field actions, product shortages or delays in product manufacturing. Efficacy or safety concerns, an increase in trends of adverse events in the marketplace, and/or manufacturing quality issues with respect to our products could lead to product recalls or related field actions, withdrawals, and/or declining sales.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>We may be subject, directly or indirectly, to U.S. federal and state health care fraud and abuse and false claims laws and regulations. Prosecutions under such laws have increased in recent years and we may become subject to such <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">litigation. If we are unable to comply or have not fully complied with such laws, we could face substantial penalties.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;">Our operations are and will continue to be directly, or indirectly through our distributors, customers and health care professionals, subject to vari<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ous U.S. federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, federal False Claims Act, and the Foreign Corrupt Practice Act of 1977 (&ldquo;FCPA&rdquo;). These laws may impact, among other things, our proposed sales, and marketing and education programs. The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal health care program such as Medicare or Medicaid. Several courts have interpreted the statute&rsquo;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal health care covered business, the statute has been violated. The Anti-Kickback Statute is broad and, despite a series of narrow safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the health care industry. Penalties for violations of the federal Anti-Kickback Statute include criminal penalties and civil and administrative sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal health care programs. An alleged violation of the Anti-Kickback Statute may be used as a predicate offense to establish liability pursuant to other federal laws and regulations such as the federal False Claims Act. Many states have also adopted laws like the federal Anti-Kickback Statute, some of which apply to the referral of patients for health care items or services reimbursed by any source, not only the Medicare and Medicaid programs.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">19</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The federal False Claims <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from, the federal government. Suits filed under the False Claims Act, known as &ldquo;qui tam&rdquo; actions, can be brought by any individual on behalf of the government and such individuals, commonly known as &ldquo;relators&rdquo; or &ldquo;whistleblowers,&rdquo; may share in any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased significantly in recent years, causing greater numbers of medical device, pharmaceutical and health care companies to have to defend False Claim Act actions. The Affordable Care Act includes provisions expanding the ability of certain relators to bring actions that would have been previously dismissed under prior law. When an entity is determined to have violated the federal False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. The Deficit Reduction Act of 2005 encouraged states to enact or modify their state false claims act to be at least as effective as the federal False Claims Act by granting states a portion of any federal Medicaid funds recovered through Medicaid-related actions. Most states have enacted state false claims laws, and many of those states included laws with qui tam provisions.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">The Affordable Care Act includes provisions known as the Physician Payments Sunshine Act, which require manufacturers of drugs, biologics, devices and medical supplies covered under Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report to the Centers for Medicare and Medicaid Services for subsequent public disclosure. Manufacturers must also disclose investment interests held by physicians and their family members. Failure to submit the required information may result in civil monetary penalties of up to $1 million per year for knowing violations and may result in liability under other federal laws or regulations. Similar reporting requirements have also been enacted on the state level in the United States, and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with health care professionals. In addition, some states, such as Massachusetts and Vermont, impose an outright ban on certain gifts to physicians. These laws could affect our promotional activities by limiting the kinds of interactions we could have with hospitals, physicians or other potential purchasers or users of our products. Both the disclosure laws and gift bans will impose administrative, cost and compliance burdens on us. If we are found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, or an administrative action of suspension or exclusion from government health care reimbursement programs and the curtailment or restructuring of our operations.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">In addition, we are subject to the Foreign Corrupt Practices Act (&ldquo;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">FCPA&rdquo;) and other countries&rsquo; anti-corruption/anti-bribery regimes, such as the U.K. Bribery Act. The FCPA prohibits improper payments or offers of payments to foreign governments and their officials for obtaining or retaining business. Safeguards we implement to discourage improper payments or offers of payments by our employees, consultants, sales agents or distributors may be ineffective, and violations of the FCPA and similar laws may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation, business, results of operations and financial condition.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Excessive returns under our Exclusive Distribution and Supply Agreement with Henry Schein, Inc. could have a material adverse effec<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">t on our business, financial condition and results of operations.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In June 2016, we entered into a new exclusive distribution and supply agreement with Henry Schein pursuant to which <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">they were appointed as the exclusive distributor for our dental products in the United States and Canada.&nbsp; Under that agreement, Henry Schein has a right to return our products for full credit against the purchase price paid by them under limited circumstances in accordance with such agreement, including but not limited to, returns due to shipment error by us or factory defect.&nbsp; Excessive returns during any calendar year could have a material adverse effect on our business, financial condition and results of operations.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Changes in laws and regulations over which we have no control can significantly affect our business and results of operations.</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Any governmental entity that regulates our operations in the country in which they are located may enact new le<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">gislation or adopt new laws and regulations or policies at any time, and new judicial decisions may change the interpretation of existing legislation or regulations at any time in any of the countries in which our operations or projects are located. We have no control over any such changes. Any new laws or regulations governing our operations could have an adverse impact on our business, results of operations and prospects.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>We rely on the continuing services of our Interim Chief Executive Officer and Dire<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ctor of Clinical Affairs.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">We depend on the personal efforts and abilities of our Interim Chief Executive Officer and Director of Clinical Affairs.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Milestone Scientific maintains a key man life insurance policy in the amount of $1,000,000 on the life of its Interim Chief Executive Officer.&nbsp; However, the loss of his services or the services of our Director of Clinical Affairs, on whom we maintain no insurance, could have a materially adverse effect on our business results of operations and prospects.</font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">20</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Mil<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">estone Scientific is effectively controlled by a limited number of stockholders. </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s principal stockholders, Leonard Osser, Gian Domenico Trombetta and K. Tucker Andersen beneficially own approximately 39.68% of the issued and outstanding shares of common stock. As a result, they can exercise substantial control over our affairs and corporate actions requiring stockholder approval, including electing directors, selling all or substantially all our assets, merging with another entity or amending our certificate of incorporation. This de facto control could delay, deter or prevent a change in control and could adversely affect the price that investors might be willing to pay in the future for Milestone Scientific&rsquo;s securities.&nbsp; In addition, because of the concentration of ownership of our shares of common stock, our stockholders may from time to time, observe instances where there may be less liquidity in the public markets for our securities.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Adherence to Sarbanes-Oxley Act and SEC rules co<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ncerning internal controls may be costly and compliance could have an adverse effect on Milestone Scientific.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The management of Milestone Scientific has assessed the effectiveness of internal control over financial reporting as of December 31, 2017.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; In making this assessment, management used the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Milestone Scientific complied with Sarbanes-Oxley requirements to include in the annual report a management report on the effectiveness of the internal control over financial reporting.&nbsp; In 2017 and 2016, Milestone Scientific utilized an outside consultant on a quarterly basis to review compliance with the internal controls over financial reporting. This expense amounted to approximately $15,000 and $20,000 in 2017 and 2016, respectively and the cost is expected to continue in 2018.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>The market price of our common stock may be volatile and may fluctuate in a way that <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">is disproportionate to our operating performance.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our stock price may experience substantial volatility because of many factors, including:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sales or potential sales of substantial amounts of our common stock;</font></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; delay or failure in initiating our strategy to commercialize our CompuFlo&reg; Epidural Computer Controlled Anesthesia System;</font></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the success of our strategy to commercialize our CompuFlo&reg; Epidural Computer Controlled Anesthesia System;</font></p>

<p style="margin: 0pt 0pt 0pt 81pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: -63pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; announcements about us or about our competitors, including clinical trial results, regulatory approvals or new product introductions that could adversely impact the market acceptance or competitive advantages of our&nbsp;CompuFlo&reg; Epidural Computer Controlled Anesthesia System;</font></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; developments concerning our licensors or product manufacturers;</font></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; litigation and other developments relating to our patents or other proprietary rights or those of our competitors;</font></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; our ability to successfully develop and commercialize to products and services for the healthcare industry;</font></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; conditions in the medical device industries;</font></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; governmental regulation and legislation;</font></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; variations in our anticipated or actual operating results; and</font></p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in securities analysts&rsquo; estimates of our performance, or our failure to meet analysts&rsquo; expectations.</font></p>

<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; text-indent: -18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Many of these factors are beyond our control.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; The stock markets in general, and the market for small, medical device companies have historically experienced extreme price and volume fluctuations.&nbsp; These fluctuations often have been unrelated or disproportionate to the operating performance of these companies.&nbsp; These broad market and industry factors could reduce the market price of our common stock, regardless of our actual operating performance.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Sales of a substantial number of shares of our common stock, or the perception that <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">such sales may occur, may adversely impact the price of our common stock.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Almost all our 33,191,571 outstanding shares of common stock, as well as a substantial number of shares of our common stock underlying outstanding warrants, are available for sale <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">in the public market, either freely or pursuant to Rule 144 under the Securities Act of 1933, as amended.&nbsp; In addition, we have an effective S-3 registration statement on file with the SEC covering the sale by us of up to $30 million of securities, including common stock, preferred stock, debt, convertible debt and warrants.&nbsp; To date, we have sold $3,435,775 (2,452,900 shares) of common stock under that registration statement.&nbsp; Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely impact the price of our common stock</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>We have never paid and do not intend to pay cash dividends in the foreseeable future.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; As a result, capital appreciation, if any, will be your sole source of gain.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">We have never paid cash divi<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">dends on any of our capital stock and we currently intend to retain future earnings, if any, to fund the development and growth of our business.&nbsp; In addition, the terms of existing and future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Provisions in our certificate of incorporation, our by-laws and Delaware law might discourage, delay or prevent a change in control of our <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">company or changes in our management and, therefore, depress the trading price of our common stock.</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Provisions of our certificate of incorporation, our by-laws and Delaware law may have the effect of deterring unsolicited takeovers or delaying or prevent<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ing a change in control of our company or changes in our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interests.&nbsp; These provisions include:</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;the inability of stockholders to call special meetings; and the ability of our Board of Directors to designate the terms of and issue new series of preferred stock without stockholder approval, which could include the right&nbsp;to approve an acquisition or other change in our control or could be used to institute a rights plan, also known as a poison pill, that would work to dilute the stock ownership of a potential hostile acquirer, likely&nbsp;preventing acquisitions that have not been approved by our Board of Directors; and</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;limitations on filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company.&nbsp; &nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">In addition, Section 203 of the Delaware General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a bus<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">iness combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years, has owned 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.&nbsp; The existence of the forgoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock.&nbsp; They could also deter potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition.&nbsp; </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>If we fail to adhere to the strict listing requirements of NYSE American, we may be subject to delisting.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; As a result, our stock price may decline, and our common stock may be delisted.&nbsp; If our stock were no longer listed on NYSE American, the liquidity of our securities likely would be impaired.</font></b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">Our common stock currently trades on the NYSE American under the symbol &ldquo;MLSS&rdquo;. If we fail to adhere to NYSE American&#39;s strict listing criteria, including with respect to stock price, our market capitalization and stockholders<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo; equity, our stock may be delisted.&nbsp; This could potentially impair the liquidity of our securities not only in the number of shares that could be bought and sold at a given price, which may be depressed by the relative illiquidity, but also through delays in the timing of transactions and the potential reduction in media coverage.&nbsp; As a result, an investor might find it more difficult to dispose of our common stock.&nbsp; Any failure at any time to meet the continuing NYSE American listing requirements could have an adverse impact on the value of and trading activity in our common stock. Although we currently satisfy the listing criteria for NYSE American, if our stock price declines, we could be at risk of falling below NYSE American continuing listing criteria.</font></p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;1B. Unresolved Staff Comments </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">None.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item 2. Description of Property</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The headquarters for Milestone Scientific is located at 220 South Orange Ave, Livingston, New Jersey. Milestone Scientific leases approximately 7,625 square feet of office space. The lease term expires January 31, 2020 at a monthly cost of $12,522. Additionally, Milestone Scientific has other smaller insignificant leases ending through 2017. A third-party distribution and logistics center in Pennsylvania handles shipping and order fulfillment on a month-to-month basis. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">22</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific does not own or intend to invest in any real property. Milestone Scientific currently has no policy with respect to investments or interests in real estate, real estate mortgages or securities of, or interests in, persons primarily engaged in real estate activities.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;3. Legal Proceedings </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp;Milestone Scientific is not involved in any material litigation.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;4. Mine Safety Disclosure </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">Not applicable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>PART II </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;5. Market for Common Equity, and Related Stockholder Matters and Small Business Issuer Purchases of Equity Securities </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Market Information </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">On June 1, 2015, our common stock was listed on the NYSE American under the symbol &ldquo;MLSS&rdquo;. Prior to its listing on the NYSE American, Milestone<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s common stock traded on the OTC Market on the OTCQB market tier under the same symbol. The following table sets forth the high and low sales prices of Milestone&rsquo;s common stock for the periods presented. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="margin-left:4.5%;width:95.5%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:21.6%;">
			<p style="margin: 0pt; text-align: center; text-indent: 36.15pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><b>2017</b></p>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:10.3%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">HIGH</p>
			</td>
			<td style="width: 3.4%; text-align: center; vertical-align: bottom;">&nbsp;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:11%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">LOW</p>
			</td>
			<td style="width: 3.4%; text-align: center; vertical-align: bottom;">&nbsp;</td>
			<td style="vertical-align:bottom;width:21.1%;">
			<p style="margin: 0pt; text-align: center; text-indent: 36.15pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><b>2016</b></p>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:11.5%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">HIGH</p>
			</td>
			<td style="width: 3.8%; text-align: center; vertical-align: bottom;">&nbsp;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:13.7%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">LOW</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:21.6%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">First Quarter</p>
			</td>
			<td style="vertical-align:bottom;width:10.3%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$1.65 </font></p>
			</td>
			<td style="vertical-align:bottom;width:3.4%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:11%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$1.10 </font></p>
			</td>
			<td style="width: 3.4%; text-align: center; vertical-align: bottom;">&nbsp;</td>
			<td style="vertical-align:bottom;width:21.1%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">First Quarter</p>
			</td>
			<td style="vertical-align:bottom;width:11.5%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$2.54 </font></p>
			</td>
			<td style="width: 3.8%; text-align: center; vertical-align: bottom;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.7%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$ 1.27 </font></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:21.6%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Second Quarter</p>
			</td>
			<td style="vertical-align:bottom;width:10.3%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$1.80 </font></p>
			</td>
			<td style="vertical-align:bottom;width:3.4%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:11%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$1.20 </font></p>
			</td>
			<td style="width: 3.4%; text-align: center; vertical-align: bottom;">&nbsp;</td>
			<td style="vertical-align:bottom;width:21.1%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Second Quarter</p>
			</td>
			<td style="vertical-align:bottom;width:11.5%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$3.10 </font></p>
			</td>
			<td style="width: 3.8%; text-align: center; vertical-align: bottom;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.7%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$ 1.70 </font></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:21.6%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Third Quarter</p>
			</td>
			<td style="vertical-align:bottom;width:10.3%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$1.55 </font></p>
			</td>
			<td style="vertical-align:bottom;width:3.4%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:11%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$1.08 </font></p>
			</td>
			<td style="width: 3.4%; text-align: center; vertical-align: bottom;">&nbsp;</td>
			<td style="vertical-align:bottom;width:21.1%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Third Quarter</p>
			</td>
			<td style="vertical-align:bottom;width:11.5%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$2.96 </font></p>
			</td>
			<td style="width: 3.8%; text-align: center; vertical-align: bottom;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.7%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$ 1.94 </font></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:21.6%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Fourth Quarter</p>
			</td>
			<td style="vertical-align:bottom;width:10.3%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$1.60 </font></p>
			</td>
			<td style="vertical-align:bottom;width:3.4%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:11%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$0.91 </font></p>
			</td>
			<td style="width: 3.4%; text-align: center; vertical-align: bottom;">&nbsp;</td>
			<td style="vertical-align:bottom;width:21.1%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Fourth Quarter</p>
			</td>
			<td style="vertical-align:bottom;width:11.5%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$2.19 </font></p>
			</td>
			<td style="width: 3.8%; text-align: center; vertical-align: bottom;">&nbsp;</td>
			<td style="vertical-align:bottom;width:13.7%;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">$ 1.29 </font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;Holders </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As of April 2, 2018, we had approximately 130 stockholders of record of our common stock. We believe that we have approximately 2,185&nbsp;beneficial owners of our common stock. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Dividends</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The holders of common stock are entitled to receive such dividends as may be declared by Milestone Scientific&rsquo;s Board of Directors. Milestone Scientific has not paid and does not expect to declare or pay any dividends in the foreseeable future. For information regarding securities authorized under the equity compensation plan, see Item 12.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Sales of Unregistered Securities</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">See NOTE K<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&ndash; STOCKHOLDERS&rsquo; EQUITY, to the audited consolidated financial statements that accompany this Report for information regarding the issuance of unregistered securities. These issuances were exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;) and a legend restricting the sale, transfer, or other disposition of these shares other than in compliance with the Act was imprinted on stock certificates evidencing the shares. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">As of December 31, 2017, Milestone Scientific issued a total of 352,015 shares of its common stock as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 63pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9679;&nbsp; &nbsp;120,000 shares to the Board of Directors with a total value of $159,480;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 63pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9679;&nbsp;&nbsp;&nbsp;10,913 shares to an employee for compensation with a total value of $15,000; and</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 63pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&#9679;&nbsp;&nbsp;&nbsp;an aggregate of 410,729 shares to consultants for services rendered with a total value of $548,511.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In addition, as of July 13, 2017, pursuant to the Asset Purchase Agreement with APAD Octrooi B.V. and APAD B.V. (collectively, the &ldquo;Sellers&rdquo;), Milestone Scientific issued an aggregate of 1,646,358 shares of its common stock to the Sellers in consideration for certain patent rights and other intellectual property rights related to the Sellers&rsquo; computer-controlled injection instrument.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The foregoing shares were issued in reliance upon the exemptions from the registration requirements of the Securities Act of 1933, as amended (the &quot;Act&quot;), pursuant to Sections 4(a)(2), Section 4(a)(5) and/or Regulation D promulgated thereunder. A legend restricting resale, transfer, or other disposition of these shares other than in compliance with the Act was imprinted on the stock certificates evidencing such shares.</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">23</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="margin: 0pt;"><b>ITEM 6. Selected Financial Data</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific is a &ldquo;smaller reporting company&rdquo; as defined by Regulations S-K and as such, is not required to provide the information contained in this item pursuant to Regulation S-K.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>ITEM 7. Management<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following discussions of the financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this annual report. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. The actual results may differ materially from those anticipated in these forward-looking statements. See &quot;Risk Factors&quot; elsewhere in this Form 10-K.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>OVERVIEW</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Our common stock was listed on the NYSE American on June&nbsp;1, 2015 and trades under the symbol &ldquo;MLSS&rdquo;. We have developed a proprietary, computer-controlled anesthetic delivery instrument, using <i>The Wand&reg;</i>, a single use disposable handpiece. The instrument is marketed in dentistry under the trademark <i>CompuDent&reg;</i>, and <i>STA Single Tooth Anesthesia System&reg;</i> and in medicine under the trademark <i>CompuMed&reg;. CompuDent&reg;</i> is suitable for all dental procedures that require local anesthetic. <i>CompuMed&reg;</i> is suitable for many medical procedures regularly performed in plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, orthopedics and several other disciplines. The dental instruments are sold in the United States, Canada, and in over 53 other countries abroad. There have been no medical instruments sold in the United States and limited amounts sold internationally as of the reporting date. Certain of our&nbsp;medical instruments have obtained&nbsp;European CE&nbsp;mark approval and can be marketed and sold in most European countries. In June 2017, the FDA approved our 510(k) applications for marketing clearance in the&nbsp;United States of our <i>CompuFlo</i>&reg; Epidural Computer Controlled Anesthesia System.&nbsp;&nbsp;We are&nbsp;in the process of introductory meetings with medical device distributors within the United States and foreign markets.&nbsp; </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 15pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:15pt;margin-top:0pt;text-align:left;">In 2017, we remained focused on advancing efforts to achieve our<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;three&nbsp;primary objectives; those being:&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:-18pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp; Worldwide distribution of the C<i>ompuFlo</i>&reg; Epidural Computer Controlled Anesthesia System.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:-18pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Identify distributors in the United States for the Epidural instruments, now that FDA clearance has been received;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:-18pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp; Complete the Cosmetic device&nbsp;and obtain European Regulatory Approve (CE market clearance)</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:-18pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Wand STA Instrument Growth</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Since its market introduction in early 2007, the Wand STA Instrument and prior C-CLAD products have been used to deliver over&nbsp;66 million safe, effective and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the STA Instrument is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Global Distribution Network</b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><u><b>United States and Canadian Market </b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beginning January 1, 2016, Milestone Scientific entered into a non-exclusive distribution agreement with Henry Schein, Inc. (&ldquo;Henry Schein&rdquo;). In June 2016, that agreement was replaced with an exclusive distribution arrangement for our dental products for the United States and Canada with Henry Schein. Under this arrangement we have a semi-dedicated independent sales force visiting dentists. We believe that this arrangement will be more effective than previous arrangements which primarily relied upon&nbsp;appearances at dental shows and catalog sales.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To date, Henry Schein has endeavored to accomplish the goals set forth in the exclusive distribution agreement for&nbsp;<i>The Wand</i>&reg; STA instrument and handpieces, including training of its exclusive products sales specialists. Specifically, 25&nbsp;exclusive product sales specialists have now been fully trained as experts in the features, advantages and benefits of&nbsp;<i>The Wand</i>&reg; STA&nbsp;instrument and handpieces and all 25 are currently in the field selling the instrument. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Henry Schein also plans to train an additional customer service representative to support dentists across North America through its exclusive product sales customer call center, as business volume increases.&nbsp;&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">24</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><u><b>International Market </b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">On the global front, we have granted exclusive marketing and distribution rights for the Wand STA Instrument to select dental suppliers in various international regions in Asia, Africa, South America and Europe. They include Istrodent (Pty) Ltd.&nbsp;in South Africa and Unident AB in the Scandinavian countries of Denmark, Sweden, Norway and Iceland.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In October 2012, the State Food and Drug Administration (CFDA) of the People<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Republic of China approved our Wand&nbsp;STA<i> Single Tooth Anesthesia System&reg; </i>(STA System). In May 2014, the CFDA also approved the Wand STA handpieces for sale in China. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In September 2014, Milestone Medical received CE clearance to distribute their epidural and intra-articular instruments in the European Community (EU). Milestone Medical signed a distribution agreement in March 2015 with a medical distributor in Poland for the distribution of the epidural instrument. This distribution agreement was terminated in late 2016 due to the distributor&rsquo;s inadequate performance under the distribution agreement. Milestone Medical is continuing to pursue distributors for the instrument in the EU community.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp; &nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In June 2014, Milestone Scientific invested $1 million in Milestone China Ltd. (&ldquo;Milestone China&rdquo;) by contributing 772 STA Instruments to Milestone China for a 40% ownership interest. Milestone Scientific recorded this investment under the equity method of accounting. Milestone Scientific recorded a loss on its investment in Milestone China of&nbsp;$0 and $164,837&nbsp;as of December 31, 2017 and 2016, respectively exclusive of deferral of gross profit. Milestone Scientific&#39;s investment in Milestone China was $0 as of December 31, 2017 and December 31, 2016, respectively. Milestone Scientific incurred cumulative&nbsp;losses beyond its investment in Milestone China of $3,147,470&nbsp;and $1,124,350 as of December 31, 2017 and December 31, 2016, respectively, which have been suspended.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In June 2017, Milestone Scientific entered into an agreement for the sale of its interest in Milestone China (a forty (40%) percent interest) (the &ldquo;Milestone China Shares&rdquo;) to an unaffiliated United States domiciled purchaser and a 10-year option agreement to repurchase the Milestone China Shares. The purchase price for the Milestone China Shares was $1,400,000 of which $125,000 was paid in cash and $1,275,000 was paid by delivery of a non-interest bearing secured promissory note. The note is payable in quarterly installments of $125,000 until paid in full and is secured by the Milestone China Shares until full repayment.&nbsp; In addition, pursuant to such note, the purchaser is precluded from selling all or substantially all its assets prior to repayment of the note. The 10-year option agreement provides Milestone Scientific an option to repurchase the Milestone China Shares at $1,400,000 within the first two years and at fair market value (as defined in such agreement) for the remainder of the 10-year term. The transaction has been accounted for as a secured financing and Milestone Scientific will continue to account for its relationship with Milestone China under the equity method of accounting. A note receivable is presented on the Company&rsquo;s balance sheet, along with a deferral from financing transaction ($1,400,000). The carrying value of the forty (40%) percent investment at the transaction date was zero.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">The sale of the Milestone China Shares allows Milestone Scientific to continue to expand in the China market by supplying Milestone China with the STA Single Tooth Anesthesia System&reg; and related hand pieces, while eliminating the burden on Milestone Scientific&#39;s management as a 40% minority owner.&nbsp; Milestone Scientific believes that the sale will provide Milestone China with a new partner that may accelerate its penetration of the China market.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp; &nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">As of March 2, 2018, the promissory note was in default. If Milestone Scientific exercises its rights as a secured party it may be obligated to return to the purchaser up to the $250,000 received for the Milestone China Shares as surplus. At this time Milestone Scientific has not received a response from the purchaser of the Milestone China Shares, Milestone Scientific has not recorded any financial benefit from the sale of Milestone China Shares to date.</p>

<p style="margin: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">25</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; The following table shows a breakdown of Milestone Scientific&rsquo;s product sales (net), domestically and internationally, by business segment product category:</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 2.5%; margin-left: 2.5%;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 155.766px;">&nbsp;</td>
			<td colspan="9" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 494.234px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D5" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="9" id=".amt.D9" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D9" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 155.766px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 95.2344px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Dental </font></b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Medical </font></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total </font></b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Dental </font></b></b></p>
			</td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D7" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Medical </font></b></b></p>
			</td>
			<td id=".trail.D7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D9" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total </font></b></b></p>
			</td>
			<td id=".trail.D9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 155.766px;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1px;">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".symb.B5">&nbsp;</td>
			<td id=".amt.B5">&nbsp;</td>
			<td id=".trail.B5">&nbsp;</td>
			<td id=".lead.B6">&nbsp;</td>
			<td id=".symb.B6">&nbsp;</td>
			<td id=".amt.B6">&nbsp;</td>
			<td id=".trail.B6">&nbsp;</td>
			<td id=".lead.B7">&nbsp;</td>
			<td id=".symb.B7">&nbsp;</td>
			<td id=".amt.B7">&nbsp;</td>
			<td id=".trail.B7">&nbsp;</td>
			<td id=".symb.B9">&nbsp;</td>
			<td id=".amt.B9">&nbsp;</td>
			<td id=".trail.B9">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 155.766px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Domestic US/Canada</b></p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 1px;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B5" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B6" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B7" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".symb.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B9" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Instruments</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">914,495</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">914,495</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">930,873</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">930,873</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Handpieces</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">4,346,664</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">4,346,664</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,356,209</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,356,209</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">78,550</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">78,550</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">65,479</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">65,479</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 155.766px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">5,339,709</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">5,339,709</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,352,561</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,352,561</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 155.766px;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1px;">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".symb.B5">&nbsp;</td>
			<td id=".amt.B5">&nbsp;</td>
			<td id=".trail.B5">&nbsp;</td>
			<td id=".lead.B6">&nbsp;</td>
			<td id=".symb.B6">&nbsp;</td>
			<td id=".amt.B6">&nbsp;</td>
			<td id=".trail.B6">&nbsp;</td>
			<td id=".lead.B7">&nbsp;</td>
			<td id=".symb.B7">&nbsp;</td>
			<td id=".amt.B7">&nbsp;</td>
			<td id=".trail.B7">&nbsp;</td>
			<td id=".symb.B9">&nbsp;</td>
			<td id=".amt.B9">&nbsp;</td>
			<td id=".trail.B9">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>International Rest of the World</b></p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 1px;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B5" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B6" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B7" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".symb.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B9" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Instruments</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">1,427,016</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">1,427,016</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">1,185,908</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">1,185,908</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Handpieces</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,325,622</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,327,622</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,363,143</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">21,253</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,384,396</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">116,539</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">116,539</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">133,540</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">133,540</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 155.766px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,869,177</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,871,177</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,682,591</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">21,253</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,703,844</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 155.766px;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1px;">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".symb.B5">&nbsp;</td>
			<td id=".amt.B5">&nbsp;</td>
			<td id=".trail.B5">&nbsp;</td>
			<td id=".lead.B6">&nbsp;</td>
			<td id=".symb.B6">&nbsp;</td>
			<td id=".amt.B6">&nbsp;</td>
			<td id=".trail.B6">&nbsp;</td>
			<td id=".lead.B7">&nbsp;</td>
			<td id=".symb.B7">&nbsp;</td>
			<td id=".amt.B7">&nbsp;</td>
			<td id=".trail.B7">&nbsp;</td>
			<td id=".symb.B9">&nbsp;</td>
			<td id=".amt.B9">&nbsp;</td>
			<td id=".trail.B9">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>International China</b></p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 1px;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B5" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B6" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B7" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".symb.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B9" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Instruments</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">643,600</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">643,600</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,000,000</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,000,000</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Handpieces</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">1,425,600</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">1,425,600</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">1,425,600</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">1,425,600</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,800</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,800</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">-</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 155.766px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,071,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,071,000</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,425,600</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,425,600</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 155.766px;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1px;">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".symb.B5">&nbsp;</td>
			<td id=".amt.B5">&nbsp;</td>
			<td id=".trail.B5">&nbsp;</td>
			<td id=".lead.B6">&nbsp;</td>
			<td id=".symb.B6">&nbsp;</td>
			<td id=".amt.B6">&nbsp;</td>
			<td id=".trail.B6">&nbsp;</td>
			<td id=".lead.B7">&nbsp;</td>
			<td id=".symb.B7">&nbsp;</td>
			<td id=".amt.B7">&nbsp;</td>
			<td id=".trail.B7">&nbsp;</td>
			<td id=".symb.B9">&nbsp;</td>
			<td id=".amt.B9">&nbsp;</td>
			<td id=".trail.B9">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Total Product Sales</b></p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 1px;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B5" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B6" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B7" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".symb.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".amt.B9" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
			<td id=".trail.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">5,339,709</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">5,339,709</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,352,561</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,352,561</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International -Rest of World</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,869,177</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">2,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,871,177</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,682,591</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">21,253</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,703,844</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px none rgb(0, 0, 0); width: 155.766px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International -China</p>
			</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">2,071,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">2,071,000</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">3,425,600</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">3,425,600</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 155.766px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">11,279,886</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">2,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">11,281,886</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">10,460,752</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">21,253</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">10,482,005</td>
			<td id=".trail.9" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp; &nbsp; &nbsp; </font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific plans to support increased sales and marketing activity through our current distributors and through newly appointed distributors of the Wand STA instruments and handpieces in the international market. In the United States and Canada, Milestone Scientific will continue the utilization of independent hygienists for training individual practitioners and group practices domestically, refined and directed advertising to dental professionals, continue to develop Key Opinion Leaders (KOL) and support and broaden our global distribution network. Additionally, with the recent FDA marketing clearance for the epidural instrument, Milestone Scientific is initiating marketing and sales efforts in the US to establish medical sector distributors for the sale of this instrument</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In February and March 2018 Milestone Scientific hired an Executive VP of Global Sales and Marketing and a Vice President of US Sales to fill a significant gap in our commercialization efforts of the CompuFlo Epidural System.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Current Produc<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">t Platform</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">See Item 1. Description of Business.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b>Summary of Critical Accounting Policies and Significant Judgments and</b> <b>Estimates</b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific&#39;s discussion and analysis of the financial condition and results of operations is based upon its consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States (&quot;GAAP&quot;) and include the accounts of its wholly-owned and majority-owned subsidiaries including, Wand Dental, Milestone Advanced Cosmetic and Milestone Medical. Milestone Education is a variable interest entity of which Milestone Scientific is the primary beneficiary and is consolidated into Milestone Scientific&#39;s financial statements. All significant, intra-entity transactions and balances have been eliminated in the consolidation.&nbsp;&nbsp;&nbsp;</font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">26</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp; &nbsp; &nbsp; T</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">he preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, Milestone Scientific evaluates its estimates, including those related to accounts receivable, inventories, stock-based compensation and contingencies. Milestone Scientific bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not clear from other sources. Actual results may differ from those estimates under different assumptions or conditions.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; While significant accounting policies are more fully described in Note C&nbsp;to the consolidated financial statements included elsewhere in this report, Milestone Scientific believes that the following accounting policies and significant judgments and estimates are most critical in understanding and evaluating the reported financial results.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Assessment of our Ability to<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Continue as a Going Concern</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 18pt;">Our management has made various estimates in assessing our ability to continue as a going concern as of the report date of<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;our independent auditor&#39;s report included in this Form 10-K. These estimates include, an increase in the revenues generated by Wand Dental because of the new distribution agreement with Henry Schein, an increase in international revenue, (non-China) a reduction in our profit margins due to the nature of the distribution relationships with both Henry Schein and Milestone China, and reduction our selling, general and administrative costs for one-time expenses incurred during 2017. Based on this assessment, management believes that our cash on hand, accounts receivable and the anticipated revenues from the dental business will be sufficient to fund our business operations for at least the next 12 months from the filing date of this Form 10-K.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Accounts Receivable</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific sells a significant amount of its products on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most of credit sales are due within ninety days from invoicing. Milestone Scientific has not incurred any significant credit losses.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Inventories</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence and product expiration requirement and regulations.</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b>&nbsp;</b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Impairment of<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Long-Lived Assets</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Milestone Scientific reviews long-lived assets for impairment whenever events or circumstances (i.e. a triggering event) indicate that the carrying amounts may not be recoverable. The carrying value of the assets is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets. Milestone Scientific adjusts the net book value of an underlying asset if its fair value is determined to be less than its net book value. There have been no impairment indicators or triggering events and therefore there was no impairment as&nbsp;of December 31, 2017. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Revenue Recognition</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue from product sales is recognized, net of discounts and allowances to domestic distributors, on the date of shipment for substantially all shipments, since the shipment terms are FOB warehouse. Milestone Scientific recognizes revenue on date of arrival of the goods at the customer&#39;s location, where shipments are FOB destination. In all cases the price to the buyer is fixed and the collectability is reasonably assured. Further, Milestone Scientific has no obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Milestone Scientific&#39;s only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&nbsp;Devices and hand pieces are not bundled but rather sold separately and, as such, there are no multiple element determinations in connection with the revenue recognition</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">27</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Results of Operations</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following table sets forth for the consolidated results of operations for the year ended December 31, 2017 compared to 2016 as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results: </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 15pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 2.5%; margin-left: 2.5%;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="5" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Years Ended</p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 68%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating results:</p>
			</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2017</p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2016</p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net Sales</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">11,281,886</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">10,482,005</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of Sales</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">4,312,507</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">4,175,533</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Gross Profit</font></p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">6,969,379</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">6,306,472</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Selling, general, and administrative</font></p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">11,930,951</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">11,549,961</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Research &amp; development</font></p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">272,746</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">1,270,471</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating Loss</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,234,318</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,513,960</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other Expenses, net</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(135,235</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(780,529</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net Loss</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">(5,369,553</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">(7,294,489</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Net loss attributable to noncontrolling interest</font></p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">182,760</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,347,982</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to Milestone Scientific Inc.</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(5,186,793</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(5,946,507</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="5" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Years Ended</p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2017</p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2016</p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash flow:</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Net cash used in operating activities</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">(1,229,434</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">(5,398,581</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Net cash (used in) provided by investing activities</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">(199,175</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">8,206</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Net cash provided by financing activities</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">463,336</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">4,798,220</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 15pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Year ended December 31, 2017 compared to year ended December 31, 2016</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Net sales <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">for 2017 and 2016 were as follows:</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; border-collapse: collapse;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2017</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="1" id=".amt.D3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>% of Revenue</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2016</b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="1" id=".amt.D5" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>%<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Increase (Decrease) $</b></p>
			</td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="1" id=".amt.D7" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>% of Change</b></p>
			</td>
			<td id=".trail.D7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dental</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,279,886</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">99.98</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,460,752</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">99.80</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">819,134</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.83</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Medical</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">2,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">0.02</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,253</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.20</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19,253</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-90.59</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total Sales</font></p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,281,886</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100.00</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,482,005</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100.00</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">799,881</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.63</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 18pt;">Consolidated revenue for the twelve months ended December 31, 2017 and 2016 were approximately $11.3 million and $10.5 million, respectively. Dental revenue for the twelve months ended December 31, 2017 and 2016 were approximately $11.3<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;million and $10.5 million, respectively. Dental revenues increased by approximately $819,000 which was principally related to increased handpiece sales in the United States and Canada sales by approximately $2 million in 2017 to 2016. International sales in 2017 decreased by approximately $1.2 million over the same period in 2016 due to a reduction in shipments to Milestone China. The reductions in shipments to Milestone China is due to Milestone China working through inventory purchases from late 2016 and the modification to their business strategy to better serve the China dental market. However, in the domestic market our exclusive distribution agreement with Henry Schein increased domestic sales in 2017 as the product and sales force training has been substantially completed as of December 31, 2017. Medical revenue for the twelve months ended December31, 2017 and 2016 were approximately $2,000 and $21,000, respectively. On June 12, 2017 the company announced that the CompuFlo&reg; Epidural Computer Controlled Anesthesia System&nbsp;received 510(k) marketing clearances from the U.S. Food and Drug Administration (FDA). Milestone is in the process of attending medical device trade shows and attending introductory meetings with medical device distributors within the United States and European markets. The Company&rsquo;s focus is on marketing its Epidural devices&nbsp;throughout Europe.</font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">28</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Gross Profit for 2017 and 2016 were as follows:</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; border-collapse: collapse;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2017</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="1" id=".amt.D3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>% of Revenue</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2016</b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="1" id=".amt.D5" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>% of Revenue</b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><b><b>Increase (Decrease) $</b></b></b></td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="1" id=".amt.D7" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>% of Change</b></p>
			</td>
			<td id=".trail.D7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dental</p>
			</td>
			<td id=".symb.2" style="width: 12px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 125px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,187,562</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103.13</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,297,402</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">99.86</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">890,162</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.14</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 1px solid rgb(0, 0, 0);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Medical</p>
			</td>
			<td id=".symb.2" style="width: 12px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 125px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(218,183</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-3.13</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">9,070</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.14</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(227,253</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-2505.55</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 3px double rgb(0, 0, 0);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total Sales</font></p>
			</td>
			<td id=".symb.2" style="width: 12px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 125px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,969,379</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100.00</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,306,472</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100.00</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">662,909</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.51</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">Consolidated gross profit for the twelve months ended December 31, 2017 and 2016 were approximately 62% and 60%, respectively. Dental gross profit for the twelve months ended December 31, 2017 and 2016 were approximately $7.2&nbsp;million and $6.3&nbsp;million, respectively. Dental gross margin for the twelve months ended December 31, 2017 was 64%, which increased from 60% for the twelve months ended December 31, 2016.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; The increase in gross profit relates to the increase in US sales which was offset by special pricing in China to facilitate an increase in market share.</font></p>

<p style="text-indent: 9pt;"><b>Selling, general and administrative expenses for 2017 and 2016 were as follows:&nbsp;</b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; border-collapse: collapse;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><b>%<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><b>%<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><b>Increase (Decrease) $</b></b></p>
			</td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><b>% of Change</b></b></td>
			<td id=".trail.D7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dental</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,968,747</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33.26</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,080,627</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35.33</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(111,880</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-2.74</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Medical</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,046,141</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17.15</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,716,970</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.52</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(670,829</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-24.691</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 1px solid rgb(0, 0, 0);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,916,063</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49.59</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,752,364</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41.15</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,163,699</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24.49</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 3px double rgb(0, 0, 0);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,930,951</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100.00</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,549,961</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100.00</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">380,984</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.30</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">Consolidated selling, general and administrative expenses for the twelve months ended December 31, 2017 and 2016 were approximately $12 million versus $11.5 million, respectively. The increase of approximately $536,000 is predominantly due to the increase in Corporate<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;expenses, as Milestone Scientific began the process of increasing the business platform in the medical segment growth.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Research and Development<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;for 2017 and 2016 were as follows:</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; border-collapse: collapse;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>2017</b></b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>% </b></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>2016</b></b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>% </b></b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 156.313px;"><b>Increase (Decrease) $</b></td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1px;">&nbsp;</td>
			<td id=".lead.D7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><b>% of Change</b></b></td>
			<td id=".trail.D7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dental</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,251</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.76</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,310</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.78</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 146.313px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25,059</td>
			<td id=".trail.6" nowrap="true" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-70.97</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Medical</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124,820</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45.76</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">509,797</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40.13</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 146.313px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(384,977</td>
			<td id=".trail.6" nowrap="true" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-75.52</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 1px solid rgb(0, 0, 0);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Corporate</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">137,675</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">50.48</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">725,364</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">57.09</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.6" style="width: 146.313px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(587,689</td>
			<td id=".trail.6" nowrap="true" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-81.02</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 3px double rgb(0, 0, 0);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">272,746</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.00</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,270,471</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.00</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.6" style="width: 146.313px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(997,725</td>
			<td id=".trail.6" nowrap="true" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-78.53</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">Consolidated research and development expenses for the twelve months ended December 31, 2017 and 2016 were approximately $273,000 and $1,270,000, respectively. The decrease is due to reduction in development costs associated with the epidural and intra articular devices.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b style="font-size: 10pt; text-indent: 1.5pt;">Profit (Loss) from Operations<font style="font-size: 10pt;">&nbsp;for 2017 and 2016 were as follows:</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; border-collapse: collapse;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2017</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>%<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2016</b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>%<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Increase (Decrease) $</b></p>
			</td>
			<td id=".lead.D8" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D8" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>% of Change</b></p>
			</td>
			<td id=".trail.D8" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9.8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dental</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,127,570</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-59.75</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,096,727</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-32.19</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,030,843</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49.16</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Medical</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,389,145</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45.64</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,217,697</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49.40</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">828,552</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-25.75</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 1px solid rgb(0, 0, 0);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,972,743</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">114.11</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,392,990</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">82.79</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(579,753)</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.75</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 3px double rgb(0, 0, 0);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,234,318</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100.00</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,513,960</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100.00</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,279,648</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-19.64</td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>The loss from operations for the twelve months ended December 31, 2017 and 2016 was approximately $5.2&nbsp;million and $6.5 million, respectively, a decrease of approximately $1.3&nbsp;million. This decrease is primarily attributable to the increase in Corporate expenses relating to our epidural and intra articular devices&nbsp;in 2017 offset by an increase in gross profit.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">29</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b style="font-size: 10pt;">Liquidity and Capital Resources</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt 0pt 17pt; text-align: left; text-indent: 1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">At December 31, 2017, Milestone Scientific had cash and cash equivalents of approximately $2.6 million, total current assets of approximately $12&nbsp;million and working capital of approximately $5.3&nbsp;million.&nbsp; We believe that our cash on hand, accounts receivable and the anticipated revenues from the dental business will be sufficient to fund our business operations for at least the next 12 months from the filing date of this Form 10-K.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Milestone Scientific continues to take positive steps to maintain adequate inventory levels and advances on contracts to maintain available inventory to meet our domestic and international sales requirements. For the twelve months ended December 31, 2017 and 2016, we had negative cash flows from operating activities of approximately $1.2 million and $5.4 million, respectively.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific has incurred annual operating losses and negative cash flows from operating activities since its inception. The capital raised in December 2016 and January 2017 provided Milestone Scientific with working capital to continue to develop its medical devices and obtain regulatory approval for one of its medical devices (the June 2017 FDA approval of the epidural device), as well as to aggressively market its dental devices. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, and a reduction in operating expenses. Management believes that the Company will have sufficient cash and liquidity to meet its anticipated obligations over the next twelve-month period following the date of this report.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Now that the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo</i> Epidural System has obtained FDA clearance in the United States (June 2017), the development costs will be reduced in 2018. The FDA clearance will provide the Company with the opportunity to establish distribution in the USA. At the same time, the Company and its parent are looking to establish additional financing opportunity for the Epidural device sales. The intra-articular device will begin the 510K application process later this year. Most of the cost associated with this application will be internal personnel cost and some low level third party review expense.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific believes that<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;the FDA clearance&nbsp;of its&nbsp;510(k) application with respect to the<i> CompuFlo</i>&reg; Epidural Computer Controlled Anesthesia will provide Milestone Scientific with the opportunity to enter the US medical device market and generate revenues in the future. Milestone Scientific believes that it&nbsp;has sufficient inventory of the epidural devices to satisfy the near-term marketing opportunities.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In February and March 2018 Milestone Scientific hired an Executive VP of Global sales and Marketing and a Vice President of US Sales to fill a significant gap in our commercialization efforts of the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>CompuFlo</i> Epidural System.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific believes that the June 2016 exclusive distribution agreement with Henry Schein will continue to improve its domestic<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;revenues in 2018. The dental agreement has provided a substantial increase in US and Canada 2017 dental revenue (approximately $2 million). To further reduce Milestone Scientific&#39;s expenditures, Milestone Medical is carefully managing expenses related to obtaining FDA clearance for the intra-articular devices. The <i>CompuFlo</i> Epidural System received FDA 510K approval in June 2017. By limiting the FDA related expenses and increasing the dental device revenue through the&nbsp;dental distribution agreement, our estimated cash flow projection of the consolidated company and its subsidiaries, management believes that Milestone Scientific will have resources to fund its operations over the next 12 months from the filing date of this Form 10-K.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Our Consolidated Balance Sheets </font>included in this Report reflects a decrease of approximately $1.3&nbsp;million in current assets from December 31, 2016 to December 31, 2017. This decrease in current assets was primarily due to a reduction in cash ($1 million), accounts receivable from related parties, other receivables and inventory of approximately $2.2 million. This was offset by an increase in accounts receivable, deferred cost, note receivable and prepaid expenses and other current assets of an aggregate of approximately $1.9&nbsp;million.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In this Report our consolidated balance sheets included reflects increase&nbsp;in current liabilities by approximately $1.1 million from approximately $5.6 million to approximately $6.7&nbsp;million. The increase&nbsp;is primarily due to a decrease in accounts payable of approximately $364,000, accounts payable related party of approximately $249,000, an increase deferred revenue of approximately $844,000 and an increase in accrued expenses of approximately $850,000.&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific does not have any off-balance sheet arrangements that are currently material or reasonably likely to be material to the financial position or results of operations. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><b>&nbsp;</b></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">30</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Contractual Obligations</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The impact of the consolidated contractual obligations at December 31, 2017, expected on the liquidity and cash flows in future periods, is as follows:</font></p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total </font></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Less than<br>
			1 Year </font></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">1-3 Years </font></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">3-5 Years </font></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Operating lease obligations </font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">313,050</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">150,264</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">162,786</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".lead.B4">&nbsp;</td>
			<td id=".symb.B4">&nbsp;</td>
			<td id=".amt.B4">&nbsp;</td>
			<td id=".trail.B4">&nbsp;</td>
			<td id=".lead.B5">&nbsp;</td>
			<td id=".symb.B5">&nbsp;</td>
			<td id=".amt.B5">&nbsp;</td>
			<td id=".trail.B5">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Purchase obligations (1) </font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,961,718</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,546,036</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">415,682</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total </font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,274,768</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,696,300</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">578,468</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:31.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:-13.5pt;">(1<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">)</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Purchase obligations include agreements for the purchase of dental devices.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Recent Accounting Pronouncements</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</font>See &ldquo;Note C&nbsp;- Summary of Significant Accounting Policies&rdquo; to the Consolidated financial statements for explanation of recent accounting pronouncements impacting Milestone Scientific.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item 7A. Quantitative and Qualitative Di<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">sclosures about Market Risk</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">Milestone Scientific is a &ldquo;smaller reporting company&rdquo; as defined by Regulation S-K and, as such, is not required to provide the information required by this item.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item 8. Financial Statements</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The financial statements of Milestone Scientific required by this Item are set forth beginning on page F-1.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item 9. Change in and Disagreements with Accountants on Accounting and</b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> <b>Financial Disclosure</b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">None.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item 9A. Controls and Procedures</b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific&rsquo;s Interim Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the design and operation of Milestone Scientific&rsquo;s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, Milestone Scientific&rsquo;s Interim Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of December 31, 2017 are effective to ensure that information required to be disclosed in the reports Milestone Scientific files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&rsquo;s rules and forms and that such information is accumulated and communicated to Milestone Scientific&#39;s management, including the Interim Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Management<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Annual Report on Internal Control over Financial Reporting</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific management is responsible for establishing and maintaining internal controls over financial reporting. The internal controls over financial reporting includes those policies and procedures that:</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:-18pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets; </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:46.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:-18pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles in the United States, and that the receipts and expenditures are being made only in accordance with authorizations of the management and directors; and </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:46.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:-18pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets that could have a material effect on the financial statements.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">31</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control instruments, no matter how well designed, have inherent limitations. Therefore, even those instruments determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific management assessed the effectiveness of its internal control over financial reporting as of December 31, 2017. In making this assessment, management used the framework in Internal Control &mdash; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (&ldquo;COSO&rdquo;) adopted in 2013. Based on the assessment and the criteria set forth by COSO, management believes that Milestone Scientific maintained effective internal control over financial reporting as of December 31, 2017. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There have been no changes in Milestone Scientific&rsquo;s internal control over financial reporting identified in connection with the evaluation that occurred during Milestone Scientific&rsquo;s last fiscal quarter ended December 31, 2017 that have materially affected, or that are reasonably likely to materially affect, Milestone Scientific&rsquo;s internal controls over financial reporting.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item 9B. Other Information</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">None.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>PART III </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item 10. Directors, Executive Officers, Promoters, <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Control Persons and Corporate</font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> <b>Governance; Compliance with Section 16 (a) of the Exchange Act.</b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific&rsquo;s directors are elected annually by the stockholders and serve for one-year terms until his/her successor is elected and qualified or until such director&rsquo;s earlier death, resignation or removal. The executive officers and key personnel are appointed by and serve at the pleasure of the Board of Directors The current executive officers and directors of Milestone Scientific and their respective ages as of&nbsp;</font>April 2, 2018&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">are as follows:&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:24.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>NAME</b></p>
			</td>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:7.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>AGE</b></p>
			</td>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:52.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>POSITION</b></p>
			</td>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DIRECTOR SINCE</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;border-bottom: 1px #000000;;width:24.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Leslie Bernhard (1) (2) (3)</p>
			</td>
			<td style="vertical-align:middle;width:7.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">73</p>
			</td>
			<td style="vertical-align:middle;width:52.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Chairman of the Board and Director</p>
			</td>
			<td style="vertical-align:middle;width:15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2003</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;border-bottom: 1px #000000;;width:24.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Leonard Osser&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:7.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">70</p>
			</td>
			<td style="vertical-align:middle;width:52.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Interim Chief Executive Office, and Director</p>
			</td>
			<td style="vertical-align:middle;width:15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1991</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;border-bottom: 1px #000000;;width:24.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Joseph D&#39;Agostino</p>
			</td>
			<td style="vertical-align:middle;width:7.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">66</p>
			</td>
			<td style="vertical-align:middle;width:52.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Chief Financial Officer and Chief Operating Officer</p>
			</td>
			<td style="vertical-align:middle;width:15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;border-bottom: 1px #000000;;width:24.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Leonard Schiller (1) (2) (3)</p>
			</td>
			<td style="vertical-align:middle;width:7.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">77</p>
			</td>
			<td style="vertical-align:middle;width:52.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Director</p>
			</td>
			<td style="vertical-align:middle;width:15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1997</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;border-bottom: 1px #000000;;width:24.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Michael McGeehan (1)</p>
			</td>
			<td style="vertical-align:middle;width:7.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">52</p>
			</td>
			<td style="vertical-align:middle;width:52.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Director</p>
			</td>
			<td style="vertical-align:middle;width:15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;border-bottom: 1px #000000;;width:24.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Gian Domenico Trombetta</p>
			</td>
			<td style="vertical-align:middle;width:7.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">57</p>
			</td>
			<td style="vertical-align:middle;width:52.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Director</p>
			</td>
			<td style="vertical-align:middle;width:15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2014</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:24.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Edward J. Zelnick, M.D.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; (1) (2) (3)</font></p>
			</td>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:7.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">72</p>
			</td>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:52.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Director</p>
			</td>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2015</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt 7.5pt; text-align: left; text-indent: 55.5pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp; &nbsp; &nbsp;&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">1</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Member of the Audit Committee</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:79.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">2<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Member of the Compensation Committee</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:79.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">3<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Member of the Nominating and Corporate Governance Committee</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:79.5pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The following are the names of individuals who are not executive officers of Milestone Scientific but are deemed key personnel of Milestone Scientific, their respective ages and positions as <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">of April 2, 2018</font></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:28.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>NAME</b></p>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:28.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>AGE</b></p>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:43%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>POSITION</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;border-bottom: 1px #000000;;width:28.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Eugene Casagrande, D.D.S.</p>
			</td>
			<td style="vertical-align:middle;width:28.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">73</p>
			</td>
			<td style="vertical-align:middle;width:43%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Director of Professional Relations</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:28.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Mark Hochman, D.D.S.</p>
			</td>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:28.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">58</p>
			</td>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:43%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Director of Clinical Affairs</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">32</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Leonard Osser, Interim Chief Executive Officer and Director</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;"><b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Leonard Osser has been Interim Chief Executive Officer since December 2017. From July 2017 to December 2017, he had been Managing Director &ndash;China Operations.&nbsp;Prior to that, he served as Milestone Scientific&rsquo;s Chairman from 1991 until September of 2009, and during that time, from 1991 until 2007, was also Chief Executive Officer of Milestone Scientific. In September 2009, he resigned as Chairman of Milestone Scientific, but remained a director, and assumed the position of Chief Executive Officer. From 1980 until the consummation of Milestone Scientific&rsquo;s public offering in November 1995, Mr. Osser was primarily engaged as the principal owner and Chief Executive Officer of U.S. Asian Consulting Group, Inc., a New Jersey-based provider of consulting services specializing in distressed or turnaround situations in both the public and private markets. Mr. Osser&rsquo;s knowledge of our business and background with us since 1980 provides the Board with valuable leadership skills and insight into our business and accordingly, the expertise needed to serve as one of our directors.</font></p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b>Joseph D&rsquo;Agostino, Chief Financial Officer and Chief Operating Officer</b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joseph D&#39;Agostino has been Milestone Scientific&#39;s Chief Financial Officer since October 2008 and Chief Operating Officer since September 2011. Mr. D&#39;Agostino joined Milestone Scientific in January 2008 as Acting CFO and has over 25 years of finance and accounting experience serving both publicly and privately held companies. A results-oriented and decisive leader, he has specific proven expertise in treasury and cash management, strategic planning, information technology, internal controls, Sarbanes-Oxley compliance, operations and financial and tax accounting. Mr. D&#39;Agostino served as Senior Vice President and Treasurer of Summit Global Logistics, a publicly traded, full service international freight forwarder and customs broker with operations in the United States and China. Previous executive posts also included Executive Vice President and CFO of Haynes Security, Inc., a leading electronic and manned security solutions company serving government agencies and commercial enterprises; Executive Vice President of Finance and Administration for Casio, Inc., the U.S. subsidiary of Casio Computer Co., Ltd., a leading manufacturer of consumer electronics with subsidiaries throughout the world; and Manager of Accounting and Auditing for Main Hurdman&#39;s National Office in New York City (merged into KPMG). Mr. D&#39;Agostino is a Certified Public Accountant and holds memberships in the American Institute of CPA&#39;s, New Jersey Society of CPA&#39;s, Financial Executive Institute, He is a graduate of William Paterson University where he earned a Bachelor of Arts degree in Science. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Leslie Bernhard, Chairman of the Board </b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leslie Bernhard has served as Milestone Scientific&rsquo;s Chairman of the Board since October 2009 and served as Interim Chief Executive Officer from October 2017 to December 19, 2017. In addition, Ms. Bernhard has also had been serving as an Independent Director (as defined below) of Milestone Scientific since May 2003. Since 2007, Ms. Bernhard has also been serving as an independent director of Universal Power Group, Inc., a global supplier of power solutions. In 1986 she co-founded AdStar, Inc., an electronic ad intake service to the newspaper industry, and served as its president, chief executive officer and executive director until 2012. Ms. Bernhard holds a BS Degree in Education from St. John&rsquo;s University. Ms. Bernhard&rsquo;s professional experience and background with AdStar and with us, as one of our directors since 2003, have given her the expertise needed to serve as Chairman of the Board, and Chairman of the Audit Committee.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Gian Domenico Trombetta, Director</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gian Domenico Trombetta has been a director of Milestone Scientific in May 2014 and the President and Chief Executive Officer of Milestone Scientific&rsquo;s Dental Division (Wand Dental Inc.) since October 2014. He founded Innovest S.p.A in 1993, a special situation firm acting in development and distressed capital investments. He has been its President and Chief Executive Officer since its inception. He served as the Chief Executive Officer or a board member of several private commercial companies in different industries including both industrial (e.g. IT, media, web, and fashion) and holding companies. Before founding Innovest, Mr. Trombetta was Project Manager for Booz Allen &amp; Hamilton Inc., a management consulting firm from 1988 to 1992. Mr. Trombetta holds a degree in business administration from the Luiss University in Rome, Italy and a MBA degree from INSEAD-Fontainbleau-France. Mr. Trombetta business background and experience has given him the expertise needed to serve as one of our directors.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">33</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Leonard M. Schiller, Director</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leonard Schiller has been a director of Milestone Scientific since April 1997. Mr. Schiller has been a partner in the Chicago law firm of Schiller Strauss &amp; Lavin PC since 1977 and since 2002, its President. Mr. Schiller also serves as a director on the boards of Jerrick Media Holdings, Inc. (OTCQB: JMDA), a public media company, since February 2016 and Point Capital, Inc. (OTCQB: PTCI), a business development company, since July 2014. Mr. Schiller&rsquo;s professional experience and background have given him the expertise needed to serve as Chairman of the Compensation&nbsp;Committee and as one of our directors.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Edward J. Zelnick, M.D., Director</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Edward J. Zelnick, M.D. has been a director of Milestone Scientific since February 2015. Dr. Zelnick has been a medical doctor for over 45 years and has a background in clinical research. Since June 2002 he has been the chief executive officer of Horizon Institute for Clinical Research, a company that recruits test subjects and clinicians for clinical research trials. Dr. Zelnick received a Bachelor of Science degree in chemistry from the University of Pittsburgh in 1966 and his M.D. degree from New York Medical College in 1970. Dr. Zelnick&#39;s professional experience and background as a medical doctor and in clinical research, have given him the expertise needed to serve as one of our directors. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Michael McGeehan</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Michael McGeehan has been a director of Milestone Scientific since October 2017. Mr. McGeehan is a business consultant with 30 years of experience in a variety of business domains, including financial services, medical and healthcare products, consumer package goods and the software technology industry. Mr. McGeehan started his career at Metaphor Computer Systems in 1988 and then went to work at Microsoft Corporation in 1991.&nbsp; In 1995, Mr. McGeehan left Microsoft and founded Forefront Information Strategies, an information technology consulting firm. In 2002, Mr. McGeehan returned to Microsoft where he worked until 2017, when he returned to and re-started Forefront. Mr. McGeehan was on the Board of Directors of&nbsp;Wand Dental Inc., (subsidiary of Milestone Scientific) a maker of a painless, anesthetic injection system for dentists. Mr. McGeehan has a Master&rsquo;s in Business Administration from Pace University and a Bachelor of Science in Electrical Engineering and Computer Science from Marquette University.&nbsp; Mr. McGeehan&nbsp;background has given him the experience needed to serve as one of&nbsp;our directors.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b style="font-size: 10pt; text-indent: 1.5pt;">Mark Hochman, D.D.S., Director of Clinical Affairs</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mark Hochman, D.D.S. has served as Milestone Scientific&rsquo;s Director of Clinical Affairs and Director of Research and Development since 1999. He has a Doctor of Dental Surgery with advanced training in the specialties of Periodontics and Orthodontics from New York University of Dentistry and has been practicing dentistry since 1984. He is a former clinical associate professor at NYU School of Dental Surgery. Recognized as a world authority on Advanced Drug Delivery Instruments, Dr. Hochman has published numerous articles in this area, and shares in the responsibility for inventing much of the technology currently available from Milestone Scientific.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Dr. Eugene Casagrande, Director of International &amp; Professional Relations</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Since 1998, Eugene Casagrande, D.D.S. has served as Director of International and Professional Relations, charged with pursuing a broad range of clinical and industry-related strategic business opportunities for Milestone Scientific. Dr. Eugene R. Casagrande has practiced Cosmetic and Restorative Dentistry for over 30 years in Los Angeles.&nbsp; He is past president of the California State Board of Dentistry and the Los Angeles Dental Society and is a Fellow of the American and International Colleges of Dentists.&nbsp; Dr. Casagrande was a member of the faculty of the University of Southern California, School of Dentistry.&nbsp; He was also the Executive Director of the Los Angeles Oral Health Foundation and the Program Director of the Los Angeles Pediatric Oral Health Access Program.&nbsp; As the Director of International &amp; Professional Relations for Milestone Scientific for over 19 years, he has published multiple articles and has lectured both nationally and internationally at over 100 dental schools and in over 50 countries on Computer-Controlled Local Anesthesia.&nbsp; </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Director Independence and Committees of the Board</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">The Board has determined as of December 19, 2017,&nbsp;Leslie Bernhard, Leonard M. Schiller, Dr. Edward J. Zelnick, and Michael McGeehan (the &ldquo;Independent Directors&rdquo;) are independent as that term is defined in the listing standards of the NYSE American. As disclosed above, Leslie Bernhard, Leonard M. Schiller, Dr. Edward J. Zelnick, and Michael McGeehan are&nbsp;members of the Audit Committee and are independent for such purposes. Leslie Bernhard, Leonard M. Schiller, and Dr. Edward J. Zelnick, are members of the Compensation Committee and are independent for such purposes.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">34</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In determining director independence, the Board considered the stock awards to the Independent Directors for the year ended December 31, 2017, disclosed in &ldquo;Item 11 &ndash; Executive Compensation &ndash; Director Compensation&rdquo; above, and determined that such awards were compensation for services rendered to the Board and therefore did not impact their ability to continue to serve as Independent Directors.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt;">Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Board of Directors has established a compensation, audit nominating and corporate governance committees (respectively, &ldquo;Compensation Committee,&rdquo; &ldquo;Audit Committee,&rdquo; and &ldquo;Nominating Committee&rdquo;.) The Compensation Committee reviews and recommends to the Board of Directors the compensation and benefits of all the officers of Milestone Scientific, reviews general policy matters relating to compensation and benefits of employees of Milestone Scientific and administers the issuance of stock options to Milestone Scientific&rsquo;s officers, employees, directors and consultants. All compensation arrangements between Milestone Scientific and its directors, officers and affiliates are reviewed by the Compensation Committee. The Audit Committee meets with management and Milestone Scientific&rsquo;s independent auditors to determine the adequacy of internal controls and other financial reporting matters; all the members are independent directors. The Board of Directors has determined that, Leslie Bernhard&nbsp;qualifies as an Audit Committee Financial Expert pursuant to Item 407(d)(5) of Regulation S-K, Leslie Bernhard&nbsp;is independent, as that term is defined in the listing standards of the NYSE American.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Nominating Committee has dual responsibilities. The Nominating Committee will assist the board by identifying and recommending individuals qualified to become member of the board. Additionally, the committee will evaluate the size and composition of the board and its members, reviewing governance issues and making recommendations to the board regarding possible changes and reviewing and monitoring compliance with the code of ethics and insider trading policy.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>Section 16(a) Beneficial Ownership Reporting Compliance </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Section 16(a) of the Securities Exchange Act of 1934 requires our executive officers and directors, and persons who own more than ten percent of a registered class of our equity securities, to file reports of ownership and changes in ownership with the SEC. Executive officers, directors and greater than ten-percent stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file. Based solely on review of the copies of such forms furnished to us, or written representations that no Forms 5 were required, we believe that all Section 16(a) filing requirements applicable to our officers and director were complied with during the fiscal year ended December 31, 2017. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>Code of Ethics</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific has adopted a code of ethics that applies to its directors, principal executive officer, principal financial officer and other persons performing similar functions. This code of ethics is filed herewith as an exhibit to this annual report and is posted on Milestone Scientific&rsquo;s web site at <u>www.milestonescientific.com.</u> Milestone Scientific will also provide a copy of the Code of Ethics to any person without charge, upon written request addressed to the Chief Financial Officer, Joseph D&rsquo;Agostino at the principal executive office, located at 220 South Orange Avenue, Livingston, NJ 07039. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>Item 11. Executive Compensation.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following Summary Compensation Table sets forth all compensation earned, in all capacities, during the fiscal years ended December 31, 2017 and 2016 by Milestone Scientific&rsquo;s (i) CEO and (ii) two most highly compensated executive officers other than the CEO who were serving as executive officers at the end of the 2017 fiscal year and whose salary as determined by Regulation S-K, Item 402, exceeded $100,000 (the individuals falling within categories (i) and (ii) are collectively referred to as the &ldquo;Named Executive Officers&rdquo;). </font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">35</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>SUMMARY COMPENSATION TABLE</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18.4%;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Name and Principal Position</b></p>
			</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 6.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Year</b></p>
			</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Salary</b></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Bonuses</b></b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Option Awards (2)</b></b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Other Compensation</b></b></b></p>
			</td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Total</b></b></b></p>
			</td>
			<td id=".trail.D7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leslie Bernhard</p>
			</td>
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interim Chief Executive Officer-Former</p>
			</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">50,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29,500</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,500</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Daniel Goldberger (3)</p>
			</td>
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Chief Executive Officer-Former</p>
			</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">68,750</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">178,600</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">247,350</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leonard A. Osser (1) (2)</p>
			</td>
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interim Chief Executive<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Officer and Managing Director of Asian Operations</font></p>
			</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">205,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">350,000</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">336,970</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">227,311</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,119,281</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">300,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">400,000</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">422,019</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">238,030</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,360,049</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gian Domenico Trombetta (1) (2)</p>
			</td>
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Chief Executive Officer - Wand Dental Inc</p>
			</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">280,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">180,000</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">460,000</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">279,999</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">160,000</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">221,743</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">661,742</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Joseph D&#39;Agostino (1) (2)</p>
			</td>
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B6" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Chief Financial Officer</p>
			</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">178,700</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90,000</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86,650</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27,027</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">382,377</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">171,600</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">80,000</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">222,344</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.6" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,144</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">509,088</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: -18pt;">1.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;Leonard Osser received $350,000, and $400,000 in a performance bonus for the years ended December 31, 2017 and 2016, respectively, of which $175,000 in 2017 and $200,000 in 2016, were deferred and will be paid in common stock upon the termination of his employment with Milestone Scientific in accordance with the terms of his employment agreement. In accordance with Mr. Osser&#39;s employment agreement, one half of his annual bonus is paid in cash and one half in common stock. On July 10, 2017, Mr. Osser resigned from his positions of Chief Executive Officer. Other compensation represents payments made for health insurance coverage $4,900 and car allowance $7,200, pension payment $203,111. Upon his resignation, Mr., Osser served as Managing Director of Asian Operations, Mr. Osser received $55,000 in compensation and $12,100 in other compensation which is included in this schedule.&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: 0pt;">Gian Domenico Trombetta received $180,000, and $160,000 in a performance bonus for the years ended December 31, 2017 and 2016, respectively, of which $<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">90,000 in 2017 and $80,000 in 2016, were deferred and will be paid in common stock upon the termination of his employment with Milestone Scientific in accordance with the terms of his employment agreement. In accordance with Mr. Trombetta employment agreement, one half of his annual bonus is paid in cash and one half in common stock. Mr. Trombetta elected not to receive&nbsp;the stock option coverage for his 2017 bonus award.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: -54pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: 0pt;">Joseph D<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;Agostino received $90,000, and $80,000 in a performance bonus for the years ended December 31, 2017 and 2016, respectively, of which $45,000 in 2017 and $40,000 in 2016, were deferred and will be paid in common stock upon the termination of his employment with Milestone Scientific in accordance with the terms of his employment agreement. In accordance with Mr. D&rsquo;Agostino&#39;s employment agreement, one half of his annual bonus is paid in cash and one half in common stock. Other compensation represents payments made for health insurance coverage $18,027 and car allowance $9,000.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify; text-indent: 9pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-18pt;">2<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">The amounts in this column reflect the fair value of the options on the date of grant. For details used in the assumption calculating the fair value of the option reward, see Note C&nbsp;to the Financial Statements for the years ended December 31, 2017 and 2016, which is located on pages F-9 through F-14 of this Report. Compensation cost is generally recognized over the vesting period of the award. See the table on page 39 entitled Outstanding Equity Awards at December 31, 2017.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">36</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 45pt; text-align: left; text-indent: -9pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">3.&nbsp;&nbsp;</font>On October 2, 2017, Milestone Scientific accepted the resignation of the then CEO, Daniel Goldberger. Included in other compensation is $175,000 for severance per the agreement with Mr. Goldberger dated February 2018<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;and $3,600 related to health insurance and car allowance.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:0pt;"><b>Employment Contracts</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In July 2017, Milestone Scientific entered into a three-year employment agreement with Daniel Goldberger to serve as President and Chief Executive Officer of Milestone Scientific. Under the agreement, Mr. Goldberger would receive base compensation of $300,000 per annum and may additionally earn annual bonuses of up to an aggregate of $400,000, payable one half in cash and one half in Milestone Scientific common stock (&ldquo;Bonus Shares&rdquo;) contingent upon achieving performance benchmarks periodically set for each year by the compensation committee of the Board. In addition to any such shares of common stock, Mr. Goldberger was entitled to receive stock options (&ldquo;Bonus Options&rdquo;) to acquire twice the number of any Bonus Shares earned, pursuant to a non-qualified stock option grant agreement under Milestone Scientific&rsquo;s then existing equity compensation plan. The Bonus Options had a five-year term and were to vest in equal annual installments on each of the first, second and third anniversary of the grant date, subject to continued employment on such vesting date and accelerated vesting upon the occurrence of certain events. The exercise price of the Bonus Options was based on the fair market value of per share of common stock on the date of grant.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:28.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In July 2017, Milestone Scientific entered into a ten-year new employment agreement with Leonard Osser, who previously served as the Company&rsquo;s President and Chief Executive Officer, to serve as Managing Director &ndash; China Operations. This new agreement provides for annual compensation of $300,000 consisting of $100,000 in cash and $200,000 in the Company&rsquo;s common stock valued at the average closing price of the Company&rsquo;s common stock on the NYSE or such other market or exchange on which its shares are then traded during the first fifteen (15) trading days of the last full calendar month of each year during the term of this agreement. This agreement supersedes all prior employment agreements between Mr. Osser and Milestone Scientific. If the Company terminates Mr. Osser&rsquo;s employment &ldquo;Without Cause,&rdquo; other than due to his death or disability, or if Mr. Osser terminates his employment for &ldquo;Good Reason&rdquo; (both as defined in the agreement), Mr. Osser is entitled to be paid in one lump sum payment as soon as practicable following such termination: an amount equal to the aggregate present value (as determined in accordance with Section 280G(d)(4) of the Code) of all compensation pursuant to this agreement from the effective date of termination hereunder through the remainder of the Employment Term.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In July 2017, Mr. Osser also resigned from his positions of Chairman of the Board, Chief Executive Office and President of Milestone Medical. Upon his resignation, Milestone Medical entered in a consulting agreement with U.S. Asian Consulting Group LLC, an entity controlled by Mr. Osser, pursuant to which he will provide specific services to Milestone Medical for a ten- year term. Pursuant to the consulting agreement, U.S. Asian Consulting Group, LLC, is entitled to receive $100,000 per year for Mr. Osser&#39;s services.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In July 2017, Milestone Scientific granted to Mr. Goldberger non-qualified stock options to purchase 921,942 shares of common stock at an exercise price of $2.00 per share. Those options had a five-year term and were to vest in equal annual installments on each of the first, second and third anniversaries of the grant date, subject to his continued employment on the vesting date and accelerated vesting upon the occurrence of certain events.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On October 5, 2017, Milestone Scientific Inc. announced that Daniel Goldberger had resigned as President and Chief Executive Officer effective October 2, 2017, upon which the previously described stock options granted to him in July 2017 terminated prior to vesting (see Note M).</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><br>
&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;On October 5, 2017, Milestone Scientific also announced the appointment of Leslie Bernhard, the Company&rsquo;s current Chairman of the Board, as the Company&rsquo;s Interim Chief Executive Officer, to serve in such role until the appointment of a new Chief Executive Officer. In connection with her appointment to serve as the Company&rsquo;s Interim Chief Executive Officer, Ms. Bernhard was&nbsp;paid an annual salary of $200,000 received a one-time bonus of 100,000 shares of the Company&rsquo;s Common Stock.&nbsp; In addition, at the completion of her service as Interim Chief Executive Officer, Ms. Bernhard shall be entitled to receive a cash bonus in an amount to be determined by the Board of Directors at that time.&nbsp;</font>On December 19 ,2017 the Board of Directors appointed Leonard Osser Interim Chief Executive Officer, replacing Leslie Bernhard. Ms. Bernhard negotiated a one-time bonus of 25,000 shares of Milestone Scientific stock for her services as Interim Chief Executive Officer in-lieu of 100,000 shares.</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">37</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-indent: 27pt;">On December 19 ,2017 the Board of Directors appointed Leonard Osser Interim Chief Executive Officer, replacing Leslie Bernhard. Mr. Osser will enter into a similar employment contract that he received during 2017 before he resigned his position as CEO of the company. <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Mr. Osser placed on hold his position as Managing Director-China Operations and his consulting agreement with Milestone Medical to rejoined Milestone Scientific Inc. as Interim Chief Executive Officer.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> &nbsp; &nbsp; &nbsp; </font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><u><b>Objective of Executive Compensation Program </b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The primary objective of the executive compensation program is to attract and retain qualified, energetic managers who are enthusiastic about the mission and culture of Milestone Scientific. A further objective of the compensation program is to provide incentives and reward each manager for their contribution. In addition, Milestone Scientific strives to promote an ownership mentality among key leadership and the Board of Directors.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Compensation Committee reviews and approves, or in some cases recommends for the approval of the full Board of Directors, the annual compensation procedures for the Named Executive Officers.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The compensation program is designed to reward teamwork, as well as each manager&rsquo;s individual contribution. In measuring the Named Executive Officers&rsquo; contribution, the Compensation Committee considers numerous factors including the growth, strategic business relationships and financial performance. Regarding most compensation matters, including executive and director compensation, the management provides recommendations to the Compensation Committee; however, the Compensation Committee does not delegate any of its functions to others in setting compensation. Milestone Scientific does not currently engage any consultant to advice on executive and/or director compensation matters.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock price performance has not been a factor in determining annual compensation because the price of Milestone Scientific&rsquo;s common stock is subject to a variety of factors outside of Milestone Scientific&rsquo;s control. Milestone Scientific does not have an exact formula for allocating between cash and non-cash compensation.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Annual CEO Compensation consists of a base salary component and periodic stock option grants. It is the Compensation Committee&rsquo;s intention to set totals for the CEO for cash compensation sufficiently high enough to attract and retain a strong motivated leadership team, but not so high that it creates a negative perception with the other stakeholders. The CEO receives stock option grants under the stock option plan. The number of stock options granted to the executive officer is made on a discretionary rather than a formula basis by the Compensation Committee. The CEO&rsquo;s current and prior compensation is considered in setting future compensation. In addition, Milestone Scientific reviews the compensation practices of 28 other companies. To some extent, the compensation plan is based on the market and the companies that compete for executive management. The elements of the plan (e.g., base salary, bonus and stock options) are like the elements used by many companies. The exact base pay, stock option grant, and bonus amounts are chosen to balance the competing objectives of fairness to all stakeholders and attracting and retaining executive managers. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">38</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Outstanding Equity Awards at December 31, 2017</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">The following table includes certain information with respect to all unexercised stock options and unvested shares of common stock of Milestone Scientific <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">outstanding owned by the Named Executive Officers at December 31, 2017.&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D5" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="12" style="border-bottom: 1px none rgb(0, 0, 0); text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Options Awards</font></b></p>
			</td>
			<td id=".lead.D7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D7" style="border-bottom: 1px none rgb(0, 0, 0); text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b><b>Stock Awards</b></b></b></b></p>
			</td>
			<td id=".trail.D7" style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10.3%;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Name</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b><b>Number of Securities<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Underlying Unexercised Options (#) Exercisable (1)</font></b></b></b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b><b>Number of Securities Underlying Unexercised Options <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">(#) Unexercisable (1)</font></b></b></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b><b>Option Exercise Price ($)</b></b></b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Option Expiration Date</b></p>
			</td>
			<td id=".lead.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b><b>Number of Shares or<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Units of Stock that have not vested (#) (2)</font></b></b></b></b></p>
			</td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Market Value of Number of Shares or Units of Stock that have not vested (#) (3)</font></b></b></b></b></p>
			</td>
			<td id=".trail.D7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leonard Osser</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,333</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.49</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">11/20/2019</p>
			</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 112px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">886,866</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,031,762</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">248,448</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.65</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">12/31/2018</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">185,186</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.23</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">11/20/2019</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,699</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,607</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.89</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">6/23/2020</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,105</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,883</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.72</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2/4/2021</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">95,238</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">76,191</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.09</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">11/10/2021</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,497</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,615</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.72</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2/4/2021</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">112,323</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">224,647</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.14</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1/18/2022</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>825,829</b></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>391,943</b></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.6" style="width: 112px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>886,866 </b></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>1,031,762</b></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gian Domenico Trombetta</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,767</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59,013</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.72</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2/4/2021</p>
			</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 112px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116,079</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">240,066</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,798</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66,580</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.61</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1/8/2022</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>106,565</b></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>125,593</b></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.6" style="width: 112px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>116,079 </b></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>240,066</b></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Joseph D<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;Agostino </font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">66,666</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.50</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">12/31/2018</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">150,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.09</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">11/11/2019</p>
			</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 112px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">191,046</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">361,378</td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49,261</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.03</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">11/20/2019</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,967</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59,173</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.72</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2/4/2021</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,397</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,292</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.61</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1/8/2022</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,883</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">57,767</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.04</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1/18/2022</p>
			</td>
			<td id=".lead.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 6px;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 112px;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>385,174</b></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>150,232</b></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.6" style="width: 112px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>191,046</b></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td>
			<td id=".amt.7" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>361,378</b></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 15pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.5pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.5pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Represents stock option grants at fair market value on the date of grant.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:15pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.5pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.5pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Issuance of the shares of common stock has been deferred until the termination of his employment with Milestone Scientific in accordance with the terms of his respective employment arrangement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.5pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.5pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Based on the closing price per share of $1.18 as reported on the NYSE American&nbsp;on December 31, 2017.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b>Director Compensation</b></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 46%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">NAME</p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Fees Earned or Paid in Cash ($)</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Bonus Paid in Stock</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Total ($)</p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leslie Bernhard (1)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38,500</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">134,500</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leonard Schiller</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">66,500</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">102,500</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Edward J. Zelnick, M.D.</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,600</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62,600</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Michael McGeehan<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,000</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 72pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 72pt;">1<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Includes $8,500 July thru December 2017 compensation for serving as Chairman of the Audit Committee.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">39</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b>Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following table, together with the accompanying footnotes, sets forth information, as of April 2, 2018&nbsp;, regarding stock ownership of all persons known by Milestone Scientific to own beneficially more than 5% of Milestone Scientific&rsquo;s outstanding common stock, Named Executives, all directors, and all directors and officers of Milestone Scientific as a group: </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 935px; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Names of Beneficial Owner (1)</p>
			</td>
			<td colspan="2" id=".amt.D2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 203px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Shares<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> of Common<br>
			Stock Beneficially<br>
			Owned (2)</font></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47px; text-align: center;">&nbsp;</td>
			<td colspan="1" id=".amt.D3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 101px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Percentage<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> of<br>
			Ownership</font></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Executive Officers and Directors</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 15px;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 182px;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47px;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 101px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leonard Osser</p>
			</td>
			<td id=".symb.2" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 182px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,183,921</td>
			<td id=".trail.2" nowrap="true" style="width: 47px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;(3)</td>
			<td id=".symb.3" style="width: 101px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;12.08%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Joseph D&#39;Agostino</p>
			</td>
			<td id=".symb.2" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 182px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,550,679</td>
			<td id=".trail.2" nowrap="true" style="width: 47px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;(4)</td>
			<td id=".symb.3" style="width: 101px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;4.48%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leslie Bernhard<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>
			</td>
			<td id=".symb.2" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 182px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75,000</td>
			<td id=".trail.2" nowrap="true" style="width: 47px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;(5)</td>
			<td id=".symb.3" style="width: 101px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;-</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leonard Schiller</p>
			</td>
			<td id=".symb.2" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 182px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">235,158</td>
			<td id=".trail.2" nowrap="true" style="width: 47px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;(6)</td>
			<td id=".symb.3" style="width: 101px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;-</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Edward J. Zelnick, M.D.</p>
			</td>
			<td id=".symb.2" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 182px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,750</td>
			<td id=".trail.2" nowrap="true" style="width: 47px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;(7)</td>
			<td id=".symb.3" style="width: 101px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;-</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Michael McGeehan<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>
			</td>
			<td id=".symb.2" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 182px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,000</td>
			<td id=".trail.2" nowrap="true" style="width: 47px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;(8)</td>
			<td id=".symb.3" style="width: 101px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;-</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gian Domenico Trombetta</p>
			</td>
			<td id=".symb.2" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 182px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,262,768</td>
			<td id=".trail.2" nowrap="true" style="width: 47px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;(9)</td>
			<td id=".symb.3" style="width: 101px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;18.09%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">All directors &amp; executive officers as<br>
			<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">group (6 persons)</font></p>
			</td>
			<td id=".symb.2" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 182px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,361,276</td>
			<td id=".trail.2" nowrap="true" style="width: 47px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;</td>
			<td id=".symb.3" style="width: 101px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;35.70%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">K. Tucker Andersen</p>
			</td>
			<td id=".symb.2" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 182px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,292,003</td>
			<td id=".trail.2" nowrap="true" style="width: 47px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;(10)</td>
			<td id=".symb.3" style="width: 101px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;9.51%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tom Cheng</p>
			</td>
			<td id=".symb.2" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 182px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,712,599</td>
			<td id=".trail.2" nowrap="true" style="width: 47px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;</td>
			<td id=".symb.3" style="width: 101px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;4.95%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Debra Ginsberg</p>
			</td>
			<td id=".symb.2" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 182px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,695,000</td>
			<td id=".trail.2" nowrap="true" style="width: 47px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;(11)</td>
			<td id=".symb.3" style="width: 101px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;4.90%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 423px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">* Less than 1%</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 15px;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 182px;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47px;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 101px; text-align: right;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -18pt;">1.&nbsp; &nbsp; The addresses of the persons named in this table are as follows: Leonard Osser, Joseph D&#39;Agostino, Gian Domenico Trombetta, Leslie Bernhard and Edward Zelnick, M.D. are at 220 South Orange Avenue in, New Jersey 07039; Leonard M. Schiller, c/o Schiller, Klein &amp; McElroy, P.C., 33 North Dearborn Street, Suite 1030, Chicago, Illinois 60602; K. Tucker Andersen, c/o Above All Advisors, 61 Above All Road, Warren, CT 06754, Tom Cheng, c/o United Systems 18725 E. Gale Ave Suite 221, City of Industry, CA 91748 and Debra Ginsberg, 5 Bay Ridge Road Key Largo, FL 33037.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -18pt;">2.&nbsp; &nbsp; A person is deemed to be a beneficial owner of securities that can be acquired by such person within 60 days from April 2, 2018, as applicable, upon the exercise of options and warrants or conversion of convertible securities. Each beneficial owner&#39;s percentage ownership is determined by assuming that options, warrants and convertible securities that are held by such person (but not held by any other person) and that are exercisable or convertible within 60 days from April 2, 2018 have been exercised or converted. Except as otherwise indicated, and subject to applicable community property and similar laws, each of the persons named has sole voting and investment power with respect to the shares shown as beneficially owned. The percentages for each beneficial owner are determined based on dividing the number of shares of common stock beneficially owned by the sum of the outstanding shares of common stock on April 2, 2018 and the number of shares underlying options exercisable and convertible securities convertible within 60 days from April 2, 2018 held by the beneficial owner</p>

<p style="margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -18pt;">3.&nbsp; &nbsp; Includes 2,283,706 shares held by Mr. Osser or his family, 1,055,350 shares to be issued at the termination of his employment agreement, and 844,865 shares subject to common stock options.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -18pt;">4.&nbsp; &nbsp; Includes 931,137 shares held by Mr. D&#39;Agostino, 234,371 shares to be issued at the termination of his employment, and 385,171 shares subject to common stock options. w.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: justify; text-indent: -18pt;">5.&nbsp; &nbsp; Includes 75,000 shares held by Ms. Bernhard.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="margin: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">40</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">6.&nbsp; &nbsp; Includes 229,533&nbsp;shares held by Mr. Schiller and 5,625 shares subject to common stock warrants.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">7.&nbsp; &nbsp; Includes 25,000 shares held by Dr. Zelnick and 3,750 shares subject to common stock warrants.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">8.&nbsp; &nbsp; Includes 1,000 shares held by Mr. McGeehan</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">9.&nbsp; &nbsp; &nbsp;Includes 202,617 shares to be issued at the termination of his employment, 106,565 shares subject to common stock options and 5,953,586 shares held directly by BP4 S.r.l. (&quot;BP4&quot;) of which 2,953,586 shares are issuable upon the conversion of $7 million of preferred stock at $2.37 per share, as adjusted to date. Innovest S.p.A. (&quot;Innovest&quot;) is the controlling shareholder of BP4 and Mr. Trombetta is a controlling shareholder and director of Innovest, and, as such, is deemed to have voting and investment power over the securities held by BP4. Mr. Trombetta disclaims beneficial ownership of all securities held by BP4.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">10.&nbsp; &nbsp;Includes an aggregate of 1,279,301 shares of common stock underlying outstanding options, 1,193,990 shares of common stock issuable upon termination of employment and 2,953,586 shares of common stock issuable<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp;upon the conversion of $7 million of preferred stock at $2.37 per share. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">11.&nbsp; The information with respect to their 5% shareholder has been derived from form<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;13G&nbsp;submitted by the owner of shares to the SEC on March 20, 2018, reporting beneficial ownership as of December 31, 2017.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: -18pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Securities Authorized fo<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">r Issuance under Equity Compensation Plans </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Equity Compensation Plan Information</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following table summarizes, as of December 31, 2017, the (i) options granted under the Milestone Scientific 2004 Stock Option Plan (the &ldquo;2004 Plan&rdquo;) and (ii) options granted under the Milestone Scientific 2011 Equity Compensation Plan (f/k/a Milestone Scientific 2011 Stock Option Plan) (the &ldquo;2011 Plan&rdquo;). The shares covered by outstanding options and warrants are subject to adjustment for changes in capitalization, stock splits, stock dividends and similar events. No other equity compensation has been issued.&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 46%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Equity compensation plan approved by stockholders</p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> of Securities to be issued upon exercise of outstanding options and warrants</font></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 178px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted-average exercise<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> price of outstanding options and warrants</font></p>
			</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> of securities remaining available for future issuance under equity compensation plan</font></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Grants under our 2004 Stock Option Plan (1)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,333</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 138px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.49</td>
			<td id=".symb.4" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 167.688px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3" style="width: 9px;">&nbsp;</td>
			<td id=".amt.B3" style="width: 138px;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1px;">&nbsp;</td>
			<td id=".amt.B4" style="width: 167.688px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Grants under our 2011 Stock Option Plan (2)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">1,912,002</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 9px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 138px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">1.73</td>
			<td id=".symb.4" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 167.688px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">1,001,889</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3" style="width: 9px;">&nbsp;</td>
			<td id=".amt.B3" style="width: 138px;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1px;">&nbsp;</td>
			<td id=".amt.B4" style="width: 167.688px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>1,985,335</b></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9px;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 138px;"><b>&nbsp;</b></td>
			<td id=".symb.4" style="width: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&nbsp;</b></td>
			<td id=".amt.4" style="width: 167.688px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><br>
			<b>1,001,889</b></td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:-18pt;"><br>
1<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">The 2004 Plan, as amended, provided for awards of options up to a maximum 750,000 shares of Milestone Scientific&#39;s common stock and expired in July 2014. Options were granted to employees, officers, directors and consultants of Milestone Scientific for the purchase of common stock of Milestone Scientific at a price not less than the fair market value of the common stock on the date of the grant. In general, options awarded under the 2004 Plan became exercisable over a three-year period from the grant date and expire five years after the date of grant. No options were exercised in 2017 or 2016.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:-18pt;">2<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The 2011 Plan, as amended, provides for awards of restricted common stock and options to purchase up to a maximum 4,000,000 shares of common stock and expires in June 2021. Options may be granted to employees, directors and consultants of Milestone Scientific for the purchase of shares of common stock at a price not less than the fair market value of common stock on the date of grant. In general, options become exercisable over a three-year period from the grant date and expire five years after the date of grant. For the year ended December 31, 2017, 83,333 shares were exercised.</font>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">41</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Item 13. Certain Relationships and Related Tra<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">nsactions and Director</font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> <b>Independence.</b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 2016, Milestone Scientific entered a three-year consulting agreement with K. Tucker Anderson to provide business and strategic services to Milestone Scientific. The fee for these services are $100,000 per year which is paid in shares of common stock on a quarterly basis, valued at the closing price per share of common stock on the last trading day of each quarter.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific has a manufacturing agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Milestone Scientific purchased $2,146,108 and $3,025,249 for the twelve months ended December 31, 2017 and 2016, respectively. Milestone Scientific owed $985,678&nbsp;and $1,235,052 to this manufacturer as of December 31, 2017 and 2016, respectively</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific had $2,071,000 of related party sales of handpieces and devices to Milestone China and Milestone China<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s agent for the twelve months ended December 31, 2017. Milestone Scientific had $3,425,000 of related party sales of handpieces and devices to Milestone China for the twelve months ended December 31, 2016. As of December 31, 2017, and 2016, Milestone Scientific recorded deferred revenues of $1,725,450 and $1,001,800, respectively, and deferred costs of $1,109,611 and $620,041, respectively, associated with sales to Milestone China.&nbsp; As of December 31, 2017, and 2016, Milestone China&rsquo;s agent owed $1,725,450 and $2,714,600, respectively, to Milestone Scientific which is included in related party accounts receivable on the condensed consolidated balance sheets.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In August 2016, a stockholder of Milestone Scientific entered a three-year agreement with Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $100,000 for each of the twelve months ended December 31, 2017 and 2016.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In January 2017, Milestone Scientific entered into a 12-month agreement with Innovest S.p.A. to provide consulting services. This agreement will renew for successive 12-month terms unless terminated by Innovest S.p.A or Milestone Scientific. Expenses recognized on this agreement were $80,000 for the twelve months ended December 31, 2017. This agreement is expected to continue into 2018.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item 14. Principal Accounting Fees and Services</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effective July 18, 2016, our Audit Committee engaged Friedman LLP (&ldquo;Friedman&rdquo;) to replace Baker Tilly Virchow Krause, LLP (&ldquo;Baker Tilly&rdquo;) as our&nbsp;principal accounting firm. The aggregate fees billed by our principal accounting firms for the years ended December 31, 2017 and 2016 are as follows:&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Audit fees*</p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Audit Fees and Audit Related fees</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">244,300</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">291,500</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;(1)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tax Fees</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,854</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total Fees</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">258,154</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">321,500</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">* Includes fees for professional services rendered for the audit of our annual financial statements and the review of financial statements included in our <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">report on Form 10-Qs or services that are reasonably related to the performance of the audit or normally provided in connection with statutory and regulatory filings.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">(1) The audit fees in 2016 includes $180,000 of fees billed by Friedman and $111,500<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> of fees billed by Baker Tilly.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Audit Committee Pre-Approval Policies and Procedures</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Audit Committee charter provides that the Audit Committee will pre-approve audit services and non-audit services to be provided by the independent auditors before the accountant is engaged to render these services. The Audit Committee may consult with management in the decision-making process but may not delegate this authority to management. The Audit Committee may delegate its authority to preapprove services to one or more committee members, provided that the designees present the pre-approvals to the full committee at the next committee meeting. All audit and non-audit services performed by the independent accountants have been pre-approved by the Audit Committee to assure that such services do not impair the auditors&rsquo; independence from us.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">42</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>PART IV </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Item 15. Exhibits and Financial Statement Schedules</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">The following documents are filed as part of this Report:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Financial Statements. See Index to Financial Statements on page F-1.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Financial Statement Schedule</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Schedules are omitted because the information required is not applicable or the required information is shown in the consolidated financial statements or notes thereto.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:7.5pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:26pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Exhibits</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:3pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain of the following exhibits were filed as Exhibits to previous filings filed by Milestone Scientific under the Securities Act of 1933, as amended, or reports filed under the Securities and Exchange Act of 1934, as amended, and are hereby incorporated by reference.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:3pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exhibit No</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Description</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">3.1</font></p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Restated Certificate of Incorporation of Milestone filed on September 6, 2013 (11)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">3.2</font></p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Certificate of Designation filed on April 18, 2014 (12)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">3.3</font></p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Certificate of Correction to the Certificate of Designation filed on May 12, 2014 (13)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">3.4</font></p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By-laws of Milestone (1)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">4.1</font></p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Specimen stock certificate (2)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">4.2</font></p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of warrant agreement, including form of warrant (4)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">4.3</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Common Stock Purchase Warrant issued in the 2016 Public Offering (16)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.1</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Lease dated November 25, 1996 between Livingston Corporate Park Associates, L.L.C. and Milestone (3)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.2</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Lease amendment dated April 28, 2004 between Livingston Corporate Park Associates, L.L.C. And Milestone (4)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.4</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Employment Agreement with Leonard Osser, dated September 1, 2009** (6)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.5</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2011 Equity Compensation Plan (7)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.6</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Amendment to the Employment Agreement with Leonard Osser, dated March 6, 2013** (11)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.7</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Master Supply and Distribution Agreement, dated July 3, 2013, between Milestone Scientific Inc and Tri-anim Health Services, Inc (9)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">10.8</font></p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Amendment to the Employment Agreement with Leonard Osser, effective March 17, 2014** (10)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">10.9</font></p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Agreement with Mark Hochman, dated July 2015 (13)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.1</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Investment Agreement, dated April 15, 2014, between Milestone Scientific Inc. and BP4 S.p.A. (12)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.11</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exclusive Distribution and Supply Agreement, dated as of June 20, 2016,<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;among Milestone Scientific Inc., Wand Dental, Inc. and Henry Schein, Inc. (14)</font></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.12</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Amended and Restated Employment Agreement, dated December 1, 2016,<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;between Wand Dental Inc. and Gian Domenico Trombetta (15)</font></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.13</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Final Form of Asset Purchase Agreement, dated June 2, 2017, among APAD Octrooi B.V., APAD B.V., and Milestone Scientific Inc. (17)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.14</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Final form of the Memorandum of Agreement, dated June 6, 2017, between Solee Science &amp; Technology U.S.A. Ltd. and Milestone Scientific Inc. (18)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.15</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Final form of the Promissory Note, dated June 6, 2017, in the principal amount of $1,275,000 made by Solee Science &amp; Technology U.S.A. Ltd. to Milestone Scientific Ltd. (18)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.16</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Final form of the Stock Option Agreement, dated June 6, 2017, Solee Science &amp; Technology U.S.A. Ltd. and Milestone Scientific Inc. (18)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.17</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">New Employment Agreement between Milestone Scientific Inc. and Leonard Osser dated as of July 10, 2017. (19)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.18</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Employment Agreement between Milestone Scientific Inc. and Daniel Goldberger dated as of July 10, 2017. (19)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.19</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Covenant Agreement between Milestone Scientific Inc. and Daniel Goldberger dated and effective as of July 10, 2017. (19)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.20</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Consultant Agreement between Milestone Medical Inc. and U.S. Asian Consulting Group, LLC dated as of July 10, 2017. (20)</p>
			</td>
		</tr>

</table>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">43</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">21.1</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">List of Subsidiaries (12)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">23.1</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Consent of Friedman, LLP*</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">23.2</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Consent of Baker Tilly Virchow Krause, LLP*</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">31.1</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Rule 13a-14(a) Certification-Chief Executive Officer*</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">31.2</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Rule 13a-14(a) Certification-Chief Financial Officer*</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">32.1</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 1350 Certifications-Chief Executive Officer***</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">32.2</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 1350 Certifications-Chief Financial Officer***</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">101.INS</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">XBRL Instance Document*</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">101.SCH</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">XBRL Taxonomy Extension Schema Document*</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">101.CAL</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">XBRL Taxonomy Extension Calculation Linkbase Document*</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">101.LAB</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">XBRL Taxonomy Extension Label Linkbase Document*</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">101.PRE</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">XBRL Taxonomy Extension Presentation Linkbase Document*</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:13.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">101.DEF</p>
			</td>
			<td style="vertical-align:middle;width:1.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:85.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">XBRL Taxonomy Extension Definition Linkbase Document*</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><u>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</font></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">*<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed herewith. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">**<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;Indicates management contract or compensatory plan or arrangement. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">***<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Furnished, not filed, in accordance with item 601(32) (ii) of Regulations-S-K.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Registration Statement on Form SB-2 No. 333-92324.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Amendment No. 1 to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Registration Statement on Form SB-2 No. 333-92324.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 10-KSB for the year ended December 31, 1996.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 10-KSB for the year ended December 31, 2004.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">5)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Registration Statement on Form S-2 No. 333-110367, Amendment No. 5.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">6)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 10-K for the year ended December 31, 2009.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">7)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Filed as Appendix A to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Proxy Statement filed with the SEC on May 2, 2011 and incorporated herein by reference.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">8)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s 10-K for the year ended December 31, 2014.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">9)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 8-K filed with the SEC on July 9, 2014.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 10-Q filed with the SEC on May 13, 2014.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">11)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 10-K for the year ended December 31, 2013.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">12)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 8-K filed with the SEC on April 18, 2014.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">13)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 10-K for the year ended December 31, 2015.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">14)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 8-K filed with the SEC on June 30, 2016.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">15)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 8-K filed with the SEC on December 2, 2016.</font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">16)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 8-K filed with the SEC on December 16, 2016.</font></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">17)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 8-K filed with the SEC on June 2, 2017.</font></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">18)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 8-K filed with the SEC on June 7, 2017.</font></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">19)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 8-K filed with the SEC on July 10, 2017.</font></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">20)</p>
			</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incorporated by reference to Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s Form 10-Q filed with the SEC on August 14, 2017.</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">44</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">In accordance with Section<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table align="right" border="0" cellpadding="0" cellspacing="0" style="width:35%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="2" style="vertical-align:middle;width:95%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Milestone Scientific Inc.</p>
			</td>
			<td style="vertical-align:middle;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">By:</p>
			</td>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:88%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">/s/ Leonard Osser</p>
			</td>
			<td style="vertical-align:middle;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:88%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Interim Chief Executive Officer</p>
			</td>
			<td style="vertical-align:middle;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:88%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">(Principal Executive Officer)</p>
			</td>
			<td style="vertical-align:middle;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">Date: April 2, 2018</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">dates indicated.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;"><b>Signature</b></p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;"><b>Date</b></p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;"><b>Title</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">/s/ Leonard Osser</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">April 2, 2018</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Interim Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Leonard Osser</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">(Principal Executive Officer)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">/s/ Joseph D&#39;Agostino</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">April 2, 2018</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Chief Financial Officer and Chief Operating Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Joseph D&#39;Agostino</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">(Principal Financial Officer)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">/s/ Leslie Bernhard</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">April 2, 2018</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Chairman and Director</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Leslie Bernhard</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">/s/ Gian Domenico Trombetta</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">April 2, 2018</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Director</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Gian Domenico Trombetta</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">/s/ Edward J. Zelnick, M.D.</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">April 2, 2018</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Director</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Edward J. Zelnick, M.D.</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;border-bottom:solid 1px #000000;;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">/s/ Leonard Schiller</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">April 2, 2018</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Director</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:42%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Leonard Schiller</p>
			</td>
			<td style="vertical-align:middle;width:3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:20%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:22.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td colspan="3" style="vertical-align:middle;width:31%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;width:43.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;border-bottom:solid 1px #000000;;width:44.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">/s/ Michael McGeehan</p>
			</td>
			<td style="vertical-align:middle;width:1.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align: middle; width: 237px;">April 2, 2018</td>
			<td style="vertical-align: middle; width: 441px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Director</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;width:44.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Michael McGeehan</p>
			</td>
			<td style="vertical-align:middle;width:1.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align: middle; width: 237px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 441px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;width:44.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:1.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align: middle; width: 237px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 441px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:22.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:3.4%;">&nbsp;</td>
			<td style="vertical-align:middle;width:18.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:10.6%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 103px;">&nbsp;</td>
			<td style="vertical-align: middle; width: 441px;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">45</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>REPORT&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;text-indent:1.5pt;"><b><u>For the Years ended December 31, 2017 and 2016</u></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="margin-left:1.6%;width:98.4%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">Reports of<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Independent Registered Public Accounting Firm</font></p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">F-2</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">Consolidated Financial Statements:</p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">Consolidated Balance Sheets</p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">F-3</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">Consolidated Statements of Operations</p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">F-4</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">Consolidated Statements of Changes in Stockholders<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo; Equity</font></p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">F-5</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">Consolidated Statements of Cash Flows</p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">F-6</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">Notes to Consolidated Financial Statements</p>
			</td>
			<td style="vertical-align:top;width:10.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp; F-7- F-26</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;,Times,Serif; font-size: 10pt;">&nbsp;</div>

<hr style="page-break-after: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">To the Board of Directors and</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Stockholders of Milestone Scientific, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Opinion on the Financial Statements</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We have audited the accompanying consolidated balance sheets of Milestone Scientific, Inc. and subsidiaries (the &ldquo;Company&rdquo;) as of December 31, 2017 and 2016, and the related consolidated statements of operations, statement of changes in stockholders<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo; equity, and cash flows for each of the years in the two-year period ended December 31, 2017, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Basis for Opinion</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">These consolidated financial statements are the responsibility of the Company<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Friedman LLP</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have served as the Company&#39;s auditor since 2016</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">East Hanover, New Jersey</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">April 2, 2018</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="4" id="13198" sectdesc="Balance Sheet">&nbsp;</div>

<div data-td-statement-type="balance-sheet" data-td-taggable-table="" data-td-v2v-id="1522337886526" id="thunderdome-statement-848163">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES </font></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">CONSOLIDATED BALANCE SHEETS </font></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 459px;">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">December 31, 2017</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">December 31, 2016</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 459px;">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><u>ASSETS</u></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current Assets:</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Cash and cash equivalents</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244792" style="font-weight: inherit; font-style: normal;">2,636,956</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244793" style="font-weight: inherit; font-style: normal;">3,602,229</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Accounts receivable, net</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244794" style="font-weight: inherit; font-style: normal;">1,535,513</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244795" style="font-weight: inherit; font-style: normal;">802,384</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Accounts receivable from related party</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244796" style="font-weight: inherit; font-style: normal;">1,725,450</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244797" style="font-weight: inherit; font-style: normal;">2,714,600</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Other receivable</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244798" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244799" style="font-weight: inherit; font-style: normal;">10,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Notes receivable from financing transaction, short term</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244800" style="font-weight: inherit; font-style: normal;">500,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244801" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Prepaid expenses and other current assets</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244802" style="font-weight: inherit; font-style: normal;">436,410</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244803" style="font-weight: inherit; font-style: normal;">291,929</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Deferred cost related party</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244804" style="font-weight: inherit; font-style: normal;">1,109,671</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244805" style="font-weight: inherit; font-style: normal;">620,041</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Inventories net</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244806" style="font-weight: inherit; font-style: normal;">3,379,209</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244807" style="font-weight: inherit; font-style: normal;">4,602,719</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Advances on contracts</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244808" style="font-weight: inherit; font-style: normal;">697,192</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244809" style="font-weight: inherit; font-style: normal;">700,900</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total current assets</p>
			</td>
			<td id=".symb.2" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244810" style="font-weight: inherit; font-style: normal;">12,020,401</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244811" style="font-weight: inherit; font-style: normal;">13,344,802</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Furniture, fixtures &amp; equipment net</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244812" style="font-weight: inherit; font-style: normal;">141,760</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">159,026</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Patents, net</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244814" style="font-weight: inherit; font-style: normal;">2,789,748</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">660,454</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Notes receivable from financing transaction long term</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244816" style="font-weight: inherit; font-style: normal;">650,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244817" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Other assets</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244818" style="font-weight: inherit; font-style: normal;">26,878</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244819" style="font-weight: inherit; font-style: normal;">17,355</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total assets</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244820" style="font-weight: inherit; font-style: normal;">15,628,787</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244821" style="font-weight: inherit; font-style: normal;">14,181,640</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 459px;">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><u>LIABILITIES AND STOCKHOLDERS<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo; EQUITY</font></u></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current Liabilities:</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Accounts payable</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244824" style="font-weight: inherit; font-style: normal;">977,623</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244825" style="font-weight: inherit; font-style: normal;">1,341,207</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Accounts payable related party</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244826" style="font-weight: inherit; font-style: normal;">985,678</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244827" style="font-weight: inherit; font-style: normal;">1,235,052</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Accrued expenses and other payables</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244828" style="font-weight: inherit; font-style: normal;">2,287,908</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244829" style="font-weight: inherit; font-style: normal;">1,436,262</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Deferred profit, related party</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244830" style="font-weight: inherit; font-style: normal;">751,500</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244831" style="font-weight: inherit; font-style: normal;">630,990</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px; text-indent: 18pt;">Deferred revenue, related party</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244832" style="font-weight: inherit; font-style: normal;">1,725,450</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244833" style="font-weight: inherit; font-style: normal;">1,001,800</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total current liabilities</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244834" style="font-weight: inherit; font-style: normal;">6,728,159</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244835" style="font-weight: inherit; font-style: normal;">5,645,311</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px; text-indent: 18pt;">Deferred gain from financing transaction</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244836" style="font-weight: inherit; font-style: normal;">1,400,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244837" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244838" style="font-weight: inherit; font-style: normal;">8,128,159</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244839" style="font-weight: inherit; font-style: normal;">5,645,311</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 459px;">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Commitments and Contingencies</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stockholders<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo; Equity</font></p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0pt; margin-left: 18pt;">Series A convertible preferred stock, par value $.001, authorized 5,000,000 shares, and 7,000 shares<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> issued and outstanding as December 31, 2017 and 2016.</font></p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244840" style="font-weight: inherit; font-style: normal;">7</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244841" style="font-weight: inherit; font-style: normal;">7</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0pt; margin-left: 18pt;">Common stock, par value $.001; authorized 50,000,000 shares; 33,191,571 shares issued, 1,401,247 shares to be issued and 33,158,238 shares outstanding as of December 31, 2017; 30,457,224 shares issued, 1,270,481 shares to be issued and 30,423,891 shares outstanding as of<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> December 31, 2016</font></p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244842" style="font-weight: inherit; font-style: normal;">34,593</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244843" style="font-weight: inherit; font-style: normal;">31,720</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Additional paid-in capital</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244844" style="font-weight: inherit; font-style: normal;">86,689,084</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244845" style="font-weight: inherit; font-style: normal;">82,761,503</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Accumulated deficit</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244846" style="font-weight: inherit; font-style: normal;">(78,568,284</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244847" style="font-weight: inherit; font-style: normal;">(73,381,491</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Treasury stock, at cost, 33,333 shares</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244848" style="font-weight: inherit; font-style: normal;">(911,516</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244849" style="font-weight: inherit; font-style: normal;">(911,516</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total Milestone Scientific Inc. stockholders&#39; equity</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244850" style="font-weight: inherit; font-style: normal;">7,243,884</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244851" style="font-weight: inherit; font-style: normal;">8,500,223</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Noncontrolling interest</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244852" style="font-weight: inherit; font-style: normal;">256,744</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244853" style="font-weight: inherit; font-style: normal;">36,106</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total equity</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244854" style="font-weight: inherit; font-style: normal;">7,500,628</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244855" style="font-weight: inherit; font-style: normal;">8,536,329</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities and stockholders<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo; equity</font></p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244856" style="font-weight: inherit; font-style: normal;">15,628,787</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244857" style="font-weight: inherit; font-style: normal;">14,181,640</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 459px;">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 459px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">See Notes to Consolidated Financial Statements</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p>&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;,Times,Serif; font-size: 10pt;">F-3</div>

<hr style="page-break-after: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="5" id="13199" sectdesc="Income Statement">&nbsp;</div>

<div data-td-statement-type="income" data-td-taggable-table="" data-td-v2v-id="1522337894904" id="thunderdome-statement-848164">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">MILESTONE SCIENTIFIC INC. </font></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">CONSOLIDATED STATEMENTS OF OPERATIONS </font></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">YEARS ENDED DECEMBER 31, 2017 AND 2016 </font></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">2017</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">2016</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Revenue</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales, net</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244871" style="font-weight: inherit; font-style: normal;">11,281,886</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244872" style="font-weight: inherit; font-style: normal;">10,482,005</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of products sold</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244873" style="font-weight: inherit; font-style: normal;">4,312,507</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244874" style="font-weight: inherit; font-style: normal;">4,175,533</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244875" style="font-weight: inherit; font-style: normal;">6,969,379</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244876" style="font-weight: inherit; font-style: normal;">6,306,472</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244877" style="font-weight: inherit; font-style: normal;">11,930,951</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244878" style="font-weight: inherit; font-style: normal;">11,549,961</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244879" style="font-weight: inherit; font-style: normal;">272,746</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244880" style="font-weight: inherit; font-style: normal;">1,270,471</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total operating expenses</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244881" style="font-weight: inherit; font-style: normal;">12,203,697</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244882" style="font-weight: inherit; font-style: normal;">12,820,432</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244883" style="font-weight: inherit; font-style: normal;">(5,234,318</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244884" style="font-weight: inherit; font-style: normal;">(6,513,960</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other expenses</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244885" style="font-weight: inherit; font-style: normal;">(4,930</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244886" style="font-weight: inherit; font-style: normal;">(5,088</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest income</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244887" style="font-weight: inherit; font-style: normal;">9,298</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244888" style="font-weight: inherit; font-style: normal;">1,285</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss before provision for income tax and equity in net earnings of equity investments</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244889" style="font-weight: inherit; font-style: normal;">(5,229,950</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244890" style="font-weight: inherit; font-style: normal;">(6,517,763</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Provision) benefit for income tax</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244891" style="font-weight: inherit; font-style: normal;">(19,093</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244892" style="font-weight: inherit; font-style: normal;">19,101</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss before equity in net earnings of equity investments</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244893" style="font-weight: inherit; font-style: normal;">(5,249,043</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244894" style="font-weight: inherit; font-style: normal;">(6,498,662</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss&nbsp;on earnings from China Joint Venture</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244895" style="font-weight: inherit; font-style: normal;">(120,510</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244896" style="font-weight: inherit; font-style: normal;">(795,827</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244897" style="font-weight: inherit; font-style: normal;">(5,369,553</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244898" style="font-weight: inherit; font-style: normal;">(7,294,489</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to noncontrolling interests</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244899" style="font-weight: inherit; font-style: normal;">(182,760</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29244900" style="font-weight: inherit; font-style: normal;">(1,347,982</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to Milestone Scientific Inc.</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244901" style="font-weight: inherit; font-style: normal;">(5,186,793</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244902" style="font-weight: inherit; font-style: normal;">(5,946,507</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share applicable to common stockholders<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&mdash;</font></p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244903" style="font-weight: inherit; font-style: normal;">(0.16</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244904" style="font-weight: inherit; font-style: normal;">(0.22</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244905" style="font-weight: inherit; font-style: normal;">(0.16</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244906" style="font-weight: inherit; font-style: normal;">(0.22</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding and to be issued<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&mdash;</font></p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244907" style="font-weight: inherit; font-style: normal;">32,703,897</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244908" style="font-weight: inherit; font-style: normal;">26,966,988</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted</p>
			</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244909" style="font-weight: inherit; font-style: normal;">32,703,897</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29244910" style="font-weight: inherit; font-style: normal;">26,966,988</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">See Notes to&nbsp;Consolidated Financial Statements</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;,Times,Serif; font-size: 10pt;">F-4</div>

<hr style="page-break-after: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="margin: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="7" id="13200" sectdesc="Stockholders' Equity">&nbsp;</div>

<div data-td-statement-type="stockholders-equity" data-td-taggable-table="" data-td-v2v-id="1522337915089" id="thunderdome-statement-848165">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 95%; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 2.5%; margin-left: 2.5%;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="25" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES </font></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="25" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#39; EQUITY </font></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="25" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">YEARS ENDED DECEMBER 31, 2017 AND 2016 </font></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; text-align: center;">&nbsp;</td>
			<td id=".amt.B2" style="width: 1px; text-align: center;">&nbsp;</td>
			<td id=".trail.B2" style="text-align: center;">&nbsp;</td>
			<td id=".symb.B3" style="text-align: center;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: center;">&nbsp;</td>
			<td id=".trail.B3" style="width: 10px; text-align: center;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: center;">&nbsp;</td>
			<td id=".trail.B4" style="text-align: center;">&nbsp;</td>
			<td id=".symb.B5" style="text-align: center;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: center;">&nbsp;</td>
			<td id=".trail.B5" style="text-align: center;">&nbsp;</td>
			<td id=".symb.B6" style="text-align: center;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center;">&nbsp;</td>
			<td id=".trail.B6" style="text-align: center;">&nbsp;</td>
			<td id=".symb.B7" style="text-align: center;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center;">&nbsp;</td>
			<td id=".trail.B7" style="text-align: center;">&nbsp;</td>
			<td id=".symb.B8" style="text-align: center;">&nbsp;</td>
			<td id=".amt.B8" style="text-align: center;">&nbsp;</td>
			<td id=".trail.B8" style="text-align: center;">&nbsp;</td>
			<td id=".symb.B9" style="text-align: center;">&nbsp;</td>
			<td id=".amt.B9" style="text-align: center;">&nbsp;</td>
			<td id=".trail.B9" style="text-align: center;">&nbsp;</td>
			<td id=".symb.B10" style="text-align: center;">&nbsp;</td>
			<td id=".amt.B10">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="4" id=".amt.D3" style="width: 120.1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Preferred Stock</p>
			</td>
			<td id=".trail.D3" style="width: 10px; text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="4" id=".amt.D5" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Common Stock</p>
			</td>
			<td id=".trail.D5" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29244946" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B6" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29244947" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B7" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B8" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B8" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29244948" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B8" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B9" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B9" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29244949" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B9" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B10" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B10" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29244950" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="1" id=".amt.D2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Shares</p>
			</td>
			<td id=".trail.D2" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Amount</p>
			</td>
			<td id=".trail.D3" style="width: 10px; text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="1" id=".amt.D4" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Shares</p>
			</td>
			<td id=".trail.D4" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Amount</p>
			</td>
			<td id=".trail.D5" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Additional<br>
			Paid-in<br>
			Capital </font></p>
			</td>
			<td id=".trail.D6" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D7" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Accumulated<br>
			Deficit </font></p>
			</td>
			<td id=".trail.D7" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D8" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Noncontrolling<br>
			interest </font></p>
			</td>
			<td id=".trail.D8" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D9" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Treasury<br>
			Stock </font></p>
			</td>
			<td id=".trail.D9" style="text-align: center; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D10" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total </font></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2016</p>
			</td>
			<td id=".amt.2" style="width: 1px; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244960" style="font-weight: inherit; font-style: normal;">7,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244961" style="font-weight: inherit; font-style: normal;">7.00</em></td>
			<td id=".trail.3" nowrap="true" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244962" style="font-weight: inherit; font-style: normal;">22,685,160</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">$</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244963" style="font-weight: inherit; font-style: normal;">22,685</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244964" style="font-weight: inherit; font-style: normal;">78,632,383</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244965" style="font-weight: inherit; font-style: normal;">(67,434,984</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244966" style="font-weight: inherit; font-style: normal;">(1,143,083)</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244967" style="font-weight: inherit; font-style: normal;">(911,516</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244968" style="font-weight: inherit; font-style: normal;">9,165,492</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Consolidation of Milestone Education<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29244969" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244970" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244971" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244972" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29244973" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244974" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244975" style="font-weight: inherit; font-style: normal;">16,346</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244976" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244977" style="font-weight: inherit; font-style: normal;">16,346</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock based compensation</p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29244978" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244979" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244980" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244981" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244982" style="font-weight: inherit; font-style: normal;">580,347</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244983" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244984" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244985" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244986" style="font-weight: inherit; font-style: normal;">580,347</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock to be issued to employee for compensation</p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29244987" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29244988" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244989" style="font-weight: inherit; font-style: normal;">14,181</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244990" style="font-weight: inherit; font-style: normal;">14</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244991" style="font-weight: inherit; font-style: normal;">29,986</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244992" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244993" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244994" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244995" style="font-weight: inherit; font-style: normal;">30,000</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock to be issued to employee for stock program</p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29244996" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29244997" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244998" style="font-weight: inherit; font-style: normal;">31,053</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29244999" style="font-weight: inherit; font-style: normal;">31</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245000" style="font-weight: inherit; font-style: normal;">58,969</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245001" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245002" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245003" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245004" style="font-weight: inherit; font-style: normal;">59,000</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock issued to employee for exercise of stock options</p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245005" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245006" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245007" style="font-weight: inherit; font-style: normal;">327,778</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245008" style="font-weight: inherit; font-style: normal;">328</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245009" style="font-weight: inherit; font-style: normal;">137,172</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245010" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245011" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245012" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245013" style="font-weight: inherit; font-style: normal;">137,500</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock issued for payment of consulting services</p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245014" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245015" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245016" style="font-weight: inherit; font-style: normal;">270,526</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245017" style="font-weight: inherit; font-style: normal;">263</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245018" style="font-weight: inherit; font-style: normal;">504,150</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245019" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245020" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245021" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245022" style="font-weight: inherit; font-style: normal;">504,413</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock to be issued to employee for bonuses</p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245023" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245024" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245025" style="font-weight: inherit; font-style: normal;">259,765</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245026" style="font-weight: inherit; font-style: normal;">260</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245027" style="font-weight: inherit; font-style: normal;">539,240</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245028" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245029" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245030" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245031" style="font-weight: inherit; font-style: normal;">539,500</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sale of Common Stock - Private Placement</p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245032" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245033" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245034" style="font-weight: inherit; font-style: normal;">1,104,200</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245035" style="font-weight: inherit; font-style: normal;">1,104</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245036" style="font-weight: inherit; font-style: normal;">2,223,896</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245037" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245038" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245039" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245040" style="font-weight: inherit; font-style: normal;">2,225,000</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sale of Common Stock - Public Offering</p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245041" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245042" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245043" style="font-weight: inherit; font-style: normal;">2,000,000</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245044" style="font-weight: inherit; font-style: normal;">2,000</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245045" style="font-weight: inherit; font-style: normal;">2,571,220</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245046" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B8" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B8" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245047" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B8" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B9" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245048" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245049" style="font-weight: inherit; font-style: normal;">2,573,220</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common Stock exchanged for MMD</p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245050" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245051" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245052" style="font-weight: inherit; font-style: normal;">5,035,042</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245053" style="font-weight: inherit; font-style: normal;">5,035</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245054" style="font-weight: inherit; font-style: normal;">(2,515,860</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245055" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245056" style="font-weight: inherit; font-style: normal;">2,510,825</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245057" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245058" style="font-weight: inherit; font-style: normal;">-</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".amt.2" style="width: 1px; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245059" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245060" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 10px; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245061" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245062" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B5" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245063" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245064" style="font-weight: inherit; font-style: normal;">(5,946,507</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245065" style="font-weight: inherit; font-style: normal;">(1,347,982)</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245066" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245067" style="font-weight: inherit; font-style: normal;">(7,294,489)</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, January 1, 2017</p>
			</td>
			<td id=".amt.2" style="width: 1px; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245068" style="font-weight: inherit; font-style: normal;">7,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245069" style="font-weight: inherit; font-style: normal;">7</em></td>
			<td id=".trail.3" nowrap="true" style="width: 10px; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245070" style="font-weight: inherit; font-style: normal;">31,727,705</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245071" style="font-weight: inherit; font-style: normal;">31,720</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245072" style="font-weight: inherit; font-style: normal;">82,761,503</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245073" style="font-weight: inherit; font-style: normal;">(73,381,491</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245074" style="font-weight: inherit; font-style: normal;">36,106</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245075" style="font-weight: inherit; font-style: normal;">(911,516</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245076" style="font-weight: inherit; font-style: normal;">8,536,329</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock based compensation</p>
			</td>
			<td id=".amt.2" style="width: 1px; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245077" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245078" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245079" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245080" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245081" style="font-weight: inherit; font-style: normal;">651,413</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245082" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245083" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245084" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245085" style="font-weight: inherit; font-style: normal;">651,413</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Common stock to be issued to employee for compensation</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245086" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245087" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245088" style="font-weight: inherit; font-style: normal;">10,913</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245089" style="font-weight: inherit; font-style: normal;">11</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245090" style="font-weight: inherit; font-style: normal;">14,989</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245091" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245092" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245093" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245094" style="font-weight: inherit; font-style: normal;">15,000</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Common stock issued to employee for exercise of stock options</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245095" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245096" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245097" style="font-weight: inherit; font-style: normal;">83,333</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245098" style="font-weight: inherit; font-style: normal;">83</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245099" style="font-weight: inherit; font-style: normal;">62,417</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245100" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245101" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245102" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245103" style="font-weight: inherit; font-style: normal;">62,500</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Common stock issued for payment of consulting services</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245104" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245105" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245106" style="font-weight: inherit; font-style: normal;">410,729</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245107" style="font-weight: inherit; font-style: normal;">419</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245108" style="font-weight: inherit; font-style: normal;">548,092</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245109" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245110" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245111" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245112" style="font-weight: inherit; font-style: normal;">548,511</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Common stock to be issued to employee for bonuses</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245113" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245114" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245115" style="font-weight: inherit; font-style: normal;">158,082</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245116" style="font-weight: inherit; font-style: normal;">158</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245117" style="font-weight: inherit; font-style: normal;">259,834</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245118" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245119" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245120" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245121" style="font-weight: inherit; font-style: normal;">259,992</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Common stock issued for asset acquisition</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245122" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245123" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245124" style="font-weight: inherit; font-style: normal;">1,646,358</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245125" style="font-weight: inherit; font-style: normal;">1,646</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245126" style="font-weight: inherit; font-style: normal;">2,484,354</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245127" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B8" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B8" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245128" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B8" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B9" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245129" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245130" style="font-weight: inherit; font-style: normal;">2,486,000</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Common Stock exchanged for MMD shares</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245131" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245132" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245133" style="font-weight: inherit; font-style: normal;">311,998</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245134" style="font-weight: inherit; font-style: normal;">312</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245135" style="font-weight: inherit; font-style: normal;">(403,710</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245136" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245137" style="font-weight: inherit; font-style: normal;">403,398</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245138" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245139" style="font-weight: inherit; font-style: normal;">-</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock issued to directors for bonuses</p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245140" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245141" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245142" style="font-weight: inherit; font-style: normal;">120,000</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245143" style="font-weight: inherit; font-style: normal;">120</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245144" style="font-weight: inherit; font-style: normal;">159,480</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245145" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245146" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245147" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245148" style="font-weight: inherit; font-style: normal;">159,600</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Sale of Common Stock</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245149" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245150" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245151" style="font-weight: inherit; font-style: normal;">123,700</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245152" style="font-weight: inherit; font-style: normal;">124</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245153" style="font-weight: inherit; font-style: normal;">150,712</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245154" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245155" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245156" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245157" style="font-weight: inherit; font-style: normal;">150,836</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".amt.2" style="width: 1px; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245158" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245159" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 10px; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245160" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245161" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B5" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245162" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245163" style="font-weight: inherit; font-style: normal;">(5,186,7934</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245164" style="font-weight: inherit; font-style: normal;">(182,760</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245165" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245166" style="font-weight: inherit; font-style: normal;">(5,369,553)</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2017</p>
			</td>
			<td id=".amt.2" style="width: 1px; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245167" style="font-weight: inherit; font-style: normal;">7,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245168" style="font-weight: inherit; font-style: normal;">7</em></td>
			<td id=".trail.3" nowrap="true" style="width: 10px; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245169" style="font-weight: inherit; font-style: normal;">34,592,818</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.5" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245170" style="font-weight: inherit; font-style: normal;">34,593</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.6" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245171" style="font-weight: inherit; font-style: normal;">86,689,084</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.7" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245172" style="font-weight: inherit; font-style: normal;">(78,568,284</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.8" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245173" style="font-weight: inherit; font-style: normal;">256,744</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.9" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.9" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245174" style="font-weight: inherit; font-style: normal;">(911,516</em></td>
			<td id=".trail.9" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.10" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.10" style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245175" style="font-weight: inherit; font-style: normal;">7,500,628</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 150.9px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">See Notes to Consolidated Financial Statements</p>
			</td>
			<td id=".amt.B2" style="width: 1px; text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="width: 10px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B6" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B7" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B7" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B8" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B8" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B8" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B9" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B9" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B10" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B10" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;,Times,Serif; font-size: 10pt;">F-5</div>

<hr style="page-break-after: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="8" id="13201" sectdesc="Cash Flows">&nbsp;</div>

<div data-td-statement-type="cash-flows" data-td-taggable-table="" data-td-v2v-id="1522337922111" id="thunderdome-statement-848166">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES </font></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;">CONSOLIDATED STATEMENTS OF CASH FLOWS<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;">YEARS ENDED DECEMBER 31, 2017 AND 2016</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 561px;">&nbsp;</td>
			<td id=".symb.B2" style="width: 6px;">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 150px;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">2017</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">2016</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash flows from operating activities:</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245185" style="font-weight: inherit; font-style: normal;">(5,369,553</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245186" style="font-weight: inherit; font-style: normal;">(7,294,489</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Depreciation expense</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245187" style="font-weight: inherit; font-style: normal;">62,474</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245188" style="font-weight: inherit; font-style: normal;">92,667</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Amortization of patents</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245189" style="font-weight: inherit; font-style: normal;">510,676</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245190" style="font-weight: inherit; font-style: normal;">70,699</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Stock compensation</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245191" style="font-weight: inherit; font-style: normal;">651,413</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245192" style="font-weight: inherit; font-style: normal;">1,850,760</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Loss China joint venture</p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245193" style="font-weight: inherit; font-style: normal;">120,510</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245194" style="font-weight: inherit; font-style: normal;">795,827</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt; width: 561px;">Increase inventories allowance</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245195" style="font-weight: inherit; font-style: normal;">219,834</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245196" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Changes in operating assets and liabilities:</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">(Increase) Decrease in accounts receivable</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245197" style="font-weight: inherit; font-style: normal;">(733,129</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245198" style="font-weight: inherit; font-style: normal;">635,017</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Decrease (Increase) in accounts receivable related party</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245199" style="font-weight: inherit; font-style: normal;">989,150</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245200" style="font-weight: inherit; font-style: normal;">(1,727,210</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Decrease in other receivable</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245201" style="font-weight: inherit; font-style: normal;">10,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245202" style="font-weight: inherit; font-style: normal;">48,515</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Decrease (Increase) in inventories</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245203" style="font-weight: inherit; font-style: normal;">1,003,676</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245204" style="font-weight: inherit; font-style: normal;">(509,462</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Decrease to advances on contracts</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245205" style="font-weight: inherit; font-style: normal;">3,708</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245206" style="font-weight: inherit; font-style: normal;">514,228</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">(Increase) Decrease&nbsp;in&nbsp;prepaid expenses and other current assets</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245207" style="font-weight: inherit; font-style: normal;">(144,481</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245208" style="font-weight: inherit; font-style: normal;">12,675</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">(Increase) Decrease in other assets</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245209" style="font-weight: inherit; font-style: normal;">(9,523</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245210" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">(Decrease) Increase in accounts payable</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245211" style="font-weight: inherit; font-style: normal;">(363,584</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245212" style="font-weight: inherit; font-style: normal;">486,348</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Decrease in accounts payable related party</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245213" style="font-weight: inherit; font-style: normal;">(249,374</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29245214" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Decrease in deferred profit, related party</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245215" style="font-weight: inherit; font-style: normal;">(489,630</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245216" style="font-weight: inherit; font-style: normal;">(620,041</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Increase (Decrease)in accrued expenses and other payables</p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245217" style="font-weight: inherit; font-style: normal;">1,834,749</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245218" style="font-weight: inherit; font-style: normal;">(755,915</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Increase in deferred revenue</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245219" style="font-weight: inherit; font-style: normal;">723,650</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245220" style="font-weight: inherit; font-style: normal;">1,001,800</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Net cash used in operating activities</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245221" style="font-weight: inherit; font-style: normal;">(1,229,434</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245222" style="font-weight: inherit; font-style: normal;">(5,398,581</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash flows from investing activities:</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Purchase of intangible assets</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245223" style="font-weight: inherit; font-style: normal;">(39,520</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245224" style="font-weight: inherit; font-style: normal;">(15,615</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Purchase of property and equipment</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245225" style="font-weight: inherit; font-style: normal;">(6,008</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245226" style="font-weight: inherit; font-style: normal;">(15,344</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt; width: 561px;">Purchase of intangibles assets-APAD</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245227" style="font-weight: inherit; font-style: normal;">(153,647</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245228" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Consolidation of variable interest entity</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245229" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245230" style="font-weight: inherit; font-style: normal;">39,165</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Net cash (used in) provided by investing activities</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245231" style="font-weight: inherit; font-style: normal;">(199,175</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245232" style="font-weight: inherit; font-style: normal;">8,206</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash flows from financing activities:</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Net proceeds on Private Placement Offering</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245233" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245234" style="font-weight: inherit; font-style: normal;">2,225,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Net proceeds on Public offering</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245235" style="font-weight: inherit; font-style: normal;">150,836</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245236" style="font-weight: inherit; font-style: normal;">2,573,220</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Proceed from financing transaction</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245237" style="font-weight: inherit; font-style: normal;">250,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29245238" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Proceeds from exercise of stock options</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245239" style="font-weight: inherit; font-style: normal;">62,500</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245240" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Net cash provided by financing activities</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245241" style="font-weight: inherit; font-style: normal;">463,336</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245242" style="font-weight: inherit; font-style: normal;">4,798,220</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net decrease in cash and cash equivalents</p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245243" style="font-weight: inherit; font-style: normal;">(965,273</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245244" style="font-weight: inherit; font-style: normal;">(592,155</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at beginning of period</p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245245" style="font-weight: inherit; font-style: normal;">3,602,229</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245246" style="font-weight: inherit; font-style: normal;">4,194,384</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at end of period</p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245247" style="font-weight: inherit; font-style: normal;">2,636,956</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245248" style="font-weight: inherit; font-style: normal;">3,602,229</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 561px;">&nbsp;</td>
			<td id=".symb.B2" style="width: 6px;">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Supplemental disclosure of cash flow information:</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Net assets acquired from variable entity</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29245249" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245250" style="font-weight: inherit; font-style: normal;">16,346</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">Shares issued to acquire APAD technology</td>
			<td style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29245251" style="font-weight: inherit; font-style: normal;">2,486,000</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245252" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Sale of Milestone China shares, financing transaction </font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245253" style="font-weight: inherit; font-style: normal;">1,150,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245254" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Shares issued to employees for bonus</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245255" style="font-weight: inherit; font-style: normal;">194,885</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245256" style="font-weight: inherit; font-style: normal;">389,318</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Shares issued to consultants in lieu of cash payments</font></p>
			</td>
			<td id=".symb.2" style="width: 6px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245257" style="font-weight: inherit; font-style: normal;">350,249</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245258" style="font-weight: inherit; font-style: normal;">366,299</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 561px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">See Notes to Consolidated Financial Statements</p>
			</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 6px;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p>&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;,Times,Serif; font-size: 10pt;">F-6</div>

<hr style="page-break-after: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b>MILESTONE SCIENTIFIC INC.</b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;text-indent:1.5pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="13202" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522337935425" id="thunderdome-statement-848167">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>NOTE A <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&mdash; ORGANIZATION AND BUSINESS </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">All references in this report to &ldquo;Milestone Scientific,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;we,&rdquo; the &ldquo;Company&rdquo; or &ldquo;Milestone&rdquo; refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Advanced Cosmetic Systems, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>ompuDent&reg;; CompuMed&reg;; CompuFlo&reg;; DPS Dynamic Pressure Sensing technology&reg;; Milestone Scientific &reg;;&nbsp;the Milestone logo &reg;; SafetyWand&reg;; STA Single Tooth Anesthesia System&reg;; and The Wand &reg;.</i>&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific was incorporated in the State of Delaware in <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> August 1989. </em>Milestone Scientific has developed a proprietary, computer-controlled anesthetic delivery device, using <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><i>The Wand&reg;</i>, a single use disposable handpiece. The device is marketed in dentistry under the trademark <i>CompuDent&reg;, </i>and <i>STA Single Tooth Anesthesia System&reg;</i> and in medicine under the trademark <i>CompuMed&reg;. CompuDent&reg;</i> is suitable for all dental procedures that require local anesthetic. <i>CompuMed&reg;</i> is suitable for many medical procedures regularly performed in Plastic Surgery, Hair Restoration Surgery, Podiatry, Colorectal Surgery, Dermatology, Orthopedics and many other disciplines. The dental devices are sold in the United States, Canada and in <em data-td-fact-id="29245601" style="font-weight: inherit; font-style: normal;">53</em>&nbsp;other countries. To date there have been <em data-td-fact-id="29245602" style="font-weight: inherit; font-style: normal;">no</em> medical devices sold in the United States and limited amounts sold internationally, although certain medical devices have obtained CE mark approval and&nbsp;can be marketed and sold in most European countries.&nbsp;In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June 2017,&nbsp;</em>Milestone Scientific received <em data-td-fact-id="29245603" style="font-weight: inherit; font-style: normal;">510</em>(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the<i> CompuFlo</i>&reg; Epidural Computer Controlled Anesthesia System (&ldquo;Epidural&rdquo;).</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">During <em data-td-fact-id="29245604" style="font-weight: inherit; font-style: normal;">2016,</em> Milestone Scientific filed for <em data-td-fact-id="29245605" style="font-weight: inherit; font-style: normal;">510</em>(k) marketing clearance with the FDA for both intra-articular and epidural injections with the CompuFlo&reg; Computer Controlled Anesthesia System.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June 2017, </em>the FDA approved the<i> CompuFlo</i>&reg; Epidural Computer Controlled Anesthesia System for epidural injections. &nbsp;Milestone Scientific is in the process of introductory meetings with medical device distributors within the United States and foreign markets. Milestone Scientific&rsquo;s immediate focus is on marketing its epidural&nbsp;device throughout the United States and Europe.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 2016, </em>we received notification from the FDA that based upon the <em data-td-fact-id="29245606" style="font-weight: inherit; font-style: normal;">510</em>(k)-application submitted for intra- articular injections,<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;we did <em data-td-fact-id="29245607" style="font-weight: inherit; font-style: normal;">not</em> adequately document that the device met the equivalency standard required for <em data-td-fact-id="29245608" style="font-weight: inherit; font-style: normal;">510</em>(k) clearances. Following consultation with the FDA Office of Device Evaluation, we intend to file a new <em data-td-fact-id="29245609" style="font-weight: inherit; font-style: normal;">510</em>(k) application for the device in <em data-td-fact-id="29245610" style="font-weight: inherit; font-style: normal;">2018.</em> </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">On <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 13, 2017, </em>Milestone Scientific consummated an asset acquisition under an Asset Purchase Agreement (the &ldquo;Agreement&rdquo;) with APAD Octrooi B.V. and APAD B.V. (each, a &ldquo;Seller&rdquo; and collectively, the &ldquo;Sellers&rdquo;) pursuant to which Milestone Scientific acquired certain patent rights and other intellectual property rights related to the Sellers<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo; computer-controlled injection device (the &ldquo;Purchased Assets&rdquo;.) </font></p>
</div>

<div contenteditable="false" docsect="9" id="13203" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522337944755" id="thunderdome-statement-848168">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>NOTE B- LIQUIDITY<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;AND UNCERTAINTIES</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> &nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In accordance with ASC <em data-td-fact-id="29245611" style="font-weight: inherit; font-style: normal;">205</em>-<em data-td-fact-id="29245612" style="font-weight: inherit; font-style: normal;">40,</em> Going Concern, the Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#39;s ability to continue as a going concern within <em data-td-fact-id="29245613" style="font-weight: inherit; font-style: normal;">one</em> year after the date that the consolidated financial statements are issued. Milestone Scientific has incurred operating losses and negative cash flows from operating activities in virtually each year<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;since its inception. The capital raised in <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 2016 </em>and <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 2017 </em>provided Milestone Scientific with working capital to continue to develop its medical devices and obtain regulatory approval for <em data-td-fact-id="29245614" style="font-weight: inherit; font-style: normal;">one</em> of its medical devices (the <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June 2017 </em>FDA approval of the epidural device), as well as to market its dental devices. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States&nbsp;(following <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June 2017 </em>FDA approval of its <i>CompuFlo</i>&reg; Epidural Computer Controlled Anesthesia System (&quot;Epidural&quot;) and worldwide, and a&nbsp;reduction in operating expenses. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Management believes that Milestone Scientific will have sufficient cash reserves to meet its anticipated obligations over the next <em data-td-fact-id="29245615" style="font-weight: inherit; font-style: normal;">twelve</em> months from the filing of this form <em data-td-fact-id="29245616" style="font-weight: inherit; font-style: normal;">10K.</em> However, Milestone Scientific will likely need to raise additional capital prior to the expected generation of sustainable positive cash flow from operating activities and <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>also need to raise additional capital to effectively launch its approved Epidural Device and eventually generate positive cash flow from the anticipated medical business.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The Company is subject to several risks similar to those of development stage companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital necessary to fund the development of its products, competition from larger companies, and other medical device companies that develop similar or substitute products. The Company&#39;s sales performance, selling and marketing expenditures to develop sales performance, as well as the status of each of its new product development programs and the resulting operating income (loss), will significantly impact its cash requirements.</p>

<p style="margin: 0pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="13204" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522337960754" id="thunderdome-statement-848169">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">NOTE C&nbsp;&mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b><em data-td-fact-id="29245617" style="font-weight: inherit; font-style: normal;">1.</em> Principles of Consolidation</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States&nbsp;(&quot;GAAP&quot;) and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned)&nbsp;and Milestone Medical (majority owned). Milestone Education is a variable interest entity of which Milestone Scientific is the primary beneficiary and is consolidated into Milestone Scientific&#39;s financial statements. All significant, intra-entity transactions and balances have been eliminated in the consolidation.&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b>&nbsp;</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><em data-td-fact-id="29245618" style="font-weight: inherit; font-style: normal;">2.</em>&nbsp;&nbsp;&nbsp;&nbsp; Reclassifications</font></b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Certain reclassifications have been made to the <em data-td-fact-id="29245619" style="font-weight: inherit; font-style: normal;">2016</em>&nbsp;financial statements to conform to the consolidated <em data-td-fact-id="29245620" style="font-weight: inherit; font-style: normal;">2017</em>&nbsp;financial statement presentation. These reclassifications had <em data-td-fact-id="29245621" style="font-weight: inherit; font-style: normal;">no</em> effect on net loss or cash flows as previously reported.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><em data-td-fact-id="29245622" style="font-weight: inherit; font-style: normal;">3.</em> Variable Interest Entities</font></b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;A variable interest entity (&quot;VIE&quot;) is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity&#39;s economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific&rsquo;s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific is the primary beneficiary of Milestone Education as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 2016. </em>Accordingly, the assets and liabilities of Milestone Education are included in the accompanying consolidated financial statements. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Because Milestone Scientific had an increasing variable interest in Milestone China, it further considered the guidance in Accounting Standard Codification (&quot;ASC&quot;) <em data-td-fact-id="29245623" style="font-weight: inherit; font-style: normal;">810</em> as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary. As Milestone China&rsquo;s equity at risk and voting rights were <em data-td-fact-id="29245624" style="font-weight: inherit; font-style: normal;">not</em> proportional to their economic interest, Milestone China was determined to be a VIE. Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="margin-left:1.4%;width:94%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:6.5%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.2%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:90.2%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">Power Criterion: The power to direct the activities that most significantly impact the entity<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s economic performance; and</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="margin-left:1.4%;width:92%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:6.5%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;width:90.2%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone management does <em data-td-fact-id="29245625" style="font-weight: inherit; font-style: normal;">not</em> have the ability to control the activities that most significantly impact Milestone China&#39;s economics and, therefore, the power criterion has <em data-td-fact-id="29245626" style="font-weight: inherit; font-style: normal;">not</em> been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the majority shareholder/CEO of Milestone China.&nbsp; As majority shareholder, majority holder of voting rights, and the active CEO, the <em data-td-fact-id="29245627" style="font-weight: inherit; font-style: normal;">53%</em> investor has the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is <em data-td-fact-id="29245628" style="font-weight: inherit; font-style: normal;">not</em> the primary beneficiary under ASC <em data-td-fact-id="29245629" style="font-weight: inherit; font-style: normal;">810.</em> Accordingly, Milestone China has <em data-td-fact-id="29245630" style="font-weight: inherit; font-style: normal;">not</em> been consolidated into the financial statements of Milestone Scientific and continues to be accounted for under the equity method.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>&nbsp;</b>&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b><em data-td-fact-id="29245631" style="font-weight: inherit; font-style: normal;">4.</em> Cash and Cash Equivalents</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific considers all highly liquid investments purchased with an original maturity of <em data-td-fact-id="29245632" style="font-weight: inherit; font-style: normal;">three</em> months or less to be cash equivalents.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b><em data-td-fact-id="29245633" style="font-weight: inherit; font-style: normal;">5.</em></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b> Accounts Receivable</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most of credit sales are due within <em data-td-fact-id="29245634" style="font-weight: inherit; font-style: normal;">ninety</em> days from invoicing. There have <em data-td-fact-id="29245635" style="font-weight: inherit; font-style: normal;">not</em> been any significant credit losses incurred to date.&nbsp;As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>and <em data-td-fact-id="29245636" style="font-weight: inherit; font-style: normal;">2016</em>&nbsp;Accounts receivable was recorded, net of allowance for doubtful accounts of <em data-td-fact-id="29245637" style="font-weight: inherit; font-style: normal;">$10,000</em> respectively.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><em data-td-fact-id="29245638" style="font-weight: inherit; font-style: normal;">6</em><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b>. Note Receivable</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Milestone Scientific values note receivable at historic cost less amount paid against principle. Milestone Scientific estimates losses on the note-based payments and credit quality of the debtor.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b><em data-td-fact-id="29245639" style="font-weight: inherit; font-style: normal;">7.</em></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b>&nbsp;Product Return and Warranty</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific generally does <em data-td-fact-id="29245640" style="font-weight: inherit; font-style: normal;">not</em> accept non-defective returns from its customers. Product returns under warranty are accepted, evaluated and repaired or replaced in accordance with the Warranty Policy. Returns <em data-td-fact-id="29245641" style="font-weight: inherit; font-style: normal;">not</em> within the Warranty Policy are evaluated and the customer is charged for the repair.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b><em data-td-fact-id="29245642" style="font-weight: inherit; font-style: normal;">8.</em></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b> Inventories</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Inventories principally consist of finished goods and component parts stated at the lower of cost (<em data-td-fact-id="29245643" style="font-weight: inherit; font-style: normal;">first</em>-in, <em data-td-fact-id="29245644" style="font-weight: inherit; font-style: normal;">first</em>-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess, slow moving, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence and product expiration requirements. As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>and <em data-td-fact-id="29245645" style="font-weight: inherit; font-style: normal;">2016</em> inventory was recorded net of allowance for slow moving inventory of&nbsp;approximately&nbsp;<em data-td-fact-id="29245646" style="font-weight: inherit; font-style: normal;">$220,000</em>&nbsp;as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017&nbsp;</em>and <em data-td-fact-id="29245647" style="font-weight: inherit; font-style: normal;">$0</em> as of&nbsp;<em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December </em><em data-td-fact-id="29245648" style="font-weight: inherit; font-style: normal;">31, 2016</em></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b><em data-td-fact-id="29245649" style="font-weight: inherit; font-style: normal;">9.</em></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b> Equity Method Investments</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Investments in which Milestone Scientific can exercise significant influence, but do <em data-td-fact-id="29245650" style="font-weight: inherit; font-style: normal;">not</em> control, are accounted for under the equity method of accounting and are included in the long-term assets on the Consolidated Balance Sheets. Under this method of accounting, Milestone Scientific&#39;s share of the net earnings or losses of the investee is presented below the income tax line on the Consolidated Statements of Operations.&nbsp;Milestone Scientific evaluates its equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b><em data-td-fact-id="29245651" style="font-weight: inherit; font-style: normal;">10.</em></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b> Furniture, Fixture and Equipment&nbsp;&nbsp; </b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from <i><em data-td-fact-id="29245652" style="font-weight: inherit; font-style: normal;">two</em></i> to <i><em data-td-fact-id="29245653" style="font-weight: inherit; font-style: normal;">seven</em></i> years. The costs of maintenance and repairs are charged to operations as incurred.&nbsp; As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>and <em data-td-fact-id="29245654" style="font-weight: inherit; font-style: normal;">2016</em> furniture, fixtures &amp; equipment was&nbsp;recorded net of accumulated depreciation of <em data-td-fact-id="29245655" style="font-weight: inherit; font-style: normal;">$721,619</em>&nbsp;and <em data-td-fact-id="29245656" style="font-weight: inherit; font-style: normal;">$659,144</em> respectively.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b><em data-td-fact-id="29245657" style="font-weight: inherit; font-style: normal;">11.</em><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Intangible Assets &ndash; Patents and Developed Technology</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized at the estimated average useful life of the patent. These patents and developed technology are recorded at the acquisition cost.&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patent defense costs, to the extent applicable, are expensed as incurred.&nbsp; Patent applications filed, and patents obtained in foreign countries are subject to the laws and procedures that differ from those in the United States. Patent protection in foreign countries <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>be different from patent protection under United States laws and <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em><em data-td-fact-id="29245658" style="font-weight: inherit; font-style: normal;">not</em> be favorable to Milestone Scientific. Milestone Scientific also attempts to protect the proprietary information using confidentiality agreements and by limiting access to its facilities. There can be <em data-td-fact-id="29245659" style="font-weight: inherit; font-style: normal;">no</em> assurance that the program of patents, confidentiality agreements and restricted access to the facilities will be sufficient to protect the proprietary technology.</font>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b><em data-td-fact-id="29245660" style="font-weight: inherit; font-style: normal;">12.</em> Impairment of Long-Lived Assets</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>Milestone Scientific has reviewed long-lived assets for any impairments. The carrying value of the assets is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets. Milestone Scientific adjusts the net book value of an underlying asset if its fair value is determined to be less than its net book value. There have been <em data-td-fact-id="29245661" style="font-weight: inherit; font-style: normal;">no</em> impairment indicators or triggering events and therefore, there are <em data-td-fact-id="29245662" style="font-weight: inherit; font-style: normal;">no</em>&nbsp;impairments as of&nbsp;<em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245663" style="font-weight: inherit; font-style: normal;">2016</em> respectively. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><em data-td-fact-id="29245664" style="font-weight: inherit; font-style: normal;">13.</em> Revenue Recognition</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Revenue from product sales is recognized, net of discounts and allowances to domestic distributors, on the date of shipment for substantially all shipments, since the shipment terms are FOB warehouse. Milestone Scientific recognizes revenue on date of arrival of the goods at the customer&#39;s location, where shipments are FOB destination. In all cases the price to the buyer is fixed and the collectability is reasonably assured. Further, Milestone Scientific has <em data-td-fact-id="29245665" style="font-weight: inherit; font-style: normal;">no</em> obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Milestone Scientific&#39;s only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&nbsp;Devices and hand pieces are <em data-td-fact-id="29245666" style="font-weight: inherit; font-style: normal;">not</em> bundled but rather sold separately and, as such, there are <em data-td-fact-id="29245667" style="font-weight: inherit; font-style: normal;">no</em> multiple element determinations in connection with the revenue recognition. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific defers the total revenue and costs of goods sold when devices and handpieces are shipped to Milestone China and Milestone China<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s agent due to market conditions and Milestone China liquidity concerns. Also, due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to <em data-td-fact-id="29245668" style="font-weight: inherit; font-style: normal;">third</em> parties, an elimination of the intra-entity profit is required as of the balance sheet date. In accordance with ASC <em data-td-fact-id="29245669" style="font-weight: inherit; font-style: normal;">323</em> Equity Method and Joint Ventures, Milestone Scientific has deferred <em data-td-fact-id="29245670" style="font-weight: inherit; font-style: normal;">40%</em> of the gross profit associated with recognized revenue from Milestone China that has <em data-td-fact-id="29245671" style="font-weight: inherit; font-style: normal;">not</em> been sold to <em data-td-fact-id="29245672" style="font-weight: inherit; font-style: normal;">third</em> parties.</font></p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><em data-td-fact-id="29245673" style="font-weight: inherit; font-style: normal;">14.</em> Shipping and Handling Costs</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific includes shipping and handling costs, if any, in cost of goods sold. These costs are paid by or billed to customers at the time of shipments. Domestic and international shipments are FOB warehouse; therefore, <em data-td-fact-id="29245674" style="font-weight: inherit; font-style: normal;">no</em> costs are incurred by Milestone Scientific.<b>&nbsp;</b>&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b><em data-td-fact-id="29245675" style="font-weight: inherit; font-style: normal;">15.</em> Research and Development</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research and development costs, which consist principally of new product development costs payable to <em data-td-fact-id="29245676" style="font-weight: inherit; font-style: normal;">third</em> parties, are expensed as incurred. Advance payments for the research are amortized to expense either as services are performed or over the relevant service period using the straight-line method.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>&nbsp;<em data-td-fact-id="29245677" style="font-weight: inherit; font-style: normal;">16.</em> Income Taxes</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><em data-td-fact-id="29245678" style="font-weight: inherit; font-style: normal;">17.</em> Basic and diluted net loss per common share</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific presents &ldquo;basic&rdquo; earnings (loss) per common share applicable to common stockholders and, if applicable, &ldquo;diluted&rdquo; earnings (loss) per common share applicable to common stockholders pursuant to the provisions of Statement of Financial Accounting Standards ASC Topic <em data-td-fact-id="29245679" style="font-weight: inherit; font-style: normal;">260.</em> Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options, warrants, and the conversion of debt were issued during the period.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Since Milestone Scientific had net losses for <em data-td-fact-id="29245680" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29245681" style="font-weight: inherit; font-style: normal;">2016,</em> the assumed effects of the exercise of potentially dilutive outstanding stock options and warrants were <em data-td-fact-id="29245682" style="font-weight: inherit; font-style: normal;">not</em> included in the calculation as their effect would have been anti-dilutive. Such outstanding options and warrants totaled&nbsp;<em data-td-fact-id="29245683" style="font-weight: inherit; font-style: normal;">3,710,335</em>&nbsp;and <em data-td-fact-id="29245684" style="font-weight: inherit; font-style: normal;">3,329,769</em> at <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245685" style="font-weight: inherit; font-style: normal;">2016,</em> respectively. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;<b><em data-td-fact-id="29245686" style="font-weight: inherit; font-style: normal;">18.</em> Use of Estimates</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates<b>.</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b><em data-td-fact-id="29245687" style="font-weight: inherit; font-style: normal;">19.</em> Fair Value of Financial Instruments</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fair Value Measurements: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in <em data-td-fact-id="29245688" style="font-weight: inherit; font-style: normal;">one</em> of the following categories:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-indent: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Level <em data-td-fact-id="29245689" style="font-weight: inherit; font-style: normal;">1</em> inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Level <em data-td-fact-id="29245690" style="font-weight: inherit; font-style: normal;">2</em> inputs which are defined as inputs other than quoted prices included within Level <em data-td-fact-id="29245691" style="font-weight: inherit; font-style: normal;">1</em> that are observable for the assets or liabilities, either directly or indirectly.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;">&#9679;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Level <em data-td-fact-id="29245692" style="font-weight: inherit; font-style: normal;">3</em> inputs are defined as unobservable inputs for the assets or liabilities.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><em data-td-fact-id="29245693" style="font-weight: inherit; font-style: normal;">20.</em> Stock-Based Compensation </b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific accounts for stock-based compensation under ASC Topic <em data-td-fact-id="29245694" style="font-weight: inherit; font-style: normal;">718,</em> Share-Based Payment. ASC Topic <em data-td-fact-id="29245695" style="font-weight: inherit; font-style: normal;">718</em> requires all share-based payments to employees, including grants of employee stock options, to be recognized in the Statements of Operations over the service period, as an operating expense, based on the grant-date fair values. </font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-11</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. In accordance with the provisions of FASB ASC <em data-td-fact-id="29245696" style="font-weight: inherit; font-style: normal;">505,</em> Milestone Scientific will re-measure the value of the grant at each presentation date unless there is a significant disincentive for non-performance or until performance has been rendered. For the <em data-td-fact-id="29245697" style="font-weight: inherit; font-style: normal;">twelve</em> months end <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>Milestone Scientific recognized <em data-td-fact-id="29245698" style="font-weight: inherit; font-style: normal;">$9,384</em> income related to non-employee options. For the <em data-td-fact-id="29245699" style="font-weight: inherit; font-style: normal;">twelve</em> months end <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016, </em>Milestone Scientific recognized <em data-td-fact-id="29245700" style="font-weight: inherit; font-style: normal;">$25,346</em> expense related to non-employee options.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b><em data-td-fact-id="29245701" style="font-weight: inherit; font-style: normal;">21.</em> </b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b><b>Recent Acc</b>ounting Pronouncements</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> May 2014, </em>the Financial Accounting Standards Board (&quot;FASB&quot;) issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in <em data-td-fact-id="29245702" style="font-weight: inherit; font-style: normal;">five</em> steps: <em data-td-fact-id="29245703" style="font-weight: inherit; font-style: normal;">1</em>) identify the contract, <em data-td-fact-id="29245704" style="font-weight: inherit; font-style: normal;">2</em>) identify performance obligations, <em data-td-fact-id="29245705" style="font-weight: inherit; font-style: normal;">3</em>) determine the transaction price, <em data-td-fact-id="29245706" style="font-weight: inherit; font-style: normal;">4</em>) allocate the transaction price, and <em data-td-fact-id="29245707" style="font-weight: inherit; font-style: normal;">5</em>) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> August 2015, </em>the FASB issued guidance approving a <em data-td-fact-id="29245708" style="font-weight: inherit; font-style: normal;">one</em>-year deferral, making the standard effective for reporting periods beginning after <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 15, 2017. </em>The FASB continues to release guidance clarifying certain aspects of the revenue guidance. We do <em data-td-fact-id="29245709" style="font-weight: inherit; font-style: normal;">not</em> believe that this new accounting pronouncement will have a material impact on our financial statements.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> February 2016, </em>the FASB issued a new standard Accounting Standards Update (&quot;ASU &quot;) <em data-td-fact-id="29245710" style="font-weight: inherit; font-style: normal;">No.2016</em>-<em data-td-fact-id="29245711" style="font-weight: inherit; font-style: normal;">02,</em> &quot;Leases&quot;(Topic <em data-td-fact-id="29245712" style="font-weight: inherit; font-style: normal;">842</em>). The new standard is intended to increase transparency and comparability among organizations to recognize lease assets and liabilities on the balance sheet and disclose key information about leasing arrangements. It will be effective for fiscal years beginning after <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 15, 2018. </em>Milestone Scientific is in the process of determining what impact, the adoption of this ASU will have on its financial position, results of operations and cash flows. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June 2016, </em>the FASB issued a new standard ASU <em data-td-fact-id="29245713" style="font-weight: inherit; font-style: normal;">No.2016</em>-<em data-td-fact-id="29245714" style="font-weight: inherit; font-style: normal;">13,</em> &ldquo;Financial Instruments <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&ndash; Credit Losses&rdquo; (Topic <em data-td-fact-id="29245715" style="font-weight: inherit; font-style: normal;">326</em>).: The new standard is intended to replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. It will be effective for all entities for fiscal years and interim periods, beginning after <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 15, 2018. </em>Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> August 2016, </em>the FASB issued a new standard ASU <em data-td-fact-id="29245716" style="font-weight: inherit; font-style: normal;">No.2016</em>-<em data-td-fact-id="29245717" style="font-weight: inherit; font-style: normal;">15,</em> &quot;Statement Cash Flows &ldquo;Classification of Certain Cash Receipts and Cash Disbursements&quot; Topic <em data-td-fact-id="29245718" style="font-weight: inherit; font-style: normal;">230</em>). The new standard provides guidance as to the conformity of presentation of certain cash receipts and disbursements. It will be effective for all entities for fiscal years and interim periods, beginning after <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 15, 2017. </em>Milestone Scientific does <em data-td-fact-id="29245719" style="font-weight: inherit; font-style: normal;">not</em> anticipate the adoption of this ASU will have a significant impact on its presentation within the statement of cash flows.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> November 2016, </em>the FASB issued a new standard ASU <em data-td-fact-id="29245720" style="font-weight: inherit; font-style: normal;">No.2016</em>-<em data-td-fact-id="29245721" style="font-weight: inherit; font-style: normal;">18,</em> &ldquo;Statement of Cash Flows <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&ndash; Restricted Cash&rdquo; (Topic <em data-td-fact-id="29245722" style="font-weight: inherit; font-style: normal;">230</em>). The new standard provides guidance as to address the diversity of treatment of restricted cash on the statement of cash flows. It will be effective for all entities for fiscal years and interim periods, beginning after <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 15, 2017 </em>and interim periods therein. Milestone Scientific does <em data-td-fact-id="29245723" style="font-weight: inherit; font-style: normal;">not</em> expect the adoption of this ASU to have a material effect on its presentation within the statement of cash flows.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> May 2017, </em>the FASB issued a new standard ASU <em data-td-fact-id="29245724" style="font-weight: inherit; font-style: normal;">No.2017</em>-<em data-td-fact-id="29245725" style="font-weight: inherit; font-style: normal;">09,</em> &ldquo;Compensation <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&ndash; Stock Compensation&rdquo; (Topic <em data-td-fact-id="29245726" style="font-weight: inherit; font-style: normal;">718</em>). The new standard provides guidance and clarity for modification to equity-based compensation programs. It will be effective for all entities for fiscal years and interim periods, beginning after <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 15, 2017. </em>Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its presentation within the statement of cash flows.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-12</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 2017, </em>the FASB issued a new standard ASU <em data-td-fact-id="29245727" style="font-weight: inherit; font-style: normal;">No.2017</em>-<em data-td-fact-id="29245728" style="font-weight: inherit; font-style: normal;">11,</em> &ldquo;Earnings Per Share&rdquo; (Topic <em data-td-fact-id="29245729" style="font-weight: inherit; font-style: normal;">260</em>), &ldquo;Distinguishing Liabilities from Equity&rdquo; (Topic <em data-td-fact-id="29245730" style="font-weight: inherit; font-style: normal;">480</em>), &ldquo;Derivatives and Hedging&rdquo; (Topic <em data-td-fact-id="29245731" style="font-weight: inherit; font-style: normal;">815</em>). The new standard provides guidance relating to equity-linked instruments that include certain features. It will be effective for public entities for fiscal years and interim periods, beginning after <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 15, 2018. </em>Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its presentation within the statement of cash flows.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> November 2017, </em>the FASB issued a new standard ASU <em data-td-fact-id="29245732" style="font-weight: inherit; font-style: normal;">No.2017</em>-<em data-td-fact-id="29245733" style="font-weight: inherit; font-style: normal;">14,</em> &ldquo;Income Statement <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&ndash; Reporting Comprehensive Income&rdquo; (Topic <em data-td-fact-id="29245734" style="font-weight: inherit; font-style: normal;">815</em>), &ldquo;Revenue Recognition&rdquo; (Topic <em data-td-fact-id="29245735" style="font-weight: inherit; font-style: normal;">605</em>) and &ldquo;Revenue from Contracts with Customers&rdquo; (Topic <em data-td-fact-id="29245736" style="font-weight: inherit; font-style: normal;">606</em>). The new standard provides guidance in these areas pursuant to certain SEC Staff Accounting Bulletin and Release, as they relate to the presentation of revenue recognition matters on the statement of comprehensive income.&nbsp; It will be effective for public entities concurrent with the effectuation of other revenue recognition standards. Milestone Scientific does <em data-td-fact-id="29245737" style="font-weight: inherit; font-style: normal;">not</em> anticipate the adoption of this ASU to have a significant impact on its presentation within the statement of comprehensive income.</font></p>
</div>

<div contenteditable="false" docsect="9" id="13205" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522337970152" id="thunderdome-statement-848170">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">NOTE D&nbsp;&mdash; NOTES RECEIVABLE</font></b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June 2017, </em>Milestone Scientific entered into an agreement for the sale of its interest in Milestone China a <em data-td-fact-id="29245738" style="font-weight: inherit; font-style: normal;">forty</em> (<em data-td-fact-id="29245739" style="font-weight: inherit; font-style: normal;">40%</em>) percent interest (the &ldquo;Milestone China Shares&rdquo;) to an unaffiliated United States domiciled purchaser and a <em data-td-fact-id="29245740" style="font-weight: inherit; font-style: normal;">10</em>-year option agreement to repurchase the Milestone China Shares. The purchase price for the Milestone China Shares was <em data-td-fact-id="29245741" style="font-weight: inherit; font-style: normal;">$1,400,000</em> of which <em data-td-fact-id="29245742" style="font-weight: inherit; font-style: normal;">$125,000</em> was paid in cash and <em data-td-fact-id="29245743" style="font-weight: inherit; font-style: normal;">$1,275,000</em> was paid by delivery of a non-interest bearing secured promissory note. The note is payable in quarterly installments of <em data-td-fact-id="29245744" style="font-weight: inherit; font-style: normal;">$125,000</em><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;and is secured by the Milestone China Shares until full repayment.&nbsp; In addition,&nbsp;the purchaser is precluded from selling all or substantially all its assets prior to repayment of the note. The <em data-td-fact-id="29245745" style="font-weight: inherit; font-style: normal;">10</em>-year option agreement provides Milestone Scientific an option to repurchase the Milestone China Shares at <em data-td-fact-id="29245746" style="font-weight: inherit; font-style: normal;">$1,400,000</em> within the <em data-td-fact-id="29245747" style="font-weight: inherit; font-style: normal;">first</em> <em data-td-fact-id="29245748" style="font-weight: inherit; font-style: normal;">two</em> years and at fair market value (as defined in such agreement) for the remainder of the&nbsp;<em data-td-fact-id="29245749" style="font-weight: inherit; font-style: normal;">10</em>-year term. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> March 2, 2018, </em>the promissory note was in default. If Milestone Scientific exercises its rights as a secured party it <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>be obligated to return to the purchaser up to the <em data-td-fact-id="29245750" style="font-weight: inherit; font-style: normal;">$250,000</em> received for the Milestone China Shares as surplus. At this time Milestone Scientific has <em data-td-fact-id="29245751" style="font-weight: inherit; font-style: normal;">not</em> received a response from the purchaser of the Milestone China Shares, Milestone Scientific has <em data-td-fact-id="29245752" style="font-weight: inherit; font-style: normal;">not</em> recorded any financial benefit from the sale of Milestone China Shares to date.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">The transaction has been accounted for as a secured financing and Milestone Scientific will continue to account for its relationship with Milestone China under the equity method of accounting.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;A note receivable is presented on the Company&rsquo;s balance sheet, along with a deferral from financing transaction (<em data-td-fact-id="29245753" style="font-weight: inherit; font-style: normal;">$1,400,000</em>). The carrying value of the <em data-td-fact-id="29245754" style="font-weight: inherit; font-style: normal;">forty</em> (<em data-td-fact-id="29245755" style="font-weight: inherit; font-style: normal;">40%</em>) percent investment at the transaction date was zero.</font></p>
</div>

<div contenteditable="false" docsect="9" id="13206" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522337997266" id="thunderdome-statement-848235">
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>NOTE<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;E&nbsp;&mdash; INVENTORIES </font></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522337997266" id="thunderdome-statement-848236">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="5" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2017</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2016</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories consist of the following:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Dental finished goods</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245271" style="font-weight: inherit; font-style: normal;">2,846,272</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245272" style="font-weight: inherit; font-style: normal;">3,832,275</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Medical finished goods, net&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245273" style="font-weight: inherit; font-style: normal;">475,285</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245274" style="font-weight: inherit; font-style: normal;">735,061</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Component parts and other materials</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245275" style="font-weight: inherit; font-style: normal;">57,652</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245276" style="font-weight: inherit; font-style: normal;">35,383</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245277" style="font-weight: inherit; font-style: normal;">3,379,209</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245278" style="font-weight: inherit; font-style: normal;">4,602,719</em></td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">At <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>a reserve for slow moving Medical finished goods was established in the amount of approximately <em data-td-fact-id="29245756" style="font-weight: inherit; font-style: normal;">$220,000.</em> The<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;reserve was provided due to the delay in commercialization of the intra-articular medical instrument.&nbsp; There were <em data-td-fact-id="29245757" style="font-weight: inherit; font-style: normal;">no</em> reserves against inventory as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016.&nbsp;</em></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="13207" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338006194" id="thunderdome-statement-848173">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"><b>NOTE<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;F&nbsp;&mdash; ADVANCES ON CONTRACTS </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The advances on contracts represent funding of future STA inventory purchases and Epidural replacements parts. The balance of the advances as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245758" style="font-weight: inherit; font-style: normal;">2016</em> is <em data-td-fact-id="29245759" style="font-weight: inherit; font-style: normal;">$697,192</em> and <em data-td-fact-id="29245760" style="font-weight: inherit; font-style: normal;">$700,900,</em> respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory.&nbsp;&nbsp; </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="13208" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338015086" id="thunderdome-statement-848174">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>NOTE<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;G&nbsp;&ndash; CONSOLIDATION OF VARIABLE INTEREST ENTITY</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></b>Milestone Education is a <em data-td-fact-id="29245761" style="font-weight: inherit; font-style: normal;">50%</em> owned subsidiary of Milestone Scientific which began operations in <em data-td-fact-id="29245762" style="font-weight: inherit; font-style: normal;">2013</em> to provide training and education to dentists throughout the world. Approximately <em data-td-fact-id="29245763" style="font-weight: inherit; font-style: normal;">81%</em> of the revenue earned by Milestone Education is from services performed for Milestone Scientific as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245764" style="font-weight: inherit; font-style: normal;">2016.</em> Because of this dependency and relationship, we determined that we had the power to direct the activities that most significantly impact Milestone Education&#39;s economic performance, and therefore Milestone Education is consolidated in our financial statements.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>
</div>

<div contenteditable="false" docsect="9" id="13209" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338026402" id="thunderdome-statement-848175">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">NOTE H&nbsp;&ndash; INVESTMENT IN </font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-transform:uppercase;"><b>UNCONSOLIDATED SUBSIDIARIES</b></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><b> </b></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Advance Ocular Science SA </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Advanced Ocular Sciences SA (&quot;Advanced Ocular&quot;) is a shell company attempting to develop an instrument to deliver injections into the eyes. As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>Milestone Scientific owns <em data-td-fact-id="29245765" style="font-weight: inherit; font-style: normal;">25%</em> of this entity. During <em data-td-fact-id="29245766" style="font-weight: inherit; font-style: normal;">2015,</em> Milestone Scientific advanced <em data-td-fact-id="29245767" style="font-weight: inherit; font-style: normal;">$78,798</em> for marketing and strategy planning to Advance Ocular, or its organizers, were obligated to repay this advance if a public offering of Advanced Ocular equity was approved and funded in Poland during <em data-td-fact-id="29245768" style="font-weight: inherit; font-style: normal;">2016.</em> However, a public offering has yet to be completed in Poland. As a result, Milestone Scientific wrote-off the <em data-td-fact-id="29245769" style="font-weight: inherit; font-style: normal;">$78,798</em> advanced to Advanced Ocular as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016. </em>Advance Ocular was <em data-td-fact-id="29245770" style="font-weight: inherit; font-style: normal;">not</em> included in the consolidated financial statements at <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>as <em data-td-fact-id="29245771" style="font-weight: inherit; font-style: normal;">no</em> further investment has been made and there is <em data-td-fact-id="29245772" style="font-weight: inherit; font-style: normal;">no</em> significant activity that would be considered material to the financial statements.&nbsp; &nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Milestone China Ltd.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June 2014, </em>Milestone Scientific invested <em data-td-fact-id="29245773" style="font-weight: inherit; font-style: normal;">$1</em> million in Milestone China Ltd. (&ldquo;Milestone China&rdquo;) by contributing <em data-td-fact-id="29245774" style="font-weight: inherit; font-style: normal;">772</em> STA Instruments to Milestone China for a <em data-td-fact-id="29245775" style="font-weight: inherit; font-style: normal;">40%</em> ownership interest. Milestone Scientific recorded this investment under the equity method of accounting. Milestone Scientific recorded a loss on its investment in Milestone China of <em data-td-fact-id="29245776" style="font-weight: inherit; font-style: normal;">$120,510</em>&nbsp;and <em data-td-fact-id="29245777" style="font-weight: inherit; font-style: normal;">$795,827,</em> as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245778" style="font-weight: inherit; font-style: normal;">2016,</em> respectively, inclusive of intra entity deferral of profit. Milestone Scientific&#39;s investment in Milestone China was <em data-td-fact-id="29245779" style="font-weight: inherit; font-style: normal;">$0</em> as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245780" style="font-weight: inherit; font-style: normal;">2016,</em> respectively. Milestone Scientific incurred cumulative losses on its investment in Milestone China of <em data-td-fact-id="29245781" style="font-weight: inherit; font-style: normal;">$3,147,470</em>&nbsp;and <em data-td-fact-id="29245782" style="font-weight: inherit; font-style: normal;">$1,124,350</em> as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245783" style="font-weight: inherit; font-style: normal;">2016,</em> respectively, which have been suspended.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June 2017, </em>Milestone Scientific entered into an agreement for the sale of the Milestone China Shares to an unaffiliated United States domiciled purchaser and a <em data-td-fact-id="29245784" style="font-weight: inherit; font-style: normal;">10</em>-year option agreement to repurchase the Milestone China Shares. The purchase price for the Milestone China Shares was <em data-td-fact-id="29245785" style="font-weight: inherit; font-style: normal;">$1,400,000</em> of which <em data-td-fact-id="29245786" style="font-weight: inherit; font-style: normal;">$125,000</em> was paid in cash and <em data-td-fact-id="29245787" style="font-weight: inherit; font-style: normal;">$1,275,000</em> was paid by delivery of a non-interest bearing secured promissory note. The note is payable in quarterly installments of <em data-td-fact-id="29245788" style="font-weight: inherit; font-style: normal;">$125,000</em> until paid in full and is secured by the Milestone China Shares until full repayment.&nbsp; In addition, pursuant to such note, the purchaser is precluded from selling all or substantially all its assets prior to repayment of the note. The <em data-td-fact-id="29245789" style="font-weight: inherit; font-style: normal;">10</em>-year option agreement provides Milestone Scientific an option to repurchase the <em data-td-fact-id="29245790" style="font-weight: inherit; font-style: normal;">40%</em> equity interest at <em data-td-fact-id="29245791" style="font-weight: inherit; font-style: normal;">$1,400,000</em> within the <em data-td-fact-id="29245792" style="font-weight: inherit; font-style: normal;">first</em> <em data-td-fact-id="29245793" style="font-weight: inherit; font-style: normal;">two</em> years and at fair value (as defined in such agreement) for the remainder of the <em data-td-fact-id="29245794" style="font-weight: inherit; font-style: normal;">10</em>-year term. The transaction has been accounted for as a secured financing and Milestone Scientific will continue to account for its relationship with Milestone China under the equity method of accounting. A note receivable is presented on the Balance Sheet, along with a deferral from financing transaction (<em data-td-fact-id="29245795" style="font-weight: inherit; font-style: normal;">$1,400,000</em>). The carrying value of the <em data-td-fact-id="29245796" style="font-weight: inherit; font-style: normal;">forty</em> (<em data-td-fact-id="29245797" style="font-weight: inherit; font-style: normal;">40%</em>) percent investment at the transaction date was zero. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-14</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> March 2, 2018, </em>the promissory note was in default. If Milestone Scientific exercises its rights as a secured party it <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>be obligated to return to the purchaser up to the <em data-td-fact-id="29245798" style="font-weight: inherit; font-style: normal;">$250,000</em> received for the Milestone China Shares as surplus. At this time Milestone Scientific has <em data-td-fact-id="29245799" style="font-weight: inherit; font-style: normal;">not</em> received a response from the purchaser of the Milestone China Shares, Milestone Scientific has <em data-td-fact-id="29245800" style="font-weight: inherit; font-style: normal;">not</em> recorded any financial benefit from the sale of Milestone China Shares to date.</p>

<p style="margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific had <em data-td-fact-id="29245801" style="font-weight: inherit; font-style: normal;">$2,071,000</em> of related party sales of handpieces and instruments to Milestone China and Milestone China<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s agent for <em data-td-fact-id="29245802" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017. </em>Milestone Scientific had <em data-td-fact-id="29245803" style="font-weight: inherit; font-style: normal;">$3,425,000</em> of related party sales of handpieces and instruments to Milestone China for <em data-td-fact-id="29245804" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016. </em>Milestone Scientific defers the total revenue and costs of goods sold when instruments and handpieces are shipped to Milestone China and Milestone China&rsquo;s agent due to market conditions and Milestone China liquidity concerns until a payment is received.</font></p>

<div style="font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div>

<p style="margin: 0pt; text-indent: 27pt;">Due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to <em data-td-fact-id="29245805" style="font-weight: inherit; font-style: normal;">third</em> parties, an elimination of the intra-entity profit is required as of the balance sheet date. In accordance with ASC <em data-td-fact-id="29245806" style="font-weight: inherit; font-style: normal;">323</em> Equity Method and Joint Ventures, Milestone Scientific has deferred <em data-td-fact-id="29245807" style="font-weight: inherit; font-style: normal;">40%</em> of the gross profit associated with recognized revenue from Milestone China that has <em data-td-fact-id="29245808" style="font-weight: inherit; font-style: normal;">not</em> been sold to <em data-td-fact-id="29245809" style="font-weight: inherit; font-style: normal;">third</em> parties. At <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245810" style="font-weight: inherit; font-style: normal;">2016,</em> the deferred profit was <em data-td-fact-id="29245811" style="font-weight: inherit; font-style: normal;">$751,500</em>&nbsp;and <em data-td-fact-id="29245812" style="font-weight: inherit; font-style: normal;">$630,990,</em> respectively, which is included in deferred profit, related party in the consolidated balance sheets. For <em data-td-fact-id="29245813" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245814" style="font-weight: inherit; font-style: normal;">2016,</em> the loss on equity investment was <em data-td-fact-id="29245815" style="font-weight: inherit; font-style: normal;">$120,510</em>&nbsp;and <em data-td-fact-id="29245816" style="font-weight: inherit; font-style: normal;">$795,827,</em> respectively, which is included in the&nbsp;consolidated&nbsp;statements of operation.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The following table includes summarized financial information (unaudited) of Milestone China:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522338026401" id="thunderdome-statement-848176">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2017</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2016</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Assets:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Current assets</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245282" style="font-weight: inherit; font-style: normal;">13,127,422</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245283" style="font-weight: inherit; font-style: normal;">9,362,198</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Non-current assets</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245284" style="font-weight: inherit; font-style: normal;">3,213,520</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245285" style="font-weight: inherit; font-style: normal;">2,467,547</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total assets:</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245286" style="font-weight: inherit; font-style: normal;">16,340,942</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245287" style="font-weight: inherit; font-style: normal;">11,829,745</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Current liabilities</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245288" style="font-weight: inherit; font-style: normal;">18,468,937</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245289" style="font-weight: inherit; font-style: normal;">9,900,611</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stockholders&#39; equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245290" style="font-weight: inherit; font-style: normal;">(2,127,995)</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245291" style="font-weight: inherit; font-style: normal;">1,929,134</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities and stockholders<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo; equity</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245292" style="font-weight: inherit; font-style: normal;">16,340,942</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245293" style="font-weight: inherit; font-style: normal;">11,829,745</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2017</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2016</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245296" style="font-weight: inherit; font-style: normal;">1,394,760</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245297" style="font-weight: inherit; font-style: normal;">1,126,484</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of goods sold</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245298" style="font-weight: inherit; font-style: normal;">477,200</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245299" style="font-weight: inherit; font-style: normal;">976,106</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gross Profit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245300" style="font-weight: inherit; font-style: normal;">917,560</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245301" style="font-weight: inherit; font-style: normal;">150,378</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other Expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245302" style="font-weight: inherit; font-style: normal;">(5,975,360)</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245303" style="font-weight: inherit; font-style: normal;">(2,834,980</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net Losses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245304" style="font-weight: inherit; font-style: normal;">(5,057,800)</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245305" style="font-weight: inherit; font-style: normal;">(2,684,602</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">F-15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="13210" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338034825" id="thunderdome-statement-848237">
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>NOTE I<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&mdash; FURNITURE, FIXTURES AND EQUIPMENT </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522338034825" id="thunderdome-statement-848238">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 85%; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 7.5%; margin-left: 7.5%;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="4" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furniture, Fixtures and Equipment consist of the<br>
			<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">following:</font></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245313" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 64%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245314" style="font-weight: inherit; font-style: normal;">24,734</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245315" style="font-weight: inherit; font-style: normal;">24,734</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Office furniture and equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245316" style="font-weight: inherit; font-style: normal;">134,947</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245317" style="font-weight: inherit; font-style: normal;">135,802</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Molds</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245318" style="font-weight: inherit; font-style: normal;">7,200</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245319" style="font-weight: inherit; font-style: normal;">7,200</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Trade show displays</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245320" style="font-weight: inherit; font-style: normal;">143,357</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245321" style="font-weight: inherit; font-style: normal;">143,357</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Computers and software</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245322" style="font-weight: inherit; font-style: normal;">231,704</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245323" style="font-weight: inherit; font-style: normal;">224,840</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tooling Safety Wand</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245324" style="font-weight: inherit; font-style: normal;">125,022</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245325" style="font-weight: inherit; font-style: normal;">125,022</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Website</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245326" style="font-weight: inherit; font-style: normal;">39,200</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245327" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tooling equipment-STA &amp; Wand</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245328" style="font-weight: inherit; font-style: normal;">11,100</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245329" style="font-weight: inherit; font-style: normal;">11,100</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">EPI and IA Instruments</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245330" style="font-weight: inherit; font-style: normal;">82,363</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245331" style="font-weight: inherit; font-style: normal;">82,363</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">STA Trials Instruments</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245332" style="font-weight: inherit; font-style: normal;">63,752</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245333" style="font-weight: inherit; font-style: normal;">63,752</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245334" style="font-weight: inherit; font-style: normal;">863,379</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245335" style="font-weight: inherit; font-style: normal;">818,170</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245336" style="font-weight: inherit; font-style: normal;">(721,619</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245337" style="font-weight: inherit; font-style: normal;">(659,144</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245338" style="font-weight: inherit; font-style: normal;">141,760</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29245339" style="font-weight: inherit; font-style: normal;">159,026</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 19.5pt;">Depreciation expense was <em data-td-fact-id="29245817" style="font-weight: inherit; font-style: normal;">$62,475</em>&nbsp;and <em data-td-fact-id="29245818" style="font-weight: inherit; font-style: normal;">$92,667</em>&nbsp;for the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">years ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245819" style="font-weight: inherit; font-style: normal;">2016,</em> respectively.</font></p>
</div>

<div contenteditable="false" docsect="9" id="13211" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338043476" id="thunderdome-statement-848179">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:-3pt;"><b>NOTE<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;J&nbsp;&mdash; PATENTS</font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522338043475" id="thunderdome-statement-848180">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;">&nbsp;</td>
			<td colspan="5" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 305px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2017</b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37px;">&nbsp;</td>
			<td colspan="5" id=".amt.D7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 313px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2016</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;">&nbsp;</td>
			<td colspan="1" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 71px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Cost</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20px;">&nbsp;</td>
			<td colspan="1" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 95px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Accumulated Amortization</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 31px;">&nbsp;</td>
			<td colspan="1" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 80px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Net</b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37px;">&nbsp;</td>
			<td colspan="1" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 91px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Cost</b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7px;">&nbsp;</td>
			<td colspan="1" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 101px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Accumulated Amortization</b></p>
			</td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 15px;">&nbsp;</td>
			<td colspan="1" id=".amt.D7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 92px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Net</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patents-foundation intellectual property</p>
			</td>
			<td id=".amt.2" style="width: 71px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245352" style="font-weight: inherit; font-style: normal;">1,377,863</em></td>
			<td id=".trail.2" nowrap="true" style="width: 20px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 95px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245353" style="font-weight: inherit; font-style: normal;">(787,821</em></td>
			<td id=".trail.3" nowrap="true" style="width: 31px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".amt.4" style="width: 80px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245354" style="font-weight: inherit; font-style: normal;">590,042</em></td>
			<td id=".trail.4" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 91px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245355" style="font-weight: inherit; font-style: normal;">1,377,543</em></td>
			<td id=".trail.5" nowrap="true" style="width: 7px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 101px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245356" style="font-weight: inherit; font-style: normal;">(717,086</em></td>
			<td id=".trail.6" nowrap="true" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".amt.7" style="width: 92px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245357" style="font-weight: inherit; font-style: normal;">660,457</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Epidural-Apad acquired patents</p>
			</td>
			<td id=".amt.2" style="width: 71px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245358" style="font-weight: inherit; font-style: normal;">2,639,647</em></td>
			<td id=".trail.2" nowrap="true" style="width: 20px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 95px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245359" style="font-weight: inherit; font-style: normal;">(439,941</em></td>
			<td id=".trail.3" nowrap="true" style="width: 31px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".amt.4" style="width: 80px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245360" style="font-weight: inherit; font-style: normal;">2,199,706</em></td>
			<td id=".trail.4" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 91px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245361" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.5" nowrap="true" style="width: 7px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 101px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245362" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.6" nowrap="true" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 92px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245363" style="font-weight: inherit; font-style: normal;">-</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p>
			</td>
			<td id=".amt.2" style="width: 71px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245364" style="font-weight: inherit; font-style: normal;">4,017,510</em></td>
			<td id=".trail.2" nowrap="true" style="width: 20px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 95px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245365" style="font-weight: inherit; font-style: normal;">(1,227,762</em></td>
			<td id=".trail.3" nowrap="true" style="width: 31px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".amt.4" style="width: 80px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245366" style="font-weight: inherit; font-style: normal;">2,789,748</em></td>
			<td id=".trail.4" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 91px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245367" style="font-weight: inherit; font-style: normal;">1,377,543</em></td>
			<td id=".trail.5" nowrap="true" style="width: 7px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 101px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245368" style="font-weight: inherit; font-style: normal;">(717,086</em></td>
			<td id=".trail.6" nowrap="true" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".amt.7" style="width: 92px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245369" style="font-weight: inherit; font-style: normal;">660,457</em></td>
		</tr>

</table>
</div>

<p style="text-indent: 27pt;">Patents are amortized utilizing the straight-line method over estimated useful lives ranging from <em data-td-fact-id="29245820" style="font-weight: inherit; font-style: normal;">3</em><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;to <em data-td-fact-id="29245821" style="font-weight: inherit; font-style: normal;">20</em> years, with a weighted average amortization period of <em data-td-fact-id="29245822" style="font-weight: inherit; font-style: normal;">5</em>&nbsp;years. Amortization expense was <em data-td-fact-id="29245823" style="font-weight: inherit; font-style: normal;">$510,676</em> and <em data-td-fact-id="29245824" style="font-weight: inherit; font-style: normal;">$70,699</em> for the year ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245825" style="font-weight: inherit; font-style: normal;">2016,</em> respectively.&nbsp;The annual amortization expense expected to be recorded for existing intangibles assets for the years <em data-td-fact-id="29245826" style="font-weight: inherit; font-style: normal;">2018</em> through <em data-td-fact-id="29245827" style="font-weight: inherit; font-style: normal;">2022</em> is&nbsp; approximately&nbsp;<em data-td-fact-id="29245828" style="font-weight: inherit; font-style: normal;">$945,000,</em> <em data-td-fact-id="29245829" style="font-weight: inherit; font-style: normal;">$932,000,</em> <em data-td-fact-id="29245830" style="font-weight: inherit; font-style: normal;">$486,000,</em> <em data-td-fact-id="29245831" style="font-weight: inherit; font-style: normal;">$39,000</em> and <em data-td-fact-id="29245832" style="font-weight: inherit; font-style: normal;">$38,000.</em></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">On <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 13, 2017, </em>Milestone Scientific consummated a previously disclosed Asset Purchase Agreement (the &ldquo;Agreement&rdquo;) with APAD Octrooi B.V. and APAD B.V. (each, a &ldquo;Seller&rdquo; and collectively, the &ldquo;Sellers&rdquo;) pursuant to which Milestone Scientific acquired certain patent rights and other intellectual property rights related to the Sellers&rsquo; computer-controlled injection instrument (the &ldquo;Purchased Assets&rdquo;) and has been accounted for as an asset acquisition. On the closing date, Milestone Scientific issued to the Sellers an aggregate of <em data-td-fact-id="29245833" style="font-weight: inherit; font-style: normal;">1,646,358</em> shares of its common stock, valued at approximately <em data-td-fact-id="29245834" style="font-weight: inherit; font-style: normal;">$2,486,000</em> for the Purchased Assets which shares are subject to certain post-closing upward or downward adjustments <em data-td-fact-id="29245835" style="font-weight: inherit; font-style: normal;">not</em> to exceed <em data-td-fact-id="29245836" style="font-weight: inherit; font-style: normal;">twenty-five</em> percent of the initial shares as of the purchase date or <em data-td-fact-id="29245837" style="font-weight: inherit; font-style: normal;">250,000</em> Euros, as defined in the agreement. As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>Milestone Scientific has recorded a <em data-td-fact-id="29245838" style="font-weight: inherit; font-style: normal;">$295,000</em> liability relating to the estimated additional shares that would have to be issued according this provision in the Agreement. Milestone Scientific paid approximately <em data-td-fact-id="29245839" style="font-weight: inherit; font-style: normal;">$153,000</em> in legal fees on behalf of the Seller as stipulated based on the terms of the Agreement. The patents purchased in the amount of approximately <em data-td-fact-id="29245840" style="font-weight: inherit; font-style: normal;">$2,639,000</em> have been capitalized and will amortized over their <em data-td-fact-id="29245841" style="font-weight: inherit; font-style: normal;">three</em>-year estimated useful life and tested for impairment as a finite lived intangible asset.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-16</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="13212" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338052347" id="thunderdome-statement-848181">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:-7.5pt;"><b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">NOTE K&nbsp;&mdash; STOCKHOLDERS&rsquo; EQUITY</font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"><b>ISSUANCES COMMON STOCK </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June 2016, </em>Milestone Scientific raised an additional <em data-td-fact-id="29245842" style="font-weight: inherit; font-style: normal;">$2.0</em> million of gross proceeds in a private placement of <em data-td-fact-id="29245843" style="font-weight: inherit; font-style: normal;">one million</em> shares of common stock, at a price of <em data-td-fact-id="29245844" style="font-weight: inherit; font-style: normal;">$2.00</em> per share, to the same investors that participated in the&nbsp;<em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;">May 2014 </em>Financing.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 2016, </em>Milestone Scientific raised gross proceeds of <em data-td-fact-id="29245845" style="font-weight: inherit; font-style: normal;">$250,000</em> in a registered direct offering of <em data-td-fact-id="29245846" style="font-weight: inherit; font-style: normal;">104,200</em> shares of common stock at <em data-td-fact-id="29245847" style="font-weight: inherit; font-style: normal;">$2.40</em> per share. The transaction was covered by the prospectus supplement, filed with the United States Securities and Exchange Commission (&quot;SEC) on <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 22, 2016, </em>to our shelf registration statement on Form S-<em data-td-fact-id="29245848" style="font-weight: inherit; font-style: normal;">3</em> (SEC File <em data-td-fact-id="29245849" style="font-weight: inherit; font-style: normal;">No.:</em> <em data-td-fact-id="29245850" style="font-weight: inherit; font-style: normal;">333</em>-<em data-td-fact-id="29245851" style="font-weight: inherit; font-style: normal;">209466</em>).&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 2016, </em>Milestone Scientific completed an underwritten public offering of <em data-td-fact-id="29245852" style="font-weight: inherit; font-style: normal;">2,000,000</em> shares of common stock and warrants to purchase up to <em data-td-fact-id="29245853" style="font-weight: inherit; font-style: normal;">1,592,775</em> shares of common stock, including <em data-td-fact-id="29245854" style="font-weight: inherit; font-style: normal;">92,775</em> additional warrants pursuant to a partial exercise of the over-allotment option granted to the underwriters. Each share of common stock was sold in combination with a warrant to purchase <em data-td-fact-id="29245855" style="font-weight: inherit; font-style: normal;">0.75</em> shares of common stock. The public offering price for each share and related <em data-td-fact-id="29245856" style="font-weight: inherit; font-style: normal;">.75</em> share warrant was <em data-td-fact-id="29245857" style="font-weight: inherit; font-style: normal;">$1.50</em> for gross proceeds of <em data-td-fact-id="29245858" style="font-weight: inherit; font-style: normal;">$3,000,000.</em> The warrants have a <em data-td-fact-id="29245859" style="font-weight: inherit; font-style: normal;">three</em>-year term and an exercise price of <em data-td-fact-id="29245860" style="font-weight: inherit; font-style: normal;">$2.55</em> per share.&nbsp; In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 2017, </em>the underwriter&nbsp;exercised a portion of&nbsp;its over-allotment option to purchase an additional <em data-td-fact-id="29245861" style="font-weight: inherit; font-style: normal;">123,700</em> shares of common stock at the public offering price of <em data-td-fact-id="29245862" style="font-weight: inherit; font-style: normal;">$1.499</em> per share for gross proceeds of&nbsp;approximately <em data-td-fact-id="29245863" style="font-weight: inherit; font-style: normal;">$186,000.</em> The gross proceeds from this offering, including proceeds from partial exercises of the over-allotment option, were approximately <em data-td-fact-id="29245864" style="font-weight: inherit; font-style: normal;">$3,200,000,</em> before deducting underwriting discounts and commissions and other offering expenses of <em data-td-fact-id="29245865" style="font-weight: inherit; font-style: normal;">$461,493.</em>&nbsp;&nbsp;<b>&nbsp;&nbsp;</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 2017, </em>the underwriter exercised a portion of its over-allotment option&nbsp;and purchased an additional <em data-td-fact-id="29245866" style="font-weight: inherit; font-style: normal;">123,700</em> shares of common stock at the public offering price of <em data-td-fact-id="29245867" style="font-weight: inherit; font-style: normal;">$1.499</em> per share. The gross proceeds were approximately <em data-td-fact-id="29245868" style="font-weight: inherit; font-style: normal;">$186,000</em> before deducting underwriting discounts and commissions and other offering expenses.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;PREFERRED STOCK</b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> May </em>of <em data-td-fact-id="29245869" style="font-weight: inherit; font-style: normal;">2014,</em> Milestone completed a private placement, which raised gross proceeds in the total of <em data-td-fact-id="29245870" style="font-weight: inherit; font-style: normal;">$10</em> million, from the sale of <em data-td-fact-id="29245871" style="font-weight: inherit; font-style: normal;">$3</em> million of Milestone Scientific common stock (<em data-td-fact-id="29245872" style="font-weight: inherit; font-style: normal;">two million</em> shares at <em data-td-fact-id="29245873" style="font-weight: inherit; font-style: normal;">$1.50</em> per share) and <em data-td-fact-id="29245874" style="font-weight: inherit; font-style: normal;">$7</em> million of our Series A Convertible Preferred Stock (&quot;preferred stock&quot;) (<em data-td-fact-id="29245875" style="font-weight: inherit; font-style: normal;">7,000</em> shares at <em data-td-fact-id="29245876" style="font-weight: inherit; font-style: normal;">$1,000</em> per share), convertible into common stock at <em data-td-fact-id="29245877" style="font-weight: inherit; font-style: normal;">$2.37</em> per share (as adjusted to date) on <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> May 14, 2019, </em>or <em data-td-fact-id="29245878" style="font-weight: inherit; font-style: normal;">$1.50</em> per share unless certain conditions are <em data-td-fact-id="29245879" style="font-weight: inherit; font-style: normal;">not</em> met both subject to anti-dilution adjustment.&nbsp;The conversion ratio adjustment becomes effective if anyone of a number of triggering events occur such as; issuance of stock dividends or distributions, subdivisions, splits, issuance of stock purchase rights, debt and distributions, cash dividends or distributions, self-tender offers and exchange offers, rights plans and issuances below the conversion price, as defined in the Investment Agreement.&nbsp;Generally, each share of preferred stock entitles the holder to vote together with the holders of Milestone Scientific common stock, as a single class, on all matters submitted for the approval of the holders of Milestone Scientific common stock and has the number of votes equal to the number of shares of our common stock into which they are then convertible.&nbsp; In addition, preferred stock is also entitled to share, pair pass, in any cash dividends declared on Milestone Scientific common stock on as converted basis.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b style="font-size: 10pt;">SH<font style="font-size: 10pt;">ARES TO BE ISSUED</font></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>and <em data-td-fact-id="29245880" style="font-weight: inherit; font-style: normal;">2016,</em> there were <em data-td-fact-id="29245881" style="font-weight: inherit; font-style: normal;">1,401,247</em> and <em data-td-fact-id="29245882" style="font-weight: inherit; font-style: normal;">1,270,481</em> shares, respectively, whose issuance has been deferred under the terms of an employment agreements with the Chief Executive Officer, Chief Financial Officer and other employees of Milestone Scientific. Such shares will be issued to each party upon termination of their employment. The number of shares was fixed at the date of grant and were fully vested upon grant date.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>SHARES RESERVED FOR FUTURE ISSUANCE</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245883" style="font-weight: inherit; font-style: normal;">2016</em> there were <em data-td-fact-id="29245884" style="font-weight: inherit; font-style: normal;">5,111,582</em>&nbsp;and <em data-td-fact-id="29245885" style="font-weight: inherit; font-style: normal;">4,600,250</em> shares reserved for future issuance and <em data-td-fact-id="29245886" style="font-weight: inherit; font-style: normal;">3,710,335</em>&nbsp;and <em data-td-fact-id="29245887" style="font-weight: inherit; font-style: normal;">3,329,769</em> shares underlying other stock options and warrants outstanding, respectively. At <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245888" style="font-weight: inherit; font-style: normal;">2016</em> there were <em data-td-fact-id="29245889" style="font-weight: inherit; font-style: normal;">1,401,247</em> shares and <em data-td-fact-id="29245890" style="font-weight: inherit; font-style: normal;">1,270,481</em> shares, respectively, reserved for issuance in settlement of deferred compensation to officers of Milestone Scientific. </font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-17</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="13213" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338063615" id="thunderdome-statement-848182">
<p style="margin: 0pt 19.5pt 0pt 15pt; text-align: left; text-indent: -16.5pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><b>NOTE<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;L&nbsp;&mdash; STOCK OPTION PLANS</font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">The <em data-td-fact-id="29245891" style="font-weight: inherit; font-style: normal;">2004</em> Stock Option Plan provided for the grant of options to purchase up to <em data-td-fact-id="29245892" style="font-weight: inherit; font-style: normal;">750,000</em> shares of Milestone Scientific&#39;s common stock. Options <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>be granted to employees, officers, directors and consultants of Milestone Scientific for the purchase of common stock at a price <em data-td-fact-id="29245893" style="font-weight: inherit; font-style: normal;">not</em> less than the fair market value of the common stock on the date of the grant. In general, options become exercisable over a <em data-td-fact-id="29245894" style="font-weight: inherit; font-style: normal;">three</em>-year period from the grant date and expire <em data-td-fact-id="29245895" style="font-weight: inherit; font-style: normal;">five</em> years after the date of grant.&nbsp;There were&nbsp;<em data-td-fact-id="29245896" style="font-weight: inherit; font-style: normal;">no</em> shares available for grant at <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>under this plan.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June 2011, </em>the stockholders of Milestone Scientific approved the <em data-td-fact-id="29245897" style="font-weight: inherit; font-style: normal;">2011</em> Stock Option Plan (the <em data-td-fact-id="29245898" style="font-weight: inherit; font-style: normal;">&quot;2011</em> Plan&quot;) which originally provided for stock options to our employees, directors and consultants and incentive and non-qualified stock options to purchase up to <em data-td-fact-id="29245899" style="font-weight: inherit; font-style: normal;">2,000,000</em> shares of common stock. In general, options become exercisable over a <em data-td-fact-id="29245900" style="font-weight: inherit; font-style: normal;">three</em>-year period from the grant date and expire <em data-td-fact-id="29245901" style="font-weight: inherit; font-style: normal;">five</em> years after the date of grant.&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> May 2016, </em>Milestone Scientific&#39;s stockholders approved the following amendments to the <em data-td-fact-id="29245902" style="font-weight: inherit; font-style: normal;">2011</em> Plan:</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 63pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">i</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Renaming of the <em data-td-fact-id="29245903" style="font-weight: inherit; font-style: normal;">2011</em> plan to the &ldquo;Milestone Scientific Inc., <em data-td-fact-id="29245904" style="font-weight: inherit; font-style: normal;">2011</em> Equity Compensation Plan&rdquo;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 63pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ii</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Providing for awards of restricted common stock; and</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 63pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">iii</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Increasing the maximum number of shares of common stock reserved for grants under the <em data-td-fact-id="29245905" style="font-weight: inherit; font-style: normal;">2011</em> Plan from <em data-td-fact-id="29245906" style="font-weight: inherit; font-style: normal;">2,000,000</em> to <em data-td-fact-id="29245907" style="font-weight: inherit; font-style: normal;">4,000,000.</em></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: -9pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific recognizes compensation expense on a straight-line basis over the requisite service period and in the case of performance-based options over the period of the expected performance. For the <em data-td-fact-id="29245908" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245909" style="font-weight: inherit; font-style: normal;">2016</em> respectively, Milestone Scientific recognized <em data-td-fact-id="29245910" style="font-weight: inherit; font-style: normal;">$636,058</em> and <em data-td-fact-id="29245911" style="font-weight: inherit; font-style: normal;">$579,103</em> of total employee compensation cost, respectively. As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>and <em data-td-fact-id="29245912" style="font-weight: inherit; font-style: normal;">2016,</em> there was <em data-td-fact-id="29245913" style="font-weight: inherit; font-style: normal;">$603,979</em>&nbsp;and <em data-td-fact-id="29245914" style="font-weight: inherit; font-style: normal;">$678,842</em> of total unrecognized compensation cost related to non- vested options, respectively.&nbsp;Milestone Scientific expects to recognize these cost over a weighted average period of 3.04&nbsp;years and <em data-td-fact-id="29245916" style="font-weight: inherit; font-style: normal;">2.97</em>&nbsp;years as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245917" style="font-weight: inherit; font-style: normal;">2016,</em> respectively.&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">A summary of option activity for employees under the plans and changes during the years ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>and <em data-td-fact-id="29245918" style="font-weight: inherit; font-style: normal;">2016</em> is presented below:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522338063610" id="thunderdome-statement-848183">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 5%; margin-left: 5%;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="1" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Number of Options</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="1" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Wei<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ghted Averaged Exercise Price $</font></b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="1" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Weighted Average Remaining Contractual Life (Years)</b></b></p>
			</td>
			<td id=".trail.D4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="1" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Aggregate Intrinsic Options Value $</b></b></p>
			</td>
			<td id=".trail.D5" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 44%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options outstanding January 1, 2016</p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29245374" style="font-weight: inherit; font-style: normal;">1,419,436</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245375" style="font-weight: inherit; font-style: normal;">1.56</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245376" style="font-weight: inherit; font-style: normal;">2.79</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245377" style="font-weight: inherit; font-style: normal;">1,220,338</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable, January 1, 2016</p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245378" style="font-weight: inherit; font-style: normal;">1,041,680</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245379" style="font-weight: inherit; font-style: normal;">1.29</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245380" style="font-weight: inherit; font-style: normal;">2.41</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245381" style="font-weight: inherit; font-style: normal;">1,135,819</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245382" style="font-weight: inherit; font-style: normal;">520,337</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245383" style="font-weight: inherit; font-style: normal;">1.79</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245384" style="font-weight: inherit; font-style: normal;">4.38</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245385" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised during 2016</p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245386" style="font-weight: inherit; font-style: normal;">(327,778</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245387" style="font-weight: inherit; font-style: normal;">0.75</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245388" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245389" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245390" style="font-weight: inherit; font-style: normal;">(100,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245391" style="font-weight: inherit; font-style: normal;">2.35</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245392" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245393" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options outstanding December 31, 2016</p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29245394" style="font-weight: inherit; font-style: normal;">1,511,995</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245395" style="font-weight: inherit; font-style: normal;">1.74</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245396" style="font-weight: inherit; font-style: normal;">2.97</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245397" style="font-weight: inherit; font-style: normal;">102,605</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable, December 31, 2016</p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245398" style="font-weight: inherit; font-style: normal;">1,054,202</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245399" style="font-weight: inherit; font-style: normal;">1.65</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245400" style="font-weight: inherit; font-style: normal;">2.51</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245401" style="font-weight: inherit; font-style: normal;">102,605</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245402" style="font-weight: inherit; font-style: normal;">1,806,741</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245403" style="font-weight: inherit; font-style: normal;">1.82</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245404" style="font-weight: inherit; font-style: normal;">4.69&nbsp;</em></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245405" style="font-weight: inherit; font-style: normal;">25,610</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised during 2017</p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245406" style="font-weight: inherit; font-style: normal;">(83,333</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245407" style="font-weight: inherit; font-style: normal;">0.75</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245408" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245409" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited, cancelled, or expired</p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245410" style="font-weight: inherit; font-style: normal;">(1,250,068</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245411" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245412" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245413" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options outstanding December 31, 2017</p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29245414" style="font-weight: inherit; font-style: normal;">1,985,325</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245415" style="font-weight: inherit; font-style: normal;">1.74</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245416" style="font-weight: inherit; font-style: normal;">3.04</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245417" style="font-weight: inherit; font-style: normal;">25,160</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable,<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> December 31, 2017</font></p>
			</td>
			<td id=".amt.2" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245418" style="font-weight: inherit; font-style: normal;">1,317,441</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245419" style="font-weight: inherit; font-style: normal;">1.84</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245420" style="font-weight: inherit; font-style: normal;">2.46</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245421" style="font-weight: inherit; font-style: normal;">8,537</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-18</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 2017, </em>Milestone Scientific&#39;s Compensation Committee approved the issuance of <em data-td-fact-id="29245919" style="font-weight: inherit; font-style: normal;">400,000</em> stock options to Gian Domenico Trombetta, CEO of Wand Dental, a Director of Milestone Scientific and a director of Innovest S.p.A., an Italian investor (<em data-td-fact-id="29245920" style="font-weight: inherit; font-style: normal;">250,000</em> options at an exercise price of <em data-td-fact-id="29245921" style="font-weight: inherit; font-style: normal;">$2.55</em> per share were issued on <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 7, 2017 </em>and <em data-td-fact-id="29245922" style="font-weight: inherit; font-style: normal;">150,000</em> options having an exercise price at the higher of <em data-td-fact-id="29245923" style="font-weight: inherit; font-style: normal;">$2.55</em> or the market price of the stock on the date of the <em data-td-fact-id="29245924" style="font-weight: inherit; font-style: normal;">2018</em> Annual Stockholder meeting, subject to approval of a new or amended equity incentive plan at such meeting.) Mr. Trombetta elected to cancel the <em data-td-fact-id="29245925" style="font-weight: inherit; font-style: normal;">400,000 options</em> granted as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017.</em></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">The weighted-average fair value of the options granted during <em data-td-fact-id="29245926" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29245927" style="font-weight: inherit; font-style: normal;">2016</em> was estimated as <em data-td-fact-id="29245928" style="font-weight: inherit; font-style: normal;">$1.73</em> and <em data-td-fact-id="29245929" style="font-weight: inherit; font-style: normal;">$1.70</em> respectively, on the date of grant. The fair value for <em data-td-fact-id="29245930" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29245931" style="font-weight: inherit; font-style: normal;">2016</em> was determined using the Black-Scholes option-pricing model with the following&nbsp; assumptions:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;</font></p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522338063613" id="thunderdome-statement-848185">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Volatility</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245424" style="font-weight: inherit; font-style: normal;">81.23% -97.24%</em></td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245425" style="font-weight: inherit; font-style: normal;">134.53%- 194.34%</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245426" style="font-weight: inherit; font-style: normal;">1.4%- 2.2%</em></td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245427" style="font-weight: inherit; font-style: normal;">.4%-1.47%</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Life</p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">2-5 years<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>
			</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5 years</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245430" style="font-weight: inherit; font-style: normal;">0%</em></td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245431" style="font-weight: inherit; font-style: normal;">0%</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeiture Rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245432" style="font-weight: inherit; font-style: normal;">6%</em></td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245433" style="font-weight: inherit; font-style: normal;">6%</em></td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">A summary of option activity for non-employees under the plans and changes during the years ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245932" style="font-weight: inherit; font-style: normal;">2016,</em> is presented below:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522338063612" id="thunderdome-statement-848184">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 90%; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 5%; margin-left: 5%;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;">&nbsp;</td>
			<td colspan="1" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 121px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number of Options</p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 25px;">&nbsp;</td>
			<td colspan="1" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 140px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Averaged Exercise Price $</p>
			</td>
			<td id=".trail.D4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 26px;">&nbsp;</td>
			<td colspan="1" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 153px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average Remaining Contractual Life (Years)</p>
			</td>
			<td id=".trail.D5" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37px;">&nbsp;</td>
			<td colspan="1" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Aggregate Intr<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">insic Options Value $</font></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding, January<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> 1, 2016</font></p>
			</td>
			<td id=".amt.3" style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245438" style="font-weight: inherit; font-style: normal;">8,333</em></td>
			<td id=".trail.3" nowrap="true" style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245439" style="font-weight: inherit; font-style: normal;">2.70</em></td>
			<td id=".trail.4" nowrap="true" style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245440" style="font-weight: inherit; font-style: normal;">4.83</em></td>
			<td id=".trail.5" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245441" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exercisable, January 1, 2016</p>
			</td>
			<td id=".amt.3" style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245442" style="font-weight: inherit; font-style: normal;">2,777</em></td>
			<td id=".trail.3" nowrap="true" style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245443" style="font-weight: inherit; font-style: normal;">2.70</em></td>
			<td id=".trail.4" nowrap="true" style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245444" style="font-weight: inherit; font-style: normal;">4.83</em></td>
			<td id=".trail.5" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245445" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 489px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</p>
			</td>
			<td id=".amt.3" style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245446" style="font-weight: inherit; font-style: normal;">216,666</em></td>
			<td id=".trail.3" nowrap="true" style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245447" style="font-weight: inherit; font-style: normal;">2.53</em></td>
			<td id=".trail.4" nowrap="true" style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245448" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.5" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.B6" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><em data-td-fact-id="29245449" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p>
			</td>
			<td id=".amt.3" style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245450" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245451" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.4" nowrap="true" style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245452" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.5" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245453" style="font-weight: inherit; font-style: normal;">-</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding, December<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> 31, 2016</font></p>
			</td>
			<td id=".amt.3" style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245454" style="font-weight: inherit; font-style: normal;">224,999</em></td>
			<td id=".trail.3" nowrap="true" style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245455" style="font-weight: inherit; font-style: normal;">2.53</em></td>
			<td id=".trail.4" nowrap="true" style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245456" style="font-weight: inherit; font-style: normal;">5.32</em></td>
			<td id=".trail.5" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245457" style="font-weight: inherit; font-style: normal;">-</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exercisable, December 31, 2016</p>
			</td>
			<td id=".amt.3" style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245458" style="font-weight: inherit; font-style: normal;">14,734</em></td>
			<td id=".trail.3" nowrap="true" style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245459" style="font-weight: inherit; font-style: normal;">2.72</em></td>
			<td id=".trail.4" nowrap="true" style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245460" style="font-weight: inherit; font-style: normal;">4.36</em></td>
			<td id=".trail.5" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><em data-td-fact-id="29245461" style="font-weight: inherit; font-style: normal;">-</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted 2017</p>
			</td>
			<td id=".amt.3" style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245462" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245463" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.4" nowrap="true" style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245464" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.5" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245465" style="font-weight: inherit; font-style: normal;">-</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised 2017</p>
			</td>
			<td id=".amt.3" style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245466" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245467" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.4" nowrap="true" style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245468" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.5" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245469" style="font-weight: inherit; font-style: normal;">-</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding, December<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> 31, 2017</font></p>
			</td>
			<td id=".amt.3" style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245470" style="font-weight: inherit; font-style: normal;">224,999</em></td>
			<td id=".trail.3" nowrap="true" style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245471" style="font-weight: inherit; font-style: normal;">2.52</em></td>
			<td id=".trail.4" nowrap="true" style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245472" style="font-weight: inherit; font-style: normal;">3.51</em></td>
			<td id=".trail.5" nowrap="true" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245473" style="font-weight: inherit; font-style: normal;">-</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 489px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exercisable, December 31, 2017</p>
			</td>
			<td id=".amt.3" style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245474" style="font-weight: inherit; font-style: normal;">23,067</em></td>
			<td id=".trail.3" nowrap="true" style="width: 25px; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245475" style="font-weight: inherit; font-style: normal;">2.22</em></td>
			<td id=".trail.4" nowrap="true" style="width: 26px; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245476" style="font-weight: inherit; font-style: normal;">4.38</em></td>
			<td id=".trail.5" nowrap="true" style="width: 37px; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245477" style="font-weight: inherit; font-style: normal;">-</em></td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. In accordance with the provisions of FASB ASC <em data-td-fact-id="29245933" style="font-weight: inherit; font-style: normal;">505,</em> Milestone Scientific will re-measure the value of the grant at each presentation date unless there is a significant disincentive for non-performance or until performance has been rendered. For the <em data-td-fact-id="29245934" style="font-weight: inherit; font-style: normal;">twelve</em> months end <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>Milestone Scientific recognized <em data-td-fact-id="29245935" style="font-weight: inherit; font-style: normal;">$9,384</em> income related to non-employee options. For the <em data-td-fact-id="29245936" style="font-weight: inherit; font-style: normal;">twelve</em> months end <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016, </em>Milestone Scientific recognized <em data-td-fact-id="29245937" style="font-weight: inherit; font-style: normal;">$25,346</em> expense related to non-employee options.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-19</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>
</div>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">&nbsp;</div>

<div contenteditable="false" docsect="9" id="13214" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338072284" id="thunderdome-statement-848186">
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>NOTE M<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&ndash;EMPLOYMENT CONTRACT AND CONSULTING AGREEMENTS</font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>Employment Contracts</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> September 1, 2009, </em>Milestone Scientific entered into a <em data-td-fact-id="29245938" style="font-weight: inherit; font-style: normal;">five</em>-year employment agreement with Leonard Osser as its Chief Executive Officer (the <em data-td-fact-id="29245939" style="font-weight: inherit; font-style: normal;">&quot;2009</em> Agreement&quot;). The terms of the <em data-td-fact-id="29245940" style="font-weight: inherit; font-style: normal;">2009</em> Agreement are automatically extended for successive <em data-td-fact-id="29245941" style="font-weight: inherit; font-style: normal;">one</em>-year periods unless prior to <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> August 1 </em>of any year, either party notifies the other that he or it chooses <em data-td-fact-id="29245942" style="font-weight: inherit; font-style: normal;">not</em> to extend the term. Under the <em data-td-fact-id="29245943" style="font-weight: inherit; font-style: normal;">2009</em> Agreement, the CEO receives base compensation of <em data-td-fact-id="29245944" style="font-weight: inherit; font-style: normal;">$300,000</em> per year. In addition, the CEO, <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>earn annual bonuses up to an aggregate of <em data-td-fact-id="29245945" style="font-weight: inherit; font-style: normal;">$400,000,</em> payable <em data-td-fact-id="29245946" style="font-weight: inherit; font-style: normal;">one</em> half in cash and <em data-td-fact-id="29245947" style="font-weight: inherit; font-style: normal;">one</em> half in common stock, contingent upon achieving targets set for each year by the Compensation Committee. In addition, if in any year of the term of the agreement the CEO earns a bonus, he shall also be granted <em data-td-fact-id="29245948" style="font-weight: inherit; font-style: normal;">five</em>-year stock options to purchase twice the number of bonus shares earned. Each such option is to be exercisable at a price per share equal to the fair market value of a share on the date of grant (<em data-td-fact-id="29245949" style="font-weight: inherit; font-style: normal;">110%</em>) of the fair market value if the CEO is a <em data-td-fact-id="29245950" style="font-weight: inherit; font-style: normal;">10%</em> or greater stockholder on the date of grant). The options shall vest and become exercisable to the extent of <em data-td-fact-id="29245951" style="font-weight: inherit; font-style: normal;">one</em>-<em data-td-fact-id="29245952" style="font-weight: inherit; font-style: normal;">third</em> of the shares covered at the end of each of the <em data-td-fact-id="29245953" style="font-weight: inherit; font-style: normal;">first</em> <em data-td-fact-id="29245954" style="font-weight: inherit; font-style: normal;">three</em> years following the date of grant but shall only be exercisable while the CEO is employed by Milestone Scientific or within <em data-td-fact-id="29245955" style="font-weight: inherit; font-style: normal;">30</em> days after the termination of his employment.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In accordance with the <em data-td-fact-id="29245956" style="font-weight: inherit; font-style: normal;">2009</em> Agreement, <em data-td-fact-id="29245957" style="font-weight: inherit; font-style: normal;">886,866</em> shares of common stock are to be paid out at the end of the term in settlement of <em data-td-fact-id="29245958" style="font-weight: inherit; font-style: normal;">$1,030,875</em>&nbsp;of deferred compensation accrued at <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29245959" style="font-weight: inherit; font-style: normal;">855,810</em>&nbsp;shares of common stock are to be paid out at the end of the contract in settlement of <em data-td-fact-id="29245960" style="font-weight: inherit; font-style: normal;">$980,906</em> of deferred compensation accrued at <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016 </em>and, accordingly, such shares have been classified in stockholders&#39; equity with the common stock classified as to be issued.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;On<em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;">&nbsp;December 1, 2016, </em>Wand Dental and Gian Domenico Trombetta (&ldquo;Trombetta&rdquo;) entered into an Amended and Restated Employment Agreement (the &ldquo;Agreement&rdquo;), pursuant to which Trombetta receives base compensation of <em data-td-fact-id="29245961" style="font-weight: inherit; font-style: normal;">$280,000</em> per year&nbsp;and is eligible to receive annual bonuses in the sole discretion of the Compensation Committee. Pursuant to the Agreement, Trombetta will continue to serve as the Chief Executive Officer of Wand Dental for a period of <em data-td-fact-id="29245962" style="font-weight: inherit; font-style: normal;">one</em>-year beginning on <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> September 1, 2016 </em>through <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> August 31, 2017 (</em>the &ldquo;Employment Term&rdquo;). The Employment Term automatically renews for a <em data-td-fact-id="29245963" style="font-weight: inherit; font-style: normal;">one</em>-year period, from <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> September 1</em></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><sup>st</sup></font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;through <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> August 31</em><sup>st</sup>&nbsp;of each successive year (each a &ldquo;Renewal Term&rdquo;), unless prior to <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June </em><em data-td-fact-id="29245964" style="font-weight: inherit; font-style: normal;">1st</em> of the Employment Term or any Renewal Term, as applicable, either party notifies the other that he or it chooses <em data-td-fact-id="29245965" style="font-weight: inherit; font-style: normal;">not</em> to extend the term of employment in accordance with the terms of the Agreement.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 2017, </em>Milestone Scientific entered into a <em data-td-fact-id="29245966" style="font-weight: inherit; font-style: normal;">three</em>-year employment agreement with Daniel Goldberger to serve as President and Chief Executive Officer of Milestone Scientific. Under the agreement, Mr. Goldberger would receive base compensation of <em data-td-fact-id="29245967" style="font-weight: inherit; font-style: normal;">$300,000</em> per annum and <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>additionally earn annual bonuses of up to an aggregate of <em data-td-fact-id="29245968" style="font-weight: inherit; font-style: normal;">$400,000,</em> payable <em data-td-fact-id="29245969" style="font-weight: inherit; font-style: normal;">one</em> half in cash and <em data-td-fact-id="29245970" style="font-weight: inherit; font-style: normal;">one</em> half in Milestone Scientific common stock (&ldquo;Bonus Shares&rdquo;) contingent upon achieving performance benchmarks periodically set for each year by the compensation committee of the Board. In addition to any such shares of common stock, Mr. Goldberger was entitled to receive stock options (&ldquo;Bonus Options&rdquo;) to acquire twice the number of any Bonus Shares earned, pursuant to a non-qualified stock option grant agreement under Milestone Scientific&rsquo;s then existing equity compensation plan. The Bonus Options had a <em data-td-fact-id="29245971" style="font-weight: inherit; font-style: normal;">five</em>-year term and were to vest in equal annual installments on each of the first, <em data-td-fact-id="29245972" style="font-weight: inherit; font-style: normal;">second</em> and <em data-td-fact-id="29245973" style="font-weight: inherit; font-style: normal;">third</em> anniversary of the grant date, subject to continued employment on such vesting date and accelerated vesting upon the occurrence of certain events. The exercise price of the Bonus Options was based on the fair market value of per share of common stock on the date of grant.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 2017, </em>Milestone Scientific granted to Mr. Goldberger non-qualified stock options to purchase <em data-td-fact-id="29245974" style="font-weight: inherit; font-style: normal;">921,942</em> shares of common stock at an exercise price of <em data-td-fact-id="29245975" style="font-weight: inherit; font-style: normal;">$2.00</em> per share. Those options had a <em data-td-fact-id="29245976" style="font-weight: inherit; font-style: normal;">five</em>-year term and were to vest in equal annual installments on each of the first, <em data-td-fact-id="29245977" style="font-weight: inherit; font-style: normal;">second</em> and <em data-td-fact-id="29245978" style="font-weight: inherit; font-style: normal;">third</em> anniversaries of the grant date, subject to his continued employment on the vesting date and accelerated vesting upon the occurrence of certain events.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 2017, </em>Milestone Scientific entered into a <em data-td-fact-id="29245979" style="font-weight: inherit; font-style: normal;">ten</em>-year new employment agreement with Leonard Osser, who previously served as the Company&rsquo;s President and Chief Executive Officer, to serve as Managing Director &ndash; China Operations. This new agreement provides for annual compensation of <em data-td-fact-id="29245980" style="font-weight: inherit; font-style: normal;">$300,000</em> consisting of <em data-td-fact-id="29245981" style="font-weight: inherit; font-style: normal;">$100,000</em> in cash and <em data-td-fact-id="29245982" style="font-weight: inherit; font-style: normal;">$200,000</em> in the Company&rsquo;s common stock valued at the average closing price of the Company&rsquo;s common stock on the NYSE or such other market or exchange on which its shares are then traded during the <em data-td-fact-id="29245983" style="font-weight: inherit; font-style: normal;">first</em> <em data-td-fact-id="29245984" style="font-weight: inherit; font-style: normal;">fifteen</em> (<em data-td-fact-id="29245985" style="font-weight: inherit; font-style: normal;">15</em>) trading days of the last full calendar month of each year during the term of this agreement. This agreement supersedes all prior employment agreements between Mr. Osser and Milestone Scientific. If the Company terminates Mr. Osser&rsquo;s employment &ldquo;Without Cause,&rdquo; other than due to his death or disability, or if Mr. Osser terminates his employment for &ldquo;Good Reason&rdquo; (both as defined in the agreement), Mr. Osser is entitled to be paid in <em data-td-fact-id="29245986" style="font-weight: inherit; font-style: normal;">one</em> lump sum payment as soon as practicable following such termination: an amount equal to the aggregate present value (as determined in accordance with Section <em data-td-fact-id="29245987" style="font-weight: inherit; font-style: normal;">280G</em>(d)(<em data-td-fact-id="29245988" style="font-weight: inherit; font-style: normal;">4</em>) of the Code) of all compensation pursuant to this agreement from the effective date of termination hereunder through the remainder of the Employment Term.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-20</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 2017, </em>Mr. Osser also resigned from his positions of Chairman of the Board, Chief Executive Office and President of Milestone Medical. Upon his resignation, Milestone Medical entered in a consulting agreement with U.S. Asian Consulting Group LLC, an entity controlled by Mr. Osser, pursuant to which he will provide specific services to Milestone Medical for a <em data-td-fact-id="29245989" style="font-weight: inherit; font-style: normal;">ten</em>- year term. Pursuant to the consulting agreement, U.S. Asian Consulting Group, LLC, is entitled to receive <em data-td-fact-id="29245990" style="font-weight: inherit; font-style: normal;">$100,000</em> per year for Mr. Osser&#39;s services.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">On <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> October 5, 2017, </em>Milestone Scientific Inc. announced that Daniel Goldberger had resigned as President and Chief Executive Officer effective <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> October 2, 2017, </em>upon which the previously described stock options granted to him in <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 2017 </em>terminated prior to vesting.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; All previous compensation expense recorded to the date of the resignation, related to the stock options, was reversed as of the resignation date.</font></p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">On <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> October 5, 2017, </em>Milestone Scientific also announced the appointment of Leslie Bernhard, the Company<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s current Chairman of the Board, as the Company&rsquo;s Interim Chief Executive Officer, to serve in such role until the appointment of a new Chief Executive Officer. In connection with her appointment to serve as the Company&rsquo;s Interim Chief Executive Officer, Ms. Bernhard was paid an annual salary of <em data-td-fact-id="29245991" style="font-weight: inherit; font-style: normal;">$200,000</em>&nbsp;received a <em data-td-fact-id="29245992" style="font-weight: inherit; font-style: normal;">one</em>-time bonus of <em data-td-fact-id="29245993" style="font-weight: inherit; font-style: normal;">100,000</em> shares of the Company&rsquo;s Common Stock.&nbsp; In addition, at the completion of her service as Interim Chief Executive Officer, Ms. Bernhard shall be entitled to receive a cash bonus in an amount to be determined by the Board of Directors at that time.&nbsp;On <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 19 ,2017 </em>the Board of Directors appointed Leonard Osser Interim Chief Executive Officer, replacing Leslie Bernhard. Ms. Bernhard agreed to accept <em data-td-fact-id="29245994" style="font-weight: inherit; font-style: normal;">25,000</em> shares of Milestone Scientific stock for her services as Interim Chief Executive Officer in-lieu of the <em data-td-fact-id="29245995" style="font-weight: inherit; font-style: normal;">100,000</em> shares she was previously awarded.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">On <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 19, 2017 </em>the Board of Directors appointed Leonard Osser Interim Chief Executive Office, replacing Leslie Bernhard. Mr. Osser will&nbsp;enter into a similar <em data-td-fact-id="29245996" style="font-weight: inherit; font-style: normal;">2009</em> employment contract that he received <em data-td-fact-id="29245997" style="font-weight: inherit; font-style: normal;">2017</em>&nbsp;before he resigned his position as CEO of the company. <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Mr. Osser placed on&nbsp;hold&nbsp;his position as Managing Director-China Operations and his consulting agreement with Milestone Medical to rejoined Milestone Scientific Inc. as Interim Chief Executive Officer and will <em data-td-fact-id="29245998" style="font-weight: inherit; font-style: normal;">not</em> receive or earn any compensation under those agreements until he is <em data-td-fact-id="29245999" style="font-weight: inherit; font-style: normal;">no</em> longer Interim Chief Executive Officer.&nbsp;</font></p>

<p style="margin: 0pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="13215" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338085826" id="thunderdome-statement-848187">
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>NOTE<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;N&nbsp;&mdash; INCOME TAXES</font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Due to Milestone Scientific&#39;s history of operating losses, a full valuation allowances have been provided for all of Milestone Scientific&#39;s deferred tax assets At <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31,</em><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;<em data-td-fact-id="29246000" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29246001" style="font-weight: inherit; font-style: normal;">2016,</em> <em data-td-fact-id="29246002" style="font-weight: inherit; font-style: normal;">no</em> recognition was given to the utilization of the remaining net operating loss carryforwards in each of these periods.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In accordance with ASU <em data-td-fact-id="29246003" style="font-weight: inherit; font-style: normal;">2015</em>-<em data-td-fact-id="29246004" style="font-weight: inherit; font-style: normal;">17,</em> Income Taxes, deferred tax assets and liabilities have been classified, and treated retrospectively, as non-current.&nbsp; Deferred tax attributes resulting from differences between financial accounting amounts and tax bases of assets and liabilities at <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29246005" style="font-weight: inherit; font-style: normal;">2016</em> are as follows:&nbsp; </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522338085823" id="thunderdome-statement-848188">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Allowance for doubtful accounts-short term</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245480" style="font-weight: inherit; font-style: normal;">3,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245481" style="font-weight: inherit; font-style: normal;">4,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warranty reserve</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245482" style="font-weight: inherit; font-style: normal;">20,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245483" style="font-weight: inherit; font-style: normal;">36,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Capital Gains</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245484" style="font-weight: inherit; font-style: normal;">45,000</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245485" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred officers compensation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245486" style="font-weight: inherit; font-style: normal;">636,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245487" style="font-weight: inherit; font-style: normal;">395,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and Amortization</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245488" style="font-weight: inherit; font-style: normal;">181,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245489" style="font-weight: inherit; font-style: normal;">135,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deferred revenue</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245490" style="font-weight: inherit; font-style: normal;">478,000</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245491" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforward</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245492" style="font-weight: inherit; font-style: normal;">15,116,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245493" style="font-weight: inherit; font-style: normal;">18,456,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Subtotal</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245494" style="font-weight: inherit; font-style: normal;">16,479,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245495" style="font-weight: inherit; font-style: normal;">19,026,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245496" style="font-weight: inherit; font-style: normal;">(16,479,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245497" style="font-weight: inherit; font-style: normal;">(19,026,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The deferred tax asset, before valuation allowance, has been calculated on rates anticipated to be effect when the temporary differences reverse.<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Accordingly, based on the change in Federal tax rates promulgated in <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 2017, </em>effective <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 1, 2018, </em>the Company utilized a Federal rate of <em data-td-fact-id="29246006" style="font-weight: inherit; font-style: normal;">21%</em> and accordingly existing deferred tax assets upon the tax law act being signed into law on <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 22, 2017, </em>the Company revalued its deferred tax assets which resulted in a tax provision charge of <em data-td-fact-id="29246007" style="font-weight: inherit; font-style: normal;">$8,677,000,</em> offset by a corresponding decrease in the valuation allowance.&nbsp; </font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-21</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>federal net operating loss carryforwards are approximately <em data-td-fact-id="29246008" style="font-weight: inherit; font-style: normal;">$60,000,000.</em><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016, </em>and Milestone Scientific has federal net operating loss carryforwards of approximately <em data-td-fact-id="29246009" style="font-weight: inherit; font-style: normal;">$56,530,000,</em> which is comprised solely of losses attributable Milestone Scientific and its subsidiaries.&nbsp; Net operating losses will be available to offset future taxable income, if any, through <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 2037. </em>As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>state net operating losses were approximately <em data-td-fact-id="29246010" style="font-weight: inherit; font-style: normal;">$24,500,000.</em> As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016 </em>Milestone, Scientific has state net operating loss carryforwards of approximately <em data-td-fact-id="29246011" style="font-weight: inherit; font-style: normal;">$22,942,000.</em>&nbsp; Net operating losses will be available to offset future taxable income, if any, through <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 2037. </em></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The utilization of Milestone Scientific&#39;s net operating losses <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>be subject to a substantial limitation due to the &quot;change of ownership provisions&quot; under Section <em data-td-fact-id="29246012" style="font-weight: inherit; font-style: normal;">382</em> of the Internal Revenue Code and similar state provisions. Such limitation <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a <em data-td-fact-id="29246013" style="font-weight: inherit; font-style: normal;">100%</em> valuation allowance for all its deferred tax assets due to uncertainty as to their future realization.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>and <em data-td-fact-id="29246014" style="font-weight: inherit; font-style: normal;">2016,</em> state tax liability was approximately <em data-td-fact-id="29246015" style="font-weight: inherit; font-style: normal;">$18,339</em> and <em data-td-fact-id="29246016" style="font-weight: inherit; font-style: normal;">$13,000</em> respectively. Such expense was recognized in the accompanying consolidated financial statements. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">A reconciliation of the statutory tax rates for the years ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, </em>is as follows:<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="margin: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522338085824" id="thunderdome-statement-848189">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>2017</b></b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>2016</b></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Statutory rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245500" style="font-weight: inherit; font-style: normal;">34</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245501" style="font-weight: inherit; font-style: normal;">34</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State income tax - all states</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245502" style="font-weight: inherit; font-style: normal;">6</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245503" style="font-weight: inherit; font-style: normal;">6</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Non-deductible Stock based compensation</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245504" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245505" style="font-weight: inherit; font-style: normal;">3</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deferred provision for effect of change in Federal rate</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245506" style="font-weight: inherit; font-style: normal;">164</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245507" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245508" style="font-weight: inherit; font-style: normal;">204</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245509" style="font-weight: inherit; font-style: normal;">43</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Valuation allowance</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245510" style="font-weight: inherit; font-style: normal;">(204</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245511" style="font-weight: inherit; font-style: normal;">(43</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effective tax rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245512" style="font-weight: inherit; font-style: normal;">0</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em data-td-fact-id="29245513" style="font-weight: inherit; font-style: normal;">0</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounting for uncertainties in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. At <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>and <em data-td-fact-id="29246017" style="font-weight: inherit; font-style: normal;">2016,</em> we had <em data-td-fact-id="29246018" style="font-weight: inherit; font-style: normal;">no</em> uncertain tax positions that required recognition in the consolidated financial statements. Milestone Scientific&#39;s policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the Statements of Operations. <em data-td-fact-id="29246019" style="font-weight: inherit; font-style: normal;">No</em> interest and penalties are present for periods open. Tax returns for the <em data-td-fact-id="29246020" style="font-weight: inherit; font-style: normal;">2014,</em> <em data-td-fact-id="29246021" style="font-weight: inherit; font-style: normal;">2015,</em> and <em data-td-fact-id="29246022" style="font-weight: inherit; font-style: normal;">2016</em> years are subject to audit by federal and state jurisdictions. </font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-22</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>
</div>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">&nbsp;</div>

<div contenteditable="false" docsect="9" id="13216" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338095194" id="thunderdome-statement-848190">
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>NOTE<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;O&nbsp;&mdash; SEGMENT AND GEOGRAPHIC DATA</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">We conduct our business through <em data-td-fact-id="29246023" style="font-weight: inherit; font-style: normal;">two</em> reportable segments:<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; dental and medical.&nbsp;&nbsp;These segments offer different products and services to different customer base. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">The following tables present information about our reportable and operating segments:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522338095191" id="thunderdome-statement-848191">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales</p>
			</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Years ended</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net Sales:</p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2017</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2016</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245518" style="font-weight: inherit; font-style: normal;">11,279,886</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245519" style="font-weight: inherit; font-style: normal;">10,460,752</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245520" style="font-weight: inherit; font-style: normal;">2,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245521" style="font-weight: inherit; font-style: normal;">21,253</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245522" style="font-weight: inherit; font-style: normal;">11,281,886</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245523" style="font-weight: inherit; font-style: normal;">10,482,005</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating Income (Loss):</p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2017</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2016</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245526" style="font-weight: inherit; font-style: normal;">3,127,570</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245527" style="font-weight: inherit; font-style: normal;">2,087,002</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245528" style="font-weight: inherit; font-style: normal;">(</em>2,389,145</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245529" style="font-weight: inherit; font-style: normal;">(</em>3,265,602</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245530" style="font-weight: inherit; font-style: normal;">(5,972,743</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245531" style="font-weight: inherit; font-style: normal;">(</em>5,335,360</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245532" style="font-weight: inherit; font-style: normal;">(</em>5,234,318</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245533" style="font-weight: inherit; font-style: normal;">(</em>6,513,960</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and Amortization:</p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2017</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2016</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245536" style="font-weight: inherit; font-style: normal;">17,305</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245537" style="font-weight: inherit; font-style: normal;">17,619</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245538" style="font-weight: inherit; font-style: normal;">26,950</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245539" style="font-weight: inherit; font-style: normal;">62,720</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245540" style="font-weight: inherit; font-style: normal;">528,895</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245541" style="font-weight: inherit; font-style: normal;">82,586</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 27pt;">Total</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245542" style="font-weight: inherit; font-style: normal;">573,150</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245543" style="font-weight: inherit; font-style: normal;">162,925</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income before taxes and equity in<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> earnings&nbsp;of affiliates:</font></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2017</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2016</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245546" style="font-weight: inherit; font-style: normal;">3,136,167</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245547" style="font-weight: inherit; font-style: normal;">2,097,652</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245548" style="font-weight: inherit; font-style: normal;">(</em>2,391,082</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245549" style="font-weight: inherit; font-style: normal;">(</em>3,219,497</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245550" style="font-weight: inherit; font-style: normal;">(</em>5,975,035</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245551" style="font-weight: inherit; font-style: normal;">(</em>5,395,918</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245552" style="font-weight: inherit; font-style: normal;">(</em>5,229,950</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245553" style="font-weight: inherit; font-style: normal;">(</em>6,517,763</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total Assets:</p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2017</b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>2016</b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245556" style="font-weight: inherit; font-style: normal;">10,255,144</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245557" style="font-weight: inherit; font-style: normal;">10,472,879</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245558" style="font-weight: inherit; font-style: normal;">655,513</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245559" style="font-weight: inherit; font-style: normal;">913,840</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245560" style="font-weight: inherit; font-style: normal;">4,718,130</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em data-td-fact-id="29245561" style="font-weight: inherit; font-style: normal;">(</em>2,794,921</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 27pt;">&nbsp;Total</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245562" style="font-weight: inherit; font-style: normal;">15,628,787</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245563" style="font-weight: inherit; font-style: normal;">14,181,640</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;,Times,Serif; font-size: 10pt;">F-23</div>

<hr style="page-break-after: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">The following table presents information about our operations by geographic area as <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29246024" style="font-weight: inherit; font-style: normal;">2017.</em><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Net sales by geographic area are based on the respective locations of our subsidiaries</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522338095193" id="thunderdome-statement-848192">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 85%; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 7.5%; margin-left: 7.5%;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Dental </font></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 64%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Total Product Sales</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic-US and Canada</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245569" style="font-weight: inherit; font-style: normal;">5,339,709</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,352,561</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International -Rest of the World</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245571" style="font-weight: inherit; font-style: normal;">3,869,177</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">3,682,591</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International -China</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245573" style="font-weight: inherit; font-style: normal;">2,071,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245574" style="font-weight: inherit; font-style: normal;">3,425,600</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245575" style="font-weight: inherit; font-style: normal;">11,279,886</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245576" style="font-weight: inherit; font-style: normal;">10,460,752</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Total Product Sales</b></p>
			</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Medical </font></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic-US and Canada</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245579" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245580" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International - Rest of the World</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245581" style="font-weight: inherit; font-style: normal;">2,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245582" style="font-weight: inherit; font-style: normal;">21,253</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245583" style="font-weight: inherit; font-style: normal;">2,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245584" style="font-weight: inherit; font-style: normal;">21,253</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
			</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total </font></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">Domestic-US and Canada</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245587" style="font-weight: inherit; font-style: normal;">5,339,709</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245588" style="font-weight: inherit; font-style: normal;">3,352,561</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International -Rest of the World</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245589" style="font-weight: inherit; font-style: normal;">3,871,177</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245590" style="font-weight: inherit; font-style: normal;">3,703,844</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">International -China</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245591" style="font-weight: inherit; font-style: normal;">2,071,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29245592" style="font-weight: inherit; font-style: normal;">3,425,600</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 36pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</font></td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245593" style="font-weight: inherit; font-style: normal;">11,281,886</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29245594" style="font-weight: inherit; font-style: normal;">10,482,005</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="13217" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338102880" id="thunderdome-statement-848193">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>NOTE P<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;-- CONCENTRATION</font></b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font>Milestone Scientific has informal arrangements with a <em data-td-fact-id="29246025" style="font-weight: inherit; font-style: normal;">third</em>-party manufacturer of the STA, CompuDent&reg;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> and CompuMed&reg; instruments, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> March 2016, </em>Milestone Scientific entered into a purchase commitment for delivery of <em data-td-fact-id="29246026" style="font-weight: inherit; font-style: normal;">3,000</em> instruments, as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>all instruments have been received.</font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> </font><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 2017 </em>Milestone Scientific entered into a purchase commitment for the delivery of <em data-td-fact-id="29246027" style="font-weight: inherit; font-style: normal;">2,000</em> instruments beginning in the <em data-td-fact-id="29246028" style="font-weight: inherit; font-style: normal;">4th</em> quarter of <em data-td-fact-id="29246029" style="font-weight: inherit; font-style: normal;">2017.</em> An advance of <em data-td-fact-id="29246030" style="font-weight: inherit; font-style: normal;">$697,192</em> was recorded at <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017. </em>At <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>Milestone Scientific&rsquo;s purchase commitment for this purchase order was <em data-td-fact-id="29246031" style="font-weight: inherit; font-style: normal;">$300,460.</em> An advance of <em data-td-fact-id="29246032" style="font-weight: inherit; font-style: normal;">$656,752</em> was recorded at <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016. </em>At <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016, </em>Milestone Scientific&rsquo;s purchase commitment for this purchase order was <em data-td-fact-id="29246033" style="font-weight: inherit; font-style: normal;">$272,231.</em> Consequently, advances on contracts have been classified as current at <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29246034" style="font-weight: inherit; font-style: normal;">2016</em> respectively.&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">For <em data-td-fact-id="29246035" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>an aggregate of approximately <em data-td-fact-id="29246036" style="font-weight: inherit; font-style: normal;">70%</em> of Milestone Scientific&#39;s net product sales were to <em data-td-fact-id="29246037" style="font-weight: inherit; font-style: normal;">two</em> customers/ distributors (<em data-td-fact-id="29246038" style="font-weight: inherit; font-style: normal;">one</em> of which, Milestone China, is a related party), <em data-td-fact-id="29246039" style="font-weight: inherit; font-style: normal;">51%</em> and <em data-td-fact-id="29246040" style="font-weight: inherit; font-style: normal;">19%,</em> respectively. For <em data-td-fact-id="29246041" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016, </em>an aggregate of approximately <em data-td-fact-id="29246042" style="font-weight: inherit; font-style: normal;">58%</em> of Milestone Scientific&#39;s net product sales were to <em data-td-fact-id="29246043" style="font-weight: inherit; font-style: normal;">two</em> customers/distributors (<em data-td-fact-id="29246044" style="font-weight: inherit; font-style: normal;">one</em> of which, Milestone China, is a related party), <em data-td-fact-id="29246045" style="font-weight: inherit; font-style: normal;">31%,</em> and <em data-td-fact-id="29246046" style="font-weight: inherit; font-style: normal;">27%,</em> respectively. Accounts receivable for the major customer/distributors amounted to an aggregate of approximately <em data-td-fact-id="29246047" style="font-weight: inherit; font-style: normal;">$2,555,476,</em> or <em data-td-fact-id="29246048" style="font-weight: inherit; font-style: normal;">78%</em> of Milestone Scientific&#39;s accounts receivable for <em data-td-fact-id="29246049" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017.</em><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Accounts receivable for the major customer/distributors amounted to an aggregate of approximately <em data-td-fact-id="29246050" style="font-weight: inherit; font-style: normal;">$2,994,686,</em> or <em data-td-fact-id="29246051" style="font-weight: inherit; font-style: normal;">85%</em> of Milestone Scientific&#39;s accounts receivable for <em data-td-fact-id="29246052" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016. &nbsp;&nbsp;</em></font></p>

<p style="margin: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">F-24</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>
</div>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">&nbsp;</div>

<div contenteditable="false" docsect="9" id="13218" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338109898" id="thunderdome-statement-848194">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>NOTE Q<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;-- RELATED PARTY TRANSACTIONS</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific has a manufacturing agreement with United Systems (an entity controlled by a significant stockholder of Milestone), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were <em data-td-fact-id="29246053" style="font-weight: inherit; font-style: normal;">$2,146,108</em> and <em data-td-fact-id="29246054" style="font-weight: inherit; font-style: normal;">$3,025,249</em> for the <em data-td-fact-id="29246055" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29246056" style="font-weight: inherit; font-style: normal;">2016,</em> respectively. Milestone Scientific owed <em data-td-fact-id="29246057" style="font-weight: inherit; font-style: normal;">$985,678</em> and <em data-td-fact-id="29246058" style="font-weight: inherit; font-style: normal;">$1,235,052</em> to this manufacturer as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29246059" style="font-weight: inherit; font-style: normal;">2016,</em> respectively.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Milestone Scientific had <em data-td-fact-id="29246060" style="font-weight: inherit; font-style: normal;">$2,071,000</em> of related party sales of handpieces and instruments to Milestone China and Milestone China&rsquo;s agent for <em data-td-fact-id="29246061" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017. </em>Milestone Scientific had <em data-td-fact-id="29246062" style="font-weight: inherit; font-style: normal;">$3,425,000</em> of related party sales of handpieces and instruments to Milestone China for <em data-td-fact-id="29246063" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2016. </em>As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>and <em data-td-fact-id="29246064" style="font-weight: inherit; font-style: normal;">2016,</em> Milestone Scientific recorded deferred revenues and deferred costs associated with sales to Milestone China of <em data-td-fact-id="29246065" style="font-weight: inherit; font-style: normal;">$1,725,450</em> and <em data-td-fact-id="29246066" style="font-weight: inherit; font-style: normal;">$1,109,671,</em> and <em data-td-fact-id="29246067" style="font-weight: inherit; font-style: normal;">$1,001,800</em> and <em data-td-fact-id="29246068" style="font-weight: inherit; font-style: normal;">$620,041,</em> respectively.&nbsp; As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>and <em data-td-fact-id="29246069" style="font-weight: inherit; font-style: normal;">2016,</em> Milestone China and Milestone China&rsquo;s agent owed <em data-td-fact-id="29246070" style="font-weight: inherit; font-style: normal;">$1,725,450</em> and <em data-td-fact-id="29246071" style="font-weight: inherit; font-style: normal;">$2,714,600,</em> respectively, to Milestone Scientific which is included in related party accounts receivable on the consolidated balance sheets.&nbsp;Milestone Scientific defers the total revenue and costs of goods sold when instruments and handpieces are shipped to Milestone China and Milestone China&rsquo;s agent due to market conditions and Milestone China liquidity concerns. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> August 2016, </em>a stockholder of Milestone Scientific entered a <em data-td-fact-id="29246072" style="font-weight: inherit; font-style: normal;">three</em>-year agreement with Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were <em data-td-fact-id="29246073" style="font-weight: inherit; font-style: normal;">$100,000</em> for the <em data-td-fact-id="29246074" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29246075" style="font-weight: inherit; font-style: normal;">2016,</em> respectively. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 2017, </em>Milestone Scientific entered into a <em data-td-fact-id="29246076" style="font-weight: inherit; font-style: normal;">12</em>-month agreement with Innovest S.p.A. to provide consulting service. This agreement is expected to continue into <em data-td-fact-id="29246077" style="font-weight: inherit; font-style: normal;">2018.</em><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Expenses recognized on this agreement were <em data-td-fact-id="29246078" style="font-weight: inherit; font-style: normal;">$80,000</em> for the <em data-td-fact-id="29246079" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017.</em></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">See Note M for related party employment and consulting agreements.</p>
</div>

<div contenteditable="false" docsect="9" id="13219" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338121738" id="thunderdome-statement-848195">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>NOTE<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;R&nbsp;&mdash; COMMITMENTS AND OTHER </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>(<em data-td-fact-id="29246080" style="font-weight: inherit; font-style: normal;">1</em>) Lease Commitments </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The headquarters for Milestone Scientific is located at <em data-td-fact-id="29246081" style="font-weight: inherit; font-style: normal;">220</em> South Orange Ave, Livingston, New Jersey. Milestone Scientific leases approximately <em data-td-fact-id="29246082" style="font-weight: inherit; font-style: normal;">7,625</em> square feet of office space. The lease term expires <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 31, 2020 </em>and provides for a monthly lease payment of <em data-td-fact-id="29246083" style="font-weight: inherit; font-style: normal;">$12,522.</em> Additionally, Milestone Scientific has other smaller insignificant leases ending through <em data-td-fact-id="29246084" style="font-weight: inherit; font-style: normal;">2017.</em> Further, a <em data-td-fact-id="29246085" style="font-weight: inherit; font-style: normal;">third</em>-party distribution and logistics center in Pennsylvania handles shipping and order fulfillment on a month-to-month basis.&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Aggregate minimum rental commitments under noncancelable operating leases are as follows:</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1522338121737" id="thunderdome-statement-848196">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="margin-right: 10%; margin-left: 10%; width: 869px; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22px; text-align: center;">&nbsp;</td>
			<td colspan="1" id=".amt.D2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 205px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Year Ending December 31, 2017</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2018</p>
			</td>
			<td id=".lead.2" style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td id=".symb.2" style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><em data-td-fact-id="29245597" style="font-weight: inherit; font-style: normal;">150,264</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</p>
			</td>
			<td id=".lead.2" style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><em data-td-fact-id="29245598" style="font-weight: inherit; font-style: normal;">150,264</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;">
			<p style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p>
			</td>
			<td id=".lead.2" style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0); text-align: right;"><em data-td-fact-id="29245599" style="font-weight: inherit; font-style: normal;">12,522</em></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;">&nbsp;</td>
			<td id=".lead.2" style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td id=".symb.2" style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><em data-td-fact-id="29245600" style="font-weight: inherit; font-style: normal;">313,050</em></td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the years ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29246086" style="font-weight: inherit; font-style: normal;">2016,</em> respectively, rent expense amounted to <em data-td-fact-id="29246087" style="font-weight: inherit; font-style: normal;">$141,428</em> and <em data-td-fact-id="29246088" style="font-weight: inherit; font-style: normal;">$133,657</em> respectively.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>(<em data-td-fact-id="29246089" style="font-weight: inherit; font-style: normal;">2</em>)<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Other Commitments </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></b><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific&#39;s employment agreement (the <em data-td-fact-id="29246090" style="font-weight: inherit; font-style: normal;">&ldquo;2009</em> Agreement&rdquo;) with Leonard Osser, its former Chief Executive Officer, provided for payments of <em data-td-fact-id="29246091" style="font-weight: inherit; font-style: normal;">$203,111</em> per year for <em data-td-fact-id="29246092" style="font-weight: inherit; font-style: normal;">five</em> years to the executive or as he directs such payments, to a <em data-td-fact-id="29246093" style="font-weight: inherit; font-style: normal;">third</em> party, to fund his acquisition of, or contribution to, an annuity, pension, or deferred distribution plan; or for an investment for the benefit of the executive and his family. Milestone Scientific expensed approximately <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> $203,111 years ended</em> <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017, </em>and <em data-td-fact-id="29246094" style="font-weight: inherit; font-style: normal;">2016</em> respectively to fund this obligation. In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 2017, </em>Milestone Scientific entered into a new employment agreement with Mr. Osser, which superseded the <em data-td-fact-id="29246095" style="font-weight: inherit; font-style: normal;">2009</em> Agreement pursuant to which he stepped down from his position as Chief Executive Officer and became Managing Director &ndash; China Operations.&nbsp;Pursuant to the new agreement, Milestone Scientific agreed to fund the last installment of <em data-td-fact-id="29246096" style="font-weight: inherit; font-style: normal;">$203,111</em> in <em data-td-fact-id="29246097" style="font-weight: inherit; font-style: normal;">2018</em> as provided for in the <em data-td-fact-id="29246098" style="font-weight: inherit; font-style: normal;">2009</em> Agreement. </font>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> &nbsp; &nbsp; &nbsp; </font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">F-25</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">On <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 19, 2017 </em>the Board of Directors appointed Leonard Osser Interim Chief Executive Officer, replacing Leslie Bernhard. Mr. Osser will enter into a similar employment contract that he received <em data-td-fact-id="29246099" style="font-weight: inherit; font-style: normal;">2017</em> before he resigned his position as CEO of the company. <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Mr. Osser placed on&nbsp;hold his position as Managing Director-China Operations and his consulting agreement with Milestone Medical to rejoined Milestone Scientific Inc. as Interim Chief Executive Officer.&nbsp; Mr. Osser will <em data-td-fact-id="29246100" style="font-weight: inherit; font-style: normal;">not</em> receive or earn any compensation under these agreements until he is <em data-td-fact-id="29246101" style="font-weight: inherit; font-style: normal;">no</em> longer Interim Chief Executive Officer.&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">The technology underlying the SafetyWand&reg; and CompuFlo&reg;, and an improvement to the controls for CompuDent&reg; were developed by the Director of Clinical Affairs and assigned to Milestone Scientific. Milestone Scientific purchased this technology pursuant to an agreement dated <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 1, 2005. </em>The Director of Clinical Affairs will receive additional payments of <em data-td-fact-id="29246102" style="font-weight: inherit; font-style: normal;">2.5%</em> of the total sales of products using certain of these technologies, and <em data-td-fact-id="29246103" style="font-weight: inherit; font-style: normal;">5%</em> of the total sales of products using certain other of the technologies until the expiration of the last patent. The Director of Clinical Affairs was granted, pursuant to the agreement, an option to purchase, at fair market value on the date of the grant <em data-td-fact-id="29246104" style="font-weight: inherit; font-style: normal;">8,333</em> shares of common stock upon the issuance of each additional patent relating to these technologies. If products produced by <em data-td-fact-id="29246105" style="font-weight: inherit; font-style: normal;">third</em> parties use any of these technologies (under license from us) then the Director of Clinical Affairs will receive the corresponding percentage of the consideration received by Milestone Scientific for such sale or license.&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">The Director of Clinical Affairs&rsquo; royalty fee was <em data-td-fact-id="29246106" style="font-weight: inherit; font-style: normal;">$554,150</em> and <em data-td-fact-id="29246107" style="font-weight: inherit; font-style: normal;">$526,737</em> for <em data-td-fact-id="29246108" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29246109" style="font-weight: inherit; font-style: normal;">2016,</em> respectively. Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of <em data-td-fact-id="29246110" style="font-weight: inherit; font-style: normal;">$275,000</em> for <em data-td-fact-id="29246111" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>and <em data-td-fact-id="29246112" style="font-weight: inherit; font-style: normal;">2016,</em> respectively.&nbsp; </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 2017, </em>Milestone Scientific entered into a <em data-td-fact-id="29246113" style="font-weight: inherit; font-style: normal;">12</em>-month agreement with Innovest S.p.A. to provide consulting services. This agreement will renew for successive <em data-td-fact-id="29246114" style="font-weight: inherit; font-style: normal;">12</em>-month terms unless terminated by Innovest S.p.A or Milestone Scientific. Expenses recognized on this agreement were <em data-td-fact-id="29246115" style="font-weight: inherit; font-style: normal;">$80,000</em> for <em data-td-fact-id="29246116" style="font-weight: inherit; font-style: normal;">twelve</em> months ended <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December 31, 2017 </em>respectively. This agreement is expected to continue into <em data-td-fact-id="29246117" style="font-weight: inherit; font-style: normal;">2018</em></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">On <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> October 2, 2017, </em>Milestone Scientific accepted the resignation of the then CEO, Daniel Goldberger. Subsequent to that date, Mr. Goldberger through his attorney advised Milestone Scientific<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s attorneys, that Mr. Goldberger was entitled, based on the circumstances he asserted with respect to his resignation after acceptance of such resignation, to his basic salary (<em data-td-fact-id="29246118" style="font-weight: inherit; font-style: normal;">$300,000</em>) for <em data-td-fact-id="29246119" style="font-weight: inherit; font-style: normal;">one</em> year and certain other benefits (health and disability insurance for <em data-td-fact-id="29246120" style="font-weight: inherit; font-style: normal;">one</em> year (<em data-td-fact-id="29246121" style="font-weight: inherit; font-style: normal;">$30,000</em> estimated) and a car allowance of <em data-td-fact-id="29246122" style="font-weight: inherit; font-style: normal;">$1,200</em> per month), in accordance with his employment contract dated <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> July 10, 2017.&nbsp; </em>Under the circumstances asserted by Mr. Goldberger, he would also be entitled to the immediate vesting of options under the Milestone Scientific&rsquo;s Stock Option Plan agreed to be granted to him pursuant to his employment agreement, exercisable for <em data-td-fact-id="29246123" style="font-weight: inherit; font-style: normal;">ninety</em> days after his resignation, for <em data-td-fact-id="29246124" style="font-weight: inherit; font-style: normal;">921,942</em> shares of Milestone Scientific at a price of <em data-td-fact-id="29246125" style="font-weight: inherit; font-style: normal;">$2.00</em> per share, which exercise price is more than the market price of Milestone Scientific&rsquo;s shares on the date hereof. In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> February 2018, </em>Milestone Scientific Inc. and Mr. Goldberger signed a settlement and released an agreement with respect to Mr. Goldberger&rsquo;s leaving the Company, the gross settlement was <em data-td-fact-id="29246126" style="font-weight: inherit; font-style: normal;">$175,000</em> and,&nbsp;<em data-td-fact-id="29246127" style="font-weight: inherit; font-style: normal;">$75,000,</em> was paid in <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> March 2018. </em>The remainder of the settlement will be paid over a <em data-td-fact-id="29246128" style="font-weight: inherit; font-style: normal;">nine</em>-month period beginning in <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> March 2018.</em><b>&nbsp;</b></font></p>
</div>

<div contenteditable="false" docsect="9" id="13220" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338129843" id="thunderdome-statement-848197">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">NOTE S&nbsp;&mdash; PENSION PLAN </font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific has a Defined Contribution Plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone Scientific does <em data-td-fact-id="29246129" style="font-weight: inherit; font-style: normal;">not</em> contribute to this plan, but does pay the administrative costs of the plan, which were <em data-td-fact-id="29246130" style="font-weight: inherit; font-style: normal;">not</em> significant.</font><b>&nbsp;</b></p>
</div>

<div contenteditable="false" docsect="9" id="13221" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1522338137792" id="thunderdome-statement-848198">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><b>NOTE<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;T&nbsp;&mdash; SUBSEQUENT EVENTS</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">In <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 2018 the Company&nbsp;</em>entered into a purchase commitment for the delivery of <em data-td-fact-id="29246131" style="font-weight: inherit; font-style: normal;">2,000</em> instruments beginning in the <em data-td-fact-id="29246132" style="font-weight: inherit; font-style: normal;">3rd</em> quarter of <em data-td-fact-id="29246133" style="font-weight: inherit; font-style: normal;">2018,</em> the Company&rsquo;s purchase commitment for this purchase order was <em data-td-fact-id="29246134" style="font-weight: inherit; font-style: normal;">$1,397,440.</em></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">As of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> March 2, 2018, </em>the Note Receivable identified on the Balance Sheet<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;was in default. If Milestone Scientific exercises its rights as a secured party it <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> may </em>be obligated to return to the purchaser up to the <em data-td-fact-id="29246135" style="font-weight: inherit; font-style: normal;">$250,000</em> received for the Milestone China Shares as surplus. At this time Milestone Scientific has <em data-td-fact-id="29246136" style="font-weight: inherit; font-style: normal;">not</em> received a response from the purchaser of the Milestone China Shares, Milestone Scientific has <em data-td-fact-id="29246137" style="font-weight: inherit; font-style: normal;">not</em> recorded any financial benefit from the sale of Milestone China Shares to date.&nbsp;</font> <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp; </font></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;,Times,Serif; font-size: 10pt;">F-26</div>

<hr style="page-break-after: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>
</div>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p>&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex_107847.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
	<title>ex_107847.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:right;"><b>Exhibit 31.1</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>Rule 13a-14(a)/15d-14(a) Certification </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">I, Leonard Osser, certify that:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">1. I have reviewed this annual report on Form 10-K of Milestone Scientific Inc.;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;respect to the period covered by this report;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">4. The registrant&#39;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under the supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under the supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(c) Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report the conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(d) Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">5. The registrant&#39;s other certifying officer(s) and I have disclosed, based on the most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(b) Any fraud, whether material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">Date: April 2, 2018</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:63.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Leonard Osser</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:63.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Leonard Osser</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:63.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Interim Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:63.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex_107848.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
	<title>ex_107848.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:right;"><b>Exhibit 31.2</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>Rule 13a-14(a)/15d-14(a) Certification </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">I, Joseph D&#39;Agostino, certify that:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">1. I have reviewed this annual report on Form 10-K of Milestone Scientific Inc.;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;respect to the period covered by this report;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">4. The registrant&#39;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under the supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under the supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(c) Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report the conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(d) Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">5. The registrant&#39;s other certifying officer(s) and I have disclosed, based on the most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(b) Any fraud, whether material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">Date: April 2, 2018</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:62.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Joseph D&#39;Agostino</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:62.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Joseph D&#39;Agostino</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:62.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer and Chief Operating Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:62.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex_107849.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
	<title>ex_107849.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:right;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">CERTIFICATION PURSUANT TO</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">18 U.S.C. SECTION 1350,</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">AS ADOPTED PURSUANT TO</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">In connection with the annual report of Milestone Scientific Inc. (&ldquo;Milestone&rdquo;) on Form 10-K for the period ending December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Leonard Osser,&nbsp; Interim Chief Executive Officer of Milestone, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(1)<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(2)<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone. </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">Date April 2, 2018</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:38.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Leonard Osser</p>
			</td>
			<td style="vertical-align:top;width:61.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Leonard Osser Interim Chief Executive Officer</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Executive Officer)</p>
			</td>
			<td style="vertical-align:top;width:61.6%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">A signed original of this certification has been provided to Milestone and will be retained by Milestone and furnished to the Securities and Exchange Commission or its staff upon request.</p>

<p style="font-size:1pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex_107850.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
	<title>ex_107850.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:right;"><b>Exhibit<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;32.2</font></b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">CERTIFICATION PURSUANT TO</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">18 U.S.C. SECTION 1350,</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">AS ADOPTED PURSUANT TO</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">In connection with the annual report of Milestone Scientific Inc. (&ldquo;Milestone&rdquo;) on Form 10-K for the period ending December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Joseph D<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;Agostino, Chief Financial Officer of Milestone, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">Date April 2, 2018</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:35.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Joseph D<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;Agostino</font></p>
			</td>
			<td style="vertical-align:top;width:64.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:35.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Joseph D<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;Agostino</font></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Operating Officer</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Financial Officer)</p>
			</td>
			<td style="vertical-align:top;width:64.6%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">A signed original of this certification has been provided to Milestone and will be retained by Milestone and furnished to the Securities and Exchange Commission or its staff upon request. <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</font></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ex_109537.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
<head>
	<title>ex_109537.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:right;"><b>Exhibit 23.1</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 No. 333-209466 and Form S-8 File No. 333-134245 and No. 333-40413 of Milestone Scientific Inc. of our report dated April 2, 2018, relating to our audit of the consolidated financial statements of Milestone Scientific Inc. as of December 31, 2017, which appear in this Form 10-K.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">/s/ Friedman LLP</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">East Hanover, New Jersey</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">April 2, 2018</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>mlss-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 10:48PM UTC 2018-03-30--><xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mlss="http://www.milestonescientific.com/20171231" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="mlss-20171231.xsd" xlink:type="simple"/>
  <dei:AmendmentFlag contextRef="d_2017-01-01_2017-12-31" id="c-15">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2017-01-01_2017-12-31" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2017-01-01_2017-12-31" id="c-14">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2017-01-01_2017-12-31" id="c-13">2017</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2017-01-01_2017-12-31" id="c-12">2017-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2017-01-01_2017-12-31" id="c-11">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2017-01-01_2017-12-31" id="c-2">0000855683</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2018-03-30" decimals="INF" id="c-9" unitRef="xbrli-shares">33158238</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2017-01-01_2017-12-31" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2017-01-01_2017-12-31" id="c-5">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="i_2017-06-30" decimals="0" id="c-10" unitRef="iso4217-usd">27489612</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="d_2017-01-01_2017-12-31" id="c-1">MILESTONE SCIENTIFIC INC.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2017-01-01_2017-12-31" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2017-01-01_2017-12-31" id="c-8">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2017-01-01_2017-12-31" id="c-3">mlss</dei:TradingSymbol>
  <mlss:AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology contextRef="d_2005-01-01_2005-01-01" decimals="3" id="c29244734" unitRef="xbrli-pure">0.025</mlss:AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology>
  <mlss:AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology contextRef="d_2005-01-01_2005-01-01" decimals="3" id="c29244735" unitRef="xbrli-pure">0.05</mlss:AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology>
  <mlss:AdvancesToContractManufacturerTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848173">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;F&amp;nbsp;&amp;#x2014; ADVANCES ON CONTRACTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; The advances on contracts represent funding of future STA inventory purchases and Epidural replacements parts. The balance of the advances as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$697,192&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$700,900,&lt;/div&gt; respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory.&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</mlss:AdvancesToContractManufacturerTextBlock>
  <mlss:AreaOfOfficeSpace contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244714" unitRef="utr-sqft">7625</mlss:AreaOfOfficeSpace>
  <mlss:AssetPurchaseAgreementPaymentsOfLegalFees contextRef="d_2017-07-13_2017-07-13_CounterpartyNameAxis-APADOctrooiBVAndAPADBVMember" decimals="INF" id="c29244206" unitRef="iso4217-usd">153000</mlss:AssetPurchaseAgreementPaymentsOfLegalFees>
  <mlss:AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum contextRef="d_2017-07-13_2017-07-13_CounterpartyNameAxis-APADOctrooiBVAndAPADBVMember" decimals="INF" id="c29244204" unitRef="iso4217-usd">250000</mlss:AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum>
  <mlss:AssetPurchaseAgreementPostclosingAdjustmentsLiabilities contextRef="i_2017-12-31_CounterpartyNameAxis-APADOctrooiBVAndAPADBVMember" decimals="INF" id="c29244205" unitRef="iso4217-usd">275000</mlss:AssetPurchaseAgreementPostclosingAdjustmentsLiabilities>
  <mlss:AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum contextRef="d_2017-07-13_2017-07-13_CounterpartyNameAxis-APADOctrooiBVAndAPADBVMember" decimals="2" id="c29244203" unitRef="xbrli-pure">0.25</mlss:AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum>
  <mlss:ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod contextRef="d_2009-09-01_2009-09-01_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" id="c29244447">P1Y</mlss:ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod>
  <mlss:ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod contextRef="d_2016-12-01_2016-12-01_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" id="c29244469">P1Y</mlss:ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod>
  <mlss:ChiefExecutiveOfficerEmploymentAgreementPeriod contextRef="d_2009-09-01_2009-09-01_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" id="c29244444">P5Y</mlss:ChiefExecutiveOfficerEmploymentAgreementPeriod>
  <mlss:ChiefExecutiveOfficerEmploymentAgreementPeriod contextRef="d_2016-12-01_2016-12-01_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" id="c29244468">P1Y</mlss:ChiefExecutiveOfficerEmploymentAgreementPeriod>
  <mlss:ClassOfWarrantOrRightExpirationPeriod contextRef="d_2016-12-01_2016-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" id="c29244256">P3Y</mlss:ClassOfWarrantOrRightExpirationPeriod>
  <mlss:ConsolidationOfVariableInterestEntity contextRef="d_2017-01-01_2017-12-31" id="c29243820" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:ConsolidationOfVariableInterestEntity contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243821" unitRef="iso4217-usd">39165</mlss:ConsolidationOfVariableInterestEntity>
  <mlss:ConsultingAgreementAnnualPayment contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" decimals="INF" id="c29244496" unitRef="iso4217-usd">100000</mlss:ConsultingAgreementAnnualPayment>
  <mlss:ConsultingAgreementTerm contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" id="c29244495">P10Y</mlss:ConsultingAgreementTerm>
  <mlss:ConsultingServicesAgreementTerm contextRef="d_2016-08-01_2016-08-31_RelatedPartyTransactionAxis-ConsultingServicesMember" id="c29244702">P3Y</mlss:ConsultingServicesAgreementTerm>
  <mlss:ConsultingServicesAgreementTerm contextRef="d_2017-01-01_2017-01-31_RelatedPartyTransactionAxis-ConsultingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-InnovestSpAMember" id="c29244707">P1Y</mlss:ConsultingServicesAgreementTerm>
  <mlss:DeferredGainOnDisposalOfInvestment contextRef="i_2017-12-31" decimals="INF" id="c29243403" unitRef="iso4217-usd">1400000</mlss:DeferredGainOnDisposalOfInvestment>
  <mlss:DeferredGainOnDisposalOfInvestment contextRef="i_2016-12-31" id="c29243404" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:DeferredProfitRelatedPartiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243397" unitRef="iso4217-usd">751500</mlss:DeferredProfitRelatedPartiesCurrent>
  <mlss:DeferredProfitRelatedPartiesCurrent contextRef="i_2016-12-31" decimals="INF" id="c29243398" unitRef="iso4217-usd">630990</mlss:DeferredProfitRelatedPartiesCurrent>
  <mlss:DeferredTaxAssetsDepreciationAndAmortizationNoncurrent contextRef="i_2017-12-31" decimals="INF" id="c29244543" unitRef="iso4217-usd">181000</mlss:DeferredTaxAssetsDepreciationAndAmortizationNoncurrent>
  <mlss:DeferredTaxAssetsDepreciationAndAmortizationNoncurrent contextRef="i_2016-12-31" decimals="INF" id="c29244544" unitRef="iso4217-usd">135000</mlss:DeferredTaxAssetsDepreciationAndAmortizationNoncurrent>
  <mlss:DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017 contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244514" unitRef="iso4217-usd">-8677000</mlss:DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017>
  <mlss:DefineBenefitPlanPaymentPeriod contextRef="d_2017-01-01_2017-12-31" id="c29244724">P5Y</mlss:DefineBenefitPlanPaymentPeriod>
  <mlss:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c29244567" unitRef="xbrli-pure">2.04</mlss:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation>
  <mlss:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation contextRef="d_2016-01-01_2016-12-31" decimals="2" id="c29244568" unitRef="xbrli-pure">0.43</mlss:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation>
  <mlss:EmployeeResignationAssertionBasicSalaryForOneYear contextRef="d_2017-10-02_2017-10-02_TitleOfIndividualAxis-FormerCeoMember" decimals="INF" id="c29244751" unitRef="iso4217-usd">300000</mlss:EmployeeResignationAssertionBasicSalaryForOneYear>
  <mlss:EmployeeResignationAssertionCarAllowanceForOneYear contextRef="d_2017-10-02_2017-10-02_TitleOfIndividualAxis-FormerCeoMember" decimals="INF" id="c29244755" unitRef="iso4217-usd">1200</mlss:EmployeeResignationAssertionCarAllowanceForOneYear>
  <mlss:EmployeeResignationAssertionGrossSettlement contextRef="d_2018-02-01_2018-02-28_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-FormerCeoMember" decimals="INF" id="c29244759" unitRef="iso4217-usd">175000</mlss:EmployeeResignationAssertionGrossSettlement>
  <mlss:EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear contextRef="d_2017-10-02_2017-10-02_TitleOfIndividualAxis-FormerCeoMember" decimals="INF" id="c29244754" unitRef="iso4217-usd">30000</mlss:EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear>
  <mlss:EmployeeResignationAssertionNumberOfOptionsVested contextRef="d_2017-10-02_2017-10-02_TitleOfIndividualAxis-FormerCeoMember" decimals="INF" id="c29244757" unitRef="xbrli-shares">921942</mlss:EmployeeResignationAssertionNumberOfOptionsVested>
  <mlss:EmployeeResignationAssertionOptionsExercisePrice contextRef="i_2017-10-02_TitleOfIndividualAxis-FormerCeoMember" decimals="INF" id="c29244758" unitRef="iso4217-usd-per-xbrli-shares">2</mlss:EmployeeResignationAssertionOptionsExercisePrice>
  <mlss:EmployeeResignationAssertionPayment contextRef="d_2018-03-01_2018-03-31_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-FormerCeoMember" decimals="INF" id="c29244760" unitRef="iso4217-usd">75000</mlss:EmployeeResignationAssertionPayment>
  <mlss:EmployeeResignationAssertionVestingTermAfterResignation contextRef="d_2017-10-02_2017-10-02_TitleOfIndividualAxis-FormerCeoMember" id="c29244756">P90D</mlss:EmployeeResignationAssertionVestingTermAfterResignation>
  <mlss:EmploymentAgreementBaseCompensation contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember" decimals="INF" id="c29244473" unitRef="iso4217-usd">300000</mlss:EmploymentAgreementBaseCompensation>
  <mlss:EmploymentAgreementBaseCompensation contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" decimals="INF" id="c29244486" unitRef="iso4217-usd">300000</mlss:EmploymentAgreementBaseCompensation>
  <mlss:EmploymentAgreementBaseCompensation contextRef="d_2017-10-05_2017-10-05_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember" decimals="INF" id="c29244497" unitRef="iso4217-usd">200000</mlss:EmploymentAgreementBaseCompensation>
  <mlss:EmploymentAgreementBaseCompensationCash contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" decimals="INF" id="c29244487" unitRef="iso4217-usd">100000</mlss:EmploymentAgreementBaseCompensationCash>
  <mlss:EmploymentAgreementBaseCompensationCommonStockValue contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" decimals="INF" id="c29244488" unitRef="iso4217-usd">200000</mlss:EmploymentAgreementBaseCompensationCommonStockValue>
  <mlss:EmploymentAgreementBaseCompensationCommonStockValue contextRef="d_2017-10-05_2017-10-05_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember" decimals="INF" id="c29244499" unitRef="iso4217-usd">100000</mlss:EmploymentAgreementBaseCompensationCommonStockValue>
  <mlss:EmploymentAgreementMaximumBonuses contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember" decimals="INF" id="c29244474" unitRef="iso4217-usd">400000</mlss:EmploymentAgreementMaximumBonuses>
  <mlss:EmploymentAgreementOnetimeBonus contextRef="d_2017-12-09_2017-12-09_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember" decimals="INF" id="c29244500" unitRef="iso4217-usd">25000</mlss:EmploymentAgreementOnetimeBonus>
  <mlss:EmploymentAgreementTerm contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember" id="c29244472">P3Y</mlss:EmploymentAgreementTerm>
  <mlss:EmploymentAgreementTerm contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember" id="c29244485">P10Y</mlss:EmploymentAgreementTerm>
  <mlss:EmploymentAndConsultingAgreementsTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848186">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE M&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2013;EMPLOYMENT CONTRACT AND CONSULTING AGREEMENTS&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Employment Contracts&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 1, 2009, &lt;/div&gt;Milestone Scientific entered into a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt;-year employment agreement with Leonard Osser as its Chief Executive Officer (the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;quot;2009&lt;/div&gt; Agreement&amp;quot;). The terms of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2009&lt;/div&gt; Agreement are automatically extended for successive &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-year periods unless prior to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 1 &lt;/div&gt;of any year, either party notifies the other that he or it chooses &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to extend the term. Under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2009&lt;/div&gt; Agreement, the CEO receives base compensation of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$300,000&lt;/div&gt; per year. In addition, the CEO, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;earn annual bonuses up to an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$400,000,&lt;/div&gt; payable &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; half in cash and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; half in common stock, contingent upon achieving targets set for each year by the Compensation Committee. In addition, if in any year of the term of the agreement the CEO earns a bonus, he shall also be granted &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt;-year stock options to purchase twice the number of bonus shares earned. Each such option is to be exercisable at a price per share equal to the fair market value of a share on the date of grant (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;110%&lt;/div&gt;) of the fair market value if the CEO is a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10%&lt;/div&gt; or greater stockholder on the date of grant). The options shall vest and become exercisable to the extent of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; of the shares covered at the end of each of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; years following the date of grant but shall only be exercisable while the CEO is employed by Milestone Scientific or within &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30&lt;/div&gt; days after the termination of his employment.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In accordance with the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2009&lt;/div&gt; Agreement, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;886,866&lt;/div&gt; shares of common stock are to be paid out at the end of the term in settlement of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,030,875&lt;/div&gt;&amp;nbsp;of deferred compensation accrued at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;855,810&lt;/div&gt;&amp;nbsp;shares of common stock are to be paid out at the end of the contract in settlement of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$980,906&lt;/div&gt; of deferred compensation accrued at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016 &lt;/div&gt;and, accordingly, such shares have been classified in stockholders' equity with the common stock classified as to be issued.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;On&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;December 1, 2016, &lt;/div&gt;Wand Dental and Gian Domenico Trombetta (&amp;#x201c;Trombetta&amp;#x201d;) entered into an Amended and Restated Employment Agreement (the &amp;#x201c;Agreement&amp;#x201d;), pursuant to which Trombetta receives base compensation of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$280,000&lt;/div&gt; per year&amp;nbsp;and is eligible to receive annual bonuses in the sole discretion of the Compensation Committee. Pursuant to the Agreement, Trombetta will continue to serve as the Chief Executive Officer of Wand Dental for a period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-year beginning on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 1, 2016 &lt;/div&gt;through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 31, 2017 (&lt;/div&gt;the &amp;#x201c;Employment Term&amp;#x201d;). The Employment Term automatically renews for a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-year period, from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 1&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;st&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 31&lt;/div&gt;&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;st&lt;/div&gt;&amp;nbsp;of each successive year (each a &amp;#x201c;Renewal Term&amp;#x201d;), unless prior to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1st&lt;/div&gt; of the Employment Term or any Renewal Term, as applicable, either party notifies the other that he or it chooses &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to extend the term of employment in accordance with the terms of the Agreement.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2017, &lt;/div&gt;Milestone Scientific entered into a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-year employment agreement with Daniel Goldberger to serve as President and Chief Executive Officer of Milestone Scientific. Under the agreement, Mr. Goldberger would receive base compensation of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$300,000&lt;/div&gt; per annum and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;additionally earn annual bonuses of up to an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$400,000,&lt;/div&gt; payable &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; half in cash and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; half in Milestone Scientific common stock (&amp;#x201c;Bonus Shares&amp;#x201d;) contingent upon achieving performance benchmarks periodically set for each year by the compensation committee of the Board. In addition to any such shares of common stock, Mr. Goldberger was entitled to receive stock options (&amp;#x201c;Bonus Options&amp;#x201d;) to acquire twice the number of any Bonus Shares earned, pursuant to a non-qualified stock option grant agreement under Milestone Scientific&amp;#x2019;s then existing equity compensation plan. The Bonus Options had a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt;-year term and were to vest in equal annual installments on each of the first, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;second&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; anniversary of the grant date, subject to continued employment on such vesting date and accelerated vesting upon the occurrence of certain events. The exercise price of the Bonus Options was based on the fair market value of per share of common stock on the date of grant.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2017, &lt;/div&gt;Milestone Scientific granted to Mr. Goldberger non-qualified stock options to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;921,942&lt;/div&gt; shares of common stock at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.00&lt;/div&gt; per share. Those options had a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt;-year term and were to vest in equal annual installments on each of the first, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;second&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; anniversaries of the grant date, subject to his continued employment on the vesting date and accelerated vesting upon the occurrence of certain events.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2017, &lt;/div&gt;Milestone Scientific entered into a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt;-year new employment agreement with Leonard Osser, who previously served as the Company&amp;#x2019;s President and Chief Executive Officer, to serve as Managing Director &amp;#x2013; China Operations. This new agreement provides for annual compensation of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$300,000&lt;/div&gt; consisting of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$100,000&lt;/div&gt; in cash and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$200,000&lt;/div&gt; in the Company&amp;#x2019;s common stock valued at the average closing price of the Company&amp;#x2019;s common stock on the NYSE or such other market or exchange on which its shares are then traded during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;fifteen&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&lt;/div&gt;) trading days of the last full calendar month of each year during the term of this agreement. This agreement supersedes all prior employment agreements between Mr. Osser and Milestone Scientific. If the Company terminates Mr. Osser&amp;#x2019;s employment &amp;#x201c;Without Cause,&amp;#x201d; other than due to his death or disability, or if Mr. Osser terminates his employment for &amp;#x201c;Good Reason&amp;#x201d; (both as defined in the agreement), Mr. Osser is entitled to be paid in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; lump sum payment as soon as practicable following such termination: an amount equal to the aggregate present value (as determined in accordance with Section &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;280G&lt;/div&gt;(d)(&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;) of the Code) of all compensation pursuant to this agreement from the effective date of termination hereunder through the remainder of the Employment Term.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2017, &lt;/div&gt;Mr. Osser also resigned from his positions of Chairman of the Board, Chief Executive Office and President of Milestone Medical. Upon his resignation, Milestone Medical entered in a consulting agreement with U.S. Asian Consulting Group LLC, an entity controlled by Mr. Osser, pursuant to which he will provide specific services to Milestone Medical for a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt;- year term. Pursuant to the consulting agreement, U.S. Asian Consulting Group, LLC, is entitled to receive &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$100,000&lt;/div&gt; per year for Mr. Osser's services.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 5, 2017, &lt;/div&gt;Milestone Scientific Inc. announced that Daniel Goldberger had resigned as President and Chief Executive Officer effective &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 2, 2017, &lt;/div&gt;upon which the previously described stock options granted to him in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2017 &lt;/div&gt;terminated prior to vesting.&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; All compensation expense recorded to the date of the resignation was reversed as of the resignation date.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 5, 2017, &lt;/div&gt;Milestone Scientific also announced the appointment of Leslie Bernhard, the Company&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2019;s current Chairman of the Board, as the Company&amp;#x2019;s Interim Chief Executive Officer, to serve in such role until the appointment of a new Chief Executive Officer. In connection with her appointment to serve as the Company&amp;#x2019;s Interim Chief Executive Officer, Ms. Bernhard was paid an annual salary of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$200,000&lt;/div&gt;&amp;nbsp;received a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-time bonus of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100,000&lt;/div&gt; shares of the Company&amp;#x2019;s Common Stock.&amp;nbsp; In addition, at the completion of her service as Interim Chief Executive Officer, Ms. Bernhard shall be entitled to receive a cash bonus in an amount to be determined by the Board of Directors at that time.&amp;nbsp;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 19 ,2017 &lt;/div&gt;the Board of Directors appointed Leonard Osser Interim Chief Executive Officer, replacing Leslie Bernhard. Ms. Bernhard agreed to accept &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,000&lt;/div&gt; shares of Milestone Scientific stock for her services as Interim Chief Executive Officer in-lieu of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100,000&lt;/div&gt; shares she was previously awarded.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 19, 2017 &lt;/div&gt;the Board of Directors appointed Leonard Osser Interim Chief Executive Office, replacing Leslie Bernhard. Mr. Osser will&amp;nbsp;enter into a similar &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2009&lt;/div&gt; employment contract that he received &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;&amp;nbsp;before he resigned his position as CEO of the company. &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;Mr. Osser placed on&amp;nbsp;hold&amp;nbsp;his position as Managing Director-China Operations and his consulting agreement with Milestone Medical to rejoined Milestone Scientific Inc. as Interim Chief Executive Officer and will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; receive or earn any compensation under those agreements until he is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer Interim Chief Executive Officer.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</mlss:EmploymentAndConsultingAgreementsTextBlock>
  <mlss:EquityMethodInvestmentDeferredIntercompanyProfitLoss contextRef="i_2017-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244114" unitRef="iso4217-usd">751500</mlss:EquityMethodInvestmentDeferredIntercompanyProfitLoss>
  <mlss:EquityMethodInvestmentDeferredIntercompanyProfitLoss contextRef="i_2016-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244115" unitRef="iso4217-usd">630990</mlss:EquityMethodInvestmentDeferredIntercompanyProfitLoss>
  <mlss:EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage contextRef="d_2017-01-01_2017-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="2" id="c29243950" unitRef="xbrli-pure">0.4</mlss:EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage>
  <mlss:IncomeFromNonemployeeOptions contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243979" unitRef="iso4217-usd">9384</mlss:IncomeFromNonemployeeOptions>
  <mlss:IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243481" unitRef="iso4217-usd">-5249043</mlss:IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <mlss:IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243482" unitRef="iso4217-usd">-6498662</mlss:IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <mlss:IncreaseDecreaseToAdvancesToContractManufacturer contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243795" unitRef="iso4217-usd">-3708</mlss:IncreaseDecreaseToAdvancesToContractManufacturer>
  <mlss:IncreaseDecreaseToAdvancesToContractManufacturer contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243796" unitRef="iso4217-usd">-514228</mlss:IncreaseDecreaseToAdvancesToContractManufacturer>
  <mlss:MinimumShareholdingPercentageInCompany contextRef="d_2009-09-01_2009-09-01_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="1" id="c29244456" unitRef="xbrli-pure">0.1</mlss:MinimumShareholdingPercentageInCompany>
  <mlss:NoteReceivableQuarterlyInstallmentAmount contextRef="d_2017-06-01_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" decimals="INF" id="c29244030" unitRef="iso4217-usd">125000</mlss:NoteReceivableQuarterlyInstallmentAmount>
  <mlss:NumberOfCustomers contextRef="d_2017-01-01_2017-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" decimals="INF" id="c29244667" unitRef="xbrli-pure">2</mlss:NumberOfCustomers>
  <mlss:NumberOfCustomers contextRef="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" decimals="INF" id="c29244673" unitRef="xbrli-pure">2</mlss:NumberOfCustomers>
  <mlss:NumberOfMedicalInstrumentsSold contextRef="d_2017-01-01_2017-12-31_StatementGeographicalAxis-US" decimals="INF" id="c29243857" unitRef="xbrli-pure">0</mlss:NumberOfMedicalInstrumentsSold>
  <mlss:OptionToRepurchasePeriod contextRef="d_2017-06-01_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" id="c29244026">P10Y</mlss:OptionToRepurchasePeriod>
  <mlss:OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod contextRef="d_2017-06-01_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" id="c29244034">P2Y</mlss:OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod>
  <mlss:OptionToRepurchaseVariableInterestEntitySharesPurchasePrice contextRef="d_2017-06-01_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" decimals="INF" id="c29244032" unitRef="iso4217-usd">1400000</mlss:OptionToRepurchaseVariableInterestEntitySharesPurchasePrice>
  <mlss:OptionsExercisablePeriod contextRef="d_2009-09-01_2009-09-01_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" id="c29244461">P30D</mlss:OptionsExercisablePeriod>
  <mlss:PercentageOfRevenueFromServicesPerformedToVariableInterestEntity contextRef="i_2017-12-31_VariableInterestEntitiesByClassificationOfEntityAxis-MilestoneEducationLLCMember" decimals="2" id="c29244064" unitRef="xbrli-pure">0.81</mlss:PercentageOfRevenueFromServicesPerformedToVariableInterestEntity>
  <mlss:PercentageOfValuationAllowance contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c29244521" unitRef="xbrli-pure">1</mlss:PercentageOfValuationAllowance>
  <mlss:PriceForSharesOfVariableInterestEntityInterestSold contextRef="i_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" decimals="INF" id="c29244027" unitRef="iso4217-usd">1400000</mlss:PriceForSharesOfVariableInterestEntityInterestSold>
  <mlss:ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase contextRef="d_2017-06-01_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" decimals="INF" id="c29244028" unitRef="iso4217-usd">125000</mlss:ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase>
  <mlss:ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243829" unitRef="iso4217-usd">250000</mlss:ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase>
  <mlss:ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase contextRef="d_2016-01-01_2016-12-31" id="c29243830" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848190">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;O&amp;nbsp;&amp;#x2014; SEGMENT AND GEOGRAPHIC DATA&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;We conduct our business through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; reportable segments:&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; dental and medical.&amp;nbsp;&amp;nbsp;These segments offer different products and services to different customer base. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;The following tables present information about our reportable and operating segments:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 64%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Sales&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Years ended&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net Sales:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Dental&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,279,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,460,752&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Medical&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,253&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,281,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,482,005&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Operating Income (Loss):&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Dental&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,127,570&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,087,002&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Medical&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;2,389,145&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;3,265,602&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,972,743&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;5,335,360&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;5,234,318&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;6,513,960&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Depreciation and Amortization:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Dental&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,305&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Medical&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,950&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;62,720&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Other&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;528,895&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82,586&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;573,150&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;162,925&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="text-indent: 27pt;"&gt;&amp;nbsp;Total&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Income before taxes and equity in&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; earnings&amp;nbsp;of affiliates:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Dental&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,136,167&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,097,652&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Medical&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;2,391,082&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;3,219,497&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;5,975,035&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;5,395,918&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;5,229,950&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;6,517,763&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Dental&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,255,144&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,472,879&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Medical&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;655,513&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;913,840&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,718,130&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;2,794,921&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-indent: 27pt;"&gt;&amp;nbsp;Total&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,628,787&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,181,640&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;The following table presents information about our operations by geographic area as &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; Net sales by geographic area are based on the respective locations of our subsidiaries&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-right: 7.5%; margin-left: 7.5%; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Dental &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 64%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Total Product Sales&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Domestic-US and Canada&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,339,709&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,331,308&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;International -Rest of the World&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,869,177&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,703,844&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;International -China&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,071,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,425,600&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,279,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,460,752&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Total Product Sales&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Medical &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Domestic-US and Canada&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;International - Rest of the World&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,253&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,253&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;Domestic-US and Canada&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,339,709&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,352,561&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;International -Rest of the World&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,871,177&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,703,844&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;International -China&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,071,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,425,600&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-indent: 36pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,281,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,482,005&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</mlss:ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock>
  <mlss:PurchaseCommitmentNumberOfUnits contextRef="d_2016-03-01_2016-03-31_ProductOrServiceAxis-InstrumentsMember" decimals="INF" id="c29244656" unitRef="xbrli-pure">3000</mlss:PurchaseCommitmentNumberOfUnits>
  <mlss:PurchaseCommitmentNumberOfUnits contextRef="d_2017-01-01_2017-01-31_ProductOrServiceAxis-InstrumentsMember" decimals="INF" id="c29244657" unitRef="xbrli-pure">2000</mlss:PurchaseCommitmentNumberOfUnits>
  <mlss:PurchaseOfIntangiblesAssetsApad contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243818" unitRef="iso4217-usd">153647</mlss:PurchaseOfIntangiblesAssetsApad>
  <mlss:PurchaseOfIntangiblesAssetsApad contextRef="d_2016-01-01_2016-12-31" id="c29243819" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:ReturnObligationAmount contextRef="i_2018-03-02_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_StatementScenarioAxis-UponExerciseOfDefaultAgreementMember_SubsequentEventTypeAxis-SubsequentEventMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" decimals="INF" id="c29244037" unitRef="iso4217-usd">250000</mlss:ReturnObligationAmount>
  <mlss:SaleOfVariableInterestEntitysShares contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243849" unitRef="iso4217-usd">1150000</mlss:SaleOfVariableInterestEntitysShares>
  <mlss:SaleOfVariableInterestEntitysShares contextRef="d_2016-01-01_2016-12-31" id="c29243850" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:SalesByProductAndByGeographicalRegionTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-26">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-right: 7.5%; margin-left: 7.5%; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Dental &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 64%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Total Product Sales&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Domestic-US and Canada&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,339,709&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,331,308&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;International -Rest of the World&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,869,177&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,703,844&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;International -China&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,071,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,425,600&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,279,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,460,752&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Total Product Sales&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Medical &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Domestic-US and Canada&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;International - Rest of the World&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,253&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,253&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;Domestic-US and Canada&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,339,709&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,352,561&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" text-indent: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;International -Rest of the World&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,871,177&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,703,844&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;International -China&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,071,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,425,600&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-indent: 36pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,281,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,482,005&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</mlss:SalesByProductAndByGeographicalRegionTableTextBlock>
  <mlss:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c29244350">P4Y138D</mlss:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
  <mlss:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="d_2017-01-01_2017-12-31" id="c29244370">P4Y251D</mlss:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
  <mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="d_2017-01-01_2017-12-31" decimals="4" id="c29255708" unitRef="xbrli-pure">0.06</mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
  <mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="d_2016-01-01_2016-12-31" decimals="4" id="c29255710" unitRef="xbrli-pure">0.06</mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
  <mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate contextRef="d_2004-07-01_2004-07-31_PlanNameAxis-StockOptionPlan2004Member" id="c29244291">P3Y</mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate>
  <mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate contextRef="d_2011-06-01_2011-06-30_PlanNameAxis-StockOptionPlan2011Member" id="c29244297">P3Y</mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate>
  <mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate contextRef="d_2004-07-01_2004-07-31_PlanNameAxis-StockOptionPlan2004Member" id="c29244292">P5Y</mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate>
  <mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate contextRef="d_2011-06-01_2011-06-30_PlanNameAxis-StockOptionPlan2011Member" id="c29244298">P5Y</mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate>
  <mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c29244351" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244371" unitRef="iso4217-usd">25610</mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue>
  <mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244403" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244419" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodSharesDirectorsBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243727" unitRef="xbrli-shares" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodSharesDirectorsBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243729" unitRef="xbrli-shares">120000</mlss:StockIssuedDuringPeriodSharesDirectorsBonuses>
  <mlss:StockIssuedDuringPeriodSharesEmployeeBonuses contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243610" unitRef="xbrli-shares" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodSharesEmployeeBonuses contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243612" unitRef="xbrli-shares">259765</mlss:StockIssuedDuringPeriodSharesEmployeeBonuses>
  <mlss:StockIssuedDuringPeriodSharesEmployeeBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243700" unitRef="xbrli-shares" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodSharesEmployeeBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243702" unitRef="xbrli-shares">158082</mlss:StockIssuedDuringPeriodSharesEmployeeBonuses>
  <mlss:StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243637" unitRef="xbrli-shares" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243639" unitRef="xbrli-shares">5035042</mlss:StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs>
  <mlss:StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243718" unitRef="xbrli-shares" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243720" unitRef="xbrli-shares">311998</mlss:StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs>
  <mlss:StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants contextRef="d_2005-01-01_2005-01-01_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" decimals="INF" id="c29244736" unitRef="xbrli-shares">8333</mlss:StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants>
  <mlss:StockIssuedDuringPeriodValueDirectorsBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243728" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueDirectorsBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243730" unitRef="iso4217-usd">120</mlss:StockIssuedDuringPeriodValueDirectorsBonuses>
  <mlss:StockIssuedDuringPeriodValueDirectorsBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243731" unitRef="iso4217-usd">159480</mlss:StockIssuedDuringPeriodValueDirectorsBonuses>
  <mlss:StockIssuedDuringPeriodValueDirectorsBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243732" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueDirectorsBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243733" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueDirectorsBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243734" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueDirectorsBonuses contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243735" unitRef="iso4217-usd">159600</mlss:StockIssuedDuringPeriodValueDirectorsBonuses>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243611" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243613" unitRef="iso4217-usd">260</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243614" unitRef="iso4217-usd">539240</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243615" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243616" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243617" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243618" unitRef="iso4217-usd">539500</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243701" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243703" unitRef="iso4217-usd">158</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243704" unitRef="iso4217-usd">259834</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243705" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243706" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243707" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueEmployeeBonuses contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243708" unitRef="iso4217-usd">259992</mlss:StockIssuedDuringPeriodValueEmployeeBonuses>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243638" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243640" unitRef="iso4217-usd">5035</mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243641" unitRef="iso4217-usd">-2515860</mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243642" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" decimals="INF" id="c29243643" unitRef="iso4217-usd">2510825</mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243644" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2016-01-01_2016-12-31" id="c29243645" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243719" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243721" unitRef="iso4217-usd">312</mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243722" unitRef="iso4217-usd">-403710</mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243723" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" decimals="INF" id="c29243724" unitRef="iso4217-usd">403398</mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243725" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs contextRef="d_2017-01-01_2017-12-31" id="c29243726" unitRef="iso4217-usd" xs:nil="true"/>
  <mlss:StockIssuedEmployeesCompensation contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243853" unitRef="iso4217-usd">350249</mlss:StockIssuedEmployeesCompensation>
  <mlss:StockIssuedEmployeesCompensation contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243854" unitRef="iso4217-usd">366299</mlss:StockIssuedEmployeesCompensation>
  <mlss:StockIssuedForPublicOffering contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243851" unitRef="iso4217-usd">194885</mlss:StockIssuedForPublicOffering>
  <mlss:StockIssuedForPublicOffering contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243852" unitRef="iso4217-usd">389318</mlss:StockIssuedForPublicOffering>
  <mlss:VariableInterestEntityMajorityShareholderOwnershipPercentage contextRef="d_2017-01-01_2017-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="2" id="c29243893" unitRef="xbrli-pure">0.53</mlss:VariableInterestEntityMajorityShareholderOwnershipPercentage>
  <mlss:VariableInterestEntityOwnershipPercentageSold contextRef="d_2017-06-01_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" decimals="INF" id="c29244099" unitRef="xbrli-pure">0.4</mlss:VariableInterestEntityOwnershipPercentageSold>
  <mlss:WriteoffOfAdvancesToAffiliate contextRef="d_2016-01-01_2016-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AdvancedOcularSciencesSAMember" decimals="INF" id="c29244070" unitRef="iso4217-usd">78798</mlss:WriteoffOfAdvancesToAffiliate>
  <us-gaap:AccountsPayableCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243391" unitRef="iso4217-usd">977623</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2016-12-31" decimals="INF" id="c29243392" unitRef="iso4217-usd">1341207</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243393" unitRef="iso4217-usd">985678</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="i_2016-12-31" decimals="INF" id="c29243394" unitRef="iso4217-usd">1235052</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:AccountsReceivableGross contextRef="i_2017-12-31" decimals="INF" id="c29244677" unitRef="iso4217-usd">2555476</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="i_2016-12-31" decimals="INF" id="c29244680" unitRef="iso4217-usd">2994686</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243360" unitRef="iso4217-usd">1535513</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2016-12-31" decimals="INF" id="c29243361" unitRef="iso4217-usd">802384</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableRelatedParties contextRef="i_2017-12-31_ProductOrServiceAxis-STAInstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244700" unitRef="iso4217-usd">1725450</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:AccountsReceivableRelatedParties contextRef="i_2016-12-31_ProductOrServiceAxis-STAInstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244701" unitRef="iso4217-usd">2714600</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243362" unitRef="iso4217-usd">1725450</us-gaap:AccountsReceivableRelatedPartiesCurrent>
  <us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="i_2016-12-31" decimals="INF" id="c29243363" unitRef="iso4217-usd">2714600</us-gaap:AccountsReceivableRelatedPartiesCurrent>
  <us-gaap:AccruedBonusesCurrent contextRef="i_2009-09-01_RangeAxis-MaximumMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="INF" id="c29244451" unitRef="iso4217-usd">400000</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243395" unitRef="iso4217-usd">2287908</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2016-12-31" decimals="INF" id="c29243396" unitRef="iso4217-usd">1436262</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2017-12-31" decimals="INF" id="c29243934" unitRef="iso4217-usd">721619</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2016-12-31" decimals="INF" id="c29243935" unitRef="iso4217-usd">659144</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2017-12-31" decimals="INF" id="c29243433" unitRef="iso4217-usd">86689084</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2016-12-31" decimals="INF" id="c29243434" unitRef="iso4217-usd">82761503</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243566" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c29243568" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243569" unitRef="iso4217-usd">580347</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243570" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243571" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243572" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243573" unitRef="iso4217-usd">580347</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243665" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c29243667" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243668" unitRef="iso4217-usd">651413</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243669" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243670" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243671" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243672" unitRef="iso4217-usd">651413</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdvancesOnInventoryPurchases contextRef="i_2017-12-31" decimals="INF" id="c29244060" unitRef="iso4217-usd">697192</us-gaap:AdvancesOnInventoryPurchases>
  <us-gaap:AdvancesOnInventoryPurchases contextRef="i_2016-12-31" decimals="INF" id="c29244061" unitRef="iso4217-usd">700900</us-gaap:AdvancesOnInventoryPurchases>
  <us-gaap:AdvancesOnInventoryPurchases contextRef="i_2017-12-31_ProductOrServiceAxis-InstrumentsMember" decimals="INF" id="c29244660" unitRef="iso4217-usd">697192</us-gaap:AdvancesOnInventoryPurchases>
  <us-gaap:AdvancesOnInventoryPurchases contextRef="i_2016-12-31_ProductOrServiceAxis-InstrumentsMember" decimals="INF" id="c29244662" unitRef="iso4217-usd">656752</us-gaap:AdvancesOnInventoryPurchases>
  <us-gaap:AdvancesToAffiliate contextRef="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AdvancedOcularSciencesSAMember" decimals="INF" id="c29244068" unitRef="iso4217-usd">78798</us-gaap:AdvancesToAffiliate>
  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="i_2017-12-31" decimals="INF" id="c29243914" unitRef="iso4217-usd">10000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="i_2016-12-31" decimals="INF" id="c29243916" unitRef="iso4217-usd">10000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="d_2017-01-01_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="INF" id="c29244190" unitRef="iso4217-usd">510676</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="d_2016-01-01_2016-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="INF" id="c29244191" unitRef="iso4217-usd">70699</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243778" unitRef="iso4217-usd">510676</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243779" unitRef="iso4217-usd">70699</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-OptionsAndWarrantsMember" decimals="INF" id="c29243964" unitRef="xbrli-shares">3679152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-OptionsAndWarrantsMember" decimals="INF" id="c29243965" unitRef="xbrli-shares">3329769</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244616" unitRef="iso4217-usd">10255144</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244617" unitRef="iso4217-usd">10472879</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244618" unitRef="iso4217-usd">655513</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244619" unitRef="iso4217-usd">913840</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2017-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" decimals="INF" id="c29244620" unitRef="iso4217-usd">4718130</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2016-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" decimals="INF" id="c29244621" unitRef="iso4217-usd">-2794921</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2017-12-31" decimals="INF" id="c29244622" unitRef="iso4217-usd">15628787</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2016-12-31" decimals="INF" id="c29244623" unitRef="iso4217-usd">14181640</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243376" unitRef="iso4217-usd">12020401</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2016-12-31" decimals="INF" id="c29243377" unitRef="iso4217-usd">13344802</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2016-12-31" decimals="INF" id="c29243837" unitRef="iso4217-usd">3602229</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="INF" id="c29243838" unitRef="iso4217-usd">4194384</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2017-12-31" decimals="INF" id="c29243839" unitRef="iso4217-usd">2636956</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243835" unitRef="iso4217-usd">-965273</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243836" unitRef="iso4217-usd">-592155</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29255638">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.&lt;/div&gt; Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Milestone Scientific considers all highly liquid investments purchased with an original maturity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less to be cash equivalents.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2016-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29244257" unitRef="iso4217-usd-per-xbrli-shares">2.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2016-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29244252" unitRef="xbrli-shares">0.75</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2016-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29244250" unitRef="xbrli-shares">1592775</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2016-12-31_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" decimals="INF" id="c29244251" unitRef="xbrli-shares">92775</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2017-12-31" id="c29243408" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2016-12-31" id="c29243409" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848195">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;R&amp;nbsp;&amp;#x2014; COMMITMENTS AND OTHER &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;) Lease Commitments &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; The headquarters for Milestone Scientific is located at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;220&lt;/div&gt; South Orange Ave, Livingston, New Jersey. Milestone Scientific leases approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,625&lt;/div&gt; square feet of office space. The lease term expires &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 31, 2020 &lt;/div&gt;and provides for a monthly lease payment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12,522.&lt;/div&gt; Additionally, Milestone Scientific has other smaller insignificant leases ending through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; Further, a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party distribution and logistics center in Pennsylvania handles shipping and order fulfillment on a month-to-month basis.&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Aggregate minimum rental commitments under noncancelable operating leases are as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 644px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 22px; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 205px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;Year Ending December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 644px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 22px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt; &lt;td style="width: 205px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;150,264&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 644px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 22px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 205px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;150,264&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 644px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 22px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 205px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0); text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,522&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 644px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 22px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt; &lt;td style="width: 205px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;313,050&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; For the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively, rent expense amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$141,428&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$133,657&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;)&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; Other Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Milestone Scientific's employment agreement (the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x201c;2009&lt;/div&gt; Agreement&amp;#x201d;) with Leonard Osser, its former Chief Executive Officer, provided for payments of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$203,111&lt;/div&gt; per year for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years to the executive or as he directs such payments, to a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; party, to fund his acquisition of, or contribution to, an annuity, pension, or deferred distribution plan; or for an investment for the benefit of the executive and his family. Milestone Scientific expensed approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; $203,111 years ended&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; respectively to fund this obligation. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2017, &lt;/div&gt;Milestone Scientific entered into a new employment agreement with Mr. Osser, which superseded the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2009&lt;/div&gt; Agreement pursuant to which he stepped down from his position as Chief Executive Officer and became Managing Director &amp;#x2013; China Operations.&amp;nbsp;Pursuant to the new agreement, Milestone Scientific agreed to fund the last installment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$203,111&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; as provided for in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2009&lt;/div&gt; Agreement. &lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &amp;nbsp; &amp;nbsp; &amp;nbsp; &lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 19, 2017 &lt;/div&gt;the Board of Directors appointed Leonard Osser Interim Chief Executive Officer, replacing Leslie Bernhard. Mr. Osser will enter into a similar employment contract that he received &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; before he resigned his position as CEO of the company. &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;Mr. Osser placed on&amp;nbsp;hold his position as Managing Director-China Operations and his consulting agreement with Milestone Medical to rejoined Milestone Scientific Inc. as Interim Chief Executive Officer.&amp;nbsp; Mr. Osser will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; receive or earn any compensation under these agreements until he is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer Interim Chief Executive Officer.&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;The technology underlying the SafetyWand&amp;reg; and CompuFlo&amp;reg;, and an improvement to the controls for CompuDent&amp;reg; were developed by the Director of Clinical Affairs and assigned to Milestone Scientific. Milestone Scientific purchased this technology pursuant to an agreement dated &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2005. &lt;/div&gt;The Director of Clinical Affairs will receive additional payments of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.5%&lt;/div&gt; of the total sales of products using certain of these technologies, and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5%&lt;/div&gt; of the total sales of products using certain other of the technologies until the expiration of the last patent. The Director of Clinical Affairs was granted, pursuant to the agreement, an option to purchase, at fair market value on the date of the grant &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,333&lt;/div&gt; shares of common stock upon the issuance of each additional patent relating to these technologies. If products produced by &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties use any of these technologies (under license from us) then the Director of Clinical Affairs will receive the corresponding percentage of the consideration received by Milestone Scientific for such sale or license.&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;The Director of Clinical Affairs&amp;#x2019; royalty fee was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$554,150&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$526,737&lt;/div&gt; for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively. Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$275,000&lt;/div&gt;&lt;/div&gt; for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively.&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2017, &lt;/div&gt;Milestone Scientific entered into a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;-month agreement with Innovest S.p.A. to provide consulting services. This agreement will renew for successive &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;-month terms unless terminated by Innovest S.p.A or Milestone Scientific. Expenses recognized on this agreement were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$80,000&lt;/div&gt; for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;respectively. This agreement is expected to continue into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 2, 2017, &lt;/div&gt;Milestone Scientific accepted the resignation of the then CEO, Daniel Goldberger. Subsequent to that date, Mr. Goldberger through his attorney advised Milestone Scientific&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2019;s attorneys, that Mr. Goldberger was entitled, based on the circumstances he asserted with respect to his resignation after acceptance of such resignation, to his basic salary (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$300,000&lt;/div&gt;) for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year and certain other benefits (health and disability insurance for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30,000&lt;/div&gt; estimated) and a car allowance of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,200&lt;/div&gt; per month), in accordance with his employment contract dated &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 10, 2017.&amp;nbsp; &lt;/div&gt;Under the circumstances asserted by Mr. Goldberger, he would also be entitled to the immediate vesting of options under the Milestone Scientific&amp;#x2019;s Stock Option Plan agreed to be granted to him pursuant to his employment agreement, exercisable for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ninety&lt;/div&gt; days after his resignation, for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;921,942&lt;/div&gt; shares of Milestone Scientific at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.00&lt;/div&gt; per share, which exercise price is more than the market price of Milestone Scientific&amp;#x2019;s shares on the date hereof. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2018, &lt;/div&gt;Milestone Scientific Inc. and Mr. Goldberger signed a settlement and released an agreement with respect to Mr. Goldberger&amp;#x2019;s leaving the Company, the gross settlement was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$175,000&lt;/div&gt; and,&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$75,000,&lt;/div&gt; was paid in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2018. &lt;/div&gt;The remainder of the settlement will be paid over a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nine&lt;/div&gt;-month period beginning in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2018.&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2017-12-31" decimals="INF" id="c29244281" unitRef="xbrli-shares">5111582</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2016-12-31" decimals="INF" id="c29244282" unitRef="xbrli-shares">4600250</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2017-12-31_AwardTypeAxis-OtherStockOptionsAndWarrantsMember" decimals="INF" id="c29244283" unitRef="xbrli-shares">3710335</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2016-12-31_AwardTypeAxis-OtherStockOptionsAndWarrantsMember" decimals="INF" id="c29244284" unitRef="xbrli-shares">3329769</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2017-12-31" decimals="INF" id="c29251053" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2016-12-31" decimals="INF" id="c29251054" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2017-12-31" decimals="INF" id="c29251055" unitRef="xbrli-shares">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2016-12-31" decimals="INF" id="c29251056" unitRef="xbrli-shares">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2017-12-31" decimals="INF" id="c29251057" unitRef="xbrli-shares">33191571</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2016-12-31" decimals="INF" id="c29251058" unitRef="xbrli-shares">30457224</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2017-12-31" decimals="INF" id="c29251061" unitRef="xbrli-shares">33158238</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2016-12-31" decimals="INF" id="c29251062" unitRef="xbrli-shares">30423891</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2017-12-31" decimals="INF" id="c29243421" unitRef="iso4217-usd">34593</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2016-12-31" decimals="INF" id="c29243422" unitRef="iso4217-usd">31720</us-gaap:CommonStockValue>
  <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848193">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE P&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;-- CONCENTRATION&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;Milestone Scientific has informal arrangements with a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party manufacturer of the STA, CompuDent&amp;reg;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; and CompuMed&amp;reg; instruments, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2016, &lt;/div&gt;Milestone Scientific entered into a purchase commitment for delivery of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,000&lt;/div&gt; instruments, as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;all instruments have been received.&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2017 &lt;/div&gt;Milestone Scientific entered into a purchase commitment for the delivery of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,000&lt;/div&gt; instruments beginning in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4th&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; An advance of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$697,192&lt;/div&gt; was recorded at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017. &lt;/div&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;Milestone Scientific&amp;#x2019;s purchase commitment for this purchase order was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$300,460.&lt;/div&gt; An advance of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$656,752&lt;/div&gt; was recorded at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016. &lt;/div&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;Milestone Scientific&amp;#x2019;s purchase commitment for this purchase order was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$272,231.&lt;/div&gt; Consequently, advances on contracts have been classified as current at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; respectively.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;For &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;an aggregate of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;70%&lt;/div&gt; of Milestone Scientific's net product sales were to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; customers/ distributors (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; of which, Milestone China, is a related party), &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;51%&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19%,&lt;/div&gt; respectively. For &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;an aggregate of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;58%&lt;/div&gt; of Milestone Scientific's net product sales were to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; customers/distributors (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; of which, Milestone China, is a related party), &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31%,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27%,&lt;/div&gt; respectively. Accounts receivable for the major customer/distributors amounted to an aggregate of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,555,476,&lt;/div&gt; or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;78%&lt;/div&gt; of Milestone Scientific's accounts receivable for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017.&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; Accounts receivable for the major customer/distributors amounted to an aggregate of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,994,686,&lt;/div&gt; or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;85%&lt;/div&gt; of Milestone Scientific's accounts receivable for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016. &amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2017-01-01_2017-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoCustomersMember" decimals="INF" id="c29244666" unitRef="xbrli-pure">0.7</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2017-01-01_2017-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember" decimals="INF" id="c29244669" unitRef="xbrli-pure">0.51</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2017-01-01_2017-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember" decimals="INF" id="c29244670" unitRef="xbrli-pure">0.19</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoCustomersMember" decimals="INF" id="c29244672" unitRef="xbrli-pure">0.58</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember" decimals="INF" id="c29244675" unitRef="xbrli-pure">0.31</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember" decimals="INF" id="c29244676" unitRef="xbrli-pure">0.27</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2017-01-01_2017-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" decimals="INF" id="c29244678" unitRef="xbrli-pure">0.78</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember" decimals="INF" id="c29244681" unitRef="xbrli-pure">0.85</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29255634">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.&lt;/div&gt; Principles of Consolidation&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States&amp;nbsp;(&amp;quot;GAAP&amp;quot;) and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned)&amp;nbsp;and Milestone Medical (majority owned). Milestone Education is a variable interest entity of which Milestone Scientific is the primary beneficiary and is consolidated into Milestone Scientific's financial statements. All significant, intra-entity transactions and balances have been eliminated in the consolidation.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="d_2017-01-01_2017-12-31" id="c29255637">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.&lt;/div&gt; Variable Interest Entities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;A variable interest entity (&amp;quot;VIE&amp;quot;) is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific&amp;#x2019;s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Milestone Scientific is the primary beneficiary of Milestone Education as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2016. &lt;/div&gt;Accordingly, the assets and liabilities of Milestone Education are included in the accompanying consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;Because Milestone Scientific had an increasing variable interest in Milestone China, it further considered the guidance in Accounting Standard Codification (&amp;quot;ASC&amp;quot;) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;810&lt;/div&gt; as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary. As Milestone China&amp;#x2019;s equity at risk and voting rights were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; proportional to their economic interest, Milestone China was determined to be a VIE. Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="margin-left:1.4%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="vertical-align:top;width:3.2%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td style="vertical-align:top;width:90.2%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;Power Criterion: The power to direct the activities that most significantly impact the entity&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2019;s economic performance; and&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="margin-left:1.4%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="vertical-align:top;width:3.3%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td style="vertical-align:top;width:90.2%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Milestone management does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the majority shareholder/CEO of Milestone China.&amp;nbsp; As majority shareholder, majority holder of voting rights, and the active CEO, the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;53%&lt;/div&gt; investor has the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; the primary beneficiary under ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;810.&lt;/div&gt; Accordingly, Milestone China has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been consolidated into the financial statements of Milestone Scientific and continues to be accounted for under the equity method.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
  <us-gaap:CostMethodInvestmentsRealizedLosses contextRef="d_2017-01-01_2017-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244083" unitRef="iso4217-usd">3147470</us-gaap:CostMethodInvestmentsRealizedLosses>
  <us-gaap:CostMethodInvestmentsRealizedLosses contextRef="d_2016-01-01_2016-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244084" unitRef="iso4217-usd">1124350</us-gaap:CostMethodInvestmentsRealizedLosses>
  <us-gaap:CostOfGoodsSold contextRef="d_2017-01-01_2017-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244144" unitRef="iso4217-usd">477200</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2016-01-01_2016-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244145" unitRef="iso4217-usd">976106</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243461" unitRef="iso4217-usd">4312507</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243462" unitRef="iso4217-usd">4175533</us-gaap:CostOfGoodsSold>
  <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance contextRef="i_2017-12-31" decimals="INF" id="c29251059" unitRef="xbrli-shares">1401247</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
  <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance contextRef="i_2016-12-31" decimals="INF" id="c29251060" unitRef="xbrli-shares">1270481</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
  <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="d_2009-09-01_2009-09-01_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="INF" id="c29244450" unitRef="iso4217-usd">300000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
  <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="d_2016-12-01_2016-12-01_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="INF" id="c29244467" unitRef="iso4217-usd">280000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
  <us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued contextRef="d_2017-01-01_2017-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="INF" id="c29245958" unitRef="iso4217-usd">1030875</us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued>
  <us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued contextRef="d_2016-01-01_2016-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="INF" id="c29244464" unitRef="iso4217-usd">980906</us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued>
  <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance contextRef="i_2017-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" decimals="INF" id="c29244278" unitRef="xbrli-shares">1401247</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
  <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance contextRef="i_2016-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" decimals="INF" id="c29244279" unitRef="xbrli-shares">1270481</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
  <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued contextRef="d_2017-01-01_2017-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="INF" id="c29245957" unitRef="xbrli-shares">886866</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
  <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued contextRef="d_2016-01-01_2016-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="INF" id="c29244463" unitRef="xbrli-shares">855810</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
  <us-gaap:DeferredCostsCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243370" unitRef="iso4217-usd">1109671</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrent contextRef="i_2016-12-31" decimals="INF" id="c29243371" unitRef="iso4217-usd">620041</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="i_2017-12-31_ProductOrServiceAxis-InstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244696" unitRef="iso4217-usd">1109671</us-gaap:DeferredCostsCurrentAndNoncurrent>
  <us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="i_2016-12-31_ProductOrServiceAxis-InstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244698" unitRef="iso4217-usd">620041</us-gaap:DeferredCostsCurrentAndNoncurrent>
  <us-gaap:DeferredRevenue contextRef="i_2017-12-31_ProductOrServiceAxis-InstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244695" unitRef="iso4217-usd">1725450</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="i_2016-12-31_ProductOrServiceAxis-InstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244697" unitRef="iso4217-usd">1001800</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243399" unitRef="iso4217-usd">1725450</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="i_2016-12-31" decimals="INF" id="c29243400" unitRef="iso4217-usd">1001800</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="i_2017-12-31" decimals="INF" id="c29244539" unitRef="iso4217-usd">45000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
  <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="i_2016-12-31" id="c29244540" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="i_2017-12-31" decimals="INF" id="c29244545" unitRef="iso4217-usd">478000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="i_2016-12-31" id="c29244546" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsGrossCurrent contextRef="i_2017-12-31" decimals="INF" id="c29244549" unitRef="iso4217-usd">16479000</us-gaap:DeferredTaxAssetsGrossCurrent>
  <us-gaap:DeferredTaxAssetsGrossCurrent contextRef="i_2016-12-31" decimals="INF" id="c29244550" unitRef="iso4217-usd">19026000</us-gaap:DeferredTaxAssetsGrossCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="i_2017-12-31" decimals="INF" id="c29244547" unitRef="iso4217-usd">15116000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="i_2016-12-31" decimals="INF" id="c29244548" unitRef="iso4217-usd">18456000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="i_2017-12-31" decimals="INF" id="c29244541" unitRef="iso4217-usd">636000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="i_2016-12-31" decimals="INF" id="c29244542" unitRef="iso4217-usd">395000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="i_2017-12-31" decimals="INF" id="c29244535" unitRef="iso4217-usd">3000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="i_2016-12-31" decimals="INF" id="c29244536" unitRef="iso4217-usd">4000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves contextRef="i_2017-12-31" decimals="INF" id="c29244537" unitRef="iso4217-usd">20000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves contextRef="i_2016-12-31" decimals="INF" id="c29244538" unitRef="iso4217-usd">36000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
  <us-gaap:DeferredTaxAssetsValuationAllowanceCurrent contextRef="i_2017-12-31" decimals="INF" id="c29244551" unitRef="iso4217-usd">16479000</us-gaap:DeferredTaxAssetsValuationAllowanceCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowanceCurrent contextRef="i_2016-12-31" decimals="INF" id="c29244552" unitRef="iso4217-usd">19026000</us-gaap:DeferredTaxAssetsValuationAllowanceCurrent>
  <us-gaap:Depreciation contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29245817" unitRef="iso4217-usd">62475</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29245818" unitRef="iso4217-usd">92667</us-gaap:Depreciation>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244593" unitRef="iso4217-usd">17305</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244594" unitRef="iso4217-usd">17619</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244595" unitRef="iso4217-usd">26950</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244596" unitRef="iso4217-usd">62720</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-MaterialReconcilingItemsMember" decimals="INF" id="c29244597" unitRef="iso4217-usd">528895</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-MaterialReconcilingItemsMember" decimals="INF" id="c29244598" unitRef="iso4217-usd">82586</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" decimals="INF" id="c29244599" unitRef="iso4217-usd">573150</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" decimals="INF" id="c29244600" unitRef="iso4217-usd">162925</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2017-01-01_2017-12-31" id="c29244602" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="d_2016-01-01_2016-12-31" id="c29244603" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848182">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt 19.5pt 0pt 15pt; text-align: left; text-indent: -16.5pt; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;L&amp;nbsp;&amp;#x2014; STOCK OPTION PLANS&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2004&lt;/div&gt; Stock Option Plan provided for the grant of options to purchase up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;750,000&lt;/div&gt; shares of Milestone Scientific's common stock. Options &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be granted to employees, officers, directors and consultants of Milestone Scientific for the purchase of common stock at a price &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; less than the fair market value of the common stock on the date of the grant. In general, options become exercisable over a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-year period from the grant date and expire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years after the date of grant.&amp;nbsp;There were&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; shares available for grant at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;under this plan.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2011, &lt;/div&gt;the stockholders of Milestone Scientific approved the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011&lt;/div&gt; Stock Option Plan (the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;quot;2011&lt;/div&gt; Plan&amp;quot;) which originally provided for stock options to our employees, directors and consultants and incentive and non-qualified stock options to purchase up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,000,000&lt;/div&gt; shares of common stock. In general, options become exercisable over a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-year period from the grant date and expire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years after the date of grant.&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2016, &lt;/div&gt;Milestone Scientific's stockholders approved the following amendments to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011&lt;/div&gt; Plan:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 63pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;i&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;.&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Renaming of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011&lt;/div&gt; plan to the &amp;#x201c;Milestone Scientific Inc., &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011&lt;/div&gt; Equity Compensation Plan&amp;#x201d;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 63pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;ii&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;.&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Providing for awards of restricted common stock; and&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 63pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;iii&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;.&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Increasing the maximum number of shares of common stock reserved for grants under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2011&lt;/div&gt; Plan from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,000,000&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,000,000.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: -9pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Milestone Scientific recognizes compensation expense on a straight-line basis over the requisite service period and in the case of performance-based options over the period of the expected performance. For the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; respectively, Milestone Scientific recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$636,058&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$579,103&lt;/div&gt; of total employee compensation cost, respectively. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; there was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$603,979&lt;/div&gt;&amp;nbsp;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$678,842&lt;/div&gt; of total unrecognized compensation cost related to non- vested options, respectively.&amp;nbsp;Milestone Scientific expects to recognize these cost over a weighted average period of&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.61&lt;/div&gt; years and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.04&lt;/div&gt;&amp;nbsp;years as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively.&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;A summary of option activity for employees under the plans and changes during the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; is presented below:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-right: 5%; margin-left: 5%; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Wei&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;ghted Averaged Exercise Price $&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Aggregate Intrinsic Options Value $&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 44%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Options outstanding January 1, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,419,436&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.56&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.79&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,220,338&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable, January 1, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,041,680&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.29&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.41&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,135,819&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;520,337&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.79&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.38&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised during 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(327,778&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.75&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited or expired&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(100,000&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.35&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Options outstanding December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,511,995&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.74&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.97&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;102,605&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable, December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,054,202&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.65&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.51&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;102,605&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,006,741&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.82&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.69&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,610&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised during 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(83,333&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.75&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited, cancelled, or expired&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,250,068&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Options outstanding December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,985,325&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.74&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.04&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,160&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable,&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; December 31, 2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,317,4416&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.84&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.46&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,537&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt;  &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2017, &lt;/div&gt;Milestone Scientific's Compensation Committee approved the issuance of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;400,000&lt;/div&gt; stock options to Gian Domenico Trombetta, CEO of Wand Dental, a Director of Milestone Scientific and a director of Innovest S.p.A., an Italian investor (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;250,000&lt;/div&gt; options at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.55&lt;/div&gt; per share were issued on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 7, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;150,000&lt;/div&gt; options having an exercise price at the higher of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.55&lt;/div&gt; or the market price of the stock on the date of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; Annual Stockholder meeting, subject to approval of a new or amended equity incentive plan at such meeting.) Mr. Trombetta elected to cancel the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;400,00options&lt;/div&gt; granted as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;"&gt;The weighted-average fair value of the options granted during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was estimated as &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.73&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.70&lt;/div&gt; respectively, on the date of grant. The fair value for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was determined using the Black-Scholes option-pricing model with the following&amp;nbsp; assumptions:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;81.23% -97.24%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;134.53%- 194.34%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.4%- 2.2%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;.04%-1.47%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Life&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"&gt;2-5 years&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"&gt;5 years&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeiture Rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;A summary of option activity for non-employees under the plans and changes during the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; is presented below:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-right: 5%; margin-left: 5%; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 489px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 121px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Number of Options&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 25px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 140px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Weighted Averaged Exercise Price $&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 26px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 153px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 37px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Aggregate Intr&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;insic Options Value $&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Outstanding, January&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; 1, 2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,333&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.70&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.83&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Exercisable, January 1, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,777&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.70&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.83&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 489px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;216,666&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.53&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 489px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Outstanding, December&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; 31, 2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;224,999&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.53&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.32&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Exercisable, December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,734&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.72&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.36&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 489px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 489px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Outstanding, December&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; 31, 2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;224,999&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.52&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.51&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Exercisable, December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,067&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.22&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.38&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;"&gt;The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. In accordance with the provisions of FASB ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;505,&lt;/div&gt; Milestone Scientific will re-measure the value of the grant at each presentation date unless there is a significant disincentive for non-performance or until performance has been rendered. For the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months end &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;Milestone Scientific recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$9,384&lt;/div&gt; income related to non-employee options. For the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months end &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;Milestone Scientific recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$25,346&lt;/div&gt; expense related to non-employee options.&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="i_2017-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember" decimals="INF" id="c29244687" unitRef="iso4217-usd">985678</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="i_2016-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember" decimals="INF" id="c29244688" unitRef="iso4217-usd">1235052</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:EarningsPerShareBasic contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243492" unitRef="iso4217-usd-per-xbrli-shares">-0.16</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243493" unitRef="iso4217-usd-per-xbrli-shares">-0.22</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243494" unitRef="iso4217-usd-per-xbrli-shares">-0.16</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243495" unitRef="iso4217-usd-per-xbrli-shares">-0.22</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29255657">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17.&lt;/div&gt; Basic and diluted net loss per common share&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Milestone Scientific presents &amp;#x201c;basic&amp;#x201d; earnings (loss) per common share applicable to common stockholders and, if applicable, &amp;#x201c;diluted&amp;#x201d; earnings (loss) per common share applicable to common stockholders pursuant to the provisions of Statement of Financial Accounting Standards ASC Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;260.&lt;/div&gt; Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options, warrants, and the conversion of debt were issued during the period.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Since Milestone Scientific had net losses for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the assumed effects of the exercise of potentially dilutive outstanding stock options and warrants were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; included in the calculation as their effect would have been anti-dilutive. Such outstanding options and warrants totaled&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,679,152&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,329,769&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c29245512" unitRef="xbrli-pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2016-01-01_2016-12-31" decimals="2" id="c29245513" unitRef="xbrli-pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2018-01-01_2018-12-31_StatementScenarioAxis-ScenarioForecastMember" decimals="2" id="c29244513" unitRef="xbrli-pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c29244557" unitRef="xbrli-pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2016-01-01_2016-12-31" decimals="2" id="c29244558" unitRef="xbrli-pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c29245510" unitRef="xbrli-pure">2.04</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2016-01-01_2016-12-31" decimals="2" id="c29245511" unitRef="xbrli-pure">0.43</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c29244565" unitRef="xbrli-pure">1.64</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="d_2016-01-01_2016-12-31" id="c29244566" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="d_2017-01-01_2017-12-31" id="c29244563" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="d_2016-01-01_2016-12-31" decimals="2" id="c29244564" unitRef="xbrli-pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c29244561" unitRef="xbrli-pure">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="d_2016-01-01_2016-12-31" decimals="2" id="c29244562" unitRef="xbrli-pure">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244307" unitRef="iso4217-usd">636058</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
  <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244308" unitRef="iso4217-usd">579103</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244310" unitRef="iso4217-usd">603979</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244311" unitRef="iso4217-usd">678842</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c29244313">P2Y222D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c29244314">P3Y14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EquityMethodInvestmentDeferredGainOnSale contextRef="d_2017-06-01_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244040" unitRef="iso4217-usd">1400000</us-gaap:EquityMethodInvestmentDeferredGainOnSale>
  <us-gaap:EquityMethodInvestmentDeferredGainOnSale contextRef="d_2017-06-01_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" decimals="INF" id="c29244097" unitRef="iso4217-usd">1400000</us-gaap:EquityMethodInvestmentDeferredGainOnSale>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="i_2017-05-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" decimals="1" id="c29244025" unitRef="xbrli-pure">0.4</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="i_2017-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AdvancedOcularSciencesSAMember" decimals="INF" id="c29244066" unitRef="xbrli-pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="i_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244076" unitRef="xbrli-pure">0.4</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="i_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" decimals="INF" id="c29244092" unitRef="xbrli-pure">0.4</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets contextRef="i_2017-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244131" unitRef="iso4217-usd">16340942</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets contextRef="i_2016-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244132" unitRef="iso4217-usd">11829745</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets contextRef="i_2017-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244127" unitRef="iso4217-usd">13127422</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets contextRef="i_2016-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244128" unitRef="iso4217-usd">9362198</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities contextRef="i_2017-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244134" unitRef="iso4217-usd">18468937</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities contextRef="i_2016-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244135" unitRef="iso4217-usd">9900611</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity contextRef="i_2017-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244136" unitRef="iso4217-usd">-2127995</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity contextRef="i_2016-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244137" unitRef="iso4217-usd">1929134</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity contextRef="i_2017-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244138" unitRef="iso4217-usd">16340942</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity contextRef="i_2016-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244139" unitRef="iso4217-usd">11829745</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets contextRef="i_2017-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244129" unitRef="iso4217-usd">3213520</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets>
  <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets contextRef="i_2016-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244130" unitRef="iso4217-usd">2467547</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets>
  <us-gaap:EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount contextRef="d_2017-01-01_2017-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244118" unitRef="iso4217-usd">-120510</us-gaap:EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount>
  <us-gaap:EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount contextRef="d_2016-01-01_2016-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember" decimals="INF" id="c29244119" unitRef="iso4217-usd">795827</us-gaap:EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount>
  <us-gaap:EquityMethodInvestments contextRef="i_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244043" unitRef="iso4217-usd">0</us-gaap:EquityMethodInvestments>
  <us-gaap:EquityMethodInvestments contextRef="i_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244074" unitRef="iso4217-usd">1000000</us-gaap:EquityMethodInvestments>
  <us-gaap:EquityMethodInvestments contextRef="i_2017-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244080" unitRef="iso4217-usd">0</us-gaap:EquityMethodInvestments>
  <us-gaap:EquityMethodInvestments contextRef="i_2016-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244081" unitRef="iso4217-usd">0</us-gaap:EquityMethodInvestments>
  <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848175">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;NOTE H&amp;nbsp;&amp;#x2013; INVESTMENT IN &lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;text-transform:uppercase;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;UNCONSOLIDATED SUBSIDIARIES&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Advance Ocular Science SA &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Advanced Ocular Sciences SA (&amp;quot;Advanced Ocular&amp;quot;) is a shell company attempting to develop an instrument to deliver injections into the eyes. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;Milestone Scientific owns &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25%&lt;/div&gt; of this entity. During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; Milestone Scientific advanced &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$78,798&lt;/div&gt; for marketing and strategy planning to Advance Ocular, or its organizers, were obligated to repay this advance if a public offering of Advanced Ocular equity was approved and funded in Poland during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; However, a public offering has yet to be completed in Poland. As a result, Milestone Scientific wrote-off the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$78,798&lt;/div&gt; advanced to Advanced Ocular as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016. &lt;/div&gt;Advance Ocular was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; included in the consolidated financial statements at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;as &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; further investment has been made and there is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; significant activity that would be considered material to the financial statements.&amp;nbsp; &amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Milestone China Ltd.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2014, &lt;/div&gt;Milestone Scientific invested &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1&lt;/div&gt; million in Milestone China Ltd. (&amp;#x201c;Milestone China&amp;#x201d;) by contributing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;772&lt;/div&gt; STA Instruments to Milestone China for a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40%&lt;/div&gt; ownership interest. Milestone Scientific recorded this investment under the equity method of accounting. Milestone Scientific recorded a loss on its investment in Milestone China of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$795,827,&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively. Milestone Scientific's investment in Milestone China was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively. Milestone Scientific incurred cumulative losses on its investment in Milestone China of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,147470&lt;/div&gt;&amp;nbsp;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,124,350&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively, which have been suspended.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2017, &lt;/div&gt;Milestone Scientific entered into an agreement for the sale of the Milestone China Shares to an unaffiliated United States domiciled purchaser and a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-year option agreement to repurchase the Milestone China Shares. The purchase price for the Milestone China Shares was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,400,000&lt;/div&gt; of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$125,000&lt;/div&gt; was paid in cash and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,275,000&lt;/div&gt; was paid by delivery of a non-interest bearing secured promissory note. The note is payable in quarterly installments of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$125,000&lt;/div&gt; until paid in full and is secured by the Milestone China Shares until full repayment.&amp;nbsp; In addition, pursuant to such note, the purchaser is precluded from selling all or substantially all its assets prior to repayment of the note. The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-year option agreement provides Milestone Scientific an option to repurchase the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40%&lt;/div&gt; equity interest at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,400,000&lt;/div&gt; within the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; years and at fair value (as defined in such agreement) for the remainder of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-year term. The transaction has been accounted for as a secured financing and Milestone Scientific will continue to account for its relationship with Milestone China under the equity method of accounting. A note receivable is presented on the Balance Sheet, along with a deferral from financing transaction (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,400,000&lt;/div&gt;). The carrying value of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;forty&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40%&lt;/div&gt;) percent investment at the transaction date was zero. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2, 2018, &lt;/div&gt;the promissory note was in default. If Milestone Scientific exercises its rights as a secured party it &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be obligated to return to the purchaser up to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$250,000&lt;/div&gt; received for the Milestone China Shares as surplus. At this time Milestone Scientific has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; received a response from the purchaser of the Milestone China Shares, Milestone Scientific has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; recorded any financial benefit from the sale of Milestone China Shares to date.&lt;/div&gt; &lt;div style=" margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;Milestone Scientific had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,071,000&lt;/div&gt; of related party sales of handpieces and instruments to Milestone China and Milestone China&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2019;s agent for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017. &lt;/div&gt;Milestone Scientific had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,425,000&lt;/div&gt; of related party sales of handpieces and instruments to Milestone China for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016. &lt;/div&gt;Milestone Scientific defers the total revenue and costs of goods sold when instruments and handpieces are shipped to Milestone China and Milestone China&amp;#x2019;s agent due to market conditions and Milestone China liquidity concerns.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;  &amp;nbsp; &lt;/div&gt; &lt;div style=" margin: 0pt; text-indent: 27pt;"&gt;Due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties, an elimination of the intra-entity profit is required as of the balance sheet date. In accordance with ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;323&lt;/div&gt; Equity Method and Joint Ventures, Milestone Scientific has deferred &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40%&lt;/div&gt; of the gross profit associated with recognized revenue from Milestone China that has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been sold to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the deferred profit was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$751,500&lt;/div&gt;&amp;nbsp;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$630,990,&lt;/div&gt; respectively, which is included in deferred profit, related party in the consolidated balance sheets. For &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the loss on equity investment was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$120,510&lt;/div&gt;&amp;nbsp;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$795,827,&lt;/div&gt; respectively, which is included in the&amp;nbsp;consolidated&amp;nbsp;statements of operation.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;The following table includes summarized financial information (unaudited) of Milestone China:&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Current assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,127,422&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,362,198&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Non-current assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,213,520&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,467,547&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,340,942&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,829,745&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Liabilities:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,468,937&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,900,611&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stockholders' equity&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,127,995)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,929,134&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total liabilities and stockholders&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2019; equity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,340,942&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,829,745&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net sales&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,666,605&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,126,484&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;477,200&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;976,106&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gross Profit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,189,405&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;150,378&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other Expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6,247,205)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,834,980&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net Losses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,057,800)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,684,602&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
  <us-gaap:EquityMethodInvestmentsPolicy contextRef="d_2017-01-01_2017-12-31" id="c29255643">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt; Equity Method Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Investments in which Milestone Scientific can exercise significant influence, but do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; control, are accounted for under the equity method of accounting and are included in the long-term assets on the Consolidated Balance Sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the income tax line on the Consolidated Statements of Operations.&amp;nbsp;Milestone Scientific evaluates its equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
  <us-gaap:EquityMethodInvestmentsTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Current assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,127,422&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,362,198&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Non-current assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,213,520&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,467,547&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,340,942&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,829,745&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Liabilities:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,468,937&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,900,611&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stockholders' equity&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,127,995)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,929,134&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total liabilities and stockholders&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2019; equity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,340,942&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,829,745&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net sales&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,666,605&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,126,484&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cost of goods sold&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;477,200&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;976,106&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gross Profit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,189,405&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;150,378&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other Expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6,247,205)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,834,980&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net Losses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,057,800)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,684,602&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2017-01-01_2017-12-31" id="c29255663">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19.&lt;/div&gt; Fair Value of Financial Instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Fair Value Measurements: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; of the following categories:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-indent: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;"&gt;&amp;#x25cf;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;"&gt;&amp;#x25cf;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; inputs which are defined as inputs other than quoted prices included within Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; that are observable for the assets or liabilities, either directly or indirectly.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;"&gt;&amp;#x25cf;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; inputs are defined as unobservable inputs for the assets or liabilities.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:FinanceLoansAndLeasesReceivablePolicy contextRef="d_2017-01-01_2017-12-31" id="c29255640">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;. Note Receivable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;Milestone Scientific values note receivable at historic cost less amount paid against principle. Milestone Scientific estimates losses on the note-based payments and credit quality of the debtor.&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinanceLoansAndLeasesReceivablePolicy>
  <us-gaap:FinancingReceivablesTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848170">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;NOTE D&amp;nbsp;&amp;#x2014; NOTES RECEIVABLE&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2017, &lt;/div&gt;Milestone Scientific entered into an agreement for the sale of its interest in Milestone China a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;forty&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40%&lt;/div&gt;) percent interest (the &amp;#x201c;Milestone China Shares&amp;#x201d;) to an unaffiliated United States domiciled purchaser and a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-year option agreement to repurchase the Milestone China Shares. The purchase price for the Milestone China Shares was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,400,000&lt;/div&gt; of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$125,000&lt;/div&gt; was paid in cash and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,275,000&lt;/div&gt; was paid by delivery of a non-interest bearing secured promissory note. The note is payable in quarterly installments of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$125,000&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;and is secured by the Milestone China Shares until full repayment.&amp;nbsp; In addition,&amp;nbsp;the purchaser is precluded from selling all or substantially all its assets prior to repayment of the note. The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-year option agreement provides Milestone Scientific an option to repurchase the Milestone China Shares at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,400,000&lt;/div&gt; within the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; years and at fair market value (as defined in such agreement) for the remainder of the&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-year term. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2, 2018, &lt;/div&gt;the promissory note was in default. If Milestone Scientific exercises its rights as a secured party it &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be obligated to return to the purchaser up to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$250,000&lt;/div&gt; received for the Milestone China Shares as surplus. At this time Milestone Scientific has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; received a response from the purchaser of the Milestone China Shares, Milestone Scientific has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; recorded any financial benefit from the sale of Milestone China Shares to date.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;The transaction has been accounted for as a secured financing and Milestone Scientific will continue to account for its relationship with Milestone China under the equity method of accounting.&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;A note receivable is presented on the Company&amp;#x2019;s balance sheet, along with a deferral from financing transaction (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,400,000&lt;/div&gt;). The carrying value of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;forty&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40%&lt;/div&gt;) percent investment at the transaction date was zero.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancingReceivablesTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2017-01-01_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MinimumMember" id="c29244187">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2017-01-01_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MaximumMember" id="c29244188">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2017-01-01_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-WeightedAverageMember" id="c29244189">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2017-07-13_2017-07-13_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" id="c29244208">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" decimals="INF" id="c29244222" unitRef="iso4217-usd">787821</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2016-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" decimals="INF" id="c29244225" unitRef="iso4217-usd">717086</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-EpiduralapadPatentsMember" decimals="INF" id="c29244228" unitRef="iso4217-usd">439941</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2016-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-EpiduralapadPatentsMember" id="c29244231" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2017-12-31" decimals="INF" id="c29244234" unitRef="iso4217-usd">1227762</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2016-12-31" decimals="INF" id="c29244237" unitRef="iso4217-usd">717086</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="i_2017-12-31" decimals="INF" id="c29244195" unitRef="iso4217-usd">945000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="i_2017-12-31" decimals="INF" id="c29244199" unitRef="iso4217-usd">38000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="i_2017-12-31" decimals="INF" id="c29244198" unitRef="iso4217-usd">39000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="i_2017-12-31" decimals="INF" id="c29244197" unitRef="iso4217-usd">486000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="i_2017-12-31" decimals="INF" id="c29244196" unitRef="iso4217-usd">932000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="i_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" decimals="INF" id="c29244221" unitRef="iso4217-usd">1377863</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="i_2016-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" decimals="INF" id="c29244224" unitRef="iso4217-usd">1377543</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="i_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-EpiduralapadPatentsMember" decimals="INF" id="c29244227" unitRef="iso4217-usd">2639647</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="i_2016-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-EpiduralapadPatentsMember" id="c29244230" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="i_2017-12-31" decimals="INF" id="c29244233" unitRef="iso4217-usd">4017510</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="i_2016-12-31" decimals="INF" id="c29244236" unitRef="iso4217-usd">1377543</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="i_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" decimals="INF" id="c29244223" unitRef="iso4217-usd">590042</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="i_2016-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember" decimals="INF" id="c29244226" unitRef="iso4217-usd">660457</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="i_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-EpiduralapadPatentsMember" decimals="INF" id="c29244229" unitRef="iso4217-usd">2199706</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="i_2016-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-EpiduralapadPatentsMember" id="c29244232" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="i_2017-12-31" decimals="INF" id="c29244235" unitRef="iso4217-usd">2789748</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="i_2016-12-31" decimals="INF" id="c29244238" unitRef="iso4217-usd">660457</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="d_2017-07-13_2017-07-13_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="INF" id="c29244207" unitRef="iso4217-usd">2639000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848179">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:-3pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;J&amp;nbsp;&amp;#x2014; PATENTS&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 278px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="5" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 305px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 37px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="5" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 313px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 278px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 71px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 20px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 95px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Accumulated Amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 31px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 80px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 37px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 91px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 7px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 101px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Accumulated Amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 15px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 92px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 278px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Patents-foundation intellectual property&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 71px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,377,863&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 20px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 95px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(787,821&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 31px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 80px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;590,042&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 91px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,377,543&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 7px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 101px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(717,086&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 15px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 92px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;660,457&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 278px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Epidural-Apad acquired patents&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 71px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,639,647&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 20px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 95px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(439,941&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 31px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 80px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,199,706&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 91px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 7px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 101px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 15px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 92px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 278px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 71px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,017,510&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 20px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 95px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,227,762&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 31px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 80px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,789,748&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 91px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,377,543&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 7px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 101px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(717,086&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 15px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 92px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;660,457&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" text-indent: 27pt;"&gt;Patents are amortized utilizing the straight-line method over estimated useful lives ranging from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt; years, with a weighted average amortization period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&amp;nbsp;years. Amortization expense was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$510,676&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$70,699&lt;/div&gt; for the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively.&amp;nbsp;The annual amortization expense expected to be recorded for existing intangibles assets for the years &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2022&lt;/div&gt; is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$945,000,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$932,000,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$486,000,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$39,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$38,000.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 13, 2017, &lt;/div&gt;Milestone Scientific consummated a previously disclosed Asset Purchase Agreement (the &amp;#x201c;Agreement&amp;#x201d;) with APAD Octrooi B.V. and APAD B.V. (each, a &amp;#x201c;Seller&amp;#x201d; and collectively, the &amp;#x201c;Sellers&amp;#x201d;) pursuant to which Milestone Scientific acquired certain patent rights and other intellectual property rights related to the Sellers&amp;#x2019; computer-controlled injection instrument (the &amp;#x201c;Purchased Assets&amp;#x201d;) and has been accounted for as an asset acquisition. On the closing date, Milestone Scientific issued to the Sellers an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,646,358&lt;/div&gt; shares of its common stock, valued at approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,486,000&lt;/div&gt; for the Purchased Assets which shares are subject to certain post-closing upward or downward adjustments &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to exceed &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twenty-five&lt;/div&gt; percent of the initial shares as of the purchase date or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;250,000&lt;/div&gt; Euros, as defined in the agreement. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;Milestone Scientific has recorded a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$275,000&lt;/div&gt; liability relating to the estimated additional shares that would have to be issued according this provision in the Agreement. Milestone Scientific paid approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$153,000&lt;/div&gt; in legal fees on behalf of the Seller as stipulated based on the terms of the Agreement. The patents purchased in the amount of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,639,000&lt;/div&gt; have been capitalized and will amortized over their &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-year estimated useful life and tested for impairment as a finite lived intangible asset.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:GrossProfit contextRef="d_2017-01-01_2017-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244146" unitRef="iso4217-usd">1189405</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="d_2016-01-01_2016-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244147" unitRef="iso4217-usd">150378</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243463" unitRef="iso4217-usd">6969379</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243464" unitRef="iso4217-usd">6306472</us-gaap:GrossProfit>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243942" unitRef="iso4217-usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243941" unitRef="iso4217-usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29255647">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12.&lt;/div&gt; Impairment of Long-Lived Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;Milestone Scientific has reviewed long-lived assets for any impairments. The carrying value of the assets is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets. Milestone Scientific adjusts the net book value of an underlying asset if its fair value is determined to be less than its net book value. There have been &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; impairment indicators or triggering events and therefore, there are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&amp;nbsp;impairments as of&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; respectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244606" unitRef="iso4217-usd">3136167</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244607" unitRef="iso4217-usd">2097652</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244608" unitRef="iso4217-usd">-2391082</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244609" unitRef="iso4217-usd">-3219497</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" decimals="INF" id="c29244610" unitRef="iso4217-usd">-5975035</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" decimals="INF" id="c29244611" unitRef="iso4217-usd">-5395918</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244612" unitRef="iso4217-usd">-5229950</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29244613" unitRef="iso4217-usd">-6517763</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="d_2017-01-01_2017-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244077" unitRef="iso4217-usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="d_2016-01-01_2016-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244078" unitRef="iso4217-usd">-795827</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243483" unitRef="iso4217-usd">-120510</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243484" unitRef="iso4217-usd">-795827</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848187">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;N&amp;nbsp;&amp;#x2014; INCOME TAXES&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;Due to Milestone Scientific's history of operating losses, a full valuation allowances have been provided for all of Milestone Scientific's deferred tax assets At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31,&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; recognition was given to the utilization of the remaining net operating loss carryforwards in each of these periods.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In accordance with ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,&lt;/div&gt; Income Taxes, deferred tax assets and liabilities have been classified, and treated retrospectively, as non-current.&amp;nbsp; Deferred tax attributes resulting from differences between financial accounting amounts and tax bases of assets and liabilities at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; are as follows:&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Allowance for doubtful accounts-short term&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warranty reserve&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;36,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Capital Gains&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;45,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred officers compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;636,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;395,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Depreciation and Amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;181,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;135,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Deferred revenue&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;478,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net operating loss carryforward&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,116,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,456,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Subtotal&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,479,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,026,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16,479,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(19,026,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;The deferred tax asset, before valuation allowance, has been calculated on rates anticipated to be effect when the temporary differences reverse.&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; Accordingly, based on the change in Federal tax rates promulgated in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2017, &lt;/div&gt;effective &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2018, &lt;/div&gt;the Company utilized a Federal rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21%&lt;/div&gt; and accordingly existing deferred tax assets upon the tax law act being signed into law on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 22, 2017, &lt;/div&gt;the Company revalued its deferred tax assets which resulted in a tax provision charge of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8,677,000,&lt;/div&gt; offset by a corresponding decrease in the valuation allowance.&amp;nbsp; &lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;federal net operating loss carryforwards are approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$60,000,000.&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;and Milestone Scientific has federal net operating loss carryforwards of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$56,530,000,&lt;/div&gt; which is comprised solely of losses attributable Milestone Scientific and its subsidiaries.&amp;nbsp; Net operating losses will be available to offset future taxable income, if any, through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2037. &lt;/div&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;state net operating losses were approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$24,500,000.&lt;/div&gt; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016 &lt;/div&gt;Milestone, Scientific has state net operating loss carryforwards of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$22,942,000.&lt;/div&gt;&amp;nbsp; Net operating losses will be available to offset future taxable income, if any, through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2037. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;The utilization of Milestone Scientific's net operating losses &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be subject to a substantial limitation due to the &amp;quot;change of ownership provisions&amp;quot; under Section &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;382&lt;/div&gt; of the Internal Revenue Code and similar state provisions. Such limitation &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100%&lt;/div&gt; valuation allowance for all its deferred tax assets due to uncertainty as to their future realization.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; state tax liability was approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$18,339&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$13,000&lt;/div&gt; respectively. Such expense was recognized in the accompanying consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;A reconciliation of the statutory tax rates for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, &lt;/div&gt;is as follows:&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; &amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;State income tax - all states&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Non-deductible Stock based compensation&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Deferred provision for effect of change in Federal&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;164&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;43&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Valuation allowance&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(43&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Effective tax rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Accounting for uncertainties in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; we had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; uncertain tax positions that required recognition in the consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the Statements of Operations. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; interest and penalties are present for periods open. Tax returns for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; years are subject to audit by federal and state jurisdictions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243479" unitRef="iso4217-usd">19093</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243480" unitRef="iso4217-usd">-19101</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29255656">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16.&lt;/div&gt; Income Taxes&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244523" unitRef="iso4217-usd">18339</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29244524" unitRef="iso4217-usd">13000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxesPaid contextRef="d_2017-01-01_2017-12-31" id="c29243845" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncomeTaxesPaid contextRef="d_2016-01-01_2016-12-31" id="c29243846" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243801" unitRef="iso4217-usd">-363584</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243802" unitRef="iso4217-usd">486348</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243803" unitRef="iso4217-usd">-249374</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
  <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="d_2016-01-01_2016-12-31" id="c29243804" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243787" unitRef="iso4217-usd">733129</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243788" unitRef="iso4217-usd">-635017</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243789" unitRef="iso4217-usd">-989150</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
  <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243790" unitRef="iso4217-usd">1727210</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
  <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243805" unitRef="iso4217-usd">489630</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243806" unitRef="iso4217-usd">620041</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243809" unitRef="iso4217-usd">723650</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243810" unitRef="iso4217-usd">1001800</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243793" unitRef="iso4217-usd">-1003676</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243794" unitRef="iso4217-usd">509462</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243807" unitRef="iso4217-usd">1834749</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243808" unitRef="iso4217-usd">-755915</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243799" unitRef="iso4217-usd">9523</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="d_2016-01-01_2016-12-31" id="c29243800" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243791" unitRef="iso4217-usd">-10000</us-gaap:IncreaseDecreaseInOtherReceivables>
  <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243792" unitRef="iso4217-usd">-48515</us-gaap:IncreaseDecreaseInOtherReceivables>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243797" unitRef="iso4217-usd">144481</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243798" unitRef="iso4217-usd">-12675</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2017-01-01_2017-12-31" id="c29255645">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; Intangible Assets &amp;#x2013; Patents and Developed Technology&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized at the estimated average useful life of the patent. These patents and developed technology are recorded at the acquisition cost.&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Patent defense costs, to the extent applicable, are expensed as incurred.&amp;nbsp; Patent applications filed, and patents obtained in foreign countries are subject to the laws and procedures that differ from those in the United States. Patent protection in foreign countries &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be different from patent protection under United States laws and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be favorable to Milestone Scientific. Milestone Scientific also attempts to protect the proprietary information using confidentiality agreements and by limiting access to its facilities. There can be &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; assurance that the program of patents, confidentiality agreements and restricted access to the facilities will be sufficient to protect the proprietary technology.&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:InventoryDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848235">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;E&amp;nbsp;&amp;#x2014; INVENTORIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="5" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Inventories consist of the following:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"&gt;Dental finished goods&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,846,272&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,832,275&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"&gt;Medical finished goods, net&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;475,285&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;735,061&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Component parts and other materials&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;57,652&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;35,383&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,379,209&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,602,719&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;a reserve for slow moving Medical finished goods was established in the amount approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$220,000.&lt;/div&gt; The&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;reserve was provided due to the delay in commercialization of the intra-articular medical instrument.&amp;nbsp; There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; reserves against inventory as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2017-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29245271" unitRef="iso4217-usd">2846272</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2016-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29245272" unitRef="iso4217-usd">3832275</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2017-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29245273" unitRef="iso4217-usd">475285</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2016-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29245274" unitRef="iso4217-usd">735061</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryNet contextRef="i_2017-12-31" decimals="INF" id="c29245277" unitRef="iso4217-usd">3379209</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="i_2016-12-31" decimals="INF" id="c29245278" unitRef="iso4217-usd">4602719</us-gaap:InventoryNet>
  <us-gaap:InventoryPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29255642">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt; Inventories&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Inventories principally consist of finished goods and component parts stated at the lower of cost (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess, slow moving, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence and product expiration requirements. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; inventory was recorded net of allowance for slow moving inventory of&amp;nbsp;approximately&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$220,000&lt;/div&gt;&amp;nbsp;as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017&amp;nbsp;&lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0&lt;/div&gt; as of&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InventoryValuationReserves contextRef="i_2017-12-31" decimals="INF" id="c29243925" unitRef="iso4217-usd">220000</us-gaap:InventoryValuationReserves>
  <us-gaap:InventoryValuationReserves contextRef="i_2016-12-31" decimals="INF" id="c29243926" unitRef="iso4217-usd">0</us-gaap:InventoryValuationReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2017-12-31" decimals="INF" id="c29245275" unitRef="iso4217-usd">57652</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2016-12-31" decimals="INF" id="c29245276" unitRef="iso4217-usd">35383</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWriteDown contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243784" unitRef="iso4217-usd">219834</us-gaap:InventoryWriteDown>
  <us-gaap:InventoryWriteDown contextRef="d_2016-01-01_2016-12-31" id="c29243785" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InvestmentIncomeInterest contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243475" unitRef="iso4217-usd">9298</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243476" unitRef="iso4217-usd">1285</us-gaap:InvestmentIncomeInterest>
  <us-gaap:LeaseAndRentalExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244719" unitRef="iso4217-usd">141428</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29244720" unitRef="iso4217-usd">133657</us-gaap:LeaseAndRentalExpense>
  <us-gaap:Liabilities contextRef="i_2017-12-31" decimals="INF" id="c29243405" unitRef="iso4217-usd">8128159</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="i_2016-12-31" decimals="INF" id="c29243406" unitRef="iso4217-usd">5645311</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2017-12-31" decimals="INF" id="c29243447" unitRef="iso4217-usd">15628787</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2016-12-31" decimals="INF" id="c29243448" unitRef="iso4217-usd">14181640</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243401" unitRef="iso4217-usd">6728159</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2016-12-31" decimals="INF" id="c29243402" unitRef="iso4217-usd">5645311</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="d_2018-01-01_2018-01-31_ProductOrServiceAxis-InstrumentsMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29244779" unitRef="iso4217-usd">1397440</us-gaap:LongTermPurchaseCommitmentAmount>
  <us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired contextRef="d_2014-06-01_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244075" unitRef="xbrli-pure">772</us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired>
  <us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired contextRef="d_2018-01-01_2018-01-31_ProductOrServiceAxis-InstrumentsMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29244776" unitRef="xbrli-pure">2000</us-gaap:LongTermPurchaseCommitmentMinimumQuantityRequired>
  <us-gaap:MinorityInterest contextRef="i_2017-12-31" decimals="INF" id="c29243443" unitRef="iso4217-usd">256744</us-gaap:MinorityInterest>
  <us-gaap:MinorityInterest contextRef="i_2016-12-31" decimals="INF" id="c29243444" unitRef="iso4217-usd">36106</us-gaap:MinorityInterest>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243833" unitRef="iso4217-usd">463336</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243834" unitRef="iso4217-usd">4798220</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243822" unitRef="iso4217-usd">-199175</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243823" unitRef="iso4217-usd">8206</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243811" unitRef="iso4217-usd">-1229434</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243812" unitRef="iso4217-usd">-5398581</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243489" unitRef="iso4217-usd">-5186793</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243490" unitRef="iso4217-usd">-5946507</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243487" unitRef="iso4217-usd">-182760</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243488" unitRef="iso4217-usd">-1347982</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29255669">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21.&lt;/div&gt; &lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Acc&lt;/div&gt;ounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2014, &lt;/div&gt;the Financial Accounting Standards Board (&amp;quot;FASB&amp;quot;) issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; steps: &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;) identify the contract, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;) identify performance obligations, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;) determine the transaction price, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;) allocate the transaction price, and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2015, &lt;/div&gt;the FASB issued guidance approving a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-year deferral, making the standard effective for reporting periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2017. &lt;/div&gt;The FASB continues to release guidance clarifying certain aspects of the revenue guidance. We do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; believe that this new accounting pronouncement will have a material impact on our financial statements.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016, &lt;/div&gt;the FASB issued a new standard Accounting Standards Update (&amp;quot;ASU &amp;quot;) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; &amp;quot;Leases&amp;quot;(Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;). The new standard is intended to increase transparency and comparability among organizations to recognize lease assets and liabilities on the balance sheet and disclose key information about leasing arrangements. It will be effective for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018. &lt;/div&gt;Milestone Scientific is in the process of determining what impact, the adoption of this ASU will have on its financial position, results of operations and cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2016, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,&lt;/div&gt; &amp;#x201c;Financial Instruments &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2013; Credit Losses&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;326&lt;/div&gt;).: The new standard is intended to replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. It will be effective for all entities for fiscal years and interim periods, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018. &lt;/div&gt;Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2016, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,&lt;/div&gt; &amp;quot;Statement Cash Flows &amp;#x201c;Classification of Certain Cash Receipts and Cash Disbursements&amp;quot; Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;230&lt;/div&gt;). The new standard provides guidance as to the conformity of presentation of certain cash receipts and disbursements. It will be effective for all entities for fiscal years and interim periods, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2017. &lt;/div&gt;Milestone Scientific does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; anticipate the adoption of this ASU will have a significant impact on its presentation within the statement of cash flows.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 2016, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,&lt;/div&gt; &amp;#x201c;Statement of Cash Flows &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2013; Restricted Cash&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;230&lt;/div&gt;). The new standard provides guidance as to address the diversity of treatment of restricted cash on the statement of cash flows. It will be effective for all entities for fiscal years and interim periods, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2017 &lt;/div&gt;and interim periods therein. Milestone Scientific does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect the adoption of this ASU to have a material effect on its presentation within the statement of cash flows.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2017, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09,&lt;/div&gt; &amp;#x201c;Compensation &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2013; Stock Compensation&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt;). The new standard provides guidance and clarity for modification to equity-based compensation programs. It will be effective for all entities for fiscal years and interim periods, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2017. &lt;/div&gt;Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its presentation within the statement of cash flows.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2017, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,&lt;/div&gt; &amp;#x201c;Earnings Per Share&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;260&lt;/div&gt;), &amp;#x201c;Distinguishing Liabilities from Equity&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;480&lt;/div&gt;), &amp;#x201c;Derivatives and Hedging&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;815&lt;/div&gt;). The new standard provides guidance relating to equity-linked instruments that include certain features. It will be effective for public entities for fiscal years and interim periods, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018. &lt;/div&gt;Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its presentation within the statement of cash flows.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 2017, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,&lt;/div&gt; &amp;#x201c;Income Statement &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2013; Reporting Comprehensive Income&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;815&lt;/div&gt;), &amp;#x201c;Revenue Recognition&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;605&lt;/div&gt;) and &amp;#x201c;Revenue from Contracts with Customers&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;606&lt;/div&gt;). The new standard provides guidance in these areas pursuant to certain SEC Staff Accounting Bulletin and Release, as they relate to the presentation of revenue recognition matters on the statement of comprehensive income.&amp;nbsp; It will be effective for public entities concurrent with the effectuation of other revenue recognition standards. Milestone Scientific does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; anticipate the adoption of this ASU to have a significant impact on its presentation within the statement of comprehensive income.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="d_2017-01-01_2017-12-31" id="c29243842" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243843" unitRef="iso4217-usd">16346</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
  <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243366" unitRef="iso4217-usd">500000</us-gaap:NotesAndLoansReceivableNetCurrent>
  <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="i_2016-12-31" id="c29243367" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="i_2017-12-31" decimals="INF" id="c29243382" unitRef="iso4217-usd">650000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
  <us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="i_2016-12-31" id="c29243383" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NotesReceivableNet contextRef="i_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember" decimals="INF" id="c29244029" unitRef="iso4217-usd">1275000</us-gaap:NotesReceivableNet>
  <us-gaap:NumberOfCountriesInWhichEntityOperates contextRef="i_2017-12-31" decimals="INF" id="c29243856" unitRef="xbrli-pure">53</us-gaap:NumberOfCountriesInWhichEntityOperates>
  <us-gaap:NumberOfReportableSegments contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244569" unitRef="xbrli-pure">2</us-gaap:NumberOfReportableSegments>
  <us-gaap:OpenTaxYear contextRef="d_2017-01-01_2017-12-31_TaxPeriodAxis-EarliestTaxYearMember" id="c29244530">2014</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear contextRef="d_2017-01-01_2017-12-31_TaxPeriodAxis-LatestTaxYearMember" id="c29244532">2016</us-gaap:OpenTaxYear>
  <us-gaap:OperatingExpenses contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243469" unitRef="iso4217-usd">12203697</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243470" unitRef="iso4217-usd">12820432</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244583" unitRef="iso4217-usd">3127570</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244584" unitRef="iso4217-usd">2087002</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244585" unitRef="iso4217-usd">-2389145</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244586" unitRef="iso4217-usd">-3265602</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" decimals="INF" id="c29244587" unitRef="iso4217-usd">-5972743</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember" decimals="INF" id="c29244588" unitRef="iso4217-usd">-5335360</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244589" unitRef="iso4217-usd">-5234318</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29244590" unitRef="iso4217-usd">-6513960</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="i_2017-12-31" decimals="INF" id="c29244773" unitRef="iso4217-usd">313050</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="i_2017-12-31" decimals="INF" id="c29244770" unitRef="iso4217-usd">150264</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="i_2017-12-31" decimals="INF" id="c29244772" unitRef="iso4217-usd">12522</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="i_2017-12-31" decimals="INF" id="c29244771" unitRef="iso4217-usd">150264</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-27">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 644px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 22px; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 205px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;Year Ending December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 644px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 22px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt; &lt;td style="width: 205px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;150,264&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 644px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 22px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 205px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;150,264&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 644px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 22px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 205px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0); text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,522&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 644px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 22px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt; &lt;td style="width: 205px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;313,050&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
  <us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244715" unitRef="iso4217-usd">12522</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2017-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" decimals="INF" id="c29244516" unitRef="iso4217-usd">60000000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2016-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" decimals="INF" id="c29244517" unitRef="iso4217-usd">56530000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2017-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" decimals="INF" id="c29244518" unitRef="iso4217-usd">24500000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2016-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" decimals="INF" id="c29244519" unitRef="iso4217-usd">22942000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="i_2017-12-31" decimals="INF" id="c29244508" unitRef="iso4217-usd">0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
  <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="i_2016-12-31" decimals="INF" id="c29244509" unitRef="iso4217-usd">0</us-gaap:OperatingLossCarryforwardsValuationAllowance>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848167">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE A &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2014; ORGANIZATION AND BUSINESS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;All references in this report to &amp;#x201c;Milestone Scientific,&amp;#x201d; &amp;#x201c;us,&amp;#x201d; &amp;#x201c;our,&amp;#x201d; &amp;#x201c;we,&amp;#x201d; the &amp;#x201c;Company&amp;#x201d; or &amp;#x201c;Milestone&amp;#x201d; refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Advanced Cosmetic Systems, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;ompuDent&amp;reg;; CompuMed&amp;reg;; CompuFlo&amp;reg;; DPS Dynamic Pressure Sensing technology&amp;reg;; Milestone Scientific &amp;reg;;&amp;nbsp;the Milestone logo &amp;reg;; SafetyWand&amp;reg;; STA Single Tooth Anesthesia System&amp;reg;; and The Wand &amp;reg;.&lt;/div&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;Milestone Scientific was incorporated in the State of Delaware in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 1989. &lt;/div&gt;Milestone Scientific has developed a proprietary, computer-controlled anesthetic delivery device, using &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;The Wand&amp;reg;&lt;/div&gt;, a single use disposable handpiece. The device is marketed in dentistry under the trademark &lt;div style="display: inline; font-style: italic;"&gt;CompuDent&amp;reg;, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic;"&gt;STA Single Tooth Anesthesia System&amp;reg;&lt;/div&gt; and in medicine under the trademark &lt;div style="display: inline; font-style: italic;"&gt;CompuMed&amp;reg;. CompuDent&amp;reg;&lt;/div&gt; is suitable for all dental procedures that require local anesthetic. &lt;div style="display: inline; font-style: italic;"&gt;CompuMed&amp;reg;&lt;/div&gt; is suitable for many medical procedures regularly performed in Plastic Surgery, Hair Restoration Surgery, Podiatry, Colorectal Surgery, Dermatology, Orthopedics and many other disciplines. The dental devices are sold in the United States, Canada and in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;53&lt;/div&gt;&amp;nbsp;other countries. To date there have been &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; medical devices sold in the United States and limited amounts sold internationally, although certain medical devices have obtained CE mark approval and&amp;nbsp;can be marketed and sold in most European countries.&amp;nbsp;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2017,&amp;nbsp;&lt;/div&gt;Milestone Scientific received &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;510&lt;/div&gt;(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the&lt;div style="display: inline; font-style: italic;"&gt; CompuFlo&lt;/div&gt;&amp;reg; Epidural Computer Controlled Anesthesia System (&amp;#x201c;Epidural&amp;#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; Milestone Scientific filed for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;510&lt;/div&gt;(k) marketing clearance with the FDA for both intra-articular and epidural injections with the CompuFlo&amp;reg; Computer Controlled Anesthesia System.&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2017, &lt;/div&gt;the FDA approved the&lt;div style="display: inline; font-style: italic;"&gt; CompuFlo&lt;/div&gt;&amp;reg; Epidural Computer Controlled Anesthesia System for epidural injections. &amp;nbsp;Milestone Scientific is in the process of introductory meetings with medical device distributors within the United States and foreign markets. Milestone Scientific&amp;#x2019;s immediate focus is on marketing its epidural&amp;nbsp;device throughout the United States and Europe.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2016, &lt;/div&gt;we received notification from the FDA that based upon the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;510&lt;/div&gt;(k)-application submitted for intra- articular injections,&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;we did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; adequately document that the device met the equivalency standard required for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;510&lt;/div&gt;(k) clearances. Following consultation with the FDA Office of Device Evaluation, we intend to file a new &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;510&lt;/div&gt;(k) application for the device in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 13, 2017, &lt;/div&gt;Milestone Scientific consummated an asset acquisition under an Asset Purchase Agreement (the &amp;#x201c;Agreement&amp;#x201d;) with APAD Octrooi B.V. and APAD B.V. (each, a &amp;#x201c;Seller&amp;#x201d; and collectively, the &amp;#x201c;Sellers&amp;#x201d;) pursuant to which Milestone Scientific acquired certain patent rights and other intellectual property rights related to the Sellers&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2019; computer-controlled injection device (the &amp;#x201c;Purchased Assets&amp;#x201d;.) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2017-12-31" decimals="INF" id="c29243384" unitRef="iso4217-usd">26878</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2016-12-31" decimals="INF" id="c29243385" unitRef="iso4217-usd">17355</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243473" unitRef="iso4217-usd">-4930</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243474" unitRef="iso4217-usd">-5088</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherOperatingIncomeExpenseNet contextRef="d_2017-01-01_2017-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244148" unitRef="iso4217-usd">6247205</us-gaap:OtherOperatingIncomeExpenseNet>
  <us-gaap:OtherOperatingIncomeExpenseNet contextRef="d_2016-01-01_2016-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244149" unitRef="iso4217-usd">2834980</us-gaap:OtherOperatingIncomeExpenseNet>
  <us-gaap:OtherReceivables contextRef="i_2017-12-31" id="c29243364" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherReceivables contextRef="i_2016-12-31" decimals="INF" id="c29243365" unitRef="iso4217-usd">10000</us-gaap:OtherReceivables>
  <us-gaap:PaymentsForPostemploymentBenefits contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29244723" unitRef="iso4217-usd">203111</us-gaap:PaymentsForPostemploymentBenefits>
  <us-gaap:PaymentsForPostemploymentBenefits contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244728" unitRef="iso4217-usd">203111</us-gaap:PaymentsForPostemploymentBenefits>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="d_2016-12-01_2017-01-31_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" decimals="INF" id="c29244262" unitRef="iso4217-usd">4461493</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243814" unitRef="iso4217-usd">39520</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243815" unitRef="iso4217-usd">15615</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243816" unitRef="iso4217-usd">6008</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243817" unitRef="iso4217-usd">15344</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848197">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;NOTE S&amp;nbsp;&amp;#x2014; PENSION PLAN &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Milestone Scientific has a Defined Contribution Plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone Scientific does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; contribute to this plan, but does pay the administrative costs of the plan, which were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; significant.&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2017-12-31" decimals="INF" id="c29243413" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2016-12-31" decimals="INF" id="c29243414" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockRedemptionPricePerShare contextRef="i_2014-05-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29244274" unitRef="iso4217-usd-per-xbrli-shares">2.37</us-gaap:PreferredStockRedemptionPricePerShare>
  <us-gaap:PreferredStockRedemptionPricePerShare contextRef="i_2014-05-31_ConversionOfStockByUniqueDescriptionAxis-ConversionPriceIfCertainConditionsAreNotMetMember_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29244275" unitRef="iso4217-usd-per-xbrli-shares">1.50</us-gaap:PreferredStockRedemptionPricePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2017-12-31" decimals="INF" id="c29243415" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2016-12-31" decimals="INF" id="c29243416" unitRef="xbrli-shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2017-12-31" decimals="INF" id="c29243417" unitRef="xbrli-shares">7000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2016-12-31" decimals="INF" id="c29243418" unitRef="xbrli-shares">7000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2017-12-31" decimals="INF" id="c29243419" unitRef="xbrli-shares">7000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2016-12-31" decimals="INF" id="c29243420" unitRef="xbrli-shares">7000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="i_2017-12-31" decimals="INF" id="c29243411" unitRef="iso4217-usd">7</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="i_2016-12-31" decimals="INF" id="c29243412" unitRef="iso4217-usd">7</us-gaap:PreferredStockValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2017-12-31" decimals="INF" id="c29243368" unitRef="iso4217-usd">436410</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2016-12-31" decimals="INF" id="c29243369" unitRef="iso4217-usd">291929</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="d_2017-01-01_2017-12-31" id="c29255636">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.&lt;/div&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Certain reclassifications have been made to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;&amp;nbsp;financial statements to conform to the consolidated &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;&amp;nbsp;financial statement presentation. These reclassifications had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; effect on net loss or cash flows as previously reported.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2016-07-01_2016-07-31" decimals="INF" id="c29244242" unitRef="iso4217-usd">250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2016-12-01_2016-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29244255" unitRef="iso4217-usd">3000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2017-01-01_2017-01-31_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" decimals="INF" id="c29244260" unitRef="iso4217-usd">186000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2016-12-01_2017-01-31_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" decimals="INF" id="c29244261" unitRef="iso4217-usd">3200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2014-05-01_2014-05-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29244268" unitRef="iso4217-usd">3000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243827" unitRef="iso4217-usd">150836</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243828" unitRef="iso4217-usd">2573220</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="d_2014-05-01_2014-05-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29244271" unitRef="iso4217-usd">7000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="d_2016-06-01_2016-06-30" decimals="INF" id="c29244239" unitRef="iso4217-usd">2000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="d_2014-05-01_2014-05-31" decimals="INF" id="c29244267" unitRef="iso4217-usd">10000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="d_2017-01-01_2017-12-31" id="c29243825" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243826" unitRef="iso4217-usd">2225000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243831" unitRef="iso4217-usd">62500</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProfessionalFees contextRef="d_2017-01-01_2017-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" decimals="INF" id="c29244742" unitRef="iso4217-usd">275000</us-gaap:ProfessionalFees>
  <us-gaap:ProfessionalFees contextRef="d_2016-01-01_2016-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" decimals="INF" id="c29244743" unitRef="iso4217-usd">275000</us-gaap:ProfessionalFees>
  <us-gaap:ProfitLoss contextRef="d_2017-01-01_2017-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244150" unitRef="iso4217-usd">-5057800</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="d_2016-01-01_2016-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244151" unitRef="iso4217-usd">-2684602</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243485" unitRef="iso4217-usd">-5369553</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243486" unitRef="iso4217-usd">-7294489</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243647" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProfitLoss contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c29243649" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProfitLoss contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" id="c29243650" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProfitLoss contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c29243651" unitRef="iso4217-usd">-5946507</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" decimals="INF" id="c29243652" unitRef="iso4217-usd">-1347982</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243653" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProfitLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243746" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProfitLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" id="c29243748" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProfitLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" id="c29243749" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProfitLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c29243750" unitRef="iso4217-usd">-5186793</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" decimals="INF" id="c29243751" unitRef="iso4217-usd">-182760</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243752" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848237">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE I&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2014; FURNITURE, FIXTURES AND EQUIPMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-right: 7.5%; margin-left: 7.5%; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="4" style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture, Fixtures and Equipment consist of the&lt;br /&gt; &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;following:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 64%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,734&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,734&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Office furniture and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;134,947&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;135,802&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Molds&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,200&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,200&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Trade show displays&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;143,357&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;143,357&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Computers and software&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;231,704&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;224,840&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tooling Safety Wand&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,022&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,022&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;Website&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39,200&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tooling equipment-STA &amp;amp; Wand&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,100&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,100&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;EPI and IA Instruments&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82,363&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82,363&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;STA Trials Instruments&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63,752&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63,752&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;863,379&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;818,170&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(721,619&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(659,144&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;141,760&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;159,026&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 19.5pt;"&gt;Depreciation expense was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$62,475&lt;/div&gt;&amp;nbsp;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$92,667&lt;/div&gt;&amp;nbsp;for the &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="INF" id="c29245314" unitRef="iso4217-usd">24734</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="INF" id="c29245315" unitRef="iso4217-usd">24734</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember" decimals="INF" id="c29245316" unitRef="iso4217-usd">134947</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember" decimals="INF" id="c29245317" unitRef="iso4217-usd">135802</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember" decimals="INF" id="c29245318" unitRef="iso4217-usd">7200</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember" decimals="INF" id="c29245319" unitRef="iso4217-usd">7200</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember" decimals="INF" id="c29245320" unitRef="iso4217-usd">143357</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember" decimals="INF" id="c29245321" unitRef="iso4217-usd">143357</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember" decimals="INF" id="c29245322" unitRef="iso4217-usd">231704</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember" decimals="INF" id="c29245323" unitRef="iso4217-usd">224840</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember" decimals="INF" id="c29245324" unitRef="iso4217-usd">125022</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember" decimals="INF" id="c29245325" unitRef="iso4217-usd">125022</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-WebsiteMember" decimals="INF" id="c29245326" unitRef="iso4217-usd">39200</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-WebsiteMember" id="c29245327" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember" decimals="INF" id="c29245328" unitRef="iso4217-usd">11100</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember" decimals="INF" id="c29245329" unitRef="iso4217-usd">11100</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember" decimals="INF" id="c29245330" unitRef="iso4217-usd">82363</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember" decimals="INF" id="c29245331" unitRef="iso4217-usd">82363</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember" decimals="INF" id="c29245332" unitRef="iso4217-usd">63752</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember" decimals="INF" id="c29245333" unitRef="iso4217-usd">63752</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31" decimals="INF" id="c29245334" unitRef="iso4217-usd">863379</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31" decimals="INF" id="c29245335" unitRef="iso4217-usd">818170</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2017-12-31" decimals="INF" id="c29245338" unitRef="iso4217-usd">141760</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2016-12-31" decimals="INF" id="c29245339" unitRef="iso4217-usd">159026</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29255644">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt; Furniture, Fixture and Equipment&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from &lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt;&lt;/div&gt; to &lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;seven&lt;/div&gt;&lt;/div&gt; years. The costs of maintenance and repairs are charged to operations as incurred.&amp;nbsp; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; furniture, fixtures &amp;amp; equipment was&amp;nbsp;recorded net of accumulated depreciation of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$721,619&lt;/div&gt;&amp;nbsp;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$659,144&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-right: 7.5%; margin-left: 7.5%; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="4" style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture, Fixtures and Equipment consist of the&lt;br /&gt; &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;following:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 64%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,734&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,734&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Office furniture and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;134,947&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;135,802&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Molds&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,200&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,200&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Trade show displays&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;143,357&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;143,357&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Computers and software&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;231,704&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;224,840&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tooling Safety Wand&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,022&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,022&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;Website&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39,200&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tooling equipment-STA &amp;amp; Wand&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,100&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,100&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;EPI and IA Instruments&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82,363&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82,363&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;STA Trials Instruments&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63,752&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63,752&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;863,379&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;818,170&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(721,619&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(659,144&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;141,760&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;159,026&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember" id="c29243931">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember" id="c29243932">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted contextRef="i_2017-12-31_ProductOrServiceAxis-InstrumentsMember" decimals="INF" id="c29244661" unitRef="iso4217-usd">300460</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
  <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted contextRef="i_2016-12-31_ProductOrServiceAxis-InstrumentsMember" decimals="INF" id="c29244663" unitRef="iso4217-usd">272231</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="d_2017-01-01_2017-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember" decimals="INF" id="c29244703" unitRef="iso4217-usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="d_2016-01-01_2016-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember" decimals="INF" id="c29244704" unitRef="iso4217-usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="d_2017-01-01_2017-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-InnovestSpAMember" decimals="INF" id="c29244709" unitRef="iso4217-usd">80000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="d_2017-01-01_2017-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember" decimals="INF" id="c29244683" unitRef="iso4217-usd">2146108</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
  <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="d_2016-01-01_2016-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember" decimals="INF" id="c29244684" unitRef="iso4217-usd">3025249</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848194">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE Q&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;-- RELATED PARTY TRANSACTIONS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Milestone Scientific has a manufacturing agreement with United Systems (an entity controlled by a significant stockholder of Milestone), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,146,108&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,025,249&lt;/div&gt; for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively. Milestone Scientific owed &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$985,678&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,235,052&lt;/div&gt; to this manufacturer as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; Milestone Scientific had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,071,000&lt;/div&gt; of related party sales of handpieces and instruments to Milestone China and Milestone China&amp;#x2019;s agent for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017. &lt;/div&gt;Milestone Scientific had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,425,000&lt;/div&gt; of related party sales of handpieces and instruments to Milestone China for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016. &lt;/div&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; Milestone Scientific recorded deferred revenues and deferred costs associated with sales to Milestone China of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,725,450&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,109,671,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,001,800&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$620,041,&lt;/div&gt; respectively.&amp;nbsp; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; Milestone China and Milestone China&amp;#x2019;s agent owed &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,725,450&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,714,600,&lt;/div&gt; respectively, to Milestone Scientific which is included in related party accounts receivable on the consolidated balance sheets.&amp;nbsp;Milestone Scientific defers the total revenue and costs of goods sold when instruments and handpieces are shipped to Milestone China and Milestone China&amp;#x2019;s agent due to market conditions and Milestone China liquidity concerns. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2016, &lt;/div&gt;a stockholder of Milestone Scientific entered a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-year agreement with Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$100,000&lt;/div&gt; for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2017, &lt;/div&gt;Milestone Scientific entered into a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;-month agreement with Innovest S.p.A. to provide consulting service. This agreement is expected to continue into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;Expenses recognized on this agreement were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$80,000&lt;/div&gt; for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;See Note M for related party employment and consulting agreements.&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243467" unitRef="iso4217-usd">272746</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243468" unitRef="iso4217-usd">1270471</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2017-01-01_2017-12-31" id="c29255655">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15.&lt;/div&gt; Research and Development&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Research and development costs, which consist principally of new product development costs payable to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties, are expensed as incurred. Advance payments for the research are amortized to expense either as services are performed or over the relevant service period using the straight-line method.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2017-12-31" decimals="INF" id="c29243435" unitRef="iso4217-usd">-78568284</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2016-12-31" decimals="INF" id="c29243436" unitRef="iso4217-usd">-73381491</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29255651">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.&lt;/div&gt; Revenue Recognition&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; &amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Revenue from product sales is recognized, net of discounts and allowances to domestic distributors, on the date of shipment for substantially all shipments, since the shipment terms are FOB warehouse. Milestone Scientific recognizes revenue on date of arrival of the goods at the customer's location, where shipments are FOB destination. In all cases the price to the buyer is fixed and the collectability is reasonably assured. Further, Milestone Scientific has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&amp;nbsp;Devices and hand pieces are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; bundled but rather sold separately and, as such, there are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; multiple element determinations in connection with the revenue recognition. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;Milestone Scientific defers the total revenue and costs of goods sold when devices and handpieces are shipped to Milestone China and Milestone China&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2019;s agent due to market conditions and Milestone China liquidity concerns. Also, due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties, an elimination of the intra-entity profit is required as of the balance sheet date. In accordance with ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;323&lt;/div&gt; Equity Method and Joint Ventures, Milestone Scientific has deferred &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40%&lt;/div&gt; of the gross profit associated with recognized revenue from Milestone China that has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been sold to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:RoyaltyExpense contextRef="d_2017-01-01_2017-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" decimals="INF" id="c29244738" unitRef="iso4217-usd">554150</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="d_2016-01-01_2016-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember" decimals="INF" id="c29244739" unitRef="iso4217-usd">526737</us-gaap:RoyaltyExpense>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_ProductOrServiceAxis-InstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244104" unitRef="iso4217-usd">2071000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_ProductOrServiceAxis-InstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244106" unitRef="iso4217-usd">3425000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244690" unitRef="iso4217-usd">2071000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember" decimals="INF" id="c29244692" unitRef="iso4217-usd">3425000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244575" unitRef="iso4217-usd">11279886</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244576" unitRef="iso4217-usd">10460752</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244577" unitRef="iso4217-usd">2000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244578" unitRef="iso4217-usd">21253</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244579" unitRef="iso4217-usd">11281886</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29244580" unitRef="iso4217-usd">10482005</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember" decimals="INF" id="c29244629" unitRef="iso4217-usd">5339709</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember" decimals="INF" id="c29244630" unitRef="iso4217-usd">3331308</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" decimals="INF" id="c29244631" unitRef="iso4217-usd">3869177</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" decimals="INF" id="c29244632" unitRef="iso4217-usd">3703844</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN" decimals="INF" id="c29244633" unitRef="iso4217-usd">2071000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN" decimals="INF" id="c29244634" unitRef="iso4217-usd">3425600</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244635" unitRef="iso4217-usd">11279886</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember" decimals="INF" id="c29244636" unitRef="iso4217-usd">10460752</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember" id="c29244639" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember" id="c29244640" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" decimals="INF" id="c29244641" unitRef="iso4217-usd">2000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember" decimals="INF" id="c29244642" unitRef="iso4217-usd">21253</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244643" unitRef="iso4217-usd">2000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember" decimals="INF" id="c29244644" unitRef="iso4217-usd">21253</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_StatementGeographicalAxis-DomesticMember" decimals="INF" id="c29244647" unitRef="iso4217-usd">5339709</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_StatementGeographicalAxis-DomesticMember" decimals="INF" id="c29244648" unitRef="iso4217-usd">3352561</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_StatementGeographicalAxis-RestOfWorldMember" decimals="INF" id="c29244649" unitRef="iso4217-usd">3871177</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_StatementGeographicalAxis-RestOfWorldMember" decimals="INF" id="c29244650" unitRef="iso4217-usd">3703844</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2017-01-01_2017-12-31_StatementGeographicalAxis-CN" decimals="INF" id="c29244651" unitRef="iso4217-usd">2071000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-12-31_StatementGeographicalAxis-CN" decimals="INF" id="c29244652" unitRef="iso4217-usd">3425600</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueNet contextRef="d_2017-01-01_2017-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244142" unitRef="iso4217-usd">1666605</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-01-01_2016-12-31_LegalEntityAxis-MilestoneChinaMember" decimals="INF" id="c29244143" unitRef="iso4217-usd">1126484</us-gaap:SalesRevenueNet>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-23">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Allowance for doubtful accounts-short term&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warranty reserve&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;36,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Capital Gains&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;45,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred officers compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;636,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;395,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Depreciation and Amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;181,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;135,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Deferred revenue&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;478,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net operating loss carryforward&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,116,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,456,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Subtotal&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,479,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,026,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16,479,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(19,026,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-24">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;State income tax - all states&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Non-deductible Stock based compensation&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Deferred provision for effect of change in Federal&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;164&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;43&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Valuation allowance&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(43&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Effective tax rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 278px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="5" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 305px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 37px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="5" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 313px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 278px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 71px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 20px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 95px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Accumulated Amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 31px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 80px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 37px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 91px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 7px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 101px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Accumulated Amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 15px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 92px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 278px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Patents-foundation intellectual property&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 71px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,377,863&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 20px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 95px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(787,821&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 31px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 80px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;590,042&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 91px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,377,543&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 7px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 101px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(717,086&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 15px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 92px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;660,457&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 278px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Epidural-Apad acquired patents&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 71px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,639,647&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 20px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 95px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(439,941&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 31px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 80px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,199,706&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 91px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 7px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 101px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 15px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 92px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 278px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 71px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,017,510&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 20px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 95px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,227,762&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 31px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 80px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,789,748&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 91px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,377,543&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 7px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 101px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(717,086&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 15px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 92px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;660,457&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="5" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;December 31&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Inventories consist of the following:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"&gt;Dental finished goods&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,846,272&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,832,275&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-indent: 18pt;"&gt;Medical finished goods, net&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;475,285&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;735,061&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Component parts and other materials&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;57,652&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;35,383&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,379,209&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,602,719&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-25">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 64%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Sales&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Years ended&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net Sales:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Dental&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,279,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,460,752&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Medical&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,253&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,281,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,482,005&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Operating Income (Loss):&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Dental&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,127,570&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,087,002&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Medical&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;2,389,145&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;3,265,602&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,972,743&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;5,335,360&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;5,234,318&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;6,513,960&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Depreciation and Amortization:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Dental&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,305&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Medical&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26,950&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;62,720&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Other&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;528,895&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82,586&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;573,150&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;162,925&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="text-indent: 27pt;"&gt;&amp;nbsp;Total&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Income before taxes and equity in&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; earnings&amp;nbsp;of affiliates:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Dental&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,136,167&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,097,652&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Medical&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;2,391,082&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;3,219,497&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;5,975,035&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;5,395,918&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;5,229,950&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;6,517,763&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Dental&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,255,144&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,472,879&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Medical&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;655,513&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;913,840&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"&gt;Corporate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,718,130&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(&lt;/div&gt;2,794,921&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-indent: 27pt;"&gt;&amp;nbsp;Total&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,628,787&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,181,640&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-right: 5%; margin-left: 5%; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Wei&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;ghted Averaged Exercise Price $&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Aggregate Intrinsic Options Value $&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 44%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Options outstanding January 1, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,419,436&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.56&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.79&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,220,338&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable, January 1, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,041,680&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.29&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.41&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,135,819&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;520,337&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.79&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.38&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised during 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(327,778&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.75&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited or expired&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(100,000&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.35&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Options outstanding December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,511,995&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.74&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.97&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;102,605&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable, December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,054,202&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.65&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.51&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;102,605&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,006,741&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.82&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.69&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,610&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised during 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(83,333&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.75&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited, cancelled, or expired&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,250,068&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Options outstanding December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,985,325&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.74&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.04&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,160&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable,&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; December 31, 2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,317,4416&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.84&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.46&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,537&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-right: 5%; margin-left: 5%; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 489px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 121px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Number of Options&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 25px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 140px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Weighted Averaged Exercise Price $&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 26px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 153px;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 37px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Aggregate Intr&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;insic Options Value $&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Outstanding, January&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; 1, 2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,333&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.70&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.83&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Exercisable, January 1, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,777&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.70&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.83&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 489px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;216,666&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.53&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 489px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Outstanding, December&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; 31, 2016&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;224,999&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.53&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.32&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Exercisable, December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,734&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.72&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.36&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 489px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 489px;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Outstanding, December&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; 31, 2017&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;224,999&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.52&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.51&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td colspan="1" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 489px;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Exercisable, December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 121px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,067&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 25px; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 140px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.22&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 26px; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 153px; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.38&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 37px; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;81.23% -97.24%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;134.53%- 194.34%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.4%- 2.2%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;.04%-1.47%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Life&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"&gt;2-5 years&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"&gt;5 years&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeiture Rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243465" unitRef="iso4217-usd">11930951</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243466" unitRef="iso4217-usd">11549961</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243780" unitRef="iso4217-usd">651413</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243781" unitRef="iso4217-usd">1850760</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2017-01-01_2017-12-31" decimals="4" id="c29255704" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2016-01-01_2016-12-31" decimals="4" id="c29255706" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember" decimals="4" id="c29255691" unitRef="xbrli-pure">0.8123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember" decimals="4" id="c29255692" unitRef="xbrli-pure">0.9724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2016-01-01_2016-12-31_RangeAxis-MinimumMember" decimals="4" id="c29255693" unitRef="xbrli-pure">1.3453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember" decimals="4" id="c29255694" unitRef="xbrli-pure">1.9434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember" decimals="4" id="c29255695" unitRef="xbrli-pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember" decimals="4" id="c29255696" unitRef="xbrli-pure">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2016-01-01_2016-12-31_RangeAxis-MinimumMember" decimals="4" id="c29255697" unitRef="xbrli-pure">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember" decimals="4" id="c29255698" unitRef="xbrli-pure">0.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2004-07-31_PlanNameAxis-StockOptionPlan2004Member" decimals="INF" id="c29244289" unitRef="xbrli-shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2016-04-30_PlanNameAxis-StockOptionPlan2011Member" decimals="INF" id="c29244303" unitRef="xbrli-shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2016-05-31_PlanNameAxis-StockOptionPlan2011Member" decimals="INF" id="c29244304" unitRef="xbrli-shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2017-12-31_PlanNameAxis-StockOptionPlan2004Member" decimals="INF" id="c29244293" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="i_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244344" unitRef="xbrli-shares">1041680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="i_2016-12-31" decimals="INF" id="c29244364" unitRef="xbrli-shares">1054202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="i_2017-12-31" decimals="INF" id="c29244384" unitRef="xbrli-shares">13174416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="i_2015-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244396" unitRef="xbrli-shares">2777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="i_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244412" unitRef="xbrli-shares">14734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="i_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244428" unitRef="xbrli-shares">23067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244345" unitRef="iso4217-usd-per-xbrli-shares">1.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2016-12-31" decimals="INF" id="c29244365" unitRef="iso4217-usd-per-xbrli-shares">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2017-12-31" decimals="INF" id="c29244385" unitRef="iso4217-usd-per-xbrli-shares">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2015-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244397" unitRef="iso4217-usd-per-xbrli-shares">2.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244413" unitRef="iso4217-usd-per-xbrli-shares">2.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244429" unitRef="iso4217-usd-per-xbrli-shares">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29244356" unitRef="xbrli-shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244376" unitRef="xbrli-shares">1250068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29244357" unitRef="iso4217-usd-per-xbrli-shares">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31" id="c29244377" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="d_2017-07-01_2017-12-31_TitleOfIndividualAxis-GianDomenicoTrombettaMember" decimals="INF" id="c29244323" unitRef="xbrli-shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2011-06-01_2011-06-30_PlanNameAxis-StockOptionPlan2011Member" decimals="INF" id="c29244296" unitRef="xbrli-shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-GianDomenicoTrombettaMember" decimals="INF" id="c29244317" unitRef="xbrli-shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2017-07-07_2017-07-07_AwardTypeAxis-EmployeeStockOptionsIssuedAt255PerShareMember_TitleOfIndividualAxis-GianDomenicoTrombettaMember" decimals="INF" id="c29244318" unitRef="xbrli-shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2017-07-07_2017-07-07_AwardTypeAxis-EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember_TitleOfIndividualAxis-GianDomenicoTrombettaMember" decimals="INF" id="c29244320" unitRef="xbrli-shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2017-01-01_2017-07-31_AwardTypeAxis-NonqualifiedStockOptionsMember_PlanNameAxis-StockOptionPlan2011Member_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember" decimals="INF" id="c29244480" unitRef="xbrli-shares">921942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244348" unitRef="xbrli-shares">520337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244368" unitRef="xbrli-shares">1006741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244400" unitRef="xbrli-shares">216666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244416" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244343" unitRef="iso4217-usd">1220338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244363" unitRef="iso4217-usd">102605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2017-12-31" decimals="INF" id="c29244383" unitRef="iso4217-usd">25160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2015-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244395" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244411" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244427" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244340" unitRef="xbrli-shares">1419436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244360" unitRef="xbrli-shares">1511995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2017-12-31" decimals="INF" id="c29244380" unitRef="xbrli-shares">1985325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2015-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244392" unitRef="xbrli-shares">8333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244408" unitRef="xbrli-shares">224999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244424" unitRef="xbrli-shares">224999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244341" unitRef="iso4217-usd-per-xbrli-shares">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244361" unitRef="iso4217-usd-per-xbrli-shares">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2017-12-31" decimals="INF" id="c29244381" unitRef="iso4217-usd-per-xbrli-shares">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244393" unitRef="iso4217-usd-per-xbrli-shares">2.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244409" unitRef="iso4217-usd-per-xbrli-shares">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244425" unitRef="iso4217-usd-per-xbrli-shares">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244353" unitRef="iso4217-usd-per-xbrli-shares">0.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244373" unitRef="iso4217-usd-per-xbrli-shares">0.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244405" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244421" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2017-07-07_2017-07-07_AwardTypeAxis-EmployeeStockOptionsIssuedAt255PerShareMember_TitleOfIndividualAxis-GianDomenicoTrombettaMember" decimals="INF" id="c29244319" unitRef="iso4217-usd-per-xbrli-shares">2.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2017-07-07_2017-07-07_AwardTypeAxis-EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember_TitleOfIndividualAxis-GianDomenicoTrombettaMember" decimals="INF" id="c29244321" unitRef="iso4217-usd-per-xbrli-shares">2.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29245928" unitRef="iso4217-usd-per-xbrli-shares">1.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29245929" unitRef="iso4217-usd-per-xbrli-shares">1.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-07-31_AwardTypeAxis-NonqualifiedStockOptionsMember_PlanNameAxis-StockOptionPlan2011Member_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember" decimals="INF" id="c29244481" unitRef="iso4217-usd-per-xbrli-shares">2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244349" unitRef="iso4217-usd-per-xbrli-shares">1.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244369" unitRef="iso4217-usd-per-xbrli-shares">1.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" decimals="INF" id="c29244401" unitRef="iso4217-usd-per-xbrli-shares">2.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244417" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2017-01-01_2017-12-31" id="c29255666">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20.&lt;/div&gt; Stock-Based Compensation &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Milestone Scientific accounts for stock-based compensation under ASC Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718,&lt;/div&gt; Share-Based Payment. ASC Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt; requires all share-based payments to employees, including grants of employee stock options, to be recognized in the Statements of Operations over the service period, as an operating expense, based on the grant-date fair values. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. In accordance with the provisions of FASB ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;505,&lt;/div&gt; Milestone Scientific will re-measure the value of the grant at each presentation date unless there is a significant disincentive for non-performance or until performance has been rendered. For the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months end &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;Milestone Scientific recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$9,384&lt;/div&gt; income related to non-employee options. For the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months end &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;Milestone Scientific recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$25,346&lt;/div&gt; expense related to non-employee options.&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243981" unitRef="iso4217-usd">25346</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2009-09-01_2009-09-01_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" id="c29244454">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember" id="c29244477">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2017-07-01_2017-07-31_AwardTypeAxis-NonqualifiedStockOptionsMember_PlanNameAxis-StockOptionPlan2011Member_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember" id="c29244482">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember" id="c29255699">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember" id="c29255700">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2016-01-01_2016-12-31" id="c29255702">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="i_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244347" unitRef="iso4217-usd">1135819</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="i_2016-12-31" decimals="INF" id="c29244367" unitRef="iso4217-usd">102605</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="i_2017-12-31" decimals="INF" id="c29244387" unitRef="iso4217-usd">8537</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="i_2015-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244399" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="i_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244415" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="i_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244431" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c29244346">P2Y149D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2016-01-01_2016-12-31" id="c29244366">P2Y186D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2017-01-01_2017-12-31" id="c29244386">P2Y167D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244398">P4Y302D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244414">P4Y131D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244430">P4Y138D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c29244342">P2Y288D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c29244362">P2Y354D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2017-01-01_2017-12-31" id="c29244382">P3Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244394">P4Y302D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244410">P5Y116D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244426">P3Y186D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="d_2009-09-01_2009-09-01_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" decimals="1" id="c29244455" unitRef="xbrli-pure">1.1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharesIssued contextRef="i_2015-12-31_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c29243547" unitRef="xbrli-shares">7000</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243549" unitRef="xbrli-shares">22685160</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="i_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c29243655" unitRef="xbrli-shares">7000</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243657" unitRef="xbrli-shares">31727705</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="i_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c29243754" unitRef="xbrli-shares">7000</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243756" unitRef="xbrli-shares">34592818</us-gaap:SharesIssued>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2016-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29244241" unitRef="iso4217-usd-per-xbrli-shares">2</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2016-07-31" decimals="INF" id="c29244244" unitRef="iso4217-usd-per-xbrli-shares">2.40</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2016-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29244254" unitRef="iso4217-usd-per-xbrli-shares">1.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2017-01-31_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" decimals="INF" id="c29244259" unitRef="iso4217-usd-per-xbrli-shares">1.499</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2014-05-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29244270" unitRef="iso4217-usd-per-xbrli-shares">1.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2014-05-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29244273" unitRef="iso4217-usd-per-xbrli-shares">1000</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29255653">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14.&lt;/div&gt; Shipping and Handling Costs&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Milestone Scientific includes shipping and handling costs, if any, in cost of goods sold. These costs are paid by or billed to customers at the time of shipments. Domestic and international shipments are FOB warehouse; therefore, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; costs are incurred by Milestone Scientific.&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
  <us-gaap:ShippingHandlingAndTransportationCosts contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243954" unitRef="iso4217-usd">0</us-gaap:ShippingHandlingAndTransportationCosts>
  <us-gaap:ShippingHandlingAndTransportationCosts contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243955" unitRef="iso4217-usd">0</us-gaap:ShippingHandlingAndTransportationCosts>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848169">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;NOTE C&amp;nbsp;&amp;#x2014; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.&lt;/div&gt; Principles of Consolidation&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States&amp;nbsp;(&amp;quot;GAAP&amp;quot;) and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned)&amp;nbsp;and Milestone Medical (majority owned). Milestone Education is a variable interest entity of which Milestone Scientific is the primary beneficiary and is consolidated into Milestone Scientific's financial statements. All significant, intra-entity transactions and balances have been eliminated in the consolidation.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.&lt;/div&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Reclassifications&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Certain reclassifications have been made to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;&amp;nbsp;financial statements to conform to the consolidated &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;&amp;nbsp;financial statement presentation. These reclassifications had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; effect on net loss or cash flows as previously reported.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.&lt;/div&gt; Variable Interest Entities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;A variable interest entity (&amp;quot;VIE&amp;quot;) is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific&amp;#x2019;s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Milestone Scientific is the primary beneficiary of Milestone Education as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2016. &lt;/div&gt;Accordingly, the assets and liabilities of Milestone Education are included in the accompanying consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;Because Milestone Scientific had an increasing variable interest in Milestone China, it further considered the guidance in Accounting Standard Codification (&amp;quot;ASC&amp;quot;) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;810&lt;/div&gt; as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary. As Milestone China&amp;#x2019;s equity at risk and voting rights were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; proportional to their economic interest, Milestone China was determined to be a VIE. Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="margin-left:1.4%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="vertical-align:top;width:3.2%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td style="vertical-align:top;width:90.2%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;Power Criterion: The power to direct the activities that most significantly impact the entity&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2019;s economic performance; and&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="margin-left:1.4%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="vertical-align:top;width:3.3%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td style="vertical-align:top;width:90.2%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Milestone management does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the majority shareholder/CEO of Milestone China.&amp;nbsp; As majority shareholder, majority holder of voting rights, and the active CEO, the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;53%&lt;/div&gt; investor has the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; the primary beneficiary under ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;810.&lt;/div&gt; Accordingly, Milestone China has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been consolidated into the financial statements of Milestone Scientific and continues to be accounted for under the equity method.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.&lt;/div&gt; Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Milestone Scientific considers all highly liquid investments purchased with an original maturity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less to be cash equivalents.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt; Accounts Receivable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most of credit sales are due within &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ninety&lt;/div&gt; days from invoicing. There have &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been any significant credit losses incurred to date.&amp;nbsp;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;&amp;nbsp;Accounts receivable was recorded, net of allowance for doubtful accounts of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10,000&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;. Note Receivable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;Milestone Scientific values note receivable at historic cost less amount paid against principle. Milestone Scientific estimates losses on the note-based payments and credit quality of the debtor.&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;Product Return and Warranty&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Milestone Scientific generally does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; accept non-defective returns from its customers. Product returns under warranty are accepted, evaluated and repaired or replaced in accordance with the Warranty Policy. Returns &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; within the Warranty Policy are evaluated and the customer is charged for the repair.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt; Inventories&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Inventories principally consist of finished goods and component parts stated at the lower of cost (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-in, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess, slow moving, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence and product expiration requirements. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; inventory was recorded net of allowance for slow moving inventory of&amp;nbsp;approximately&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$220,000&lt;/div&gt;&amp;nbsp;as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017&amp;nbsp;&lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0&lt;/div&gt; as of&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt; Equity Method Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Investments in which Milestone Scientific can exercise significant influence, but do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; control, are accounted for under the equity method of accounting and are included in the long-term assets on the Consolidated Balance Sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the income tax line on the Consolidated Statements of Operations.&amp;nbsp;Milestone Scientific evaluates its equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt; Furniture, Fixture and Equipment&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from &lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt;&lt;/div&gt; to &lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;seven&lt;/div&gt;&lt;/div&gt; years. The costs of maintenance and repairs are charged to operations as incurred.&amp;nbsp; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; furniture, fixtures &amp;amp; equipment was&amp;nbsp;recorded net of accumulated depreciation of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$721,619&lt;/div&gt;&amp;nbsp;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$659,144&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; Intangible Assets &amp;#x2013; Patents and Developed Technology&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized at the estimated average useful life of the patent. These patents and developed technology are recorded at the acquisition cost.&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Patent defense costs, to the extent applicable, are expensed as incurred.&amp;nbsp; Patent applications filed, and patents obtained in foreign countries are subject to the laws and procedures that differ from those in the United States. Patent protection in foreign countries &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be different from patent protection under United States laws and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be favorable to Milestone Scientific. Milestone Scientific also attempts to protect the proprietary information using confidentiality agreements and by limiting access to its facilities. There can be &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; assurance that the program of patents, confidentiality agreements and restricted access to the facilities will be sufficient to protect the proprietary technology.&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp; &amp;nbsp; &amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12.&lt;/div&gt; Impairment of Long-Lived Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;Milestone Scientific has reviewed long-lived assets for any impairments. The carrying value of the assets is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets. Milestone Scientific adjusts the net book value of an underlying asset if its fair value is determined to be less than its net book value. There have been &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; impairment indicators or triggering events and therefore, there are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&amp;nbsp;impairments as of&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.&lt;/div&gt; Revenue Recognition&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; &amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Revenue from product sales is recognized, net of discounts and allowances to domestic distributors, on the date of shipment for substantially all shipments, since the shipment terms are FOB warehouse. Milestone Scientific recognizes revenue on date of arrival of the goods at the customer's location, where shipments are FOB destination. In all cases the price to the buyer is fixed and the collectability is reasonably assured. Further, Milestone Scientific has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&amp;nbsp;Devices and hand pieces are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; bundled but rather sold separately and, as such, there are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; multiple element determinations in connection with the revenue recognition. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;Milestone Scientific defers the total revenue and costs of goods sold when devices and handpieces are shipped to Milestone China and Milestone China&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2019;s agent due to market conditions and Milestone China liquidity concerns. Also, due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties, an elimination of the intra-entity profit is required as of the balance sheet date. In accordance with ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;323&lt;/div&gt; Equity Method and Joint Ventures, Milestone Scientific has deferred &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40%&lt;/div&gt; of the gross profit associated with recognized revenue from Milestone China that has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been sold to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14.&lt;/div&gt; Shipping and Handling Costs&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Milestone Scientific includes shipping and handling costs, if any, in cost of goods sold. These costs are paid by or billed to customers at the time of shipments. Domestic and international shipments are FOB warehouse; therefore, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; costs are incurred by Milestone Scientific.&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15.&lt;/div&gt; Research and Development&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Research and development costs, which consist principally of new product development costs payable to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties, are expensed as incurred. Advance payments for the research are amortized to expense either as services are performed or over the relevant service period using the straight-line method.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16.&lt;/div&gt; Income Taxes&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17.&lt;/div&gt; Basic and diluted net loss per common share&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Milestone Scientific presents &amp;#x201c;basic&amp;#x201d; earnings (loss) per common share applicable to common stockholders and, if applicable, &amp;#x201c;diluted&amp;#x201d; earnings (loss) per common share applicable to common stockholders pursuant to the provisions of Statement of Financial Accounting Standards ASC Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;260.&lt;/div&gt; Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options, warrants, and the conversion of debt were issued during the period.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Since Milestone Scientific had net losses for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the assumed effects of the exercise of potentially dilutive outstanding stock options and warrants were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; included in the calculation as their effect would have been anti-dilutive. Such outstanding options and warrants totaled&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,679,152&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,329,769&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18.&lt;/div&gt; Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates&lt;div style="display: inline; font-weight: bold;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19.&lt;/div&gt; Fair Value of Financial Instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Fair Value Measurements: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; of the following categories:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-indent: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;"&gt;&amp;#x25cf;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;"&gt;&amp;#x25cf;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; inputs which are defined as inputs other than quoted prices included within Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; that are observable for the assets or liabilities, either directly or indirectly.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;"&gt;&amp;#x25cf;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; inputs are defined as unobservable inputs for the assets or liabilities.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20.&lt;/div&gt; Stock-Based Compensation &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Milestone Scientific accounts for stock-based compensation under ASC Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718,&lt;/div&gt; Share-Based Payment. ASC Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt; requires all share-based payments to employees, including grants of employee stock options, to be recognized in the Statements of Operations over the service period, as an operating expense, based on the grant-date fair values. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. In accordance with the provisions of FASB ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;505,&lt;/div&gt; Milestone Scientific will re-measure the value of the grant at each presentation date unless there is a significant disincentive for non-performance or until performance has been rendered. For the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months end &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;Milestone Scientific recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$9,384&lt;/div&gt; income related to non-employee options. For the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months end &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2016, &lt;/div&gt;Milestone Scientific recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$25,346&lt;/div&gt; expense related to non-employee options.&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21.&lt;/div&gt; &lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Acc&lt;/div&gt;ounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2014, &lt;/div&gt;the Financial Accounting Standards Board (&amp;quot;FASB&amp;quot;) issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; steps: &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;) identify the contract, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;) identify performance obligations, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;) determine the transaction price, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;) allocate the transaction price, and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2015, &lt;/div&gt;the FASB issued guidance approving a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-year deferral, making the standard effective for reporting periods beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2017. &lt;/div&gt;The FASB continues to release guidance clarifying certain aspects of the revenue guidance. We do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; believe that this new accounting pronouncement will have a material impact on our financial statements.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016, &lt;/div&gt;the FASB issued a new standard Accounting Standards Update (&amp;quot;ASU &amp;quot;) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; &amp;quot;Leases&amp;quot;(Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;). The new standard is intended to increase transparency and comparability among organizations to recognize lease assets and liabilities on the balance sheet and disclose key information about leasing arrangements. It will be effective for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018. &lt;/div&gt;Milestone Scientific is in the process of determining what impact, the adoption of this ASU will have on its financial position, results of operations and cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2016, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,&lt;/div&gt; &amp;#x201c;Financial Instruments &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2013; Credit Losses&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;326&lt;/div&gt;).: The new standard is intended to replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. It will be effective for all entities for fiscal years and interim periods, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018. &lt;/div&gt;Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 2016, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,&lt;/div&gt; &amp;quot;Statement Cash Flows &amp;#x201c;Classification of Certain Cash Receipts and Cash Disbursements&amp;quot; Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;230&lt;/div&gt;). The new standard provides guidance as to the conformity of presentation of certain cash receipts and disbursements. It will be effective for all entities for fiscal years and interim periods, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2017. &lt;/div&gt;Milestone Scientific does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; anticipate the adoption of this ASU will have a significant impact on its presentation within the statement of cash flows.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 2016, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,&lt;/div&gt; &amp;#x201c;Statement of Cash Flows &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2013; Restricted Cash&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;230&lt;/div&gt;). The new standard provides guidance as to address the diversity of treatment of restricted cash on the statement of cash flows. It will be effective for all entities for fiscal years and interim periods, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2017 &lt;/div&gt;and interim periods therein. Milestone Scientific does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect the adoption of this ASU to have a material effect on its presentation within the statement of cash flows.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2017, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09,&lt;/div&gt; &amp;#x201c;Compensation &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2013; Stock Compensation&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718&lt;/div&gt;). The new standard provides guidance and clarity for modification to equity-based compensation programs. It will be effective for all entities for fiscal years and interim periods, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2017. &lt;/div&gt;Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its presentation within the statement of cash flows.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2017, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,&lt;/div&gt; &amp;#x201c;Earnings Per Share&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;260&lt;/div&gt;), &amp;#x201c;Distinguishing Liabilities from Equity&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;480&lt;/div&gt;), &amp;#x201c;Derivatives and Hedging&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;815&lt;/div&gt;). The new standard provides guidance relating to equity-linked instruments that include certain features. It will be effective for public entities for fiscal years and interim periods, beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018. &lt;/div&gt;Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its presentation within the statement of cash flows.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 2017, &lt;/div&gt;the FASB issued a new standard ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,&lt;/div&gt; &amp;#x201c;Income Statement &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2013; Reporting Comprehensive Income&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;815&lt;/div&gt;), &amp;#x201c;Revenue Recognition&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;605&lt;/div&gt;) and &amp;#x201c;Revenue from Contracts with Customers&amp;#x201d; (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;606&lt;/div&gt;). The new standard provides guidance in these areas pursuant to certain SEC Staff Accounting Bulletin and Release, as they relate to the presentation of revenue recognition matters on the statement of comprehensive income.&amp;nbsp; It will be effective for public entities concurrent with the effectuation of other revenue recognition standards. Milestone Scientific does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; anticipate the adoption of this ASU to have a significant impact on its presentation within the statement of comprehensive income.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StandardProductWarrantyPolicy contextRef="d_2017-01-01_2017-12-31" id="c29255641">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;Product Return and Warranty&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Milestone Scientific generally does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; accept non-defective returns from its customers. Product returns under warranty are accepted, evaluated and repaired or replaced in accordance with the Warranty Policy. Returns &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; within the Warranty Policy are evaluated and the customer is charged for the repair.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StandardProductWarrantyPolicy>
  <us-gaap:StockIssued1 contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243847" unitRef="iso4217-usd">2486000</us-gaap:StockIssued1>
  <us-gaap:StockIssued1 contextRef="d_2016-01-01_2016-12-31" id="c29243848" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243583" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243585" unitRef="xbrli-shares">31053</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243601" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243603" unitRef="xbrli-shares">270526</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243691" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243693" unitRef="xbrli-shares">410729</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2016-07-01_2016-07-31" decimals="INF" id="c29244243" unitRef="xbrli-shares">104200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2016-12-01_2016-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29244249" unitRef="xbrli-shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-01-01_2017-01-31_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" decimals="INF" id="c29244258" unitRef="xbrli-shares">123700</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2014-05-01_2014-05-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29244269" unitRef="xbrli-shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2014-05-01_2014-05-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29244272" unitRef="xbrli-shares">7000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" id="c29243619" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29243621" unitRef="xbrli-shares">1104200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" id="c29243628" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29243630" unitRef="xbrli-shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" id="c29243736" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29243738" unitRef="xbrli-shares">123700</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="d_2017-07-13_2017-07-13_CounterpartyNameAxis-APADOctrooiBVAndAPADBVMember" decimals="INF" id="c29244200" unitRef="xbrli-shares">1646358</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243709" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243711" unitRef="xbrli-shares">1646358</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243574" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243576" unitRef="xbrli-shares">14181</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243673" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243675" unitRef="xbrli-shares">10913</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244352" unitRef="xbrli-shares">327778</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29244372" unitRef="xbrli-shares">83333</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244404" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember" id="c29244420" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243592" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243594" unitRef="xbrli-shares">327778</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243682" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243684" unitRef="xbrli-shares">83333</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243584" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243586" unitRef="iso4217-usd">31</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243587" unitRef="iso4217-usd">58969</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243588" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243589" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243590" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243591" unitRef="iso4217-usd">59000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243602" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243604" unitRef="iso4217-usd">263</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243605" unitRef="iso4217-usd">504150</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243606" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243607" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243608" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243609" unitRef="iso4217-usd">504413</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243692" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243694" unitRef="iso4217-usd">419</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243695" unitRef="iso4217-usd">548092</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243696" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243697" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243698" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243699" unitRef="iso4217-usd">548511</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" id="c29243620" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29243622" unitRef="iso4217-usd">1104</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29243623" unitRef="iso4217-usd">2223896</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" id="c29243624" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" id="c29243625" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" id="c29243626" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29243627" unitRef="iso4217-usd">2225000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" id="c29243629" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29243631" unitRef="iso4217-usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29243632" unitRef="iso4217-usd">2571220</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" id="c29243633" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" id="c29243634" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" id="c29243635" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-01-01_2016-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29243636" unitRef="iso4217-usd">2573220</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" id="c29243737" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29243739" unitRef="iso4217-usd">124</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29243740" unitRef="iso4217-usd">150712</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" id="c29243741" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" id="c29243742" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" id="c29243743" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2017-01-01_2017-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" decimals="INF" id="c29243744" unitRef="iso4217-usd">150836</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="d_2017-07-13_2017-07-13_CounterpartyNameAxis-APADOctrooiBVAndAPADBVMember" decimals="INF" id="c29244201" unitRef="iso4217-usd">2486000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243710" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243712" unitRef="iso4217-usd">1646</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243713" unitRef="iso4217-usd">2484354</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243714" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243715" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243716" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243717" unitRef="iso4217-usd">2486000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29244240" unitRef="iso4217-usd">1000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243575" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243577" unitRef="iso4217-usd">14</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243578" unitRef="iso4217-usd">29986</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243579" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243580" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243581" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243582" unitRef="iso4217-usd">30000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243674" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243676" unitRef="iso4217-usd">11</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243677" unitRef="iso4217-usd">14989</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243678" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243679" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243680" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243681" unitRef="iso4217-usd">15000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243593" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243595" unitRef="iso4217-usd">328</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243596" unitRef="iso4217-usd">137172</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243597" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243598" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243599" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243600" unitRef="iso4217-usd">137500</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" id="c29243683" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243685" unitRef="iso4217-usd">83</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243686" unitRef="iso4217-usd">62417</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243687" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" id="c29243688" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243689" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243690" unitRef="iso4217-usd">62500</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31" decimals="INF" id="c29243441" unitRef="iso4217-usd">7243884</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31" decimals="INF" id="c29243442" unitRef="iso4217-usd">8500223</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2017-12-31" decimals="INF" id="c29243445" unitRef="iso4217-usd">7500628</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2016-12-31" decimals="INF" id="c29243446" unitRef="iso4217-usd">8536329</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c29243548" unitRef="iso4217-usd">7</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243550" unitRef="iso4217-usd">22685</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243551" unitRef="iso4217-usd">78632383</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c29243552" unitRef="iso4217-usd">-67434984</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" decimals="INF" id="c29243553" unitRef="iso4217-usd">-1143083</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_StatementEquityComponentsAxis-TreasuryStockMember" decimals="INF" id="c29243554" unitRef="iso4217-usd">-911516</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31" decimals="INF" id="c29243555" unitRef="iso4217-usd">9165492</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-PreferredStockMember" id="c29243557" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-CommonStockMember" id="c29243559" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" id="c29243560" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-RetainedEarningsMember" id="c29243561" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-NoncontrollingInterestMember" decimals="INF" id="c29243562" unitRef="iso4217-usd">16346</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-TreasuryStockMember" id="c29243563" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember" decimals="INF" id="c29243564" unitRef="iso4217-usd">16346</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c29243656" unitRef="iso4217-usd">7</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243658" unitRef="iso4217-usd">31720</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243659" unitRef="iso4217-usd">82761503</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c29243660" unitRef="iso4217-usd">-73381491</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" decimals="INF" id="c29243661" unitRef="iso4217-usd">36106</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember" decimals="INF" id="c29243662" unitRef="iso4217-usd">-911516</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c29243755" unitRef="iso4217-usd">7</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29243757" unitRef="iso4217-usd">34593</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29243758" unitRef="iso4217-usd">86689084</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c29243759" unitRef="iso4217-usd">-78568284</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" decimals="INF" id="c29243760" unitRef="iso4217-usd">256744</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember" decimals="INF" id="c29243761" unitRef="iso4217-usd">-911516</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848181">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:-7.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;NOTE K&amp;nbsp;&amp;#x2014; STOCKHOLDERS&amp;#x2019; EQUITY&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;ISSUANCES COMMON STOCK &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2016, &lt;/div&gt;Milestone Scientific raised an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.0&lt;/div&gt; million of gross proceeds in a private placement of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one million&lt;/div&gt; shares of common stock, at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.00&lt;/div&gt; per share, to the same investors that participated in the&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;May 2014 &lt;/div&gt;Financing.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 2016, &lt;/div&gt;Milestone Scientific raised gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$250,000&lt;/div&gt; in a registered direct offering of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;104,200&lt;/div&gt; shares of common stock at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.40&lt;/div&gt; per share. The transaction was covered by the prospectus supplement, filed with the United States Securities and Exchange Commission (&amp;quot;SEC) on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; July 22, 2016, &lt;/div&gt;to our shelf registration statement on Form S-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; (SEC File &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.:&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;333&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;209466&lt;/div&gt;).&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2016, &lt;/div&gt;Milestone Scientific completed an underwritten public offering of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,000,000&lt;/div&gt; shares of common stock and warrants to purchase up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,592,775&lt;/div&gt; shares of common stock, including &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;92,775&lt;/div&gt; additional warrants pursuant to a partial exercise of the over-allotment option granted to the underwriters. Each share of common stock was sold in combination with a warrant to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.75&lt;/div&gt; shares of common stock. The public offering price for each share and related &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;.75&lt;/div&gt; share warrant was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.50&lt;/div&gt; for gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,000,000.&lt;/div&gt; The warrants have a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;-year term and an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.55&lt;/div&gt; per share.&amp;nbsp; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2017, &lt;/div&gt;the underwriter&amp;nbsp;exercised a portion of&amp;nbsp;its over-allotment option to purchase an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;123,700&lt;/div&gt; shares of common stock at the public offering price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.499&lt;/div&gt; per share for gross proceeds of&amp;nbsp;approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$186,000.&lt;/div&gt; The gross proceeds from this offering, including proceeds from partial exercises of the over-allotment option, were approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3,200,000,&lt;/div&gt; before deducting underwriting discounts and commissions and other offering expenses of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4461,493.&lt;/div&gt;&amp;nbsp;&amp;nbsp;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2017, &lt;/div&gt;the underwriter exercised a portion of its over-allotment option&amp;nbsp;and purchased an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;123,700&lt;/div&gt; shares of common stock at the public offering price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.499&lt;/div&gt; per share. The gross proceeds were approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$186,000&lt;/div&gt; before deducting underwriting discounts and commissions and other offering expenses.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;PREFERRED STOCK&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May &lt;/div&gt;of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014,&lt;/div&gt; Milestone completed a private placement, which raised gross proceeds in the total of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10&lt;/div&gt; million, from the sale of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3&lt;/div&gt; million of Milestone Scientific common stock (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two million&lt;/div&gt; shares at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.50&lt;/div&gt; per share) and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7&lt;/div&gt; million of our Series A Convertible Preferred Stock (&amp;quot;preferred stock&amp;quot;) (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,000&lt;/div&gt; shares at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,000&lt;/div&gt; per share), convertible into common stock at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.37&lt;/div&gt; per share (as adjusted to date) on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 14, 2019, &lt;/div&gt;or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.50&lt;/div&gt; per share unless certain conditions are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; met both subject to anti-dilution adjustment.&amp;nbsp;The conversion ratio adjustment becomes effective if anyone of a number of triggering events occur such as; issuance of stock dividends or distributions, subdivisions, splits, issuance of stock purchase rights, debt and distributions, cash dividends or distributions, self-tender offers and exchange offers, rights plans and issuances below the conversion price, as defined in the Investment Agreement.&amp;nbsp;Generally, each share of preferred stock entitles the holder to vote together with the holders of Milestone Scientific common stock, as a single class, on all matters submitted for the approval of the holders of Milestone Scientific common stock and has the number of votes equal to the number of shares of our common stock into which they are then convertible.&amp;nbsp; In addition, preferred stock is also entitled to share, pair pass, in any cash dividends declared on Milestone Scientific common stock on as converted basis.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold; font-size: 10pt;"&gt;SH&lt;div style="display: inline; font-size: 10pt;"&gt;ARES TO BE ISSUED&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; there were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,401,247&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,270,481&lt;/div&gt; shares, respectively, whose issuance has been deferred under the terms of an employment agreements with the Chief Executive Officer, Chief Financial Officer and other employees of Milestone Scientific. Such shares will be issued to each party upon termination of their employment. The number of shares was fixed at the date of grant and were fully vested upon grant date.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;SHARES RESERVED FOR FUTURE ISSUANCE&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; there were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,111,582&lt;/div&gt;&amp;nbsp;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,600,250&lt;/div&gt; shares reserved for future issuance and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,710,335&lt;/div&gt;&amp;nbsp;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,329,769&lt;/div&gt; shares underlying other stock options and warrants outstanding, respectively. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; there were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,401,247&lt;/div&gt; shares and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,270,481&lt;/div&gt; shares, respectively, reserved for issuance in settlement of deferred compensation to officers of Milestone Scientific. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848198">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;T&amp;nbsp;&amp;#x2014; SUBSEQUENT EVENTS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2018 the Company&amp;nbsp;&lt;/div&gt;entered into a purchase commitment for the delivery of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,000&lt;/div&gt; instruments beginning in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3rd&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; the Company&amp;#x2019;s purchase commitment for this purchase order was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,397,440.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 2, 2018, &lt;/div&gt;the Note Receivable identified on the Balance Sheet&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;was in default. If Milestone Scientific exercises its rights as a secured party it &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be obligated to return to the purchaser up to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$250,000&lt;/div&gt; received for the Milestone China Shares as surplus. At this time Milestone Scientific has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; received a response from the purchaser of the Milestone China Shares, Milestone Scientific has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; recorded any financial benefit from the sale of Milestone China Shares to date.&amp;nbsp;&lt;/div&gt; &lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848168">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE B- LIQUIDITY&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;AND UNCERTAINTIES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;In accordance with ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;205&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40,&lt;/div&gt; Going Concern, the Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year after the date that the consolidated financial statements are issued. Milestone Scientific has incurred operating losses and negative cash flows from operating activities in virtually each year&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;since its inception. The capital raised in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2016 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2017 &lt;/div&gt;provided Milestone Scientific with working capital to continue to develop its medical devices and obtain regulatory approval for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; of its medical devices (the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2017 &lt;/div&gt;FDA approval of the epidural device), as well as to market its dental devices. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States&amp;nbsp;(following &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2017 &lt;/div&gt;FDA approval of its &lt;div style="display: inline; font-style: italic;"&gt;CompuFlo&lt;/div&gt;&amp;reg; Epidural Computer Controlled Anesthesia System (&amp;quot;Epidural&amp;quot;) and worldwide, and a&amp;nbsp;reduction in operating expenses. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;Management believes that Milestone Scientific will have sufficient cash reserves to meet its anticipated obligations over the next &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt; months from the filing of this form &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10K.&lt;/div&gt; However, Milestone Scientific will likely need to raise additional capital prior to the expected generation of sustainable positive cash flow from operating activities and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;also need to raise additional capital to effectively launch its approved Epidural Device and eventually generate positive cash flow from the anticipated medical business.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;The Company is subject to several risks similar to those of development stage companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital necessary to fund the development of its products, competition from larger companies, and other medical device companies that develop similar or substitute products. The Company's sales performance, selling and marketing expenditures to develop sales performance, as well as the status of each of its new product development programs and the resulting operating income (loss), will significantly impact its cash requirements.&lt;/div&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
  <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="d_2017-01-01_2017-12-31" id="c29255639">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt; Accounts Receivable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most of credit sales are due within &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ninety&lt;/div&gt; days from invoicing. There have &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been any significant credit losses incurred to date.&amp;nbsp;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;&amp;nbsp;Accounts receivable was recorded, net of allowance for doubtful accounts of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10,000&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <us-gaap:TreasuryStockShares contextRef="i_2017-12-31" decimals="INF" id="c29243439" unitRef="xbrli-shares">33333</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockShares contextRef="i_2016-12-31" decimals="INF" id="c29243440" unitRef="xbrli-shares">33333</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockValue contextRef="i_2017-12-31" decimals="INF" id="c29243437" unitRef="iso4217-usd">911516</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValue contextRef="i_2016-12-31" decimals="INF" id="c29243438" unitRef="iso4217-usd">911516</us-gaap:TreasuryStockValue>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2017-12-31" decimals="INF" id="c29244526" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2016-12-31" decimals="INF" id="c29244527" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29244528" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29244529" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UseOfEstimates contextRef="d_2017-01-01_2017-12-31" id="c29255659">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18.&lt;/div&gt; Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates&lt;div style="display: inline; font-weight: bold;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="d_2017-01-01_2017-12-31_ValuationAllowanceByDeferredTaxAssetAxis-DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" decimals="INF" id="c29244515" unitRef="iso4217-usd">-8677000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848174">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;G&amp;nbsp;&amp;#x2013; CONSOLIDATION OF VARIABLE INTEREST ENTITY&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/div&gt;&lt;/div&gt;Milestone Education is a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; owned subsidiary of Milestone Scientific which began operations in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2013&lt;/div&gt; to provide training and education to dentists throughout the world. Approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;81%&lt;/div&gt; of the revenue earned by Milestone Education is from services performed for Milestone Scientific as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; Because of this dependency and relationship, we determined that we had the power to direct the activities that most significantly impact Milestone Education's economic performance, and therefore Milestone Education is consolidated in our financial statements.&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;nbsp; &lt;/div&gt;&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
  <us-gaap:VariableInterestEntityOwnershipPercentage contextRef="d_2017-01-01_2017-12-31_VariableInterestEntitiesByClassificationOfEntityAxis-MilestoneEducationLLCMember" decimals="2" id="c29244062" unitRef="xbrli-pure">0.5</us-gaap:VariableInterestEntityOwnershipPercentage>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243499" unitRef="xbrli-shares">32703897</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243500" unitRef="xbrli-shares">26966988</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29243497" unitRef="xbrli-shares">32703897</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29243498" unitRef="xbrli-shares">26966988</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="utr-sqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="d_2004-07-01_2004-07-31_PlanNameAxis-StockOptionPlan2004Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:StockOptionPlan2004Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2004-07-01</xbrli:startDate>
      <xbrli:endDate>2004-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2005-01-01_2005-01-01">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2005-01-01</xbrli:startDate>
      <xbrli:endDate>2005-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2005-01-01_2005-01-01_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:DirectorOfClinicalAffairsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2005-01-01</xbrli:startDate>
      <xbrli:endDate>2005-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2009-09-01_2009-09-01_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-09-01</xbrli:startDate>
      <xbrli:endDate>2009-09-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2009-09-01_2009-09-01_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-09-01</xbrli:startDate>
      <xbrli:endDate>2009-09-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-06-01_2011-06-30_PlanNameAxis-StockOptionPlan2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:StockOptionPlan2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-05-01_2014-05-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-01</xbrli:startDate>
      <xbrli:endDate>2014-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-05-01_2014-05-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mlss:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-01</xbrli:startDate>
      <xbrli:endDate>2014-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-05-01_2014-05-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-05-01</xbrli:startDate>
      <xbrli:endDate>2014-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-06-01_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-06-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-NonEmployeeOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:NonEmployeeOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-OptionsAndWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mlss:OptionsAndWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:NonEmployeeOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsReceivableFromRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneEducationLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mlss:CustomerOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mlss:CustomerTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoCustomersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mlss:TwoCustomersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-MaterialReconcilingItemsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_LegalEntityAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ProductOrServiceAxis-InstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mlss:InstrumentsAndHandpiecesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ConsultingServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AdvancedOcularSciencesSAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:AdvancedOcularSciencesSAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementGeographicalAxis-CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementGeographicalAxis-DomesticMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementGeographicalAxis-RestOfWorldMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:DirectorOfClinicalAffairsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2016-03-31_ProductOrServiceAxis-InstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-06-01_2016-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-06-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-06-01_2016-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-06-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-07-01_2016-07-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>
      <xbrli:endDate>2016-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-08-01_2016-08-31_RelatedPartyTransactionAxis-ConsultingServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ConsultingServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-08-01</xbrli:startDate>
      <xbrli:endDate>2016-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-12-01_2016-12-01_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>
      <xbrli:endDate>2016-12-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-12-01_2016-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-12-01_2017-01-31_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>
      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-01-31_ProductOrServiceAxis-InstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-01-31_RelatedPartyTransactionAxis-ConsultingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-InnovestSpAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ConsultingServicesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mlss:InnovestSpAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-01-31_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-07-31_AwardTypeAxis-NonqualifiedStockOptionsMember_PlanNameAxis-StockOptionPlan2011Member_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:NonqualifiedStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:StockOptionPlan2011Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-OptionsAndWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mlss:OptionsAndWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:NonEmployeeOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsReceivableFromRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mlss:CustomerOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mlss:CustomerTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueGoodsNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-TwoCustomersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mlss:TwoCustomersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-MaterialReconcilingItemsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember_RangeAxis-WeightedAverageMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_LegalEntityAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ProductOrServiceAxis-InstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mlss:InstrumentsAndHandpiecesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ConsultingServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_RelatedPartyTransactionAxis-ConsultingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-InnovestSpAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ConsultingServicesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mlss:InnovestSpAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-DomesticMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-DomesticMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember_StatementGeographicalAxis-RestOfWorldMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementGeographicalAxis-CN">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementGeographicalAxis-DomesticMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:DomesticMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementGeographicalAxis-RestOfWorldMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mlss:RestOfWorldMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementGeographicalAxis-US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_TaxPeriodAxis-EarliestTaxYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_TaxPeriodAxis-LatestTaxYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_TitleOfIndividualAxis-DirectorOfClinicalAffairsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:DirectorOfClinicalAffairsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ValuationAllowanceByDeferredTaxAssetAxis-DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">mlss:DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_VariableInterestEntitiesByClassificationOfEntityAxis-MilestoneEducationLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">mlss:MilestoneEducationLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-06-01_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>
      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-06-01_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">mlss:SaleOfVariableInterestEntitysSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>
      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-07-31_AwardTypeAxis-NonqualifiedStockOptionsMember_PlanNameAxis-StockOptionPlan2011Member_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:NonqualifiedStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:StockOptionPlan2011Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-GianDomenicoTrombettaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:GianDomenicoTrombettaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-07-31_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:PreviousPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-12-31_TitleOfIndividualAxis-GianDomenicoTrombettaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:GianDomenicoTrombettaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-07_2017-07-07_AwardTypeAxis-EmployeeStockOptionsIssuedAt255PerShareMember_TitleOfIndividualAxis-GianDomenicoTrombettaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:EmployeeStockOptionsIssuedAt255PerShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:GianDomenicoTrombettaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-07</xbrli:startDate>
      <xbrli:endDate>2017-07-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-07_2017-07-07_AwardTypeAxis-EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember_TitleOfIndividualAxis-GianDomenicoTrombettaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:GianDomenicoTrombettaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-07</xbrli:startDate>
      <xbrli:endDate>2017-07-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-13_2017-07-13_CounterpartyNameAxis-APADOctrooiBVAndAPADBVMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mlss:APADOctrooiBVAndAPADBVMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-13</xbrli:startDate>
      <xbrli:endDate>2017-07-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-13_2017-07-13_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-13</xbrli:startDate>
      <xbrli:endDate>2017-07-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-10-02_2017-10-02_TitleOfIndividualAxis-FormerCeoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:FormerCeoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-10-02</xbrli:startDate>
      <xbrli:endDate>2017-10-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-10-05_2017-10-05_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-10-05</xbrli:startDate>
      <xbrli:endDate>2017-10-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-09_2017-12-09_TitleOfIndividualAxis-InterimChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:InterimChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-09</xbrli:startDate>
      <xbrli:endDate>2017-12-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-01-31_ProductOrServiceAxis-InstrumentsMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementScenarioAxis-ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-02-01_2018-02-28_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-FormerCeoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:FormerCeoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-02-01</xbrli:startDate>
      <xbrli:endDate>2018-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-03-01_2018-03-31_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-FormerCeoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:FormerCeoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2004-07-31_PlanNameAxis-StockOptionPlan2004Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:StockOptionPlan2004Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2004-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2009-09-01_RangeAxis-MaximumMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-09-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-05-31_ConversionOfStockByUniqueDescriptionAxis-ConversionPriceIfCertainConditionsAreNotMetMember_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mlss:ConversionPriceIfCertainConditionsAreNotMetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mlss:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-05-31_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mlss:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-05-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AwardTypeAxis-NonEmployeeOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:NonEmployeeOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AdvancedOcularSciencesSAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:AdvancedOcularSciencesSAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneEducationLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneEducationLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneEducationLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneEducationLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneEducationLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneEducationLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneEducationLLCMember_StatementEquityComponentsAxis-TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneEducationLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-04-30_PlanNameAxis-StockOptionPlan2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:StockOptionPlan2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-05-31_PlanNameAxis-StockOptionPlan2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:StockOptionPlan2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-07-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AwardTypeAxis-NonEmployeeOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:NonEmployeeOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AwardTypeAxis-OtherStockOptionsAndWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:OtherStockOptionsAndWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsReceivableFromRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-EpiduralapadPatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mlss:EpiduralapadPatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mlss:FoundationIntellectualPropertyPatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_LegalEntityAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ProductOrServiceAxis-InstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mlss:InstrumentsAndHandpiecesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ProductOrServiceAxis-InstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ProductOrServiceAxis-STAInstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mlss:STAInstrumentsAndHandpiecesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ComputerAndSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:EPIAndIAInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:STATrialsInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingEquipmentSTAAndWandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingSafetyWandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:TradeShowDisplaysMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-WebsiteMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:WebsiteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mlss:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-01-31_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-05-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">mlss:SaleOfVariableInterestEntitysSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">mlss:SaleOfVariableInterestEntitysSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-10-02_TitleOfIndividualAxis-FormerCeoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:FormerCeoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-10-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_AwardTypeAxis-NonEmployeeOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:NonEmployeeOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_AwardTypeAxis-OtherStockOptionsAndWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mlss:OtherStockOptionsAndWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_BalanceSheetLocationAxis-AccountsReceivableFromRelatedPartiesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mlss:AccountsReceivableFromRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ConsolidationItemsAxis-CorporateNonSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-DentalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_StatementBusinessSegmentsAxis-MedicalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_CounterpartyNameAxis-APADOctrooiBVAndAPADBVMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mlss:APADOctrooiBVAndAPADBVMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-EpiduralapadPatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mlss:EpiduralapadPatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-FoundationIntellectualPropertyPatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">mlss:FoundationIntellectualPropertyPatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_LegalEntityAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PlanNameAxis-StockOptionPlan2004Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mlss:StockOptionPlan2004Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ProductOrServiceAxis-InstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mlss:InstrumentsAndHandpiecesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ProductOrServiceAxis-InstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mlss:InstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ProductOrServiceAxis-STAInstrumentsAndHandpiecesMember_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">mlss:STAInstrumentsAndHandpiecesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerAndSoftwareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ComputerAndSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-EPIAndIAInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:EPIAndIAInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeFurnitureAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-STATrialsInstrumentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:STATrialsInstrumentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingEquipmentSTAAndWandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingEquipmentSTAAndWandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingSafetyWandMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:ToolingSafetyWandMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolsDiesAndMoldsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-TradeShowDisplaysMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:TradeShowDisplaysMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-WebsiteMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mlss:WebsiteMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_RelatedPartyTransactionAxis-ManufacturingAgreementForHandpiecesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mlss:ManufacturingAgreementForHandpiecesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-AdvancedOcularSciencesSAMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:AdvancedOcularSciencesSAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementBusinessSegmentsAxis-DentalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:DentalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementBusinessSegmentsAxis-MedicalSegmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mlss:MedicalSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_TitleOfIndividualAxis-ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mlss:ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_VariableInterestEntitiesByClassificationOfEntityAxis-MilestoneEducationLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">mlss:MilestoneEducationLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-02_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-MilestoneChinaMember_StatementScenarioAxis-UponExerciseOfDefaultAgreementMember_SubsequentEventTypeAxis-SubsequentEventMember_TransactionTypeAxis-SaleOfVariableInterestEntitysSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">mlss:MilestoneChinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">mlss:UponExerciseOfDefaultAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">mlss:SaleOfVariableInterestEntitysSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000855683</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>mlss-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 10:48PM UTC 2018-03-30--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mlss="http://www.milestonescientific.com/20171231" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.milestonescientific.com/20171231">
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mlss-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mlss-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mlss-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mlss-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.milestonescientific.com/20171231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations" roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statement-of-changes-in-stockholders-equity" roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-statement-of-changes-in-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statement of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-a-organization-and-business" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note A - Organization and Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-b-liquidity-and-uncertainties" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-b-liquidity-and-uncertainties">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note B - Liquidity and Uncertainties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-c-summary-of-significant-accounting-policies" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note C - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-d-notes-receivable" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note D - Notes Receivable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-e-inventories" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note E - Inventories</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-f-advances-on-contracts" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note F - Advances on Contracts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-g-consolidation-of-variable-interest-entity" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note G - Consolidation of Variable Interest Entity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-h-investment-in-unconsolidated-subsidiaries" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note H - Investment in Unconsolidated Subsidiaries</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-i-furniture-fixtures-and-equipment" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note I - Furniture, Fixtures and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-j-patents" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note J - Patents</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-k-stockholders-equity" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note K - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-l-stock-option-plans" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note L - Stock Option Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-m-employment-contract-and-consulting-agreements" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note M - Employment Contract and Consulting Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-n-income-taxes" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note N - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-o-segment-and-geographic-data" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note O - Segment and Geographic Data</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-p-concentration" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-p-concentration">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note P - Concentration</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-q-related-party-transzactions" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note Q - Related Party Transzactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-r-commitments-and-other" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note R - Commitments and Other</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-s-pension-plan" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-s-pension-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Document - Note S - Pension Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-t-subsequent-events" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note T - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.milestonescientific.com/20171231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-e-inventories-tables" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note E - Inventories (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-h-investment-in-unconsolidated-subsidiaries-tables" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note H - Investment in Unconsolidated Subsidiaries (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-i-furniture-fixtures-and-equipment-tables" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note I - Furniture, Fixtures and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-j-patents-tables" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note J - Patents (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-l-stock-option-plans-tables" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note L - Stock Option Plans (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-n-income-taxes-tables" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note N - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-o-segment-and-geographic-data-tables" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note O - Segment and Geographic Data (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-r-commitments-and-other-tables" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note R - Commitments and Other (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-a-organization-and-business-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note A - Organization and Business (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-c-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note C - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-d-notes-receivable-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note D - Notes Receivable (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-e-inventories-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note E - Inventories (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-e-inventories-summary-of-inventories-details" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-summary-of-inventories-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note E - Inventories - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-f-advances-on-contracts-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note F - Advances on Contracts (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-g-consolidation-of-variable-interest-entity-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note G - Consolidation of Variable Interest Entity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-h-investment-in-unconsolidated-subsidiaries-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note H - Investment in Unconsolidated Subsidiaries (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note H - Investment in Unconsolidated Subsidiaries - Summarized Financial Information (Unaudited) of Milestone China (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-i-furniture-fixtures-and-equipment-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note I - Furniture, Fixtures and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note I - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-j-patents-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note J - Patents (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-j-patents-summary-of-patents-details" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-summary-of-patents-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note J - Patents - Summary of Patents (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-k-stockholders-equity-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note K - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-l-stock-option-plans-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note L - Stock Option Plans (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note L - Stock Option Plans - Summary of Option Activity for Employees and Non-employees (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note L - Summary of Significant Accounting Policies - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-m-employment-contract-and-consulting-agreements-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note M - Employment Contract and Consulting Agreements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-n-income-taxes-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note N - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-n-income-taxes-deferred-tax-assets-details" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-deferred-tax-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note N - Income Taxes - Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note N - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-o-segment-and-geographic-data-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">056 - Disclosure - Note O - Segment and Geographic Data (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">057 - Disclosure - Note O - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">058 - Disclosure - Note O - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-p-concentration-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-p-concentration-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">059 - Disclosure - Note P - Concentration (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-q-related-party-transzactions-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">060 - Disclosure - Note Q - Related Party Transzactions (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-r-commitments-and-other-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">061 - Disclosure - Note R - Commitments and Other (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">062 - Disclosure - Note R - Commitments and Other - Aggregate Minimum Rental Commitments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-t-subsequent-events-details-textual" roleURI="http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">063 - Disclosure - Note T - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="mlss_APADOctrooiBVAndAPADBVMember" name="APADOctrooiBVAndAPADBVMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_AccountsReceivableFromRelatedPartiesMember" name="AccountsReceivableFromRelatedPartiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology" name="AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology" name="AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_AdvancedOcularSciencesSAMember" name="AdvancedOcularSciencesSAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_AdvancesToContractManufacturerTextBlock" name="AdvancesToContractManufacturerTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_AreaOfOfficeSpace" name="AreaOfOfficeSpace" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_AssetPurchaseAgreementPaymentsOfLegalFees" name="AssetPurchaseAgreementPaymentsOfLegalFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum" name="AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities" name="AssetPurchaseAgreementPostclosingAdjustmentsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum" name="AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod" name="ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" name="ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod" name="ChiefExecutiveOfficerEmploymentAgreementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ClassOfWarrantOrRightExpirationPeriod" name="ClassOfWarrantOrRightExpirationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ComputerAndSoftwareMember" name="ComputerAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ConsolidationOfVariableInterestEntity" name="ConsolidationOfVariableInterestEntity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ConsultingAgreementAnnualPayment" name="ConsultingAgreementAnnualPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ConsultingAgreementTerm" name="ConsultingAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ConsultingServicesAgreementTerm" name="ConsultingServicesAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ConsultingServicesMember" name="ConsultingServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ConversionPriceIfCertainConditionsAreNotMetMember" name="ConversionPriceIfCertainConditionsAreNotMetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_CustomerOneMember" name="CustomerOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_CustomerTwoMember" name="CustomerTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_DeferredGainOnDisposalOfInvestment" name="DeferredGainOnDisposalOfInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="mlss_DeferredProfitRelatedPartiesCurrent" name="DeferredProfitRelatedPartiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" name="DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017" name="DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" name="DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_DefineBenefitPlanPaymentPeriod" name="DefineBenefitPlanPaymentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_DentalSegmentMember" name="DentalSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_DirectorOfClinicalAffairsMember" name="DirectorOfClinicalAffairsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_DomesticMember" name="DomesticMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_EPIAndIAInstrumentsMember" name="EPIAndIAInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" name="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmployeeResignationAssertionBasicSalaryForOneYear" name="EmployeeResignationAssertionBasicSalaryForOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmployeeResignationAssertionCarAllowanceForOneYear" name="EmployeeResignationAssertionCarAllowanceForOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmployeeResignationAssertionGrossSettlement" name="EmployeeResignationAssertionGrossSettlement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear" name="EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmployeeResignationAssertionNumberOfOptionsVested" name="EmployeeResignationAssertionNumberOfOptionsVested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmployeeResignationAssertionOptionsExercisePrice" name="EmployeeResignationAssertionOptionsExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="mlss_EmployeeResignationAssertionPayment" name="EmployeeResignationAssertionPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmployeeResignationAssertionVestingTermAfterResignation" name="EmployeeResignationAssertionVestingTermAfterResignation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_EmployeeStockOptionsIssuedAt255PerShareMember" name="EmployeeStockOptionsIssuedAt255PerShareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" name="EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmploymentAgreementBaseCompensation" name="EmploymentAgreementBaseCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmploymentAgreementBaseCompensationCash" name="EmploymentAgreementBaseCompensationCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmploymentAgreementBaseCompensationCommonStockValue" name="EmploymentAgreementBaseCompensationCommonStockValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmploymentAgreementMaximumBonuses" name="EmploymentAgreementMaximumBonuses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmploymentAgreementOnetimeBonus" name="EmploymentAgreementOnetimeBonus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmploymentAgreementTerm" name="EmploymentAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EmploymentAndConsultingAgreementsTextBlock" name="EmploymentAndConsultingAgreementsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_EpiduralapadPatentsMember" name="EpiduralapadPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" name="EquityMethodInvestmentDeferredIntercompanyProfitLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" name="EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_FormerCeoMember" name="FormerCeoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_FoundationIntellectualPropertyPatentsMember" name="FoundationIntellectualPropertyPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_GianDomenicoTrombettaMember" name="GianDomenicoTrombettaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_IncomeFromNonemployeeOptions" name="IncomeFromNonemployeeOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" name="IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" name="IncreaseDecreaseToAdvancesToContractManufacturer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_InnovestSpAMember" name="InnovestSpAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_InstrumentsAndHandpiecesMember" name="InstrumentsAndHandpiecesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_InstrumentsMember" name="InstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_InterimChiefExecutiveOfficerMember" name="InterimChiefExecutiveOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ManufacturingAgreementForHandpiecesMember" name="ManufacturingAgreementForHandpiecesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_MedicalSegmentMember" name="MedicalSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_MilestoneChinaMember" name="MilestoneChinaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_MilestoneEducationLLCMember" name="MilestoneEducationLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_MinimumShareholdingPercentageInCompany" name="MinimumShareholdingPercentageInCompany" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_NonEmployeeOptionsMember" name="NonEmployeeOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_NonqualifiedStockOptionsMember" name="NonqualifiedStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_NoteReceivableQuarterlyInstallmentAmount" name="NoteReceivableQuarterlyInstallmentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_NumberOfCustomers" name="NumberOfCustomers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_NumberOfMedicalInstrumentsSold" name="NumberOfMedicalInstrumentsSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_OfficeFurnitureAndEquipmentMember" name="OfficeFurnitureAndEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_OptionToRepurchasePeriod" name="OptionToRepurchasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" name="OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" name="OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_OptionsAndWarrantsMember" name="OptionsAndWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_OptionsExercisablePeriod" name="OptionsExercisablePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_OtherStockOptionsAndWarrantsMember" name="OtherStockOptionsAndWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity" name="PercentageOfRevenueFromServicesPerformedToVariableInterestEntity" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="mlss_PercentageOfValuationAllowance" name="PercentageOfValuationAllowance" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_PresidentAndChiefExecutiveOfficerMember" name="PresidentAndChiefExecutiveOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" name="PreviousPresidentAndChiefExecutiveOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_PriceForSharesOfVariableInterestEntityInterestSold" name="PriceForSharesOfVariableInterestEntityInterestSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" name="ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" name="ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_PurchaseCommitmentNumberOfUnits" name="PurchaseCommitmentNumberOfUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_PurchaseOfIntangiblesAssetsApad" name="PurchaseOfIntangiblesAssetsApad" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_RestOfWorldMember" name="RestOfWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ReturnObligationAmount" name="ReturnObligationAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="mlss_STAInstrumentsAndHandpiecesMember" name="STAInstrumentsAndHandpiecesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_STATrialsInstrumentsMember" name="STATrialsInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_SaleOfVariableInterestEntitysShares" name="SaleOfVariableInterestEntitysShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_SaleOfVariableInterestEntitysSharesMember" name="SaleOfVariableInterestEntitysSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" name="SalesByProductAndByGeographicalRegionTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedDuringPeriodSharesDirectorsBonuses" name="StockIssuedDuringPeriodSharesDirectorsBonuses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedDuringPeriodSharesEmployeeBonuses" name="StockIssuedDuringPeriodSharesEmployeeBonuses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs" name="StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants" name="StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedDuringPeriodValueDirectorsBonuses" name="StockIssuedDuringPeriodValueDirectorsBonuses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" name="StockIssuedDuringPeriodValueEmployeeBonuses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs" name="StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedEmployeesCompensation" name="StockIssuedEmployeesCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="mlss_StockIssuedForPublicOffering" name="StockIssuedForPublicOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_StockOptionPlan2004Member" name="StockOptionPlan2004Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_StockOptionPlan2011Member" name="StockOptionPlan2011Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ToolingEquipmentSTAAndWandMember" name="ToolingEquipmentSTAAndWandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_ToolingSafetyWandMember" name="ToolingSafetyWandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_TradeShowDisplaysMember" name="TradeShowDisplaysMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_TwoCustomersMember" name="TwoCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_UponExerciseOfDefaultAgreementMember" name="UponExerciseOfDefaultAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage" name="VariableInterestEntityMajorityShareholderOwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_VariableInterestEntityOwnershipPercentageSold" name="VariableInterestEntityOwnershipPercentageSold" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_WebsiteMember" name="WebsiteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" name="WeightedAverageSharesOutstandingBasicAndDilutedAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="mlss_WriteoffOfAdvancesToAffiliate" name="WriteoffOfAdvancesToAffiliate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-e-inventories-summary-of-inventories-details" name="statement-statement-note-e-inventories-summary-of-inventories-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-e-inventories-tables" name="statement-statement-note-e-inventories-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" name="statement-statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-tables" name="statement-statement-note-h-investment-in-unconsolidated-subsidiaries-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" name="statement-statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-tables" name="statement-statement-note-i-furniture-fixtures-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-j-patents-summary-of-patents-details" name="statement-statement-note-j-patents-summary-of-patents-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-j-patents-tables" name="statement-statement-note-j-patents-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" name="statement-statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-l-stock-option-plans-tables" name="statement-statement-note-l-stock-option-plans-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" name="statement-statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-n-income-taxes-deferred-tax-assets-details" name="statement-statement-note-n-income-taxes-deferred-tax-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" name="statement-statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-n-income-taxes-tables" name="statement-statement-note-n-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" name="statement-statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" name="statement-statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-o-segment-and-geographic-data-tables" name="statement-statement-note-o-segment-and-geographic-data-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" name="statement-statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-note-r-commitments-and-other-tables" name="statement-statement-note-r-commitments-and-other-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="mlss_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>mlss-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 10:48PM UTC 2018-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:href="mlss-20171231.xsd#statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:href="mlss-20171231.xsd#statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-deferred-tax-assets-details" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes-deferred-tax-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-operations" xlink:href="mlss-20171231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-cash-flows" xlink:href="mlss-20171231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsolidationOfVariableInterestEntity" xlink:label="mlss_ConsolidationOfVariableInterestEntity" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:label="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PurchaseOfIntangiblesAssetsApad" xlink:label="mlss_PurchaseOfIntangiblesAssetsApad" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="arc"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="mlss_ConsolidationOfVariableInterestEntity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="mlss_PurchaseOfIntangiblesAssetsApad" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets" xlink:href="mlss-20171231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredGainOnDisposalOfInvestment" xlink:label="mlss_DeferredGainOnDisposalOfInvestment" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredProfitRelatedPartiesCurrent" xlink:label="mlss_DeferredProfitRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivables" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="mlss_DeferredProfitRelatedPartiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="mlss_DeferredGainOnDisposalOfInvestment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>mlss-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 10:48PM UTC 2018-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-s-pension-plan" xlink:href="mlss-20171231.xsd#statement-note-s-pension-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-s-pension-plan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-b-liquidity-and-uncertainties" xlink:href="mlss-20171231.xsd#statement-note-b-liquidity-and-uncertainties" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-b-liquidity-and-uncertainties" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-document-and-entity-information" xlink:href="mlss-20171231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="mlss-20171231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business" xlink:href="mlss-20171231.xsd#statement-note-a-organization-and-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies" xlink:href="mlss-20171231.xsd#statement-note-c-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionsAndWarrantsMember" xlink:label="mlss_OptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mlss_OptionsAndWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable" xlink:href="mlss-20171231.xsd#statement-note-d-notes-receivable" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancingReceivablesTextBlock" xlink:label="us-gaap_FinancingReceivablesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FinancingReceivablesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories" xlink:href="mlss-20171231.xsd#statement-note-e-inventories" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts" xlink:href="mlss-20171231.xsd#statement-note-f-advances-on-contracts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdvancesToContractManufacturerTextBlock" xlink:label="mlss_AdvancesToContractManufacturerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_AdvancesToContractManufacturerTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity" xlink:href="mlss-20171231.xsd#statement-note-g-consolidation-of-variable-interest-entity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneEducationLLCMember" xlink:label="mlss_MilestoneEducationLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="mlss_MilestoneEducationLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries" xlink:href="mlss-20171231.xsd#statement-note-h-investment-in-unconsolidated-subsidiaries" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AccountsReceivableFromRelatedPartiesMember" xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdvancedOcularSciencesSAMember" xlink:label="mlss_AdvancedOcularSciencesSAMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsAndHandpiecesMember" xlink:label="mlss_InstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneEducationLLCMember" xlink:label="mlss_MilestoneEducationLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_AdvancedOcularSciencesSAMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mlss_InstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneEducationLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment" xlink:href="mlss-20171231.xsd#statement-note-i-furniture-fixtures-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents" xlink:href="mlss-20171231.xsd#statement-note-j-patents" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-j-patents" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_APADOctrooiBVAndAPADBVMember" xlink:label="mlss_APADOctrooiBVAndAPADBVMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="us-gaap_WeightedAverageMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_WeightedAverageMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mlss_APADOctrooiBVAndAPADBVMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity" xlink:href="mlss-20171231.xsd#statement-note-k-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:label="mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OtherStockOptionsAndWarrantsMember" xlink:label="mlss_OtherStockOptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SeriesAConvertiblePreferredStockMember" xlink:label="mlss_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UnderwrittenPublicOfferingMember" xlink:label="mlss_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mlss_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mlss_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mlss_OtherStockOptionsAndWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans" xlink:href="mlss-20171231.xsd#statement-note-l-stock-option-plans" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:label="mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:label="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_GianDomenicoTrombettaMember" xlink:label="mlss_GianDomenicoTrombettaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2004Member" xlink:label="mlss_StockOptionPlan2004Member" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2011Member" xlink:label="mlss_StockOptionPlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mlss_StockOptionPlan2004Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mlss_StockOptionPlan2011Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_GianDomenicoTrombettaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements" xlink:href="mlss-20171231.xsd#statement-note-m-employment-contract-and-consulting-agreements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:label="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NonqualifiedStockOptionsMember" xlink:label="mlss_NonqualifiedStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2011Member" xlink:label="mlss_StockOptionPlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_PresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mlss_NonqualifiedStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mlss_StockOptionPlan2011Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:label="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data" xlink:href="mlss-20171231.xsd#statement-note-o-segment-and-geographic-data" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:label="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-p-concentration" xlink:href="mlss-20171231.xsd#statement-note-p-concentration" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-p-concentration" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_CustomerOneMember" xlink:label="mlss_CustomerOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_CustomerTwoMember" xlink:label="mlss_CustomerTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_TwoCustomersMember" xlink:label="mlss_TwoCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="us-gaap_SalesRevenueGoodsNetMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueGoodsNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mlss_TwoCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mlss_CustomerOneMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mlss_CustomerTwoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions" xlink:href="mlss-20171231.xsd#statement-note-q-related-party-transzactions" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InnovestSpAMember" xlink:label="mlss_InnovestSpAMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsAndHandpiecesMember" xlink:label="mlss_InstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ManufacturingAgreementForHandpiecesMember" xlink:label="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_STAInstrumentsAndHandpiecesMember" xlink:label="mlss_STAInstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mlss_InstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mlss_STAInstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mlss_InnovestSpAMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other" xlink:href="mlss-20171231.xsd#statement-note-r-commitments-and-other" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_FormerCeoMember" xlink:label="mlss_FormerCeoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InnovestSpAMember" xlink:label="mlss_InnovestSpAMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mlss_InnovestSpAMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_FormerCeoMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events" xlink:href="mlss-20171231.xsd#statement-note-t-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-significant-accounting-policies-policies" xlink:href="mlss-20171231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:label="us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="us-gaap_StandardProductWarrantyPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StandardProductWarrantyPolicy" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-tables" xlink:href="mlss-20171231.xsd#statement-note-e-inventories-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:href="mlss-20171231.xsd#statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-tables" xlink:href="mlss-20171231.xsd#statement-note-i-furniture-fixtures-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-tables" xlink:href="mlss-20171231.xsd#statement-note-j-patents-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-tables" xlink:href="mlss-20171231.xsd#statement-note-l-stock-option-plans-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-tables" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-tables" xlink:href="mlss-20171231.xsd#statement-note-o-segment-and-geographic-data-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-tables" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:label="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-tables" xlink:href="mlss-20171231.xsd#statement-note-r-commitments-and-other-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business-details-textual" xlink:href="mlss-20171231.xsd#statement-note-a-organization-and-business-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NumberOfMedicalInstrumentsSold" xlink:label="mlss_NumberOfMedicalInstrumentsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NumberOfMedicalInstrumentsSold" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:href="mlss-20171231.xsd#statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncomeFromNonemployeeOptions" xlink:label="mlss_IncomeFromNonemployeeOptions" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionsAndWarrantsMember" xlink:label="mlss_OptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage" xlink:label="mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShippingHandlingAndTransportationCosts" xlink:label="us-gaap_ShippingHandlingAndTransportationCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mlss_OptionsAndWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShippingHandlingAndTransportationCosts" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_IncomeFromNonemployeeOptions" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable-details-textual" xlink:href="mlss-20171231.xsd#statement-note-d-notes-receivable-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteReceivableQuarterlyInstallmentAmount" xlink:label="mlss_NoteReceivableQuarterlyInstallmentAmount" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchasePeriod" xlink:label="mlss_OptionToRepurchasePeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" xlink:label="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" xlink:label="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PriceForSharesOfVariableInterestEntityInterestSold" xlink:label="mlss_PriceForSharesOfVariableInterestEntityInterestSold" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:label="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ReturnObligationAmount" xlink:label="mlss_ReturnObligationAmount" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentDeferredGainOnSale" xlink:label="us-gaap_EquityMethodInvestmentDeferredGainOnSale" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="us-gaap_NotesReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchasePeriod" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PriceForSharesOfVariableInterestEntityInterestSold" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesReceivableNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NoteReceivableQuarterlyInstallmentAmount" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ReturnObligationAmount" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentDeferredGainOnSale" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-details-textual" xlink:href="mlss-20171231.xsd#statement-note-e-inventories-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts-details-textual" xlink:href="mlss-20171231.xsd#statement-note-f-advances-on-contracts-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity-details-textual" xlink:href="mlss-20171231.xsd#statement-note-g-consolidation-of-variable-interest-entity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneEducationLLCMember" xlink:label="mlss_MilestoneEducationLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity" xlink:label="mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="mlss_MilestoneEducationLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-details-textual" xlink:href="mlss-20171231.xsd#statement-note-h-investment-in-unconsolidated-subsidiaries-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AccountsReceivableFromRelatedPartiesMember" xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdvancedOcularSciencesSAMember" xlink:label="mlss_AdvancedOcularSciencesSAMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsAndHandpiecesMember" xlink:label="mlss_InstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneEducationLLCMember" xlink:label="mlss_MilestoneEducationLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteReceivableQuarterlyInstallmentAmount" xlink:label="mlss_NoteReceivableQuarterlyInstallmentAmount" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchasePeriod" xlink:label="mlss_OptionToRepurchasePeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" xlink:label="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" xlink:label="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PriceForSharesOfVariableInterestEntityInterestSold" xlink:label="mlss_PriceForSharesOfVariableInterestEntityInterestSold" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:label="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ReturnObligationAmount" xlink:label="mlss_ReturnObligationAmount" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_VariableInterestEntityOwnershipPercentageSold" xlink:label="mlss_VariableInterestEntityOwnershipPercentageSold" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_WriteoffOfAdvancesToAffiliate" xlink:label="mlss_WriteoffOfAdvancesToAffiliate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvancesToAffiliate" xlink:label="us-gaap_AdvancesToAffiliate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostMethodInvestmentsRealizedLosses" xlink:label="us-gaap_CostMethodInvestmentsRealizedLosses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentDeferredGainOnSale" xlink:label="us-gaap_EquityMethodInvestmentDeferredGainOnSale" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount" xlink:label="us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:label="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="us-gaap_NotesReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_AdvancedOcularSciencesSAMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mlss_InstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneEducationLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvancesToAffiliate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_WriteoffOfAdvancesToAffiliate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostMethodInvestmentsRealizedLosses" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchasePeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PriceForSharesOfVariableInterestEntityInterestSold" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesReceivableNet" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NoteReceivableQuarterlyInstallmentAmount" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentDeferredGainOnSale" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_VariableInterestEntityOwnershipPercentageSold" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ReturnObligationAmount" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-details-textual" xlink:href="mlss-20171231.xsd#statement-note-i-furniture-fixtures-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-details-textual" xlink:href="mlss-20171231.xsd#statement-note-j-patents-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_APADOctrooiBVAndAPADBVMember" xlink:label="mlss_APADOctrooiBVAndAPADBVMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPaymentsOfLegalFees" xlink:label="mlss_AssetPurchaseAgreementPaymentsOfLegalFees" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum" xlink:label="mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities" xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum" xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="us-gaap_WeightedAverageMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_WeightedAverageMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mlss_APADOctrooiBVAndAPADBVMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AssetPurchaseAgreementPaymentsOfLegalFees" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity-details-textual" xlink:href="mlss-20171231.xsd#statement-note-k-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ClassOfWarrantOrRightExpirationPeriod" xlink:label="mlss_ClassOfWarrantOrRightExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:label="mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OtherStockOptionsAndWarrantsMember" xlink:label="mlss_OtherStockOptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SeriesAConvertiblePreferredStockMember" xlink:label="mlss_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UnderwrittenPublicOfferingMember" xlink:label="mlss_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mlss_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mlss_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mlss_OtherStockOptionsAndWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ClassOfWarrantOrRightExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-details-textual" xlink:href="mlss-20171231.xsd#statement-note-l-stock-option-plans-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:label="mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:label="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_GianDomenicoTrombettaMember" xlink:label="mlss_GianDomenicoTrombettaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncomeFromNonemployeeOptions" xlink:label="mlss_IncomeFromNonemployeeOptions" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2004Member" xlink:label="mlss_StockOptionPlan2004Member" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2011Member" xlink:label="mlss_StockOptionPlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mlss_StockOptionPlan2004Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mlss_StockOptionPlan2011Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_GianDomenicoTrombettaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_IncomeFromNonemployeeOptions" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements-details-textual" xlink:href="mlss-20171231.xsd#statement-note-m-employment-contract-and-consulting-agreements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod" xlink:label="mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod" xlink:label="mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingAgreementAnnualPayment" xlink:label="mlss_ConsultingAgreementAnnualPayment" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingAgreementTerm" xlink:label="mlss_ConsultingAgreementTerm" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementBaseCompensation" xlink:label="mlss_EmploymentAgreementBaseCompensation" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementBaseCompensationCash" xlink:label="mlss_EmploymentAgreementBaseCompensationCash" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementBaseCompensationCommonStockValue" xlink:label="mlss_EmploymentAgreementBaseCompensationCommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementMaximumBonuses" xlink:label="mlss_EmploymentAgreementMaximumBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementOnetimeBonus" xlink:label="mlss_EmploymentAgreementOnetimeBonus" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementTerm" xlink:label="mlss_EmploymentAgreementTerm" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MinimumShareholdingPercentageInCompany" xlink:label="mlss_MinimumShareholdingPercentageInCompany" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NonqualifiedStockOptionsMember" xlink:label="mlss_NonqualifiedStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionsExercisablePeriod" xlink:label="mlss_OptionsExercisablePeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2011Member" xlink:label="mlss_StockOptionPlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_PresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mlss_NonqualifiedStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mlss_StockOptionPlan2011Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedBonusesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_MinimumShareholdingPercentageInCompany" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionsExercisablePeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementTerm" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementBaseCompensation" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementMaximumBonuses" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementBaseCompensationCash" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementBaseCompensationCommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ConsultingAgreementTerm" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ConsultingAgreementAnnualPayment" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementOnetimeBonus" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-details-textual" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017" xlink:label="mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:label="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PercentageOfValuationAllowance" xlink:label="mlss_PercentageOfValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PercentageOfValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-details-textual" xlink:href="mlss-20171231.xsd#statement-note-o-segment-and-geographic-data-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-p-concentration-details-textual" xlink:href="mlss-20171231.xsd#statement-note-p-concentration-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-p-concentration-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_CustomerOneMember" xlink:label="mlss_CustomerOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_CustomerTwoMember" xlink:label="mlss_CustomerTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NumberOfCustomers" xlink:label="mlss_NumberOfCustomers" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PurchaseCommitmentNumberOfUnits" xlink:label="mlss_PurchaseCommitmentNumberOfUnits" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_TwoCustomersMember" xlink:label="mlss_TwoCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="us-gaap_SalesRevenueGoodsNetMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueGoodsNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mlss_TwoCustomersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mlss_CustomerOneMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mlss_CustomerTwoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PurchaseCommitmentNumberOfUnits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NumberOfCustomers" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableGross" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions-details-textual" xlink:href="mlss-20171231.xsd#statement-note-q-related-party-transzactions-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesAgreementTerm" xlink:label="mlss_ConsultingServicesAgreementTerm" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InnovestSpAMember" xlink:label="mlss_InnovestSpAMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsAndHandpiecesMember" xlink:label="mlss_InstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ManufacturingAgreementForHandpiecesMember" xlink:label="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_STAInstrumentsAndHandpiecesMember" xlink:label="mlss_STAInstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mlss_InstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mlss_STAInstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mlss_InnovestSpAMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ConsultingServicesAgreementTerm" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-details-textual" xlink:href="mlss-20171231.xsd#statement-note-r-commitments-and-other-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology" xlink:label="mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology" xlink:label="mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AreaOfOfficeSpace" xlink:label="mlss_AreaOfOfficeSpace" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DefineBenefitPlanPaymentPeriod" xlink:label="mlss_DefineBenefitPlanPaymentPeriod" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionBasicSalaryForOneYear" xlink:label="mlss_EmployeeResignationAssertionBasicSalaryForOneYear" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionCarAllowanceForOneYear" xlink:label="mlss_EmployeeResignationAssertionCarAllowanceForOneYear" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionGrossSettlement" xlink:label="mlss_EmployeeResignationAssertionGrossSettlement" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear" xlink:label="mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionNumberOfOptionsVested" xlink:label="mlss_EmployeeResignationAssertionNumberOfOptionsVested" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionOptionsExercisePrice" xlink:label="mlss_EmployeeResignationAssertionOptionsExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionPayment" xlink:label="mlss_EmployeeResignationAssertionPayment" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionVestingTermAfterResignation" xlink:label="mlss_EmployeeResignationAssertionVestingTermAfterResignation" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_FormerCeoMember" xlink:label="mlss_FormerCeoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InnovestSpAMember" xlink:label="mlss_InnovestSpAMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants" xlink:label="mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForPostemploymentBenefits" xlink:label="us-gaap_PaymentsForPostemploymentBenefits" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mlss_InnovestSpAMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mlss_FormerCeoMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AreaOfOfficeSpace" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForPostemploymentBenefits" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DefineBenefitPlanPaymentPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfessionalFees" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionBasicSalaryForOneYear" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionCarAllowanceForOneYear" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionVestingTermAfterResignation" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionNumberOfOptionsVested" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionOptionsExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionGrossSettlement" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionPayment" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events-details-textual" xlink:href="mlss-20171231.xsd#statement-note-t-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ReturnObligationAmount" xlink:label="mlss_ReturnObligationAmount" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:label="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ReturnObligationAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:href="mlss-20171231.xsd#statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NonEmployeeOptionsMember" xlink:label="mlss_NonEmployeeOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mlss_NonEmployeeOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:href="mlss-20171231.xsd#statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:href="mlss-20171231.xsd#statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:href="mlss-20171231.xsd#statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-summary-of-patents-details" xlink:href="mlss-20171231.xsd#statement-note-j-patents-summary-of-patents-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-summary-of-patents-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EpiduralapadPatentsMember" xlink:label="mlss_EpiduralapadPatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_FoundationIntellectualPropertyPatentsMember" xlink:label="mlss_FoundationIntellectualPropertyPatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="mlss_FoundationIntellectualPropertyPatentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="mlss_EpiduralapadPatentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:href="mlss-20171231.xsd#statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="us-gaap_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="us-gaap_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="us-gaap_ConsolidationItemsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="us-gaap_CorporateNonSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="us-gaap_MaterialReconcilingItemsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConsolidationItemsAxis" xlink:to="us-gaap_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConsolidationItemsAxis" xlink:to="us-gaap_ConsolidationItemsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConsolidationItemsDomain" xlink:to="us-gaap_CorporateNonSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConsolidationItemsDomain" xlink:to="us-gaap_MaterialReconcilingItemsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-summary-of-inventories-details" xlink:href="mlss-20171231.xsd#statement-note-e-inventories-summary-of-inventories-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-summary-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:href="mlss-20171231.xsd#statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ComputerAndSoftwareMember" xlink:label="mlss_ComputerAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EPIAndIAInstrumentsMember" xlink:label="mlss_EPIAndIAInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OfficeFurnitureAndEquipmentMember" xlink:label="mlss_OfficeFurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_STATrialsInstrumentsMember" xlink:label="mlss_STATrialsInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ToolingEquipmentSTAAndWandMember" xlink:label="mlss_ToolingEquipmentSTAAndWandMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ToolingSafetyWandMember" xlink:label="mlss_ToolingSafetyWandMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_TradeShowDisplaysMember" xlink:label="mlss_TradeShowDisplaysMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_WebsiteMember" xlink:label="mlss_WebsiteMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_OfficeFurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ToolsDiesAndMoldsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_TradeShowDisplaysMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_ComputerAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_ToolingSafetyWandMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_WebsiteMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_ToolingEquipmentSTAAndWandMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_EPIAndIAInstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mlss_STATrialsInstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-deferred-tax-assets-details" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes-deferred-tax-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:href="mlss-20171231.xsd#statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CN" xlink:label="country_CN" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DomesticMember" xlink:label="mlss_DomesticMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_RestOfWorldMember" xlink:label="mlss_RestOfWorldMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="mlss_DomesticMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="mlss_RestOfWorldMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_CN" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-operations" xlink:href="mlss-20171231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:label="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_GrossProfit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-cash-flows" xlink:href="mlss-20171231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsolidationOfVariableInterestEntity" xlink:label="mlss_ConsolidationOfVariableInterestEntity" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:label="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PurchaseOfIntangiblesAssetsApad" xlink:label="mlss_PurchaseOfIntangiblesAssetsApad" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysShares" xlink:label="mlss_SaleOfVariableInterestEntitysShares" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedEmployeesCompensation" xlink:label="mlss_StockIssuedEmployeesCompensation" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedForPublicOffering" xlink:label="mlss_StockIssuedForPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="mlss_PurchaseOfIntangiblesAssetsApad" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="mlss_ConsolidationOfVariableInterestEntity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_StockIssued1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="mlss_SaleOfVariableInterestEntitysShares" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="mlss_StockIssuedForPublicOffering" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="mlss_StockIssuedEmployeesCompensation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets" xlink:href="mlss-20171231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredGainOnDisposalOfInvestment" xlink:label="mlss_DeferredGainOnDisposalOfInvestment" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredProfitRelatedPartiesCurrent" xlink:label="mlss_DeferredProfitRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mlss_DeferredProfitRelatedPartiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mlss_DeferredGainOnDisposalOfInvestment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-statement-of-changes-in-stockholders-equity" xlink:href="mlss-20171231.xsd#statement-consolidated-statement-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-statement-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneEducationLLCMember" xlink:label="mlss_MilestoneEducationLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesDirectorsBonuses" xlink:label="mlss_StockIssuedDuringPeriodSharesDirectorsBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesEmployeeBonuses" xlink:label="mlss_StockIssuedDuringPeriodSharesEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs" xlink:label="mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodValueDirectorsBonuses" xlink:label="mlss_StockIssuedDuringPeriodValueDirectorsBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs" xlink:label="mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UnderwrittenPublicOfferingMember" xlink:label="mlss_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="mlss_MilestoneEducationLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mlss_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodSharesEmployeeBonuses" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodSharesDirectorsBonuses" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodValueDirectorsBonuses" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>mlss-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 10:48PM UTC 2018-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DocumentAndEntityInformation" xlink:label="mlss_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="mlss_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DocumentAndEntityInformation" xlink:to="mlss_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="mlss_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="mlss_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-significant-accounting-policies-policies" xlink:label="mlss_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-significant-accounting-policies-policies" xlink:to="mlss_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_VariableInterestEntityOwnershipPercentage</link:label>
    <link:label xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-e-inventories-tables" xlink:label="mlss_statement-statement-note-e-inventories-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-e-inventories-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note E - Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-e-inventories-tables" xlink:to="mlss_statement-statement-note-e-inventories-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:label="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note H - Investment in Unconsolidated Subsidiaries</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:to="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-i-furniture-fixtures-and-equipment-tables" xlink:label="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note I - Furniture, Fixtures and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-tables" xlink:to="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-j-patents-tables" xlink:label="mlss_statement-statement-note-j-patents-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-j-patents-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note J - Patents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-j-patents-tables" xlink:to="mlss_statement-statement-note-j-patents-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-l-stock-option-plans-tables" xlink:label="mlss_statement-statement-note-l-stock-option-plans-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-l-stock-option-plans-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note L - Stock Option Plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-l-stock-option-plans-tables" xlink:to="mlss_statement-statement-note-l-stock-option-plans-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancingReceivablesTextBlock" xlink:label="us-gaap_FinancingReceivablesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancingReceivablesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivables [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivablesTextBlock" xlink:to="us-gaap_FinancingReceivablesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-n-income-taxes-tables" xlink:label="mlss_statement-statement-note-n-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-n-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note N - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-n-income-taxes-tables" xlink:to="mlss_statement-statement-note-n-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-o-segment-and-geographic-data-tables" xlink:label="mlss_statement-statement-note-o-segment-and-geographic-data-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-o-segment-and-geographic-data-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note O - Segment and Geographic Data</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-o-segment-and-geographic-data-tables" xlink:to="mlss_statement-statement-note-o-segment-and-geographic-data-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage" xlink:label="mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage" xlink:type="locator"/>
    <link:label xlink:label="mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage</link:label>
    <link:label xlink:label="mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Majority Shareholder Ownership Percentage</link:label>
    <link:label xlink:label="mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of majority shareholder ownership interest in a Variable Interest Entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage" xlink:to="mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-r-commitments-and-other-tables" xlink:label="mlss_statement-statement-note-r-commitments-and-other-tables" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-r-commitments-and-other-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note R - Commitments and Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-r-commitments-and-other-tables" xlink:to="mlss_statement-statement-note-r-commitments-and-other-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-e-inventories-summary-of-inventories-details" xlink:label="mlss_statement-statement-note-e-inventories-summary-of-inventories-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-e-inventories-summary-of-inventories-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note E - Inventories - Summary of Inventories (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-e-inventories-summary-of-inventories-details" xlink:to="mlss_statement-statement-note-e-inventories-summary-of-inventories-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:label="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note H - Investment in Unconsolidated Subsidiaries - Summarized Financial Information (Unaudited) of Milestone China (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:to="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:label="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note I - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:to="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-j-patents-summary-of-patents-details" xlink:label="mlss_statement-statement-note-j-patents-summary-of-patents-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-j-patents-summary-of-patents-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note J - Patents - Summary of Patents (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-j-patents-summary-of-patents-details" xlink:to="mlss_statement-statement-note-j-patents-summary-of-patents-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:label="mlss_statement-statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note L - Stock Option Plans - Summary of Option Activity for Employees and Non-employees (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:to="mlss_statement-statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:label="mlss_statement-statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note L - Summary of Significant Accounting Policies - Weighted Average Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:to="mlss_statement-statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-n-income-taxes-deferred-tax-assets-details" xlink:label="mlss_statement-statement-note-n-income-taxes-deferred-tax-assets-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-n-income-taxes-deferred-tax-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note N - Income Taxes - Deferred Tax Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-n-income-taxes-deferred-tax-assets-details" xlink:to="mlss_statement-statement-note-n-income-taxes-deferred-tax-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:label="mlss_statement-statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note N - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:to="mlss_statement-statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:label="mlss_statement-statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note O - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:to="mlss_statement-statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:label="mlss_statement-statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note O - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:to="mlss_statement-statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:label="mlss_statement-statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:type="locator"/>
    <link:label xlink:label="mlss_statement-statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note R - Commitments and Other - Aggregate Minimum Rental Commitments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_statement-statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:to="mlss_statement-statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneEducationLLCMember" xlink:label="mlss_MilestoneEducationLLCMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_MilestoneEducationLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Education LLC [Member]</link:label>
    <link:label xlink:label="mlss_MilestoneEducationLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The name of an equity method investment of the reporting entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_MilestoneEducationLLCMember" xlink:to="mlss_MilestoneEducationLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatements" xlink:label="mlss_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="mlss_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NotesToFinancialStatements" xlink:to="mlss_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="mlss_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="mlss_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments</link:label>
    <link:label xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before equity in net earnings of equity investments</link:label>
    <link:label xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, before income or loss from equity method investments, extraordinary items, and noncontrolling interest, but after income taxes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="us-gaap_VariableInterestEntityDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:label="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:label xlink:label="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding and to be issued&#8212;</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:to="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_MilestoneChinaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone China [Member]</link:label>
    <link:label xlink:label="mlss_MilestoneChinaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Milestone China, an equity method investment of the reporting entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_MilestoneChinaMember" xlink:to="mlss_MilestoneChinaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesEmployeeBonuses" xlink:label="mlss_StockIssuedDuringPeriodSharesEmployeeBonuses" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodSharesEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock to be issued to employee for bonuses (in shares)</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodSharesEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock issued for employee bonuses during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedDuringPeriodSharesEmployeeBonuses" xlink:to="mlss_StockIssuedDuringPeriodSharesEmployeeBonuses-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock to be issued to employee for bonuses</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued for employee bonuses during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:to="mlss_StockIssuedDuringPeriodValueEmployeeBonuses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestments</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvancesToAffiliate" xlink:label="us-gaap_AdvancesToAffiliate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvancesToAffiliate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdvancesToAffiliate</link:label>
    <link:label xlink:label="us-gaap_AdvancesToAffiliate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances to Affiliate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesToAffiliate" xlink:to="us-gaap_AdvancesToAffiliate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease)in accrued expenses and other payables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:type="locator"/>
    <link:label xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_IncreaseDecreaseToAdvancesToContractManufacturer</link:label>
    <link:label xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease to advances on contracts</link:label>
    <link:label xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease to advances to contract manufacturer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:to="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Decrease) Increase in accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in accounts payable related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedEmployeesCompensation" xlink:label="mlss_StockIssuedEmployeesCompensation" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedEmployeesCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares issued to consultants in lieu of cash payments</link:label>
    <link:label xlink:label="mlss_StockIssuedEmployeesCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued to employees in lieu of cash compensation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedEmployeesCompensation" xlink:to="mlss_StockIssuedEmployeesCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SalesRevenueNet</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfCountriesInWhichEntityOperates</link:label>
    <link:label xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="us-gaap_NumberOfCountriesInWhichEntityOperates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares to be issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConcentrationRiskPercentage1</link:label>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsolidationOfVariableInterestEntity" xlink:label="mlss_ConsolidationOfVariableInterestEntity" xlink:type="locator"/>
    <link:label xlink:label="mlss_ConsolidationOfVariableInterestEntity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation of variable interest entity</link:label>
    <link:label xlink:label="mlss_ConsolidationOfVariableInterestEntity-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net cash inflow or outflow associated with the consolidation of variable interest entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ConsolidationOfVariableInterestEntity" xlink:to="mlss_ConsolidationOfVariableInterestEntity-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionsAndWarrantsMember" xlink:label="mlss_OptionsAndWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_OptionsAndWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options and Warrants [Member]</link:label>
    <link:label xlink:label="mlss_OptionsAndWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to options and warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_OptionsAndWarrantsMember" xlink:to="mlss_OptionsAndWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued</link:label>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued</link:label>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Shares Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_DentalSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dental Segment [Member]</link:label>
    <link:label xlink:label="mlss_DentalSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the Dental segment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DentalSegmentMember" xlink:to="mlss_DentalSegmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance</link:label>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_MedicalSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Segment [Member]</link:label>
    <link:label xlink:label="mlss_MedicalSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the medical segment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_MedicalSegmentMember" xlink:to="mlss_MedicalSegmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TreasuryStockValue</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, 33,333 shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="locator"/>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeiture Rate</link:label>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The forfeiture rate assumption that is used in valuing an option on its own shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherOperatingAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Increase) Decrease in other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="us-gaap_NotesReceivableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesReceivableNet</link:label>
    <link:label xlink:label="us-gaap_NotesReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Receivable, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNet" xlink:to="us-gaap_NotesReceivableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Increase) Decrease in prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued for asset acquisition (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDeferredCharges</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in deferred profit, related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued for asset acquisition</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssued</link:label>
    <link:label xlink:label="us-gaap_SharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net assets acquired from variable entity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="us-gaap_SalesRevenueGoodsNetMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNetMember" xlink:to="us-gaap_SalesRevenueGoodsNetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ComputerAndSoftwareMember" xlink:label="mlss_ComputerAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ComputerAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer and Software [Member]</link:label>
    <link:label xlink:label="mlss_ComputerAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to computer and software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ComputerAndSoftwareMember" xlink:to="mlss_ComputerAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ToolingSafetyWandMember" xlink:label="mlss_ToolingSafetyWandMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ToolingSafetyWandMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tooling Safety Wand [Member]</link:label>
    <link:label xlink:label="mlss_ToolingSafetyWandMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to tooling safety wand.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ToolingSafetyWandMember" xlink:to="mlss_ToolingSafetyWandMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OfficeFurnitureAndEquipmentMember" xlink:label="mlss_OfficeFurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_OfficeFurnitureAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Furniture and Equipment [Member]</link:label>
    <link:label xlink:label="mlss_OfficeFurnitureAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to office furniture and equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_OfficeFurnitureAndEquipmentMember" xlink:to="mlss_OfficeFurnitureAndEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity" xlink:label="mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity" xlink:type="locator"/>
    <link:label xlink:label="mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity</link:label>
    <link:label xlink:label="mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Revenue from Services Performed to Variable Interest Entity</link:label>
    <link:label xlink:label="mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of revenue from services performed to variable interest entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity" xlink:to="mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_TradeShowDisplaysMember" xlink:label="mlss_TradeShowDisplaysMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_TradeShowDisplaysMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Show Displays [Member]</link:label>
    <link:label xlink:label="mlss_TradeShowDisplaysMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to trade show displays.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_TradeShowDisplaysMember" xlink:to="mlss_TradeShowDisplaysMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_STATrialsInstrumentsMember" xlink:label="mlss_STATrialsInstrumentsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_STATrialsInstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">STA Trials Instruments [Member]</link:label>
    <link:label xlink:label="mlss_STATrialsInstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to STA trials instruments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_STATrialsInstrumentsMember" xlink:to="mlss_STATrialsInstrumentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ToolingEquipmentSTAAndWandMember" xlink:label="mlss_ToolingEquipmentSTAAndWandMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ToolingEquipmentSTAAndWandMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tooling Equipment - STA and Wand [Member]</link:label>
    <link:label xlink:label="mlss_ToolingEquipmentSTAAndWandMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to tooling equipments for STA and wand.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ToolingEquipmentSTAAndWandMember" xlink:to="mlss_ToolingEquipmentSTAAndWandMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EPIAndIAInstrumentsMember" xlink:label="mlss_EPIAndIAInstrumentsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_EPIAndIAInstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EPI and IA Instruments [Member]</link:label>
    <link:label xlink:label="mlss_EPIAndIAInstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to EPI and IA instruments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EPIAndIAInstrumentsMember" xlink:to="mlss_EPIAndIAInstrumentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UnderwrittenPublicOfferingMember" xlink:label="mlss_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_UnderwrittenPublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label xlink:label="mlss_UnderwrittenPublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the underwritten public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_UnderwrittenPublicOfferingMember" xlink:to="mlss_UnderwrittenPublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock to be issued to employee for stock program (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock to be issued to employee for stock program</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdvancedOcularSciencesSAMember" xlink:label="mlss_AdvancedOcularSciencesSAMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_AdvancedOcularSciencesSAMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Ocular Sciences SA [Member]</link:label>
    <link:label xlink:label="mlss_AdvancedOcularSciencesSAMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The name of an unconsolidated subsidiary of the reporting entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AdvancedOcularSciencesSAMember" xlink:to="mlss_AdvancedOcularSciencesSAMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to employee for exercise of stock options (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of options exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to employee for exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease (Increase) in accounts receivable related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in other receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ClassOfWarrantOrRightExpirationPeriod" xlink:label="mlss_ClassOfWarrantOrRightExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_ClassOfWarrantOrRightExpirationPeriod</link:label>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expiration Period</link:label>
    <link:label xlink:label="mlss_ClassOfWarrantOrRightExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period from issue date that a warrant expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ClassOfWarrantOrRightExpirationPeriod" xlink:to="mlss_ClassOfWarrantOrRightExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock to be issued to employee for compensation (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Increase) Decrease in accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer, Chief Financial Officer and Employees [Member]</link:label>
    <link:label xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Chief Executive Officer, Chief Financial Officer and employees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:to="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredCostsCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NonEmployeeOptionsMember" xlink:label="mlss_NonEmployeeOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_NonEmployeeOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Options [Member]</link:label>
    <link:label xlink:label="mlss_NonEmployeeOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to stock options for non-employees of the reporting entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NonEmployeeOptionsMember" xlink:to="mlss_NonEmployeeOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock to be issued to employee for compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of options granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OtherStockOptionsAndWarrantsMember" xlink:label="mlss_OtherStockOptionsAndWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_OtherStockOptionsAndWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Stock Options and Warrants [Member]</link:label>
    <link:label xlink:label="mlss_OtherStockOptionsAndWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to other stock options and warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_OtherStockOptionsAndWarrantsMember" xlink:to="mlss_OtherStockOptionsAndWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllowanceForDoubtfulAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life, granted (Year)</link:label>
    <link:label xlink:label="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based payment award options grants in period weighted average remaining contractual term.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:to="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued for payment of consulting services (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued for payment of consulting services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionPayment" xlink:label="mlss_EmployeeResignationAssertionPayment" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmployeeResignationAssertionPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmployeeResignationAssertionPayment</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Resignation Assertion, Payment</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of payment in connection to an employee resignation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmployeeResignationAssertionPayment" xlink:to="mlss_EmployeeResignationAssertionPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SeriesAConvertiblePreferredStockMember" xlink:label="mlss_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_SeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="mlss_SeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to series A convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SeriesAConvertiblePreferredStockMember" xlink:to="mlss_SeriesAConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Common Stock (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionGrossSettlement" xlink:label="mlss_EmployeeResignationAssertionGrossSettlement" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmployeeResignationAssertionGrossSettlement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmployeeResignationAssertionGrossSettlement</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionGrossSettlement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Resignation Assertion, Gross Settlement</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionGrossSettlement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the gross settlement in connection to a employee resignation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmployeeResignationAssertionGrossSettlement" xlink:to="mlss_EmployeeResignationAssertionGrossSettlement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ReturnObligationAmount" xlink:label="mlss_ReturnObligationAmount" xlink:type="locator"/>
    <link:label xlink:label="mlss_ReturnObligationAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_ReturnObligationAmount</link:label>
    <link:label xlink:label="mlss_ReturnObligationAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Return Obligation, Amount</link:label>
    <link:label xlink:label="mlss_ReturnObligationAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount received that would be required to be returned to the purchaser.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ReturnObligationAmount" xlink:to="mlss_ReturnObligationAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product sales, net</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="us-gaap_DeferredTaxAssetDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_UponExerciseOfDefaultAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Exercise of Default Agreement [Member]</link:label>
    <link:label xlink:label="mlss_UponExerciseOfDefaultAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to the exercise of a default agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_UponExerciseOfDefaultAgreementMember" xlink:to="mlss_UponExerciseOfDefaultAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease (Increase) in inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGrossCurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="us-gaap_DeferredTaxAssetsGrossCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowanceCurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod" xlink:label="mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod" xlink:type="locator"/>
    <link:label xlink:label="mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod</link:label>
    <link:label xlink:label="mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer, Employment Agreement Period</link:label>
    <link:label xlink:label="mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the employment agreement period for the Chief Executive Officer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod" xlink:to="mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionsExercisablePeriod" xlink:label="mlss_OptionsExercisablePeriod" xlink:type="locator"/>
    <link:label xlink:label="mlss_OptionsExercisablePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_OptionsExercisablePeriod</link:label>
    <link:label xlink:label="mlss_OptionsExercisablePeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options Exercisable Period</link:label>
    <link:label xlink:label="mlss_OptionsExercisablePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the options exercisable period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_OptionsExercisablePeriod" xlink:to="mlss_OptionsExercisablePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod" xlink:label="mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod" xlink:type="locator"/>
    <link:label xlink:label="mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod</link:label>
    <link:label xlink:label="mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer, Automatic Extended Employment Agreement Period</link:label>
    <link:label xlink:label="mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the automatic extended employment agreement period for the Chief Executive Officer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod" xlink:to="mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MinimumShareholdingPercentageInCompany" xlink:label="mlss_MinimumShareholdingPercentageInCompany" xlink:type="locator"/>
    <link:label xlink:label="mlss_MinimumShareholdingPercentageInCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_MinimumShareholdingPercentageInCompany</link:label>
    <link:label xlink:label="mlss_MinimumShareholdingPercentageInCompany-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum Shareholding Percentage in Company</link:label>
    <link:label xlink:label="mlss_MinimumShareholdingPercentageInCompany-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the minimum shareholding percentage in the Company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_MinimumShareholdingPercentageInCompany" xlink:to="mlss_MinimumShareholdingPercentageInCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PercentageOfValuationAllowance" xlink:label="mlss_PercentageOfValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="mlss_PercentageOfValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_PercentageOfValuationAllowance</link:label>
    <link:label xlink:label="mlss_PercentageOfValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Valuation Allowance</link:label>
    <link:label xlink:label="mlss_PercentageOfValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of valuation allowance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PercentageOfValuationAllowance" xlink:to="mlss_PercentageOfValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfReportableSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent</link:label>
    <link:label xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:to="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedForPublicOffering" xlink:label="mlss_StockIssuedForPublicOffering" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedForPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares issued to employees for bonus</link:label>
    <link:label xlink:label="mlss_StockIssuedForPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The fair value of stock issued for public offering in noncash financing activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedForPublicOffering" xlink:to="mlss_StockIssuedForPublicOffering-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NumberOfCustomers" xlink:label="mlss_NumberOfCustomers" xlink:type="locator"/>
    <link:label xlink:label="mlss_NumberOfCustomers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_NumberOfCustomers</link:label>
    <link:label xlink:label="mlss_NumberOfCustomers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Customers</link:label>
    <link:label xlink:label="mlss_NumberOfCustomers-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NumberOfCustomers" xlink:to="mlss_NumberOfCustomers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warranty reserve</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CN" xlink:label="country_CN" xlink:type="locator"/>
    <link:label xlink:label="country_CN-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate" xlink:type="locator"/>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate</link:label>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expire Period after Grant Date</link:label>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the expiration period from grant date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2004Member" xlink:label="mlss_StockOptionPlan2004Member" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockOptionPlan2004Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Plan 2004 [Member]</link:label>
    <link:label xlink:label="mlss_StockOptionPlan2004Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the 2004 Stock Option Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockOptionPlan2004Member" xlink:to="mlss_StockOptionPlan2004Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts-short term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate" xlink:type="locator"/>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate</link:label>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Period from Grant Date</link:label>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the exercisable period from grant date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2011Member" xlink:label="mlss_StockOptionPlan2011Member" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockOptionPlan2011Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Plan 2011 [Member]</link:label>
    <link:label xlink:label="mlss_StockOptionPlan2011Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the 2011 Stock Option Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockOptionPlan2011Member" xlink:to="mlss_StockOptionPlan2011Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred officers compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Component parts and other materials</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GrossProfit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GrossProfit</link:label>
    <link:label xlink:label="us-gaap_GrossProfit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:label xlink:label="us-gaap_GrossProfit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesRentExpenseMinimumRentals</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWriteDown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase inventories allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value $.001; authorized 50,000,000 shares; 33,191,571 shares issued, 1,401,247 shares to be issued and 33,158,238 shares outstanding as of December 31, 2017; 30,457,224 shares issued, 1,270,481 shares to be issued and 30,423,891 shares outstanding as of December 31, 2016</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, granted</link:label>
    <link:label xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options granted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes receivable from financing transaction long term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</link:label>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation</link:label>
    <link:label xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US"/>
    <link:label xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation at federal statutory rate and state and local income tax rate and stock-based compensation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:to="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A convertible preferred stock, par value $.001, authorized 5,000,000 shares, and 7,000 shares issued and outstanding as December 31, 2017 and 2016.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetUsefulLife</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefExecutiveOfficerMember" xlink:to="us-gaap_ChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DepreciationDepletionAndAmortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvancesOnInventoryPurchases-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advances on contracts</link:label>
    <link:label xlink:label="us-gaap_AdvancesOnInventoryPurchases-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances on Inventory Purchases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesOnInventoryPurchases" xlink:to="us-gaap_AdvancesOnInventoryPurchases-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockRedemptionPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockRedemptionPricePerShare</link:label>
    <link:label xlink:label="us-gaap_PreferredStockRedemptionPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_TwoCustomersMember" xlink:label="mlss_TwoCustomersMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_TwoCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Customers [Member]</link:label>
    <link:label xlink:label="mlss_TwoCustomersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to two customers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_TwoCustomersMember" xlink:to="mlss_TwoCustomersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_WriteoffOfAdvancesToAffiliate" xlink:label="mlss_WriteoffOfAdvancesToAffiliate" xlink:type="locator"/>
    <link:label xlink:label="mlss_WriteoffOfAdvancesToAffiliate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_WriteoffOfAdvancesToAffiliate</link:label>
    <link:label xlink:label="mlss_WriteoffOfAdvancesToAffiliate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write-off of Advances to Affiliate</link:label>
    <link:label xlink:label="mlss_WriteoffOfAdvancesToAffiliate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of write-off of advances to affiliate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_WriteoffOfAdvancesToAffiliate" xlink:to="mlss_WriteoffOfAdvancesToAffiliate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdvancesToContractManufacturerTextBlock" xlink:label="mlss_AdvancesToContractManufacturerTextBlock" xlink:type="locator"/>
    <link:label xlink:label="mlss_AdvancesToContractManufacturerTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advances to Contract Manufacturer [Text Block]</link:label>
    <link:label xlink:label="mlss_AdvancesToContractManufacturerTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advances to contract manufacturer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AdvancesToContractManufacturerTextBlock" xlink:to="mlss_AdvancesToContractManufacturerTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForPostemploymentBenefits" xlink:label="us-gaap_PaymentsForPostemploymentBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForPostemploymentBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForPostemploymentBenefits</link:label>
    <link:label xlink:label="us-gaap_PaymentsForPostemploymentBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Postemployment Benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPostemploymentBenefits" xlink:to="us-gaap_PaymentsForPostemploymentBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_InstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Instruments [Member]</link:label>
    <link:label xlink:label="mlss_InstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A product of the reporting entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_InstrumentsMember" xlink:to="mlss_InstrumentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:label="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Sales and Significant Customers and Vendors Disclosure [Text Block]</link:label>
    <link:label xlink:label="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entire disclosure of product sales and significant customers and vendors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:to="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred cost related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinorityInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_CustomerOneMember" xlink:label="mlss_CustomerOneMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_CustomerOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label xlink:label="mlss_CustomerOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unspecified major customer one.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_CustomerOneMember" xlink:to="mlss_CustomerOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_CustomerTwoMember" xlink:label="mlss_CustomerTwoMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_CustomerTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label xlink:label="mlss_CustomerTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unspecified major customer two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_CustomerTwoMember" xlink:to="mlss_CustomerTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NumberOfMedicalInstrumentsSold" xlink:label="mlss_NumberOfMedicalInstrumentsSold" xlink:type="locator"/>
    <link:label xlink:label="mlss_NumberOfMedicalInstrumentsSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_NumberOfMedicalInstrumentsSold</link:label>
    <link:label xlink:label="mlss_NumberOfMedicalInstrumentsSold-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Medical Instruments Sold</link:label>
    <link:label xlink:label="mlss_NumberOfMedicalInstrumentsSold-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of medical instruments sold during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NumberOfMedicalInstrumentsSold" xlink:to="mlss_NumberOfMedicalInstrumentsSold-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:label="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="mlss_SalesByProductAndByGeographicalRegionTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales by Product and by Geographical Region [Table Text Block]</link:label>
    <link:label xlink:label="mlss_SalesByProductAndByGeographicalRegionTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entire disclosure of sales by product and by geographical region.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:to="mlss_SalesByProductAndByGeographicalRegionTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DomesticMember" xlink:label="mlss_DomesticMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_DomesticMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic [Member]</link:label>
    <link:label xlink:label="mlss_DomesticMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The domestic country of the reporting entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DomesticMember" xlink:to="mlss_DomesticMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax paid</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShippingHandlingAndTransportationCosts" xlink:label="us-gaap_ShippingHandlingAndTransportationCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShippingHandlingAndTransportationCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShippingHandlingAndTransportationCosts</link:label>
    <link:label xlink:label="us-gaap_ShippingHandlingAndTransportationCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping, Handling and Transportation Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingHandlingAndTransportationCosts" xlink:to="us-gaap_ShippingHandlingAndTransportationCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredProfitRelatedPartiesCurrent" xlink:label="mlss_DeferredProfitRelatedPartiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="mlss_DeferredProfitRelatedPartiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred profit, related party</link:label>
    <link:label xlink:label="mlss_DeferredProfitRelatedPartiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The carrying amount of deferred profit from related parties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DeferredProfitRelatedPartiesCurrent" xlink:to="mlss_DeferredProfitRelatedPartiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="us-gaap_StandardProductWarrantyPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StandardProductWarrantyPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandardProductWarrantyPolicy" xlink:to="us-gaap_StandardProductWarrantyPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" xlink:label="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" xlink:type="locator"/>
    <link:label xlink:label="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod</link:label>
    <link:label xlink:label="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to Repurchase Variable Entity Shares at Specified Purchase Price, Period</link:label>
    <link:label xlink:label="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period to repurchase the variable entity shares at a specified purchase price under the agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" xlink:to="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryValuationReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryValuationReserves</link:label>
    <link:label xlink:label="us-gaap_InventoryValuationReserves-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" xlink:label="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" xlink:type="locator"/>
    <link:label xlink:label="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice</link:label>
    <link:label xlink:label="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to Repurchase Variable Interest Entity Shares, Purchase Price</link:label>
    <link:label xlink:label="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase price under the agreement to repurchase the variable interest entity shares within the first two years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" xlink:to="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchasePeriod" xlink:label="mlss_OptionToRepurchasePeriod" xlink:type="locator"/>
    <link:label xlink:label="mlss_OptionToRepurchasePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_OptionToRepurchasePeriod</link:label>
    <link:label xlink:label="mlss_OptionToRepurchasePeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to Repurchase, Period</link:label>
    <link:label xlink:label="mlss_OptionToRepurchasePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of option to repurchase pursuant to the agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_OptionToRepurchasePeriod" xlink:to="mlss_OptionToRepurchasePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities" xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities" xlink:type="locator"/>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities</link:label>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement, Post-closing Adjustments, Liabilities</link:label>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of liabilities related to the post-closing adjustments pursuant to the asset purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities" xlink:to="mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum" xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum" xlink:type="locator"/>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum</link:label>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement, Post-closing Adjustments, Percentage of Initial Shares, Maximum</link:label>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum percentage of initial shares subject to post-closing adjustment pursuant to asset purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum" xlink:to="mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Milestone Scientific Inc. stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InnovestSpAMember" xlink:label="mlss_InnovestSpAMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_InnovestSpAMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovest S.p.A. [Member]</link:label>
    <link:label xlink:label="mlss_InnovestSpAMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Innovest S.p.A.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_InnovestSpAMember" xlink:to="mlss_InnovestSpAMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionBasicSalaryForOneYear" xlink:label="mlss_EmployeeResignationAssertionBasicSalaryForOneYear" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmployeeResignationAssertionBasicSalaryForOneYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmployeeResignationAssertionBasicSalaryForOneYear</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionBasicSalaryForOneYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Resignation Assertion, Basic Salary for One Year</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionBasicSalaryForOneYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of basic salary would be paid to a resigned employee for one year according to the his or her assertion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmployeeResignationAssertionBasicSalaryForOneYear" xlink:to="mlss_EmployeeResignationAssertionBasicSalaryForOneYear-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ConsultingServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:label xlink:label="mlss_ConsultingServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents consulting services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ConsultingServicesMember" xlink:to="mlss_ConsultingServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_FormerCeoMember" xlink:label="mlss_FormerCeoMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_FormerCeoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former CEO [Member]</link:label>
    <link:label xlink:label="mlss_FormerCeoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the former CEO of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_FormerCeoMember" xlink:to="mlss_FormerCeoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPaymentsOfLegalFees" xlink:label="mlss_AssetPurchaseAgreementPaymentsOfLegalFees" xlink:type="locator"/>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPaymentsOfLegalFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_AssetPurchaseAgreementPaymentsOfLegalFees</link:label>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPaymentsOfLegalFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement, Payments of Legal Fees</link:label>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPaymentsOfLegalFees-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of cash paid for legal fees on behalf of the settler as stipulated based on the terms of the agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AssetPurchaseAgreementPaymentsOfLegalFees" xlink:to="mlss_AssetPurchaseAgreementPaymentsOfLegalFees-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:label="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Options Issued at the Higher of $2.55 Per Share or Market Price [Member]</link:label>
    <link:label xlink:label="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents employee stock options issued at the higher of $2.55 or the market price of the stock on the date of the 2018 Annual Stockholder meeting, subject to approval of a new amended equity incentive plan at such meeting.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:to="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionCarAllowanceForOneYear" xlink:label="mlss_EmployeeResignationAssertionCarAllowanceForOneYear" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmployeeResignationAssertionCarAllowanceForOneYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmployeeResignationAssertionCarAllowanceForOneYear</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionCarAllowanceForOneYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Resignation Assertion, Car Allowance for One Year</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionCarAllowanceForOneYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of car allowance will be paid to a resigned employee for one year according to the his or her assertion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmployeeResignationAssertionCarAllowanceForOneYear" xlink:to="mlss_EmployeeResignationAssertionCarAllowanceForOneYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ManufacturingAgreementForHandpiecesMember" xlink:label="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ManufacturingAgreementForHandpiecesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Agreement for Handpieces [Member]</link:label>
    <link:label xlink:label="mlss_ManufacturingAgreementForHandpiecesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the manufacturing agreement for handpieces.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ManufacturingAgreementForHandpiecesMember" xlink:to="mlss_ManufacturingAgreementForHandpiecesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionNumberOfOptionsVested" xlink:label="mlss_EmployeeResignationAssertionNumberOfOptionsVested" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmployeeResignationAssertionNumberOfOptionsVested-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmployeeResignationAssertionNumberOfOptionsVested</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionNumberOfOptionsVested-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Resignation Assertion, Number of Options Vested</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionNumberOfOptionsVested-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of options would be vested immediate according to a resigned employee's assertion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmployeeResignationAssertionNumberOfOptionsVested" xlink:to="mlss_EmployeeResignationAssertionNumberOfOptionsVested-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_GianDomenicoTrombettaMember" xlink:label="mlss_GianDomenicoTrombettaMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_GianDomenicoTrombettaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gian Domenico Trombetta [Member]</link:label>
    <link:label xlink:label="mlss_GianDomenicoTrombettaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Gian Domenico Trombetta, CEO of Wand Dental and a director of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_GianDomenicoTrombettaMember" xlink:to="mlss_GianDomenicoTrombettaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:label="mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmployeeStockOptionsIssuedAt255PerShareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Options Issued at $2.55 Per Share [Member]</link:label>
    <link:label xlink:label="mlss_EmployeeStockOptionsIssuedAt255PerShareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents employee stock options issued at $2.54 per share.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:to="mlss_EmployeeStockOptionsIssuedAt255PerShareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear" xlink:label="mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Resignation Assertion, Health and Disability Insurance for One Year</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of health and disability insurance would be paid in behalf of a resigned employee for one year according to the his or her assertion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear" xlink:to="mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionOptionsExercisePrice" xlink:label="mlss_EmployeeResignationAssertionOptionsExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmployeeResignationAssertionOptionsExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmployeeResignationAssertionOptionsExercisePrice</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionOptionsExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Resignation Assertion, Options Exercise Price</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionOptionsExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The exercise price of options according to a resigned employee's assertion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmployeeResignationAssertionOptionsExercisePrice" xlink:to="mlss_EmployeeResignationAssertionOptionsExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:label xlink:label="us-gaap_CostOfGoodsSold-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PurchaseCommitmentNumberOfUnits" xlink:label="mlss_PurchaseCommitmentNumberOfUnits" xlink:type="locator"/>
    <link:label xlink:label="mlss_PurchaseCommitmentNumberOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_PurchaseCommitmentNumberOfUnits</link:label>
    <link:label xlink:label="mlss_PurchaseCommitmentNumberOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment Number Of Units</link:label>
    <link:label xlink:label="mlss_PurchaseCommitmentNumberOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of units commitment to purchase.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PurchaseCommitmentNumberOfUnits" xlink:to="mlss_PurchaseCommitmentNumberOfUnits-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionVestingTermAfterResignation" xlink:label="mlss_EmployeeResignationAssertionVestingTermAfterResignation" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmployeeResignationAssertionVestingTermAfterResignation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmployeeResignationAssertionVestingTermAfterResignation</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionVestingTermAfterResignation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Resignation Assertion, Vesting Term After Resignation</link:label>
    <link:label xlink:label="mlss_EmployeeResignationAssertionVestingTermAfterResignation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The versing term for options according to a employees's assertion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmployeeResignationAssertionVestingTermAfterResignation" xlink:to="mlss_EmployeeResignationAssertionVestingTermAfterResignation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes receivable from financing transaction, short term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:label xlink:label="country_US-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentDeferredGainOnSale" xlink:label="us-gaap_EquityMethodInvestmentDeferredGainOnSale" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentDeferredGainOnSale-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestmentDeferredGainOnSale</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentDeferredGainOnSale-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Deferred Gain on Sale</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDeferredGainOnSale" xlink:to="us-gaap_EquityMethodInvestmentDeferredGainOnSale-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount" xlink:label="us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Unrealized Intercompany Profit (Loss) Not Eliminated, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount" xlink:to="us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OverAllotmentOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total assets:</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DefineBenefitPlanPaymentPeriod" xlink:label="mlss_DefineBenefitPlanPaymentPeriod" xlink:type="locator"/>
    <link:label xlink:label="mlss_DefineBenefitPlanPaymentPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_DefineBenefitPlanPaymentPeriod</link:label>
    <link:label xlink:label="mlss_DefineBenefitPlanPaymentPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Define Benefit Plan, Payment Period</link:label>
    <link:label xlink:label="mlss_DefineBenefitPlanPaymentPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined benefit plan payment period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DefineBenefitPlanPaymentPeriod" xlink:to="mlss_DefineBenefitPlanPaymentPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AreaOfOfficeSpace" xlink:label="mlss_AreaOfOfficeSpace" xlink:type="locator"/>
    <link:label xlink:label="mlss_AreaOfOfficeSpace-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_AreaOfOfficeSpace</link:label>
    <link:label xlink:label="mlss_AreaOfOfficeSpace-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Office Space</link:label>
    <link:label xlink:label="mlss_AreaOfOfficeSpace-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Area of office space.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AreaOfOfficeSpace" xlink:to="mlss_AreaOfOfficeSpace-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology" xlink:label="mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology" xlink:type="locator"/>
    <link:label xlink:label="mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology</link:label>
    <link:label xlink:label="mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Percentage of Director Compensation on Sales Value Using Certain Specify Technology</link:label>
    <link:label xlink:label="mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional payment to director as percentage of sales value using certain specify technology.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology" xlink:to="mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenue</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants" xlink:label="mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Stock Options Exercised, Attributable to Consultants</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock issued during period shares stock options exercised attributable to consultants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants" xlink:to="mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology" xlink:label="mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology" xlink:type="locator"/>
    <link:label xlink:label="mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology</link:label>
    <link:label xlink:label="mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Percentage of Director Compensation Sales Value Using Other Kind of Technology</link:label>
    <link:label xlink:label="mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional payment to director as percentage of sales value using other kind of technology.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology" xlink:to="mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_DirectorOfClinicalAffairsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director of Clinical Affairs [Member]</link:label>
    <link:label xlink:label="mlss_DirectorOfClinicalAffairsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A personnel of the company with the title "Director of Clinical Affairs."</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DirectorOfClinicalAffairsMember" xlink:to="mlss_DirectorOfClinicalAffairsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncontrollingInterestMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds on Private Placement Offering</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum" xlink:label="mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum" xlink:type="locator"/>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum</link:label>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement, Post-closing Adjustments, Amount of Initial Shares, Maximum</link:label>
    <link:label xlink:label="mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount of initial shares subject to post-closing adjustment pursuant to asset purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum" xlink:to="mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds on Public offering</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransactionTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesAgreementTerm" xlink:label="mlss_ConsultingServicesAgreementTerm" xlink:type="locator"/>
    <link:label xlink:label="mlss_ConsultingServicesAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_ConsultingServicesAgreementTerm</link:label>
    <link:label xlink:label="mlss_ConsultingServicesAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting Services Agreement, Term</link:label>
    <link:label xlink:label="mlss_ConsultingServicesAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the expiration period under the consulting services agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ConsultingServicesAgreementTerm" xlink:to="mlss_ConsultingServicesAgreementTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_WebsiteMember" xlink:label="mlss_WebsiteMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_WebsiteMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Website [Member]</link:label>
    <link:label xlink:label="mlss_WebsiteMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Website.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_WebsiteMember" xlink:to="mlss_WebsiteMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017" xlink:label="mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017" xlink:type="locator"/>
    <link:label xlink:label="mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017</link:label>
    <link:label xlink:label="mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Gross, Increase (Decrease) Due to New Tax Cuts and Jobs Act 2017</link:label>
    <link:label xlink:label="mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of adjustment to gross deferred tax assets due to the new Tax Cuts and Jobs Act 2017.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017" xlink:to="mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ToolsDiesAndMoldsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tools, Dies and Molds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ToolsDiesAndMoldsMember" xlink:to="us-gaap_ToolsDiesAndMoldsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:label="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:type="locator"/>
    <link:label xlink:label="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Related to New Tax Cuts and Jobs Act 2017 [Member]</link:label>
    <link:label xlink:label="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the deferred tax assets related to the new Tax Cuts and Jobs Act 2017.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:to="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioForecastMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncomeFromNonemployeeOptions" xlink:label="mlss_IncomeFromNonemployeeOptions" xlink:type="locator"/>
    <link:label xlink:label="mlss_IncomeFromNonemployeeOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_IncomeFromNonemployeeOptions</link:label>
    <link:label xlink:label="mlss_IncomeFromNonemployeeOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from Non-employee Options</link:label>
    <link:label xlink:label="mlss_IncomeFromNonemployeeOptions-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of income related to non-employee options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_IncomeFromNonemployeeOptions" xlink:to="mlss_IncomeFromNonemployeeOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermPurchaseCommitmentAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermPurchaseCommitmentAmount</link:label>
    <link:label xlink:label="us-gaap_LongTermPurchaseCommitmentAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:label="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired</link:label>
    <link:label xlink:label="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment, Minimum Quantity Required</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:to="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:label="us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLoansAndLeasesReceivablePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance, Loans and Leases Receivable, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:to="us-gaap_FinanceLoansAndLeasesReceivablePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="us-gaap_CorporateNonSegmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateNonSegmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNonSegmentMember" xlink:to="us-gaap_CorporateNonSegmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="us-gaap_MaterialReconcilingItemsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaterialReconcilingItemsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaterialReconcilingItemsMember" xlink:to="us-gaap_MaterialReconcilingItemsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="us-gaap_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationItemsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationItemsDomain" xlink:to="us-gaap_ConsolidationItemsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="us-gaap_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationItemsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationItemsAxis" xlink:to="us-gaap_ConsolidationItemsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingSegmentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="us-gaap_WeightedAverageMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageMember" xlink:to="us-gaap_WeightedAverageMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss attributable to noncontrolling interests</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</link:label>
    <link:label xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MajorCustomersAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NameOfMajorCustomerDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="us-gaap_NameOfMajorCustomerDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostMethodInvestmentsRealizedLosses" xlink:label="us-gaap_CostMethodInvestmentsRealizedLosses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostMethodInvestmentsRealizedLosses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostMethodInvestmentsRealizedLosses</link:label>
    <link:label xlink:label="us-gaap_CostMethodInvestmentsRealizedLosses-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost-method Investments, Realized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMethodInvestmentsRealizedLosses" xlink:to="us-gaap_CostMethodInvestmentsRealizedLosses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvesteeNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvesteeNameDomain" xlink:to="us-gaap_EquityMethodInvesteeNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LatestTaxYearMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Latest Tax Year [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarliestTaxYearMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earliest Tax Year [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherOperatingIncomeExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherOperatingIncomeExpenseNet</link:label>
    <link:label xlink:label="us-gaap_OtherOperatingIncomeExpenseNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Losses</link:label>
    <link:label xlink:label="us-gaap_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwardsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income before taxes and equity in earnings of affiliates:</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before provision for income tax and equity in net earnings of equity investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss on earnings from China Joint Venture</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromEquityMethodInvestments</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss China joint venture</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Provision) benefit for income tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AccountsReceivableFromRelatedPartiesMember" xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable from Related Parties [Member]</link:label>
    <link:label xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Primary financial statement caption encompassing accounts receivable from related parties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:to="mlss_AccountsReceivableFromRelatedPartiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred provision for effect of change in Federal</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:type="locator"/>
    <link:label xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss</link:label>
    <link:label xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Deferred Intercompany Profit (Loss)</link:label>
    <link:label xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate amount of deferred intercompany profits and losses on transactions between the Entity and unconsolidated subsidiaries (including certain corporate joint ventures, and noncontrolled corporations), accounted for under the equity method of accounting,as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:to="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementBusinessSegmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-deductible Stock based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State income tax - all states</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost</link:label>
    <link:label xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Capitalized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsReceivableRelatedParties</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EpiduralapadPatentsMember" xlink:label="mlss_EpiduralapadPatentsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_EpiduralapadPatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Epidural-Apad Patents [Member]</link:label>
    <link:label xlink:label="mlss_EpiduralapadPatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to epidural-apad patents.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EpiduralapadPatentsMember" xlink:to="mlss_EpiduralapadPatentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_FoundationIntellectualPropertyPatentsMember" xlink:label="mlss_FoundationIntellectualPropertyPatentsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_FoundationIntellectualPropertyPatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foundation Intellectual Property Patents [Member]</link:label>
    <link:label xlink:label="mlss_FoundationIntellectualPropertyPatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to foundation intellectual property patents.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_FoundationIntellectualPropertyPatentsMember" xlink:to="mlss_FoundationIntellectualPropertyPatentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementOnetimeBonus" xlink:label="mlss_EmploymentAgreementOnetimeBonus" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmploymentAgreementOnetimeBonus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmploymentAgreementOnetimeBonus</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementOnetimeBonus-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Agreement, One-Time Bonus</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementOnetimeBonus-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of a one-time bonus related to an employment agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmploymentAgreementOnetimeBonus" xlink:to="mlss_EmploymentAgreementOnetimeBonus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable from related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseAndRentalExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LeaseAndRentalExpense</link:label>
    <link:label xlink:label="us-gaap_LeaseAndRentalExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue, related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredGainOnDisposalOfInvestment" xlink:label="mlss_DeferredGainOnDisposalOfInvestment" xlink:type="locator"/>
    <link:label xlink:label="mlss_DeferredGainOnDisposalOfInvestment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred gain from financing transaction</link:label>
    <link:label xlink:label="mlss_DeferredGainOnDisposalOfInvestment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of gain on the disposal of investment that does not qualify for gain recognition as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_DeferredGainOnDisposalOfInvestment" xlink:to="mlss_DeferredGainOnDisposalOfInvestment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RoyaltyExpense</link:label>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs" xlink:label="mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock exchanged for MMD (in shares)</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock issued during the period in exchange for common stock of variable interest entities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs" xlink:to="mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs" xlink:label="mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock exchanged for MMD</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the value of shares of stock issued or exchanged during the period as part of a transaction to exchange shares of the entity's common stock for that of variable interest entities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs" xlink:to="mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life, exercisable (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" xlink:type="locator"/>
    <link:label xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage</link:label>
    <link:label xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Deferred Intercompany Profit (Loss), Percentage</link:label>
    <link:label xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The deferred percentage of the gross profit with recognized revenue from Entity and unconsolidated subsidiaries (including certain corporate joint ventures, and noncontrolled corporations), accounted for under the equity method of accounting.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" xlink:to="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_RestOfWorldMember" xlink:label="mlss_RestOfWorldMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_RestOfWorldMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of World [Member]</link:label>
    <link:label xlink:label="mlss_RestOfWorldMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the rest of the world, excluding domestic sales and sales to China.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_RestOfWorldMember" xlink:to="mlss_RestOfWorldMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_InterimChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Chief Executive Officer [Member]</link:label>
    <link:label xlink:label="mlss_InterimChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Interim Chief Executive Officer of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_InterimChiefExecutiveOfficerMember" xlink:to="mlss_InterimChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of options exercisable (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life, outstanding (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:label="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmploymentAndConsultingAgreementsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment and Consulting Agreements [Text Block]</link:label>
    <link:label xlink:label="mlss_EmploymentAndConsultingAgreementsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for employment and consulting agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:to="mlss_EmploymentAndConsultingAgreementsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other payables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodValueDirectorsBonuses" xlink:label="mlss_StockIssuedDuringPeriodValueDirectorsBonuses" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodValueDirectorsBonuses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to directors for bonuses</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodValueDirectorsBonuses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued for directors bonuses during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedDuringPeriodValueDirectorsBonuses" xlink:to="mlss_StockIssuedDuringPeriodValueDirectorsBonuses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinitelivedIntangibleAssetsAcquired1</link:label>
    <link:label xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesDirectorsBonuses" xlink:label="mlss_StockIssuedDuringPeriodSharesDirectorsBonuses" xlink:type="locator"/>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodSharesDirectorsBonuses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to directors for bonuses (in shares)</link:label>
    <link:label xlink:label="mlss_StockIssuedDuringPeriodSharesDirectorsBonuses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock issued for directors bonuses during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_StockIssuedDuringPeriodSharesDirectorsBonuses" xlink:to="mlss_StockIssuedDuringPeriodSharesDirectorsBonuses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, outstanding (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, outstanding (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PurchaseOfIntangiblesAssetsApad" xlink:label="mlss_PurchaseOfIntangiblesAssetsApad" xlink:type="locator"/>
    <link:label xlink:label="mlss_PurchaseOfIntangiblesAssetsApad-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_PurchaseOfIntangiblesAssetsApad</link:label>
    <link:label xlink:label="mlss_PurchaseOfIntangiblesAssetsApad-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangibles assets-APAD</link:label>
    <link:label xlink:label="mlss_PurchaseOfIntangiblesAssetsApad-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow to acquire asset from Apad.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PurchaseOfIntangiblesAssetsApad" xlink:to="mlss_PurchaseOfIntangiblesAssetsApad-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysShares" xlink:label="mlss_SaleOfVariableInterestEntitysShares" xlink:type="locator"/>
    <link:label xlink:label="mlss_SaleOfVariableInterestEntitysShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Milestone China shares, financing transaction</link:label>
    <link:label xlink:label="mlss_SaleOfVariableInterestEntitysShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The value of variable interest entity's shares sold in noncash or partial noncash transactions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SaleOfVariableInterestEntitysShares" xlink:to="mlss_SaleOfVariableInterestEntitysShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedBonusesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedBonusesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedBonusesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, forfeited or expired (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_VariableInterestEntityOwnershipPercentageSold" xlink:label="mlss_VariableInterestEntityOwnershipPercentageSold" xlink:type="locator"/>
    <link:label xlink:label="mlss_VariableInterestEntityOwnershipPercentageSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_VariableInterestEntityOwnershipPercentageSold</link:label>
    <link:label xlink:label="mlss_VariableInterestEntityOwnershipPercentageSold-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Ownership Percentage Sold</link:label>
    <link:label xlink:label="mlss_VariableInterestEntityOwnershipPercentageSold-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of ownership interest in a variable interest entity sold during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_VariableInterestEntityOwnershipPercentageSold" xlink:to="mlss_VariableInterestEntityOwnershipPercentageSold-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of patents</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PriceForSharesOfVariableInterestEntityInterestSold" xlink:label="mlss_PriceForSharesOfVariableInterestEntityInterestSold" xlink:type="locator"/>
    <link:label xlink:label="mlss_PriceForSharesOfVariableInterestEntityInterestSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_PriceForSharesOfVariableInterestEntityInterestSold</link:label>
    <link:label xlink:label="mlss_PriceForSharesOfVariableInterestEntityInterestSold-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price for Shares of Variable Interest Entity Interest Sold</link:label>
    <link:label xlink:label="mlss_PriceForSharesOfVariableInterestEntityInterestSold-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The price for shares of variable interest entity interest sold pursuant the agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PriceForSharesOfVariableInterestEntityInterestSold" xlink:to="mlss_PriceForSharesOfVariableInterestEntityInterestSold-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteReceivableQuarterlyInstallmentAmount" xlink:label="mlss_NoteReceivableQuarterlyInstallmentAmount" xlink:type="locator"/>
    <link:label xlink:label="mlss_NoteReceivableQuarterlyInstallmentAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_NoteReceivableQuarterlyInstallmentAmount</link:label>
    <link:label xlink:label="mlss_NoteReceivableQuarterlyInstallmentAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note Receivable, Quarterly Installment Amount</link:label>
    <link:label xlink:label="mlss_NoteReceivableQuarterlyInstallmentAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of quarterly installment amount in related to the note receivable pursuant to the agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NoteReceivableQuarterlyInstallmentAmount" xlink:to="mlss_NoteReceivableQuarterlyInstallmentAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Variable Interest Entity's Shares [Member]</link:label>
    <link:label xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A transaction of selling variable interest entity's shares that are accounted for as secured financing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:label="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:type="locator"/>
    <link:label xlink:label="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceed from financing transaction</link:label>
    <link:label xlink:label="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Variable Interest Entity Shares with Agreement to Repurchase</link:label>
    <link:label xlink:label="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of cash inflow from the sale of variable interest entity shares with agreement to repurchase.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:to="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of options forfeited and expired (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProfessionalFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProfessionalFees</link:label>
    <link:label xlink:label="us-gaap_ProfessionalFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional Fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireIntangibleAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EquityMethodInvestmentOwnershipPercentage</link:label>
    <link:label xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:label="mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_ConversionPriceIfCertainConditionsAreNotMetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Price if Certain Conditions are Not Met [Member]</link:label>
    <link:label xlink:label="mlss_ConversionPriceIfCertainConditionsAreNotMetMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the conversion price of convertible preferred stock if certain conditions are not met.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:to="mlss_ConversionPriceIfCertainConditionsAreNotMetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Milestone Scientific Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsAndHandpiecesMember" xlink:label="mlss_InstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_InstrumentsAndHandpiecesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Instruments and Handpieces [Member]</link:label>
    <link:label xlink:label="mlss_InstrumentsAndHandpiecesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to instruments and handpieces.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_InstrumentsAndHandpiecesMember" xlink:to="mlss_InstrumentsAndHandpiecesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementTerm" xlink:label="mlss_EmploymentAgreementTerm" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmploymentAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmploymentAgreementTerm</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Agreement Term</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The term of the employment agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmploymentAgreementTerm" xlink:to="mlss_EmploymentAgreementTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_STAInstrumentsAndHandpiecesMember" xlink:label="mlss_STAInstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_STAInstrumentsAndHandpiecesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">STA Instruments and Handpieces [Member]</link:label>
    <link:label xlink:label="mlss_STAInstrumentsAndHandpiecesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to STA instruments and handpieces.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_STAInstrumentsAndHandpiecesMember" xlink:to="mlss_STAInstrumentsAndHandpiecesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementBaseCompensation" xlink:label="mlss_EmploymentAgreementBaseCompensation" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmploymentAgreementBaseCompensation</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Agreement, Base Compensation</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of annual base compensation pursuant to the employment agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmploymentAgreementBaseCompensation" xlink:to="mlss_EmploymentAgreementBaseCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementMaximumBonuses" xlink:label="mlss_EmploymentAgreementMaximumBonuses" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmploymentAgreementMaximumBonuses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmploymentAgreementMaximumBonuses</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementMaximumBonuses-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Agreement, Maximum Bonuses</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementMaximumBonuses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount of annual bonuses pursuant the employment agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmploymentAgreementMaximumBonuses" xlink:to="mlss_EmploymentAgreementMaximumBonuses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Patents, net</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares issued to acquire APAD technology</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_PresidentAndChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">President and Chief Executive Officer [Member]</link:label>
    <link:label xlink:label="mlss_PresidentAndChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the present and Chief Executive Officer of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PresidentAndChiefExecutiveOfficerMember" xlink:to="mlss_PresidentAndChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</link:label>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</link:label>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Patents, accumulated amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Patents, cost</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsGross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NonqualifiedStockOptionsMember" xlink:label="mlss_NonqualifiedStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_NonqualifiedStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-qualified Stock Options [Member]</link:label>
    <link:label xlink:label="mlss_NonqualifiedStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to non-qualified stock options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_NonqualifiedStockOptionsMember" xlink:to="mlss_NonqualifiedStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementBaseCompensationCash" xlink:label="mlss_EmploymentAgreementBaseCompensationCash" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensationCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmploymentAgreementBaseCompensationCash</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensationCash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Agreement, Base Compensation, Cash</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensationCash-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of base compensation that will be paid in cash.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmploymentAgreementBaseCompensationCash" xlink:to="mlss_EmploymentAgreementBaseCompensationCash-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementBaseCompensationCommonStockValue" xlink:label="mlss_EmploymentAgreementBaseCompensationCommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensationCommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_EmploymentAgreementBaseCompensationCommonStockValue</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensationCommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Agreement, Base Compensation, Common Stock Value</link:label>
    <link:label xlink:label="mlss_EmploymentAgreementBaseCompensationCommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of base compensation that will be paid in the issuance of common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_EmploymentAgreementBaseCompensationCommonStockValue" xlink:to="mlss_EmploymentAgreementBaseCompensationCommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previous President and Chief Executive Officer [Member]</link:label>
    <link:label xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the previous president and chief executive officer of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingAgreementTerm" xlink:label="mlss_ConsultingAgreementTerm" xlink:type="locator"/>
    <link:label xlink:label="mlss_ConsultingAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_ConsultingAgreementTerm</link:label>
    <link:label xlink:label="mlss_ConsultingAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting Agreement, Term</link:label>
    <link:label xlink:label="mlss_ConsultingAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The term of consulting agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ConsultingAgreementTerm" xlink:to="mlss_ConsultingAgreementTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingAgreementAnnualPayment" xlink:label="mlss_ConsultingAgreementAnnualPayment" xlink:type="locator"/>
    <link:label xlink:label="mlss_ConsultingAgreementAnnualPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">mlss_ConsultingAgreementAnnualPayment</link:label>
    <link:label xlink:label="mlss_ConsultingAgreementAnnualPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting Agreement, Annual Payment</link:label>
    <link:label xlink:label="mlss_ConsultingAgreementAnnualPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">the annual payment will be paid by the company pursuant to the consulting agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_ConsultingAgreementAnnualPayment" xlink:to="mlss_ConsultingAgreementAnnualPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture, fixtures &amp; equipment net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_APADOctrooiBVAndAPADBVMember" xlink:label="mlss_APADOctrooiBVAndAPADBVMember" xlink:type="locator"/>
    <link:label xlink:label="mlss_APADOctrooiBVAndAPADBVMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APAD Octrooi B.V. and APAD B.V. [Member]</link:label>
    <link:label xlink:label="mlss_APADOctrooiBVAndAPADBVMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to APAD Octrooi B.V. and APAD B.V.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mlss_APADOctrooiBVAndAPADBVMember" xlink:to="mlss_APADOctrooiBVAndAPADBVMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture, fixtures and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsReceivableGross</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share applicable to common stockholders&#8212;</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>mlss-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 10:48PM UTC 2018-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-s-pension-plan" xlink:href="mlss-20171231.xsd#statement-note-s-pension-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-s-pension-plan" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-b-liquidity-and-uncertainties" xlink:href="mlss-20171231.xsd#statement-note-b-liquidity-and-uncertainties" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-b-liquidity-and-uncertainties" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-document-and-entity-information" xlink:href="mlss-20171231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="mlss-20171231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business" xlink:href="mlss-20171231.xsd#statement-note-a-organization-and-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="country_US" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies" xlink:href="mlss-20171231.xsd#statement-note-c-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionsAndWarrantsMember" xlink:label="mlss_OptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="mlss_OptionsAndWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable" xlink:href="mlss-20171231.xsd#statement-note-d-notes-receivable" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancingReceivablesTextBlock" xlink:label="us-gaap_FinancingReceivablesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FinancingReceivablesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories" xlink:href="mlss-20171231.xsd#statement-note-e-inventories" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts" xlink:href="mlss-20171231.xsd#statement-note-f-advances-on-contracts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdvancesToContractManufacturerTextBlock" xlink:label="mlss_AdvancesToContractManufacturerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_AdvancesToContractManufacturerTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity" xlink:href="mlss-20171231.xsd#statement-note-g-consolidation-of-variable-interest-entity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneEducationLLCMember" xlink:label="mlss_MilestoneEducationLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="mlss_MilestoneEducationLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries" xlink:href="mlss-20171231.xsd#statement-note-h-investment-in-unconsolidated-subsidiaries" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AccountsReceivableFromRelatedPartiesMember" xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdvancedOcularSciencesSAMember" xlink:label="mlss_AdvancedOcularSciencesSAMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsAndHandpiecesMember" xlink:label="mlss_InstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneEducationLLCMember" xlink:label="mlss_MilestoneEducationLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_AdvancedOcularSciencesSAMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="mlss_InstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneEducationLLCMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment" xlink:href="mlss-20171231.xsd#statement-note-i-furniture-fixtures-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents" xlink:href="mlss-20171231.xsd#statement-note-j-patents" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-j-patents" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_APADOctrooiBVAndAPADBVMember" xlink:label="mlss_APADOctrooiBVAndAPADBVMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="us-gaap_WeightedAverageMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_WeightedAverageMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="mlss_APADOctrooiBVAndAPADBVMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity" xlink:href="mlss-20171231.xsd#statement-note-k-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:label="mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OtherStockOptionsAndWarrantsMember" xlink:label="mlss_OtherStockOptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SeriesAConvertiblePreferredStockMember" xlink:label="mlss_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UnderwrittenPublicOfferingMember" xlink:label="mlss_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="mlss_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="mlss_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="mlss_OtherStockOptionsAndWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans" xlink:href="mlss-20171231.xsd#statement-note-l-stock-option-plans" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:label="mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:label="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_GianDomenicoTrombettaMember" xlink:label="mlss_GianDomenicoTrombettaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2004Member" xlink:label="mlss_StockOptionPlan2004Member" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2011Member" xlink:label="mlss_StockOptionPlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="mlss_StockOptionPlan2004Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="mlss_StockOptionPlan2011Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_GianDomenicoTrombettaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements" xlink:href="mlss-20171231.xsd#statement-note-m-employment-contract-and-consulting-agreements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:label="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NonqualifiedStockOptionsMember" xlink:label="mlss_NonqualifiedStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2011Member" xlink:label="mlss_StockOptionPlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_PresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="mlss_NonqualifiedStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="mlss_StockOptionPlan2011Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_EmploymentAndConsultingAgreementsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:label="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_LatestTaxYearMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data" xlink:href="mlss-20171231.xsd#statement-note-o-segment-and-geographic-data" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:label="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-p-concentration" xlink:href="mlss-20171231.xsd#statement-note-p-concentration" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-p-concentration" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_CustomerOneMember" xlink:label="mlss_CustomerOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_CustomerTwoMember" xlink:label="mlss_CustomerTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_TwoCustomersMember" xlink:label="mlss_TwoCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="us-gaap_SalesRevenueGoodsNetMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueGoodsNetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="mlss_TwoCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="mlss_CustomerOneMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="mlss_CustomerTwoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions" xlink:href="mlss-20171231.xsd#statement-note-q-related-party-transzactions" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InnovestSpAMember" xlink:label="mlss_InnovestSpAMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsAndHandpiecesMember" xlink:label="mlss_InstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ManufacturingAgreementForHandpiecesMember" xlink:label="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_STAInstrumentsAndHandpiecesMember" xlink:label="mlss_STAInstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="mlss_InstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="mlss_STAInstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="mlss_InnovestSpAMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other" xlink:href="mlss-20171231.xsd#statement-note-r-commitments-and-other" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_FormerCeoMember" xlink:label="mlss_FormerCeoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InnovestSpAMember" xlink:label="mlss_InnovestSpAMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="mlss_InnovestSpAMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_FormerCeoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events" xlink:href="mlss-20171231.xsd#statement-note-t-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NotesToFinancialStatementsAbstract" xlink:label="mlss_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-significant-accounting-policies-policies" xlink:href="mlss-20171231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-significant-accounting-policies-policies" xlink:label="mlss_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:label="us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="us-gaap_StandardProductWarrantyPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StandardProductWarrantyPolicy" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-tables" xlink:href="mlss-20171231.xsd#statement-note-e-inventories-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-e-inventories-tables" xlink:label="mlss_statement-statement-note-e-inventories-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-e-inventories-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:href="mlss-20171231.xsd#statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:label="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-tables" xlink:href="mlss-20171231.xsd#statement-note-i-furniture-fixtures-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-i-furniture-fixtures-and-equipment-tables" xlink:label="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-tables" xlink:href="mlss-20171231.xsd#statement-note-j-patents-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-tables" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-j-patents-tables" xlink:label="mlss_statement-statement-note-j-patents-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-j-patents-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-tables" xlink:href="mlss-20171231.xsd#statement-note-l-stock-option-plans-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-tables" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-l-stock-option-plans-tables" xlink:label="mlss_statement-statement-note-l-stock-option-plans-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-l-stock-option-plans-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-tables" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-n-income-taxes-tables" xlink:label="mlss_statement-statement-note-n-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-n-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-tables" xlink:href="mlss-20171231.xsd#statement-note-o-segment-and-geographic-data-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-tables" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:label="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-o-segment-and-geographic-data-tables" xlink:label="mlss_statement-statement-note-o-segment-and-geographic-data-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-o-segment-and-geographic-data-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="mlss_SalesByProductAndByGeographicalRegionTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-tables" xlink:href="mlss-20171231.xsd#statement-note-r-commitments-and-other-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-tables" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-r-commitments-and-other-tables" xlink:label="mlss_statement-statement-note-r-commitments-and-other-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-r-commitments-and-other-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business-details-textual" xlink:href="mlss-20171231.xsd#statement-note-a-organization-and-business-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NumberOfMedicalInstrumentsSold" xlink:label="mlss_NumberOfMedicalInstrumentsSold-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="us-gaap_NumberOfCountriesInWhichEntityOperates-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="country_US" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfCountriesInWhichEntityOperates-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NumberOfMedicalInstrumentsSold-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:href="mlss-20171231.xsd#statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncomeFromNonemployeeOptions" xlink:label="mlss_IncomeFromNonemployeeOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionsAndWarrantsMember" xlink:label="mlss_OptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage" xlink:label="mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShippingHandlingAndTransportationCosts" xlink:label="us-gaap_ShippingHandlingAndTransportationCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="mlss_OptionsAndWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShippingHandlingAndTransportationCosts-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_IncomeFromNonemployeeOptions-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable-details-textual" xlink:href="mlss-20171231.xsd#statement-note-d-notes-receivable-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteReceivableQuarterlyInstallmentAmount" xlink:label="mlss_NoteReceivableQuarterlyInstallmentAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchasePeriod" xlink:label="mlss_OptionToRepurchasePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" xlink:label="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" xlink:label="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PriceForSharesOfVariableInterestEntityInterestSold" xlink:label="mlss_PriceForSharesOfVariableInterestEntityInterestSold-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:label="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ReturnObligationAmount" xlink:label="mlss_ReturnObligationAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentDeferredGainOnSale" xlink:label="us-gaap_EquityMethodInvestmentDeferredGainOnSale-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="us-gaap_NotesReceivableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchasePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PriceForSharesOfVariableInterestEntityInterestSold-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesReceivableNet-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NoteReceivableQuarterlyInstallmentAmount-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ReturnObligationAmount-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentDeferredGainOnSale-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-details-textual" xlink:href="mlss-20171231.xsd#statement-note-e-inventories-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts-details-textual" xlink:href="mlss-20171231.xsd#statement-note-f-advances-on-contracts-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity-details-textual" xlink:href="mlss-20171231.xsd#statement-note-g-consolidation-of-variable-interest-entity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneEducationLLCMember" xlink:label="mlss_MilestoneEducationLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity" xlink:label="mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:to="mlss_MilestoneEducationLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-details-textual" xlink:href="mlss-20171231.xsd#statement-note-h-investment-in-unconsolidated-subsidiaries-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AccountsReceivableFromRelatedPartiesMember" xlink:label="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdvancedOcularSciencesSAMember" xlink:label="mlss_AdvancedOcularSciencesSAMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss" xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage" xlink:label="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsAndHandpiecesMember" xlink:label="mlss_InstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneEducationLLCMember" xlink:label="mlss_MilestoneEducationLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteReceivableQuarterlyInstallmentAmount" xlink:label="mlss_NoteReceivableQuarterlyInstallmentAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchasePeriod" xlink:label="mlss_OptionToRepurchasePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod" xlink:label="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice" xlink:label="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PriceForSharesOfVariableInterestEntityInterestSold" xlink:label="mlss_PriceForSharesOfVariableInterestEntityInterestSold-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:label="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ReturnObligationAmount" xlink:label="mlss_ReturnObligationAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_VariableInterestEntityOwnershipPercentageSold" xlink:label="mlss_VariableInterestEntityOwnershipPercentageSold-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_WriteoffOfAdvancesToAffiliate" xlink:label="mlss_WriteoffOfAdvancesToAffiliate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvancesToAffiliate" xlink:label="us-gaap_AdvancesToAffiliate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostMethodInvestmentsRealizedLosses" xlink:label="us-gaap_CostMethodInvestmentsRealizedLosses-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentDeferredGainOnSale" xlink:label="us-gaap_EquityMethodInvestmentDeferredGainOnSale-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount" xlink:label="us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:label="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="us-gaap_NotesReceivableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_AdvancedOcularSciencesSAMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="mlss_InstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="mlss_AccountsReceivableFromRelatedPartiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneEducationLLCMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvancesToAffiliate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_WriteoffOfAdvancesToAffiliate-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments-n2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostMethodInvestmentsRealizedLosses-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchasePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PriceForSharesOfVariableInterestEntityInterestSold-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesReceivableNet-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NoteReceivableQuarterlyInstallmentAmount-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentDeferredGainOnSale-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_VariableInterestEntityOwnershipPercentageSold-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ReturnObligationAmount-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-details-textual" xlink:href="mlss-20171231.xsd#statement-note-i-furniture-fixtures-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-details-textual" xlink:href="mlss-20171231.xsd#statement-note-j-patents-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_APADOctrooiBVAndAPADBVMember" xlink:label="mlss_APADOctrooiBVAndAPADBVMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPaymentsOfLegalFees" xlink:label="mlss_AssetPurchaseAgreementPaymentsOfLegalFees-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum" xlink:label="mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities" xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum" xlink:label="mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="us-gaap_WeightedAverageMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_WeightedAverageMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="mlss_APADOctrooiBVAndAPADBVMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AssetPurchaseAgreementPaymentsOfLegalFees-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity-details-textual" xlink:href="mlss-20171231.xsd#statement-note-k-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:label="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ClassOfWarrantOrRightExpirationPeriod" xlink:label="mlss_ClassOfWarrantOrRightExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:label="mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OtherStockOptionsAndWarrantsMember" xlink:label="mlss_OtherStockOptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SeriesAConvertiblePreferredStockMember" xlink:label="mlss_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UnderwrittenPublicOfferingMember" xlink:label="mlss_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="mlss_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="mlss_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="mlss_ConversionPriceIfCertainConditionsAreNotMetMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="mlss_OtherStockOptionsAndWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ClassOfWarrantOrRightExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-details-textual" xlink:href="mlss-20171231.xsd#statement-note-l-stock-option-plans-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:label="mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:label="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_GianDomenicoTrombettaMember" xlink:label="mlss_GianDomenicoTrombettaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncomeFromNonemployeeOptions" xlink:label="mlss_IncomeFromNonemployeeOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2004Member" xlink:label="mlss_StockOptionPlan2004Member" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2011Member" xlink:label="mlss_StockOptionPlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="mlss_StockOptionPlan2004Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="mlss_StockOptionPlan2011Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_GianDomenicoTrombettaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="mlss_EmployeeStockOptionsIssuedAt255PerShareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_IncomeFromNonemployeeOptions-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements-details-textual" xlink:href="mlss-20171231.xsd#statement-note-m-employment-contract-and-consulting-agreements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod" xlink:label="mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod" xlink:label="mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingAgreementAnnualPayment" xlink:label="mlss_ConsultingAgreementAnnualPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingAgreementTerm" xlink:label="mlss_ConsultingAgreementTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementBaseCompensation" xlink:label="mlss_EmploymentAgreementBaseCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementBaseCompensationCash" xlink:label="mlss_EmploymentAgreementBaseCompensationCash-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementBaseCompensationCommonStockValue" xlink:label="mlss_EmploymentAgreementBaseCompensationCommonStockValue-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementMaximumBonuses" xlink:label="mlss_EmploymentAgreementMaximumBonuses-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementOnetimeBonus" xlink:label="mlss_EmploymentAgreementOnetimeBonus-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmploymentAgreementTerm" xlink:label="mlss_EmploymentAgreementTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InterimChiefExecutiveOfficerMember" xlink:label="mlss_InterimChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MinimumShareholdingPercentageInCompany" xlink:label="mlss_MinimumShareholdingPercentageInCompany-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NonqualifiedStockOptionsMember" xlink:label="mlss_NonqualifiedStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OptionsExercisablePeriod" xlink:label="mlss_OptionsExercisablePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:label="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockOptionPlan2011Member" xlink:label="mlss_StockOptionPlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_PresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="mlss_NonqualifiedStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="mlss_StockOptionPlan2011Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_PreviousPresidentAndChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_InterimChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedBonusesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_MinimumShareholdingPercentageInCompany-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_OptionsExercisablePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementTerm-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementBaseCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementMaximumBonuses-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementBaseCompensationCash-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementBaseCompensationCommonStockValue-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ConsultingAgreementTerm-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ConsultingAgreementAnnualPayment-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmploymentAgreementOnetimeBonus-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-details-textual" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017" xlink:label="mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017-n2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:label="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PercentageOfValuationAllowance" xlink:label="mlss_PercentageOfValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-n2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_LatestTaxYearMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017-n2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PercentageOfValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-details-textual" xlink:href="mlss-20171231.xsd#statement-note-o-segment-and-geographic-data-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-p-concentration-details-textual" xlink:href="mlss-20171231.xsd#statement-note-p-concentration-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-p-concentration-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_CustomerOneMember" xlink:label="mlss_CustomerOneMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_CustomerTwoMember" xlink:label="mlss_CustomerTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NumberOfCustomers" xlink:label="mlss_NumberOfCustomers-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PurchaseCommitmentNumberOfUnits" xlink:label="mlss_PurchaseCommitmentNumberOfUnits-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_TwoCustomersMember" xlink:label="mlss_TwoCustomersMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="us-gaap_SalesRevenueGoodsNetMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueGoodsNetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="mlss_TwoCustomersMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="mlss_CustomerOneMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="mlss_CustomerTwoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_PurchaseCommitmentNumberOfUnits-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_NumberOfCustomers-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableGross-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions-details-textual" xlink:href="mlss-20171231.xsd#statement-note-q-related-party-transzactions-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesAgreementTerm" xlink:label="mlss_ConsultingServicesAgreementTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InnovestSpAMember" xlink:label="mlss_InnovestSpAMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsAndHandpiecesMember" xlink:label="mlss_InstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ManufacturingAgreementForHandpiecesMember" xlink:label="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_STAInstrumentsAndHandpiecesMember" xlink:label="mlss_STAInstrumentsAndHandpiecesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="us-gaap_AccountsReceivableRelatedParties-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ManufacturingAgreementForHandpiecesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="mlss_InstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="mlss_STAInstrumentsAndHandpiecesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="mlss_InnovestSpAMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ConsultingServicesAgreementTerm-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-details-textual" xlink:href="mlss-20171231.xsd#statement-note-r-commitments-and-other-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology" xlink:label="mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology" xlink:label="mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_AreaOfOfficeSpace" xlink:label="mlss_AreaOfOfficeSpace-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsultingServicesMember" xlink:label="mlss_ConsultingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DefineBenefitPlanPaymentPeriod" xlink:label="mlss_DefineBenefitPlanPaymentPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DirectorOfClinicalAffairsMember" xlink:label="mlss_DirectorOfClinicalAffairsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionBasicSalaryForOneYear" xlink:label="mlss_EmployeeResignationAssertionBasicSalaryForOneYear-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionCarAllowanceForOneYear" xlink:label="mlss_EmployeeResignationAssertionCarAllowanceForOneYear-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionGrossSettlement" xlink:label="mlss_EmployeeResignationAssertionGrossSettlement-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear" xlink:label="mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionNumberOfOptionsVested" xlink:label="mlss_EmployeeResignationAssertionNumberOfOptionsVested-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionOptionsExercisePrice" xlink:label="mlss_EmployeeResignationAssertionOptionsExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionPayment" xlink:label="mlss_EmployeeResignationAssertionPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EmployeeResignationAssertionVestingTermAfterResignation" xlink:label="mlss_EmployeeResignationAssertionVestingTermAfterResignation-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_FormerCeoMember" xlink:label="mlss_FormerCeoMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InnovestSpAMember" xlink:label="mlss_InnovestSpAMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants" xlink:label="mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForPostemploymentBenefits" xlink:label="us-gaap_PaymentsForPostemploymentBenefits-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_DirectorOfClinicalAffairsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="mlss_InnovestSpAMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="mlss_ConsultingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="mlss_FormerCeoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AreaOfOfficeSpace-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseAndRentalExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForPostemploymentBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DefineBenefitPlanPaymentPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RoyaltyExpense-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfessionalFees-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionBasicSalaryForOneYear-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionCarAllowanceForOneYear-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionVestingTermAfterResignation-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionNumberOfOptionsVested-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionOptionsExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionGrossSettlement-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EmployeeResignationAssertionPayment-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events-details-textual" xlink:href="mlss-20171231.xsd#statement-note-t-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_InstrumentsMember" xlink:label="mlss_InstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NoteToFinancialStatementDetailsTextual" xlink:label="mlss_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ReturnObligationAmount" xlink:label="mlss_ReturnObligationAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysSharesMember" xlink:label="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UponExerciseOfDefaultAgreementMember" xlink:label="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired" xlink:label="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="mlss_InstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="mlss_SaleOfVariableInterestEntitysSharesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="mlss_UponExerciseOfDefaultAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ReturnObligationAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:href="mlss-20171231.xsd#statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_NonEmployeeOptionsMember" xlink:label="mlss_NonEmployeeOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:label="mlss_statement-statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="mlss_NonEmployeeOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:href="mlss-20171231.xsd#statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:label="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:label="mlss_statement-statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:href="mlss-20171231.xsd#statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:label="mlss_statement-statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation" xlink:label="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-3" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:label="mlss_statement-statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:href="mlss-20171231.xsd#statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneChinaMember" xlink:label="mlss_MilestoneChinaMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:label="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="mlss_MilestoneChinaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsSold-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet-n9" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-summary-of-patents-details" xlink:href="mlss-20171231.xsd#statement-note-j-patents-summary-of-patents-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-j-patents-summary-of-patents-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EpiduralapadPatentsMember" xlink:label="mlss_EpiduralapadPatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_FoundationIntellectualPropertyPatentsMember" xlink:label="mlss_FoundationIntellectualPropertyPatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-j-patents-summary-of-patents-details" xlink:label="mlss_statement-statement-note-j-patents-summary-of-patents-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-j-patents-summary-of-patents-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="mlss_FoundationIntellectualPropertyPatentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="mlss_EpiduralapadPatentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n9" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:href="mlss-20171231.xsd#statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:label="mlss_statement-statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="us-gaap_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="us-gaap_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="us-gaap_CorporateNonSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="us-gaap_MaterialReconcilingItemsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationItemsAxis" xlink:to="us-gaap_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationItemsAxis" xlink:to="us-gaap_CorporateNonSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationItemsAxis" xlink:to="us-gaap_MaterialReconcilingItemsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-summary-of-inventories-details" xlink:href="mlss-20171231.xsd#statement-note-e-inventories-summary-of-inventories-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-summary-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-e-inventories-summary-of-inventories-details" xlink:label="mlss_statement-statement-note-e-inventories-summary-of-inventories-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-e-inventories-summary-of-inventories-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:href="mlss-20171231.xsd#statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ComputerAndSoftwareMember" xlink:label="mlss_ComputerAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_EPIAndIAInstrumentsMember" xlink:label="mlss_EPIAndIAInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_OfficeFurnitureAndEquipmentMember" xlink:label="mlss_OfficeFurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_STATrialsInstrumentsMember" xlink:label="mlss_STATrialsInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ToolingEquipmentSTAAndWandMember" xlink:label="mlss_ToolingEquipmentSTAAndWandMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ToolingSafetyWandMember" xlink:label="mlss_ToolingSafetyWandMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_TradeShowDisplaysMember" xlink:label="mlss_TradeShowDisplaysMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_WebsiteMember" xlink:label="mlss_WebsiteMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:label="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_OfficeFurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ToolsDiesAndMoldsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_TradeShowDisplaysMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_ComputerAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_ToolingSafetyWandMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_WebsiteMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_ToolingEquipmentSTAAndWandMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_EPIAndIAInstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="mlss_STATrialsInstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n9" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-deferred-tax-assets-details" xlink:href="mlss-20171231.xsd#statement-note-n-income-taxes-deferred-tax-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent" xlink:label="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-n-income-taxes-deferred-tax-assets-details" xlink:label="mlss_statement-statement-note-n-income-taxes-deferred-tax-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowanceCurrent" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-n-income-taxes-deferred-tax-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGrossCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowanceCurrent-n8" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:href="mlss-20171231.xsd#statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CN" xlink:label="country_CN" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DentalSegmentMember" xlink:label="mlss_DentalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DomesticMember" xlink:label="mlss_DomesticMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MedicalSegmentMember" xlink:label="mlss_MedicalSegmentMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_RestOfWorldMember" xlink:label="mlss_RestOfWorldMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_statement-statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:label="mlss_statement-statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_statement-statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_DentalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="mlss_DomesticMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="mlss_RestOfWorldMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="country_CN" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="mlss_MedicalSegmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-operations" xlink:href="mlss-20171231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:label="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_GrossProfit-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments-1" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ProfitLoss-3" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-cash-flows" xlink:href="mlss-20171231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ConsolidationOfVariableInterestEntity" xlink:label="mlss_ConsolidationOfVariableInterestEntity" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_IncreaseDecreaseToAdvancesToContractManufacturer" xlink:label="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-n8" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:label="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_PurchaseOfIntangiblesAssetsApad" xlink:label="mlss_PurchaseOfIntangiblesAssetsApad-n8" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_SaleOfVariableInterestEntitysShares" xlink:label="mlss_SaleOfVariableInterestEntitysShares" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedEmployeesCompensation" xlink:label="mlss_StockIssuedEmployeesCompensation" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedForPublicOffering" xlink:label="mlss_StockIssuedForPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments-n9" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n9" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mlss_IncreaseDecreaseToAdvancesToContractManufacturer-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="mlss_PurchaseOfIntangiblesAssetsApad-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="mlss_ConsolidationOfVariableInterestEntity" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_StockIssued1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="mlss_SaleOfVariableInterestEntitysShares" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="mlss_StockIssuedForPublicOffering" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="mlss_StockIssuedEmployeesCompensation" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets" xlink:href="mlss-20171231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredGainOnDisposalOfInvestment" xlink:label="mlss_DeferredGainOnDisposalOfInvestment" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_DeferredProfitRelatedPartiesCurrent" xlink:label="mlss_DeferredProfitRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mlss_DeferredProfitRelatedPartiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mlss_DeferredGainOnDisposalOfInvestment" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.milestonescientific.com/20171231/role/statement-consolidated-statement-of-changes-in-stockholders-equity" xlink:href="mlss-20171231.xsd#statement-consolidated-statement-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.milestonescientific.com/20171231/role/statement-consolidated-statement-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="mlss-20171231.xsd#mlss_MilestoneEducationLLCMember" xlink:label="mlss_MilestoneEducationLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesDirectorsBonuses" xlink:label="mlss_StockIssuedDuringPeriodSharesDirectorsBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesEmployeeBonuses" xlink:label="mlss_StockIssuedDuringPeriodSharesEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs" xlink:label="mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodValueDirectorsBonuses" xlink:label="mlss_StockIssuedDuringPeriodValueDirectorsBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:label="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs" xlink:label="mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs" xlink:type="locator"/>
    <link:loc xlink:href="mlss-20171231.xsd#mlss_UnderwrittenPublicOfferingMember" xlink:label="mlss_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="mlss_MilestoneEducationLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="mlss_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="us-gaap_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodSharesEmployeeBonuses" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodValueEmployeeBonuses" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss-1" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodSharesDirectorsBonuses" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mlss_StockIssuedDuringPeriodValueDirectorsBonuses" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued-5" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6838659792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MILESTONE SCIENTIFIC INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000855683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">mlss<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,158,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,489,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839140592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,636,956<span></span>
</td>
<td class="nump">$ 3,602,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,535,513<span></span>
</td>
<td class="nump">802,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from related party</a></td>
<td class="nump">1,725,450<span></span>
</td>
<td class="nump">2,714,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Notes receivable from financing transaction, short term</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">436,410<span></span>
</td>
<td class="nump">291,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred cost related party</a></td>
<td class="nump">1,109,671<span></span>
</td>
<td class="nump">620,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">3,379,209<span></span>
</td>
<td class="nump">4,602,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances on contracts</a></td>
<td class="nump">697,192<span></span>
</td>
<td class="nump">700,900<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">12,020,401<span></span>
</td>
<td class="nump">13,344,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture, fixtures &amp; equipment net</a></td>
<td class="nump">141,760<span></span>
</td>
<td class="nump">159,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">2,789,748<span></span>
</td>
<td class="nump">660,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Notes receivable from financing transaction long term</a></td>
<td class="nump">650,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">26,878<span></span>
</td>
<td class="nump">17,355<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">15,628,787<span></span>
</td>
<td class="nump">14,181,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">977,623<span></span>
</td>
<td class="nump">1,341,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable related party</a></td>
<td class="nump">985,678<span></span>
</td>
<td class="nump">1,235,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other payables</a></td>
<td class="nump">2,287,908<span></span>
</td>
<td class="nump">1,436,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_DeferredProfitRelatedPartiesCurrent', window );">Deferred profit, related party</a></td>
<td class="nump">751,500<span></span>
</td>
<td class="nump">630,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, related party</a></td>
<td class="nump">1,725,450<span></span>
</td>
<td class="nump">1,001,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,728,159<span></span>
</td>
<td class="nump">5,645,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_DeferredGainOnDisposalOfInvestment', window );">Deferred gain from financing transaction</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,128,159<span></span>
</td>
<td class="nump">5,645,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A convertible preferred stock, par value $.001, authorized 5,000,000 shares, and 7,000 shares issued and outstanding as December 31, 2017 and 2016.</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $.001; authorized 50,000,000 shares; 33,191,571 shares issued, 1,401,247 shares to be issued and 33,158,238 shares outstanding as of December 31, 2017; 30,457,224 shares issued, 1,270,481 shares to be issued and 30,423,891 shares outstanding as of December 31, 2016</a></td>
<td class="nump">34,593<span></span>
</td>
<td class="nump">31,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">86,689,084<span></span>
</td>
<td class="nump">82,761,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(78,568,284)<span></span>
</td>
<td class="num">(73,381,491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 33,333 shares</a></td>
<td class="num">(911,516)<span></span>
</td>
<td class="num">(911,516)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Milestone Scientific Inc. stockholders' equity</a></td>
<td class="nump">7,243,884<span></span>
</td>
<td class="nump">8,500,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">256,744<span></span>
</td>
<td class="nump">36,106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">7,500,628<span></span>
</td>
<td class="nump">8,536,329<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 15,628,787<span></span>
</td>
<td class="nump">$ 14,181,640<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_DeferredGainOnDisposalOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gain on the disposal of investment that does not qualify for gain recognition as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_DeferredGainOnDisposalOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_DeferredProfitRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of deferred profit from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_DeferredProfitRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An amount representing an agreement for an unconditional promise by the maker to pay the Company (holder) a definite sum of money within one year from the balance sheet date (or the normal operating cycle, whichever is longer), net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82891408&amp;loc=d3e4531-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date more than one year from the balance sheet date, net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6838733040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">33,191,571<span></span>
</td>
<td class="nump">30,457,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Common stock, shares to be issued (in shares)</a></td>
<td class="nump">1,401,247<span></span>
</td>
<td class="nump">1,270,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">33,158,238<span></span>
</td>
<td class="nump">30,423,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, at cost, shares (in shares)</a></td>
<td class="nump">33,333<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839137328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">$ 11,281,886<span></span>
</td>
<td class="nump">$ 10,482,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of products sold</a></td>
<td class="nump">4,312,507<span></span>
</td>
<td class="nump">4,175,533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">6,969,379<span></span>
</td>
<td class="nump">6,306,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">11,930,951<span></span>
</td>
<td class="nump">11,549,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">272,746<span></span>
</td>
<td class="nump">1,270,471<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">12,203,697<span></span>
</td>
<td class="nump">12,820,432<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,234,318)<span></span>
</td>
<td class="num">(6,513,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses</a></td>
<td class="num">(4,930)<span></span>
</td>
<td class="num">(5,088)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">9,298<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before provision for income tax and equity in net earnings of equity investments</a></td>
<td class="num">(5,229,950)<span></span>
</td>
<td class="num">(6,517,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision) benefit for income tax</a></td>
<td class="num">(19,093)<span></span>
</td>
<td class="nump">19,101<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before equity in net earnings of equity investments</a></td>
<td class="num">(5,249,043)<span></span>
</td>
<td class="num">(6,498,662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on earnings from China Joint Venture</a></td>
<td class="num">(120,510)<span></span>
</td>
<td class="num">(795,827)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,369,553)<span></span>
</td>
<td class="num">(7,294,489)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(182,760)<span></span>
</td>
<td class="num">(1,347,982)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Milestone Scientific Inc.</a></td>
<td class="num">$ (5,186,793)<span></span>
</td>
<td class="num">$ (5,946,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share applicable to common stockholders&#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract', window );"><strong>Weighted average shares outstanding and to be issued&#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">32,703,897<span></span>
</td>
<td class="nump">26,966,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">32,703,897<span></span>
</td>
<td class="nump">26,966,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, before income or loss from equity method investments, extraordinary items, and noncontrolling interest, but after income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_IncomeLossFromContinuingOperationsBeforeMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6845038256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Milestone Education LLC [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Milestone Education LLC [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Milestone Education LLC [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Milestone Education LLC [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>Milestone Education LLC [Member] </div>
<div>Noncontrolling Interest [Member]</div>
</th>
<th class="th">
<div>Milestone Education LLC [Member] </div>
<div>Treasury Stock [Member]</div>
</th>
<th class="th"><div>Milestone Education LLC [Member]</div></th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Noncontrolling Interest [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Treasury Stock [Member]</div>
</th>
<th class="th"><div>Private Placement [Member]</div></th>
<th class="th">
<div>Underwritten Public Offering [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Underwritten Public Offering [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Underwritten Public Offering [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Underwritten Public Offering [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th">
<div>Underwritten Public Offering [Member] </div>
<div>Noncontrolling Interest [Member]</div>
</th>
<th class="th">
<div>Underwritten Public Offering [Member] </div>
<div>Treasury Stock [Member]</div>
</th>
<th class="th"><div>Underwritten Public Offering [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">22,685,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2015</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,346<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 22,685<span></span>
</td>
<td class="nump">$ 78,632,383<span></span>
</td>
<td class="num">$ (67,434,984)<span></span>
</td>
<td class="num">$ (1,143,083)<span></span>
</td>
<td class="num">$ (911,516)<span></span>
</td>
<td class="nump">$ 9,165,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">580,347<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">580,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock to be issued to employee for compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock to be issued to employee for compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">29,986<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock to be issued to employee for stock program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">31,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock to be issued to employee for stock program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">58,969<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">59,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued to employee for exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">327,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued to employee for exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">137,172<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">137,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for payment of consulting services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">270,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for payment of consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
<td class="nump">504,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">504,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodSharesEmployeeBonuses', window );">Common stock to be issued to employee for bonuses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">259,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodValueEmployeeBonuses', window );">Common stock to be issued to employee for bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
<td class="nump">539,240<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">539,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,104,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,104<span></span>
</td>
<td class="nump">$ 2,223,896<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,225,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,571,220<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,573,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs', window );">Common Stock exchanged for MMD (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,035,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs', window );">Common Stock exchanged for MMD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,035<span></span>
</td>
<td class="num">(2,515,860)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,510,825<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,946,507)<span></span>
</td>
<td class="num">(1,347,982)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,294,489)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">31,727,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 31,720<span></span>
</td>
<td class="nump">82,761,503<span></span>
</td>
<td class="num">(73,381,491)<span></span>
</td>
<td class="nump">36,106<span></span>
</td>
<td class="num">(911,516)<span></span>
</td>
<td class="nump">8,536,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">651,413<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">651,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock to be issued to employee for compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock to be issued to employee for compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">14,989<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued to employee for exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued to employee for exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">62,417<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for payment of consulting services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">410,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for payment of consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 419<span></span>
</td>
<td class="nump">548,092<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">548,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodSharesEmployeeBonuses', window );">Common stock to be issued to employee for bonuses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">158,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodValueEmployeeBonuses', window );">Common stock to be issued to employee for bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">259,834<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">259,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">123,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 150,712<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 150,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs', window );">Common Stock exchanged for MMD (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">311,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs', window );">Common Stock exchanged for MMD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="num">(403,710)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">403,398<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,186,793)<span></span>
</td>
<td class="num">(182,760)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,369,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Common stock issued for asset acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,646,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Common stock issued for asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,646<span></span>
</td>
<td class="nump">2,484,354<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,486,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodSharesDirectorsBonuses', window );">Common stock issued to directors for bonuses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodValueDirectorsBonuses', window );">Common stock issued to directors for bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">159,480<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">159,600<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">34,592,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 34,593<span></span>
</td>
<td class="nump">$ 86,689,084<span></span>
</td>
<td class="num">$ (78,568,284)<span></span>
</td>
<td class="nump">$ 256,744<span></span>
</td>
<td class="num">$ (911,516)<span></span>
</td>
<td class="nump">$ 7,500,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedDuringPeriodSharesDirectorsBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued for directors bonuses during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedDuringPeriodSharesDirectorsBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedDuringPeriodSharesEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued for employee bonuses during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedDuringPeriodSharesEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period in exchange for common stock of variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedDuringPeriodSharesExchangedForCommonStockOfVIEs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedDuringPeriodValueDirectorsBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for directors bonuses during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedDuringPeriodValueDirectorsBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedDuringPeriodValueEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for employee bonuses during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedDuringPeriodValueEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of shares of stock issued or exchanged during the period as part of a transaction to exchange shares of the entity's common stock for that of variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedDuringPeriodValueExchangedForCommonStockOfVIEs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817602816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (5,369,553)<span></span>
</td>
<td class="num">$ (7,294,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">62,475<span></span>
</td>
<td class="nump">92,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of patents</a></td>
<td class="nump">510,676<span></span>
</td>
<td class="nump">70,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation</a></td>
<td class="nump">651,413<span></span>
</td>
<td class="nump">1,850,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss China joint venture</a></td>
<td class="nump">120,510<span></span>
</td>
<td class="nump">795,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Increase inventories allowance</a></td>
<td class="nump">219,834<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) Decrease in accounts receivable</a></td>
<td class="num">(733,129)<span></span>
</td>
<td class="nump">635,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Decrease (Increase) in accounts receivable related party</a></td>
<td class="nump">989,150<span></span>
</td>
<td class="num">(1,727,210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease in other receivable</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">48,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (Increase) in inventories</a></td>
<td class="nump">1,003,676<span></span>
</td>
<td class="num">(509,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_IncreaseDecreaseToAdvancesToContractManufacturer', window );">Decrease to advances on contracts</a></td>
<td class="nump">3,708<span></span>
</td>
<td class="nump">514,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) Decrease in prepaid expenses and other current assets</a></td>
<td class="num">(144,481)<span></span>
</td>
<td class="nump">12,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">(Increase) Decrease in other assets</a></td>
<td class="num">(9,523)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">(Decrease) Increase in accounts payable</a></td>
<td class="num">(363,584)<span></span>
</td>
<td class="nump">486,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Decrease in accounts payable related party</a></td>
<td class="num">(249,374)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Decrease in deferred profit, related party</a></td>
<td class="num">(489,630)<span></span>
</td>
<td class="num">(620,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Increase (Decrease)in accrued expenses and other payables</a></td>
<td class="nump">1,834,749<span></span>
</td>
<td class="num">(755,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase in deferred revenue</a></td>
<td class="nump">723,650<span></span>
</td>
<td class="nump">1,001,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,229,434)<span></span>
</td>
<td class="num">(5,398,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(39,520)<span></span>
</td>
<td class="num">(15,615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(6,008)<span></span>
</td>
<td class="num">(15,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_PurchaseOfIntangiblesAssetsApad', window );">Purchase of intangibles assets-APAD</a></td>
<td class="num">(153,647)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ConsolidationOfVariableInterestEntity', window );">Consolidation of variable interest entity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">39,165<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(199,175)<span></span>
</td>
<td class="nump">8,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds on Private Placement Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds on Public offering</a></td>
<td class="nump">150,836<span></span>
</td>
<td class="nump">2,573,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase', window );">Proceed from financing transaction</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">463,336<span></span>
</td>
<td class="nump">4,798,220<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(965,273)<span></span>
</td>
<td class="num">(592,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">3,602,229<span></span>
</td>
<td class="nump">4,194,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">2,636,956<span></span>
</td>
<td class="nump">3,602,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net assets acquired from variable entity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income tax paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued to acquire APAD technology</a></td>
<td class="nump">2,486,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_SaleOfVariableInterestEntitysShares', window );">Sale of Milestone China shares, financing transaction</a></td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedForPublicOffering', window );">Shares issued to employees for bonus</a></td>
<td class="nump">194,885<span></span>
</td>
<td class="nump">389,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedEmployeesCompensation', window );">Shares issued to consultants in lieu of cash payments</a></td>
<td class="nump">$ 350,249<span></span>
</td>
<td class="nump">$ 366,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ConsolidationOfVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow associated with the consolidation of variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ConsolidationOfVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_IncreaseDecreaseToAdvancesToContractManufacturer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease to advances to contract manufacturer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_IncreaseDecreaseToAdvancesToContractManufacturer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from the sale of variable interest entity shares with agreement to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_PurchaseOfIntangiblesAssetsApad">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset from Apad.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_PurchaseOfIntangiblesAssetsApad</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_SaleOfVariableInterestEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of variable interest entity's shares sold in noncash or partial noncash transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_SaleOfVariableInterestEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedEmployeesCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued to employees in lieu of cash compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedEmployeesCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedForPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued for public offering in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedForPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829714960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note A - Organization and Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><div style="display: inline; font-weight: bold;">NOTE A <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2014; ORGANIZATION AND BUSINESS </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">All references in this report to &#x201c;Milestone Scientific,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;we,&#x201d; the &#x201c;Company&#x201d; or &#x201c;Milestone&#x201d; refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Advanced Cosmetic Systems, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;">ompuDent&reg;; CompuMed&reg;; CompuFlo&reg;; DPS Dynamic Pressure Sensing technology&reg;; Milestone Scientific &reg;;&nbsp;the Milestone logo &reg;; SafetyWand&reg;; STA Single Tooth Anesthesia System&reg;; and The Wand &reg;.</div>&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific was incorporated in the State of Delaware in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 1989. </div>Milestone Scientific has developed a proprietary, computer-controlled anesthetic delivery device, using <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;">The Wand&reg;</div>, a single use disposable handpiece. The device is marketed in dentistry under the trademark <div style="display: inline; font-style: italic;">CompuDent&reg;, </div>and <div style="display: inline; font-style: italic;">STA Single Tooth Anesthesia System&reg;</div> and in medicine under the trademark <div style="display: inline; font-style: italic;">CompuMed&reg;. CompuDent&reg;</div> is suitable for all dental procedures that require local anesthetic. <div style="display: inline; font-style: italic;">CompuMed&reg;</div> is suitable for many medical procedures regularly performed in Plastic Surgery, Hair Restoration Surgery, Podiatry, Colorectal Surgery, Dermatology, Orthopedics and many other disciplines. The dental devices are sold in the United States, Canada and in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">53</div>&nbsp;other countries. To date there have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> medical devices sold in the United States and limited amounts sold internationally, although certain medical devices have obtained CE mark approval and&nbsp;can be marketed and sold in most European countries.&nbsp;In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2017,&nbsp;</div>Milestone Scientific received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the<div style="display: inline; font-style: italic;"> CompuFlo</div>&reg; Epidural Computer Controlled Anesthesia System (&#x201c;Epidural&#x201d;).</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> Milestone Scientific filed for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) marketing clearance with the FDA for both intra-articular and epidural injections with the CompuFlo&reg; Computer Controlled Anesthesia System.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2017, </div>the FDA approved the<div style="display: inline; font-style: italic;"> CompuFlo</div>&reg; Epidural Computer Controlled Anesthesia System for epidural injections. &nbsp;Milestone Scientific is in the process of introductory meetings with medical device distributors within the United States and foreign markets. Milestone Scientific&#x2019;s immediate focus is on marketing its epidural&nbsp;device throughout the United States and Europe.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2016, </div>we received notification from the FDA that based upon the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k)-application submitted for intra- articular injections,<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;we did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> adequately document that the device met the equivalency standard required for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) clearances. Following consultation with the FDA Office of Device Evaluation, we intend to file a new <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) application for the device in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 13, 2017, </div>Milestone Scientific consummated an asset acquisition under an Asset Purchase Agreement (the &#x201c;Agreement&#x201d;) with APAD Octrooi B.V. and APAD B.V. (each, a &#x201c;Seller&#x201d; and collectively, the &#x201c;Sellers&#x201d;) pursuant to which Milestone Scientific acquired certain patent rights and other intellectual property rights related to the Sellers<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2019; computer-controlled injection device (the &#x201c;Purchased Assets&#x201d;.) </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821556928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note B - Liquidity and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Substantial Doubt about Going Concern [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><div style="display: inline; font-weight: bold;">NOTE B- LIQUIDITY<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;AND UNCERTAINTIES</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> &nbsp;&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In accordance with ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">205</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,</div> Going Concern, the Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year after the date that the consolidated financial statements are issued. Milestone Scientific has incurred operating losses and negative cash flows from operating activities in virtually each year<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;since its inception. The capital raised in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2016 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>provided Milestone Scientific with working capital to continue to develop its medical devices and obtain regulatory approval for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> of its medical devices (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2017 </div>FDA approval of the epidural device), as well as to market its dental devices. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States&nbsp;(following <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2017 </div>FDA approval of its <div style="display: inline; font-style: italic;">CompuFlo</div>&reg; Epidural Computer Controlled Anesthesia System (&quot;Epidural&quot;) and worldwide, and a&nbsp;reduction in operating expenses. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Management believes that Milestone Scientific will have sufficient cash reserves to meet its anticipated obligations over the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months from the filing of this form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10K.</div> However, Milestone Scientific will likely need to raise additional capital prior to the expected generation of sustainable positive cash flow from operating activities and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>also need to raise additional capital to effectively launch its approved Epidural Device and eventually generate positive cash flow from the anticipated medical business.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">&nbsp;</div>  <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The Company is subject to several risks similar to those of development stage companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital necessary to fund the development of its products, competition from larger companies, and other medical device companies that develop similar or substitute products. The Company's sales performance, selling and marketing expenditures to develop sales performance, as well as the status of each of its new product development programs and the resulting operating income (loss), will significantly impact its cash requirements.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829743648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note C - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">NOTE C&nbsp;&#x2014; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Principles of Consolidation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States&nbsp;(&quot;GAAP&quot;) and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned)&nbsp;and Milestone Medical (majority owned). Milestone Education is a variable interest entity of which Milestone Scientific is the primary beneficiary and is consolidated into Milestone Scientific's financial statements. All significant, intra-entity transactions and balances have been eliminated in the consolidation.&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div>&nbsp;&nbsp;&nbsp;&nbsp; Reclassifications</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Certain reclassifications have been made to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>&nbsp;financial statements to conform to the consolidated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>&nbsp;financial statement presentation. These reclassifications had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> effect on net loss or cash flows as previously reported.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div> Variable Interest Entities</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;A variable interest entity (&quot;VIE&quot;) is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific&#x2019;s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific is the primary beneficiary of Milestone Education as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2016. </div>Accordingly, the assets and liabilities of Milestone Education are included in the accompanying consolidated financial statements. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Because Milestone Scientific had an increasing variable interest in Milestone China, it further considered the guidance in Accounting Standard Codification (&quot;ASC&quot;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">810</div> as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary. As Milestone China&#x2019;s equity at risk and voting rights were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> proportional to their economic interest, Milestone China was determined to be a VIE. Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <table style="margin-left:1.4%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="vertical-align:middle;width:6.5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> </td> <td style="vertical-align:top;width:3.2%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&#x25cf;</div> </td> <td style="vertical-align:top;width:90.2%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">Power Criterion: The power to direct the activities that most significantly impact the entity<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2019;s economic performance; and</div></div> </td> </tr>  </table> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <table style="margin-left:1.4%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="vertical-align:middle;width:6.5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> </td> <td style="vertical-align:top;width:3.3%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&#x25cf;</div> </td> <td style="vertical-align:top;width:90.2%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE.</div> </td> </tr>  </table> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone management does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the majority shareholder/CEO of Milestone China.&nbsp; As majority shareholder, majority holder of voting rights, and the active CEO, the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">53%</div> investor has the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> the primary beneficiary under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">810.</div> Accordingly, Milestone China has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been consolidated into the financial statements of Milestone Scientific and continues to be accounted for under the equity method.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div>&nbsp;</div>  <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.</div> Cash and Cash Equivalents</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific considers all highly liquid investments purchased with an original maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less to be cash equivalents.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> Accounts Receivable</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most of credit sales are due within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ninety</div> days from invoicing. There have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been any significant credit losses incurred to date.&nbsp;As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>&nbsp;Accounts receivable was recorded, net of allowance for doubtful accounts of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10,000</div> respectively.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">. Note Receivable</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Milestone Scientific values note receivable at historic cost less amount paid against principle. Milestone Scientific estimates losses on the note-based payments and credit quality of the debtor.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">&nbsp;Product Return and Warranty</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific generally does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> accept non-defective returns from its customers. Product returns under warranty are accepted, evaluated and repaired or replaced in accordance with the Warranty Policy. Returns <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> within the Warranty Policy are evaluated and the customer is charged for the repair.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> Inventories</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Inventories principally consist of finished goods and component parts stated at the lower of cost (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess, slow moving, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence and product expiration requirements. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> inventory was recorded net of allowance for slow moving inventory of&nbsp;approximately&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$220,000</div>&nbsp;as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017&nbsp;</div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0</div> as of&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,2016</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> Equity Method Investments</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Investments in which Milestone Scientific can exercise significant influence, but do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> control, are accounted for under the equity method of accounting and are included in the long-term assets on the Consolidated Balance Sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the income tax line on the Consolidated Statements of Operations.&nbsp;Milestone Scientific evaluates its equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> Furniture, Fixture and Equipment&nbsp;&nbsp; </div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from <div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div></div> to <div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div></div> years. The costs of maintenance and repairs are charged to operations as incurred.&nbsp; As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> furniture, fixtures &amp; equipment was&nbsp;recorded net of accumulated depreciation of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$721,619</div>&nbsp;and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$659,144</div> respectively.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div>  <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Intangible Assets &#x2013; Patents and Developed Technology</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized at the estimated average useful life of the patent. These patents and developed technology are recorded at the acquisition cost.&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patent defense costs, to the extent applicable, are expensed as incurred.&nbsp; Patent applications filed, and patents obtained in foreign countries are subject to the laws and procedures that differ from those in the United States. Patent protection in foreign countries <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be different from patent protection under United States laws and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be favorable to Milestone Scientific. Milestone Scientific also attempts to protect the proprietary information using confidentiality agreements and by limiting access to its facilities. There can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that the program of patents, confidentiality agreements and restricted access to the facilities will be sufficient to protect the proprietary technology.</div>&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.</div> Impairment of Long-Lived Assets</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>Milestone Scientific has reviewed long-lived assets for any impairments. The carrying value of the assets is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets. Milestone Scientific adjusts the net book value of an underlying asset if its fair value is determined to be less than its net book value. There have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impairment indicators or triggering events and therefore, there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div>&nbsp;impairments as of&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> respectively. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.</div> Revenue Recognition</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp;&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Revenue from product sales is recognized, net of discounts and allowances to domestic distributors, on the date of shipment for substantially all shipments, since the shipment terms are FOB warehouse. Milestone Scientific recognizes revenue on date of arrival of the goods at the customer's location, where shipments are FOB destination. In all cases the price to the buyer is fixed and the collectability is reasonably assured. Further, Milestone Scientific has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&nbsp;Devices and hand pieces are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> bundled but rather sold separately and, as such, there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> multiple element determinations in connection with the revenue recognition. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific defers the total revenue and costs of goods sold when devices and handpieces are shipped to Milestone China and Milestone China<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2019;s agent due to market conditions and Milestone China liquidity concerns. Also, due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties, an elimination of the intra-entity profit is required as of the balance sheet date. In accordance with ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">323</div> Equity Method and Joint Ventures, Milestone Scientific has deferred <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40%</div> of the gross profit associated with recognized revenue from Milestone China that has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been sold to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties.</div></div> <div style=" margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.</div> Shipping and Handling Costs</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific includes shipping and handling costs, if any, in cost of goods sold. These costs are paid by or billed to customers at the time of shipments. Domestic and international shipments are FOB warehouse; therefore, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> costs are incurred by Milestone Scientific.<div style="display: inline; font-weight: bold;">&nbsp;</div>&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.</div> Research and Development</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research and development costs, which consist principally of new product development costs payable to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties, are expensed as incurred. Advance payments for the research are amortized to expense either as services are performed or over the relevant service period using the straight-line method.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div>  <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16.</div> Income Taxes</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17.</div> Basic and diluted net loss per common share</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific presents &#x201c;basic&#x201d; earnings (loss) per common share applicable to common stockholders and, if applicable, &#x201c;diluted&#x201d; earnings (loss) per common share applicable to common stockholders pursuant to the provisions of Statement of Financial Accounting Standards ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260.</div> Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options, warrants, and the conversion of debt were issued during the period.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Since Milestone Scientific had net losses for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the assumed effects of the exercise of potentially dilutive outstanding stock options and warrants were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the calculation as their effect would have been anti-dilutive. Such outstanding options and warrants totaled&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,679,152</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,329,769</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;<div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18.</div> Use of Estimates</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates<div style="display: inline; font-weight: bold;">.</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19.</div> Fair Value of Financial Instruments</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fair Value Measurements: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> of the following categories:</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-indent: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;">&#x25cf;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;">&#x25cf;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> inputs which are defined as inputs other than quoted prices included within Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> that are observable for the assets or liabilities, either directly or indirectly.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;">&#x25cf;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> inputs are defined as unobservable inputs for the assets or liabilities.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.</div> Stock-Based Compensation </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific accounts for stock-based compensation under ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718,</div> Share-Based Payment. ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> requires all share-based payments to employees, including grants of employee stock options, to be recognized in the Statements of Operations over the service period, as an operating expense, based on the grant-date fair values. </div></div>  <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. In accordance with the provisions of FASB ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">505,</div> Milestone Scientific will re-measure the value of the grant at each presentation date unless there is a significant disincentive for non-performance or until performance has been rendered. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months end <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>Milestone Scientific recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9,384</div> income related to non-employee options. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months end <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>Milestone Scientific recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$25,346</div> expense related to non-employee options.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21.</div> </div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Recent Acc</div>ounting Pronouncements</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the Financial Accounting Standards Board (&quot;FASB&quot;) issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> steps: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) identify the contract, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) identify performance obligations, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>) determine the transaction price, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) allocate the transaction price, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2015, </div>the FASB issued guidance approving a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-year deferral, making the standard effective for reporting periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017. </div>The FASB continues to release guidance clarifying certain aspects of the revenue guidance. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe that this new accounting pronouncement will have a material impact on our financial statements.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued a new standard Accounting Standards Update (&quot;ASU &quot;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> &quot;Leases&quot;(Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>). The new standard is intended to increase transparency and comparability among organizations to recognize lease assets and liabilities on the balance sheet and disclose key information about leasing arrangements. It will be effective for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>Milestone Scientific is in the process of determining what impact, the adoption of this ASU will have on its financial position, results of operations and cash flows. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2016, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> &#x201c;Financial Instruments <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2013; Credit Losses&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">326</div>).: The new standard is intended to replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. It will be effective for all entities for fiscal years and interim periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2016, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> &quot;Statement Cash Flows &#x201c;Classification of Certain Cash Receipts and Cash Disbursements&quot; Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230</div>). The new standard provides guidance as to the conformity of presentation of certain cash receipts and disbursements. It will be effective for all entities for fiscal years and interim periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017. </div>Milestone Scientific does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> anticipate the adoption of this ASU will have a significant impact on its presentation within the statement of cash flows.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2016, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> &#x201c;Statement of Cash Flows <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2013; Restricted Cash&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230</div>). The new standard provides guidance as to address the diversity of treatment of restricted cash on the statement of cash flows. It will be effective for all entities for fiscal years and interim periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017 </div>and interim periods therein. Milestone Scientific does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect the adoption of this ASU to have a material effect on its presentation within the statement of cash flows.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2017, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> &#x201c;Compensation <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2013; Stock Compensation&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>). The new standard provides guidance and clarity for modification to equity-based compensation programs. It will be effective for all entities for fiscal years and interim periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017. </div>Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its presentation within the statement of cash flows.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div>  <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> &#x201c;Earnings Per Share&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div>), &#x201c;Distinguishing Liabilities from Equity&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">480</div>), &#x201c;Derivatives and Hedging&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">815</div>). The new standard provides guidance relating to equity-linked instruments that include certain features. It will be effective for public entities for fiscal years and interim periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its presentation within the statement of cash flows.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2017, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,</div> &#x201c;Income Statement <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2013; Reporting Comprehensive Income&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">815</div>), &#x201c;Revenue Recognition&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>) and &#x201c;Revenue from Contracts with Customers&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>). The new standard provides guidance in these areas pursuant to certain SEC Staff Accounting Bulletin and Release, as they relate to the presentation of revenue recognition matters on the statement of comprehensive income.&nbsp; It will be effective for public entities concurrent with the effectuation of other revenue recognition standards. Milestone Scientific does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> anticipate the adoption of this ASU to have a significant impact on its presentation within the statement of comprehensive income.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821559088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note D - Notes Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesTextBlock', window );">Financing Receivables [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">NOTE D&nbsp;&#x2014; NOTES RECEIVABLE</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2017, </div>Milestone Scientific entered into an agreement for the sale of its interest in Milestone China a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">forty</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40%</div>) percent interest (the &#x201c;Milestone China Shares&#x201d;) to an unaffiliated United States domiciled purchaser and a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-year option agreement to repurchase the Milestone China Shares. The purchase price for the Milestone China Shares was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,400,000</div> of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$125,000</div> was paid in cash and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,275,000</div> was paid by delivery of a non-interest bearing secured promissory note. The note is payable in quarterly installments of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$125,000</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;and is secured by the Milestone China Shares until full repayment.&nbsp; In addition,&nbsp;the purchaser is precluded from selling all or substantially all its assets prior to repayment of the note. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-year option agreement provides Milestone Scientific an option to repurchase the Milestone China Shares at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,400,000</div> within the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years and at fair market value (as defined in such agreement) for the remainder of the&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-year term. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2, 2018, </div>the promissory note was in default. If Milestone Scientific exercises its rights as a secured party it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be obligated to return to the purchaser up to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250,000</div> received for the Milestone China Shares as surplus. At this time Milestone Scientific has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> received a response from the purchaser of the Milestone China Shares, Milestone Scientific has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recorded any financial benefit from the sale of Milestone China Shares to date.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div>&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">The transaction has been accounted for as a secured financing and Milestone Scientific will continue to account for its relationship with Milestone China under the equity method of accounting.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;A note receivable is presented on the Company&#x2019;s balance sheet, along with a deferral from financing transaction (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,400,000</div>). The carrying value of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">forty</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40%</div>) percent investment at the transaction date was zero.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financing receivables. Examples of financing receivables include, but are not limited to, loans, trade accounts receivables, notes receivable, credit cards, and receivables relating to a lessor's right(s) to payment(s) from a lease other than an operating lease that is recognized as assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -URI http://asc.fasb.org/topic&amp;trid=2196771<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821434928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note E - Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;">NOTE<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;E&nbsp;&#x2014; INVENTORIES </div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</div> <div> <table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2016</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories consist of the following:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Dental finished goods</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,846,272</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,832,275</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Medical finished goods, net&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">475,285</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">735,061</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Component parts and other materials</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">57,652</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35,383</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,379,209</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,602,719</div></td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>a reserve for slow moving Medical finished goods was established in the amount approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$220,000.</div> The<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;reserve was provided due to the delay in commercialization of the intra-articular medical instrument.&nbsp; There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> reserves against inventory as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016.&nbsp;</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821556928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note F - Advances on Contracts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_AdvancesToContractManufacturerTextBlock', window );">Advances to Contract Manufacturer [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">NOTE<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;F&nbsp;&#x2014; ADVANCES ON CONTRACTS </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The advances on contracts represent funding of future STA inventory purchases and Epidural replacements parts. The balance of the advances as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$697,192</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$700,900,</div> respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory.&nbsp;&nbsp; </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_AdvancesToContractManufacturerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advances to contract manufacturer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_AdvancesToContractManufacturerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821504000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note G - Consolidation of Variable Interest Entity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entity Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">NOTE<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;G&nbsp;&#x2013; CONSOLIDATION OF VARIABLE INTEREST ENTITY</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div>Milestone Education is a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> owned subsidiary of Milestone Scientific which began operations in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013</div> to provide training and education to dentists throughout the world. Approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81%</div> of the revenue earned by Milestone Education is from services performed for Milestone Scientific as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> Because of this dependency and relationship, we determined that we had the power to direct the activities that most significantly impact Milestone Education's economic performance, and therefore Milestone Education is consolidated in our financial statements.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; </div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821556928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note H - Investment in Unconsolidated Subsidiaries<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investments and Joint Ventures Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">NOTE H&nbsp;&#x2013; INVESTMENT IN </div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;text-transform:uppercase;"><div style="display: inline; font-weight: bold;">UNCONSOLIDATED SUBSIDIARIES</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">Advance Ocular Science SA </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Advanced Ocular Sciences SA (&quot;Advanced Ocular&quot;) is a shell company attempting to develop an instrument to deliver injections into the eyes. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>Milestone Scientific owns <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> of this entity. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> Milestone Scientific advanced <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$78,798</div> for marketing and strategy planning to Advance Ocular, or its organizers, were obligated to repay this advance if a public offering of Advanced Ocular equity was approved and funded in Poland during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> However, a public offering has yet to be completed in Poland. As a result, Milestone Scientific wrote-off the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$78,798</div> advanced to Advanced Ocular as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016. </div>Advance Ocular was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the consolidated financial statements at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> further investment has been made and there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> significant activity that would be considered material to the financial statements.&nbsp; &nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;">Milestone China Ltd.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2014, </div>Milestone Scientific invested <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1</div> million in Milestone China Ltd. (&#x201c;Milestone China&#x201d;) by contributing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">772</div> STA Instruments to Milestone China for a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40%</div> ownership interest. Milestone Scientific recorded this investment under the equity method of accounting. Milestone Scientific recorded a loss on its investment in Milestone China of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$795,827,</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively. Milestone Scientific's investment in Milestone China was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively. Milestone Scientific incurred cumulative losses on its investment in Milestone China of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,147470</div>&nbsp;and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,124,350</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, which have been suspended.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2017, </div>Milestone Scientific entered into an agreement for the sale of the Milestone China Shares to an unaffiliated United States domiciled purchaser and a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-year option agreement to repurchase the Milestone China Shares. The purchase price for the Milestone China Shares was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,400,000</div> of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$125,000</div> was paid in cash and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,275,000</div> was paid by delivery of a non-interest bearing secured promissory note. The note is payable in quarterly installments of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$125,000</div> until paid in full and is secured by the Milestone China Shares until full repayment.&nbsp; In addition, pursuant to such note, the purchaser is precluded from selling all or substantially all its assets prior to repayment of the note. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-year option agreement provides Milestone Scientific an option to repurchase the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40%</div> equity interest at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,400,000</div> within the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years and at fair value (as defined in such agreement) for the remainder of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-year term. The transaction has been accounted for as a secured financing and Milestone Scientific will continue to account for its relationship with Milestone China under the equity method of accounting. A note receivable is presented on the Balance Sheet, along with a deferral from financing transaction (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,400,000</div>). The carrying value of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">forty</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40%</div>) percent investment at the transaction date was zero. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div></div>  <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2, 2018, </div>the promissory note was in default. If Milestone Scientific exercises its rights as a secured party it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be obligated to return to the purchaser up to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250,000</div> received for the Milestone China Shares as surplus. At this time Milestone Scientific has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> received a response from the purchaser of the Milestone China Shares, Milestone Scientific has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recorded any financial benefit from the sale of Milestone China Shares to date.</div> <div style=" margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,071,000</div> of related party sales of handpieces and instruments to Milestone China and Milestone China<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2019;s agent for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017. </div>Milestone Scientific had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,425,000</div> of related party sales of handpieces and instruments to Milestone China for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016. </div>Milestone Scientific defers the total revenue and costs of goods sold when instruments and handpieces are shipped to Milestone China and Milestone China&#x2019;s agent due to market conditions and Milestone China liquidity concerns.</div></div> <div style="font-size: 10pt; margin: 0pt; text-indent: 27pt;">  &nbsp; </div> <div style=" margin: 0pt; text-indent: 27pt;">Due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties, an elimination of the intra-entity profit is required as of the balance sheet date. In accordance with ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">323</div> Equity Method and Joint Ventures, Milestone Scientific has deferred <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40%</div> of the gross profit associated with recognized revenue from Milestone China that has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been sold to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the deferred profit was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$751,500</div>&nbsp;and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$630,990,</div> respectively, which is included in deferred profit, related party in the consolidated balance sheets. For <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the loss on equity investment was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$120,510</div>&nbsp;and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$795,827,</div> respectively, which is included in the&nbsp;consolidated&nbsp;statements of operation.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The following table includes summarized financial information (unaudited) of Milestone China:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div> <table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2016</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Assets:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Current assets</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,127,422</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,362,198</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Non-current assets</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,213,520</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,467,547</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total assets:</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,340,942</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,829,745</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Liabilities:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Current liabilities</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,468,937</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,900,611</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stockholders' equity</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,127,995)</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,929,134</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities and stockholders<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2019; equity</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,340,942</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,829,745</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2016</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,666,605</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,126,484</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of goods sold</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">477,200</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">976,106</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gross Profit</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,189,405</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">150,378</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other Expenses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,247,205)</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,834,980</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net Losses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,057,800)</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,684,602</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" nowrap="nowrap">)</td> </tr>  </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821504000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note I - Furniture, Fixtures and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;">NOTE I<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2014; FURNITURE, FIXTURES AND EQUIPMENT </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 7.5%; margin-left: 7.5%; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31</div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="4" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furniture, Fixtures and Equipment consist of the<br /> <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">following:</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 64%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,734</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,734</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Office furniture and equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">134,947</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">135,802</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Molds</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,200</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,200</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Trade show displays</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">143,357</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">143,357</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Computers and software</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">231,704</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,840</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tooling Safety Wand</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,022</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,022</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Website</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,200</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tooling equipment-STA &amp; Wand</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,100</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,100</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">EPI and IA Instruments</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82,363</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82,363</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">STA Trials Instruments</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63,752</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63,752</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">863,379</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">818,170</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(721,619</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(659,144</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">141,760</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">159,026</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 19.5pt;">Depreciation expense was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$62,475</div>&nbsp;and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$92,667</div>&nbsp;for the <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821434928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note J - Patents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:-3pt;"><div style="display: inline; font-weight: bold;">NOTE<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;J&nbsp;&#x2014; PATENTS</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;">&nbsp;</td> <td colspan="5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 305px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div></div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37px;">&nbsp;</td> <td colspan="5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 313px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div></div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 71px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Cost</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 95px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Accumulated Amortization</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 31px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 80px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Net</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 91px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Cost</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 101px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Accumulated Amortization</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 15px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 92px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Net</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patents-foundation intellectual property</div> </td> <td style="width: 71px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,377,863</div></td> <td nowrap="nowrap" style="width: 20px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 95px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(787,821</div></td> <td nowrap="nowrap" style="width: 31px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 80px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">590,042</div></td> <td nowrap="nowrap" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 91px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,377,543</div></td> <td nowrap="nowrap" style="width: 7px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 101px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(717,086</div></td> <td nowrap="nowrap" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 92px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">660,457</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Epidural-Apad acquired patents</div> </td> <td style="width: 71px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,639,647</div></td> <td nowrap="nowrap" style="width: 20px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 95px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(439,941</div></td> <td nowrap="nowrap" style="width: 31px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 80px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,199,706</div></td> <td nowrap="nowrap" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 91px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 7px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 101px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 92px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 71px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,017,510</div></td> <td nowrap="nowrap" style="width: 20px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 95px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,227,762</div></td> <td nowrap="nowrap" style="width: 31px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 80px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,789,748</div></td> <td nowrap="nowrap" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 91px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,377,543</div></td> <td nowrap="nowrap" style="width: 7px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 101px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(717,086</div></td> <td nowrap="nowrap" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 92px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">660,457</div></td> </tr>  </table> </div> <div style=" text-indent: 27pt;">Patents are amortized utilizing the straight-line method over estimated useful lives ranging from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div> years, with a weighted average amortization period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>&nbsp;years. Amortization expense was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$510,676</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$70,699</div> for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.&nbsp;The annual amortization expense expected to be recorded for existing intangibles assets for the years <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2022</div> is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$945,000,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$932,000,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$486,000,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$39,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$38,000.</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 13, 2017, </div>Milestone Scientific consummated a previously disclosed Asset Purchase Agreement (the &#x201c;Agreement&#x201d;) with APAD Octrooi B.V. and APAD B.V. (each, a &#x201c;Seller&#x201d; and collectively, the &#x201c;Sellers&#x201d;) pursuant to which Milestone Scientific acquired certain patent rights and other intellectual property rights related to the Sellers&#x2019; computer-controlled injection instrument (the &#x201c;Purchased Assets&#x201d;) and has been accounted for as an asset acquisition. On the closing date, Milestone Scientific issued to the Sellers an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,646,358</div> shares of its common stock, valued at approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,486,000</div> for the Purchased Assets which shares are subject to certain post-closing upward or downward adjustments <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to exceed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twenty-five</div> percent of the initial shares as of the purchase date or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">250,000</div> Euros, as defined in the agreement. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>Milestone Scientific has recorded a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$275,000</div> liability relating to the estimated additional shares that would have to be issued according this provision in the Agreement. Milestone Scientific paid approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$153,000</div> in legal fees on behalf of the Seller as stipulated based on the terms of the Agreement. The patents purchased in the amount of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,639,000</div> have been capitalized and will amortized over their <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-year estimated useful life and tested for impairment as a finite lived intangible asset.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821555344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note K - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:-7.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">NOTE K&nbsp;&#x2014; STOCKHOLDERS&#x2019; EQUITY</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">ISSUANCES COMMON STOCK </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2016, </div>Milestone Scientific raised an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.0</div> million of gross proceeds in a private placement of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one million</div> shares of common stock, at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.00</div> per share, to the same investors that participated in the&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">May 2014 </div>Financing.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2016, </div>Milestone Scientific raised gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250,000</div> in a registered direct offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104,200</div> shares of common stock at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.40</div> per share. The transaction was covered by the prospectus supplement, filed with the United States Securities and Exchange Commission (&quot;SEC) on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 22, 2016, </div>to our shelf registration statement on Form S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> (SEC File <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.:</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">333</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">209466</div>).&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2016, </div>Milestone Scientific completed an underwritten public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000,000</div> shares of common stock and warrants to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,592,775</div> shares of common stock, including <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92,775</div> additional warrants pursuant to a partial exercise of the over-allotment option granted to the underwriters. Each share of common stock was sold in combination with a warrant to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.75</div> shares of common stock. The public offering price for each share and related <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.75</div> share warrant was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.50</div> for gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,000,000.</div> The warrants have a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-year term and an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.55</div> per share.&nbsp; In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017, </div>the underwriter&nbsp;exercised a portion of&nbsp;its over-allotment option to purchase an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">123,700</div> shares of common stock at the public offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.499</div> per share for gross proceeds of&nbsp;approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$186,000.</div> The gross proceeds from this offering, including proceeds from partial exercises of the over-allotment option, were approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,200,000,</div> before deducting underwriting discounts and commissions and other offering expenses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4461,493.</div>&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">&nbsp;&nbsp;</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017, </div>the underwriter exercised a portion of its over-allotment option&nbsp;and purchased an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">123,700</div> shares of common stock at the public offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.499</div> per share. The gross proceeds were approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$186,000</div> before deducting underwriting discounts and commissions and other offering expenses.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;PREFERRED STOCK</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May </div>of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> Milestone completed a private placement, which raised gross proceeds in the total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10</div> million, from the sale of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3</div> million of Milestone Scientific common stock (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two million</div> shares at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.50</div> per share) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7</div> million of our Series A Convertible Preferred Stock (&quot;preferred stock&quot;) (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,000</div> shares at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div> per share), convertible into common stock at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.37</div> per share (as adjusted to date) on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 14, 2019, </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.50</div> per share unless certain conditions are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> met both subject to anti-dilution adjustment.&nbsp;The conversion ratio adjustment becomes effective if anyone of a number of triggering events occur such as; issuance of stock dividends or distributions, subdivisions, splits, issuance of stock purchase rights, debt and distributions, cash dividends or distributions, self-tender offers and exchange offers, rights plans and issuances below the conversion price, as defined in the Investment Agreement.&nbsp;Generally, each share of preferred stock entitles the holder to vote together with the holders of Milestone Scientific common stock, as a single class, on all matters submitted for the approval of the holders of Milestone Scientific common stock and has the number of votes equal to the number of shares of our common stock into which they are then convertible.&nbsp; In addition, preferred stock is also entitled to share, pair pass, in any cash dividends declared on Milestone Scientific common stock on as converted basis.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold; font-size: 10pt;">SH<div style="display: inline; font-size: 10pt;">ARES TO BE ISSUED</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,401,247</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,270,481</div> shares, respectively, whose issuance has been deferred under the terms of an employment agreements with the Chief Executive Officer, Chief Financial Officer and other employees of Milestone Scientific. Such shares will be issued to each party upon termination of their employment. The number of shares was fixed at the date of grant and were fully vested upon grant date.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">SHARES RESERVED FOR FUTURE ISSUANCE</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,111,582</div>&nbsp;and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,600,250</div> shares reserved for future issuance and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,710,335</div>&nbsp;and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,329,769</div> shares underlying other stock options and warrants outstanding, respectively. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,401,247</div> shares and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,270,481</div> shares, respectively, reserved for issuance in settlement of deferred compensation to officers of Milestone Scientific. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821434928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note L - Stock Option Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 19.5pt 0pt 15pt; text-align: left; text-indent: -16.5pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;L&nbsp;&#x2014; STOCK OPTION PLANS</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2004</div> Stock Option Plan provided for the grant of options to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">750,000</div> shares of Milestone Scientific's common stock. Options <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be granted to employees, officers, directors and consultants of Milestone Scientific for the purchase of common stock at a price <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> less than the fair market value of the common stock on the date of the grant. In general, options become exercisable over a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-year period from the grant date and expire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years after the date of grant.&nbsp;There were&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> shares available for grant at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>under this plan.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2011, </div>the stockholders of Milestone Scientific approved the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> Stock Option Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&quot;2011</div> Plan&quot;) which originally provided for stock options to our employees, directors and consultants and incentive and non-qualified stock options to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000,000</div> shares of common stock. In general, options become exercisable over a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-year period from the grant date and expire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years after the date of grant.&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2016, </div>Milestone Scientific's stockholders approved the following amendments to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> Plan:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 63pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">i</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Renaming of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> plan to the &#x201c;Milestone Scientific Inc., <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> Equity Compensation Plan&#x201d;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 63pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">ii</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Providing for awards of restricted common stock; and</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 63pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">iii</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Increasing the maximum number of shares of common stock reserved for grants under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011</div> Plan from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000,000</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,000,000.</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: -9pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific recognizes compensation expense on a straight-line basis over the requisite service period and in the case of performance-based options over the period of the expected performance. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> respectively, Milestone Scientific recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$636,058</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$579,103</div> of total employee compensation cost, respectively. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$603,979</div>&nbsp;and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$678,842</div> of total unrecognized compensation cost related to non- vested options, respectively.&nbsp;Milestone Scientific expects to recognize these cost over a weighted average period of&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.61</div> years and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.04</div>&nbsp;years as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">A summary of option activity for employees under the plans and changes during the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> is presented below:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 5%; margin-left: 5%; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of Options</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Wei<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">ghted Averaged Exercise Price $</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average Remaining Contractual Life (Years)</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate Intrinsic Options Value $</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 44%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options outstanding January 1, 2016</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,419,436</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.56</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.79</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,220,338</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable, January 1, 2016</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,041,680</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.29</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.41</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,135,819</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">520,337</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.79</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.38</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised during 2016</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(327,778</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.75</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(100,000</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.35</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options outstanding December 31, 2016</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,511,995</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.74</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.97</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102,605</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable, December 31, 2016</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,054,202</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.65</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.51</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102,605</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,006,741</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.82</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.69&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,610</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised during 2017</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(83,333</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.75</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited, cancelled, or expired</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,250,068</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options outstanding December 31, 2017</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,985,325</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.74</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.04</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,160</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable,<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> December 31, 2017</div></div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,317,4416</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.84</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.46</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,537</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div>  <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017, </div>Milestone Scientific's Compensation Committee approved the issuance of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">400,000</div> stock options to Gian Domenico Trombetta, CEO of Wand Dental, a Director of Milestone Scientific and a director of Innovest S.p.A., an Italian investor (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">250,000</div> options at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.55</div> per share were issued on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 7, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">150,000</div> options having an exercise price at the higher of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.55</div> or the market price of the stock on the date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> Annual Stockholder meeting, subject to approval of a new or amended equity incentive plan at such meeting.) Mr. Trombetta elected to cancel the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">400,00options</div> granted as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">The weighted-average fair value of the options granted during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was estimated as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.73</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.70</div> respectively, on the date of grant. The fair value for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was determined using the Black-Scholes option-pricing model with the following&nbsp; assumptions:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;</div></div> <div> <table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81.23% -97.24%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">134.53%- 194.34%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.4%- 2.2%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.04%-1.47%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Life</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">2-5 years<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5 years</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeiture Rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">A summary of option activity for non-employees under the plans and changes during the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> is presented below:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div> <table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 5%; margin-left: 5%; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 121px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number of Options</div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 25px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 140px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Averaged Exercise Price $</div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 26px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 153px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average Remaining Contractual Life (Years)</div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Aggregate Intr<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">insic Options Value $</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding, January<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> 1, 2016</div></div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,333</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.70</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.83</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exercisable, January 1, 2016</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,777</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.70</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.83</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 489px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216,666</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.53</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding, December<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> 31, 2016</div></div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,999</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.53</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.32</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exercisable, December 31, 2016</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,734</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.72</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.36</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted 2017</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised 2017</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding, December<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> 31, 2017</div></div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,999</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.52</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.51</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exercisable, December 31, 2017</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,067</div></td> <td style="width: 25px; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.22</div></td> <td style="width: 26px; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.38</div></td> <td style="width: 37px; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr>  </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. In accordance with the provisions of FASB ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">505,</div> Milestone Scientific will re-measure the value of the grant at each presentation date unless there is a significant disincentive for non-performance or until performance has been rendered. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months end <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>Milestone Scientific recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9,384</div> income related to non-employee options. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months end <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>Milestone Scientific recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$25,346</div> expense related to non-employee options.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821492624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note M - Employment Contract and Consulting Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmploymentAndConsultingAgreementsTextBlock', window );">Employment and Consulting Agreements [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;">NOTE M<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2013;EMPLOYMENT CONTRACT AND CONSULTING AGREEMENTS</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">Employment Contracts</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 1, 2009, </div>Milestone Scientific entered into a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-year employment agreement with Leonard Osser as its Chief Executive Officer (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&quot;2009</div> Agreement&quot;). The terms of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div> Agreement are automatically extended for successive <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-year periods unless prior to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 1 </div>of any year, either party notifies the other that he or it chooses <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to extend the term. Under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div> Agreement, the CEO receives base compensation of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$300,000</div> per year. In addition, the CEO, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>earn annual bonuses up to an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$400,000,</div> payable <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> half in cash and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> half in common stock, contingent upon achieving targets set for each year by the Compensation Committee. In addition, if in any year of the term of the agreement the CEO earns a bonus, he shall also be granted <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-year stock options to purchase twice the number of bonus shares earned. Each such option is to be exercisable at a price per share equal to the fair market value of a share on the date of grant (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110%</div>) of the fair market value if the CEO is a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> or greater stockholder on the date of grant). The options shall vest and become exercisable to the extent of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> of the shares covered at the end of each of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> years following the date of grant but shall only be exercisable while the CEO is employed by Milestone Scientific or within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div> days after the termination of his employment.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In accordance with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div> Agreement, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">886,866</div> shares of common stock are to be paid out at the end of the term in settlement of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,030,875</div>&nbsp;of deferred compensation accrued at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">855,810</div>&nbsp;shares of common stock are to be paid out at the end of the contract in settlement of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$980,906</div> of deferred compensation accrued at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016 </div>and, accordingly, such shares have been classified in stockholders' equity with the common stock classified as to be issued.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;On<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;December 1, 2016, </div>Wand Dental and Gian Domenico Trombetta (&#x201c;Trombetta&#x201d;) entered into an Amended and Restated Employment Agreement (the &#x201c;Agreement&#x201d;), pursuant to which Trombetta receives base compensation of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$280,000</div> per year&nbsp;and is eligible to receive annual bonuses in the sole discretion of the Compensation Committee. Pursuant to the Agreement, Trombetta will continue to serve as the Chief Executive Officer of Wand Dental for a period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-year beginning on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 1, 2016 </div>through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 31, 2017 (</div>the &#x201c;Employment Term&#x201d;). The Employment Term automatically renews for a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-year period, from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 1</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">st</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 31</div><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">st</div>&nbsp;of each successive year (each a &#x201c;Renewal Term&#x201d;), unless prior to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1st</div> of the Employment Term or any Renewal Term, as applicable, either party notifies the other that he or it chooses <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to extend the term of employment in accordance with the terms of the Agreement.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017, </div>Milestone Scientific entered into a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-year employment agreement with Daniel Goldberger to serve as President and Chief Executive Officer of Milestone Scientific. Under the agreement, Mr. Goldberger would receive base compensation of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$300,000</div> per annum and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>additionally earn annual bonuses of up to an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$400,000,</div> payable <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> half in cash and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> half in Milestone Scientific common stock (&#x201c;Bonus Shares&#x201d;) contingent upon achieving performance benchmarks periodically set for each year by the compensation committee of the Board. In addition to any such shares of common stock, Mr. Goldberger was entitled to receive stock options (&#x201c;Bonus Options&#x201d;) to acquire twice the number of any Bonus Shares earned, pursuant to a non-qualified stock option grant agreement under Milestone Scientific&#x2019;s then existing equity compensation plan. The Bonus Options had a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-year term and were to vest in equal annual installments on each of the first, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> anniversary of the grant date, subject to continued employment on such vesting date and accelerated vesting upon the occurrence of certain events. The exercise price of the Bonus Options was based on the fair market value of per share of common stock on the date of grant.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017, </div>Milestone Scientific granted to Mr. Goldberger non-qualified stock options to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">921,942</div> shares of common stock at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.00</div> per share. Those options had a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-year term and were to vest in equal annual installments on each of the first, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> anniversaries of the grant date, subject to his continued employment on the vesting date and accelerated vesting upon the occurrence of certain events.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017, </div>Milestone Scientific entered into a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div>-year new employment agreement with Leonard Osser, who previously served as the Company&#x2019;s President and Chief Executive Officer, to serve as Managing Director &#x2013; China Operations. This new agreement provides for annual compensation of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$300,000</div> consisting of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$100,000</div> in cash and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$200,000</div> in the Company&#x2019;s common stock valued at the average closing price of the Company&#x2019;s common stock on the NYSE or such other market or exchange on which its shares are then traded during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fifteen</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div>) trading days of the last full calendar month of each year during the term of this agreement. This agreement supersedes all prior employment agreements between Mr. Osser and Milestone Scientific. If the Company terminates Mr. Osser&#x2019;s employment &#x201c;Without Cause,&#x201d; other than due to his death or disability, or if Mr. Osser terminates his employment for &#x201c;Good Reason&#x201d; (both as defined in the agreement), Mr. Osser is entitled to be paid in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> lump sum payment as soon as practicable following such termination: an amount equal to the aggregate present value (as determined in accordance with Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">280G</div>(d)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) of the Code) of all compensation pursuant to this agreement from the effective date of termination hereunder through the remainder of the Employment Term.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></div>  <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017, </div>Mr. Osser also resigned from his positions of Chairman of the Board, Chief Executive Office and President of Milestone Medical. Upon his resignation, Milestone Medical entered in a consulting agreement with U.S. Asian Consulting Group LLC, an entity controlled by Mr. Osser, pursuant to which he will provide specific services to Milestone Medical for a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div>- year term. Pursuant to the consulting agreement, U.S. Asian Consulting Group, LLC, is entitled to receive <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$100,000</div> per year for Mr. Osser's services.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 5, 2017, </div>Milestone Scientific Inc. announced that Daniel Goldberger had resigned as President and Chief Executive Officer effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2, 2017, </div>upon which the previously described stock options granted to him in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017 </div>terminated prior to vesting.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; All compensation expense recorded to the date of the resignation was reversed as of the resignation date.</div></div> <div style=" margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 5, 2017, </div>Milestone Scientific also announced the appointment of Leslie Bernhard, the Company<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2019;s current Chairman of the Board, as the Company&#x2019;s Interim Chief Executive Officer, to serve in such role until the appointment of a new Chief Executive Officer. In connection with her appointment to serve as the Company&#x2019;s Interim Chief Executive Officer, Ms. Bernhard was paid an annual salary of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$200,000</div>&nbsp;received a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-time bonus of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div> shares of the Company&#x2019;s Common Stock.&nbsp; In addition, at the completion of her service as Interim Chief Executive Officer, Ms. Bernhard shall be entitled to receive a cash bonus in an amount to be determined by the Board of Directors at that time.&nbsp;On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 19 ,2017 </div>the Board of Directors appointed Leonard Osser Interim Chief Executive Officer, replacing Leslie Bernhard. Ms. Bernhard agreed to accept <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,000</div> shares of Milestone Scientific stock for her services as Interim Chief Executive Officer in-lieu of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div> shares she was previously awarded.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 19, 2017 </div>the Board of Directors appointed Leonard Osser Interim Chief Executive Office, replacing Leslie Bernhard. Mr. Osser will&nbsp;enter into a similar <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div> employment contract that he received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>&nbsp;before he resigned his position as CEO of the company. <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Mr. Osser placed on&nbsp;hold&nbsp;his position as Managing Director-China Operations and his consulting agreement with Milestone Medical to rejoined Milestone Scientific Inc. as Interim Chief Executive Officer and will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> receive or earn any compensation under those agreements until he is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer Interim Chief Executive Officer.&nbsp;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmploymentAndConsultingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employment and consulting agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmploymentAndConsultingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821414960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note N - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;">NOTE<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;N&nbsp;&#x2014; INCOME TAXES</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Due to Milestone Scientific's history of operating losses, a full valuation allowances have been provided for all of Milestone Scientific's deferred tax assets At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31,</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> recognition was given to the utilization of the remaining net operating loss carryforwards in each of these periods.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In accordance with ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> Income Taxes, deferred tax assets and liabilities have been classified, and treated retrospectively, as non-current.&nbsp; Deferred tax attributes resulting from differences between financial accounting amounts and tax bases of assets and liabilities at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> are as follows:&nbsp; </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Allowance for doubtful accounts-short term</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warranty reserve</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Capital Gains</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred officers compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">636,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">395,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and Amortization</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">181,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">135,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deferred revenue</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">478,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforward</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,116,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,456,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Subtotal</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,479,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,026,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,479,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(19,026,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td> </tr>  </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The deferred tax asset, before valuation allowance, has been calculated on rates anticipated to be effect when the temporary differences reverse.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Accordingly, based on the change in Federal tax rates promulgated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2017, </div>effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018, </div>the Company utilized a Federal rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21%</div> and accordingly existing deferred tax assets upon the tax law act being signed into law on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 22, 2017, </div>the Company revalued its deferred tax assets which resulted in a tax provision charge of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8,677,000,</div> offset by a corresponding decrease in the valuation allowance.&nbsp; </div></div>  <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>federal net operating loss carryforwards are approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$60,000,000.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>and Milestone Scientific has federal net operating loss carryforwards of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$56,530,000,</div> which is comprised solely of losses attributable Milestone Scientific and its subsidiaries.&nbsp; Net operating losses will be available to offset future taxable income, if any, through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2037. </div>As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>state net operating losses were approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$24,500,000.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016 </div>Milestone, Scientific has state net operating loss carryforwards of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22,942,000.</div>&nbsp; Net operating losses will be available to offset future taxable income, if any, through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2037. </div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The utilization of Milestone Scientific's net operating losses <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be subject to a substantial limitation due to the &quot;change of ownership provisions&quot; under Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">382</div> of the Internal Revenue Code and similar state provisions. Such limitation <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100%</div> valuation allowance for all its deferred tax assets due to uncertainty as to their future realization.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> state tax liability was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$18,339</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$13,000</div> respectively. Such expense was recognized in the accompanying consolidated financial statements. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">A reconciliation of the statutory tax rates for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, </div>is as follows:<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" margin: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Statutory rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State income tax - all states</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Non-deductible Stock based compensation</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deferred provision for effect of change in Federal</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">164</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Valuation allowance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effective tax rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td> </tr>  </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounting for uncertainties in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> we had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> uncertain tax positions that required recognition in the consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the Statements of Operations. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> interest and penalties are present for periods open. Tax returns for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> years are subject to audit by federal and state jurisdictions. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829854224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note O - Segment and Geographic Data<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock', window );">Product Sales and Significant Customers and Vendors Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;">NOTE<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;O&nbsp;&#x2014; SEGMENT AND GEOGRAPHIC DATA</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">We conduct our business through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> reportable segments:<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; dental and medical.&nbsp;&nbsp;These segments offer different products and services to different customer base. </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">The following tables present information about our reportable and operating segments:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="6" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Years ended</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net Sales:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,279,886</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,460,752</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,253</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,281,886</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,482,005</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating Income (Loss):</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,127,570</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,087,002</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>2,389,145</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>3,265,602</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,972,743</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>5,335,360</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>5,234,318</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>6,513,960</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and Amortization:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,305</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,619</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,950</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">62,720</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Other<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">528,895</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82,586</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">573,150</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">162,925</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-indent: 27pt;">&nbsp;Total</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income before taxes and equity in<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> earnings&nbsp;of affiliates:</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,136,167</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,097,652</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>2,391,082</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>3,219,497</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>5,975,035</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>5,395,918</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>5,229,950</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>6,517,763</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total Assets:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,255,144</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,472,879</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">655,513</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">913,840</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,718,130</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>2,794,921</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 27pt;">&nbsp;Total</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,628,787</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,181,640</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</div>  <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">The following table presents information about our operations by geographic area as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Net sales by geographic area are based on the respective locations of our subsidiaries</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 7.5%; margin-left: 7.5%; min-width: 700px;">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Dental </div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 64%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Total Product Sales</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic-US and Canada</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,339,709</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,331,308</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International -Rest of the World</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,869,177</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,703,844</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International -China</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,071,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,425,600</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,279,886</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,460,752</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Total Product Sales</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Medical </div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic-US and Canada</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International - Rest of the World</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,253</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,253</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total </div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">Domestic-US and Canada</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,339,709</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,352,561</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International -Rest of the World</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,871,177</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,703,844</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">International -China</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,071,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,425,600</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 36pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,281,886</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,482,005</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of product sales and significant customers and vendors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ProductSalesAndSignificantCustomersAndVendorsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821407088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note P - Concentration<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration Risk Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">NOTE P<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;-- CONCENTRATION</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div>Milestone Scientific has informal arrangements with a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party manufacturer of the STA, CompuDent&reg;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> and CompuMed&reg; instruments, pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2016, </div>Milestone Scientific entered into a purchase commitment for delivery of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,000</div> instruments, as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>all instruments have been received.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Milestone Scientific entered into a purchase commitment for the delivery of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000</div> instruments beginning in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4th</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> An advance of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$697,192</div> was recorded at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017. </div>At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>Milestone Scientific&#x2019;s purchase commitment for this purchase order was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$300,460.</div> An advance of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$656,752</div> was recorded at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016. </div>At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>Milestone Scientific&#x2019;s purchase commitment for this purchase order was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$272,231.</div> Consequently, advances on contracts have been classified as current at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> respectively.&nbsp;&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">For <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>an aggregate of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70%</div> of Milestone Scientific's net product sales were to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> customers/ distributors (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> of which, Milestone China, is a related party), <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">51%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19%,</div> respectively. For <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>an aggregate of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">58%</div> of Milestone Scientific's net product sales were to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> customers/distributors (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> of which, Milestone China, is a related party), <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31%,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27%,</div> respectively. Accounts receivable for the major customer/distributors amounted to an aggregate of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,555,476,</div> or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78%</div> of Milestone Scientific's accounts receivable for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Accounts receivable for the major customer/distributors amounted to an aggregate of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,994,686,</div> or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85%</div> of Milestone Scientific's accounts receivable for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016. &nbsp;&nbsp;</div></div></div> <div style=" margin: 0pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821560816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Q - Related Party Transzactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">NOTE Q<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;-- RELATED PARTY TRANSACTIONS</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific has a manufacturing agreement with United Systems (an entity controlled by a significant stockholder of Milestone), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,146,108</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,025,249</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively. Milestone Scientific owed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$985,678</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,235,052</div> to this manufacturer as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Milestone Scientific had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,071,000</div> of related party sales of handpieces and instruments to Milestone China and Milestone China&#x2019;s agent for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017. </div>Milestone Scientific had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,425,000</div> of related party sales of handpieces and instruments to Milestone China for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016. </div>As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> Milestone Scientific recorded deferred revenues and deferred costs associated with sales to Milestone China of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,725,450</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,109,671,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,001,800</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$620,041,</div> respectively.&nbsp; As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> Milestone China and Milestone China&#x2019;s agent owed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,725,450</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,714,600,</div> respectively, to Milestone Scientific which is included in related party accounts receivable on the consolidated balance sheets.&nbsp;Milestone Scientific defers the total revenue and costs of goods sold when instruments and handpieces are shipped to Milestone China and Milestone China&#x2019;s agent due to market conditions and Milestone China liquidity concerns. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2016, </div>a stockholder of Milestone Scientific entered a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-year agreement with Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$100,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017, </div>Milestone Scientific entered into a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div>-month agreement with Innovest S.p.A. to provide consulting service. This agreement is expected to continue into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Expenses recognized on this agreement were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$80,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017.</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">See Note M for related party employment and consulting agreements.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821538368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note R - Commitments and Other<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">NOTE<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;R&nbsp;&#x2014; COMMITMENTS AND OTHER </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) Lease Commitments </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The headquarters for Milestone Scientific is located at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">220</div> South Orange Ave, Livingston, New Jersey. Milestone Scientific leases approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,625</div> square feet of office space. The lease term expires <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 31, 2020 </div>and provides for a monthly lease payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12,522.</div> Additionally, Milestone Scientific has other smaller insignificant leases ending through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> Further, a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party distribution and logistics center in Pennsylvania handles shipping and order fulfillment on a month-to-month basis.&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Aggregate minimum rental commitments under noncancelable operating leases are as follows:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.5pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22px; text-align: center;">&nbsp;</td> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 205px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Year Ending December 31, 2017</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2018</div> </td> <td style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">150,264</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</div> </td> <td style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">150,264</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</div> </td> <td style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,522</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;">&nbsp;</td> <td style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">313,050</div></td> </tr>  </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, rent expense amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$141,428</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$133,657</div> respectively.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>)<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Other Commitments </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific's employment agreement (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x201c;2009</div> Agreement&#x201d;) with Leonard Osser, its former Chief Executive Officer, provided for payments of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$203,111</div> per year for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years to the executive or as he directs such payments, to a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party, to fund his acquisition of, or contribution to, an annuity, pension, or deferred distribution plan; or for an investment for the benefit of the executive and his family. Milestone Scientific expensed approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> $203,111 years ended</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> respectively to fund this obligation. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017, </div>Milestone Scientific entered into a new employment agreement with Mr. Osser, which superseded the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div> Agreement pursuant to which he stepped down from his position as Chief Executive Officer and became Managing Director &#x2013; China Operations.&nbsp;Pursuant to the new agreement, Milestone Scientific agreed to fund the last installment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$203,111</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> as provided for in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div> Agreement. </div>&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> &nbsp; &nbsp; &nbsp; </div></div>  <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 19, 2017 </div>the Board of Directors appointed Leonard Osser Interim Chief Executive Officer, replacing Leslie Bernhard. Mr. Osser will enter into a similar employment contract that he received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> before he resigned his position as CEO of the company. <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Mr. Osser placed on&nbsp;hold his position as Managing Director-China Operations and his consulting agreement with Milestone Medical to rejoined Milestone Scientific Inc. as Interim Chief Executive Officer.&nbsp; Mr. Osser will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> receive or earn any compensation under these agreements until he is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer Interim Chief Executive Officer.&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">The technology underlying the SafetyWand&reg; and CompuFlo&reg;, and an improvement to the controls for CompuDent&reg; were developed by the Director of Clinical Affairs and assigned to Milestone Scientific. Milestone Scientific purchased this technology pursuant to an agreement dated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2005. </div>The Director of Clinical Affairs will receive additional payments of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.5%</div> of the total sales of products using certain of these technologies, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> of the total sales of products using certain other of the technologies until the expiration of the last patent. The Director of Clinical Affairs was granted, pursuant to the agreement, an option to purchase, at fair market value on the date of the grant <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,333</div> shares of common stock upon the issuance of each additional patent relating to these technologies. If products produced by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties use any of these technologies (under license from us) then the Director of Clinical Affairs will receive the corresponding percentage of the consideration received by Milestone Scientific for such sale or license.&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">The Director of Clinical Affairs&#x2019; royalty fee was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$554,150</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$526,737</div> for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively. Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$275,000</div></div> for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017, </div>Milestone Scientific entered into a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div>-month agreement with Innovest S.p.A. to provide consulting services. This agreement will renew for successive <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div>-month terms unless terminated by Innovest S.p.A or Milestone Scientific. Expenses recognized on this agreement were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$80,000</div> for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>respectively. This agreement is expected to continue into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: 27pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2, 2017, </div>Milestone Scientific accepted the resignation of the then CEO, Daniel Goldberger. Subsequent to that date, Mr. Goldberger through his attorney advised Milestone Scientific<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2019;s attorneys, that Mr. Goldberger was entitled, based on the circumstances he asserted with respect to his resignation after acceptance of such resignation, to his basic salary (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$300,000</div>) for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year and certain other benefits (health and disability insurance for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30,000</div> estimated) and a car allowance of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,200</div> per month), in accordance with his employment contract dated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 10, 2017.&nbsp; </div>Under the circumstances asserted by Mr. Goldberger, he would also be entitled to the immediate vesting of options under the Milestone Scientific&#x2019;s Stock Option Plan agreed to be granted to him pursuant to his employment agreement, exercisable for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ninety</div> days after his resignation, for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">921,942</div> shares of Milestone Scientific at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.00</div> per share, which exercise price is more than the market price of Milestone Scientific&#x2019;s shares on the date hereof. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018, </div>Milestone Scientific Inc. and Mr. Goldberger signed a settlement and released an agreement with respect to Mr. Goldberger&#x2019;s leaving the Company, the gross settlement was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$175,000</div> and,&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$75,000,</div> was paid in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2018. </div>The remainder of the settlement will be paid over a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div>-month period beginning in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2018.</div><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829854224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note S - Pension Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefits Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">NOTE S&nbsp;&#x2014; PENSION PLAN </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific has a Defined Contribution Plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone Scientific does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> contribute to this plan, but does pay the administrative costs of the plan, which were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> significant.</div><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821556064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note T - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;"><div style="display: inline; font-weight: bold;">NOTE<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;T&nbsp;&#x2014; SUBSEQUENT EVENTS</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:1.5pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2018 the Company&nbsp;</div>entered into a purchase commitment for the delivery of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000</div> instruments beginning in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3rd</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company&#x2019;s purchase commitment for this purchase order was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,397,440.</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2, 2018, </div>the Note Receivable identified on the Balance Sheet<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;was in default. If Milestone Scientific exercises its rights as a secured party it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be obligated to return to the purchaser up to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250,000</div> received for the Milestone China Shares as surplus. At this time Milestone Scientific has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> received a response from the purchaser of the Milestone China Shares, Milestone Scientific has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recorded any financial benefit from the sale of Milestone China Shares to date.&nbsp;</div> <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp; </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840175456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Principles of Consolidation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States&nbsp;(&quot;GAAP&quot;) and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned)&nbsp;and Milestone Medical (majority owned). Milestone Education is a variable interest entity of which Milestone Scientific is the primary beneficiary and is consolidated into Milestone Scientific's financial statements. All significant, intra-entity transactions and balances have been eliminated in the consolidation.&nbsp;&nbsp;&nbsp; </div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div>&nbsp;&nbsp;&nbsp;&nbsp; Reclassifications</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Certain reclassifications have been made to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>&nbsp;financial statements to conform to the consolidated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>&nbsp;financial statement presentation. These reclassifications had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> effect on net loss or cash flows as previously reported.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div> Variable Interest Entities</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;A variable interest entity (&quot;VIE&quot;) is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific&#x2019;s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific is the primary beneficiary of Milestone Education as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2016. </div>Accordingly, the assets and liabilities of Milestone Education are included in the accompanying consolidated financial statements. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Because Milestone Scientific had an increasing variable interest in Milestone China, it further considered the guidance in Accounting Standard Codification (&quot;ASC&quot;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">810</div> as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary. As Milestone China&#x2019;s equity at risk and voting rights were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> proportional to their economic interest, Milestone China was determined to be a VIE. Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics:</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <table style="margin-left:1.4%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align:middle;width:6.5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> </td> <td style="vertical-align:top;width:3.2%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&#x25cf;</div> </td> <td style="vertical-align:top;width:90.2%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">Power Criterion: The power to direct the activities that most significantly impact the entity<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2019;s economic performance; and</div></div> </td> </tr> </table> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <table style="margin-left:1.4%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align:middle;width:6.5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> </td> <td style="vertical-align:top;width:3.3%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&#x25cf;</div> </td> <td style="vertical-align:top;width:90.2%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE.</div> </td> </tr> </table> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone management does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the majority shareholder/CEO of Milestone China.&nbsp; As majority shareholder, majority holder of voting rights, and the active CEO, the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">53%</div> investor has the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> the primary beneficiary under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">810.</div> Accordingly, Milestone China has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been consolidated into the financial statements of Milestone Scientific and continues to be accounted for under the equity method.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.</div> Cash and Cash Equivalents</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific considers all highly liquid investments purchased with an original maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less to be cash equivalents.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade and Other Accounts Receivable, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> Accounts Receivable</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most of credit sales are due within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ninety</div> days from invoicing. There have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been any significant credit losses incurred to date.&nbsp;As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>&nbsp;Accounts receivable was recorded, net of allowance for doubtful accounts of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10,000</div> respectively.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy', window );">Finance, Loans and Leases Receivable, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">. Note Receivable</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Milestone Scientific values note receivable at historic cost less amount paid against principle. Milestone Scientific estimates losses on the note-based payments and credit quality of the debtor.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; </div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Standard Product Warranty, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">&nbsp;Product Return and Warranty</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Milestone Scientific generally does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> accept non-defective returns from its customers. Product returns under warranty are accepted, evaluated and repaired or replaced in accordance with the Warranty Policy. Returns <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> within the Warranty Policy are evaluated and the customer is charged for the repair.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> Inventories</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Inventories principally consist of finished goods and component parts stated at the lower of cost (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess, slow moving, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence and product expiration requirements. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> inventory was recorded net of allowance for slow moving inventory of&nbsp;approximately&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$220,000</div>&nbsp;as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017&nbsp;</div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0</div> as of&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,2016</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> Equity Method Investments</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Investments in which Milestone Scientific can exercise significant influence, but do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> control, are accounted for under the equity method of accounting and are included in the long-term assets on the Consolidated Balance Sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the income tax line on the Consolidated Statements of Operations.&nbsp;Milestone Scientific evaluates its equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period. </div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.</div></div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> Furniture, Fixture and Equipment&nbsp;&nbsp; </div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from <div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div></div> to <div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div></div> years. The costs of maintenance and repairs are charged to operations as incurred.&nbsp; As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> furniture, fixtures &amp; equipment was&nbsp;recorded net of accumulated depreciation of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$721,619</div>&nbsp;and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$659,144</div> respectively.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Intangible Assets &#x2013; Patents and Developed Technology</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized at the estimated average useful life of the patent. These patents and developed technology are recorded at the acquisition cost.&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patent defense costs, to the extent applicable, are expensed as incurred.&nbsp; Patent applications filed, and patents obtained in foreign countries are subject to the laws and procedures that differ from those in the United States. Patent protection in foreign countries <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be different from patent protection under United States laws and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be favorable to Milestone Scientific. Milestone Scientific also attempts to protect the proprietary information using confidentiality agreements and by limiting access to its facilities. There can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that the program of patents, confidentiality agreements and restricted access to the facilities will be sufficient to protect the proprietary technology.</div>&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.</div> Impairment of Long-Lived Assets</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>Milestone Scientific has reviewed long-lived assets for any impairments. The carrying value of the assets is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets. Milestone Scientific adjusts the net book value of an underlying asset if its fair value is determined to be less than its net book value. There have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impairment indicators or triggering events and therefore, there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div>&nbsp;impairments as of&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> respectively. </div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.</div> Revenue Recognition</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; &nbsp;&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Revenue from product sales is recognized, net of discounts and allowances to domestic distributors, on the date of shipment for substantially all shipments, since the shipment terms are FOB warehouse. Milestone Scientific recognizes revenue on date of arrival of the goods at the customer's location, where shipments are FOB destination. In all cases the price to the buyer is fixed and the collectability is reasonably assured. Further, Milestone Scientific has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.&nbsp;Devices and hand pieces are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> bundled but rather sold separately and, as such, there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> multiple element determinations in connection with the revenue recognition. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp; </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Milestone Scientific defers the total revenue and costs of goods sold when devices and handpieces are shipped to Milestone China and Milestone China<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2019;s agent due to market conditions and Milestone China liquidity concerns. Also, due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties, an elimination of the intra-entity profit is required as of the balance sheet date. In accordance with ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">323</div> Equity Method and Joint Ventures, Milestone Scientific has deferred <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40%</div> of the gross profit associated with recognized revenue from Milestone China that has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been sold to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling Cost, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.</div> Shipping and Handling Costs</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific includes shipping and handling costs, if any, in cost of goods sold. These costs are paid by or billed to customers at the time of shipments. Domestic and international shipments are FOB warehouse; therefore, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> costs are incurred by Milestone Scientific.<div style="display: inline; font-weight: bold;">&nbsp;</div>&nbsp;</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.</div> Research and Development</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research and development costs, which consist principally of new product development costs payable to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties, are expensed as incurred. Advance payments for the research are amortized to expense either as services are performed or over the relevant service period using the straight-line method.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16.</div> Income Taxes</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17.</div> Basic and diluted net loss per common share</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific presents &#x201c;basic&#x201d; earnings (loss) per common share applicable to common stockholders and, if applicable, &#x201c;diluted&#x201d; earnings (loss) per common share applicable to common stockholders pursuant to the provisions of Statement of Financial Accounting Standards ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260.</div> Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options, warrants, and the conversion of debt were issued during the period.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Since Milestone Scientific had net losses for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the assumed effects of the exercise of potentially dilutive outstanding stock options and warrants were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the calculation as their effect would have been anti-dilutive. Such outstanding options and warrants totaled&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,679,152</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,329,769</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively. </div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18.</div> Use of Estimates</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates<div style="display: inline; font-weight: bold;">.</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19.</div> Fair Value of Financial Instruments</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fair Value Measurements: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> of the following categories:</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-indent: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;">&#x25cf;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;">&#x25cf;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp; Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> inputs which are defined as inputs other than quoted prices included within Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> that are observable for the assets or liabilities, either directly or indirectly.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-indent: -27pt;">&#x25cf;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> inputs are defined as unobservable inputs for the assets or liabilities.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.</div> Stock-Based Compensation </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Milestone Scientific accounts for stock-based compensation under ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718,</div> Share-Based Payment. ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> requires all share-based payments to employees, including grants of employee stock options, to be recognized in the Statements of Operations over the service period, as an operating expense, based on the grant-date fair values. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. In accordance with the provisions of FASB ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">505,</div> Milestone Scientific will re-measure the value of the grant at each presentation date unless there is a significant disincentive for non-performance or until performance has been rendered. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months end <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>Milestone Scientific recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9,384</div> income related to non-employee options. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months end <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016, </div>Milestone Scientific recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$25,346</div> expense related to non-employee options.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21.</div> </div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Recent Acc</div>ounting Pronouncements</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the Financial Accounting Standards Board (&quot;FASB&quot;) issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> steps: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) identify the contract, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) identify performance obligations, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>) determine the transaction price, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) allocate the transaction price, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2015, </div>the FASB issued guidance approving a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-year deferral, making the standard effective for reporting periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017. </div>The FASB continues to release guidance clarifying certain aspects of the revenue guidance. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe that this new accounting pronouncement will have a material impact on our financial statements.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued a new standard Accounting Standards Update (&quot;ASU &quot;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> &quot;Leases&quot;(Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>). The new standard is intended to increase transparency and comparability among organizations to recognize lease assets and liabilities on the balance sheet and disclose key information about leasing arrangements. It will be effective for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>Milestone Scientific is in the process of determining what impact, the adoption of this ASU will have on its financial position, results of operations and cash flows. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2016, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> &#x201c;Financial Instruments <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2013; Credit Losses&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">326</div>).: The new standard is intended to replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. It will be effective for all entities for fiscal years and interim periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2016, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> &quot;Statement Cash Flows &#x201c;Classification of Certain Cash Receipts and Cash Disbursements&quot; Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230</div>). The new standard provides guidance as to the conformity of presentation of certain cash receipts and disbursements. It will be effective for all entities for fiscal years and interim periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017. </div>Milestone Scientific does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> anticipate the adoption of this ASU will have a significant impact on its presentation within the statement of cash flows.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2016, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> &#x201c;Statement of Cash Flows <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2013; Restricted Cash&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230</div>). The new standard provides guidance as to address the diversity of treatment of restricted cash on the statement of cash flows. It will be effective for all entities for fiscal years and interim periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017 </div>and interim periods therein. Milestone Scientific does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect the adoption of this ASU to have a material effect on its presentation within the statement of cash flows.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2017, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> &#x201c;Compensation <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2013; Stock Compensation&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>). The new standard provides guidance and clarity for modification to equity-based compensation programs. It will be effective for all entities for fiscal years and interim periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017. </div>Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its presentation within the statement of cash flows.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2017, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> &#x201c;Earnings Per Share&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div>), &#x201c;Distinguishing Liabilities from Equity&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">480</div>), &#x201c;Derivatives and Hedging&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">815</div>). The new standard provides guidance relating to equity-linked instruments that include certain features. It will be effective for public entities for fiscal years and interim periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its presentation within the statement of cash flows.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2017, </div>the FASB issued a new standard ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,</div> &#x201c;Income Statement <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2013; Reporting Comprehensive Income&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">815</div>), &#x201c;Revenue Recognition&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>) and &#x201c;Revenue from Contracts with Customers&#x201d; (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>). The new standard provides guidance in these areas pursuant to certain SEC Staff Accounting Bulletin and Release, as they relate to the presentation of revenue recognition matters on the statement of comprehensive income.&nbsp; It will be effective for public entities concurrent with the effectuation of other revenue recognition standards. Milestone Scientific does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> anticipate the adoption of this ASU to have a significant impact on its presentation within the statement of comprehensive income.</div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77990344&amp;loc=SL6759159-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77990344&amp;loc=d3e5728-111685<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=77990344&amp;loc=SL6759068-111685<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finance, loan and lease receivables, including those held for investment and those held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the allowance for loan and lease losses is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition (revenues, expenses and gains and losses arising from committing to issue, issuing, granting, collecting, terminating, modifying and holding loans) policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5093-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5144-111524<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=SL6953423-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (b,d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5212-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLoansAndLeasesReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82851458&amp;loc=d3e221937-122793<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68075638&amp;loc=d3e60635-111653<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68080631&amp;loc=d3e61069-111654<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5212-111524<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5093-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829675696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note E - Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2016</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories consist of the following:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Dental finished goods</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,846,272</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,832,275</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Medical finished goods, net&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">475,285</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">735,061</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Component parts and other materials</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">57,652</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35,383</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,379,209</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,602,719</div></td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821521376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note H - Investment in Unconsolidated Subsidiaries (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2016</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Assets:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Current assets</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,127,422</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,362,198</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Non-current assets</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,213,520</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,467,547</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total assets:</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,340,942</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,829,745</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Liabilities:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Current liabilities</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,468,937</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,900,611</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stockholders' equity</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,127,995)</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,929,134</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities and stockholders<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2019; equity</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,340,942</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,829,745</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2016</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,666,605</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,126,484</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of goods sold</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">477,200</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">976,106</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gross Profit</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,189,405</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">150,378</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other Expenses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,247,205)</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,834,980</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net Losses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,057,800)</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,684,602</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" nowrap="nowrap">)</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597615872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note I - Furniture, Fixtures and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 7.5%; margin-left: 7.5%; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31</div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="4" style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furniture, Fixtures and Equipment consist of the<br /> <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">following:</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 64%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,734</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,734</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Office furniture and equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">134,947</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">135,802</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Molds</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,200</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,200</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Trade show displays</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">143,357</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">143,357</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Computers and software</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">231,704</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,840</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tooling Safety Wand</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,022</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,022</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">Website</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,200</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tooling equipment-STA &amp; Wand</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,100</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,100</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">EPI and IA Instruments</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82,363</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82,363</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">STA Trials Instruments</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63,752</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63,752</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">863,379</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">818,170</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(721,619</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(659,144</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">141,760</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">159,026</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821513264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note J - Patents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;">&nbsp;</td> <td colspan="5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 305px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div></div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37px;">&nbsp;</td> <td colspan="5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 313px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div></div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 71px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Cost</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 95px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Accumulated Amortization</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 31px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 80px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Net</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 91px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Cost</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 101px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Accumulated Amortization</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 15px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 92px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Net</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patents-foundation intellectual property</div> </td> <td style="width: 71px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,377,863</div></td> <td nowrap="nowrap" style="width: 20px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 95px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(787,821</div></td> <td nowrap="nowrap" style="width: 31px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 80px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">590,042</div></td> <td nowrap="nowrap" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 91px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,377,543</div></td> <td nowrap="nowrap" style="width: 7px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 101px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(717,086</div></td> <td nowrap="nowrap" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 92px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">660,457</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Epidural-Apad acquired patents</div> </td> <td style="width: 71px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,639,647</div></td> <td nowrap="nowrap" style="width: 20px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 95px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(439,941</div></td> <td nowrap="nowrap" style="width: 31px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 80px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,199,706</div></td> <td nowrap="nowrap" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 91px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 7px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 101px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 92px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 278px;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 71px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,017,510</div></td> <td nowrap="nowrap" style="width: 20px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 95px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,227,762</div></td> <td nowrap="nowrap" style="width: 31px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 80px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,789,748</div></td> <td nowrap="nowrap" style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 91px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,377,543</div></td> <td nowrap="nowrap" style="width: 7px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 101px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(717,086</div></td> <td nowrap="nowrap" style="width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 92px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">660,457</div></td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821577856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note L - Stock Option Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 5%; margin-left: 5%; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of Options</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Wei<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">ghted Averaged Exercise Price $</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average Remaining Contractual Life (Years)</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate Intrinsic Options Value $</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 44%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options outstanding January 1, 2016</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,419,436</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.56</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.79</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,220,338</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable, January 1, 2016</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,041,680</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.29</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.41</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,135,819</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">520,337</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.79</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.38</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised during 2016</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(327,778</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.75</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(100,000</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.35</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options outstanding December 31, 2016</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,511,995</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.74</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.97</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102,605</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable, December 31, 2016</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,054,202</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.65</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.51</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102,605</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,006,741</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.82</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.69&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,610</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised during 2017</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(83,333</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.75</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited, cancelled, or expired</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,250,068</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Options outstanding December 31, 2017</div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,985,325</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.74</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.04</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,160</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable,<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> December 31, 2017</div></div> </td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,317,4416</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.84</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.46</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,537</div></td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 5%; margin-left: 5%; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 121px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number of Options</div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 25px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 140px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Averaged Exercise Price $</div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 26px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 153px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average Remaining Contractual Life (Years)</div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37px;">&nbsp;</td> <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Aggregate Intr<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">insic Options Value $</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding, January<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> 1, 2016</div></div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,333</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.70</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.83</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exercisable, January 1, 2016</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,777</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.70</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.83</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 489px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216,666</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.53</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding, December<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> 31, 2016</div></div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,999</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.53</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.32</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exercisable, December 31, 2016</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,734</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.72</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.36</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted 2017</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 489px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised 2017</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px none rgb(0, 0, 0); width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding, December<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> 31, 2017</div></div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,999</div></td> <td style="width: 25px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.52</div></td> <td style="width: 26px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.51</div></td> <td style="width: 37px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 489px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exercisable, December 31, 2017</div> </td> <td style="width: 121px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,067</div></td> <td style="width: 25px; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 140px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.22</div></td> <td style="width: 26px; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 153px; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.38</div></td> <td style="width: 37px; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81.23% -97.24%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">134.53%- 194.34%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.4%- 2.2%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.04%-1.47%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Life</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">2-5 years<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5 years</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeiture Rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821577856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note N - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Allowance for doubtful accounts-short term</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warranty reserve</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Capital Gains</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred officers compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">636,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">395,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and Amortization</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">181,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">135,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deferred revenue</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">478,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforward</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,116,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,456,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Subtotal</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,479,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,026,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,479,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(19,026,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Statutory rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State income tax - all states</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Non-deductible Stock based compensation</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deferred provision for effect of change in Federal</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">164</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Valuation allowance</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effective tax rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807736800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note O - Segment and Geographic Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="6" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Years ended</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net Sales:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,279,886</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,460,752</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,253</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,281,886</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,482,005</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating Income (Loss):</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,127,570</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,087,002</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>2,389,145</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>3,265,602</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,972,743</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>5,335,360</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>5,234,318</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>6,513,960</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and Amortization:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,305</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,619</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,950</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">62,720</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Other<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">528,895</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82,586</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">573,150</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">162,925</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-indent: 27pt;">&nbsp;Total</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income before taxes and equity in<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> earnings&nbsp;of affiliates:</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,136,167</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,097,652</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>2,391,082</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>3,219,497</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>5,975,035</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>5,395,918</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>5,229,950</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>6,517,763</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total Assets:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2017</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td> <td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2016</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Dental</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,255,144</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,472,879</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Medical</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">655,513</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">913,840</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Corporate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,718,130</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(</div>2,794,921</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 27pt;">&nbsp;Total</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,628,787</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,181,640</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_SalesByProductAndByGeographicalRegionTableTextBlock', window );">Sales by Product and by Geographical Region [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-right: 7.5%; margin-left: 7.5%; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Dental </div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 64%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Total Product Sales</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic-US and Canada</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,339,709</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,331,308</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International -Rest of the World</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,869,177</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,703,844</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International -China</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,071,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,425,600</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,279,886</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,460,752</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Total Product Sales</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Medical </div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic-US and Canada</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International - Rest of the World</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,253</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,253</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total </div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 18pt;">Domestic-US and Canada</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,339,709</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,352,561</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" text-indent: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">International -Rest of the World</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,871,177</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,703,844</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">International -China</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,071,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,425,600</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 36pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">Total</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,281,886</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,482,005</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_SalesByProductAndByGeographicalRegionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of sales by product and by geographical region.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_SalesByProductAndByGeographicalRegionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8813-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821618400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note R - Commitments and Other (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Lessee, Operating Lease, Disclosure [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22px; text-align: center;">&nbsp;</td> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 205px;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Year Ending December 31, 2017</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2018</div> </td> <td style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">150,264</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</div> </td> <td style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">150,264</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;"> <div style=" font-family: &quot;Times New Roman&quot;,Times,serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</div> </td> <td style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,522</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 644px;">&nbsp;</td> <td style="width: 22px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 205px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">313,050</div></td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164451&amp;loc=d3e36991-112694<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=82913245&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829697072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note A - Organization and Business (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of Countries in which Entity Operates</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_NumberOfMedicalInstrumentsSold', window );">Number of Medical Instruments Sold</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_NumberOfMedicalInstrumentsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of medical instruments sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_NumberOfMedicalInstrumentsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826505104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note C - Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for Doubtful Accounts Receivable</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Valuation Reserves</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</a></td>
<td class="nump">721,619<span></span>
</td>
<td class="nump">659,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of Long-Lived Assets Held-for-use</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingHandlingAndTransportationCosts', window );">Shipping, Handling and Transportation Costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_IncomeFromNonemployeeOptions', window );">Income from Non-employee Options</a></td>
<td class="nump">$ 9,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost', window );">Share-based Goods and Nonemployee Services Transaction, Capitalized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mlss_OptionsAndWarrantsMember', window );">Options and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">3,679,152<span></span>
</td>
<td class="nump">3,329,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage', window );">Variable Interest Entity Majority Shareholder Ownership Percentage</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage', window );">Equity Method Investment, Deferred Intercompany Profit (Loss), Percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The deferred percentage of the gross profit with recognized revenue from Entity and unconsolidated subsidiaries (including certain corporate joint ventures, and noncontrolled corporations), accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_IncomeFromNonemployeeOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income related to non-employee options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_IncomeFromNonemployeeOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of majority shareholder ownership interest in a Variable Interest Entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_VariableInterestEntityMajorityShareholderOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 225<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84241808&amp;loc=d3e92212-112881<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which an asset or assets increased resulting from the transaction in which equity securities were issued to pay for goods or nonemployee services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingHandlingAndTransportationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost incurred during the reporting period in transporting goods and services to customers. Includes freight-out costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68080631&amp;loc=d3e61069-111654<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68075638&amp;loc=d3e60635-111653<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82851458&amp;loc=d3e221937-122793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingHandlingAndTransportationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mlss_OptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mlss_OptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6844675584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note D - Notes Receivable (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 02, 2018</div></th>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase', window );">Proceeds from Sale of Variable Interest Entity Shares with Agreement to Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDeferredGainOnSale', window );">Equity Method Investment, Deferred Gain on Sale</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member] | Sale of Variable Interest Entity's Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_OptionToRepurchasePeriod', window );">Option to Repurchase, Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_PriceForSharesOfVariableInterestEntityInterestSold', window );">Price for Shares of Variable Interest Entity Interest Sold</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase', window );">Proceeds from Sale of Variable Interest Entity Shares with Agreement to Repurchase</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Financing Receivable, Net</a></td>
<td class="nump">1,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_NoteReceivableQuarterlyInstallmentAmount', window );">Note Receivable, Quarterly Installment Amount</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice', window );">Option to Repurchase Variable Interest Entity Shares, Purchase Price</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod', window );">Option to Repurchase Variable Entity Shares at Specified Purchase Price, Period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDeferredGainOnSale', window );">Equity Method Investment, Deferred Gain on Sale</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member] | Sale of Variable Interest Entity's Shares [Member] | Upon Exercise of Default Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ReturnObligationAmount', window );">Return Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_NoteReceivableQuarterlyInstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of quarterly installment amount in related to the note receivable pursuant to the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_NoteReceivableQuarterlyInstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_OptionToRepurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of option to repurchase pursuant to the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_OptionToRepurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period to repurchase the variable entity shares at a specified purchase price under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price under the agreement to repurchase the variable interest entity shares within the first two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_PriceForSharesOfVariableInterestEntityInterestSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price for shares of variable interest entity interest sold pursuant the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_PriceForSharesOfVariableInterestEntityInterestSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from the sale of variable interest entity shares with agreement to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ReturnObligationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received that would be required to be returned to the purchaser.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ReturnObligationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDeferredGainOnSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents disclosure of the amount of gain which has been deferred as the result of the sale of a business or operating assets to a highly leveraged entity which deferred gain has been reflected in the accompanying statement of financial position as reduction from the related asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDeferredGainOnSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of the investment in a contractual right to receive money on demand or on fixed or determinable dates that is recognized as an asset in the creditor's statement of financial position. Examples include, but are not limited to, credit card receivables, notes receivable and receivables relating to lessor's rights to payments from leases other than operating leases that have been recorded as assets. Excludes trade accounts receivable with contractual maturity of one year or less and arose from the sale of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=mlss_SaleOfVariableInterestEntitysSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=mlss_SaleOfVariableInterestEntitysSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=mlss_UponExerciseOfDefaultAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=mlss_UponExerciseOfDefaultAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829803680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note E - Inventories (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Valuation Reserves</a></td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826926608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note E - Inventories - Summary of Inventories (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Component parts and other materials</a></td>
<td class="nump">$ 57,652<span></span>
</td>
<td class="nump">$ 35,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">3,379,209<span></span>
</td>
<td class="nump">4,602,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember', window );">Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">2,846,272<span></span>
</td>
<td class="nump">3,832,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember', window );">Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 475,285<span></span>
</td>
<td class="nump">$ 735,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829661376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note F - Advances on Contracts (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances on Inventory Purchases</a></td>
<td class="nump">$ 697,192<span></span>
</td>
<td class="nump">$ 700,900<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839164336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note G - Consolidation of Variable Interest Entity (Details Textual) - Milestone Education LLC [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity', window );">Percentage of Revenue from Services Performed to Variable Interest Entity</a></td>
<td class="nump">81.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue from services performed to variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_PercentageOfRevenueFromServicesPerformedToVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77990344&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=mlss_MilestoneEducationLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=mlss_MilestoneEducationLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6844414240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note H - Investment in Unconsolidated Subsidiaries (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 02, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2017</div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (120,510)<span></span>
</td>
<td class="num">$ (795,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase', window );">Proceeds from Sale of Variable Interest Entity Shares with Agreement to Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Sales Revenue, Goods, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,281,886<span></span>
</td>
<td class="nump">10,482,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_AdvancedOcularSciencesSAMember', window );">Advanced Ocular Sciences SA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvancesToAffiliate', window );">Advances to Affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_WriteoffOfAdvancesToAffiliate', window );">Write-off of Advances to Affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired', window );">Long-term Purchase Commitment, Minimum Quantity Required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(795,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostMethodInvestmentsRealizedLosses', window );">Cost-method Investments, Realized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,147,470<span></span>
</td>
<td class="nump">1,124,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDeferredGainOnSale', window );">Equity Method Investment, Deferred Gain on Sale</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Sales Revenue, Goods, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,071,000<span></span>
</td>
<td class="nump">3,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage', window );">Equity Method Investment, Deferred Intercompany Profit (Loss), Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member] | Accounts Receivable from Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss', window );">Equity Method Investment, Deferred Intercompany Profit (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 751,500<span></span>
</td>
<td class="nump">630,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount', window );">Equity Method Investment, Unrealized Intercompany Profit (Loss) Not Eliminated, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member] | Instruments and Handpieces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Sales Revenue, Goods, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,071,000<span></span>
</td>
<td class="nump">3,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member] | Sale of Variable Interest Entity's Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_OptionToRepurchasePeriod', window );">Option to Repurchase, Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_PriceForSharesOfVariableInterestEntityInterestSold', window );">Price for Shares of Variable Interest Entity Interest Sold</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase', window );">Proceeds from Sale of Variable Interest Entity Shares with Agreement to Repurchase</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Financing Receivable, Net</a></td>
<td class="nump">1,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_NoteReceivableQuarterlyInstallmentAmount', window );">Note Receivable, Quarterly Installment Amount</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice', window );">Option to Repurchase Variable Interest Entity Shares, Purchase Price</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod', window );">Option to Repurchase Variable Entity Shares at Specified Purchase Price, Period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDeferredGainOnSale', window );">Equity Method Investment, Deferred Gain on Sale</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_VariableInterestEntityOwnershipPercentageSold', window );">Variable Interest Entity Ownership Percentage Sold</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member] | Sale of Variable Interest Entity's Shares [Member] | Subsequent Event [Member] | Upon Exercise of Default Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ReturnObligationAmount', window );">Return Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneEducationLLCMember', window );">Milestone Education LLC [Member] | Accounts Receivable from Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount', window );">Equity Method Investment, Unrealized Intercompany Profit (Loss) Not Eliminated, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of deferred intercompany profits and losses on transactions between the Entity and unconsolidated subsidiaries (including certain corporate joint ventures, and noncontrolled corporations), accounted for under the equity method of accounting,as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EquityMethodInvestmentDeferredIntercompanyProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The deferred percentage of the gross profit with recognized revenue from Entity and unconsolidated subsidiaries (including certain corporate joint ventures, and noncontrolled corporations), accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EquityMethodInvestmentDeferredIntercompanyProfitLossPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_NoteReceivableQuarterlyInstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of quarterly installment amount in related to the note receivable pursuant to the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_NoteReceivableQuarterlyInstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_OptionToRepurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of option to repurchase pursuant to the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_OptionToRepurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period to repurchase the variable entity shares at a specified purchase price under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_OptionToRepurchaseVariableEntitySharesAtSpecifiedPurchasePricePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price under the agreement to repurchase the variable interest entity shares within the first two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_OptionToRepurchaseVariableInterestEntitySharesPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_PriceForSharesOfVariableInterestEntityInterestSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price for shares of variable interest entity interest sold pursuant the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_PriceForSharesOfVariableInterestEntityInterestSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from the sale of variable interest entity shares with agreement to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ProceedsFromSaleOfVariableInterestEntitySharesWithAgreementToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ReturnObligationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received that would be required to be returned to the purchaser.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ReturnObligationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_VariableInterestEntityOwnershipPercentageSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership interest in a variable interest entity sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_VariableInterestEntityOwnershipPercentageSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_WriteoffOfAdvancesToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of write-off of advances to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_WriteoffOfAdvancesToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMethodInvestmentsRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For investments in debt and equity securities accounted for at cost, the excess of the carrying amount over net sale proceeds of investments disposed of during the period and any losses recognized thereon for impairments of other than a temporary nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMethodInvestmentsRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDeferredGainOnSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents disclosure of the amount of gain which has been deferred as the result of the sale of a business or operating assets to a highly leveraged entity which deferred gain has been reflected in the accompanying statement of financial position as reduction from the related asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDeferredGainOnSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the amount of unrealized intercompany profits and losses on transactions between the Entity and unconsolidated subsidiaries (including certain corporate joint ventures, and noncontrolled corporations), accounted for under the equity method of accounting, which have not been eliminated in preparing the Entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.3A-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355119-122828<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99375318&amp;loc=d3e32367-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentUnrealizedIntercompanyProfitLossNotEliminatedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of units of goods that must be purchased within the specified time period of the agreement to avoid penalties or unfavorable effects on pricing, among other adverse consequences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of the investment in a contractual right to receive money on demand or on fixed or determinable dates that is recognized as an asset in the creditor's statement of financial position. Examples include, but are not limited to, credit card receivables, notes receivable and receivables relating to lessor's rights to payments from leases other than operating leases that have been recorded as assets. Excludes trade accounts receivable with contractual maturity of one year or less and arose from the sale of goods or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_AdvancedOcularSciencesSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_AdvancedOcularSciencesSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mlss_AccountsReceivableFromRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mlss_AccountsReceivableFromRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=mlss_InstrumentsAndHandpiecesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=mlss_InstrumentsAndHandpiecesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=mlss_SaleOfVariableInterestEntitysSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=mlss_SaleOfVariableInterestEntitysSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=mlss_UponExerciseOfDefaultAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=mlss_UponExerciseOfDefaultAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneEducationLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneEducationLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841375776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note H - Investment in Unconsolidated Subsidiaries - Summarized Financial Information (Unaudited) of Milestone China (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">$ 4,312,507<span></span>
</td>
<td class="nump">$ 4,175,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">6,969,379<span></span>
</td>
<td class="nump">6,306,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Losses</a></td>
<td class="num">(5,369,553)<span></span>
</td>
<td class="num">(7,294,489)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets', window );">Current assets</a></td>
<td class="nump">13,127,422<span></span>
</td>
<td class="nump">9,362,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">3,213,520<span></span>
</td>
<td class="nump">2,467,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets', window );">Total assets:</a></td>
<td class="nump">16,340,942<span></span>
</td>
<td class="nump">11,829,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">18,468,937<span></span>
</td>
<td class="nump">9,900,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity', window );">Stockholders' equity</a></td>
<td class="num">(2,127,995)<span></span>
</td>
<td class="nump">1,929,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">16,340,942<span></span>
</td>
<td class="nump">11,829,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Net sales</a></td>
<td class="nump">1,666,605<span></span>
</td>
<td class="nump">1,126,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">477,200<span></span>
</td>
<td class="nump">976,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">1,189,405<span></span>
</td>
<td class="nump">150,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other Expenses</a></td>
<td class="num">(6,247,205)<span></span>
</td>
<td class="num">(2,834,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Losses</a></td>
<td class="num">$ (5,057,800)<span></span>
</td>
<td class="num">$ (2,684,602)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33912-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33912-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33912-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity, including noncontrolling interest, reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.g)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities and equity reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33912-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilitiesAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of noncurrent assets reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33912-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mlss_MilestoneChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mlss_MilestoneChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6838932672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note I - Furniture, Fixtures and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 62,475<span></span>
</td>
<td class="nump">$ 92,667<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826626432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note I - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">$ 863,379<span></span>
</td>
<td class="nump">$ 818,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(721,619)<span></span>
</td>
<td class="num">(659,144)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">141,760<span></span>
</td>
<td class="nump">159,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">24,734<span></span>
</td>
<td class="nump">24,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_OfficeFurnitureAndEquipmentMember', window );">Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">134,947<span></span>
</td>
<td class="nump">135,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Tools, Dies and Molds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_TradeShowDisplaysMember', window );">Trade Show Displays [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">143,357<span></span>
</td>
<td class="nump">143,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ComputerAndSoftwareMember', window );">Computer and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">231,704<span></span>
</td>
<td class="nump">224,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingSafetyWandMember', window );">Tooling Safety Wand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">125,022<span></span>
</td>
<td class="nump">125,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_WebsiteMember', window );">Website [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">39,200<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingEquipmentSTAAndWandMember', window );">Tooling Equipment - STA and Wand [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">11,100<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_EPIAndIAInstrumentsMember', window );">EPI and IA Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">82,363<span></span>
</td>
<td class="nump">82,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_STATrialsInstrumentsMember', window );">STA Trials Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures and equipment</a></td>
<td class="nump">$ 63,752<span></span>
</td>
<td class="nump">$ 63,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_TradeShowDisplaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_TradeShowDisplaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ComputerAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ComputerAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingSafetyWandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingSafetyWandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_WebsiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_WebsiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingEquipmentSTAAndWandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_ToolingEquipmentSTAAndWandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_EPIAndIAInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_EPIAndIAInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_STATrialsInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mlss_STATrialsInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827214048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note J - Patents (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 13, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 510,676<span></span>
</td>
<td class="nump">$ 70,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Stock Issued During Period, Value, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mlss_APADOctrooiBVAndAPADBVMember', window );">APAD Octrooi B.V. and APAD B.V. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="nump">1,646,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Stock Issued During Period, Value, Purchase of Assets</a></td>
<td class="nump">$ 2,486,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum', window );">Asset Purchase Agreement, Post-closing Adjustments, Percentage of Initial Shares, Maximum</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum', window );">Asset Purchase Agreement, Post-closing Adjustments, Amount of Initial Shares, Maximum</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities', window );">Asset Purchase Agreement, Post-closing Adjustments, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_AssetPurchaseAgreementPaymentsOfLegalFees', window );">Asset Purchase Agreement, Payments of Legal Fees</a></td>
<td class="nump">$ 153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 510,676<span></span>
</td>
<td class="nump">$ 70,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">$ 2,639,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member] | Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_AssetPurchaseAgreementPaymentsOfLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for legal fees on behalf of the settler as stipulated based on the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_AssetPurchaseAgreementPaymentsOfLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of initial shares subject to post-closing adjustment pursuant to asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_AssetPurchaseAgreementPostClosingAdjustmentsAmountOfIntialSharesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the post-closing adjustments pursuant to the asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_AssetPurchaseAgreementPostclosingAdjustmentsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of initial shares subject to post-closing adjustment pursuant to asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_AssetPurchaseAgreementPostclosingAdjustmentsPercentageOfInitialSharesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mlss_APADOctrooiBVAndAPADBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mlss_APADOctrooiBVAndAPADBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842799024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note J - Patents - Summary of Patents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents, cost</a></td>
<td class="nump">$ 4,017,510<span></span>
</td>
<td class="nump">$ 1,377,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Patents, accumulated amortization</a></td>
<td class="num">(1,227,762)<span></span>
</td>
<td class="num">(717,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">2,789,748<span></span>
</td>
<td class="nump">660,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mlss_FoundationIntellectualPropertyPatentsMember', window );">Foundation Intellectual Property Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents, cost</a></td>
<td class="nump">1,377,863<span></span>
</td>
<td class="nump">1,377,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Patents, accumulated amortization</a></td>
<td class="num">(787,821)<span></span>
</td>
<td class="num">(717,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">590,042<span></span>
</td>
<td class="nump">660,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mlss_EpiduralapadPatentsMember', window );">Epidural-Apad Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents, cost</a></td>
<td class="nump">2,639,647<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Patents, accumulated amortization</a></td>
<td class="num">(439,941)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 2,199,706<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mlss_FoundationIntellectualPropertyPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mlss_FoundationIntellectualPropertyPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mlss_EpiduralapadPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mlss_EpiduralapadPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6843959088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note K - Stockholders' Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>May 31, 2014</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,836<span></span>
</td>
<td class="nump">$ 2,573,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,111,582<span></span>
</td>
<td class="nump">4,600,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,270,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,401,247<span></span>
</td>
<td class="nump">1,270,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mlss_OtherStockOptionsAndWarrantsMember', window );">Other Stock Options and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,329,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,710,335<span></span>
</td>
<td class="nump">3,329,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember', window );">Chief Executive Officer, Chief Financial Officer and Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,270,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,401,247<span></span>
</td>
<td class="nump">1,270,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock Issued During Period, Value, Restricted Stock Award, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred Stock, Redemption Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Series A Convertible Preferred Stock [Member] | Conversion Price if Certain Conditions are Not Met [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred Stock, Redemption Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mlss_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,592,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,592,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ClassOfWarrantOrRightExpirationPeriod', window );">Class of Warrant or Right, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 1.499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">123,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,461,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from issue date that a warrant expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21564-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21488-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mlss_OtherStockOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mlss_OtherStockOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mlss_ChiefExecutiveOfficerChiefFinancialOfficerAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mlss_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mlss_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mlss_ConversionPriceIfCertainConditionsAreNotMetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=mlss_ConversionPriceIfCertainConditionsAreNotMetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mlss_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mlss_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842508096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note L - Stock Option Plans (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 07, 2017</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2011</div></th>
<th class="th"><div>Jul. 31, 2004</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_IncomeFromNonemployeeOptions', window );">Income from Non-employee Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost', window );">Share-based Goods and Nonemployee Services Transaction, Capitalized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mlss_GianDomenicoTrombettaMember', window );">Gian Domenico Trombetta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006,741<span></span>
</td>
<td class="nump">520,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 636,058<span></span>
</td>
<td class="nump">$ 579,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 603,979<span></span>
</td>
<td class="nump">$ 603,979<span></span>
</td>
<td class="nump">$ 678,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 222 days<span></span>
</td>
<td class="text">3 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mlss_EmployeeStockOptionsIssuedAt255PerShareMember', window );">Employee Stock Options Issued at $2.55 Per Share [Member] | Gian Domenico Trombetta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember', window );">Employee Stock Options Issued at the Higher of $2.55 Per Share or Market Price [Member] | Gian Domenico Trombetta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mlss_StockOptionPlan2004Member', window );">Stock Option Plan 2004 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Period from Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expire Period after Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mlss_StockOptionPlan2011Member', window );">Stock Option Plan 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Period from Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expire Period after Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_IncomeFromNonemployeeOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income related to non-employee options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_IncomeFromNonemployeeOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the exercisable period from grant date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisePeriodFromGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expiration period from grant date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirePeriodAfterGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which an asset or assets increased resulting from the transaction in which equity securities were issued to pay for goods or nonemployee services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mlss_GianDomenicoTrombettaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mlss_GianDomenicoTrombettaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mlss_EmployeeStockOptionsIssuedAt255PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mlss_EmployeeStockOptionsIssuedAt255PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mlss_EmployeeStockOptionsIssuedAtTheHigherOf255PerShareOrMarketPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mlss_StockOptionPlan2004Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mlss_StockOptionPlan2004Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mlss_StockOptionPlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mlss_StockOptionPlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842022656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note L - Stock Option Plans - Summary of Option Activity for Employees and Non-employees (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, outstanding (Year)</a></td>
<td class="text">3 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 25,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable (in shares)</a></td>
<td class="nump">13,174,416<span></span>
</td>
<td class="nump">1,054,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable (Year)</a></td>
<td class="text">2 years 167 days<span></span>
</td>
<td class="text">2 years 186 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 8,537<span></span>
</td>
<td class="nump">$ 102,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life, granted (Year)</a></td>
<td class="text">4 years 251 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue', window );">Aggregate intrinsic value, granted</a></td>
<td class="nump">$ 25,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options forfeited and expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited or expired (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options (in shares)</a></td>
<td class="nump">1,985,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding (in dollars per share)</a></td>
<td class="nump">$ 1.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options (in shares)</a></td>
<td class="nump">1,511,995<span></span>
</td>
<td class="nump">1,419,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding (in dollars per share)</a></td>
<td class="nump">$ 1.74<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, outstanding (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 354 days<span></span>
</td>
<td class="text">2 years 288 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,605<span></span>
</td>
<td class="nump">$ 1,220,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 149 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,135,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="nump">1,006,741<span></span>
</td>
<td class="nump">520,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life, granted (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 138 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue', window );">Aggregate intrinsic value, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised (in shares)</a></td>
<td class="num">(83,333)<span></span>
</td>
<td class="num">(327,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in dollars per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options forfeited and expired (in shares)</a></td>
<td class="num">(1,250,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511,995<span></span>
</td>
<td class="nump">1,419,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.74<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mlss_NonEmployeeOptionsMember', window );">Non-employee Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options (in shares)</a></td>
<td class="nump">224,999<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding (in dollars per share)</a></td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, outstanding (Year)</a></td>
<td class="text">3 years 186 days<span></span>
</td>
<td class="text">5 years 116 days<span></span>
</td>
<td class="text">4 years 302 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable (in shares)</a></td>
<td class="nump">23,067<span></span>
</td>
<td class="nump">14,734<span></span>
</td>
<td class="nump">2,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 2.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable (Year)</a></td>
<td class="text">4 years 138 days<span></span>
</td>
<td class="text">4 years 131 days<span></span>
</td>
<td class="text">4 years 302 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">216,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue', window );">Aggregate intrinsic value, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options (in shares)</a></td>
<td class="nump">224,999<span></span>
</td>
<td class="nump">224,999<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding (in dollars per share)</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="nump">$ 2.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based payment award options grants in period weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mlss_NonEmployeeOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mlss_NonEmployeeOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821831376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note L - Summary of Significant Accounting Policies - Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture Rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">81.23%<span></span>
</td>
<td class="nump">134.53%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (Year)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">97.24%<span></span>
</td>
<td class="nump">194.34%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">1.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The forfeiture rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842155216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note M - Employment Contract and Consulting Agreements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 09, 2017</div></th>
<th class="th"><div>Oct. 05, 2017</div></th>
<th class="th"><div>Dec. 01, 2016</div></th>
<th class="th"><div>Sep. 01, 2009</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2011</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mlss_StockOptionPlan2011Member', window );">Stock Option Plan 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006,741<span></span>
</td>
<td class="nump">520,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod', window );">Chief Executive Officer, Employment Agreement Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod', window );">Chief Executive Officer, Automatic Extended Employment Agreement Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Deferred Compensation Arrangement with Individual, Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_MinimumShareholdingPercentageInCompany', window );">Minimum Shareholding Percentage in Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_OptionsExercisablePeriod', window );">Options Exercisable Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued', window );">Deferred Compensation Arrangement with Individual, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">886,866<span></span>
</td>
<td class="nump">855,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued', window );">Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,030,875<span></span>
</td>
<td class="nump">$ 980,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued Bonuses, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mlss_PresidentAndChiefExecutiveOfficerMember', window );">President and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmploymentAgreementTerm', window );">Employment Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmploymentAgreementBaseCompensation', window );">Employment Agreement, Base Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmploymentAgreementMaximumBonuses', window );">Employment Agreement, Maximum Bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mlss_PresidentAndChiefExecutiveOfficerMember', window );">President and Chief Executive Officer [Member] | Non-qualified Stock Options [Member] | Stock Option Plan 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mlss_PreviousPresidentAndChiefExecutiveOfficerMember', window );">Previous President and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmploymentAgreementTerm', window );">Employment Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmploymentAgreementBaseCompensation', window );">Employment Agreement, Base Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmploymentAgreementBaseCompensationCash', window );">Employment Agreement, Base Compensation, Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmploymentAgreementBaseCompensationCommonStockValue', window );">Employment Agreement, Base Compensation, Common Stock Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ConsultingAgreementTerm', window );">Consulting Agreement, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ConsultingAgreementAnnualPayment', window );">Consulting Agreement, Annual Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mlss_InterimChiefExecutiveOfficerMember', window );">Interim Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmploymentAgreementBaseCompensation', window );">Employment Agreement, Base Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmploymentAgreementBaseCompensationCommonStockValue', window );">Employment Agreement, Base Compensation, Common Stock Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmploymentAgreementOnetimeBonus', window );">Employment Agreement, One-Time Bonus</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the automatic extended employment agreement period for the Chief Executive Officer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ChiefExecutiveOfficerAutomaticExtendedEmploymentAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the employment agreement period for the Chief Executive Officer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ChiefExecutiveOfficerEmploymentAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ConsultingAgreementAnnualPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>the annual payment will be paid by the company pursuant to the consulting agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ConsultingAgreementAnnualPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ConsultingAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term of consulting agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ConsultingAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmploymentAgreementBaseCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of annual base compensation pursuant to the employment agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmploymentAgreementBaseCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmploymentAgreementBaseCompensationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of base compensation that will be paid in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmploymentAgreementBaseCompensationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmploymentAgreementBaseCompensationCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of base compensation that will be paid in the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmploymentAgreementBaseCompensationCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmploymentAgreementMaximumBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of annual bonuses pursuant the employment agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmploymentAgreementMaximumBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmploymentAgreementOnetimeBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a one-time bonus related to an employment agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmploymentAgreementOnetimeBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmploymentAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term of the employment agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmploymentAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_MinimumShareholdingPercentageInCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum shareholding percentage in the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_MinimumShareholdingPercentageInCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_OptionsExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the options exercisable period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_OptionsExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total fair value of shares issued during the period under a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued pursuant to the terms of a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mlss_StockOptionPlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mlss_StockOptionPlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mlss_PresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mlss_PresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mlss_NonqualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mlss_NonqualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mlss_PreviousPresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mlss_PreviousPresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mlss_InterimChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mlss_InterimChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842984560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note N - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Operating Loss Carryforwards, Valuation Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017', window );">Deferred Tax Assets Gross, Increase (Decrease) Due to New Tax Cuts and Jobs Act 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,677,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_PercentageOfValuationAllowance', window );">Percentage of Valuation Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,339<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member', window );">Deferred Tax Assets Related to New Tax Cuts and Jobs Act 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,677,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="nump">56,530,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="nump">$ 22,942,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of adjustment to gross deferred tax assets due to the new Tax Cuts and Jobs Act 2017.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_DeferredTaxAssetsGrossIncreaseDecreaseDueToNewTaxCutsAndJobsAct2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_PercentageOfValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_PercentageOfValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=75018887&amp;loc=d3e30536-109315<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=mlss_DeferredTaxAssetsRelatedToNewTaxCutsAndJobsAct2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821403824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note N - Income Taxes - Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful accounts-short term</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves', window );">Warranty reserve</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital Gains</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Deferred officers compensation</a></td>
<td class="nump">636,000<span></span>
</td>
<td class="nump">395,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent', window );">Depreciation and Amortization</a></td>
<td class="nump">181,000<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">478,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">15,116,000<span></span>
</td>
<td class="nump">18,456,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossCurrent', window );">Subtotal</a></td>
<td class="nump">16,479,000<span></span>
</td>
<td class="nump">19,026,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowanceCurrent', window );">Valuation allowance</a></td>
<td class="num">$ (16,479,000)<span></span>
</td>
<td class="num">$ (19,026,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_DeferredTaxAssetsDepreciationAndAmortizationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31938-109318<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowanceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance of deferred tax asset attributable to deductible temporary differences and carryforwards, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31928-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowanceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826846064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note N - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax - all states</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Deferred provision for effect of change in Federal</a></td>
<td class="nump">164.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation', window );"></a></td>
<td class="nump">204.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(204.00%)<span></span>
</td>
<td class="num">(43.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation at federal statutory rate and state and local income tax rate and stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryRateAndStateAndLocalIncomeTaxRateAndStockbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6604336480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note O - Segment and Geographic Data (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6845143232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note O - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">$ 11,281,886<span></span>
</td>
<td class="nump">$ 10,482,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="num">(5,234,318)<span></span>
</td>
<td class="num">(6,513,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before taxes and equity in earnings of affiliates:</a></td>
<td class="num">(5,229,950)<span></span>
</td>
<td class="num">(6,517,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">15,628,787<span></span>
</td>
<td class="nump">14,181,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="num">(5,972,743)<span></span>
</td>
<td class="num">(5,335,360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">573,150<span></span>
</td>
<td class="nump">162,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before taxes and equity in earnings of affiliates:</a></td>
<td class="num">(5,975,035)<span></span>
</td>
<td class="num">(5,395,918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,718,130<span></span>
</td>
<td class="num">(2,794,921)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">528,895<span></span>
</td>
<td class="nump">82,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember', window );">Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">11,279,886<span></span>
</td>
<td class="nump">10,460,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember', window );">Dental Segment [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">11,279,886<span></span>
</td>
<td class="nump">10,460,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="nump">3,127,570<span></span>
</td>
<td class="nump">2,087,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">17,305<span></span>
</td>
<td class="nump">17,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before taxes and equity in earnings of affiliates:</a></td>
<td class="nump">3,136,167<span></span>
</td>
<td class="nump">2,097,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">10,255,144<span></span>
</td>
<td class="nump">10,472,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember', window );">Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">21,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember', window );">Medical Segment [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">21,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="num">(2,389,145)<span></span>
</td>
<td class="num">(3,265,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">26,950<span></span>
</td>
<td class="nump">62,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before taxes and equity in earnings of affiliates:</a></td>
<td class="num">(2,391,082)<span></span>
</td>
<td class="num">(3,219,497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 655,513<span></span>
</td>
<td class="nump">$ 913,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828259488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note O - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">$ 11,281,886<span></span>
</td>
<td class="nump">$ 10,482,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=mlss_DomesticMember', window );">Domestic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">5,339,709<span></span>
</td>
<td class="nump">3,352,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=mlss_RestOfWorldMember', window );">Rest of World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">3,871,177<span></span>
</td>
<td class="nump">3,703,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_CN', window );">CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">2,071,000<span></span>
</td>
<td class="nump">3,425,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember', window );">Dental Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">11,279,886<span></span>
</td>
<td class="nump">10,460,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember', window );">Dental Segment [Member] | Domestic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">5,339,709<span></span>
</td>
<td class="nump">3,331,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember', window );">Dental Segment [Member] | Rest of World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">3,869,177<span></span>
</td>
<td class="nump">3,703,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember', window );">Dental Segment [Member] | CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">2,071,000<span></span>
</td>
<td class="nump">3,425,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember', window );">Medical Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">21,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember', window );">Medical Segment [Member] | Domestic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember', window );">Medical Segment [Member] | Rest of World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales, net</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 21,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=mlss_DomesticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=mlss_DomesticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=mlss_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=mlss_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6843436576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note P - Concentration (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances on Inventory Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,192<span></span>
</td>
<td class="nump">$ 700,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts Receivable, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,555,476<span></span>
</td>
<td class="nump">$ 2,994,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_NumberOfCustomers', window );">Number of Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Two Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember', window );">Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Customer Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=mlss_InstrumentsMember', window );">Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_PurchaseCommitmentNumberOfUnits', window );">Purchase Commitment Number Of Units</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances on Inventory Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,192<span></span>
</td>
<td class="nump">$ 656,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase Commitment, Remaining Minimum Amount Committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,460<span></span>
</td>
<td class="nump">$ 272,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_PurchaseCommitmentNumberOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units commitment to purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_PurchaseCommitmentNumberOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For unclassified balance sheet, amounts due from customers or clients for goods or services that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mlss_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mlss_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mlss_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mlss_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mlss_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mlss_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=mlss_InstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=mlss_InstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828246128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Q - Related Party Transzactions (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Sales Revenue, Goods, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,281,886<span></span>
</td>
<td class="nump">$ 10,482,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Sales Revenue, Goods, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071,000<span></span>
</td>
<td class="nump">3,425,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member] | Instruments and Handpieces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Sales Revenue, Goods, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071,000<span></span>
</td>
<td class="nump">3,425,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725,450<span></span>
</td>
<td class="nump">1,001,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrentAndNoncurrent', window );">Deferred Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,109,671<span></span>
</td>
<td class="nump">620,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member] | STA Instruments and Handpieces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts Receivable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725,450<span></span>
</td>
<td class="nump">2,714,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mlss_ManufacturingAgreementForHandpiecesMember', window );">Manufacturing Agreement for Handpieces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related Party Transaction, Purchases from Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,146,108<span></span>
</td>
<td class="nump">3,025,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">985,678<span></span>
</td>
<td class="nump">1,235,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember', window );">Consulting Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ConsultingServicesAgreementTerm', window );">Consulting Services Agreement, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember', window );">Consulting Services [Member] | Innovest S.p.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ConsultingServicesAgreementTerm', window );">Consulting Services Agreement, Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ConsultingServicesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expiration period under the consulting services agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ConsultingServicesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=mlss_InstrumentsAndHandpiecesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=mlss_InstrumentsAndHandpiecesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=mlss_STAInstrumentsAndHandpiecesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=mlss_STAInstrumentsAndHandpiecesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mlss_ManufacturingAgreementForHandpiecesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mlss_ManufacturingAgreementForHandpiecesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_InnovestSpAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_InnovestSpAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827736320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note R - Commitments and Other (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 02, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2005 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_AreaOfOfficeSpace', window );">Area of Office Space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Operating Leases, Rent Expense, Minimum Rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,428<span></span>
</td>
<td class="nump">$ 133,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPostemploymentBenefits', window );">Payments for Postemployment Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,111<span></span>
</td>
<td class="nump">203,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_DefineBenefitPlanPaymentPeriod', window );">Define Benefit Plan, Payment Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology', window );">Additional Percentage of Director Compensation on Sales Value Using Certain Specify Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology', window );">Additional Percentage of Director Compensation Sales Value Using Other Kind of Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember', window );">Consulting Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_InnovestSpAMember', window );">Innovest S.p.A. [Member] | Consulting Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mlss_DirectorOfClinicalAffairsMember', window );">Director of Clinical Affairs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants', window );">Stock Issued During Period, Shares, Stock Options Exercised, Attributable to Consultants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554,150<span></span>
</td>
<td class="nump">526,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mlss_FormerCeoMember', window );">Former CEO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmployeeResignationAssertionBasicSalaryForOneYear', window );">Employee Resignation Assertion, Basic Salary for One Year</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear', window );">Employee Resignation Assertion, Health and Disability Insurance for One Year</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmployeeResignationAssertionCarAllowanceForOneYear', window );">Employee Resignation Assertion, Car Allowance for One Year</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmployeeResignationAssertionVestingTermAfterResignation', window );">Employee Resignation Assertion, Vesting Term After Resignation</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmployeeResignationAssertionNumberOfOptionsVested', window );">Employee Resignation Assertion, Number of Options Vested | shares</a></td>
<td class="nump">921,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmployeeResignationAssertionOptionsExercisePrice', window );">Employee Resignation Assertion, Options Exercise Price | $ / shares</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mlss_FormerCeoMember', window );">Former CEO [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmployeeResignationAssertionGrossSettlement', window );">Employee Resignation Assertion, Gross Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_EmployeeResignationAssertionPayment', window );">Employee Resignation Assertion, Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payment to director as percentage of sales value using certain specify technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_AdditionalPercentageOfDirectorCompensationOnSalesValueUsingCertainSpecifyTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payment to director as percentage of sales value using other kind of technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_AdditionalPercentageOfDirectorCompensationSalesValueUsingOtherKindOfTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_DefineBenefitPlanPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan payment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_DefineBenefitPlanPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmployeeResignationAssertionBasicSalaryForOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of basic salary would be paid to a resigned employee for one year according to the his or her assertion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmployeeResignationAssertionBasicSalaryForOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmployeeResignationAssertionCarAllowanceForOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of car allowance will be paid to a resigned employee for one year according to the his or her assertion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmployeeResignationAssertionCarAllowanceForOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmployeeResignationAssertionGrossSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the gross settlement in connection to a employee resignation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmployeeResignationAssertionGrossSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of health and disability insurance would be paid in behalf of a resigned employee for one year according to the his or her assertion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmployeeResignationAssertionHealthAndDisabilityInsuranceForOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmployeeResignationAssertionNumberOfOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of options would be vested immediate according to a resigned employee's assertion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmployeeResignationAssertionNumberOfOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmployeeResignationAssertionOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of options according to a resigned employee's assertion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmployeeResignationAssertionOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmployeeResignationAssertionPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment in connection to an employee resignation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmployeeResignationAssertionPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_EmployeeResignationAssertionVestingTermAfterResignation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The versing term for options according to a employees's assertion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_EmployeeResignationAssertionVestingTermAfterResignation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options exercised attributable to consultants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_StockIssuedDuringPeriodSharesStockOptionsExercisedAttributableToConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77910348&amp;loc=d3e34039-112682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflows for payments of postemployment benefits (such as severance pay and health insurance benefits) recognized during the period. Postemployment benefits are benefits paid to employees after employment but before retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mlss_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_InnovestSpAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_InnovestSpAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mlss_DirectorOfClinicalAffairsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mlss_DirectorOfClinicalAffairsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mlss_FormerCeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mlss_FormerCeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821453936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note R - Commitments and Other - Aggregate Minimum Rental Commitments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">$ 150,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">150,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">12,522<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );"></a></td>
<td class="nump">$ 313,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829069248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note T - Subsequent Events (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th">
<div>Mar. 02, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember', window );">Milestone China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired', window );">Long-term Purchase Commitment, Minimum Quantity Required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Milestone China [Member] | Sale of Variable Interest Entity's Shares [Member] | Upon Exercise of Default Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mlss_ReturnObligationAmount', window );">Return Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=mlss_InstrumentsMember', window );">Instruments [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired', window );">Long-term Purchase Commitment, Minimum Quantity Required</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term Purchase Commitment, Amount</a></td>
<td class="nump">$ 1,397,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mlss_ReturnObligationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received that would be required to be returned to the purchaser.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mlss_ReturnObligationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mlss_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of units of goods that must be purchased within the specified time period of the agreement to avoid penalties or unfavorable effects on pricing, among other adverse consequences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mlss_MilestoneChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=mlss_SaleOfVariableInterestEntitysSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=mlss_SaleOfVariableInterestEntitysSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=mlss_UponExerciseOfDefaultAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=mlss_UponExerciseOfDefaultAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=mlss_InstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=mlss_InstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_A=A%TP=F?_L?%9L&OAUUUT7U!+ P04    " "DB8),F5R<(Q &  "<)P
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M\][H^:1OCM.^;W'9?%[^"U!+ P04    " "DB8),-M^H]V@"  "<"   &
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MUQFR_XKON!)R22)BG$C%U-LYW1@G]>!%H-3HK2_+1I5=/Q(E@YG=P!\,_-$
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M?I=$P@$L#&"G /8B0/)B$(X2/TGVDV3AV"?G6"0#A(&2M;'@R$%'3J?D*QS
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MQ*RI2$2N*A&("V_A@(I14I$![5P5659J0$<N,%')$Z8B RI&2476K)NRE^P
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MGLGQ8&@/I_V@Y7E3ZO8_4$L#!!0    ( *2)@DR-*++NL@$  -(#   8
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL;5/;;MLP#/T501]0.8J[#8%MH.E0
M=, &!!VV/2LV?4%U\20Y[OY^E.QX;N87BZ1Y#@\I*AN-?74M@"=O2FJ7T];[
M_L"8*UM0PMV9'C3^J8U5PJ-K&^9Z"Z**("493Y(/3(E.TR*+L9,M,C-XV6DX
M6>(&I83]<P1IQISNZ#7PTC6M#P%69+UHX#OX'_W)HL<6EJI3H%UG-+%0Y_1A
M=SBF(3\F_.Q@="N;A$[.QKP&YTN5TR0( @FE#PP"CPL\@I2!"&7\GCGI4C(
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MC,Z_;.Q_C>C IY)<^1%J_0=;# FU"\<O_FRF,9L,A_W\@]CRC8N_4$L#!!0
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M^9>-_:\1'?A4DAL_0JW_8(NAH';A^,&?S31FD^&PGW\06[YQ\1=02P,$%
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M7S;VOS;& Z:2W. (M?C!%D-![</Q#L]V&K/)\*:??Q!;OG'Q%U!+ P04
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M^]\@.O!2DCL_0IW_8*LAH7'A^-Z?S3QFL^%P6'X06[]Q^0=02P,$%     @
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M7#A^\&<SC]EL.!R6'\36;US^ 5!+ P04    " "DB8),V+Y^+KX"  #D"P
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M@)L  16>CW0 0$5(![@/$%#DQ4@'"!32 6X%!-1Y,=(! H5T@+L! :5>C'2
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M/[J]GM_R'%@U+&-*UO^*\@]02P,$%     @ I(F"3.,G]-/& 0  -P0  !D
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MV+T*#SD81@[SC)+E1U'^ U!+ P04    " "DB8),-Q?+%[\"  !7"@  &0
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M<V7AQV" \>W=74 8Y#Q6PYA.(BB$K2H$:NEY%02*K^A<L40$A$A<'?2YPX9
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MWRYQ;Z9)F0*GA_@(Z/P2ZS=02P,$%     @ I(F"3.UK+S^X 0  ]@,  !D
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M[7N_-],H3H'#?GYE;'GJQ1]02P,$%     @ I8F"3,EH!+1A!   '14  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULC9AK;Z,X%(;_2I3O._C8@"%*
M(C673E?:E:I9[<YGFC@7#80,D&;VWR\0-QM\7M)\:<!]S\6WAV./SWGQH]P9
M4PU^9>FAG QW574<>5ZYVIDL*;_D1W.H_[/)BRRIZM=BZY7'PB3KUBA+/2E$
MZ&7)_C"<CMNVUV(ZSD]5NC^8UV)0GK(L*?Z=F30_3X8T_&CXMM_NJJ;!FXZ/
MR=;\9:J_CZ]%_>9=O:SWF3F4^_PP*,QF,GRBT8N*&H-6\<_>G,N;YT'3E;<\
M_]&\_+Z>#$63D4G-JFI<)/7/NYF;-&T\U7G\M$Z'UYB-X>WSA_?GMO-U9]Z2
MTLSS]/M^7>TFPV@X6)M-<DJK;_GYQ=@.!<.![?T?YMVDM;S)I(ZQRM.R_3M8
MG<HJSZR7.I4L^77YW1_:W[/U_V&&#:0UD%<#27<-E#50CQKXUL!_U""P!L&C
M!J$U"!\UT-9 7PU(W36(K$'D1/ NT]'.[R*IDNFXR,^#XK)$CTFS$V@4U2MH
MU32V"Z;]7SW%9=WZ/E6Q/_;>&T=6,[MHY*TF5%W-@FOHJO#J#*YI2)3&3/(0
M<= -,4>:T$D#:717LT2:J*MY1IJXJ_D*-*&3\PO7^$+@@5%P?E3KP.\X(*?3
M%TW8:@ZMYC>2(B#A=!SH=!Q$4N.$?)B0SQ)2H3/"BXLFN DD R&$FP]P%>%4
M IA* ,9&.JD$K,]$,J(H<E;.,F YD_"C^B,0X)1"F%((4E+8@88.-!A>9W$N
MN,87/@X2P2 1<."NW(@-G(YTW#,_,0P3@S#NL,=LV.^$(8$9)OB@!3V+FGHP
M2)^/^QR*>C!'D'-/)+D++5S>2C;VPDV%2T@(OL<6G_M:6DD )=U.8481@I1V
M,U9\IK7LB8/10QP8'(;$X<,ZS"5W04@8/X3XX^Y5XEQ1Y&O?G?0E$-:D\E70
M-Q<80,0)I,+876 A7SU^=_5T8V%6$0*1"V KNHTEA2;^-;#"SDCY[7>C)RG,
M-N)P4R';%4C4MY,QW C1+<8N).:6Y-SRW8_VPHHZ( XH8,-G=;?#%RH1QSVC
M)S$')4><3^X6LZ+._G$*CFXLS$+)6>A3#Q$D)H]$Y'%7H.1U#UZ!DB/J[@J4
M&%,2U#6ZKQK&:)$<+>QS-(,B9ZZ^?B+J)H.1(@%2M'230:*>RD=BG$A0^VCW
M+"(Y3NZB2V)*2 0 [<:*.)+O+0<,"LE!H73@AN)U$$G='TMAHBA0"6FGY)HI
M3HI[W5*8% H40]H=02MZ>+84)H5"59.['9 HZ"F+5<]AB^.$?SP5Q\G]/F%*
M*%#,D')CH=-6S^Y5&"4*5"G4-RP8  KL[<B!Y[/B-85SZ.N&P@Q0H*2@GA.8
MPEM;@=.-^PE;*G"\016@=W./DIEBV]ZSE8-5?CI4S9']IO5ZE_<DFWL8IWU&
MHSF!]@6-EI=[F__=7RX._TR*[?Y0#M[RJLJS]HYFD^>5J=,77^I)W9ED?7U)
MS:9J'G7]7%PN["XO57ZTEY'>]49T^A]02P,$%     @ I8F"3'*1" $X P
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MY'V 5:R@!(Y P21H;\_>)2&#) :-Z#7-H*&8<!3H5H .2\XIA8$8",0 H#P
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MM!8$W +0#[3T)5840D4A4!0113T3CP,M8G(+M@@* RPE@E(B("4F4A"3$"6
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ME&5CK$9_8:?T9++]_4MN#DW[,;*?J_[HK/_2E-?A6-"[GTVN_P-02P,$%
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M-;95WO3_%]NWIJT*F\50*=*?PV=6]I\GF_\C# Z@-H"> PB_&,!L )L;P&T
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M^<G;)NU(<IP>YO4GRQNL_@%02P,$%     @ I8F"3/[M\<S_ P  RA$  !D
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M;A>&1EN=QYN3^'9]L_X/4$L#!!0    ( *6)@DS$+4F0!@,  &T,   9
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MR\( 139! =K-/8X_D@\ \@H&!.438F [P;Z?D'SBIF'8 C#D 5X^ "@OW7P
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M#TCX7C_ZK_)5Y@;>5&(XUBJOVV]O?:RU*OHLII0B?>N>6=D^3WW^]S Z /L
M/ >P^&H ZP/8.0"O,_ ^@'\$P-4 T0>(_PV(^H#H(X!?#8C[@-AB"+K9;9?K
M+M7I?%JIDU=U.^Z0-AL;;F.S(=9-9[O^[6]FQ6K3^SJ/DG@:O#:)>LRBP^
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M_1,W+(EV!R"D#V.CHK4/E+ MAUGTH,MJV36QT X K@7$D-A4B;-6;)P)::=
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MLIL20(=')AR1G6(%NTV6WP5 #;>H!M)"'S5>F?QAI# O-CB_]M54;W'7U:0
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M2)U M+)9&M\@I8O@P+_UQ'H%S3."!4I2N,_$WQ]C(FTX.B!>R_ZZ,7=,'E<
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M2^P&*.. )MX/@-T,0=-9'90+-8! $D#C7M &-.OV!UZO.Q!F+?EO!+Q]IPM
M IT9]+@A&H6[O5(M>3V_:0("A.WVA]ZH,X %((OK^WZE4J04C?<#6NQHU'LK
M?&\$$_B=KMA>]%DGM,EQ]LRE[IF+;0)+S-%F9SMT]?K]OH>Z(W[V@[[7'7;%
M8<W5!X+A (2YMA@-^IX/:B;7R;VDHA'8<SB"L]T#-;<-<M]0<,79B3+_[O>Q
M<#D, "\.0!AVNMX(-.2WM!:V,< "]N$L@C Y;+??XE^!UQ^2Y"@<Z7<GP##K
M(5%9.2;*4@6 2C5X6)) &K^*L*EFG)&E@Q,MHQU_N#H_N?YP-8%%G/P'?IA2
M8M[DIP\GE\0:[=+]UL5OD/E/L:P X@?:J=/DDQ380.CO>@/ *OV!HY P,ICG
M*M>H@ ,$>P%'P0?Y?=C&RX46L.>\V?P3[]1!%2QY1&<""(=/@/-=D.][ _W[
M4&9:2MQ-;G/*2PT Z0;MK@A@+<-N&Y--2;?F_%E.@2'F <=7_?XY BD'=K<S
MHMD/=">]Y@.48_F:"AX!\ ^Y#_^:7)[0(D[&P,@4[\_$, #BT%&_<(1K5E_,
M1OV.-P!51O[B@SGLDRH#\MS0\X&!GFX*HA/[*D(-$%W%J+W52I'?!7CTV_@)
MGK7)CF:)N4/M9P\H&6AC8F\$YZ _$$\1EM/%S$(GL;<>DA\ @I?V D;OX7B3
M!8# 50NB>['X_(,^()<@#9Z#VE*@/I$8LYQ_J>@2DH7M+>1K'=PFH.G(?"90
M 2BH!=THNBJ+#QL(= 7V?7\PA ^!#WO2 U[81E)/#WM=? CR3GO8AX?]/EV*
MH+6B@_$#!N4KEJS"M6!K $W[<'SVN_!AU,6!D0,!-08B>4#_\>9W/92FD*_N
M@^0$7&#0#ZCQ8(BD>[AY'6:<HA'+EP/'^&U[/)\C'A-#+RE[!PTH'90N@#D"
MQL$BO?X HRWA]\CM%D59#7X@ZQUU^78-^-0)Y*?NL"\_ 6A(3NP,6<NO9VS#
MF>D"2^L-49B3'5FZ>83W?CH@^[@2"*T6!"V+]CK\@?>&A#N*<+>>CA\QF])2
MU-E:ZZM:^)GMJB_6I7XL4BJO+PY__/[B]&AR-=6WH0 / ;7R9#K]P': PXNS
M,]!!J6W%D+\7M-KD*UC"J<;C@%^TM9O!M%FS7Z(MQ?8ND5IH#32:6P3*>]%!
M\_0W J_."-JC;K]O2<\/]#4F(&L"O1H W9*_VBWX@?_V_%8/44 U;<EM@4E[
MO5)B.6!#  28-K/5!?S;\QDA2&(/N#OB5[</"L6HPVI3DP'$Y=7D>')UA9JI
M E_A@]E#F;=#RHJ&'R]Z(&^)V?,E:K5 UL..V TZCSS9$C%V^KT8HP!P?2'>
M36C?8#JW5LD!!OINE^+*E>GW- S\FUQ]A"&.+ZY T$#A0B.#U9S&]+7G^< /
M>\. C&]M#_8:). !G.Q.I[<UY,&V(.OY.57G1UR0^XV$JGI5ME(,@NEK$5<R
M=OF0H[/(C"^=BY<J3^%YW.>T?*S$Q279;BY/Q^=L/P-,ZHJ!/ ,JMI61DLB-
M-8;5.'#\E2^^HI_%&3"&*/"K+QO' IV 6*"$+7,RH]273_$Q785 ECLRZ3]2
MZ M%5F@7F!EFP[E1,74]*5+&R),>?HZ7ZZ58K>DE*.2.:^S?EH909E=V(I"3
M-#,,^Y7WZQ9'>%O\:\D_K*0;#(6H,"L97Z9BS\E%34*@K,PJ0T5D=" 'KZK2
M:T66F,0;Y4O6P\G.$MHZ&LOHV1+',N=KHW*,2C00$N12/0P>:G?<1WJOW^YX
MHP&F*@R&'OIA@U;?%YT6()V+H8ZE,DVQB/P:*IGNB2OJZLI3Q>X\X(GC !=9
M&-((MMDH-2I]4&/'A83<SU$L^&Z&,0?<@TJBLE4N*8!D3^CK&V03P&J\X%16
M,B%C-,I@IQBBOX\W)V9OQ?CN#L-M<C+5PAKQU@8U)X>O[.F_S6L@%'%7&BQ0
M)Z"YW0Y\:O7Z %@ ,PI52-R&:JD<U5;OV@89O _*I]\*1M 51#;0&U#Y :']
M/:(^O%./A@+BAR-W6\6@Y(W056S$?@<%.=!WWS*C0W$/,.DVHA![*H'\0 +C
MOB\/#TA\K0XWM+UI75L'(@Z49C3JX6) DVJ-8%GM@'3VTIO:NK9[R-E!QFWU
M>]"UY^NNZDV1H_5!_H0G+606+> )H(CU@1?:7AD$W2'?HV5[8T]0,,J"TAI*
M;^^1K-%'0#5]=60]HV$/.)5\=3HZL#:_W][\YMBS ^C=[2(06D.$6K<OAEZO
M,ZCX[94]4HE"4AK!!@,U5ND1R;S<2]$9BV41V<NC/" '*FFE'@*C1KB3FV'"
MF>D-O'B'?K:-;XM/'Q-TSU(HUA#PN?-&'(P&K:#[!M7Z5J_SYD#X(\!?^.(J
MSGX]N$7.I'.(03B"!D$K>", M&\.X._!&S+:$'VDHQL<]"014;^/L)8-5A%\
MBJ/%7+3A/XD R-^O\'3WX;^MM,R,__DR]$R%C]CHV>]/SH2#GA4H7J=&0SI*
M 6YOMS7L;"9=*% /C,;J" ?PTOT^DL%>!\Y6<6P/Y'^E)=3)!!IG1J,1]^^U
M.D$QB).RL&D)UH(DHX.:KEX-;H2:N5A+Z>N-"QJ8"PK@U /5VK(@Z )Z11^!
M$P1,KP]>H\XXZLPJMI\A1 D*9 /43FIY7Z>J9#0&_+;7CC0Z._MLMZ">*2_B
MY.SR].(7LI0J'S<94-&9^.&4B@F-WU]-)F=D1;*L/),:UA1K_7# %0(" [U(
M$/\*/],7I!^K8GDD\M.W>YUVH0CL=962B8WQ'\?G^12Y](:^8;>+]&^1Q-]I
MN[:89AB"#CKL]TF)[+2]X<!FK1_V4! !9C,:HKN\;SE[%X;Z;>SVD)=/LG@9
M".@^X??5T^Q7VPE^BV1]=U\TQB])V?&S7 73&;Q3ZN\- )=A38>Y!%EYD%'@
MLQ>#+!7;6N.-+7K"/253[04E;^-M?)MC:)3?HQ4 9-Z+KFT@U1\@>C'+$P1$
M3YTO]46@OM"=J2R15;'1^:0J6,6(H0>&&]]Q3A.1&PR33V66J*4)=FU9%Z8]
MG,J]=7B/4>JA#H!YEX#"Z*GR+-6(*HJ1B.F"N^@6J>IL36G%["5(/8X!QQ <
MO$M@C0E(0.=D7)U,6,9@@J(B'>9,.48CF@>;N9*9I70@J!"Z,8B>\+DK/LNP
MGDJZNL=*)A0X1 43,#1]A3P["Q=2#-&(@GBA=K\X3"/A,3-1WFR-'D8;+6H0
M/8%/9_":%QG&$E+<#/$/\LM@B=J'1.83P[*H'"))NO).AP-V^1J77E(*GBR9
M).EIJ.AI-?Q.A7%1]"%>+Q Y@ORXZ.M60+)/&MT!['"W,HYSBE&A_+-KS&=S
MU'&&9SNYTLZ-D+C#B[.)N![_!\;$K9WW'OXEDQ4SI'RIRA]QP@^@/P>!6K,O
MS,)R,L2,+"V+A:O:VU\R:YJ7T_Q&V8C60IP?*(9$^,XP#N/3>'.JRT%Q,SW%
MVQ$I9.M,4:)#!=3)*A<=MH.JVZ;>8U$1P;9[H6\$Y]H#:<5\TY=].R/5W/!<
M(>Z4_#/^D&VEJ%F7!E?)O]T!.0/(D5/>/E BT_0)7ADM7Q@X[?L\,SK:>_QQ
M"K @MPH\Z@[8S.^31XT^6C+ZT*-L-"8/L]'C+<F+]4WVU!VC%DSRBC!<.(@S
MZ::"%C)AT:A0RIE_$><?ZJ@1>U*F9 U<D(=2DQ9/7CFSA#4C)-''T9S*EN*"
M>5K Z>5Z<:>*WIFF^D%5J1C"3S-,+=#L;F_H]0<#YN5.X_5>7U]@[@J<0MD$
M]JS7D7*!L9S.H&5WY70Q8(4'K8L_>[!&$!@JCWDTW$+VB>D@0L=I7M6P3M8X
MZ P#66Y%QR:Y37P^ZF_H7N##-]8WU<2ED%2J+,H!/'J7;J6]<;M"2QF2W!V[
M"M"[WO /K@-MI ,?<"T#+FW9AQ;X#T-AC 1<UUUKT+DCWA3GM'S5K\1<M!O7
M4,_OXV(.8+'XNXNCV,[?/CU_BYY2_#6A$9'_**"(-O3$?T;N)\Z]-FLJ\_TO
M9D)U*JN58TR@-#US[2\03S-BQ)3?9&1 J7MU([T+MMQG<ZSJ""3XT&4%BK_G
MX:_12MJ\S&1?_A[SY/@]J8J2IRIV(//)BNILE!9HS.N)<DE*K[#=T #1*J2R
MP9Z9Y4DYVQ@#'W-I"'O(M>92YXET?P5MF:-2NV"+./\%>GJB(F'L?80%<!_N
M0< X"O/0$F9#6?13KJP%'<S2LX=%20!X\A'0/TF_0,#!1>'RF;PG;1*5R/>3
MB_=7X\OO3P[%T?AZC F$J&!0?;*U489&Z3_H )QS1#WO.\E9JMA!QC#(^&(2
M3;CSXEIQBH!1=]1193S51%5"H./7LH75Z9R(4@0=EPG'Q7+R+-<,PU!\3<+4
MLKZ1$/_%H"O(8NG;;PRJ(G,&*'HL *8(ZBG^T?:Z0-0Q^D7)EP$;2-&$6T3W
M8R?@\$6G(3;K*5F6[IWDVL<8W?76.C%'[O4P)A4G&2*W*:;=QP@:^'>HRM]C
M>-AH$'B#;D<^4HO99VXNWFZ62>QO/_ Z'/TVH+ =_=9];]1KBS[,%[1E.%LO
M&'K#40]CB'K#OK&R/=$;P-OT*+ 'NHR"GER<A(*4(9ABE>]*-V\K#T'P0M[A
MV"F8 F0POS]@@(TX[V(#P)QPXF]44*4-+.@Q[E'T$N\O 'XX*,#3AX<]OR-&
MP/HPL*N8M.MAWJ??:9>F!M+2!^@-A@.*@O)0/.QC0)@ELE07/[ ?@>*:>\P%
MNRO(4)A&(>HY5C8*TD$1]VCK9U:AJ)3<4K5X:(]P"69-YSKT^)W+!%#5-SGX
M,&6#&>B"\Q 1!R4(;T!I,NA8\0$=AZRJZ0HH!YC\J(2)GY,46!I O3_R_,$
MG?IMW(-NM1,KET5H- <[]S&@+]E\\FTOH#;>^2(']*^R!E%?N96<!%)Y*7W=
M%&8].(Y]OQ', !1? &8VPF?EF9><UH(IOZGCXECC(;EH7LX$8=(#-)P>3M"0
M2C$/;$IC0VWIOHXB.0)D"+-.AZZG@E6_=.*2*B^G.!T[;?"<<-42?;]92E'+
M6,%0EZ5>/7$)!5)75;H2"DQ8V@*#%'1OC$R(<YVY*5,#.!C)4:JQ$@ D\:F;
MW\NCK].0++XZFPJ")L8NEAC9ZX/R@F?"EAE@,[H#G0PZOF54)A''&Q(2/#$
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M+Q8%-C26]=HZX*Y)1,<>YDUT SSIG0XH/>C #*129FZNP]AGHIC&7?/:+_8
M!R 3^K[/3D@&I_ZN21R=X5XL#QAPG#Q\Y7 E_1_R(K6,-S&<25S HBB_2RBX
M>%(Q%=7[] I95=_MQS8S3.@MTIV4HU7R3SY5U2OJB$@5-8!E_1 %/0I(7L!9
M02",;S%@1%=A RY<K3): ,15N4\7W2=::;RRR7Y):E([PLG=)<-\NX=7TX#
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M1*P6E&:VTED)E^V=M^&5IXM+LPUXMS'+*!K"RW.U:S0HEH9U@?Z+X@!T^O
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M'_:MSS< U)A\9[C<R?S7WP$F>F@K/+J*Z_3\7=]7#KP=>6YUQKNL7LE)WR]
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M*+(6*+(6*+(6*+(6*+(61Y1U/.:=:?K?DCQ9N_Z<S\:_?RW> %!+ 0(4 Q0
M   ( *2)@DP?(\\#P    !,"   +              "  0    !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( *2)@DQF\PM@@@   +$    0              "
M >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ I(F"3$A')MCN
M*P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ I(F"3)E<G",0!@  G"<  !,              ( !M@(  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "DB8),[G[NA*P"   &"@  &
M            @ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ I(F"3"OE]7.T!   B!8  !@              ( !V0L  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *2)@DPVWZCW: (  )P(
M   8              "  <,0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " "DB8),EGCIT]@#  #8#P  &               @ %A$P
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ I(F"3.Z''4S)
M"   ZC0  !@              ( !;Q<  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( *2)@DRL_L++8P4  * :   8              "
M 6X@  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "DB8),
MC2BR[K(!  #2 P  &               @ $')@  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ I(F"3($H')*W 0  T@,  !@
M     ( ![R<  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M *2)@DRG'40YM@$  -(#   8              "  =PI  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " "DB8),S]9P+[8!  #2 P  &0
M            @ '(*P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( *2)@DS>?0,%M@$  -(#   9              "  ;4M  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ I(F"3/#.>\6W 0
MT@,  !D              ( !HB\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " "DB8),)9IL%+0!  #2 P  &0              @ &0
M,0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *2)@DQ"
MU/"6MP$  -(#   9              "  7LS  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ I(F"3(.3.VRW 0  T@,  !D
M     ( !:34  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M" "DB8),UD(R4;8!  #2 P  &0              @ %7-P  >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( *2)@DS[)%3YM0$  -(#   9
M              "  40Y  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!
M A0#%     @ I(F"3/Z>K>6W 0  T@,  !D              ( !,#L  'AL
M+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "DB8),@L?'8K8!
M  #2 P  &0              @ $>/0  >&PO=V]R:W-H965T<R]S:&5E=#$Y
M+GAM;%!+ 0(4 Q0    ( *2)@DRQP;UJM@$  -(#   9              "
M 0L_  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ I(F"
M3!69 URW 0  T@,  !D              ( !^$   'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " "DB8),JP4Q0K<!  #2 P  &0
M        @ 'F0@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( *2)@DR7A'-YM0$  -(#   9              "  =1$  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ I(F"3"&F-HRW 0  T@,
M !D              ( !P$8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " "DB8),"(?W1;@!  #2 P  &0              @ &N2
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *2)@DS:05F=
MM@$  -(#   9              "  9U*  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ I(F"3-B^?BZ^ @  Y L  !D
M ( !BDP  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "D
MB8),0AH;A+<!  #2 P  &0              @ %_3P  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( *2)@DR^\..[M@$  -(#   9
M          "  6U1  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#
M%     @ I(F"3&GZ<QNX 0  T@,  !D              ( !6E,  'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "DB8),)60!M;@!  #2
M P  &0              @ %)50  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;%!+ 0(4 Q0    ( *2)@DQ5ZLFOP0$  #<$   9              "  3A7
M  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ I(F"3.,G
M]-/& 0  -P0  !D              ( !,%D  'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6Q02P$"% ,4    " "DB8),BMPT-L4!   W!   &0
M    @ $M6P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M *2)@DQ'S$3;N $  -(#   9              "  2E=  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ I(F"3.;@$U+) 0  - 0  !D
M             ( !&%\  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " "DB8),-Q?+%[\"  !7"@  &0              @ $880  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( *2)@DQ>,$A4\P(
M $8,   9              "  0YD  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ I(F"3%P[RKZF 0  D ,  !D              ( !
M.&<  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "DB8),
M]%QEY P"  #%!0  &0              @ $5:0  >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( *2)@DP5QJEUJP$  )4#   9
M      "  5AK  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ I(F"3.UK+S^X 0  ]@,  !D              ( !.FT  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "EB8),R6@$M&$$   =%0
M&0              @ $I;P  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( *6)@DQRD0@!. ,  /$+   9              "  <%S  !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ I8F"3'E+O,G5
M 0  )00  !D              ( !,'<  'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " "EB8),/O=X9/X"  #R#   &0
M@ $\>0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( *6)
M@DQ*MBU?]0(  ,4,   9              "  7%\  !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ I8F"3*YG\J%X @  F@@  !D
M         ( !G7\  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
M    " "EB8),-MG%[I,$   #%P  &0              @ %,@@  >&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( *6)@DQ2UR6%K@,  &,1
M   9              "  1:'  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL
M4$L! A0#%     @ I8F"3*4\!25%!0  IQP  !D              ( !^XH
M 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "EB8),PHGS
MO&$"  "-"   &0              @ %WD   >&PO=V]R:W-H965T<R]S:&5E
M=#4R+GAM;%!+ 0(4 Q0    ( *6)@DP@T8_X)00  %T5   9
M  "  0^3  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
MI8F"3!3$X3SM @  R0L  !D              ( !:Y<  'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " "EB8),/26=L%4"   1"   &0
M            @ &/F@  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( *6)@DP#[MG/.0(  #$'   9              "  1N=  !X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ I8F"3,%IFS6M 0
MCP,  !D              ( !BY\  'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " "EB8),_NWQS/\#  #*$0  &0              @ %O
MH0  >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( *6)@DS$
M+4F0!@,  &T,   9              "  :6E  !X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ I8F"3!]EVU#U @  F L  !D
M     ( !XJ@  'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *6)@DSDTU2QW4(  +=! 0 4              "
M 5RW  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( *6)@DRL3BF$
M/ (  ( *   -              "  6OZ  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ I8F"3")L<=SG!   .RH   \              ( !TOP  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( *6)@DRWT,(/* (  *4F   :
M      "  >8! 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( *6)@DS>GY_G\@$   8F   3              "  48$ 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !) $D \1,  &D& 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>268</ContextCount>
  <ElementCount>359</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-operations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statement of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-consolidated-statement-of-changes-in-stockholders-equity</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note A - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business</Role>
      <ShortName>Note A - Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note B - Liquidity and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-b-liquidity-and-uncertainties</Role>
      <ShortName>Note B - Liquidity and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note C - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies</Role>
      <ShortName>Note C - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note D - Notes Receivable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable</Role>
      <ShortName>Note D - Notes Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note E - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-e-inventories</Role>
      <ShortName>Note E - Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note F - Advances on Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts</Role>
      <ShortName>Note F - Advances on Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note G - Consolidation of Variable Interest Entity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity</Role>
      <ShortName>Note G - Consolidation of Variable Interest Entity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note H - Investment in Unconsolidated Subsidiaries</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries</Role>
      <ShortName>Note H - Investment in Unconsolidated Subsidiaries</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note I - Furniture, Fixtures and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment</Role>
      <ShortName>Note I - Furniture, Fixtures and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note J - Patents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-j-patents</Role>
      <ShortName>Note J - Patents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note K - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity</Role>
      <ShortName>Note K - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note L - Stock Option Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans</Role>
      <ShortName>Note L - Stock Option Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note M - Employment Contract and Consulting Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements</Role>
      <ShortName>Note M - Employment Contract and Consulting Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note N - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes</Role>
      <ShortName>Note N - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note O - Segment and Geographic Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data</Role>
      <ShortName>Note O - Segment and Geographic Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note P - Concentration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-p-concentration</Role>
      <ShortName>Note P - Concentration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note Q - Related Party Transzactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions</Role>
      <ShortName>Note Q - Related Party Transzactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note R - Commitments and Other</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other</Role>
      <ShortName>Note R - Commitments and Other</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Document - Note S - Pension Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-s-pension-plan</Role>
      <ShortName>Note S - Pension Plan</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note T - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events</Role>
      <ShortName>Note T - Subsequent Events</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note E - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-tables</Role>
      <ShortName>Note E - Inventories (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note H - Investment in Unconsolidated Subsidiaries (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-tables</Role>
      <ShortName>Note H - Investment in Unconsolidated Subsidiaries (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note I - Furniture, Fixtures and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-tables</Role>
      <ShortName>Note I - Furniture, Fixtures and Equipment (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note J - Patents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-j-patents-tables</Role>
      <ShortName>Note J - Patents (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note L - Stock Option Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-tables</Role>
      <ShortName>Note L - Stock Option Plans (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note N - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-tables</Role>
      <ShortName>Note N - Income Taxes (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note O - Segment and Geographic Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-tables</Role>
      <ShortName>Note O - Segment and Geographic Data (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note R - Commitments and Other (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-tables</Role>
      <ShortName>Note R - Commitments and Other (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note A - Organization and Business (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-a-organization-and-business-details-textual</Role>
      <ShortName>Note A - Organization and Business (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note C - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-c-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note C - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note D - Notes Receivable (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-d-notes-receivable-details-textual</Role>
      <ShortName>Note D - Notes Receivable (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note E - Inventories (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-details-textual</Role>
      <ShortName>Note E - Inventories (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note E - Inventories - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-e-inventories-summary-of-inventories-details</Role>
      <ShortName>Note E - Inventories - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note F - Advances on Contracts (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-f-advances-on-contracts-details-textual</Role>
      <ShortName>Note F - Advances on Contracts (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note G - Consolidation of Variable Interest Entity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-g-consolidation-of-variable-interest-entity-details-textual</Role>
      <ShortName>Note G - Consolidation of Variable Interest Entity (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note H - Investment in Unconsolidated Subsidiaries (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-details-textual</Role>
      <ShortName>Note H - Investment in Unconsolidated Subsidiaries (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note H - Investment in Unconsolidated Subsidiaries - Summarized Financial Information (Unaudited) of Milestone China (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-h-investment-in-unconsolidated-subsidiaries-summarized-financial-information-unaudited-of-milestone-china-details</Role>
      <ShortName>Note H - Investment in Unconsolidated Subsidiaries - Summarized Financial Information (Unaudited) of Milestone China (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note I - Furniture, Fixtures and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-details-textual</Role>
      <ShortName>Note I - Furniture, Fixtures and Equipment (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note I - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-i-furniture-fixtures-and-equipment-summary-of-furniture-fixtures-and-equipment-details</Role>
      <ShortName>Note I - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note J - Patents (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-j-patents-details-textual</Role>
      <ShortName>Note J - Patents (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note J - Patents - Summary of Patents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-j-patents-summary-of-patents-details</Role>
      <ShortName>Note J - Patents - Summary of Patents (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note K - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-k-stockholders-equity-details-textual</Role>
      <ShortName>Note K - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note L - Stock Option Plans (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-details-textual</Role>
      <ShortName>Note L - Stock Option Plans (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note L - Stock Option Plans - Summary of Option Activity for Employees and Non-employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-l-stock-option-plans-summary-of-option-activity-for-employees-and-nonemployees-details</Role>
      <ShortName>Note L - Stock Option Plans - Summary of Option Activity for Employees and Non-employees (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note L - Summary of Significant Accounting Policies - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-l-summary-of-significant-accounting-policies-weighted-average-assumptions-details</Role>
      <ShortName>Note L - Summary of Significant Accounting Policies - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note M - Employment Contract and Consulting Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-m-employment-contract-and-consulting-agreements-details-textual</Role>
      <ShortName>Note M - Employment Contract and Consulting Agreements (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note N - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-details-textual</Role>
      <ShortName>Note N - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note N - Income Taxes - Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-deferred-tax-assets-details</Role>
      <ShortName>Note N - Income Taxes - Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note N - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-n-income-taxes-reconciliation-of-the-statutory-tax-rates-details</Role>
      <ShortName>Note N - Income Taxes - Reconciliation of the Statutory Tax Rates (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note O - Segment and Geographic Data (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-details-textual</Role>
      <ShortName>Note O - Segment and Geographic Data (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Note O - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details</Role>
      <ShortName>Note O - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Note O - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-o-segment-and-geographic-data-summary-of-operations-by-geographic-area-details</Role>
      <ShortName>Note O - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Note P - Concentration (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-p-concentration-details-textual</Role>
      <ShortName>Note P - Concentration (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Note Q - Related Party Transzactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-q-related-party-transzactions-details-textual</Role>
      <ShortName>Note Q - Related Party Transzactions (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Note R - Commitments and Other (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-details-textual</Role>
      <ShortName>Note R - Commitments and Other (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Note R - Commitments and Other - Aggregate Minimum Rental Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-r-commitments-and-other-aggregate-minimum-rental-commitments-details</Role>
      <ShortName>Note R - Commitments and Other - Aggregate Minimum Rental Commitments (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mlss-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Note T - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.milestonescientific.com/20171231/role/statement-note-t-subsequent-events-details-textual</Role>
      <ShortName>Note T - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mlss-20171231.xml</File>
    <File>mlss-20171231.xsd</File>
    <File>mlss-20171231_cal.xml</File>
    <File>mlss-20171231_def.xml</File>
    <File>mlss-20171231_lab.xml</File>
    <File>mlss-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001437749-18-006069-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-18-006069-xbrl.zip
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M3_57H &\UDMX#3X"&K?4QDCJ!OV.>Y X'T(:8!JNF!:>OPAU5Y0STKL<I&V
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M(LB([E&BQZ62NFU/"8WJ)>%I'O%#PZ"^CW3=/YC CHO<,&%[F3[XG<"Q/IG
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MKV-CGSK <.HLW)<4H=<Y@8X+37C8%&G5$X:F@(6]H2-TI9X@*2>@:^K)9W6
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M?!Q5P>G@7&61^1IZ"*< =*XBIV!Y9OKUK0GH@BF!5_')<-CM#CG =A_A*\L
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M';M+!%'J2VHW?]73+]X0NC+TZQ5#)W;4KBQWMH7N.@PP'&>E3IL04"LVST!
ML,Y*;PF(J;=O V<)4FK%5A=("5#VERUT&3@W'B_9*1XXJW34OI(+5]X<R96P
MK)ZGV"F>0*M(73E?7'-A<;!JCM?(W5K^GSN8W:)4/;NE@NV:;;H,7%W?7Y";
MZO;@6RUR?GUU?G%U?SNXO[R^.H;ML+KL?=6RJ&)EV@?'#UC.D(6PA#FWC]$)
M'#Y4\! UP5&K?T V'.H&^KU)MN'N?B#D')_8-T%GYSU^T-0I$#Q@ZX51BX+%
MT\0 < :+J+!Y5CS/\BB8*\L<RN##"7SR$/)\FAL&K#(:3R6UV 2.9!/ ]9(.
M],G=LQ[T5:4:DYR'MGY%30[8+'-M4MMZHEY%$RR5A;Q?9FGUBHH<5U7>V78:
M+I#=)VP,06<5ZNOGG+8Z5USARZJO#ML9*[,-@$K965[&SMF4:#6'XCO!* -.
M--BI(FHL3+(9.%AF4>&NK];O"E(_NTN&27VL5O/,JH97+:J7;'Y_<!@@5AN-
M[+Y1L9Q9_IP1K6KG" M#.IIX:"Y3-:&KUH[+M#IP60G7I/9<)G=E05:DN7'O
MKA,5F^'ICHCAV,9S["6F'04#I]8"LL@,/C%"C_4K/9#VJ5L7IO2DK\V:Z>V_
MG_&_0Q^8=9H7YU4445;ZZ>A.=WQ]M77>\TW5B)Y,20/S5_F(2W'A''M!)TJ'
M%?:PD#PZX,Z."512<AX\9QN/&"#=[AB"_W>S!H'85*B"BLGY2DT@&,MBI$\,
MLC8W I9'Z?R,.; :R]6\%:KH3"!EE[0:BR'U?UYVN/+5RKM6+WE7>\<M[XVX
M+^3DI#G!J\A#["Z5]X%A8$]_/TJY)>6_O$KTW]@+-EK3[)*F1P$<6E9^D@55
M585.=^Z$;26JK%M:4/4"4K]*==NM-+6;<L!/A.'[_8Z@]0[!\+W%CDH-PY?+
M&N6%AIOL2*=#N9)UM>DJB-5U#BLJ(VZ2!D-2F8J(/Q8>\'GZF3K&"(\AL-+$
M._1;;ND3=4+ZS75-_XH&O"0Q[]ZDHO$\DM2%:Z)[?Z \QQ?Y[);[9S?Y8F71
MHZ8M5H--@$Y87-==0M$4?4Z7DO%?UPXM0<A^(2%5J:$D_PMX<S4ENV(A):7^
M_BFIS2BIU8^2ZTEW=[' +F'*WFLGY5KBW5VL[8TIJ50@WL=!R7+B76QQY)J:
MG-BCODV\O.WIN)1$BR7&B5&NJ=A63:*<$T@QB7KJAB1BXV39E3?PR9AN4!3+
M"IM53>E44!9[#$_<S79:P7RP;>IT*TA#9W=];SS+,:Q)U(XWPVW5[DWN@YC;
MS8W;T^9?O-4G]:KL.8HI 78R.CH4$2TS#C6Q'!U8 +LRX\FD^8K B4<G.B].
M6V@I$>496.O;&1\]4H=ZV"-RUOPFJ@_[!30C_,5.0/FSU7DSH^>WP>!F]A?O
MKP$/MD.3]]M-,AN%/0'P!BPZ'KD(@?O,SIS#ERS%A)U+^%=^^.!;IJ5[K",V
M?P7@(1!LSTZP)A@(\B;]E+?IC/: ET=@+:\_I@&\^$WV!6]GZ+&S\ M#&N:O
M3S=8OS!#@[>Q82GS)X"2Y7 L5B?H![S!Q33)M>>3 ONQCU@G@C&6(O*.+K#0
M\)E1R<_R 2L^+$@HY?%(FPQLFYWJQXMT;&5AH4EK1<#!1\?7C=D8BP?=COKX
M),Q%;2ONT1:QB)'60"OJ* KW],M\SACC0A.[Q!C_&JW*9;0H%PQM?O_ZEKG;
M6.8*-/#>3?,VJ?+];X1E37_,P"3F8,)8&!3B1KG1"A:N-F=SJK?A,]P'Q?8@
M94A_O;Q(VU&T(TY\&6O"1BW6Y^N-]38ZNN.'.(T&E3ZA?X7L.A>;7XRM@,];
MB&YV(VM F9U%!?_$F&9VQ&0V1@"L+#@,D89/&9%P,G$]=NKDC14!$+V33ZS$
M?1^PO<36(<IA9F&D8P4BD,<'8\O,OQZ/0K%9D^GDX3%1P#X1H,*"G7N8,L!S
MS"(?&I%G+Q' !S<8<8/J/F/#*#<:,1KY)0D9&'7'+JQ*RC:"$V&!^V6D28G#
M:P$R=XQ'=JC'CDXA6?5H]-YL>B/;^GKP7>^!V*Z/W4FC?3,/)9_/>^(S"9*V
M;6RP07K9$"J#=<F:N#C;P6(>V@--0QGWRP*R;39GO3IQ:U0!=CHN<()-RIO?
MQMP($HP<[/*Q8NBM,Q8NR6CSO%70^CTE9'[,15@;7."#Y@\4RI9.@S)P[6C\
M$3X>.#G$IT<2R%#S%V0M&0K,.?\9.VQ&% @=]AA/9[/1,(V# W5;8_U/-E@M
MZFW(.@[]2:<QP9@J&\*]W)=%/1=YJ_P5I<M]Z_2I5@6QC8"OFG2^+)K+Q,*S
MV+&RPX:IPV[S1S18P@!DRXXZLF$;QX"'@[;%Y<V:[_"7PL"C<?2?!(CK)3+:
M#9O7ELUGN'^FAHYCFPH.EO-1>([A49U-"5OT?X$W%JL- ]#9'G-RXRE,41OF
MQ]#B22RX;3!+8=UAUPZ<LWKNFLR4,!Y,^=2#N_.T3UU!Q8\TUT/01ZQX!24;
MJ1(;>@0?[!Q#=HX0/(7$;+%C E6&Q'?A'Y.1-QE-F&N@!_[\P[+F.7+9P0J#
M6_XG$^HGEY&2^:5^56WRYT>%3CP7PPMNM[DS8'DS7SOFFH4*57;\*O&=XJ:N
MC'@%XP]YV]D'.L]A!5HZ]HI@$2*'A 45T2]#%UL(,[66C7;>'ZT."YB81M#Q
M9[4PK?]>:G=^_I!^GOAA"W6"O0M:SY89C-Z3KBA.7CZ<$8/:MC]A<Y _GHG\
M[PF&IM'?#^S$'7Z<0>O-/IHQU. +!IBPC38EQI9IVO0#?YG65G_^<'84*_$N
M,%<C%[B3"#.E+=</,U \JC'<&K>^6#/D;E@X<PXZ#EN-PL7W.\PR5&+%9R8A
M)Z'!"NZ7JK#T KY+2>$[IC_JLU"-ICN"E5A;TRGUP^Q4-=UWEE1Z]SG.4L[I
MO&6)J'()S)5YT:WRH*>BK X/6V49%+A!?XP&C[NTBNX*\]$(V^UFUCM*+T83
MJ3S77M.HSX4KJ?T#GP=W&/]1,+M42&U4&+&,L8"C>OS91O^8!A!"S=8"7FI$
ML1+#ES\]GG+ QTY#2#6R)BRLG)&#]T!)T2R3.N)A7"2]28$%:]XY<FVP@N_.
M+ZYS;DE/(X&H-^].8?8M_P(?DPEWA22ASL"C?*Q3-7V15"5[-BC>1F-KOJ--
MJ[R]JAQ2II<9WPZW11D\/ORI(+E9/6,6!>J\F][@[KR:#,]<KY]TQG2>L0\H
MP(NE0BQED5<[MJPT*Q[%Y\?)%9Y^P^PM,.ML%$^46@*U,7(7F]'MH,YG6?7.
M?-&/'_Q@<%PRH6)(WE*@['^HR1V:4N7<=\:(FJ%-KX<7#+GY9RY^2^F5/N8E
MR0E!&2.LK$,6>P4=U[$U;Z?;Z6::\Z[$;P<$R2G>KI8@!?W;SSY)DMQ1U&T)
M<CUD9QGNP#24XH;O]%&W.=-M@H_4*<2GT^W*XAPZ*>C6!#UGW;8&72T"O=_5
M)%';%>AY)7?%S:RUPL;:'4625;&[/XHN!:NPQW9'ZJJJHI0$ZPL=4L^C)O:>
MI8[/=.!@UJ7W-RL873J@,BTSU.U4O^X=#FC!)O6+IQ'CSNI21P1!3%%YYQ!7
M3I RK>87#Q4F!)&[8J<GU98@R471R.0%3A?[+?Q/2G^\Q[E\U\/9@_B!FY%%
MAQ<OU C1;[[&.C3JK50D'54L-')S\R*VQ6W/E.*<DM()NZ:4UBVBE-RK#:6^
MZI;'Q@-<#PNG8129TQU22^UG1FED?051$7M==4-R%2!8!<ERS/AN&:S0'>GW
MQ'[:IA^88O/C8D IKAYHM0:IV)=?X[ H^G+@F!=L]B>E)08^Y1RSW(V17()[
M513=@/EV0=$E;L=65G:?%#V8]BL><]3K:3UM4UG>J0 ?3,\5CZ/KJ6I/VM22
MEB&.'_CG49_=#28'*=U";TF2Q+[6S96!V3LW@6IU?*-T"\,N#=S&SM9 @:*X
M<AUC!=W^N.%]_*Z].W"5@148CUS.>MW#8_ZA.^;$HD:L<"K-7VA];:O5RY!A
M:ZII1T.U0D^N#'>5(%K4Q^*8&:LP&R-U9;6CYFBT".DU*7(\3%,8+$FB*/7R
MHJ4R%-E&=_?[FR[24D6Y"K(2^2FQV*JL(-92R.[UEP$K%8_&F&+:]5SWO.G0
M]7"VJK\!&3NJ4DC&CIH;!:\$8V?0:_.'@@'<3A%MR8O_WK'LCV<@,_3LW0H@
MXB\N'<,=;S1862U.V7:ZO>64R[Y]2U!SJ51D&=>CTC><%;^YC (<Q3*J=;K]
MY51*OWTK0%</E5:+TV927Y2UG0%Z'1\WVXWP=HK5LBI)*\ NAF6'2)2@?:<X
MM=3KJ/M" C[$WT5INDQ0XIAQ058<4Z=_WFRQBMUZ90666P%;+2'*+'CQC-3^
M"IM3+2&B70)TOP:&X4%,Z@_P/ +F,KZZWA<W? B&H9UT\=W(_A::$65=4JP)
M;O7D*,$;2F%,USD"<D03[*?Q3YMQ1/'&1/Z^Q'8P5H-WF:4OM /KJ\?M\<84
M.U<J,<]LXPBIA;J_A"-4",KN4"CC(A5J[1(N4FD4)AX L&A:UBY>4'M2H1AI
M<B>[7S5[Z3K@K%.T . 4<G=?UK3NNN# 9YM&-F\PQI-]_RE-M3\R55^7 1WS
MWJ")+W5''UG:(<XTQ'5LGT,?&RCX\>_L+MX7+/IJ929![1=684E=12Q8EB)L
M=T&?_!::AZ-/<5%65TLW5:Z*/OOFGZCY6WD"%3I,LM;/9GU.@X'6)E"A"Z7)
M7?D !"K/03]T+,O7[5LLK#8L[&+$?BR!=*&V5^5>KU]KO;(%UH5&I2>K/:W.
M2WWN>A,7I(%>N4YYUB[,)ZE=1:JW\&^"L+8DE:QAM5P=5C@+<)&7N"+SN!O:
M9T$I\C26@Y(,(+D>II,'MWQ&%]L+8SO3GW6?FC?ZE"GJ#?I/^[T..(5R!3TN
MT\?/B-3'GL+\HUIB^F9+TE@3XO4/Q?$3:05'XK;I.GEU?7]172.6[W.=HMBY
M[LX'<G=_??XO<GUS?WE]16Z^#Z[NEAV]V">L&_;S6?6J,L<84WQSN*&Y->H$
M4F:*;16MK?=_(@IK!3+49G75Y'K"=/6-K6.;;/?),J-S3*S)D,?.(P^).^%M
MX[";9CSM.YQ4,R:RJXJ"*&:;"/%ZI273PPQ6.@Y0 8[M",DJSIT!BTTSXOT0
M49&WXJ%QO9\ L+-R+?C$3S.R,7'\=)D?VH&^[!1:O#ZSR>O##,;8SDC'<X'&
M(5H7 <#L,"8_!SO4+0\%[T\:D"<L@XU;!64 C@[-FM%,O(3YVN32B9NQ"PD;
M/E"VM4I?J&=8/NM:P?H=ZE5,AQMY-#,<KC6ENH<'2BW7G+4LY:+#\,%5I2\3
MJY(^4D-K;G0=0@><-0RB4XDQB3EY9UKY'L]=LVY7:]J$+7DG3Z[U)]VRDXE_
MG)3 TA6([\*DR8PPQV<[+1\/?SNUZB];RI+5IIU"'>PN:)8J&DN&H+N!DZ3L
MB&@41:;Z^$'\)2>.<3SH4]1GH HW09)6N EOJH%DQE\+,"$8Z2Z&?("$ZUG
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M?+090K>[7L>QQN#79_$:@W^T:]<8_,;@KZYCREC2_51&;%_55"K=MJ\A[:_
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M F5T?*;K<ZJQM0DG44Z.QE/1 ""V3'&\*9!GW<-$%'QB9$>JN@XLEA\3E3X
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MC@WQ\KP/B/?JB_CY2'<>X8(O=$@]CYIPT0 <L\#',9O\E;;M/K,-W^V4F%A
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MR-Z3ZP#7:FT>;G.R.YIJ, PQCJ:-2CFB%BRL&T;+9Q8/^\[X.:B\$>>4Q5?
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M.K&' 04M9HE'2XES%@]$A'(I375?!-,9K-XB5S'\&1AJ>73;-IH0$HL0& 3
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M^OI"T#!M,&%<X)HS11W*TN#5S]BA5]C&,\:%GSI3%7FH#5^]3FR^QBZ"<!8
M0>0Z\!M/@,P#"_SU3!^:NJ3JKWT"FB^9[2: FY$[T]6A/I0'KWT"-LEP C^Y
MZ=DS75&&0UUZ[?S<)-T-_.1N$YP9NFR:9;3<CO!S%]UZ9T^(DWCD9ES_E.5O
M";FVIF2;#2')Y#J87"$])#MJ-%V[[."[;^90'RA<7Z!=&5FUBS7@KQ99D2J
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M$2'J8@3J:Z/G9$4NZW'+>2&Z?;2O;*G18MI#%EY>.OE@31EC4F<K;2>8XSZ
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MTJ]\N"P.PCUHHR'?_ +=JF$:J^@N$;(3S1LJ&:ZCK4M#S5#V1/$-Q&CA@I,
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ML"SV-BWR"A@)11EJY9BW.57[&\V&&$-\(=/5X4 O0S'L,!H6,WX.HEW9KZW
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M/[(8ML,LI)@X+9RFJE*$U2:V%7,):J=L0J\2E2[9_Y!L$;-EASY+E"H4AC,
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M;SD.>]>I!E,OSP_]F(2-':W=^A=AM]H*1VK7U]A%04$CUYD%EA_-A]5#*7M
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M1/,7M#[48$QFRT*+IY/2PVCT7 9#(6\P$*Y%.Y-5S1P.=M1,&P_D/B16E$#
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M>@KI?@B%G^K2B'O/UXT#SPN>0;K?KTR[=D/IOLK7+J=V3W)IUJ?).\+MEF*
MU/8:VF$.+W;F<'5^FD!P2\<)&BJ55W7 L^/',%O2#8HFFNJ)-&,XJ@ =GX)>
MA%^R"/<=N7:V?>S(5;'Y1EW]?+.MMX%]*[]J@8^JB4/-/'7%T47!.3X%+UUT
M=7$@O5"(UU/8_^F,S:,'47O3UNN'BGXP>S3:7G![P3UEL_:Z0SEZ1E^()L&S
MD$I9;^1Z7;'8=%$55;V/WWK1[47WA W=ZX[?L@8FK"XA2GN8]+:N5QC5/0Y5
M%DWIY#<YNB@XQZ?@A8NNHHD#K0_J^J N;40CL Y/ G:@Z0U=KRVJGK&BBY)R
M\CL;712<XU/0B^X)B&Z]H>M2\)9VFCL%B3\^!2][S:G#E[!AT$6Y.3X%+UMR
MSTY=:/N :&\!45ZCB+T 2XU"^@BI5QS+;J8LRKW)ZR6WE]P3MGNO>]/K\O:*
M;G==C812S]O>TO7ZHJ(O!HJH&NJIZXLNRLWQ*>@EM_N2VT=X.ULZC.=8<_?>
MTE4X>-CF.=U71*?>/<A015/??*^CA7X^O<'N%V"_ $]Y ?81]AXRRR!4O9MQ
M*LJHK; $E(9J#C=6&AW3#UT4G.-3\,)%5QZ(LMDGC_N0^O,J')/>Y!U-;S0#
MS>%ZX.^%>.+ZS(>NNN$M:9BW=8 7G54Q[TY!M+:A8(T8]>*]K7C78*F<D'CW
M,6$?$W8N%:1R4T%.D#QXA(VVNPT:#SSP%BI*-%DTC<VC@L4LF-K!+%B_&/O%
M>%J+$1P,23%>Y&(LNQ\_44"U?'C-T>0VQ9'[1O$S/[MCT@1([L^O"*9)$<6_
MN+X[3:89B'@.S*P.5?G-K[?*OQH06[S\X-1:WWG4*D"MN1.U26A/K(A<!-.I
M&^.57PF"7(*\I4P:3<%-C-GOF$U8A5CO)'9\$]Z1\,FU&>T;0+9KAB'S4+%5
M2=(JT-V;DKWW41O[&S47J%XQ%465]S;JKX3F@VXM$)#[T/(CR\:4T"7#LHT^
MA<&T]'7TAQM/RK<TD]KZ=U"N7,!#$R\&:E->K6>.*7&9(TOXOX(Y.X[NP*PR
M"E89AV*5]C)8M2>IXMT4?9B7?TG7JQ\\D2B^FXT:\'G(X_.@?39G*H$^;:]\
M_6+YR1C^3D)@[>@Q)!0IXU,0_L/RG9E+FLBD,>#K-EDS9&FPEEO< >Z;/1NN
MT/VPA[MD54G1%6UX8/9$']W(]H(H"<D6F+S10!O(0^U0L+Q[AUM#7%WXHA2Z
M4,RB,MZO3*]H'@]DOO]#X*6%+=<W]Y?"_V["D6V@L0I'_.Q,^'KY>71_^5&X
M'7V]_Y=P_W5T?3>ZN+^ZN;Y;"C5X&%K'YG4EKFB'<3M]VH:7>\RBIP'Q,OQ6
M!;M:'IPJ?X4OK@?F./")<&>[,!AW[-H"Z#G! @Z4%*]@99I7> ;S*7P#90K>
M^MT\BLDT$MY:OH!WI_H^##P/?GV8PV,BX!H^%>(D8 ;H/<2$(B'BW.4O?R<B
MYITP@S?9[LSR2N_&AG1PJ1M'0%:F\$5AEH11@H^, ^%YXMH3N*)\5P0/H_%"
M!'H?7X=0[71PLU21"S1/ 8]Z2-B8 OCOE'GWQ45V'@%$YT)N X0QJ%3<1XDJ
ME K/)"2+HGD(-'I%!*,N@E6OK D\R-3"RU413*8(-K/R\G$0TCD\/ 'Q,_&>
MJHT)IW#I) ()=$@;+!!*:-:B@-9:*)/3SCR@^R16N !2#T(>NT_$FY_7K^S@
MN14&_3 <Z*)A'D4\95%1=5&J5J2BFEA>KA95+;V\H+R<MJ4]+6K;\0MXMKV5
M5:B(DBF+4O60-:ZVD 5(PHP&AY$%).+7A6VG>L(M\GJX=(N17$Q<WZ*7+'Q'
MQ_U?WT'*AS_#,Q[14T&;]#KMT7E%P1Q3$%11PVYD!Q*$5SO#1G6&1T>S9&(G
M3%FMA(?$1A\?ZS+') SA0TB>B)^DHI5_:P<12)<510'6;L(7-,)A$EDC<ZTP
M&MP8$]:-IDO'\:%D:0@.G"P>Y^V2)(L#Z2A#-Q1)E#1YE:=46-A^V6UEE]N*
M0HZZAA31E#71D"2^*(E5]5)276E*(X+WV%Z".LSU%RRF9=NX!1FAFB/N$U8"
M"(%/8W [\&EY)[WZP?(LWT8(&T+BJ"2]M2^F2C&B3XFQ2B]3F91K3%&"Q#\&
M@1-A"2GHR@GQ*U8:+RP;\1!?[<YF0,KVGIR3(#WH?/]-8AR?X]*T>MW]@N?^
M.W&=-!=ED]"/JL;R] *&TZ+VD.'-E=^&NATECTD44S]K0=%R4YCE103_)>A8
M6&WXII.05%S3LSFQPL5T;2V9L*!F8?#D.D08P[KQP?OQZ()Z2"*@+H(5'H>@
M0Q[AVBC=\CT7LEU5ZEX]^C ]#M,[;E1^:TN94!GTZV)PT:<BC^X85%.1O?(]
M)+7MJ,1_6GYBA?,:YW.E"G1]T#)MZ$&YDN\]H\MP40MFU2?"W?GL?'1>5H!V
M7MR2J;ISX;ZJTN /\AVEFGDRN,_EHF=$A]C*(ALL96G;R21V2^4/>HV_D.S;
MN?J@U[4-J;TC1+@.8B)\H3)7C<C(=.8%<[H66+24JY1\D43<N5I;@%170K18
M>Q2!ZV=/1K[S$:(V+Z %R>GB;59MQ*N@4C7#7%$\:VI&F?X59.Q$\7+EV$J*
M!]PR3<64-%/>/\FW$'7;C2H""TIUW=#U%DJ[3N&);2_S7>K/VCC&4M$60B9Z
M5+N4A*\3!6?;*O,6Z.A6&59U&IUB&EEZ34QS?V@]7'!5\YHH;X[Y!EQ/:673
M\KU@A^8T#]B*0PKN7U@%!4 SZ"*_,.E'F$ITL,H"AI#@5LNY,'*>:#82*&7I
MPLQU"W.NP+W6-( G_8<YVNF#! (N/"O:R)(1]-H9">$94W1)0P'<^^QQ'GFB
M)6?L6KS,#1P!,QN/] K,;>!(SY ?PI3$D\!IY$DUL>!K;<2B48DMH,*YM$(\
M8Q*-BJ8B'PF$4V[,/0VTR@*J.L\"GID#W1@H ZU,]#H:=J>Y@=56#3[-JCJ0
MM:&\"\TTF?V5A3&TK)O.QA8UV9GIEGO3W8+I[KBA5A<--=LS*<E9-\*RC45A
MQPJDTRWI5LRVV)4)"RTISDP[*SYPRQD7$19DC"X 4)#N_*$# 8Y!\(PFE=8J
M. &\+<9]// =0O<AB0,L<4[W!7%#$)^ ^W'3K$ J2AZB&"RE2UT,^%?^,Y+M
MHK&FYC*[)R;AE%G>3S<?!,0(GP1)1#@%ISG]4;Z3",1DA%AAZ#Y9'G[$=[!M
M12MFFY@)/&Q*PO^.!-#,M*<6^D8D+&@IR'!PU#Z]Z%RX\NDP;%JIG=:5VX25
M@!+A(9F#CP"L';O?T3L!'K(]4\\C=FP]N![N'%+66U'@@S\UQ]J0A+HOGY(0
MG1"17S=_>&WC!]52J@<08CKR=)K!56+B@[-K^7-A!KXAW:(%KJ1\C$A\ELS0
M8\)CK3'!W1\BIG<_D,Q'PC0^^J$I4])IHARLGV^8K,!'3[4@RAK'6'X/%"%3
M\7XV&%I:3T*ZZ012%((( J,?+21TX>P!;DIC);_+W@_#((]I60_=8Z . YLR
MN,-/*WA<)O3YLYD'6-H !]_,S>K,<,=:*&U9MS&-E< -N.H[]-!$$@NA15U=
MNL$>$7"K8;V@&/J@!=#_3>P)G2QTE5LBMIKRQ+S6#&84O&RJ%!R":B%=@>CO
MHR/E$YJX8KEW)DY, X2%73R5S:&2/3AJ;'ER[-ICE8FSL%ZWKS!I8^+V7<$R
M\J) S!X#'CI5C.X8&$FH]0>&42XA4UT?V FF?\ZX5\.5BFM!:: W+UX6$<]C
M\V390!+;T<N>??0L@P_ZQ\VT3F:=P)R%UEEZ& W\J7%F&E+ZV:$/:L?*E5'4
M)V&^@XUEH_07JKE&=Q<MC%-5*B@M C84@0%\H7D).D'_#&!HPN\P,CS?ML(%
MR0M;#T^U)OVX6-=-';DPB**,^8N%M26Y"\N^[Z+LQ1/P!-MRJ19L,2%^OG2.
M*.-[RT>M27LL9$F"N>7%\PTVCOZ\=V./W(RO0*L]N4YB>?3H_D=8<#:HBIOQ
M!; *VR..QF/+#1OTV%"YFS>ZKLEZN?E#A=K-1E+3BF#_(^%VL= 5PU3-9B.Y
M0X\^G<??T"Y>D[C1S*QKFS/RG<5&"G_>V1/B),@&IH68$KKRL7:"9C*7OB7D
MVIIF+9_294Q7\5K^R/QN*HIDRI4^'W5,V(9--=/>?39Q\Z*JIN@'85.--+4Y
M9&,H=4$RVAVRTH59OLCKQ\%47.$!?SJ8&XB@+=;_Y['4<NO/NQB,.W[Q(:T;
MS7YGJA,^65[ZU5H.Z"9WST*6%7,X&!BMS/I16<!=ZC(V9S-UY?2DX MQT&HV
MYP&_W*2MA7_<\7/]'T56=+4- 5A)'M>I@54ZD%M:I:LH''"-!RRB 0B1WH[!
MW%0Q%'?\1H+'T)I-J+=)KTZ3^^O-B,+W.55U:$K#=BSG4<:N<B=>5559+7="
M.Y%Y_PHCOQG_$82>TV#X_-:> V,HF^;)3?UFP^<[4*:D#C3MY&;_XGKE>/E]
M_]KTD=L;+[^1'SC(1EMAT![=/8-?I=.JQ[O?,77#A=W<)]O !)6'R[.WPO?H
MO>]ZO[R)PX2\^:F5J=K?L#2>*=W#L X]6QM9#8UK-%N+-HXX>*[);"W4V&_P
M9&@KC&)GIW/E@/@YTO:G: ??7.-&]4>)2W89"3<^5U4='!'YR'.RF0;@AHOJ
MP)1;CQEV&XS.C_^.$0%LZ-_J*RS1$?SY3:E?F;[>P3MORO;/Y-'R+NG>_U:[
M+'Q;*!OP/U[2:'/::YB^,^U\! =9 87%$?QEVO,-CX]I(<&]]7T4183N@GUV
M68FD2Z)[/&NR3>G\F:(>JFJ>(N*D&$2_O %58!//2W%]\K^CF65G?Z>O3V%Y
M0K9C+TL_+B#UT&^62J)VK;&JU$Q)B#8TA3>R?Z>X1*:$WY<0 CN$U;LOA,SV
M7PR, 2'P?WFCY!)0KFBS";8OV'U^.35T*[ YY=GW(T)S+E47[OW47OF\7LKE
MK+N!N53.V(ZT;#0%O33WTMQ(FHV3EN8#@]RND^C7_?M>F,\W]]T>_+%_[RJ\
M\[IEG[J+AO)CZ7T[G0?8$]CS*#N@1L\C(1!H/$Z\O'WE630)0G:JK*'&[!*F
M^P%HJ$$(10(:P,4:QP*8;\F>JXM]GVI8LH"E>KSY.K(4=8&&7I*YQR9>AB0?
MV%$Y:$#5&?OX1W8^%3N@A N]Y5ZM[MB8AI>N,I2EKH>GJ3.Z*3U=H.&E2[!J
MO P)KK=ZG8D$Z3LNK!E.DO ;ME,X#?'O @TO?0EJ2TA,I[D$NRD]7:#AI4OP
M B].6HK[\&D/X5-6HR $X[%K8U<1.YCB 6IKL>U:'TS]_^Q]:7/;1K;H]U=U
M_P/*=^:.4P4I!+C;,ZZB9#G17-O2M>2DYE,*(IH2QB# 8)'$^?7OG.[&1@(D
M0 (@0'8JDZ%(+-VGS[X*+L*YR.!8=-%FHD\3UG#L*-P='XDNU]* 6].DX,(A
MV&2'=MRS=&G".B@+(2@X2!8'449K YK;R4&:B3Y-6,/1HW#WJ(5@LTR^CRM3
ME-M! DU8P[&386\X.@XR;";Z-&$-QX["PJ\H+*J$18556W;0ZDDRL9_I5'.<
MY<QV7K25;IWM(.$FK.'8V8C2EQ5%^!8%%K<;BT=RKW\D6"R";"4(PSO_@?;I
M%U)/\(LT?C&0>\/Q<?"+9F)0$]9P]%@,&*P*J2=,P& AOVFFSR-J00V;$(#I
MZ+A:==Q=O-)2/Y.DE!TWN0"HT$:JYTEO6R5:"P'O)T$^@GPJ)Y\VR?3]R"<N
M\G^F;9#"K:X-!-JQQ5-6GZBK&1_$>&U-[3F!9WW3/#INR)K"@Z@,W:-95$\T
MBQ+-HD1[G74&<:KM=7+M;<=!X*7=MMK1*L_G#29%Z=@ENEX)LCQ-LAP</5FV
MU/W3W"9&V!#7IT-O<12W\ ()!W):24:O!48F7>E?VX$P35B#0-K&(JT([9<D
MV7!H.CIN)$][E<XPV@'+@J]=(>@$STCA&>L*=%M81C/QI0EK$#C;5)QM0[^A
MK[9UIA.<H&Z@2_W.0Q__@^82?;T=0^-)H0EK.'9R/&L+.;8-<9JPAF-'WFY;
MD'<_67+H.M.%8S\;+N9?8>=P0H/,DCV3ID^:]8@VB_2)Z,3A:<F-IXHJCKWD
M(,[!";A9H11ET ;GR"K,O">@C"R@G:Y%)&CEY!6Z0I22C0,MC:XU@0B;L ;!
M""IN5-Y&H;D)9D)F"E*IIF]*&PS)O2BES2&ZK/*?4V0$[:'PNBH+VB'F&%6>
M;JF-P-M5O&V%S,E VS8;7HU)^ B+=6BVATAGS-)U-Y>NM8&E-*P8[^A*\(1=
M*&A%T,J.M+);N6KQ2M.LFM5/AF5XY#,\2K^V/,UZQ,055@*[1ZEJI]FEJL/S
M_FJM*OMJ[;3W19_C+E8-"E74X2C8PD8N%Y:J]0]=JL87WNWTPX57SLR.X0UK
M5759G_=2\?.=)S_*% RJJEZUS@*X $.'+:4LI2LH2U!6WI+3-<IJJ8]C9XFH
M-(1NATI]9)N[1+OQJ'UINUZ#A(;::2?RC6O4QHX'^2;3J3_W33  L^=='5J+
M4=J)D*..0,CB"/F5-(D9%M6@FX)[8R&)VR^)6XI[2D<@WW%*8J7?3HP<JP(A
MJY7$+<U12[&X]\\QR(FFV[,,;H$76)Y[-D-(L2PZ T[5-,G4\S43:[L6 .%E
ML=P#:J0?=7Z.(G>'0WDTV"]+A]K!M0$E?WR7VKE'?7YOAR,X/E79Z_BHU5@7
M3+8G!U)C\*A/K3_NR)V>NM^A#1M*<R?",_M[9C8V]/B817+4Y_=VJ SESFC/
M#BW]1O%,JK8?]:D-!AVYUU\/&1]E+*M!FO75PM!]!\ W66BZI$W_] W:+($I
MW*W1IYM5B:7*@^Y8'O0VHK-0N]M^S&][<,KCGM#.C_%P55D9C^5A9S\]0JCQ
M#3_F_1I--/1T#ZGE']/QUFH%%*'>PYD#+3I>X8FOP%ZX+SZX^?C=[#VYHPSE
MOK)?G8W0]P_F,E)D51W*P\&>/ENARM=[;JH\'(&.WAL)';V5YR=<[>T^/^%J
M;^.I%72UYR^GS5T$FU5%>VT]$POG8EWZC@.?=B^=58;5EL[R9S9]=.M:'>]J
MG6]4 MQ&4RDW2Z[_Q8VI)#R-RK[#IQ9^)%,R?R .6 $;S>.61C';0&J'GMQZ
MNGFUJ]7>-69D"_QH!WX,JN>*A_/5ECABMC1/;:!,&_ BT)Q=PZ7C+KPG @_%
M%J2@ [YK+-&*%XL75_/BEBI@2:M/&04;_0A_:Z8T ]O;!3M:>K1MW=WNG*JB
MIU?&"HOXS.KK!_J7[8LY]NZMJCSJ#61UN"WJ<9 S6O4:"DQJ,"9UY5%7!4SJ
M'V,\/H.M?2$ZKGN%\\J21;P#XVF#::7(JHZ=:'K#OJR.-I*,8+X"H?(CU+#;
MESN#C>G(+55^&V1;9VJY!:)-?UM9XM]65A8M+-K]I3U?V!:\5%IHCN=*FJ5+
M-ACS#BS2@[LTTUT[^-PI6J<CA<0,HFI+7X?RH"_L"8&=C<1.D(_=T<9DHY;:
M* V2C[MF"9^N"-K8Z;[)SH6&33GHRMWA6%8[8R%^!&8V"C-[\J"CRD-E(V;N
MEG.W.64N*]'NCCS.X>)O9('=U:S':VN&R\7&2A=+_N-N(ROZ8F1%T22]-BH<
M8>"[U[S ]YUFDKR="ZIQ%J=UGLN5H3)(S5!!/#TB-]4!,F":E0V3"P#K70C_
M133'E0BP%'T'3X^(LK?1D/I*/(GRLT-EZNS)T-)3[HZ,H34PX6Y'%M.4J3T[
M(5VC%B,HH+44D'^Z3KNEZTF[*3>GTPG7Y7[Y3OTCC[0KBJP.Q_)HW]+79N9)
M"'0^-73NR+U!1QYNC=RV )V%X5F5:.0)CT(V[K2&@_&09H7@5;G3:<,X\E;B
M6!/6(/"<X3EHB/W]^MHT M&%I5FN.%6'=26,KN7@",$MK(!M1NU($4:M0.?C
M0&<P:D>H;FZKL&D!.E=LU&[#X]/^7:A I82R;Q;$T3#93+JVIO:<2&\_VZ[[
M4W-;4(@07FM#>"*(+8+8ITT!IQ+$%IYZ$<06!M*.]3**.I3[0^&.%]C<?FP&
M2W\T!&M?A+"%P2E"V,<5VJN)A;R-XX4J=T=C6>GUF\Q#MH\S: 3B-&$-)X6\
M75D=]+'HM%7(*PS"JN3>I>TL;$?SB)!\[6(>S4IJ>=N7QT-5'NXYL$D(R":N
M0>#XNASMRUWL&33HM K'A?TH<K:.BI<)KU=.;J5V>W)7&;6*6PDL%E@<Q^*!
MW%>Z\O@49:[(T!(96@?,T/I(%@Z9&K0-&.TO/)EC>[#_T"]$GE8S>.519:F(
M/*U2%B,HH+44(/*T3D"ZBCPM81WM4<@RE+O'4,0B4%F@\E >;.Z"W Y4%@:G
MR-!JXAJ.G7^H WG<%_G* H-;B\$#51ZJ1X#!PBBL2@+>X%"W7(@XVSW0O.9#
M$<*V/:RJ60DS?74DC\;"/A68?NR8/E+E_C$TQQ'6J\BS%HZP@YH!_6%75H0E
M*W#Y"'!9 9MVK!Z! EB339N56QRN*\H";E".U:%_3S^<PLI)LS=YZ-^%5Z>4
M1#K>X.R!S&R'2)[V"B_$?#KRIV]X2^"HE;MWB.98AO7H1D=MSR1M-C-, [33
MY#2QG+IJ_4)=I#6U-JU))/:5LAA! :VE@%-)[!-^()'8)PSG71NP=0>R,E@7
MEJTSG04VGSPVJW)G/)0'8H:8,(.S!:-([VME'/80=<"JW!TK<F?4KAY6S42<
M)JSAI)"W*ZO*6.Z-AZU"7F$0BL2 9JY!9""EM7L9#_MRIRLZE H</UX<[XX!
MSUO6TDC8CZ(!VU'Q,N'URLFM5'4<5JBUA5L)+!98',=B;, VE(>#;JNPN&+;
M=1OZGO;O0N$I)6^,:A_2Q'6)YXI^:\U@C4>5E"+2LDI9C*" UE* 2,LZ 6$J
MTK*$,;1'/5-'1C54Z?76>$5#C:&V>;H%.M>+SKVA*H^&HN^:L#-%8M9QA>YJ
MXB$#()>^TIJI7VU#GR:LX=A1>*QTY5'O"#HN"/-0)&DU<PTB@86^H2</E9&L
M=(^ US03SYJP!H'K:1G[PW%/'JM*DY']6)*U,C.D0B3.:"/31&H2#J$Z'4)]
M>:".Y.%(U)T*=#X"=.[)RDB1!\=FV_WL:0\F60U3_OUGWSU[U+3%N[OI$]%]
MD]S,[LCC'*3 -[+ <7W6X[4U0_C@U+Z+)?_Q'C#@PK2G/S[\U_^3I+^G/.1)
M<\B%YA+]TIXOB.72^^\\N.5F@1_=R=0SG@UO>8_K"I\G36'3\,<W,H/C_0.3
M#,XZ"OS+/BKJ65=Y(QGZ/]Y,SU3ES8=<"!&<@4<A;P'D'83\&H1#%*.P"IZY
M(AL[B]<=CI:=[):#=1B.(HDECII^ 7^Q_W(,&W9P)6^D*3$Q?6 *)_6/-QWV
M]T+3]>!OIN#AQT;:^1L!4R!W0DG-G>!1_HK.*TN-CL,L5*%7+@GX!&)3\A?.
ME*@67A?7RYV443 +GJ=?X,?8L920>['C;5_]^0-Q)'LF<2Z4E;^1TV?#"2UN
M/I6-;((&! V42@._$Z.(U-RE[@7>2'1I M)%>X0/5Z_$F1HND6X=8TJDO^0A
M.D& @@"/EP 3!")](W/-P :;TB7<X6A3S]=,Z;,Q(]+;?Q'-<7\25"*HY,2H
M9/+XZ)!'S2/2-="$8;G&-%#:I-\TT\\I1QI-%34YBSD"]WJ[."4VDU?YQ&39
M@!0EA7=SL8;MA30!VMF^YWJ:A4@C_5.S?,U92@K ?24//$>,5RG)BW9XWA<=
M5PV^.;F';7"ZVX;FE."*:PI@5]V,17W'!T*TNA#BO-\\7!!GMKFQX_G6U&%Q
M9@T[,T56U8[<[8[:?G!-S7832M9[[B3"R(O<3NVJ-F+L]!1Y,-H6H&P\,9[<
MP9VK0O*U[,S4\YXBSJQ=9Z;(2K<OCY36$UM3<PF%MO+^%T>S/*(+Q20QNAMM
MA&UI@(VGNE,[-D48Y*T[L]YY^VWQE1&F59Y33:>RLM>M9].^6)-P?53H^B"Z
MI/L.!I>$SV.U,*BK#N7AL"4\+T=/U.,^KL[Y<-L [X8<E5 I@C,[$P<F#DRX
M-X1&@@OY9#LS8F".HNU(Y'5A.,+7D51(E$Y'[G1:$H,Y>85$/>\*A:1E9]9Z
M^28.K&4')EPDC55(TE)P/Y(IH>5\W5:EB;0^";>O*/)XW#QY*I)P#Q4_VM;:
MN/&<_]3.3#T?BSAMR\Y,Z:CRH-,\MBN\/L>B9"52<)NB7>W=TLY[,JP#]K13
MY$Z_)ZL=M>V$*XXX6P,:M)XMB]/-UI7Z(@7X:$]7:%7"=252A0]0P]09R$-1
M6]&Z@SL?'9$B>RR)I[WSP7AEO\U*/CTU,E'[\D!I27* <-6T4*E(2QD>"A4C
MGJ$SZLK=[K8A4PVAP9-/T!$9P^T[L];G>X@#:]F!"2]'8Q62,&-8EJ::A4WH
M\:/('L[('I;5?D?N#-I?T'0L)K0PGQM$'ZT75.+ 6G9@PM716,TB3^IO2UP?
MK4_]'8_Z<E=MGJ4N4G]%ZJ\0U;G.K'O>$6?6LC-3^[(R$.&D@XV@:XPN%,_0
MS85VL]V'.&U6LDY6X:IUV(LB=Y6AW.LIQ=O<US#=Y'CX>.OQY'Q47*@+##DA
M#%'/>X*'" S9@"$CN;]#\]8VH,CV.=A%="DQ1KJ!.ORV,H1@!-IHC+O=RE&J
MFE6X=[4$D%=:L42P/T55POU5SC"D#12TC_6Q?1+AQC'.&ZR1<IA53EQ3^\>-
M:KW.*:#:ZK#6S=.,&X-[@^/&O7[W%'&OX*#@IB!C=WA09#PQ-?YPZ)J<V%NU
M>[+01. U4J@ZWK\%F1'=#L57,;"9SE9CVO%&CW<IF$-!P +\46 _G/Q6N7,[
MI:E%09<V5;4/4T-=FT>@: $%U7GK ,"^/B*JO![UX:GGPV(10ZHSMN'LJ/)W
MU&?7.Q\5HSNJ8C7Y[$H0?NW)$JXZT"V4B_S*18EC98]?X*OR<%@L!" $?G,.
M3PC\UIZ=$/A"X&^O'DA(TM(/OUF9;KMU33H!$:T,Y,&@6"J'$-+-.;[S?D&/
MBA#233F[8D5N0D(?G81N1-Y*8R1TV()(R.B]&(60SFT]."&:VWEPC1?-IU'5
MMO'01("^.3[T1( ^J JK/$*?-G="J!JK]J3:D\?CL5 X6GI\PAW0VK/KGW>+
MM<(6:D<CSJUZM4.$[LL/W>\[CNJ JD#3)I[TY&&W6+6PT!A:=\KJ^;"8=!*:
M1>O.N'?>+18(/#D-I.TG?% 7R0G&-'C6P2XM!8_?UR#"&J=Q<$(1:.?!G9QT
M%_X%(;/CHY"$U!92^V0/3DCM=AZ<D-K-/S21C-"<J,!!DQ'V:8%[_*J&2$9H
M]_&=]T7(H*5GUSWO%YNE+M2.1IR;2$8H[ERH,\V@1?Z$G#WTZA(F7;DSV*67
M0#VMZ8Y*/VC8R9^KNZ@1;3WW!J4C'/;<>^?=8N-,F0K2UG,77>:K57C2&[7_
M_6??/7O4M,6[N^D3T7V3W,SNGC2'7&@NT2_M^8)8KH8](>\\>_J#MX><3#WC
MV?"6]_C(>SBT"Q-^_/!?_T^2_K[I>;?:<DXL;_*B.7K\>=AMDKYDXKK^G'V7
M?#;H5A9BQS<R S#^@9K$64>!?]E'13WK@M)EZ/]X,SU3U3<?BC@P=FQ G^P.
MKW16V\/3;]80<%]*7&]Z?Z(MZ',SF/I?'-H!ZH';0-?$@P[7(K> 12'0X*C1
M8'/^>LM3^P;J7W/8\64BS_8T@=]L$T2V"5I 09-^ET&*9<F")JUA<*B<W)K8
MP4@Y5[M_E<[&PW.U]]="EDPCSJ<):SAV'%&ZO?-^]Z]GDC(&<W<SEK0TU:MI
M?/N;X?XXFSF$P.F  "6N)_BWH,TTVCSO 6&JYZK@W0(_4O#CO /X 4@RK)YK
MUZ]Y-XUK7[TNR!0K:7 X45LMWF.C@'H-7@8]9N^>]:4ESJ<JXN;<*4]KC;0%
MVITNVL60KEI/B]#2/QK/ADXL75H:Q"S:$;()VD\3UG#L&EBQ\02-.)(FK.&D
MT4+HXZ7PYT^V,R.&YSM$^J9Y>37R)E%!$]9P[)18K)M((XZD"6LX:;38-V=G
M]QR;E?P=8L)^'W\A%G$T<V+I$WUN6(;K.?"49X(."<LE^?)R=#(U8/?N/]Y<
M?_W$TW34L=KK]@;]-Y)O&>Q^P[5[*MSEN_J;#XHR[G;&?26VVUPK*F<7@V@7
M@QR[&&3OHM\;CP?[[B(U(VM/V ]'G:Q5#_I*3^G&UISZ_MW66 BRPY&2"=E1
MOS,<=,I8Y,1Q-.N1(-E<+-,IZ9-F.'0F<HQZ I]<8*NA(E#T3'K1;OO]8:<7
MV^WK@V,:9PM0,=Y\V+K-$K=P<(AMQI 5B U. V)1MD5>+/OC&[YO\FJX9U^
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M[S1V2?3),W&T1Q+T +YUC"FI5B1F! #/%L0Y6T')<W5<"6PW;;XA$,\C2XM
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M>$S]%@F-W%,!SEV,+$:.T8N"<GW%9(G%$%QFX,6J&*)@Q30@,FITU+]_EK1
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M&74#IZ$'A4^V&W*(Q'2M@##Q=H],V3"IM%<?QA?)-H'KH_M8K*V5N;\36XI
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M!ER6E7 %[97B+9> 2UJPN, 3NG8O-CP-<L,.:WYD94E*$_V9F@]A:]:H95T
M%2>>[ L["8KFB$$]/^CD(0XW=U'*L! J:_@7)BH[Q"3/6-//K^4NKBV)S@VI
M>VD,QSR.:I4:XZ?*8"7%AC4ON-=>L_O?->=(#[V0AC'J])R*H,G^C!9P!+TI
M"!T1Y/JQ<: LHP*9O&D$L1->3\&K=)G?)>:5B/6ZX*DD\=N-< Q:6#Q,N6?0
M8B'A\WH@W@OA/J^4L6LLN /O8?WC,."4\4)T-="L5EBI;WHTM5Q[I6(&AP\0
M%$6T7"IH;\&#"SR5)>P@1RR-IL[21AY!VK9#L[ACY2X<=HQ;QQJYT!A=;'N!
MA)GR$A=M-J,)MGQE#)#GTF\T"X?&6J)@(+W7Q?&KK&LA=>]9Z#!U->:[<W!7
M)#J7V($$A\LZEL>7\(!2!YC&?XB0(^WR=B0[>$L70!+,]M0-DY(9AI=I\Y(%
M#DBUYW- *-KB1IQSNWAZ?C[/6Q'%RS^G[Y%93J,O]/=1^YJWB!\_K2'("F\+
M?O+LZ0\V%I:/XD772JS,*/Y2CH1EOW957(7-0ZDT"#LJX1^?0ODQB?I,P166
MKCG I#$*<&\O &@UY(8-.FG$NA4>V'%#,Z>\[/\!9>6S@7-3*6USN<M[4^4
M'CR !M#ILF,EB)9/D^=H9]OH[0!1W\-,$CWPK#%Q8;BNC\%Z%LHG&LBYH.T1
MRS%E"^81G( 9A7M-VZ1I_.!%+G#'0Q(VJ]?+M$7LPHN*8G2"(WLM3)C$AP%8
M,-.#B3?N(F1I"N$V-9T%ZWC20K1CIC?0R>E1*F@<# ;M9IH8JTYWR,I98X^2
M6;<L.IB8UK8!U.C9^ N>O!,V<T,W(AZ39"]H!%$.4AQBPY;!L(;#<@.@D@><
M)NVL'D:DA A9?@P\_HYF:V7$!2,!SU.#:LEQ'2;.L+[46CGQ7FZI^.A (3.6
M3,1#E7&R2B73.#DGZ(Y%S3GI,?*J/U*YV@ QSD[9E'/#X5M>8U28]'<6[/-<
MND,&%-]MZCYIO@87U#7Y&[KR8#B6E;YZ %SJREUU+ \'X^2[O8.4>APH33U)
M2\W-4R\UXG2"HJ>QIFMR(HCTG7'KJV V6M:Y->H,&[.09NDQU 9@K69"&R#%
MDQ>DE&(0A#5,\9ZD7R:3V\B_"$L$XV3.B]'IX-MH>A[-E$<%8!$FJ 8IJU&N
M\\)VJ)D3=;#-<!<RKXD[!67*9QV L:$Q/(CZ'#/N\1(I^!D>RZ &?WTI/%7*
M#>=36*C'Q11Y=A.OMPO-JSFF,,3;/T<P8;US0E_?YG&K<BSO[SGP-S)[(RS=
M2T#8(8]@-[,JM.!Z[D].5.2NER/B,Q]MWI0!DQ_#^?4:MW?PBN<TIR>6%JR[
M,\_!HO=\+7#N8EM*5(36&XJ0.$?9@15N[/G:& ;0F(54RHD:*\R20P2D3UB%
M^EM0KAHYH:XMUW/\AO;J/UFL*B[?8N?[A6@H+^B9OF,_A.7'L3*ER*?T$$R5
M9<XI3,;&I&<6<P-.2G//D'^#:>8B+]-B43B<!@CBU*'%S^P2C=5C!%$SGHM.
M$QHP^R(6UPH3,H*+N/B:1UM@HNPM>34\MO*?SJ7?">\NQG.MT;%HPG*-V3)>
M;AU["GUC]51G6XDH1BB!;90=5-3 9A[I_*]WC2"Q\'^TDB)97-$D"@S_U^^M
MK?-LI6CFOU_5_G169_WI9TP>J@&]E!6?S,*G\Q0,GND#.@EM+*"Y$@(8AS8[
M-+7GK6^Q]@5$_XD2+"MG8S3'M27:J@FGC 43+9SUT'52_^.U#]B'BK=PRJ#>
M9GA]!0I11TMN%.*_Q>9/))$J= GR(LC#$ '%2SH?Y0&STV@L(TB#2\5D.<A]
MTT%T3#USR9J'!G\)7-V*JW4==#<-55>0U+=BY\XOV7C\S3C?QLA5MI#(',CR
M*F"_0:9A&?%)EL'\43#^38H5H/#04V!T"0IGW"<0=OA+T]#.I1O?H>]WW<!H
MIZFEX0.F0:<=_H9-3XO\-?_V]<<P2:L&;_IJ9\L@F8K/ $K4$,;6OMD+Q.(K
M=/XVZ\D?U9W'GO%D$ ?3?I?L,)*X+CSEQYEPI:[D<-QA[/#L@E+HI3U'!Q[#
MN2, 9B,1H\%>@?P96HE,7!I^/F-,?AI'(=8UN,X4I:$R2H8%[S"-A:/W+:M[
M.*][12MQ2BYH6$L;7!V#7%B5@647\X5I+PFA_FU4F]%^>F21;N#\P<^K"3=!
M(FQ8R,QY?M:(OJAD(UFI0;MYH)<F[)7'/?MR4I33%9U1ATLD5MP-T==#UYQE
MS7&_7Q.NK"&,=1:".L@ZP,G04?O[E0Y&%""Q.I<+D, _@&Z>< XW?\09VD-X
MP=S600-:"<#0)Z36^Z_G"7Z:W%W4U :@W^DGZ2J5*_!4]3.N6"4'&88(@UMF
M^78LS9/Q"@H W^+M#5E2F*0E]$'8%V826=09@8P'#RC>Q9'.Z?0,,]':$4OU
M:5Z)0Y =T79)7..O'F[>"S&?DSZ^.5SZA",6:E$O=^G+&6,@U:_P+V.Y.TI.
M0^(9H;$A&FF4>-+'.&C<,:I]N=M+MHX,B@>W'62]N23%]<!*ZNEVL.6;5-=7
MO9VBK)NCM350KA HZ[=](RC3,+T_OL<@U?_6L2WXS QY$7/=AM^'F'U>AP#X
MHBV1[_>2?!^EWY8"D0L;_D]Z&P$5M<;HKY^"W/M'W]##/)N4CGCT>SH@79O2
M%IP^*%E@"X0)^]C)V_;=U'NYT<.[=VJ87,.46IH'1%X-EZX:#L]W/6=YAJF<
M5(8%JV)90^$:(R/*"L)*M'(0>XE'BZPGACLS5C0#UR,+]UW=D8V?>$ANM@PJ
M+2@0ZNC&HF:L(Z&:AYTWW3J6U$TN*>RBSKK>Q)(.:'"JCA7UDBO"[# ^JCYU
M0?5XG_O)184:8T#$C.RP[X7+&<IJ.3*QGO!\XXF'\20[:D9K;&HLRQJ4@R:!
MN$.4:PY.XF)=7,-VBXY!36B: Q>1,^4880^CIB1Y-W\LZOK:ZI%9$_\1#@O%
M5C]%;*'S8E7V: OJX4#LJ#_[Y@RG1_-$3<V4,5<WZE?"L9^5K 3^A]7<5G0T
M .QI[B[K+URG:8A01@L_21CW :Q9+K#/^AA@BQ;-C4G4J0E$-Z/3*#A)2AHM
MJ @KD@+BC$3R[SAM\R!M$$T#%A/DF!@NY5!:I/TLXCHSXUBTO$B3T&OGH*Z$
MV;Y3#_UWMN^DICP?,!K61I927URC'N;UB3PX/K:D6/>VK+(O+2DA4]7P[PN6
MEQA!?7+W78KKX=7OZ:M]OCK>XZSZMW;4I.<XVO-G9$%N]/?;NF(RHUY294U1
M<V@%MH<>XZ  FU9C,U4-!Q!;TR5O"SW'(A&>W0HZ#E8H.H\:J%$\R$+9;:!8
M,;:;$;KGT81D ^!850>1?I#DE$CMP?8]^E J<[ 8\I&S+^G:"R<B)L76#)X&
MK [%72,DUNA\NS/3B.4 VS1YD!:01[4R+S2!A')UF:7SZ,R_R.27@:T2OL=D
M@<T&*$6<?V&S0<-R6(\!-]I1K"Q14R*TS\9KG__T 8.*,V_DRD?*B95N"B?F
MC4Y2*SSR06)?SSQ=0?>]=.D0W?"DS[050/2+_EZJ33!TU4%2,+S;*AG !L T
M*][CG7>?I9U,8@5EK/48FW..%8-X%7Q-*P6I5:LE+J&*K4-F)M6_PSY74P8@
MWBN!5>1Q/UBB%(TFATD/CJUA^@45"<RZYH-CV#P#UU^@]<(S(2.10J4=_AE_
M7U2#MD&N8$8#]<89O)5#0M"$_82->6 NR<<I?8)6S35((2&$3CLL$+E8A)B+
M6C=G&1Q18ZU+)*%/=*YG7 I>\ISE:<A'+[DSA-Z D3ICP15W^LU'PWWP'9<'
MY\(7U=>2J]O99LE0CQJVEX^\;&$GQ5CI.O:9B>?C8/4XWSOE-TY\[WI\VT<G
M$88Y)()NDT-, ,'>.%@ R0,'6Z1+,GTJ<GFAR$D<=BP_W(TWGVNII&ER,LEQ
M&5E?[6=&.D(")3K#9!M:B>:.<3%4IZGUC> 83FI4X!(.8VSM(;LT77=XHB@V
MD\26@GP.)!@Y7@!=)]HE963V9@YW=&)LK2_7RBI9GJUA9<Q(/9"(8^9NMGB#
MXU\-YO!&<B<@V9JUMEI3GX:-%2_#FL5+9YPM7M9*N&J3*;20+%%"=ABQLE)P
MDU.LH%L%0^ @1I#!SVT],@.Q((>./4RK<8)G/3K:_ C%1P/\8B?!RIM:%%57
MF,84[#UI/2C9[/TJZ"=^"X1*:QL/I+L/DKI[LFO^1Y;/ZQON$S*!S[$0-TWI
M8T-D#[/RWFCCRN'F9PTY-V/,OQ(=*.?Q,$L=*?WBDHP6V]"\M5!JP7I^T&+0
M*+#'VBWPKO*!GV]&:*;F)E&V\!],;&O?.FG6A"C//M*LJ4*B>>9)W0(L[@(3
M0BR:8IPMQ/A@ML@35K/O*TC:15O%(4^@RB-[8ZMJ!J=/"J5O///V6U11<YAE
M#CHK!0.T2B%EI53*7]J)Q/W+(''_4&L?%!>FC$&[M'VDEAS;$PC-NZM+Q.39
M+)[W>>&;)O%HJTL=CHTF_<E\\,%RI</Q:M0MK7YJKGD>CKY)]6 FL)@/7XOU
M[\@MR[&M,4],"1L.L#NB+D2LNUO:$@,HNLWR)N8)F$4>Q7W#9:E'D6&3QC__
M_6??/7O4M,6[NV@%$3[=V@ ).*)[D',7ICW]\>&__I\D_3V\AX/^ELVF_9W-
MQ%C2NY8T[Q_N^T9F / _4!2<=13XEWU4U+.N\D8R]'^\F:ICM=\?])0W'XHP
M9#I$G*7@.\B0UX1UX72+ACRQ;A6KV?78PXV(7*GTWA$D(0OD= &,&,P;QI,#
M&LE#G(=6O1NF9^>R"BI&B50)\T@LXK A20>2-5,ZT0U[7& 5&9.T#D4Z[OA
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M*.$/SND@Z/:S3;ZN.AP.\_*MU$V4#X04C"@!"!OLWE$7_FD6#+8BPE?;"L#
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M"!E0<1)=I@SH*3D5Y8:=XLXR8)PM WJCSEAM)31RR(#Q(61 X8WDE@'C0\B
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M1NQ6Y10,!ZYN^P@88LXX$CFL MP-S'5<Y"=XG'1W5OU:NXDS>PM DCX!S&N
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M,MF=.A<0/4YNX,$Y']GP;;[/W3AA_IT,X1[BM:6$V<,I2"DT"=QPP>_9JY/
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M2&X!*;"J(TRY.]@(P:OK7T:CKV9"6Y:@;5A7)$C4V8@58-+3(#T-FR8TTM/
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M2S6C-NKBJZC5YAV8V?,\GQZZFWK,4]#(;_L(EQ17U$]X^3]02P,$%     @
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M9TK]!5WN;::5<8Y:'2(\]6T%FW.L*S#7A<(U#ID?_&AW,Y:F?:HF_[$X6T5
M75B4)]75L%B9PJI#=]\A6^R>V9QW:^:A"SCR['EEJ\[!5378I-3A:V;:" 1:
MV.E"@SP]7D9#Q5G4(;+OT)!>B[%!]Z#&3Q<XY"GSIFLY#GY#91?>YK"AQ$X7
M-.2Y\J;=?P=@++=4R=FGS_%X[ /V;YB@IE=RT#2N]  ;^0/]0]"&!-0$OC?R
M_'L#^"KC5_IFD IN@.#IY2(T#7L_@5ZYY(=QK@"$^KZ/1\JF,TP,D0?*R92:
M) 1JT?(; JMFV73AM&6+M/I&%=/XFLIL#!*9C4$A\P&AJUU:M,%Q>%U)=*%/
MGOWO?)W28?1NWV2_.2 M8:0+)_+<^N*V_@,,VJWC4,YA8(%_<5"A&\D-=&"J
M"Q[RI/<"/*!0*@P^P"&*'O($37;C%*]<8B[+=QY$,RH^K!1'/@0R:$Y.HHW$
M]FN+H@M8\@RV!%CW%1$Q9@(1Q8>@A(@";_<HX@%N2H>!-C=B=>.K"TCRC/;2
MTTB'\:R#[;(IUN09/ 9^SEP$L7BD*/F6(_R7DF_"9^F731?VY/GS9=@K)H"3
M9W!OJ<S)&:E,YJR"@U?KAH+*UTT1$Z6"A---[*O1+)@N;,K3]^K8K'RI%9%:
M*CH @0_ E-^@N<$!=ADG7="1I_<7[NX\#*)=;MG<("ZZ\=6$DI_E>?@EMWT>
M,*-X3'MS:%'EJ LG\CQXRPGQ T*4[$6F4TZG!'/.(/<\GH,7 #'<2G']X8X6
M<71A2Y[E;L:6:0PR,8W;1$SP5BAFA> 0VC3>/;I!QZ3"31=PY&EOZ<VG>^60
MWA\_A?8[$@2XV5\\2Y]X8"*2Z_H>GU$W^48[F81B%>G#4<1C>B2 -'?#\#^#
MN\'%T(JX[[.S+P//QO_/OMS2^00ON/;(G'XX6E*&N2X>>\JJ1H!$+(I1D(_<
MCX,/1VAC]HX!D(Z,"!3Y<.3YGA?/W]G^G##O&EZ@?D=&4A"F-,RWQZ*@':>7
MWA]W42I9I0V+H^-7W)^G(0]&/(R&-16[4&Q-X4)!VQ:@(^X=Y1CMDRD=.A>,
M4ROR.;A)O&=:5#/T1@3Z^1?BQO1SR+SI>?)-[E% +>8\CZDU\WS7GS[G+;&1
MJE=J,FBO()'A!S9832<Q)OV3>?;06:>M%&O=4C,U=Z3DM*P]1._(1SA06#0<
M#6J=9UFI/G28Y-COV,_6TV^)%SOP%X86CH/&F>M;WVH:*11?0[4HJV9][3@E
M0V?HP!!.1P&Q:*Z'Y,6J&,,,V/J2XJKC7<RM&0SR^1:&.R+V.H1#YP;B/O>*
MXBU;J08="%;1+'DRAS H(ORYKM^$N(@#4(Y.6*1;:S^,SB&X 7\PL'^/DS-R
MX6". ]'0N8:0C+BC&31[>$N>, Q>TB8K5+>#+68MJ'C#R(2Y+&)+4:- OL$6
ML3BUY4W"/ BSO4A;BY1'HVL,3SL#::4ZMSW(G\\8=2Z?J 4L'VCB]?@@CGP\
M/&I=/D74LZE=[*TJ-!:<LE99OYK5093IJ7TDERHE'N8';3--/3O?<%L=Y]>L
M8_M1@%2!U?#03_,7FKHDA-'Q*^$<',N0W^,&U<NG@"6T-045"_<1UA!CQY$
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MWW X',X,I8^_/R["WCT5DO'HI#]\==3OT<CG 8MF)_UO-][H9GQ^WN])1:*
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M%EA^*P1P$@-6G .V:H, RG.^IJ[ZE?>  ";\9WTMV]YN[N3 2GRB$9TR)<_
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MHVLN<OETI975GE.0YL.(7.ODT?T9D4BNW$QVHEU);4F<R^-DP85^"]6V&D;
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M-ET(6KXXO:PV_0(+ 4_@_J3 ^ _4;=F4Z>)N?Z@UAJ5 ?48</CT!"/X75H@
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MN*EO[3&$ G"' E!:Y>_*4 VJOV_5'ZX.>=3\YQ,2/ZF[8[*)7-!J52@XMC9
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M;M2L@1=V7U/@2I'R:)VF$U;6'I$&VW/;#!CC&#XL4H! P18-MN@%G5,A:/Q
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M?ZEZDIG."'0TJH_I8.NU-*_^3M)8#KZ0DI=BJF2V4MU0XFE7@%7G0"())))
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M, (\[/OM(XW?[*%"=T@9%$;>@2.,\X3JIDEW.I$P%E%IPR?#MX !JBYWDT:
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MN;\V71P()U_Y'K/^_>A;#:_:3:-(6?;9'8TH>U('J>DNX8;6&,0WYKTT-?<
M('Y2?I=LEEZG3W)E<K'9+5?M2P!T&1[(^>$WX(YEOY_1-%JNB/C=:&5"NYT,
M(/_6\[&$F[V,!IL4V@T%H+<WI#1CJ;\CQRN,EQ#1!RB.FBX(@*BYM=LTQSU&
M#@/!MM^J'$="&K^8P%[#P_E(?N-BKT89]KJ^X?!"JWM*9O-7$AD75&/[$4/P
MOR-N!8^+*)^)>RJ>6&3Z8)B:>A-<Q5FW\F3&=]#8?L00$"RC(_/RCBK)6+K8
M5D&OHJ?5W_.7FM!O(;8=QT- @"14&E'2^BCHKYS'V2?:4,2BL<.( V(G ,'_
M+@HQO1#3"S$]($:#3LNMM4>, (WZ%K?6;#!"A/@@> L3>218ZWU')L!&S^!H
M(^_-E@6Z])SF3<=AD2B4E(+.1P^&1#F'"]3.[XMNL8*/$6YOK:!<OWV<M1AN
MU>UW2=>[__&OYAHMX!"HC?=V+*NYI9;4:0WC2_5M<FNC6[K-U@@'\B-0+M2.
M)AD&I<'I2VR@8:%+3[5'IN%WH7MG;30@&%%FV+320'<.=.=W1G>VIR^B.U>!
M5V:#.6W#*FS. '8,[@U[TCI##><G 0&B2N%OH#D#(6'+V@=Q?#WF5?PQ$569
MG\F:B'PSD:LKS?Y%RCII7:_::S6VCYR+#H)VR\#8WS&Y\WG6WJ+Y*AT"UL5%
M=L;1DPQ)&@UMG>1JI/Q)OMK[]=24JZ%IY#999)K&?R=IO&;4."NP'@Y$^TC2
M8BZ7:R$.KRN]X@(BI75G%P+O=NGYDJ7$()NAG0,Q[A^F]F\5W E#_L:VAMNM
M/-:8/@4"V&UX0+L"&N<\R[/S0OY3W<(;?Y**4/6#!A&XGS](VX!( X WK3R(
MJ\IBO5X.-N_!KO?P\"[_*%B^^4CS)8^5K93EE"K?E9'W!>MT$F#\,]D"K?@$
M(/A?1@>'D/F*2WW#40F-:\8?E$%5V5.&_0OH@08&^'5H^YP %+2+;%LG+[L2
M?'7PZ^PKRY>'7>Q VXZ*9CKVSE\E>7O\C<.@ 9R=;0[_8G_F& ; D1^B@6-J
M.N*$BA. X/^LO(^6-"X2.IL?Z_S*EZ&S!$Q9& Z&#,DQ(3DF),>@339X![DC
M$+N#M]+N1X36I/%HP(\%L9.O%&_G_QMM)@W8&$='C87M3]XM_(62T.;R(,-
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MU"[4YJ;;NWQO$Y+>DHW:C?*U,?ZV5+%%#Q>B;5?+;'XN&[.()-/YG##3U3K
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M4%-BP]%$MZ&&FB2(288NE6RHR>DO4WFXU-[AYLH<O46WB&"?K+:\&'0?HA9
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MP1A:ILP.S(V.!(\QW*T\0PG5(DB+.$BN6/E8K!]96?P KZ<O@559.N5IU.\
M*<7JA&P+< <)$5!( %B( $,J-/Y?MR)FALUGM\="=6JN<95/3)2C<^SR/JE
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MT^:KV\WB TN?(+ZF?K$/#[)B<9TT&HVM^AER YGJWE4,]10.3'BT^;$AU@T
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M;QWG??Y[&1>'+D!*P2H:-5W5/L)F@A[MW/Y[XWJ25@2H^C5F%1G-<-SS9GM
MM.7[A+U,&;8JG\RW-<ZZ=FICB-!:07Y!ML4PM_MMB@D6.D[PQ&'E117X-'JO
M/M(2FZ3IO$?;TB1)-H%H?N_:QSC*--CDO/A!$BO*S&A;?/&#\SYMRTU-="&2
M,\Y7IL4LUTG%MS0J$WJS.=]\87D<VI+'LET:Z!*=H!Q/VKUQYC&'IHDI8C;X
M[LVLNR]8^.N6)1$_^4FXZO;=]+?S#;UA&DXMOBZ,+X@$LB#;3V$F^HU 5?8Z
M?C,!C^N;!X@R+O3=YSU-<_J)#@FFVD?8EQ6CG3M[;#&* O7^PM2X_B3'E=(G
M43X0\3)#Y(ZH:/OQ%BE*$,.QSW%8:L:B,A3%&^]I]AR'=#P/Q&1[;)CI4+^V
M=:8F+-["UJ3]>H:F><RT&>=%JFZR"M*(.3S6=)XL'77I28S\V;"C?#V7GQ%F
M>3MQ;38T+.)GVF1;O.-[1I/\222N>!!//Z;B)0UT.?_$I4W:?K4"B0WLU@8=
MZ23E!(#D&"'Y16#TGA/ R)3VG]!FSI/CQ&/!YUN:Q6R\@-Y *VPRL>/>K*<-
MXY(HZ?G=E8>8R!0YXTDP1K;>WC9SA<+%9ML5"7\[;#_[^L1A.7OJ61UW2 P;
M!X]\92L@[%QO.T7U-GLGU:+J<A.M@<F,U@*:S#'<@EO>_HF;P]ZM<\;$.#^>
M;.(" C2&#R4G#?!'D:HC?4%\IMDCTW6/U$_!48\=9X#5TQI?*!%Q2Y]$T6=L
M]-4LL*P($ANS;^_$>:HT;)H3CG="F:3N!\J>LF"_C<,@&2\]/=4>NYL-]6M;
M\[H4/5><GF0MT^:7I^NQ+BR5.H=#[>=>@YWVZU:8%E#S<)"Q?;=:X]SRE/L4
M%LC+(,L.&Y:]!%F4_Q0DI7 ZK).$O4!!AZ%[+407<[.D*I!RF&!,&1,R YG%
M,>-2E%4Y8P$1.8*T(@THHCAJ>VG,]*6R+[VL-MN7HL#:ZFI-.?VKHEG%\ZYF
M"],H/?WQJ2UM"B\H#7_)X#%=R4%6:%F:OZ4<9^N#I_G'.!6%MNJ\7NLT.NZE
M/[1JO(R:4P1(?7:(U)&/HKIB>A2P20&(A9^,RG"I."4TR""W3PY>M6"S$?<N
M-/\S9OE8-/MPZZO#(?W3<1SA5!'K?B6L^XP]QSF85?Q'+JE"D+D$G\AO2HLC
M&6[^HLA82UN'CT7OK&JB!\'PN;G-V99<;"A^MP*A6ZRSX(/ DLMMG ;D/UB<
M%N0GCJ;,4$>V!2_:UI9;<PNEOJE<[>M? I:OY$Q6$= ?S][]+F&DLV-1Y8E
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M9=,0#YDJ8^Q8/\*)9\KX4>_,H.TS3=2OZ6/*W+$Q3IRU<T?W_*]B+0>#YAF
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M?1T(-F0U?)'7I@4Z-;W%L>*T='U45Q7>*-,D@=N;Z;@P45 U@!#HHX(J 6]
MPQ*NUIO(N67&A UDM$?.T>PS$ LIC?+W? AC""2 G^-BVSQ<?6#M:];^@Y'1
MKG&G)2,0;*\ %4P9SF\F[M/;R%%'*(E5CG]J.:P70U'AJ0$-.W0+^_6PRX21
M(V)AXU0\$1$L!%,EK]@X?&?>86/096/6#,?+"<SLHL%L3O#";GC47^']?]T=
MV8[C-O)7""R0)V^ Y&F1/'GZF#0PZ6[,- ;81[5,3PN01:TD.]WY^N4A6Y(M
MBF3Q=%X&;HW$.L@J%HMU>.TI((43/V<Z3$\!;XA'3M^%<@^<\7S9G %8KR<Y
M9AAG+5NP(M&H4;F:\)-Y?/V]*91AK;$BQU./#K\6A:\D)(;.<\E=FT3O2PTX
MQ-6S<KKCP/IKUHOZTA8R8CZFWKRL.+Q^;7EK HG"4W\ U%3R@;U7J!+@T B#
MWZ(L;PW>$G.&A5U0K-<P;ENZOK/R'E\D(*M> RZ>\^%"[4KG<"&;B#WN,+_0
M"2A28^YIP4M7 =%ESY58F6*#?=H*%\CZD!4E\X_0K8%'P+HV+C7!A;8I%6@E
M;THJ\ ]J03KGI:> >T6\_6!Y]J[G$R7\YDF#KZF9FKJRY\+"-%H$857E9T(V
M?Q5E24W>\T##VU/+(5DC*KM!@&K-#)AO977$AI^_+LN\#Q@9]*;R)"K 62)N
M6!\XT'LQH-M)X#8PKOF FU=BJL%?2$?MOTPCB-DMLK"-6R?8VBV>'>./+Y;Z
MB@N7QW];Q'E';E)ZK'#'0T"?MJ(1 :]+WV?N+IG07@&&;CFJ1"RH&>V% K A
MG0@_XYC2IVJ=(FR>FM1]NPY.S II,3>USJ[Z8NBB@:OA6KA.Y\.^>R--\3=V
M?J6E@A/9W7#"Y]K\#"?$8SH8++B7BF=!DX^).Q0NQ<J#)T$RVU=B+ YW;.J[
M>Y?CAS8%S_%(WO([1SBHH6?/K3B*;, ;Z7 M-0M.*BPN#+;E.0U\\RGP:E](
MW[-0LPR ]G?0NU'5^,$N2U6(@&Y/'5+GOE="3#^0_KHB8':&E; [BE'W\2>F
MQLGFH3K@MF.XSM1PDTB:\?= B=.&$TKRM!&"2*!':@$;KL &"730@,]JMM1C
M%,$T7X;$FMN6J6PWA()J6! &=XT\;&]PTV5%19]O"A[,MF[P(^DH7O+44_ @
MD/0T8V#^^R >$>H==,46]3BA 2F>?4G18@L8GI,:@'A8<M77:4YX/O"D/CHM
MQ;..[YXU79.X89&G?9]=^M\]R_(IRRK*LAV.D3L.7]7$S6Q%MG*?&U)3?#^>
MZ41W+,"5/JUW\AL9\P%<V;U20-$,8"E&3BQA%_2Z,HGK'A<13JY'9BB[6+T
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MP#UBNV_\D?WN6#<'M1U66(X63-23ED,)>O/V08B,-6AS"R(WV3N0ID.)6JU
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MS?"B/O!@OV3C/?F[)1&E6#:T\.$-HRFL4%PDB!V@)YL UX1$6X/,E=W!D!:
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MD1X^[=Q/KA!F6ZPI>*S6%<JG)ECZ! 17V(YZ0!D81JXP_?2 ,@CK@H'Z-Y>
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M&"Y'JECTF:H 5WBG;QCTF;H#QW'ZED.7.4)PW*9O4+3+A8,CY9KEH$=9M9H
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M2D)_^_OHP#&@9(+1F7Y>3T=,*#!BT\_PT0Q%@I&9?AY/#_%+,'K3S_8!\.'
M:$P_M:>S8*G5?!\29&A9_ABF<;!$9$G#S0I'01SF8<OT'Z.Q[60#M1"U57+0
M&+-,NJ$B?"JXS3Y?/* -H3FW;1\KA$7L"G&',5 XI\Z"]+3!J=,&IQ7$]>P9
MSY[Q<7_O'K:BDL-5":NZ]R;@C@SV8U4$LJ6V#1S-CGZM)5PKC?JR8,*MV=M/
MFZ][EC?J(!M[-_;3-Z(6X*11!P+<I!G[_,KE+A9 V.B\4N=W.\7N?1RKF,V-
MS P24?9^7;F4U]O!.9_M[GF?T],T TB73L5C*W0_;_%R$K<:7O^>11'WLV0/
M*$+XA>_^LDO$!:UMVIRG(DGSU53-+4P@?N%^L&R>WJ0O;'42NMTM6>%KD'2Q
M^2XN#X^M!YS]?H'2:+4.Z>]2-P"TVQ@FM-W+)K&QH=U&,:'C&X#4<VF^2<OJ
M--X"@A^@\SCH,JIOAJ.K][F<]K PC?I .Q%.NAL#>PT_G;OP-T+WA[3D\Q W
MM.!%#M=HOG@GD70A*=L//X5[2N(BRN?T$=$7',DV)EE3:X+S&&@M3R;%7MG>
MPA1.%.4'Q"7"Z;*NAU_%Y*J_YR@634UW'*LABY 9Z ^(:5$%^I60./N$%)4G
ME!U\W,7'721R^[C+:/S&/N[BXRZ&N$CT/J*M8;D"BE0E(]K*CRNP0$QH8F#?
M.8Q/L[M$!I+49^0*4H +BI56D2O!7M5F XG<N(*%>EWHN21=P<5D9X$:>*XD
ML1JMG687L,/+1GI@ZW@QSR?C5^4:=66UR$T!4,37E;T$ (6"3>+*YZ&!A(#6
MXLJ:,#F#85'Z_K(>Q[:5=LGAU$YR'"T8 @_P&7$X30A._1V[HX/'A"_3W[8[
M6GA:!^SZ.[1'BYD.G:2_<VIT\, HH/V=5:,#1),Y:95B_T= J^)" 9MUO@W8
MZDZS?X5E7;>VM]L9C6V'?M]"U'9D_/W5D+N@R+NK,W=/>L>,EW?IE-M\^BP)
M8U_1MA/B?DI>V,M]W,QDQ'U!HVXS!V9I_/<PC3<825&!]>A M+LP+19LP1;T
M\)[1CX1"I-3NW(7 N^_T<H734"*;I-UYY6(\/LWT%R"XTQAH_'6ANWNV!V,Q
M$U[1;0RW,UZ2+,\N"\H5"8;Y)Z8Y5C\(YJ3L-X9)U0$2Q13J5E8%YE7&WB\*
MG7<!ZVUS@M=_%#C?WJ%\16)NWF8Y0IQW(F4 PCIY_N\Y\7\/EKG\^DAQ0[M"
M/W%%O=+3)>L&T&,TTP"_!F&?T4REK@B6?63&\\&OLZ\X7QUVT9LL=%2;&[1
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M#2,+A6OR(-L'30)> "QO>_.SQHAV"M9H"]BJ6,U!E5W03<'^KMUCP09/)'Y
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MZH*]KQ'RA.C0U1J&PM>, NM*I;'A4)9S!US9%6"Z@"FOJX<3WOIW;H"%%$D
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H<RTR,#$W,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  *.S @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
